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Abbreviations
3D  three dimensional  
ACN  Acetonitrile  
All  Allyl  
ar  Aryl  
Bn  Benzyl  
Boc  tert-Butoxycarbonyl  
Bu  Butyl 
BuS  tert-Butylsulfinyl  
CD  Circular Dichroism 
cy  cyclohexyl 
d  doublet  
DCM  Dichlormethane 
DIPEA  Di iso-Propylethylamine  
DMF  N,N-Dimethylformamide  
DMSO  Dimethylsulfoxide  
dr  Diastereomeric Ratio  
ee  Enantiomeric Excess  
eq  Equivalents 
ESI  Electrospray Ionization  
Et  Ethyl  
Et2O  Diethyl Ether  
EtOAc  Ethylacetate  
FT  Fourier Transform 
h  Hours 
HATU  1-[Bis(dimethylamino) 
methyliumyl]-1H-1,2,3-
triazolo[4,5-b]pyridine-3-
oxide Hexafluorophosphate  
HOAt  1-Hydroxy-7-
azabenzotriazole  
HPLC  High Performance Liquid 
Chromatography 
IBCF  Chloroformic Acid 
Isobutylester  
IR  Infrared 
m  Multiplett  
M  Molar [mol L -1]  
Me  Methyl 
MeOH  Methanol 
MD  Molecular Dynamics  
MHz  Megahertz 
MMFF  Merck Molecular Force-Field 
mp  Melting Point  
MS  Mass Spectrometry 
NMM  N-Methyl Morpholine  
NMR  Nuclear Magnetic Resonance  
PE  petrolether  
Ph  Phenyl 
PPI  Protein-Protein Interaction 
q  Quartet  
Rf   Retention Factor  
RGD  Amino Acid sequence,  
  Arg-Gly-Asp 
rt  Room Temperature  
s  Singlet  
tert   tertiary 
SAR  Structure Affinity 
Relationship  
TFA  Trifluoracetic Acid  
TFE  trifluoroethanol  
THF  Tetrahydrofurane 
TIPS  Triisopropylsilane  
TLC  Thin Layer Chromatography 
TMS  Trimethylsilyl  
t  Triplet  
UV  Ultra Violet  
Vis   Visible
Table of Contents 
viii 
Table of Contents 
Peptidomimetics, Propargylamide-Based Isosteres   of Peptide Structures ................................ i 
Danksagung ............................................................................................................................. i 
Abbreviations ....................................................................................................................... vii 
Table of Contents ................................................................................................................ viii 
I Structure and Objectives .......................................................................................................... 1 
I-1. Abstract ............................................................................................................................ 1 
I-2. Published Chapters .......................................................................................................... 2 
II Asymmetric Synthesis of Propargylamines as Amino Acid Surrogates ................................ 2 
References (1-28) ................................................................................................................... 6 
III Peptidomimetics .................................................................................................................... 8 
III-1. Concept and Definition ................................................................................................. 8 
III-2. Rational Design Principles ............................................................................................ 9 
III-3. Fusion of current Peptidomimetic-Classifications ...................................................... 12 
III-4. Modification of Amino Acids ..................................................................................... 14 
III-5. Peptide backbone modifications ................................................................................. 17 
III-6. Foldamers .................................................................................................................... 19 
III-7. Structural Helix Mimetics ........................................................................................... 23 
III-8. A Geometric Contemplation of Structure-Design ...................................................... 26 
III-9. Synthesis of Peptidomimetics with ortho-Substituted Arenes .................................... 28 
III-10. A Surprising Intramolecular Hydrocarboxylation Reaction ..................................... 29 
III-11. ortho-Substituted Peptidomimetics as Foldamers .................................................... 30 
III-12. Conformational Preference ....................................................................................... 31 
III-13. Synthesis of meta-substituted Aminopropynylbenzoates ......................................... 32 
III-14. Smart sterically enforced Helix Mimetics ................................................................ 35 
III-15. Conformational Preference in meta-substituted Peptidomimetics ............................ 37 
III-16. para-Substituted Arenes ........................................................................................... 39 
III-17. Heteroaromatic Derivatives ...................................................................................... 41 
 Table of Contents 
ix 
III-18. Prop-1-yn-1-yl Benzoates as Helix Mimetics ........................................................... 42 
III-19. Propargylamine-Based Mimetics of α,α- and α,β-Dipeptides .................................. 45 
III-20. Propargylamides rearrange to Enimines ................................................................... 51 
III-21. Conclusion ................................................................................................................ 53 
III-22. References (29-131) .................................................................................................. 53 
IV Propynyl-Aryl Scaffolds as Turn Motif Mimetics .............................................................. 60 
IV-1. The Concept of Turn Motif Inducers .......................................................................... 60 
IV-2. Structural Turn Motif Mimetics .................................................................................. 62 
IV-3. Propargyl-aryl Architectures as Turn Motif Mimetics ............................................... 66 
IV-4. Naphthoate-Based Turn Mimetics .............................................................................. 66 
IV-5. Biphenyl-Based Hairpin Mimetics ............................................................................. 68 
IV-6. Smart Azobenzene-Based Turn Mimetics .................................................................. 71 
IV-7. Hydrazines and Hydrazones induce Backbone Bending ............................................ 74 
IV-8. Conclusion .................................................................................................................. 76 
IV-9. References (132-169) .................................................................................................. 77 
V Structure-Activity Relationship of Propargylamine-Based HDAC Inhibitors ..................... 80 
V-1. Peptidomimetics as HDAC Inhibitors .......................................................................... 80 
V-2. Synthesis of Inhibitors from Peptidomimetics ............................................................. 82 
V-3. SAR of HDAC Inhibitors ............................................................................................. 83 
V-4. References (170-194) ................................................................................................... 84 
VI Peptidomimetics as RGD-Mimetics .................................................................................... 87 
VI-1. Design of mechanistic Peptidomimetics ..................................................................... 87 
VI-2. Preparation of RGD analogous Class B modified Peptides ........................................ 90 
VI-3. Biological Evaluation of novel RGD Mimetics .......................................................... 93 
VI-4. Conclusion .................................................................................................................. 96 
VI-5. References (195-214) .................................................................................................. 96 
VII Summary and Perspectives ................................................................................................ 99 
IIX Experimental Part ............................................................................................................ 105 
Table of Contents 
x 
IIX-1. General Methods and Materials .............................................................................. 105 
IIX-2. Propargylamides .......................................................................................................... 108 
IIX-3. Peptidomimetics .......................................................................................................... 108 
IIX-3. a) ortho-Substituted Peptidomimetics (26-27) ........................................................ 108 
Catalyzed Hydrocarboxylation of Propargylic Derivatives (28-29) .................................. 122 
IIX-3. b) Oligomerization (30-35) ..................................................................................... 123 
IIX-3. c) Peptidomimetics from meta-Substituted Aromatics (36-44) .............................. 126 
IIX-3. d) para-Substituted Peptidomimetics (45-46) ......................................................... 151 
IIX-3. e) Heteroaromatic Peptidomimetics (47-50) ........................................................... 161 
IIX-3. f) Oligomerization to access Helix Mimetics (51-60) ............................................. 171 
IIX-3. g) Triazole-Based Peptidomimetics (61-63) ........................................................... 184 
IIX-3. h) Synthesis of Olefin Halides (64-72) .................................................................... 191 
IIX-3. i) Hydroalkynylation of Propynoates (73-75) ......................................................... 194 
IIX-3. j) Propargylamide-Enimine Rearrangement (76-78) ............................................... 212 
IIX-3. k) UV/Vis Spectra, pH-Dependence and Photoisomerization Experiments ............ 216 
IIX-3. l) CD Spectroscopy ................................................................................................. 220 
IIX-3. m) Molecular Dynamics (MD) Simulations ............................................................ 223 
IIX-3. n) X-ray Crystal Structure Analysis ........................................................................ 231 
IIX-3. o) References (215-236) .......................................................................................... 262 
IIX-4. Propynyl-Aryl Scaffolds as Turn Motif Mimetics ...................................................... 264 
IIX-4. a) Halogenated Naphthoate Derivatives (91-92) ..................................................... 264 
IIX-4. b) Biphenyl-Based Turn Motifs (93-94) ................................................................. 266 
IIX-4. c) Introduction of Peptidomimetics into Peptides (95-97) ...................................... 270 
IIX-4. d) Smart Azobenzene-Based Turn Mimetics (98-101) ........................................... 280 
IIX-4. e) Propargyl Hydrazides (102-106) ......................................................................... 288 
IIX-4. f) Conformationally relevant 1H NMR Shifts ......................................................... 295 
IIX-4. g) UV/Vis Spectra .................................................................................................... 298 
IIX-4. h) Circular Dichroism Spectra ................................................................................. 300 
 Table of Contents 
xi 
IIX-4. i) X-ray Structure Analysis ...................................................................................... 301 
IIX-4. j) References (237-247) ........................................................................................... 305 
IIX-5. Peptidomimetics as HDAC Inhibitors ......................................................................... 306 
IIX-6. Peptidomimetics as RGD-Mimetics ............................................................................ 306 
IIX-6. a) Synthesis of Aromatic Halides (120-124) ........................................................... 306 
IIX-6. b) Azides in Aspartic Acid Derivatives (125-126) .................................................. 310 
IIX-6. c) Synthesis of Peptidomimetics 127-132 by Click-Reactions ............................... 315 
IIX-6. d) Cleavage of Protective Groups to obtain RGD Mimetics 133-137 .................... 322 
IIX-6. e) Chromatograms of Samples 133-137 for the Affinity Assays ............................ 326 
IIX-6. f) Integrin Binding Assay ........................................................................................ 329 
IIX-6. g) Cell Adhesion Assay ........................................................................................... 331 
IIX-6. h) Docking Studies .................................................................................................. 333 
IIX-6. i) X-ray Structure Analysis ...................................................................................... 337 
IIX-6. j) References (248-263) ........................................................................................... 338 
Appendix ................................................................................................................................ 339 
 
 
I-1. Abstract 
1 
I Structure and Objectives  
I-1. Abstract 
In medicinal chemistry, the importance of peptidomimetics as small-molecular, orally 
bioavailable PPI disruptors increases with the structural elucidation of PPI interfaces. 
However, the design of peptidomimetics, which accurately represent the peptide-template 
requires a sophisticated diversity of structural devices and reactions. In this thesis, a 
versatile peptidomimetic scaffold consisting of 3-amino-prop-1-yn-1-yl-benzoates is 
contributed. This structure is obtained by connection of enantiomerically pure 
propargylamides with halo-benzoates by Sonogashira cross-coupling. To access a variety 
of side chains, an array of propargylamides is prepared asymmetrically, comprising all 
kinds of functional groups (Chapter II).  
Variation of the aromatic substitution pattern, application of heteroarenes and olefins (by 
hydroalkynylation of propynoates) in the C-terminal moiety enables the introduction of 
versatile side chains and a well-defined curvature in the backbone. Conformational 
preferences are analyzed by NMR- and CD spectroscopy, MD simulations and X-ray 
crystal structure analysis. Oligomerization of the peptidomimetic scaffolds is performed to 
investigate their properties as structural helix mimetics. Additionally, interesting dipeptide 
analogous peptidomimetics with unique properties are presented (Chapter III).  
Particularly rigid peptidomimetic structures based on naphthalene-, biphenyl-, azobenzene- 
and hydrazine scaffolds direct N- and C-termini into the same direction and are therefore 
applied as sterically enforced turn motif mimetics. Their introduction in peptide chains to 
induce a hairpin formation is studied by 1H NMR spectroscopy, temperature coefficient, 
CD spectra and X-ray structure analysis (Chapter IV).  
para-Substituted peptidomimetics are applied as isosteres of the natural HDAC substrate 
(e.g. acetylated lysine). By functionalization with a hydroxamic acid, potent HDAC 
inhibitors can be generated. From a SAR study, interesting information on the influence of 
the aromatic, the side chain and its configuration on the affinity are derived (Chapter V).  
An arginine analogous propargylamide is linked to different carboxylate moieties by Click 
reactions giving alkynylarene-, triazole- and amide-based spacers with a similar size as the 
RGD sequence. These novel RGD isosteres are evaluated by docking experiments, as well 
as a competitive ELISA based assay (Chapter VI).  
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II Asymmetric Synthesis of Propargylamines as Amino Acid Surrogates [1].  
V SAR of Propargylamine-Based HDAC Inhibitors [2].  
 
II Asymmetric Synthesis of Propargylamines as Amino Acid 
Surrogates 
This chapter is a summary of the results, published in 2017 in the article “Asymmetric 
synthesis of propargylamines as amino acid surrogates in peptidomimetics” (appendix) [1].  
While amino acids with a terminal alkyne in the side chain are well-known due to their 
antibiotic effects [3], the synthesis of analogs with a terminal alkyne instead of the carboxy 
group is still tedious. This scaffold is called propargylamines. Propargylamines play an 
important role as substructure of diverse active pharmaceutical agents. Exemplarily, 
selective MAO-B inhibitors with neuroprotective properties (Selegilin) have been 
developed [4] and used in the clinical treatment of Alzheimer’s disease [5], as well as to 
target mitochondrial pathogenic processes in the treatment of ageing and age-related 
neurodegenerative diseases [6]. In other propargylamine derivatives, psychoactive 
properties have been reported [7]. Additionally, a very important feature of such terminal 
alkynes is their unique versatility as building blocks in organic and medicinal chemistry. 
Their chemistry involves various highly selective reactions, e.g. [3+2]-cycloadditions with 
nitrile oxides [8], azides and other isoelectronic functional groups [9,10], Sonogashira 
cross-coupling [2], thiol-yne reactions [11], Diels-Alder reactions [12], intramolecular 
Pauson-Khand reactions [13] and gold-catalized azetidine-3-one formations [14]. All these 
reactions can be performed with achiral N-Boc-propargylamide 1.  
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Figure 1. Comparison of the reactivity of amino acids with structurally related designed 
propargylamines.  
 
The unique reactivity of propargylamines allows the preparation of various potentially 
bioactive scaffolds. Hence, the enantioselective synthesis of versatile amino-CHR-alkyne 
building blocks in analogy to natural amino acids has stimulated various drug-design 
projects.  
In preliminary works, propargylamines have been synthesized using the Corey-Fuchs or 
the Seyferth-Gilbert homologation of enantiomerically pure -amino acids [15,16]. 
However, racemization and incompatibility with various functional groups limited the 
broad application of these strategies.  
In this work, a de-novo approach for the synthesis of enantiomerically pure 
propargylamines is reported as recently published in the course of this work [1]. The 
synthesis of N-propargylsulfinamides 6 started with the Lewis-Acid mediated condensation 
of Ellman’s chiral sulfinamide 2 with an aldehyde 3a-u under typical imine-formation 
conditions [17–20]. Diastereoselective addition of trimethylsilylethynyl lithium to the 
purified imines 4a-u under optimized conditions [13,21–25] gave the TMS-alkynes 5a-u, 
which were desilylated in common procedures [26–28] to form diastereomerically pure 
N-propargylsulfinamides 6a-x (Figure 2).  
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Figure 2. Asymmetric synthesis of N-protected propargylamides 6a-x. The side chains are 
classified according to their reactivity, properties and functional groups into aliphatic, polar,  
acidic, electron withdrawing substituents  in C -position, aromatic, electron withdrawing 
substituents in C-position, halogenated, basic,  (non-)proteinogenic and side  chain protected  
groups. Annotations show the analogy to  proteinogenic amino acids. Side chains shown in 
Figure 2 refer to synthesized N-propargylsulfinamides 6 . However, the substituent of a few 
precursors 3-5  differ in exceptional cases: 3h-5h, the alcohol function was TBDMS-
protected. Precursors 3r-5r  were converted into propargylamides 6r-t  and 6x. Precursors 3-
5u were converted into propargylamides 6u-w .   
 
While propargylamides 6a-g with aliphatic residues are directly accessible by this 
approach, polar and acidic substituents in the side chain of compounds 6h-l have to be 
carefully protected or masked to prevent side reactions.  
Electron withdrawing groups adjacent to the imine acidify the respective proton of 
sulfinylimines 4 and result in a competition between nucleophilic addition and 
C-deprotonation during the reaction of imine 4m and trimethylsilylethynyl lithium. As a 
result, the reported method is not appropriate for the synthesis of propargylamides 6 with 
electron withdrawing substituents in C-position. However, if an electron withdrawing 
substituent is located at the C-atom of 5, extremely mild desilylation-conditions have to 
be employed to prevent the irreversible base-catalyzed enimine rearrangement 
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(Chapter III-20) of propargylamides 6n-q in alkaline milieu. As electron withdrawing 
groups also increase the electrophilicity of the imino moiety 4n-q, addition of water as well 
as a ligand transfer from the Lewis acids AlMe3 and Ti(O
iPr)4 to the imine 4p has been 
observed.  
To introduce basic substituents into the side chain, azides 4r and 4u were used as central 
intermediate, which are stable under the conditions of the nucleophilic addition. 
Unexpectedly, an intramolecular Huisgen reaction (Figure 3) occurred without any catalyst 
at room temperature even in the presence of the TMS group. The azides 5r,u and 6r,u 
reacted to form bicyclic triazoles 7r,u and 8r,u as side products, which dramatically 
reduced the yields of propargylamides 6r and 6u.   
 
Figure 3. Side reaction, occurring in the synthesis of propargylamides 6r,u with an azide in 
the side chain. a) Observation of a remarkable  non-catalyzed low-temperature Huisgen  
reaction. b) X-ray crystal structure of cyclization product 7r.   
 
The intramolecular Huisgen reaction can be completely suppressed, if azides 5r and 5u 
were reduced with PPh3 immediately after the nucleophilic addition of 
trimethylsilylethynyl lithium. Surprisingly, this reduction also lead to complete removal of 
the TMS group affording propargylamides 6s and 6v. Cleavage of the TMS group could 
never be realized under these reaction conditions with silylalkynes 5 bearing aliphatic side 
chains (e.g. 5f). Therefore it is assumed, that an intramolecular interaction of the TMS 
group and the intermediate phosphorus ylide, which is formed as intermediate in the 
Staudinger reaction, induces this cycloaddition.  
In this chapter, the asymmetric de-novo synthesis of a set of 24 N-propargylsulfinamides 
6a-x is described. The synthesized propargylamides 6 contain aliphatic, polar, acidic, 
aromatic and basic functional groups in the side chain. Some side reactions occurring 
during the synthesis of compounds with particular residues were analyzed in detail. The 
References (1-28) 
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side reactions include the competing deprotonation of imine 4m, the base-catalyzed 
enamine rearrangement of propargylamides 5n-q and 6n-q, the ligand transfer from Lewis 
acids to imine 4p and the intramolecular Huisgen reaction of 5r,u and 6r,u. 
Propargylamides 6 were designed as analog of proteinogenic and non-natural amino acids 
and represent the basis of the peptidomimetic scaffolds described in the following 
Chapters III-VI.  
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III Peptidomimetics  
The propargylamides, presented in Chapter II, inaugurate the design of versatile molecular 
scaffolds, based on the unique reactivity of the alkyne moiety. Using the Sonogashira cross-
coupling or the copper-catalyzed 1,3-dipolar cycloaddition facilitates the converging 
composition of complex structures. In this chapter, the propargylamine moiety is regarded 
as the N-terminus of a peptidomimetic. The additional aromatic or olefinic moiety of the 
molecule bearing a carboxylic acid at various positions represents the C-terminus of the 
peptidomimetic. As both the propargylamine- and the carboxy moiety are formed 
independently, a considerable diversity of peptidomimetic entities can be achieved. In the 
following, the newly designed peptidomimetics will be grouped according to their 
structural elements bearing the carboxy moiety: alkynylarenes with different substitution 
patterns, alkynylalkenes and triazoles. Side reactions, rearrangements and reasonable 
conformational preferences of the new structures are discussed, as well as possible 
applications as photosensitive backbone, aspartam analogues or hydrogel inducer.  
 
III-1. Concept and Definition 
Peptide-based active compounds have frequently proven their high affinity and selectivity 
towards all kinds of peptides, serving as antagonists, agonists or protein-protein interaction 
(PPI) disruptors. However, the big size and high polarity of peptide-based drugs are 
unlikely to comply with Lipinski’s guidelines for oral application [29]. Furthermore, their 
numerous amide bonds imply inconvenient pharmacodynamic properties, as they are 
flexible and prone to digestion by proteases. The application of peptidomimetics is still the 
most common concept to circumvent drawbacks and maintain the activity of peptide-based 
drugs. Therefore, structural elements are introduced to increase proteolytic stability, to 
reduce the degrees of freedom, to lock convenient conformations and to reduce size and 
polarity to enable cell-permeation.  
As several different design approaches are pursued in Medicinal Chemistry [30], the 
definition and classification of peptidomimetics is inconsistent in literature over the past 40 
years [31]. Early definitions rather focus on small molecular scaffolds, which arrange their 
functional groups in 3D space analog to the topology of the active conformation of a peptide 
[32]. More recent considerations distinguish between small-molecule peptidomimetics, 
which only mimic a local part of a protein and proteomimetics, which imitate larger parts 
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of a protein [33]. As functional peptidomimetics (type II mimetics, see chapter III-3) 
interact with their target structure differently than native peptide ligands [32], their rational 
design is rather difficult. Therefore, functional peptidomimetics lost their impact in the 
early 21st century, remaining completely unmentioned in most publications and even 
excluded from some recommended definitions [34,35]. As the relevance of 
peptidomimetics in the field of influencing protein-protein interaction (PPI) increased, 
Azzarito et al. emphasized the imitation of secondary structural elements, like helix 
mimetics, turn mimetics and foldamers [36]. Taking all approaches in peptidomimetic 
design and classification into account, current definitions are very broad, covering all 
molecules, that are designed to mimic the interaction potential of natural peptides 
[31,37,38]. Due to different structural features, interaction mechanisms and design 
principles, it is rather difficult to come up with a consistent definition and classification of 
peptidomimetics.  
 
III-2. Rational Design Principles 
The large pool of established lead structures allows various approaches to design 
peptidomimetics [30]. The benefit of each design approach complies with the desired 
mechanism of action. Akram et al. recently formulated a rational strategy for the 
identification of lead structures [37], which was completed by the hierarchical principle for 
chemical modifications and abstractions by Trabocchi and Guarna [38] (illustrated in 
Figure 4).  
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Figure 4. Systematic approach for the rational design of peptidomimet ics as active 
compounds. The concept for lead structure identification was outlined by Akram et al .  [37]. 
The chemical modifications have been summarized by Trabocchi and Guarna [38]. The 
workflow is chronological and classified by the operating scientific  fields. The result of 
each operation defines the next work step.   
 
The acquired PPI contact region can be identified using biomolecular techniques, like 
protein arrays, two-protein hybrid interaction systems, tandem-affinity purification coupled 
mass spectrometry, pull-down assays with bait proteins or co-immunoprecipitation 
experiments [37]. High-throughput screening of peptide libraries for possible lead 
structures is helpful to find effector candidates, which are further characterized by ligand 
binding assays like Surface Plasmon Resonance (SPR). In current approaches, the 
employment of chemogenomics helps to organize the scanning of chemical libraries much 
more efficiently [39]. Computational methods, like molecular modelling or docking 
experiments allow an evaluation of the interaction potential of the new lead structures with 
the PPI interfaces [40]. If available, X-ray crystal structures of drug-protein complexes add 
valuable information on the desired pharmacophores of the lead structure.  
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To construct peptidomimetics with improved stability and pharmacodynamic properties, 
an identified peptide-based lead compound is processed in a series of chemical 
modifications [38]:  
1) Size Reduction: Individual amino acids are eliminated, if this doesn’t affect the 
peptides affinity. Size reduction often leads to a loss of selectivity.  
2) Alanine Scan: Single amino acids are replaced by alanine. This procedure leads to 
the identification of key amino acids which are essential for the biological activity.  
3) D-Amino Acid Scan: Replacement of natural L-amino acids by D-amino acids will 
give information about biological activity and proteolytic stability.  
4) N-Methylation: N-methylation of the backbone amides will give information about 
the importance of a particular H-bond donor property of a particular peptide. The 
nonessential amides are substituted by isosteres.  
5) Conformational constraints: Cyclization by disulfide bridges, lactams or connection 
of N- and C-terminus are possibilities to lock certain conformations. If such a 
constraint results in promising biological activity, further non-peptidic structural 
elements leading to similar conformations will be incorporated in order to further 
improve the activity.  
In 1st generation peptidomimetics, the flexibility of all segments is preserved. They are 
accessed by either chemical modifications of the peptide template, or small fragments like 
D-amino acids, non-proteinogenic side chains or flexible amide bond isosteres are 
introduced [30]. The 2nd generation peptidomimetics comprise rigid structural elements, 
that are introduced in the side chains, as well as in the backbone of the existing scaffold 
[41]. These conformational constraints are chosen on the basis of the available knowledge 
about the spatial 3D topology of the bioactive conformation using X-ray crystal structures 
of protein-ligand complexes as well as preliminary SAR studies [38]. The more abstract 
new molecular scaffolds become, the more elaborate is their de novo synthesis. Fortunately, 
current literature compiles a plethora of useful frameworks, structural elements and 
isosteres of functional groups. Moreover, several selective chemical operations are reported 
to form the designed scaffolds and connect them with the peptide framework in order to 
end up with the desired conformation.  
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This chapter contributes convenient structural devices as well as corresponding synthesis 
concepts to the established pool of molecular fragments that are fit for the chemical 
abstraction of peptide-based effectors.  
 
III-3. Fusion of current Peptidomimetic-Classifications 
The growing diversity of peptidomimetics in drug design resulted in classification 
according to their structural features, design strategies, abstraction from the native peptide 
interaction with the target protein. Most publications still use the historic chronological 
typification defined by Ripka et al. in 1998 [32]. Pelay-Gimeno et al. recently considered 
this typification too general to assign the current approaches or to visualize the abstraction 
from the parent peptide sufficiently. Consequently, they proposed an updated classification 
[31]. The overlaps of both grouping approaches suggest distribution of Ripka’s types into 
the subclasses introduced by Pelay-Gimeno et al. (Figure 5).  
 
Figure 5. Fusion of Ripka’s historical (yellow) and Pelay -Gimeno’s (blue) updated 
classification of peptidomimetics. Exemplary structures are selected to illustrate the concept 
systematically. Comments in green refer to the side chains and modifications. C omments in 
red refer to the backbone and its modifications.  
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Type I, Structural- or Peptide Backbone Mimetics 
Class A, Modified Peptides are short amino acid sequences, which differ from the parent 
peptides only by exchanged functional groups in the side chains, amino acid configuration, 
replacement of single atoms in the backbone as well as alkylation of the secondary amide 
or the C. Peptidomimetics with such modifications are able to replicate the 3D topology 
of the native peptide and stabilize conformations analog to their secondary structure by 
cyclization via side chains or backbone [31].  
Class B, Modified Peptides and Foldamers are Class A peptidomimetics with major 
structural abstractions in the side chain and the backbone is no longer related to an amide. 
Class B peptidomimetics are rigidified by constraints to align the side chains in orientations 
similar to those of the native peptide. Foldamers such as - and -peptides and peptoids 
are also included in Class B peptidomimetics [31].  
 
Type II, Functional Peptidomimetics are small non-peptide compounds characterized 
predominantly by their effects on the target protein [36]. Therefore, a structural 
classification and a rational design are unpractical. Usually, functional peptidomimetics 
interact with the same target protein as the natural peptide, but in a different manner. It is 
not necessary that all PPI are featured by the functional type II peptidomimetic. Even 
allosteric ligands of a target protein belong to the type II peptidomimetics, as confirmed by 
site-directed mutagenesis of the receptor [35]. As type II peptidomimetics cannot be 
structurally defined or categorized, they are excluded from the updated classification of 
Pelay-Gimeno (Figure 5).  
 
Type III, Ideal or Topographical Peptidomimetics 
Class C, Structural Mimetics are novel, nonpeptidic compounds, with an arrangement of 
side chains participating in the PPI, in an analogous manner to the native peptide. 
Secondary structural elements such as helices are imitated partially by Class C 
peptidomimetics [31].  
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Class D, Mechanistic Mimetics are small nonpeptidic compounds, with functional groups 
not related to proteinogenic side chains. Despite different side chains, the PPIs of the native 
peptide are imitated accurately [31]. Usually, mechanistic peptidomimetics are detected by 
screening of compound libraries, in silico screening of virtual libraries or by SAR 
optimizations of Class C peptidomimetics [42].  
 
Type IV, Non-Peptide Mimetics 
The type of non-peptide mimetics has been added by Kharb et al. [35] and comprises type 
I peptidomimetics with additional PPIs not covered by the native peptide. They can be 
designed by Group Replacement Assisted Binding (GRAB). As Type IV peptidomimetics 
are only characterized by their interaction potential with the target protein, they can be 
derived from all four classes A-D of structural devices.  
Whereas Class A peptidomimetics are based on peptide templates, the design of Class B-D 
peptidomimetics requires an extensive pool of structural devices, containing functional 
groups imitating the peptide side chains. Moreover, the building blocks should allow an 
easy coupling to the peptidomimetic framework. In order to select appropriate building 
blocks to imitate the secondary structure of the parent peptide, a deep knowledge about 
their conformation is essential. In this chapter, a novel concept for the preparation of Class 
B-D peptidomimetics is presented in order to expand the options to imitate secondary 
structure elements for a Medicinal Chemist.  
 
III-4. Modification of Amino Acids 
Incorporation of particularly modified amino acids into the active part of a peptide is a 
simple option to optimize PPIs. Such Class A peptidomimetics can be quickly prepared by 
solid phase organic synthesis or biochemically by using engineered DNA with installed 
mutated codons for the non-proteinogenic amino acids [43]. Amino acids 9 with non-
proteinogenic side chains can be grouped according to their features (Figure 6).  
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Figure 6. Four groups of side chains of Class  A peptidomimetics. The different groups are 
illustrated with prototypes.  
 
Length variation: To reduce or increase the flexibility of a peptide, variation of the side 
chain length but preserving the natural functional group is a reasonable approach for SAR 
studies. Even though the CH acidity renders phenylglycine derivatives 9a susceptible to 
epimerization, its reduced flexibility is a common feature to replace phenylalanine, e.g. in 
Dengue Virus protease inhibitors [44] or -lactam antibiotics, e.g. ampicillin, cephalixin 
[45]. Examples for peptidomimetics with enhanced side chain lengths are pentahomoserine 
(or 5-hydroxynorvaline, 9b), a biosynthetic precursor of glutamate, which accumulates in 
plants as defensive agent to be mis-incorporated by herbivores [46]. Non-proteinogenic 
amino acids with enhanced side chains are used in drug design, if the molecular scaffold is 
too rigid for a good interaction, as demonstrated in the SAR study of the 
immunosuppressive 5-hydroxynorvaline-2-cyclosporin [47]. Synthetic amino acids 
containing side chains with substituted or protected functional groups are used in peptide 
synthesis, as well as to bind side chain converting enzymes. For example, lysine analogs 
such as 9c are promising antibiotics, binding to riboswitches of Bacillus subtilis resulting 
in the suppression of lysine biosynthesis [48].  
D-Amino acids: Incorporation of D-amino acids, like 9d-e enhances the stability of 
peptides against degradation by ribosomes [49] and facilitates cyclization (e.g. in 
Cilengitide®) [50].  
Modified reactivity: A reasonable approach for the selective conversion of peptides is the 
incorporation of amino acids with unique functional groups in the side chain. Appropriately 
selected substituents in the side chain can undergo orthogonal conversions including Heck 
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reactions (e.g. 9f,i) [51], [3+2]-cycloadditions (e.g. 9g,h) [52], transition metal catalyzed 
cross-coupling reactions (e.g. 9h-j) [53] to mention only few well investigated 
representatives.  
Modified physical properties: Amino acids with halogen atoms in the side chains (e.g. 
9k-m) can be used as tools to enhance the stability of a peptide. F atoms in the side chain 
allow the investigation of conformational properties of the peptides in solution or even in 
vivo by HOESY or 19F NMR spectroscopy [54]. Smart materials are accessed by the 
incorporation of photosensitive groups. Peptides including azobenzene (e.g. 9n) have been 
reported to form smart hydrogels, which collapse upon irradiation [55]. Fluorescent-labeled 
amino acids, such as the BODIPY558-AF labeled amino acid 9o was incorporated into 
calmodulin to monitor its conformational changes via FRET [56].  
Propargylamide 6 based peptidomimetics of all four groups of unnatural amino acid side 
chains are discussed in Chapters III-9 to III-20.  
 
A further concept of Class A peptidomimetics comprises the introduction of additional 
substituents at various positions of the amino acid backbone as a conformational constraint 
or secondary side chain.  
 
Figure 7. Class A peptidomimetics with additional substituents at the N-atom and/or the 
C-atom of an amino acid. X=CH3 ,  NH2 or OH.  
 
Alkylation of the backbone amide eliminates one H-bond donor increasing the 
bioavailability, restricting the rotational freedom around the amide bond [57] and 
supporting secondary structures. This concept has been realized in the turn motif of 
cilengitide® [50,58]. Electrophilic amination the backbone amide is an approach to 
increase the number of H-bond donors leading to improved solubility and rigidity of the 
backbone. A strategy to convert most of the canonical amino acids into hydrazine acids for 
solid phase organic synthesis has been recently reported [59]. Epimerization can be 
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completely prevented by alkylation or fluorination of the C-atom. Helix motifs are 
stabilized in dependence on the constrained dihedral angles  and  [60]. While connection 
of two C-substituents forming a cycle only locks the orientation of the side chain and 
defines the angle , prolin analogs with a bridge between C-atom and the amide N-atom 
also lock the backbone angle  [38].  
 
III-5. Peptide backbone modifications 
Partial substitution of backbone elements is usually performed by the incorporation of a 
dipeptide analog into the peptide. Expected effects of such modifications are enhanced 
proteolytic stability, conformational variance and optimization of protein-inhibitor 
interactions. Larger substituted units constitute an elevated degree of abstraction, 
constituting Class B peptidomimetics.  
 
Figure 8. Options for the exchange of single peptide moieties illustrated by well documented 
representatives [35,38,61,62]. C replacement: Peptoids (X=CH 2), -Aminoxypeptoids 
(X=O), Azapeptoids (X=NH).  
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Reduction of some functional groups in the backbone leads to an increased backbone 
flexibility. Among the isosteric groups of the NH moiety, O atoms resulting in 
depsipeptides or CH2 moieties forming ketomethylene groups are best documented and 
often found in cyclopeptides [35].  
During enzymatic amide hydrolysis the carbonyl moiety is converted into a tetrahedral 
intermediate. Thus, proteolysis can be suppressed by replacement of the carbonyl moiety 
by stable tetrahedral isosteres, imitating the tetrahedral hydrolysis intermediate. Since the 
tetrahedral peptide isoster is tightly bound within the active site of the enzyme but cannot 
be hydrolyzed, the catalytic activity of the enzyme is blocked. This concept of transition 
state mimetics was exploited in e.g. aspartyl protease inhibitors, and comprises numerous 
surrogates, including aminomethylene, hydroxyethylene, dihydroxyethylene, phosphinate, 
thioamide, phosphonamide, sulfinamide and sulfonamide components [63,64]. 
Hydroxyethylurea derivatives were applied as lead compounds for the development of 
-Secretase inhibitors as anti-cancer drugs (e.g. neuroblastoma) [65]. Sulfonamide 
derivatives were oligomerized to form -peptidosulfonamide peptide hybrids. Although 
such oligomers were characterized as potent helix breakers and transition state mimetics, 
their application is limited due to fast racemization and diffraction [64].  
The side chain of an amino acid within a peptide can be attached to the amino moiety 
instead of the C atom, giving achiral peptidomimetics which can fold into chiral helices 
[66] or sheet-structural elements of (N-hydroxy) peptoids (Figure 7) [67]. 
-Aminoxypeptoids exhibit an even stronger preference for cis-amide bonds [68], forming 
probably more stable helices. The macrodipole of a peptoid helix is oriented opposite to 
that of a peptide helix. Combining high stability against proteases with improved cell 
permeability peptoids are promising PPI disruptors. The biologically active oligomers of 
azapeptoids in proteasome inhibitor mimetics [69] represent interesting examples for tumor 
therapy [70]. Moreover, diverse flexible, amphipathic peptoid-oligomers have been 
reported to be effective antimicrobials [71].  
Numerous approaches for the replacement of the complete amide structure have been 
reported. Cyclopropane and alkene moieties are used to lock the dihedral angle  in Ras 
Farnesyltransferase inhibitors . In retro-inverso peptidomimetics, formally the 
stereochemistry is inverted and C- and N-termini are exchanged, enhancing their in vivo 
half-life [74]. Aromatic heterocycles including 1,5-disubstituted 1,2,3-triazoles and 
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tetrazoles resemble the amide in size and length and are used as cis configured amide bond 
replacement, enforcing a reverse turn on a peptide [75,76].  
The most abstract isosteres of peptidic amides are extended amino acids, which allow the 
introduction of peptide-like side chains in a three-dimensionally defined orientation into 
the linker between the amino- and carboxy moiety. Usually, extended amide isosteres are 
classified according to the number n of bonds between two N-atoms: : n=3, 
: n=4, : n=5, : n=6, etc. Polymeric -amino acids are closely related to the native 
peptides consisting of -amino acids. They are able to form well defined secondary 
structures. 1,4-Disubstituted 1,2,3-triazoles, 2,5-disubstituted 1,3,4-oxadiazoles and 
disubstituted butadiynes do not feature any peptide related functional group. Yet, Ko and 
coworkers managed to mimic the spatial 3D topology of native peptides with oligomers of 
these scaffolds [15]. Oligomers of this type are termed foldamers.  
 
III-6. Foldamers 
Oligomeric Class B peptidomimetics with modified CH moiety or replaced or extended 
amide moiety form predictable secondary structures, which are called foldamers. Creative 
modifications of the backbone of foldamers result in many new hydrolytically stable 
secondary structural elements rendering foldamers a promising approach for the 
development of diverse antimicrobials and anti-tumor agents [36]. In the following part, 
foldamers are categorized according to the size of their monomers and the driving force of 
their folding process.  
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Figure 9. A selection of representative foldamers: 1,5 -Disubstituted 1,2,3 -triazolamer 10 ,  
R1= iPr, R2=Me, R3= iBu, R4= iPr [75]. Pyrrolinone 11 , R1=CH2Ph, R2=CH2indole, 
R3=(CH2)4NH2, R4= iPr [77]. -Aminoxy peptoid 12 , R1=CH2CH=CH2, R2=CH(Me)Ph, 
R3=CH2-3,5-dimethoxybenzene, R4=CH(Me)Ph [68]. 1,4-Disubstituted 1,2,3 -triazolamer 13 ,  
R1= iPr, R2=CH2Ph, R3=CH2Ph, R4=Me [78]. Oxetane 14 , R1 -6=Bn [79]. -Amino 
acid/ -Cyclopropane amino acid hybrid 15 , X=Ac-Arg-His-Tyr-Ile-Asn-Leu, R1=CH(Me)Et, 
R2=R3=(CH2)4NHC(NH)NH2, R4=CH2(4-OH-Phenyl) [80]. Oligohydrazide 16 , R1=CH3,  
R2=C8H1 7 [81].  
 
In -foldamers three bonds are between the Ci and Ci+1 atoms of adjacent monomeric 
units. Usually, this distance induces an -helix with a 13-atom-circle, closed by an H-bond 
and 3.6 monomers per turn. The 1,5-disubstituted 1,2,3-triazolamers like 10 are constructed 
of alternating amide isosteres and amides. The 1,5-disubstituted 1,2,3-triazole mimics a cis 
amide moiety bending the backbone and stabilizing a helical turn even in short chains, as 
exemplified by the homochiral tetramer 10. Analogously to -helices, the conserved amide 
moieties form H-bonds between the COi and NHi+4 moieties, which was confirmed by 
X-ray structure analysis [75]. Homochiral pyrrolinone chains are rather rigid and 
compensate the angle of each monomer by antiparallel arrangement forming -strand and 
-sheet secondary structures. Oligopyrrolinones, e.g. tetrapyrrolinone 11 are considered as 
potential inhibitors for the aspartyl proteases renin and HIV-1 protease. Heterochiral 
oligopyrrolinones, like 11, consist of alternating R- and S-configured monomers. The 
angles of parallel arranged monomers add up to a turn and even to helix-like structure. 
Crystal structure analysis of oligomers revealed a cavity in the middle of the helix, which 
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can be described as a nanotube. Tetrapyrrolinone derivatives are currently investigated as 
inhibitors of somatostatin receptors hsst4 an hsst5 [77].  
An increased length of four bonds between Ci and Ci+1 of adjacent monomeric units in 
 foldamers increases the flexibility. As a result, various secondary structures are available 
comprising 6- and 8-ribbons, 10-, 12- and 14-helices as well as miscellaneous 12/14-helices 
with 1.7-3.1 residues per turn. With the amplified pool of secondary structural elements, 
PPIs can be addressed more precisely, enhancing selectivity and affinity of foldamer-based 
PPI disruptors. In contrast to the flexible -peptides and peptoids, NBO, X-ray and NOESY 
experiments prove a preferred cis configuration around the amide bond of -aminoxy 
peptoids like 12. Consequently, -aminoxy peptoids are able to stabilize a helical structure 
with an H-bond between CH2
i and COi+1. Furthermore, the facile synthetic access to 
versatile functional groups in the side chain makes -aminoxy peptoids a promising 
alternative to peptoids and -peptides [68]. The antiparallel orientation of the dipole 
moments of the planar monomers of homochiral 1,4-disubstituated 1,2,3-triazolamers align 
their dipole moments antiparallel, compensat the angle of each monomer. Thus, this type 
of oligomers is able to form stable -strand structures, especially if the side chains consist 
of bulky residues [78]. As HIV protease cleaves 4-5 amino acids in -strand conformation, 
X-ray crystal structures of co-crystallized HIV1-protease and the established ligands L-
700,417 and A-74704 were used as template to design 1,4-disubstituted 1,2,3-triazolamer 
13, a peptidomimetic with a HIV inhibiting activity in micromolar range [82]. NMR and 
MD studies show that the chirality of cis-substituted oxetane -amino acids such as 14 
induces a well-defined left-handed 10-helix, which is stabilized by an H-bond between NHi 
and COi+1 [79].  
Hybrid foldamers combine different building blocks like - and -peptidomimetics. The 
combination of two structural elements adds further secondary structural elements to the 
variety of secondary structures produced by homogeneous foldamers, like the 11- and 
14/15-helix, consisting of 3 or 4.5 monomers per turn, respectively. As the kind and number 
of functional groups in the side chain of Class B peptidomimetics are limited, in most cases 
for synthetic reasons, hybrid foldamers allow the combination of two or more side chain 
pools, enhancing the options for the design of PPI disruptors. For instance, 
-cycloaminopropane hybrid 15 consing of -amino acids and peptidomimetics in an 
alternating fashion forms a stable 13-helix in solution, which combines the proteinogenic 
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side chain diversity of -amino acids with the proteolytic and conformational stability of 
the peptidomimetic [83]. Hybrid 15 has been applied as mimetic of neuropeptide NPY with 
high affinity on Y1 and Y5 receptors [80].  
Whereas the secondary structure of foldamers 10-15 discussed above are stabilized by 
intramolecular H-bonds, the secondary structure arrangement of hydrophobic foldamers 
is arranged by solvophobic forces like -stacking. Even though oligohydrazide 16 forms 
intramolecular H-bonds between Ar-ORi, NiH and COi, these H-bonds are only established 
within a single monomer. These H-bonds induce the backbone curvature in the monomers, 
but do not contribute to the overall folding process of the oligomer. Formation of the helix 
structure is navigated by the parallel arrangement of the hydrophobic aliphatic- and 
aromatic entities. Similar to tetrapyrrolinone 11, a polar, hydrophilic cavity emerges within 
the helix, in which disaccharides perfectly fit. With NOESY spectroscopy, H-bonds 
between the hydroxy-groups of -D-glucose and the carbonyl moiety of the foldamer were 
observed. Moreover, temperature resolved CD spectroscopy indicates an immense 
stabilization of the helix in the presence of -D-glucose in chloroform [81].  
 
Figure 10. Additional hydrophobic foldamers 17-18  designed from extended amide isoster es: 
oligo ethynylarenes 17a , n=2-18, R1=H, R2=CO2(CH2CH2O)3CH3 [84]. 17b, n=18, R1=Me, 
R2=CO2(CH2CH2O)3CH3 [85]. Clickamer 18  [86]. Strongly hydrophilic oligo 5 -amino-
salicylates 19 ,  R=(CH2)4NHC(NH)NH2 [87].  
 
Due to their high lipophilicity, the achiral oligo ethynylarenes 17 require a short 
polyoxyethylene side chain to remain in solution when prolonged. In polar solvents, 17 
folds controlled solely by hydrophobic -stacking forces into a helix, enclosing a cavity as 
described in oligohydrazide 16. The hydrophobic cavity of oligo ethynylarenes like 17a 
can host appropriately sized nonpolar guests in stoichiometric ratio. Nonpolar solvents or 
elevated temperature induce a transition of the helix into a random coil structure [84]. 
Insertion of chiral bicycloheptane- or pinene derivatives into the helix cavity of oligo 
ethynylarenes 17b conducts a defined helix-direction [85]. Similarly, the amphiphilic 
clickamer 18 forms a helix of 8.5 aromatic units per turn in polar solvents [86]. Driving 
force for helix formation are - interactions between the aromatics. Halide ions are 
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stoichiometrically coordinated by an H-bond to the triazole-CH, bending clickamer 18 to a 
half circle around the halide ion and thus inverting the helix. An enhanced chain length 
increases the number of triazoles and thus the positive polarity inside the cavity. 
Consequently, the coordination of halides is strengthened [88]. Basic research on the 
selective hosting of (non-)polar, anionic and cationic molecules in helical cavities has been 
performed in the past years to investigate the potential of foldamers as substrate specific 
catalysts [89].  
The high polarity and thus solvophilicity of the basic side chains of oligo 5-amino-salicylat 
19 has the opposite effect. It inhibits the folding to afford a helix, but induces the formation 
of a -sheet like structure, which inhibits spontaneous fibrilization of amyloids A42 and 
A43. Therefore, foldamers of type 19 are considered as promising approach for the 
treatment of Alzheimer’s disease [87]. As the secondary structure of oligo 5-amino-
salicylates is still under investigation, an unequivocal categorization is not yet possible.  
 
III-7. Structural Helix Mimetics 
The -helix motif occurs in protein-membrane interfaces, DNA binding motifs and in 62 % 
of all PPI interfaces [90], making it a fundamental mimicry-target. While foldamers mimic 
a complete secondary structural element, structural helix mimetics only recapitulate the 
topology of a certain face of the helix template. Their rod-like scaffold aligns in a parallel 
manner to the helix template and presents residues only on one side analogously to the 
helix. Thus, helix mimetics are comparatively small and nonpolar molecules, complying 
possibly with Lipinski’s criteria for oral bioavailability. Design of appropriate structural 
helix mimetics represents a valuable approach for the development of innovative PPI 
disruptors or synthetic antibodies [91]. The concept of helix-mimicry was also observed in 
nature. The natural compounds Sekikaic- and Lobaric acid were identified to interact with 
the dynamic interface of the coactivator complex CBP/p300 in low micromolar 
concentrations [92].  
Thorough investigation of helical PPIs by analysis of X-ray crystal structures from the PDB 
revealed that most helices (60 %) interact with only one face with the complementary 
protein. Simultaneous interactions of two helix-faces was also frequently observed (33 %), 
whereas interactions with three faces is rather seldom (7 %) and mainly occurs in 
membrane proteins. The location of helical hot spot residues reflects the interaction side: 
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i+1 (12%), i+2 (4%), i+3 (10%), i+4 (27%), i+5 (5%), i+6 (4%), i+7 (15%), i+8 (9%), i+9 
(3%), i+10 (4%), i+11 (7%) [90]. The side chains in positions i, i+3/4, i+7 are assembled 
on the same helix side. Therefore, the nature and orientation of these side chains are easy 
to reproduce using non-peptidic scaffolds. In contrast, two-faced helix mimetics require a 
correct arrangement of appropriate residues on opposing sides of the scaffold. In both cases, 
sophisticated conformational constraints are necessary for an accurate orientations of the 
residues [93]. Structural helix mimetics can be assigned to three groups, according to their 
align mechanisms [31].  
 
Figure 11. Types of structural helix mimetics organized according to their align mechanism. 
Exemplary representatives with defined side chains R are given here: Sterically reinforced ,  
terphenyls 20 , R1=CH2 iPr, R2=CH2Ph, R3= CH2 iPr [94]. Teroxazoles 21 ,  R1= Me, R2=CH2 iPr, 
R3=Et [95]. N-Alkylated oligobenzamides 22 ,  R1=Ph, R2=naphthyl, R3= iPr [96]. Hydrogen 
bond guided , 3-alcoxy oligobenzamide ethers 23a ,  X=CH, R1=Bn, R2= -CH2-2-naphthyl,  
R3= iPr [97]. Trispyridylamides 23b,  X=N, R1= iPr, R2= R3=Bn [98]. Trispyrimidonamides 24 ,  
R1=(CH2)4NH2, R2=CH2 iPr, R3=CH2CH2 indole [99].  Covalently constrained ,  spiroligomers 
25 ,  R1=CH2CH2Ph, R2=CH2-(3,4-dichlorophenyl), R3=CH2 iPr, R4=CO2H [100].  
 
Sterically reinforced helix mimetics are characterized by a low energy barrier between 
different conformations, that allows fast conformational interconversion at room 
temperature. Despite the high flexibility, this type of helix mimetics adopts a defined 
conformation by induced fit, i.e. by adaptation of the helix mimetic at the template. Design 
of such helix mimetics requires only information about key residues, but not on their spatial 
3D topology [101]. Terphenyl derivatives (e.g. 20) belong to the earliest helix mimetics. 
The -delocalization of the phenyl rings leads to a parallel alignment of the monomers, 
while steric repulsion results in dihedral angles [102]. As example, rather flexible terphenyl 
20 disrupts the Bcl-xL/Bak interaction (IC50=1.5 M). The side chains of terphenyl 20 are 
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oriented in such a manner to mimic the side chains in position i, i+3/4, i+7 of an -helix. 
Whereas free Bcl-xL is removed by interaction with helix mimetic 20, the unbound pro-
apoptotic Bak-protein induces the programmed cell death. Although terphenyl derivatives 
represent promising lead compounds for the development of anti-tumor drugs, their tedious 
synthesis and low log P value limits their broad application [94]. The more polar 
teroxazoles like 21 were prepared on solid phase. MD studies confirm a planar arrangement 
of the side chains in helix position i, i+3, i+6, as well as a curve in the backbone. Libraries 
of such scaffolds are currently under evaluation as PPI disruptors [95]. A much greater 
diversity of side chains can be achieved by solid phase organic synthesis of N-alkylated 
oligobenzamides such as 22 [103,104]. Oligobenzamides of type 22 orient their side chains 
on one face (-helix residues i, i+3/4, i+7). Representative 22 was designed as anti-cancer 
agent by disruption of the interactions between P53 and HDM2 in low micromolar range 
[96]. However, increase of solubility by addition of polar substituents led to reduced 
activity [102].  
 
Hydrogen bond constrained helix mimetics with the monomers arranged in a parallel 
manner require much higher energy conformational interconversion [93]. The residues of 
3-alcoxy oligobenzamide ethers 23a are oriented analogously to the -helix side chains in 
i, i+3/4 and i+7 position [97]. Large side chain diversity and oligomerization by amide 
bond formation allow a quick composition of compound libraries by solid phase organic 
synthesis [105,106]. However, 3-alcoxy oligobenzamide ether 23a is a far less active 
inhibitor of P53/HDM2 interactions than therphenyl 20 [97]. Investigation of the 
preorganized H-bonds stabilizing trispyridylamides 23b indicates an altered backbone 
curvature than in 3-alcoxy oligobenzamide ether 23a [98]. Target helices could be 
reproduced very well by oligomers composed of a combination of both monomers, 
affording Bak mimetics which inhibit Bcl-XL in nanomolar range [107]. Extensive 
investigation of the conformation of the closely related trispyrimidonamide 24 showed that 
side chain orientation on alternating sides of the backbone by 180° rotation has to be 
expected if no H-bonds link the monomers [99].   
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The backbone of covalently constrained helix mimetics does not show any 
conformational freedom. As it is difficult to match such a structure to a helix template, only 
few examples are conversant. Schafmeister et al. synthesized flexible oligomers on resin, 
which were rigidified by formation of diketopiperazine spiroligomers [108]. The mere 
backbone was first used as a spacer in metal-ligand complexes [108]. However, an -helix 
face (i, i+4, i+8) could be imitated by attachement of nonpolar side chains [109]. Passive 
diffusion of fluorescein-bound spiroligomers into human liver cells was visualized by 
confocal microscopy and fluorescent imaging. These convenient cell permeation properties 
stimulated the design of further spiroligomer. Thus, spiroligomer 25 reacted as mimetic of 
the p53 activation domain to bind to HDM2. Renoval of HDM2 represents a promising 
tumor treatment approach [100]. The probable reproduction of stereochemical PPI aspects 
by chiral helix mimetics is still under investigation [93].  
 
III-8. A Geometric Contemplation of Structure-Design 
In this chapter, novel structural devices for the design of peptidomimetics are developed. 
According to the novel concept, propargylamides 6 (see Chapter II [1]) should be coupled 
with appropriately substituted aromatic halides via Sonogashira cross-coupling. The 
propargylamide represents the N-terminus and the carboxylic acid at the aromatic system 
imitates the C-terminus of a dipeptide. Various side chains can be introduced at the 
aromatic ring (resulting in a locked  angle) and at the propargylic C-atom. While diverse 
amino acid like side chains are introduced into the propargylic moiety geometric properties, 
such as size, distance, angles and conformational degrees of freedom of the peptidomimetic 
scaffold are defined by the kind of the aromatic system and the position of the carboxylic 
acid.  
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Figure 12. Comparison of geometric properties of aminopropynylarenecarboxylic acids with 
analog peptides. a) Size of one segment in comparison to the peptide. b) Introduction of a 
defined bending into the backbone in dependence of the substitution pattern of the aromatic 
ring. c) Amino acids based on the arylalkyne framework show certain conformational 
constraints and decreased rotational degrees of freedom.  
 
The peptidomimetic aminopropynylarene scaffold of this work represents a rather rigid 
spacer. The length and backbone bending depend on the substitution pattern of the aromatic 
ring. Some energetically favored conformations can be predicted, as the rotation around 
several bonds is restricted. Free rotation is only possible around the axis between C and 
aryl, referred to as . Aminopropynylarenecarboxylic acid dipeptide analogs comply with 
Lipinski’s rules with respect to lipophilicity (logP < 5) and molecular weight (mw < 500) 
for oral application [29]. Furthermore, hydrolysis of the designed dipeptide analogs is no 
longer possible, since due to the great degree of abstraction from the native peptide 
backbone hydrolysable functional groups are absent. The designed structures belong to the 
Class B dipeptidomimetics with extended amide isoster. Typically, prolongation of such 
monomers by orthogonal Click reactions (here amide formation and the Sonogashira cross-
coupling) leads to defined secondary structure elements, as observed for Class C foldamers. 
Moreover, rigid scaffolds like these aminopropynylarenecarboxylic acids are required in 
the design of topographical type III peptidomimetics, like helix- and mechanistic mimetics.  
Synthetic aspects, compound library formation and properties are discussed for each 
geometric entity.  
III-9. Synthesis of Peptidomimetics with ortho-Substituted Arenes 
28 
III-9. Synthesis of Peptidomimetics with ortho-Substituted Arenes 
Sonogashira cross-coupling of N-propargylamides 6 with 2-haloarenecarboxylic acid 
derivatives 26a-f gave the dipeptidomimetics 27 in varying yields. This strategy was used 
to synthesize a small compound library of 17 peptidomimetics 27a-q including a great 
diversity of side chains and heteroarenes. Since the palladium catalyst PdCl2(PPh3)2 led to 
higher yields of coupling products than the catalysts Pd(PPh3)4, Pd(dppf) and Pd(OAc)2 it 
was used as standard catalyst throughout this work.  
Table 1. Synthesis of a set of diverse peptidomimetics 27a-q by cross-coupling of various 
propargylamides 6  and haloarenecarboxylates 26a-f .   
 
entry propargylamide */*' R 26 27, Yield 
a) 6b (S/S) CH(CH3)2 26b 27a, 68% 
b) 6b (S/S) CH(CH3)2 26a 27b, 85% 
c) 6c (R/R) CH2CH(CH3)2 26b 27c, 97% 
d) 6c (S/S) CH2CH(CH3)2 26a 27d, 78% 
e) 6c (R/R) CH2CH(CH3)2 26d 27e, 0% 
f) 6c (R/R) CH2CH(CH3)2 26e 27f, 18% 
g) 6c (R/R) CH2CH(CH3)2 26f 27g, 10% 
h) 6e (S/S) cyclohexyl 26a 27h, 82% 
i) 6f (S/S) C(CH3)3 26a 27i, 66% 
j) 6f (S/R) C(CH3)3 26a 27j, 19% 
k) 6l (S/S) CH2CH2CO2C(CH3)3 26a 27k, 78% 
l) a 6o (S/R) C6F5 26a 27l, 62% 
m) a 6o (S/R) C6F5 26c 27m, 0% 
n) a 6p (S/S) CF3 26a 27n, 32% 
o) a 6p (S/R) CF3 26a 27o, 52% 
p) 6w (S/S) CH2CH2CH2CH2NHBoc 26a 27p, 20% 
q) 6x (S/S) CH2CH2CH2NHC(=NBoc)NHBoc 26a 27q, 60% 
a The milder base DIPEA was used instead of piperidine.  
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As the iodo substituent is only slightly shielded by the ester moiety in o-position [110], the 
o-substituted benzoates 27a-d with aliphatic side chains were obtained in high yields. In 
order to introduce a dipole moment to peptidomimetics 27 an H-bond accepting heteroatom 
should be introduced into the aromatic system. Thus, propargylamide 6c was reacted with 
the bromopyridines 26d-f. The lower reactivity of bromides is compensated by the 
increased electron withdrawing character of the pyridine ring of 26d-f [111]. However, the 
coordinating character of electron poor pyridine derivatives to Pd0 in alkaline medium can 
poison the catalyst resulting in low yields of 18 % (27f) and 10 % (27g). Although several 
experiments under varied conditions were performed, the bromopyridine 26e did not react 
with the alkynes 6 to yield arylalkynes 27. This result is in good accordance with literature, 
reporting the extraordinarily low reactivity of 2,6-disubstituted aryl halides in Sonogashira 
reactions [110].  
Sterically demanding substituents at the alkyne are considered to be the most serious factor 
to reduce the reaction rate of Sonogashira reactions [110]. As small phosphine ligands are 
recommended to accelerate the conversion rate [110], electron donating PPh3 [112] with a 
low Tolman cone angle of 145° [113] was chosen for the synthesis of the sterically 
demanding compounds 27h-q. Propargylamides 6f and 6p with unlike configuration (S,R) 
of the centers of chirality gave lower yields than the like-configured diastereomers 6f and 
6p with (S,S)-configuration. It is postulated that the unlike diastereomers form more 
shielded complexes with the phosphine ligands.  
 
III-10. A Surprising Intramolecular Hydrocarboxylation Reaction 
Surprisingly, cross-coupling product 27m could not be isolated after the reaction of 
propargylamide 6o with 2-iodobenzoate (26c). Instead, the alkylidenelactone 28 was 
isolated in 27 %. Apparently, the Sonogashira cross-coupling had been successful, but was 
followed by an unexpectedly intramolecular hydrocarboxylation. The free carboxylic acid 
had reacted with the adjacent alkyne to provide lactone 28.  
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Figure 13. a) A Sonogashira  cross-coupling reaction of propargylamide 6o  with 2-iodo 
carboxylate 26c,  in situ  succeeded by a hydrocarboxylation reaction. b) X -ray crystal 
structure of deprotected hydrocarboxylation product 29 .   
 
The X-ray crystal structure of the deprotected amine 29 confirmed the 5-exo-dig cyclization 
forming the benzofurane derivative. Analogous hydrocarboxylation reactions catalyzed by 
CuI and Pd0 on carbon nanotubes have been reported under harsh conditions (100 °C in 
DMF, 3-15 h), giving mixtures of benzofuranone- and coumarin derivatives [114]. As the 
electronic properties of the catalyst determine the regioselectivity, the AuCl catalysis 
selectively induces 5-exo-dig cyclization forming benzofuranones [115], while the 
ReCl(CO)5 catalyst selectively initiates 6-endo-dig cyclization forming coumarins [116]. 
This unexpected domino reaction comprising of a Sonogashira cross-coupling and a 
subsequent hydrocarboxylation reaction under mild conditions is unprecedented.  
 
III-11. ortho-Substituted Peptidomimetics as Foldamers 
Usually, oligomerized Class B dipeptidomimetics with extended amide isosteres fold in a 
predictable manner to adopt a secondary structure [15]. The narrow angle in the backbone 
of scaffold 27 of 75.4° already enforces a turn to the backbone, enhancing the formation of 
a particular foldamer conformation. As dipeptidomimetic 27 has orthogonal protective 
groups at both the N- and C-termini, selective oligomerization by peptide-bond formation 
was performed. Thus, hybrid peptidomimetics 32-35 with different length had been 
prepared and discussed in my preliminary master thesis [117] (Figure 14).  
a) 
b) 
29 
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Figure 14. Oligomerization of dipeptidomimetic 27  with a narrow angle. (a) Aqueous LiOH 
(1 M, 3 eq)/MeOH (1:2), 0  °C, 12 h. (b) HCl (dioxane, 4  M, 4 eq), MeOH (15 mL), 4-8 h, 
rt. (c) TBTU or HATU (3 eq), HOBt or HOAt (2 eq), DIPEA (6 eq), DMF (2-6 mL), rt,  16 h.  
 
The solubility of non-polar scaffolds such as 27 decreases with increased number of 
monomers (e.g. proceeding prolongation), reducing the yield of subsequent reactions. 
Therefore, further elongation of tetramer 35 turned out to be impossible under the given 
conditions. The aggregation, which lead to precipitation of the tetramer resulted from 
intermolecular interaction rather than intramolecular folding. Nevertheless, CD spectra of 
monomer 27c and dimer 32c at different concentrations indicate a folding which is not 
associated with aggregation (Diagram EP8a,b Experimental Part). Nelson et al. [84] and 
Prince et al. [85] reported a promising approach to circumvent similar aggregations by 
introduction of a polyoxethylene unit at the aromatic ring. The amphiphilic foldamers 
maintain solubility, while solvophobic interactions of the nonpolar scaffolds led to 
nanotube formation [84] with a cavity for nonpolar guest molecules [85]. Conversion of 
peptidomimetic scaffolds 27 into solvophobic foldamers with amphiphilic properties 
induced by polyoxyethylene substituents at the aromatic rings will be the subject of 
successive investigations.  
 
III-12. Conformational Preference  
Although the conformation of oligomers 32-35 could not be determined unequivocally, the 
torsion angles of monomers should induce a secondary structure of the oligomers as 
observed for peptides [118]. The dihedral angles of dipeptidomimetics L-27n and D-31o in 
the solid state were determined by X-ray crystal structure analysis. These dihedral angles 
were used to validate MD simulations resulting in energy profiles of each torsion. The 
energy profiles were used to detect convenient dihedral angles and deduce constraints 
analogously to the work of Krieger et al. [68].  
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Figure 15. Comparison of the torsion angles  of peptidomimetics 27 .  a) Model compound, 
used for the MD calculation of the energy profiles of the respective torsion angles. The 
angles observed in the X-ray crystal structures are marked with an asterisk (L -27n) and a 
triangle (D-31o)  in the colors,  corresponding to the respective ang les. b) X-ray crystal 
structure of compound L-27n (1 = -156°,  = -107°,  = 57°,   = 75°,  = − and 2 
= -180°) and c) X-ray crystal structure of N-terminal deprotected D-31o  (1 n.d.,  n.d.,   
= 156.9°,   = °,  = −  and 2 = -178°) (for more details, see Diagram EP14 and Table 
EP1 Experimental Part).  
 
As expected, the energy profiles of  and  suggest a preference of trans-configured 
amides, as well as a stretched arrangement of the N-terminal moiety (large ). As steric 
repulsions exceed electronic interactions in the MMFF94, calculation of  was not very 
accurate. However, the orientation of the ester moiety in the crystal structure increases the 
backbone bending giving hints for solvophobic folding. The narrow backbone angle of 
dipeptidomimetic 27 induces a turn motif into the chain. Since the axis between the C and 
the arene moiety is rotatable without any restriction, the dipeptidomimetic backbone 
contains at least one flexible substructure.  
 
III-13. Synthesis of meta-substituted Aminopropynylbenzoates  
Versatile substitution patterns are possible, when the carboxy moiety is in meta-position of 
the arene ring in the peptidomimetic. Under analogous Sonogashira cross-coupling 
conditions, a compound library could be prepared (Table 2) comprising compounds with 
diverse side chains at the propargylamide moiety, heteroarenes as well as side chains at the 
(hetero)arene opening a new dimension of diversity.  
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Table 2. Newly prepared peptidomimetics, based on meta-substituted arenes. The library 
includes compounds 40a-i with diverse protective groups at the C-terminus, disubstituted 
pyridine derivatives 41a-c and benzoates 42a-d and 43a-c with different substituents in 4 - 
and 6-position, respectively.  
 
a Standard base piperidine was substituted by mild DIPEA.  
 
In accordance to the hypothesis of Schlitz and Plenio on the size dependence of alkyne 
substituents on Sonogashira reactions [110], -dibranched propargylamides 6b,e reacted 
with aromatic halides 36a,b in slightly lower yields than -monobranched propargylamides 
6c,d. Despite the prevailing opinion the sulfur-containing side chain of propargylamide 6d 
did not reduce the conversion by catalyst poisoning. In contrast to 2-iodobenzoic acid 26c, 
3-iodobenzoic acid 36c reacted as expected without subsequent lactone formation to 
provide peptidomimetic 40e in 52 % yield. This yield is lower compared to the yield of 
ester 40b (98 %).  
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Fluorinated amino acid analogs have been incorporated in foldamers as 19F NMR probes to 
investigate their folding and helix inversion behavior [119]. Moreover, enhanced stability, 
lipophilicity and dipolar moment at comparable size render fluorinated amino acid analogs 
important tools in drug design [120]. Consequently, considerable effort was spent on the 
synthesis of fluorinated dipeptidomimetic building blocks 40f-i. The Sonogashira reaction 
of alkyne 6p containing a trifluoromethyl moiety with ester 36a (45 %) and amide 36d 
(17 %) showed that aromatic amides obstruct conversion. Catalyst coordination or reduced 
solubility may account for the lower yield of amide 40i.  
Nicotinate and picolinate-based peptidomimetics 41a-c were designed to enhance the 
dipole moment of the hydrophobic scaffold. In particular, nicotinate based compounds 
41a,b contain a dipole moment antiparallel to the amide moiety. The rather high yields (58-
90 %) of the coupling products 41a-c indicate a compensation of the lower reactivity of 
aromatic bromides 37a,b by the reduced electron density in the pyridine rings.  
In order to further modify the electronic properties of the peptidomimetics, additional 
functional groups were introduced in 4- (42) or 6-position (43) as side chain isosteres with 
a locked orientation . In particular, ester (42a) and amino moieties (42b, 43a,b) were 
selected, as these groups allow the introduction of further versatile substituents by amide 
coupling. The coupling products can be further developed in the direction of helix mimetics 
20, 22 and 23 (see Chapter III-18.). As example of the versatility of this concept, side chains 
with modified physical properties were installed. Smart peptidomimetic 42d represents a 
photoswitchable compound changing the orientation of it’s terminal phenyl moiety upon 
irradiation with UV light. Protonation of azobenzene 42c with an additional amino moiety 
in para-position leads to a bathochromic shift of UV absorption, rendering peptidomimetic 
42c an UV/Vis active pH indicator (Figure EP1, Experimental Part). Titration experiments 
and UV/Vis spectra (Diagram EP1, Experimental Part) verify a narrow pH sensitivity in 
physiological milieu (max(pH<7.8) = 448 nm, max(pH>8.2) = 469 nm). Incorporation of 
peptidomimetic 42c into short peptides could give valuable information on the pH value of 
the environment of the corresponding peptide area. Although substituents in ortho-position 
of the halide are generally well tolerated in Sonogashira reactions [110], reactions with 
azobenzenes 38c,d led to considerably reduced yields of 7-16 %.  
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Introduction of substituents in ortho-position of the ester, directing towards the C-terminus, 
of the complete peptide influences the conformation of the adjacent amide and therefore 
the backbone orientation. Therefore, amino moieties were attached to the benzoate, as 
exemplified with peptidomimetics 43a,b. The introduced amino groups will enable 
connection of the peptidomimetic to versatile further structural elements. The yield of the 
Sonogashira reaction depends only on the protective group of the carboxylate.  
 
 
 
 
 
 
 
 
 
 
III-14. Smart sterically enforced Helix Mimetics 
Photoisomerizing azobenzene groups in peptide side chains were used to control the 
hydrogel-sol transition of amphiphilic Class A peptidomimetics by irradiation, as only the 
E-configured isomer is able to self-assemble [55]. The introduction of azobenzene units 
into the is a new approach to control the 3D-structure of the backbone by irradiation, as the 
terminal bulky phenyl group of the azobenzene 43c is located close to the C-terminus. To 
investigate the effects of this isomerization, L-proline was linked to the dipeptidomimetic 
43c and the N-terminus was deprotected by acidic methanolysis to obtain the tripeptide 
analog 44.  
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Figure 16. Introduction and effects of a photo -isomerizing side chain adjacent to the C-
terminal amide. a) Synthesis of peptidomimetic 44 . (a) Methyl L-prolinate (2 eq), HOAt 
(3 eq), HATU (2 eq),  DMF/DIPEA (2:1), r t, 16  h, 98 %. (b) HCl (4 M, dioxane)/MeOH (1:3),  
rt, 90 min, 81 % (71 % over two steps). Structures of E-  and Z-44  with marked protons. b) 
Part of the 1H NMR spectrum (4.7-3.6 ppm) of 44  after irradiation for 5  min at 420 nm. The 
multipletts refer to the marked protons of E-44  and Z-44  in reaction scheme 17a) Integration 
of these signals leads to a ratio E/Z-44  of 87:13. c) Part of the 1H NMR spectrum of the same 
sample of 44  after irradiation for 5  min at 350 nm. Integration of the marked signals shows 
a ratio E/Z-44  of 55:45. d) UV/Vis spectra of a sample of 44  in the dark (black curve), after 
irradiation for 5 min at 420 nm (blue curve) and after irradiation for 5  min at 420 nm (red 
curve). e) CD spectra of a sample of 44  in the dark (black curve), after irradiation for 5  min 
at 350 nm (blue curve), after irrad iation for 5 min at 420 nm (red curve) and after a second 
irradiation for 5 min at 350 nm (violet curve) (More experimental details are given in 
Diagram EP2-6 Experimental Part).  
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Although UV/Vis spectra (Figure 16d) indicate complete and reversible E/Z isomerization 
of peptidomimetic 44 (Figure 16a), investigation by 1H NMR spectroscopy (Figure 16b,c) 
proved only E/Z ratio of 87:13 (420 nm) and 55:45 (350 nm). The irradiation cycle was 
repeated 6 times to demonstrate the reversibility of the isomerization. The change of the 
azobenzene configuration was examined by CD spectroscopy (Figure 16e). A significant 
CD was observed in the backbone relevant region (180-300 nm) of the E-azobenzene E-
44, indicating a distinct backbone conformation. However, a CD could not be observed for 
the Z-isomer Z-44 pointing towards a loss of structure. It is assumed, that the bulky E-
azobenzene E-44 restricts conformational interconversions of the adjacent proline, while 
Z-azobenzene allows free rotation rendering dipeptidomimetic 43c with the azobenzene 
scaffold a promising building block for smart sterically enforced helix mimetics.  
 
III-15. Conformational Preference in meta-substituted Peptidomimetics 
Reports about hydrophobic folding of 3-alkynylbenzene oligomers 17 [84,85] led to the 
idea, that hybrid oligomers of peptidomimetic scaffolds 40-43 are capable of similar 
folding. In order to analyze the geometrical properties of the scaffolds 40-43 MD 
simulations were performed. These simulations led to the detection of rotational 
constraints, which were confirmed by X-ray crystal structures of (R)-40d and (S)-41a 
(Figure 17).  
 
Figure 17. Comparison of the torsion angles  of peptidomimetics 40d and 41a .  a) Model 
compound used for the calculation of the energy profiles resulting by rotation around 
particular single bonds. The angles observed in the X -ray crystal structures are marked with 
a pentagon for D-40d and an asterisk for L-41a  in the colors, corresponding to the respective 
angles. b) X-ray crystal structure of compounds D-40d (mirrored angles: 1 = -145°,   
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= -140°,  = -65°,   =  122°,  = − and 2 = 178°). c) X-ray crystal structure of L-41a  
(1 = -156°,  = -107°,   = 66°,   = °,  =  and 2 = -178°) (for more details, see 
Table EP2 Experimental Part).  
 
All dihedral angles (except for ) measured in the crystal structures are in good agreement 
with the energetic minima of the calculations supporting the quality of the force field 
calculations. Only the accurate prediction of  is limited due to overinterpretation of the 
steric repulsion effects. As expected, rotation around the single bonds  of the alkyne is 
completely unobstructed enabling independent orientation of the N- and C-terminal 
moieties. The dihedral angles  and  are estimated to be 0° or 180° defining the curve of 
the backbone. According to this angle hydrophobic folding (==0°) or a stretched 
orientation (==180°) like a helix mimetic are possible. Although the crystal structure of 
40d indicates a folding of the backbone (=0°), the stretched conformation (see 41a) is 
energetically favored. Interestingly, the impact of the stereocenter can be observed in the 
asymmetry of the energy profile resulting from rotation  around the bond between amine 
and C-atom. The impact of chirality in helix mimetics on PPIs is subject to current 
investigations [93].  
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III-16. para-Substituted Arenes 
In 4-(3-aminoprop-1-yn-1-yl)-benzoate based peptidomimetics 46 the C-atom and the 
carbonyl group are linked in a linear manner. A compound library of building blocks 46 
comprising diverse side chains at the propargylamide moiety (46a-j) as well as 
(hetero)arenes in the backbone (40k,l) were synthesized under the same Sonogashira cross-
coupling conditions as described above.  
 
Table 3. Synthesis of a compound library of compounds 46  by Sonogashira  cross-coupling 
of propargylamides 6  with haloarenes 45 .   
 
entry */*'      propargylamide, R= arene 45 46, yield 
a) a - 1 -H 45a, X=I, Y=Me, U=V=CH 46a, 58% 
b) (S/S) 6b -CH(CH3)2 45a, X=I, Y=Me, U=V=CH 46b, 83% 
c) (R/R) 6b -CH(CH3)2 45a, X=I, Y=Me, U=V=CH 46c, 64% 
d) (S/S) 6c -CH2CH(CH3)2 45b, X=I, Y=Et, U=V=CH 46d, 94% 
e) (R/R) 6c -CH2CH(CH3)2 45b, X=I, Y=Et, U=V=CH 46e, 95% 
f) (S/S) 6e -cyclohexyl 45a, X=I, Y=Me, U=V=CH 46f, 66% 
g) (R/R) 6e -cyclohexyl 45a, X=I, Y=Me, U=V=CH 46g, 74% 
h) (R/R) 6j -CH2SCH2Ph 45a, X=I, Y=Me, U=V=CH 46h, 11% 
i) (R/R) 6m -CH2Ph 45b, X=I, Y=Et, U=V=CH 46i, 59% 
j) b (S/S) 6n -Ph 45a, X=I, Y=Me, U=V=CH 46j, 54% 
k) (R/R) 6e -cyclohexyl 45c, X=Br, Y=Me, U=N, V=CH 46k, 2% 
l) (R/R) 6e -cyclohexyl 45d, X=Br, Y=Me, U=CH, V=N 46l, 41% 
a The protective group was Boc instead of tert-Butylsulfinyl.  
b Mild base DIPEA was used instead of p iperidine.  
 
Aliphatic propargylamides 6b-c,e were linked to the aromatic iodides 45a,b to give the 
hydrophobic peptidomimetics 46b-j in high yields of 64-95 %. In contrast to the hypothesis 
that the steric demands of the alkyne define the reactivity of Sonogashira reactions, 
conversion of Boc protected, glycine analogous propargylamide 1 provided only 58 % 
yield of the coupling product 46a. The catalyst poisoning sulfur of the cysteine analogue 
propargylamide 6j apparently hinders the cross-coupling reaction dramatically decreasing 
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the yield of 46h to 11 %. Bulky, electron withdrawing aromatic substituents in - or -
position (6m,n) do not seem to interfere with the reaction procedure. The position of the 
N-atom in the arene ring has a considerable effect on the yield of coupling compounds. The 
more reactive nicotinic derivative 45c, which is isoelectronic to an acetyl bromide afforded 
the cross-coupling product 46k in only 2 % yield. On the other hand, less reactive picolinate 
45d gave 41 % yield of the coupling product 46l. The direction of the induced dipole 
moment of the pyridine derivatives 46k and 46l is not predefined due to free rotation of the 
backbone around the linear axis. However, the additional N-atom represents a coordination 
site to influence the conformation of the adjacent carbonyl moiety in analogy to the 
hydrogen bond guided helix mimetics 23 [97,98] and 24 [99].  
The locked backbone angle of 180° caused by the substitution pattern of the arene, reduces 
the rotational degree of freedom of the peptidomimetics 46 by one assembling  and  on 
one axis. Preferred dihedral angles were identified by MD simulations and X-ray crystal 
structures of 46j, 52b and 55c (Figure EP2 and Table EP3, Experimental Part) and suggest 
a straight, unbent conformation. Certainly, formation of foldamers cannot be expected by 
oligomerization of this type of building blocks. However, formation of helix type 
superstructures might be possible. Very recently, the peptidomimetics 46 were used to 
prepare HDAC inhibitors by mimicking the acetylated lysine moiety (see Chapter V, SAR 
of Propargylamine-Based HDAC Inhibitors [2]).  
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III-17. Heteroaromatic Derivatives  
Whereas the backbone curvature of benzoate based scaffolds is limited to three angles of 
75° (ortho substituted benzoates 27a-q), 122° (meta-substituted benzoates 40-43) and 175° 
(para-substituted benzoates 46a-l), asymmetric, distorted heteroaromatic five-membered 
rings access multiple different angles. This work focuses on 2,5-disubstituted furan- (129°) 
and thiophene derivatives (147°). For this purpose, the furan- and thiophenecarboxylic 
derivatives were brominated to obtain aromatic halides 47a and 48a,b (Table 4).  
 
Table 4: Preparation of furan- and thiophene-based peptidomimetics.  
 
entry (*/*') propargylamide aromatic yield 
a) (S/S) 6b CH(CH3)2 47a, X=O, Z=Br, Y=OMe 49a, 63% 
   b) a - 1 H 48a, X=S, Z=Br, Y=OMe 50a, 64% 
c) (S/S) 6b CH(CH3)2 48a, X=S, Z=Br, Y=OMe 50b, 21% 
d) (R/R) 6c CH2CH(CH3)2 48a, X=S, Z=Br, Y=OMe 50c, 44% 
e) (R/R) 6e cyclohexane 48a, X=S, Z=Br, Y=OMe 50d, 23% 
f) (R/R) 6b CH(CH3)2 48c, X=S, Z=I, Y=OH 50e, 50% 
a The protective group was Boc instead of tert-Butylsulfinyl.  
 
In the subsequent Sonogashira reaction, the conversion of bromo thiophenes 48a,b resulted 
in considerably lower yields of coupling products 50 (21-63 %) than the conversion of the 
corresponding bromo furane 47a (64 %). It is possible, that the S-atom of the thiophene 
derivatives 48 reduces the activity of the Pd catalyst leading to lower yields of 
peptidomimetic 50.  
The dipole moment, which is added by the furan moiety of 49a to the backbone is likely to 
be parallel to the adjacent carbonyl enhancing the backbone curvature similar to the 3D 
structure of Teroxazoles 21 (Figure 11) [95]. The conformational preference of 49 and 50 
is supported by MD simulations of the dihedral angles and the X-ray crystal structure of 
49a and 56b (Figure EP3, EP4 and Table EP4, EP5, Experimental Part). The rotation of 
the structure determining dihedral angle  is predicted accurately in accordance to the 
X-ray crystal structures. The energy minimum conformations suggest a turn and a 
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cumulation of hydrogen acceptors on one face of the backbone. Similar to meta-substituted 
benzoate derivatives 27, a hydrophobic folding of oligomers from scaffolds 49 and 50 can 
be expected as reported in 3-alkynylbenzene oligomers 17 [84,85].  
 
III-18. Prop-1-yn-1-yl Benzoates as Helix Mimetics 
Combining a stretched, rigid backbone scaffold with low bending tendency, the prop-1-yn-
1-yl benzoate based peptidomimetics of this work qualify for applications in helix 
mimetics. In order to investigate relevant parameters, like the distance between side chains 
and their relative orientation towards each other, hybrid dimers were formed by connecting 
different peptidomimetics described in previous passages (Chapter III-9,13,16,17). The 
designed oligomers should contain amides and alkynyl aryl moieties in an alternating 
fashion. The orthogonal protective groups of the N- and C-termini were cleaved off by 
acidic methanolysis (tert-butylsulfinyl group) and saponification with LiOH (ester) prior 
to peptide coupling, using uronium coupling agents TBTU or HATU (Figure 18).  
 
Figure 18. Oligomerization of wide angled dipeptidomimetics 27 . (a) Aqueous LiOH (1  M, 
3 eq)/MeOH (1:2),  0 °C, 12 h. (b) HCl(dioxane, 4  M, 4 eq),  MeOH (15 mL), 4-8 h, rt. (c) 
TBTU or HATU (3 eq), HOBt or HOAt (2  eq), DIPEA (6 eq), DMF (2-6 mL), rt, 16 h.  
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Homochiral dimers of meta- (57a,b) and para-substituted benzoates (58a,b) as well as the 
furan-based dimer 59a were prepared in acceptable to high yields (19-87 %). However, 
most attempts on a dimerization of dimers 58 and 59 repeating the synthesis cycle of Figure 
18 failed. The low conversion rate of the dimers compared to the monomers 40-43, 46 and 
50 is attributed to their decreased polarity causing aggregation and precipitation. Only 4-
(3-aminoprop-1-yn-1-yl) benzoate 46e could be oligomerized into tetramer 60 in a 
remarkable yield of 23 %, referred to dimer 57a which had been obtained in 71 %.  
Comparison of the CD spectra of the monomers and the dimers visualized significant 
differences (Diagram EP9-EP13, Experimental Part). All (S)-configured monomers show 
only a small local minimum at 190-210 nm. However, the corresponding dimers led to 
more complex CD spectra with an additional 5- to 10-fold more intensive local minimum 
at 220-250 nm and a local maximum of similar intensity at 250-280 nm. (R)-Configured 
peptidomimetics generate mirror-image CD spectra. Independent on the concentration, the 
CD effects of the dimers are enhanced in polar solvents (e.g. TFE) and weakened in 
nonpolar solvents (e.g. CH3CN), suggesting intermolecular solvophobic interaction similar 
to the aggregation reported for arylethynenes 17 [84,85] and clickamer 18 [86]. Elongation 
of the chain length leads to stronger interactions and thus reduced solubility, which requires 
the introduction of polar groups. Nicotinates, like 57b, possess a dipole moment, oriented 
antiparallel to the amide, which increases the polarity but eliminates completely the CD 
effects. It is assumed, that intermolecular hydrophobic interactions occur between nonpolar 
substructures of the backbone. Due to free rotation around the alkyne axis, the side chains 
can assemble on one or more faces of the helix axis. In contrast, the dipole moment of the 
furan based peptidomimetics such as 59a is oriented parallel to the amide, which enhances 
the CD effect in both polar and nonpolar solvents. Presumably, the increased polarity 
contrast between the two faces of helix mimetic 59a assist the amphiphilic agglomeration 
behavior.  
The most important parameter for the evaluation of helix mimetics is the distance between 
two side chains Ci-Ci+1. This distance defines the number of amino acids bypassed by the 
mimetic (Figure 19).  
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Figure 19. Comparison of the distances between different side chains, C  i-C i+n of the helix 
mimetic scaffolds of this work with a canonical -helix (parallel aligned residues are 
marked). From left to right: 42a , R i=(S)-(CH2)3CN, R i +1=CO2Me, Y=OH. 42b, R i=CHMe2,  
R i +1=NH2, Y=OMe. 42c ,  R i=CHMe2, R i+1=NN-Ph-4-NMe2,  Y=OMe. 42d,  R i=CH2CHMe2,  
R i +1=NN-Ph, Y=OMe. 57a , X=CH, R i=R i +1=(R)-CH2CHMe2, n=1. 57b, X=N, R i=R i +1=(S)-
CHMe2,  n=1. 60 , X=CH, R i=R i+1=(R)-CH2CHMe2, n=3. 58a ,  R i=R i +1=CHMe2, Y=OH. 58b,  
R i=R i+1=CH2CHMe2, Y=OEt. 58c,  R i=R i +1=CH2CHMe2, Y=OH. 59a ,  R i=R i+1=CHMe2,  
Y=OMe. 59b,  R i=R i +1=CHMe2, Y=OH. The given distances were calculated using MMFF94 
and are correlated with the distances measured in available X -ray crystal structures.  
 
The residues Ri, Ri+1, Ri+3/4, Ri+7/8 and Ri+11 of an -helix which are oriented on the same 
face enabling PPI are marked in Figure 19. Scaffold 42 comprises two side chains in one 
monomer, imitating one helix turn. The distance of the two side chains (Ci-Ci+1 5.12 Å) 
is slightly longer than in the helix (Ci-Ci+4 3.92 Å). The shorter distance in the helix is 
compensated by the locked angle  directing residue Ri+1 towards the N-terminus. In dimers 
57 and the tetramer 60 only one benzene moiety of the backbone can be correlated with the 
Ri+3 position of the helix as they do not contain an aromatic side chain. The Ci-Ci+1 
distance between the propargylic side chains of two monomers in 57 equals the distance of 
Ri-Ri+11 of an -helical undecapeptide, representing three helix turns. Altogether, 
meta-substituted benzoate scaffolds 57 and 60 represent promising -helix mimetics. The 
Ci-Ci+1 distance of the stretched para-substituted scaffolds 58 also correlates with the 
distance between residues Ri and Ri+11 of an -helix. Despite its favored dipole moment, 
leading to the desired amphiphilic backbone character, the side chain arrangement of furan-
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based scaffold 59 do not reproduce the side chains for the PPI of one -helix face. Their 
Ci-Ci+1 distance is only comparable to the Ri-Ri+6 distance of a 310-helix (7.53 Å), which 
is in good accordance to two turns.  
Although free rotation around the alkyne axis enables the adoption of each relative 
orientation of the helix mimetic side chains, the chirality of the C has a local impact on 
the conformation. The asymmetric energy profile of the dihedral rotation around  suggests 
constraints in the conformation of  and  which control the interaction potential of the side 
chain. This approach of helix imitation combines the free rotation of unselective sterically 
enforced mimetics (see Chapter III-7) with the rare character of chirality, which is expected 
to severely influence the PPI of helix mimetics [93]. An important advantage of the 
presented structures is the direct connection of the versatile building blocks by Click 
reactions.  
 
III-19. Propargylamine-Based Mimetics of α,α- and α,β-Dipeptides 
The aromatic moiety of the discussed peptidomimetics is optimal for the adjustment of 
almost any desired angle in the backbone by application of different (hetero)aromatic 
substitution patterns. Unfortunately, the preparation of aromatic precursors with amino acid 
side chain analogous residues is elaborate. Propargylamine derived olefins or triazoles offer 
versatile options to introduce a second substituent, representing innovative analogues to 
- or -dipeptides (overview in Figure 20).  
 
Figure 20. Propargylamine based triazoles and propargylamine substituted olefins as 
peptidomimetics of - and   -dipeptides.  
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The cis-configuration of the amide moiety and its dipole moment are well imitated by 
1,5-disubstituted triazoles inducing a helix turn to the backbone, as very recently reported 
by Kracker et al. [75]. 1,4-Disubstituted triazoles reproduce the dipole moment, planarity 
and alignement of a trans-configured amide. The additional backbone atom evokes 
accurate analogy to 2-dipeptides. Oligomerization of such scaffolds on solid phase is a 
well-established approach to generate versatile triazolamers [121]. Investigation of their 
secondary structure by ROESY experiments revealed an anti-conformation of the triazoles, 
leading to a zigzag structure with parallel axial orientation of side chains Ri and Ri+2 
forming an ideal -strand mimetic [122]. As HIV-1 protease preferably converts such 
-strand motifs, oligo phenylalanine analogous triazolamers have been explored as potent 
HIV-1 protease inhibitors with IC50-values in the low M range [78]. The side chain 
diversity of this type of triazole-based peptidomimetics as well as oligomers were 
extensively expanded by Tanja Fröhr [123]. Dipeptidomimetics 63 (Scheme 1) contribute 
to the side chain diversity of the important triazole-based peptidomimetic structure, 
imitating important natural dipeptides.  
 
Scheme 1. Synthesis of triazole -based peptidomimetic 63  as analogs of a potential 
hydrogelation inducer (63a) and of the synthetic sweetener aspartam ( 63c).   
 
Azide-transfer to methyl (S)-phenylalanine gave the C-terminal moiety 61, which 
underwent a [3+2]-cycloaddition with the propargylamide analogs of leucine 6c (38 %) and 
glutamic acid 6l (39 %). Acidic methanolysis successfully cleaved off the N-terminal 
tert-butyl sulfinyl group of 2-dipeptide analogs 62a and b. Further cleavage of the 
tert-butyl ester of 63b, however required harsher conditions (Scheme 1).  
The dipeptide H2N-Leu-Phe-OMe has been reported to self-assemble to a nanofiber 
network inducing hydrogelation at extraordinaryly low concentrations (2.3 mM, 0.07 % 
w/v) [124]. Using this nanofiber network led to a method to remove dyes and heavy metal 
ions from water by diffusion and hydrogel-sol transition [124]. Peptidomimetic 63a was 
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designed to mimic the properties of the dipeptide. Therefore, the reported gelation 
experiments were recapitulated with peptidomimetic 63a. However, the rigidity and 
increased hydrophobicity of 63a led to a much higher minimum gelation concentration of 
22-32 mM (50-75 mg mL-1) and frequent precipitation. When the solvent was changed to 
CH2Cl2 or 
iPrOH, gelation was observed at concentrations lower than 2 mM (<5 mg mL-1), 
while in other organic solvents solutions (MeOH) or suspensions (Et2O, CHCl3, CH3CN, 
EtOAc, acetone) were formed. Apparently, the nanostructures responsible for the gelation 
differ from the nanofibers, which the peptide-based template forms in aqueous environment 
(see Picture EP2, Experimental Part).  
Peptidomimetic 63c was designed as analogue to the natural dipeptide H2N-Asp-Phe-OMe 
(aspartame), which is an FDA-approved synthetic sweetener E951 tasting about 200-fold 
sweeter than saccharose. The impact of the structural abstraction on the taste receptor has 
to be examined by a recently published assay, which investigates in vitro the interaction of 
sweeteners with the Class C G protein-coupled receptor subunits TAS1R2 and TAS1R3 
[125].  
 
Connection of propargylamides to acrylates affords versatile -dipeptidomimetics with 
considerably (50 %) reduced rotational freedom in the backbone and a locked angle  
fixing the side chains in a particular orientation (see Figure 20). Sonogashira type cross-
coupling of alkynes with 2-bromo acrylates was reported for inert substrates, i.e. alkynes 
and acrylates with stabilizing substituents [126–128].  
 
Figure 21. First approach on the preparation of 3 -(alkynyl)acrylates as 
 3-dipeptidomimetics. (a) nBuLi, THF, -78 °C, overnight. (b) 1.)  Br 2,  CH2Cl2,  -78 °C, 
2-6 h. 2.) KO tBu, THF, 0 °C, overnight. (c) PdCl2(PPh3)2, CuI, THF/piperidine (3:1), rt .  
 
The -halogenated acrylates 68 were prepared by addition of Br2 to methyl acrylate 66 
affording 2,3-dibromopropanoates 67 and subsequent HBr elimination. The aromatic of 66 
was also brominated under these conditions. Cross-coupling reactions of propargylamides 
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6 with -bromoacrylates under the described Sonogashira conditions do not result in the 
desired 2-(alkynyl)acrylates since fast comproportionation occurs [129]. Only the coupling 
of alanine analogous propargylamide 6a and brominated olefin 68 provided 
dipeptidomimetic 69 in a very low yield of 5 %. Recently, Trost et al. [130] reported the 
synthesis of 3-(alkynyl)acrylates by hydroalkynylation of propynoates. Employing our 
propargylamides 6 in this reaction will result in 3-(alkynyl)acrylates 74, which can be 
considered as mimetics of 3-dipeptides as displayed in Figure 20. In Table 5, 
3-dipeptidopeptidomimetics prepared in this thesis are summarized.  
 
Table 5: Synthesis of 3-(alkynyl)acrylates 74  by hydroalkynylation of propynoates 73  as 
 3-dipeptidomimetics. Cleavage of the tert-butylsulfinyl protective group by acidic 
methanolysis usually proceeded quantitatively.  
 
entry (*/*‘) Propargylamide, R= acceptor alkyne 73 74, yield 
   a) a - 1, H  73b, R'=Ph, X=Me 74a, 87% 
b) (S,S) 6c, CH2CH(CH3)2 73b, R'=Ph, X=Me 74b, 45% 
c) (S,S) 6e, cyclohexyl 73b, R'=Ph, X=Me 74c, 64% 
d) (S,S) 6l, CH2CH2CO2C(CH3)3 73b, R'=Ph, X=Me 74d, 40% 
e) (S,S) 6c, CH2CH(CH3)2 73a, R'=Me, X=Et 74e, 76% 
f) (S,S) 6e, cyclohexyl 73a, R'=Me, X=Et 74f, 69% 
g) (R,R) 6n, Ph 73a, R'=Me, X=Et 74g, 0% 
h) (S,S) 6c, CH2CH(CH3)2 73c, R'=(CH2)5CH3, X=Me 74h, 18% 
i) (S,S) 6e, cyclohexyl 73d, R'=CH2OCO2CH3, X=Me 74i, 47% 
j) (S,S) 6b, CH(CH3)2 73e, R'=CO2CH3, X=Me 74j, 8% 
k) (S,S) 6c, CH2CH(CH3)2 73e, R'=CO2CH3, X=Me 74k, 11% 
a The protective group was Boc instead of tert-butylsulfinyl.  
 
Propynoate precursors 73 with side chains analogously to substituents of proteinogenic 
amino acids were accessed by reaction of respective lithiated alkynes with methyl 
chloroformate [130]. Under the reaction conditions developed by Trost et al., aromatic 
propynoate 73b gave stable dipeptidomimetics 74a-d in yields of 40-87 % in dependence 
on the reactivity of propargylamides 1 and 6. The hydroalkynylation reaction of the 
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propargylamide 6n with an electron withdrawing phenyl substituent in C-position led to 
the desired product, which subsequently underwent a non-base-induced enimine-
rearrangement (Chapter III-20). The reactivity of propynoates 73a and c with aliphatic side 
chains and propynoates 73d with an additional polar functional group in the side chain 
seems to depend on the size of the substituent. Thus, propynoate 73d with the large aliphatic 
nhexyl group in the side chain afforded only 18 % of 74h. The low yield may be attributed 
to the size of the nhexyl substituent and agglomeration and reduced solubility of the starting 
material 73c. Butynedioate 73e with two ester moieties at the triple bond did not give a 
clear transformation. The desired addition products 74j and 74k were obtained in only 8-
11 % yields out of a complex mixture of reaction products. In order to prepare 
dipeptidomimetics 75 with a free amino moiety capable of peptide coupling, the 
tert-butylsulfinyl protective group was cleaved off by acidic methanolysis to afford 
aminoesters 75 in quantitative yields. Moreover, the methyl ester of the glycine analog 74a 
was hydrolyzed with LiOH to give the free acid for an amide coupling. Due to the structural 
similarity of 75b to 63a and the superhydrogel dipeptide H-Leu-Phe-OMe the formation of 
a hydrogel was investigated. However, despite the structural relationships, the formation of 
a hydrogel could not be observed, yet. After cleavage of the tert-butyl ester of 75d with 
TFA, the aspartam (H-Asp-Phe-OMe) analogous peptidomimetic 75l was achieved as 
potential artificial sweetener in a yield of 24 %.  
In order to detect energetically favored conformations of dipeptidomimetics 75, MD 
simulations were performed for a model compound and X-ray crystal structures of 75e and 
75f were recorded (Figure 22).  
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Figure 22. Comparison of the torsion angles  of dipeptidomimetics 75e  and 75f .  a) Calculated 
energy profiles resulting from rotation of the given model compound around various single 
bonds. The angles observed in the X-ray crystal structures are marked with a pentagon ( 75e)  
and an asterisk (75f) in the colors corresponding to the respective bonds. b) X -ray crystal 
structure of compound 75e  (1 n.a.,  n.a.,  = 29°,   =  176°,  =  and 2 = 179°). c) 
X-ray crystal structure of compound 75f  (1 n.a.,  n.a.,  = 37°,   = °,   =  and 
2 = 176°) (for more details, see Table  EP6 Experimental Part).  
 
The X-ray crystal structures of both 75e and 75f reveal a short distance between the 
carbonyl O-atom and one proton of the CH3-group in C-position. The distances in the 
isobutyl- and cyclohexyl derivatives 75e and 75f are 2.25 Å and 2.68 Å, respectively. This 
H-bond additionally stabilizes the energetically favored trans-configuration of the double 
bond with a defined backbone torsion angle . Although the free rotation around the alkyne 
axis  allows each relative orientation of the side chains, the X-ray crystal structures suggest 
an almost parallel arrangement of the isobutyl or cyclohexyl side chain and the methyl 
group with dihedral angles of -30° for 75e and -18° for 75f. In contrast to the zigzag shaped 
-strand preferably formed by triazolamers [122], 3-(alkynyl)acrylates arrange their 
nonpolar regions on one face inducing an amphiphilic character to the molecule. Moreover, 
the parallel alignment of side chains led to the orientations of C- and N-termini in the same 
direction imposing a bend to the backbone. Compared to one face of an -helix (see 
Figure 19), the distances between the side chains Ri and Ri+1 are 4.10 Å for 75e and 4.08 Å 
for 75f, which is in good accordance to one helical turn (d(Ci-Ci+4): 3.92 Å). These 
structural features render scaffolds 74 and 75 promising structural helix mimetics. A 
convenient feature of the presented approach are the versatile options to combine various 
functional groups in the side chains of both moieties, independently.  
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III-20. Propargylamides rearrange to Enimines 
First observations of an enimine rearrangement have been published as part of this work 
under the title “Asymmetric synthesis of propargylamines as amino acid surrogates in 
peptidomimetics” [1]. Propargylamides substituted with an electron withdrawing group in 
C-position are able to rearrange under basic conditions into ,-unsaturated 
sulfinylimines. At first, deprotonation in CH position initiates the rearrangement into a 
sulfinamido substituted allene, which further rearranges into ,-unsaturated sulfinylimine 
76 (concrete examples in Table 6). Similar rearrangements have been observed in propargyl 
alcohols [131].  
 
Table 6. Rearrangement of various propargylamides with an electron withdrawing group 
(EWG) in C-position into  -unsaturated sulfinylimines 76a-f . Yields refer to isolated 
rearranged products.  
 
Various sulfinamides with electron withdrawing groups such as phenyl, trifluoromethyl or 
pentafluorophenyl in C-position underwent an enimine rearrangement upon treatment 
with piperidine. The conversion was complete within 10 min (checked by TLC and 
analytical HPLC). Sometimes, decomposition during workup and purification reduced the 
yields to 24-98 %. In the absence of acidifying substituents in C-position (e.g. cyclohexyl 
in 46f), even strong bases such as KOH, KOtBu or LDA could not induce the enimine 
rearrangement. Activated olefin based peptidomimetics with EWG substituted C (e.g. 
74g) even underwent the rearrangement under neutral conditions at rt making the isolation 
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of hydroalkynylation product 74g impossible. Cleavage of the N-terminal tert-butylsulfinyl 
group by acidic methanolysis resulted in the -unsaturated imines 77c,f. Since imines 
77c and 77f underwent further hydrolysis, the -unsaturated ketones 78c,f were isolated 
by crystallization. The X-ray crystal structures of conjugated ketones 78c,f are presented 
in the Experimental Part. The extended -system of the -unsaturated sulfinylimines 76 
allows monitoring the progress of the enimine rearrangement by UV/Vis spectroscopy or 
optically with the naked eye (Figure 23). 
 
Figure 23. Visualization of the enimine rearrangement. a) X -ray crystal structure of 
propargylamide 46j .  b) UV/Vis spectra of propargylamides 40g  and 46j (see also Diagram 
EP2 Experimental Part) .  c) X-ray crystal structure of rearrangement product 76e. d) 
Exemplary UV/Vis spectra of  -unsaturated sulfinylimines 76c and  76e  (also see Diagram 
EP7 Experimental Part) .  
 
The locked antiparallel orientation of side chains Ri (EWG) and Ri+1 (arene) in the 
-unsaturated sulfinylimines 76 is confirmed by X-ray crystal structures of 76e and 78c,f. 
This structure corresponds to the zigzag structure adopted by -strand analogous 
1,4-disubstituted triazolamers [122]. Both, the rearrangement of the alkyne into the allene 
and the subsequent tautomerism to the -unsaturated sulfinylimine are irreversible. A 
reversible enimine rearrangement would lead to epimerization in C-position. Thus, due to 
the irreversibility, epimerization could be excluded.  
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III-21. Conclusion 
In this part of the thesis, several peptidomimetics with great diversity were prepared and 
characterized. Variations have been realized with respect to the total length and the angle 
associated with the arene moiety. Conformational preferences were elucidated by MD 
simulations and X-ray crystal structure analysis. The peptidomimetics were classified as 
foldamers and helix mimetics. The conformational preferences could be influenced by the 
photoswitchable configuration of an azobenzene unit introduced into the backbone. 
-Dipeptide analogues were realized in the form of triazoles and alkynes linked to 
olefins. In the course of 3-(alkynyl)acrylate synthesis, the substrate scope of the recently 
reported hydroalkynylation reaction was enhanced. Special dipeptide sequences were 
selected as model compounds for the design and synthesis of functional analogues, such as 
the synthetic sweetener aspartame or the super hydrogel forming leucine-phenylalanine 
dimer. An enimine rearrangement was observed and investigated. This reaction occurred 
in the course of the synthesis of peptidomimetics with electron withdrawing substituents in 
C-position of propargylamides. The presented dipeptidomimetics are elementary for the 
preparation of -turn mimetics, HDAC inhibitors and RGD mimetics, which will be subject 
to chapters IV, V and VI.  
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IV Propynyl-Aryl Scaffolds as Turn Motif Mimetics 
The low flexibility of the Class B peptidomimetics introduced in Chapter III can be 
exploited to define the orientation of the side chains and the N- and C-termini. Herein, novel 
turn motif mimetics were developed by expanding the monocyclic aromatic moiety to a 
naphthalene system, a flexible biphenyl unit and a photoswitchable azobenzene moiety. 
Additionally, the propargylamide moiety was aminated to afford hydrazine and hydrazone 
derivatives. Orientation of N- and C- termini of the novel scaffolds was examined by 
1H NMR spectroscopy, temperature coefficient T, CD spectroscopy and X-ray crystal 
structure analysis.  
 
IV-1. The Concept of Turn Motif Inducers 
Peptide turn motifs usually terminate -sheet structures, leading to H-bonds between 
antiparallel peptide strands as well as spatial proximity between the C-atoms in -position 
[132]. Therefore, they are usually located at the protein surface exposed to the solvent, 
which requires the presence of hydrophilic side chains (e.g. Ser, Asn) and a flexible 
backbone element with a preference of a cis-configured amide bond (e.g. Gly, Pro) [133]. 
The location at the surface combined with their major influence on protein folding makes 
turn motifs a distinctive feature, which is involved in various molecular recognition events 
as observed in the X-ray crystal structures of peptide-antibody complexes [134,135]. 
Participation of turn motifs in the peptide induced activation of G-protein coupled receptors 
by PPI is well investigated [136]. Therefore, the responsible turn motifs are promising 
pharmacological targets. As turn motifs frequently participate in PPIs, they are popular 
structural elements for the design of protein epitope mimetics [137]. Well investigated 
targets of current research comprise serine protease inhibitors based on the Bowman-Birk 
motif, mimetics of protegrine I as novel antibacterials and inhibitors of CXCR4 [138]. In 
contrast to -sheets and -helices, turn motifs lack the preference of a defined torsion angle 
  and are therefore termed irregular structures [133]. They are classified according to 
their direction into forward- (NHN-term-COC-term) and reverse turns (COC-term-NHN-term). A 
further sub-classification is performed according to the loop size represented by the number 
of ring members defined by the H-bond. Forward turns: -Turn, 8-ring, NHi-COi+1. -Turn, 
11-ring, NHi-OCi+2. Reverse turns: -Turn, 7-ring, COi-HNi+2. -Turn, 10-ring, COi-HNi+3. 
IV-1. The Concept of Turn Motif Inducers 
61 
-Turn, 13-ring, COi-HNi+4. -Turn, 16-ring, COi-HNi+4. -Turn, >18-ring, COi-HNi+6+n 
[139] (Figure 24a).  
 
Figure 24. Concept of turn motif induction. a) Different classes of forward and reverse turns 
in peptides [133]. b) Approaches to enforce antiparallel alignment of peptide strands [31].  
 
Whereas forward turns typically do not occur in natural peptides, -turns are the most 
common turn structures in peptides. Therefore, they are further subtypified by their 
backbone conformation and side chain orientation [61]. Attachment of amino acids aligning 
to a -sheet that may be assisted by inter side chain interactions builds a hairpin. This 
structure represents the template for the design of complementary peptidomimetics [140]. 
Hairpin mimetics are distinguished by the subdomains subjected to chemical modifications 
(Figure 24b).  
Macrocyclization is an option to support the formation of a turn motif, directing N- and 
C-termini into the same direction and avoiding terminal unfolding. Usually, Class A 
modified peptides are used as global constraints connecting the backbone (NN-termH-
CC-termO) or the side chains by lactams (Lys-Glu/Asp), disulfide bridges (Cys-Cys), -
stacking (Phe/Trp) and tethers based on non-natural amino acids [31]. A famous example 
is the induction of -turns [141] or type II’ -turn [142] conformations of the RGD sequence 
by backbone cyclization enhancing its affinity to integrine vIII by 146 fold [143].  
-Strand enforcing mimetics or -strand mimetics are Class B modified peptides with 
nonpeptide elements that assist -sheet formation. They either reproduce the typical 
interstrand H-bond pattern [144] or connect the -strands covalently [145]. However, 
peptidomimetics of this type have not yet been used as PPI disruptors.  
Turn mimetics are discussed in Chapter IV.2.  
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IV-2. Structural Turn Motif Mimetics 
Structural turn motif mimetics (Figure 24b) contain strongly constrained backbone 
elements orienting N- and C-termini into the same direction and in appropriate spatial 
proximity for antiparallel alignment of the -strands. The rigid scaffolds induce stable 
hairpin structures in much shorter peptides than in their peptide templates (1-3 instead of 
>20) [146]. While the side chains of peptide turn motifs are usually hydrophilic as they are 
located on the protein surface exposed to water, the substituents of turn mimetics are not 
restricted to polar groups. In conclusion, small molecules comprising a turn mimetic can 
be designed as stable, versatile substituted hairpin analogues. In internal turn motif 
mimetics (Class A peptidomimetics), the backbone constraint is realized by exchanging an 
H-bond of the turn by a covalent bond [147]. The group of Class B turn mimetics consists 
of abstract scaffolds designed as constrained dipeptide isosteres [133]. These Class B 
peptidomimetics are referred to as external turn motifs. They are subclassified according to 
their sterical constraints (Figure 25) in analogy to the characterization of helix mimetics 
(Chapter III-7) [133].  
Figure 25. Established structural turn motif mimetics organized by their mechanism to 
induce  -folds. Sterically controlled : Biphenyls 79  [148]. Tolanes 80  [149]. Z-Azobenzenes 
81  [150]. Hydrogen bond induced:  1,4-Diphenyl-1,2,3-Triazoles 82 , R1=-Val-NH iPr, 
R2=-Gly-NHnBu [151]. Covalently constrained : Pyrrolizidinone amino acids 83  [152]. 
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2,8-Dimethylphenoxathiine 84a , X=SO2,  R1=H, R2=Me [153]. Dibenzofurane 84b,  X=-, 
R1=Boc [154]. Bicyclooctanes 85a  R1=Boc, R2=OH, 85b R1=Ala-CO iPr, R2=Phe-OMe [155]. 
Spiro-bicycles 86  [156]. Spiroketale 87  [157]. Metal coordinated:  Ferrocenes 88  [158]. cis-
Platinates 89 ,  R1=R2=CH2Ph [159]. Rhenium complexes 90 , R1=CH2Ph, R2=R3=Me [160].  
 
Sterically controlled Turn Motifs keep the peptide strands in a defined distance, but 
contain a single bond allowing free rotation and thus various relative orientations of the 
-strands can be adopted. Interstrand interactions stabilize the hairpin motif. The axial 
rotation of ortho-substituted biphenyl derivatives 79 is free in the limits of the steric 
constraints. MD-simulations revealed a preferred dihedral angle of 90° between the 
aromatic rings [148]. Still, 79 turned out to be an appropriate -sheet inducer forming a 
15-membered ring stabilized by an appropriate H-bond (-turn) when incorporated into a 
peptide [148]. Peptide strands terminated by aromatic boronates and halides could be 
connected via Suzuki coupling in yields of 15-38 % [148]. Extension of the axis led to 
tolane derivatives 80 with completely unconstrained axial rotation around the triple bond. 
Diarylalkynes of type 80 have been used as disulfide bridge isosteres. They can be obtained 
after establishing the corresponding peptide by final intramolecular Sonogashira cross 
coupling on solid phase forming a macrocycle [149]. The exposed -loop of the C3 
domain in human IgE could be successfully stabilized by tolane derivative 80 affording a 
promising agent against hypersensitivity responses [149]. Smart turn mimetics like 
azobenzene 81 have been developed to control the backbone conformation and therefore 
the interstrand distance by light. Azobenzene derivative 81 has been linked by an Ala-Ala 
dipeptide to the binding -sheet motif Phe-Trp-Lys-Thr as a somatostatin analogue. MD 
simulations suggest a hairpin conformation for Z-configured azobenzene 81 and more 
extended conformations for E-configured azobenzene. Biological evaluation confirmed the 
change of conformation rendering the light-induced Z-isomer twice as active as the 
thermodynamically preferred E-isomer [150]. When the substituents of the aromatic rings 
of 81 were in meta position, a hairpin formation could only be observed for the light-
induced Z-isomer. Attachment of the substituents in ortho position can lead to an H-bond 
between the NH and C=O moieties of different strands in the E-isomer of the azobenzene 
[161]. Reisomerization of an analog of (Z)-configured azobenzenes 81 with attached 
peptide chains proceeded 30 % slower than that of amino acid 81. As the reduced 
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reisomerization tendency depends on the stability of the -fold, incorporation of 81 into 
-sheets enables the evaluation of its stability [162].  
 
Hydrogen Bond induced Turn Motifs 
Additional H-bonds in the turn mimetic support the orientation of peptide strands by 
enhancing the stability of particular conformations. In diphenyl-triazoles 82, the axial 
rotation around the single bonds connecting the triazole ring with the phenyl rings is 
constrained by several H-bonds (Figure 25). 1,4-Diphenyl-1,2,3-triazoles 82 were obtained 
by a copper catalyzed 1,3-dipolar cycloaddition after preparation of appropriately 
substituted peptides. As this turn mimetic additionally contains the features of a retro-
inverso amide isostere, the peptide strands R1 and R2 align to a parallel -sheet [151].  
 
Covalently constrained Turn Motifs 
Covalently constrained turn motifs are completely rigid scaffolds without any 
conformational degrees of freedom. The subdivision into aromatic and spirocyclic 
skeletons as proposed by Nair et al. [133] is not considered herein because it does not cover 
all representatives belonging to this group. Internal turn motif mimetics are Class A 
modified peptides containing a turn-generating ring formed by covalent bonds instead of 
H-bonds. The covalent tethers in internal - and -turn mimetics lead to rigid scaffolds 
justifying their assignment to the covalently constrained turn motifs. A type II’ -turn 
conformation is fixed in pyrrolizidinones 83. The low temperature coefficients of the amide 
protons confirm the induced -sheet [152]. Modification of the peptide template adaptation 
and the turn class is realized by a variation of the configuration of the center of chirality 
and the ring size of azabicycloalkanes like 83 [163]. The macrocyclic system consisting of 
the tripeptide -Ile-Val-Gly-, which is connected at its N- and C-termini by 
2,8-dimethylphenoxathiine 84a forms H-bonds leading to a -loop in the amino acids and 
a -turn with its methyl groups at the heterocycle representing the side chains of the amino 
acids i+1 and i+2 in a peptide -turn [153]. However, the X-ray crystal structure of a 
peptide incorporating the closely related dibenzofuran 84b reveals an H-bond resulting in 
a 15-membered ring, referred to as -turn. Interestingly, interactions of nonpolar side 
chains with the hydrophobic turn inducing scaffold 84b could be deduced from ROESY 
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experiments [154]. This hydrophobic cluster is expected to support -sheet formation 
[154]. The conformation of bicyclooctane 85a mimicking a -amino acid is highly 
constrained. The X-ray crystal structure of hairpin mimetic 85b, a peptide with 
incorporated bicyclooctane 85a, confirms the narrow -turn conformation [155].  
Two of the best investigated representatives of spirocyclic turn mimetics are bicyclic 86 
and spiroketal 87. Three of their four dihedral angles   characterizing a peptide 
conformation are locked. The conformational analogy of the spirocyclic compound 86 to a 
type II -turn was confirmed by determination of the temperature coefficient, MD 
simulations and NOESY experiments [156]. Different hairpin motifs derived from 86 by 
variation of the lactam and thiazolidine ring sizes were active in the 6-hydroxydopamine-
lesioned animal model of Parkinson’s disease in nanomolar range [164]. The solid phase 
synthesis compatible spiroketal 87 arranges in analogy to a -turn [157]. 
 
Turn Motifs by Metal Coordination  
The most recently established group of turn motif mimetics resulting from a coordination 
of the backbone to a metal ion like Fe, Pt, Rh or Ni. X-ray crystal structures of oligopeptides 
of different length containing ferrocene based amino acid 88 were recorded. Depending on 
the number of additional amino acids, different turn structures can be adopted. In short 
oligomers, a forward -turn was found, while longer oligomers form interstrand H-bonds 
which rather indicate a helix structure (NHi+2-COi+4 and COi-NHi+3) [158]. Therefore, turn 
motif mimetic 88 does not necessarily induce hairpin formation. Introduction of 
cis-platinate 89 as warhead for DNA interaction terminating a hairpin structure represents 
an innovative approach for the development of anti-cancer drugs. The driving forces for 
the self-assembly of the Pt-complex 89 combines metal coordination, weak H-bonds and 
-stacking. X-ray crystal structure analysis and thermodynamic investigations confirmed 
the resulting exceptional stability of the X2M complex [159]. A similar self-assembly 
provided Re-complex 90 [160], which is related to a crown ether. The distance between 
two adjacent -C-atoms in the Re-chelat is proportional to the metal ion radius [165]. 
Consequently, the turn motif can be modified by introduction of different metal cations.  
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IV-3. Propargyl-aryl Architectures as Turn Motif Mimetics 
The scaffolds discussed above differ in their lipophilicity, rigidity, degrees of 
conformational freedom and modification options. These features make them promising 
tools to generate structural turn motif mimetics. In analogy to the peptidomimetics 
described in Chapter III, the compounds of this part are based on propargylamides 6, linked 
via Sonogashira cross coupling to an aromatic moiety. The alkyne in the backbone leads to 
a linear structure, which only allows rotation around the alkyne axis. Therefore, the 
corresponding compounds are referred to as sterically controlled turn mimetics.  
 
Figure 26. Overview of the turn motif mimetics presented in this work. As all scaffolds are 
based on a connection of propargylamides to  aromatic systems, the discussion is structured 
in analogy to Chapter  III  according to the aromatic system (compare the captions of the 
scaffolds).  
 
 
IV-4. Naphthoate-Based Turn Mimetics 
Reports of the selective mercuration of 1,8-naphthoic anhydride in 8 position by Chen et 
al. allowed the versatile functionalization of naphthalene-1-carboxylates in 8-position 
[166]. Wiley et al. further developed a procedure for the synthesis of 8-iodonaphthalene-1-
carboxylate 91a [167], which can be used in various transition metal catalyzed cross 
coupling reactions. Therefore, 91 represents a promising aromatic scaffold for novel 
peptidomimetics.  
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Scheme 2. Preparation of naphthoate -based turn motif mimetic 92 . (a) Iodination of 
naphthoate was performed as described by Wiley et al.  [167]. 1.  NaOH, H2O, 100 °C, 1 h. 
2. Hg(OAc) 2, HOAc/H2O (2:1), 120 °C, 48 h. (b) I2 , KI, H2O, 100 °C, 24 h. (c) TMSCHN2,  
DIPEA, THF, rt, 1 h. (d) Sonogashira  cross coupling: THF/piperidine (3:1),  PdCl2(PPh3)2,  
CuI, rt,  overnight.  
 
First attempts to react iodonaphthoate 91a with propargylamide 6e by a Sonogashira cross 
coupling reaction failed possibly due to various side reactions including intramolecular 
hydrocarboxylation (compare Chapter III-10). Additionally, coordination of palladium 
species by the carboxy group could inhibit the transformation especially in proximity to the 
aromatic halide. However, the methyl ester 91b was converted into peptidomimetic 92 in a 
yield of at least 17 %.  
The rigid naphthalene scaffold leads to a parallel orientation of N- and C-termini. 
Nevertheless, the free rotation around the alkyne axis and the steric interactions possibly 
separate the peptide strands spatially. Hints for hairpin formation can be derived from the 
chemical shifts in the 1H NMR spectra (Figure 27).  
  
Figure 27. Comparison of 1H NMR chemical shifts of propargylamide 6e and peptidomimetic 
92  in the range of 5.0 -3.0 ppm. The magenta signals at 3.85  ppm (A for 6e)  and 4.32 (B for 
92) are caused by the protons in -position. The purple signals at 3.28  ppm (C for 6e) and 
4.54 ppm (D for 92) are caused by the protons of the amide NH group. The methyl ester 
protons resonate as singlet at 4.00  ppm (E for 92 , blue).  
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Remarkably, the resonance of the amide proton of 92 is downfield shifted by  1.26 ppm 
compared to the NH-signal of 6e. Moreover, the signal of the amide proton of 92 is 
extraordinarily broad. Both phenomena usually indicate strong intramolecular H-bonds. A 
lower downfield shift of  0.47 ppm for the signal of the -proton of 92 compared to 6e 
indicates a weaker intramolecular H-bond. Due to the parallel orientation of the substituents 
in 1- and 8-position of the naphthalene ring, a coordination of both protons to the carbonyl 
O-atom is very probable. These H-bonds lead to a 10-membered ring with a similar 
structure as found in non-natural forward -turns. To confirm this hairpin structure, 
peptidomimetic 92 was incorporated into a larger peptide by Sonogashira reaction of H-
Pro-Tyr-Thr-6e with 91a-Leu-Thr-Val-OH. The resulting hairpin mimetic H-Pro-Tyr-Thr-
92-Leu-Thr-Val-OH was isolated in very low amounts and a yield of 27 %. Investigation 
by NMR spectroscopy is not yet completed, but temperature resolved CD spectroscopy 
indicates the existence of a distinct secondary structure, which is stable even at elevated 
temperatures of >70 °C (Diagram EP24, Experimental Part).  
Nonpolar naphthoate scaffolds such as 92 were reported to diffuse through cell walls and 
intercalate into DNA provoking cancer. On the other hand, 92 was suggested as lead 
scaffold for the development of various patented active agents [168]. In the presented 
hairpin mimetics H-Pro-Tyr-Thr-92-Leu-Thr-Val-OH the naphthoate moiety terminates a 
-sheet and thus acts as a DNA intercalating warhead in analogy to cis-platinate 89 
(Figure 25) [159].  
 
IV-5. Biphenyl-Based Hairpin Mimetics 
Biphenyl derivatives are closely related to the presented naphthalene species. A 
3,2’-substitution pattern of the biphenyl scaffold was used to maintain rotation around the 
Ph-Ph single bond. These biphenyls can adopt conformations with parallel orientation of 
C- and N-termini bringing a carbonyl and an amino moiety in close proximity to form a 
strong H-bond. Various substitution patterns of the aromatic system can be accessed by the 
Suzuki reaction of iodo-benzoates 26, 36-39, 45, 47 and 48 with 2-aminophenyl-boronic 
acid (Scheme 3).  
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Scheme 3. Preparation of biphenyl -based turn mimetics. (a) Suzuki  coupling: K3PO4,  
1,4-dioxane/H2O (4:1),  PdCl2(PPh3)2,  sonication, rt, overnight. (b) Sandmeyer-type reaction: 
1) NaNO2, NaI, HCl (6 M), 0 °C, 5 min. 2) I2, rt, 14 h. (c) Sonogashira  reaction: 
PdCl2(PPh3)2, CuI, THF/DIPEA (3:1), r t, overnight.  
a Both stereocenters of propargylamide 6e  and turn mimetic 94b  were (R) configured.  
 
The obtained aminobiphenyl 93a was converted by a Sandmeyer-type reaction into iodo 
arene 93b. Hydroxylation competed with the iodination and reduced the yield to only 14 %. 
Alkynes 6 and aromatic halide 93b were connected by a Sonogashira reaction, affording 
peptidomimetics 94a-c. Steric repulsion of the connected phenyl rings as well as high 
electron density of the aromatic system inhibited the oxidative addition reducing the yields 
to 20-33 %. The amide protons of peptidomimetics 94a-c resonate in a very similar range 
as the amide protons of the corresponding propargylamides 6c,e,p (Diagram EP15, 
Experimental Part). Therefore, it was concluded that intramolecular H-bonds do not exist 
in 94a-c. Indeed, previous MD-simulations confirm a preferred dihedral angle of 90° 
between the phenyl rings [148]. In order to induce a possible hairpin conformation 
peptidomimetic 94 was incorporated into a short peptide (Scheme 4).  
 
Scheme 4. Incorporation of turn mimetic 94  in a short peptide. R1=-Gly-Phe-Tyr-NHBoc, 
R2=-Ala-Val-Leu-OMe. (a) 1. HCl (4 M in dioxane), MeOH, rt, overnight. 2.  HATU, HOAt,  
CH2Cl2, DIPEA, rt, 3 d. (b) 1. LiOH x H2O, MeOH/H2O (2:1). 2. HATU, HOAt, CH2Cl2,  
DIPEA, rt, 3 d. (c) PdCl2(PPh3)2, CuI, dioxane/DIPAH/DMSO (15:4:1), microwave, 60  °C, 
2 h.  
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After hydrolysis of the tert-butylsulfinamide 6a, the resulting primary amine was coupled 
with the tripeptide BocHN-Tyr-Phe-Gly-OH using HATU and HOAt to form the 
peptidomimetic 95 with an N-terminal alkyne moiety. Ester 93b was hydrolyzed and the 
resulting acid was linked to the tripeptide H2N-Ala-Val-Leu-OMe also using HATU and 
HOAt to give peptidomimetic 96 with an iodobiphenyl at the C-terminus. Both 
peptidomimetics were connected by a Sonogashira reaction at elevated temperatures to 
give peptidomimetic 97. Interstrand H-bonds were identified by temperature gradient 
determination (Figure 28).  
 
Figure 28: Detection of intramolecular H -bonds in hairpin mimetic 97  by temperature 
coefficient T determination. Left side: 1H NMR shift of amide protons in dependence 
on the temperature in CD 3OH. A low chemical shift is typical for a strong intramolecular  
H-bond. Right side: Assumed conformation of hairpin mimetic 97  with H-bonds assigned to 
protons with low temperature dependence of the chemical shifts (see also Diagram EP16, 
Experimental Part).  
 
The chemical shift of each amide proton was plotted against the corresponding temperature. 
Determination of the gradient allows an evaluation, whether the proton is surrounded by 
solvent (high gradient) or coordinated intramolecularly to a carbonyl moiety (low gradient). 
Using this technique led to the identification of three interstrand H-bonds (Figure 28) 
stabilizing the two -strands in an antiparallel manner. The H-bonds result in an 
18-membered ring classifying the motif as forward -turn. Apparently, the dihedral angle 
of 90° between the phenyl rings of the biphenyl system does not align the peptide strands 
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in a parallel manner and renders the biphenyl scaffold a poor hairpin inducer. Although 
temperature resolved CD spectroscopy indicates a secondary structure with high stability 
(Diagram EP26, Experimental Part), a comparison of hairpin 97 and turn motif 94b shows 
that the observed CD effect is generated mainly by the turn motif mimetic and not by the 
-strand (Diagram EP25, Experimental Part).  
 
IV-6. Smart Azobenzene-Based Turn Mimetics 
The distance between two peptide strands and therefore the initiation of -sheet formation 
can be optically controlled if their linker is an azobenzene derivative [150]. The stability of 
such smart hairpin motifs depends on the substitution pattern [161], as well as the inherent 
tendency of the strands to form -sheets [162]. For the incorporation of such structural 
motifs into peptidomimetics the synthesis of versatile iodo-diazenylbenzoates as aromatic 
scaffold is a central task. In first attempts, 4-methylaniline was substituted with methyl 
2-diazonium-benzoate to afford the azobenzene derivative in 94 % yield. Subsequently, the 
aromatic amine was converted into an iodo substituted by a Sandmeyer-type reaction 
(17 %). Unfortunately, purification of the iodo compound was difficult and only ortho 
iodinated azobenzene derivatives could be isolated using this procedure. A far more 
versatile approach to access azobenzene derivatives 98 and 99 with diverse substitution 
patterns was the oxidation of methyl benzoates with amino groups in 2- or 3-position to 
obtain the corresponding nitroso derivatives and subsequent condensation with 2- or 
3-iodo-anilines (Table 7).  
 
 
 
 
 
 
 
IV-6. Smart Azobenzene-Based Turn Mimetics 
72 
Table 7. Preparation of azobenzene-based turn motif mimetics 100  and 101 . (a) Oxone®, 
CH2Cl2 /H2O (2:8),  rt, 20 h. (b) 2- or 3-iodo-aniline, AcOH, 0 °C-rt, 14 h. (c) Propargylamide 
1 ,  6 , PdCl2(PPh3)2, CuI, THF/piperidine (3:1), r t, overnight.  
 
a The tert-butylsulfinyl protective group of the amide was replaced by Boc.  
 
Sonogashira reaction of iodinated azobenzenes 98-99 with propargylamides 1 and 6 gave 
the smart peptidomimetics 100-101. The sterically hindered 2-iodo-anilines were much less 
reactive in the diazotation reaction than the 3-iodo-anilines giving 98 in yields of only 25-
38 % instead of 76 % yield obtained for 99. The subsequent Sonogashira reaction is 
hindered in a similar manner by the adjacent diazobenzenecarboxylate resulting in a yield 
of 8 % for 2-substituted azobenzene 100b instead of 48 % for the 3-substituted azobenzene 
101.  
 
UV/Vis spectroscopic investigation of ortho-substituted azobenzene derivatives showed 
reversible isomerization for precursor 98a (Diagram EP21, Experimental Part), but not for 
peptidomimetic 100b (Diagram EP22, Experimental Part). The photoisomerization of 
meta-substituted peptidomimetic 101 could be confirmed by UV/Vis- as well as 1H NMR 
spectroscopy (Figure 29).  
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Figure 29. Photoisomerization of azobenzene -based peptidomimetic 101 . a) UV/Vis spectra 
of E-101  (blue) and Z-101  (red and green, also compare Diagram EP23, Experimental Part).  
Reisomerization could not be observed. b) 1H NMR spectra in the range of 3.40-3.10 ppm of 
E-101  ( top) and Z-101  (bottom) in CDCl 3 (also compare Diagram EP17, Experimental Part).  
c) Chemical structures of E-101  (top) and Z-101  (bottom) corresponding to the 1H NMR 
spectra in Figure 29b with marked azobenzene isomers and remaining rotat ional degrees of 
freedom.  
 
In the dark, the E/Z ratio of peptidomimetic 101 was 100:0 as confirmed by 1H NMR 
spectroscopy. Irradiation of 101 for 5 min at 420 nm led to almost complete isomerization, 
i.e. an E/Z ratio of 4:96 (Figure 29b and Diagram EP17, Experimental Part). Still, 
reisomerization could not be observed even within 3 weeks in the dark. The presence of 
internal H-bonds was confirmed 1H NMR spectroscopically by comparison of the chemical 
shifts of propargylamide 6c with those of the E- and Z-isomers of peptidomimetic 101 
(Figure 30). 
 
Figure 30. Identification of intramolecular H -bonds by comparing the chemical shifts of the 
amide protons. a) Parts of the 1H NMR spectra (4.40-3.10 ppm) measured in CDCl3  of b) 
propargylamide 6c, c) E-isomer of 101  and d) Z-isomer of 101  (the postulated H-bond is 
visualized with a dotted line).  
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In comparison to propargylamide 6c and E-101, the signal of the amide proton of Z-101 is 
significantly shifted to the downfield by  0.8-0.9 ppm. Such a downfield shift  is typical 
for the existence of an H-bond and, therefore indicates an intramolecular H-bond between 
the amide proton and the carbonyl moiety in the Z-isomer Z-101. This H-bond encloses a 
15-membered ring in Z-101, which cannot be observed for the E-isomer E-101. In 
conclusion, peptidomimetic 101 forms a forward -turn motif when exposed to irradiation 
at 420 nm and a more extended conformation in the dark and is therefore referred to as a 
smart turn mimetic.  
 
 
 
 
 
 
IV-7. Hydrazines and Hydrazones induce Backbone Bending 
In the last application of the peptidomimetic scaffolds of this work as turn mimetics, the 
N-terminal moiety was expanded instead of the aromatic part. The propargylamine was 
converted into a propargylhydrazide to spatially enable the formation of an H-bond 
between the terminal NH group of the hydrazide and the carbonyl moiety of an ortho-
substituted benzoate. Therefore, the propargylamides 6 described in Chapter II had to be 
deprotected and converted into propargylhydrazides 104. According to a reported method, 
an excess of propargylamine 102a (>5 eq) was aminated with hydroxylamine-O-sulfonic 
acid (1 eq) and the propargylhydrazide 104a was isolated by distillation [169]. However, 
most propargylamides 6 and their derivatives are not volatile and wasting four out of fife 
equivalents of propargylamine was not efficient. In a very new approach recently reported 
by Kang et al. [59], the electrophilic amination reagent 103 was used to transfer an NHBoc 
moiety to an amine. Reaction of propargylamines 102a-c with 103 afforded Boc protected 
hydrazides 104, which were subsequently linked to 2-iodo-benzoate 26a by the 
Sonogashira reaction (Table 8).  
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Table 8. Preparation of hydrazine - and hydrazone-based turn motifs. Reaction conditions: 
(a) HCl (4 M in dioxane, 4  eq), MeOH (5-15 mL), rt, 4-7 h. (b) Aqueous, saturated NaHCO 3 
solution/THF (1:1, 40 mL), diethyl 2-Boc-1,2-oxaziridine-3,3-dicarboxylate (103 , 1.2 eq),  
rt, overnight [59]. (c) Methyl 2-iodobenzoate (26a ,  1.6 eq), PdCl2(PPh3)2 (1 mol%) CuI 
(2 mol%), THF/piperidine (3:1). All given yields refer to isolated compounds.  
 
a Propargylamine 102a  was commercially available.  
 
The amination of propargylamines 102 using the Boc-amine transfer reagent 103 proceeded 
in yields of 51-86 %. Formation of a byproduct could be observed by TLC of the crude 
product. NMR spectroscopic investigation revealed that the amine of 104 had been partially 
oxidized to provide propynal hydrazones 105. According to the 1H NMR spectra, the ratio 
of hydrazines 104 : hydrazones 105 was 66:44. It is assumed that amine transfer reagent 
103 was contaminated by the oxidant Oxone®, which was used for the preparation of 103 
and does not produce any signals during NMR spectroscopy. Coupling of hydrazines 104 
and hydrazones 105 to iodoarene 26a by Sonogashira cross coupling provided 
peptidomimetics 106 and 107 in equimolar ratio. The yields decreased with extension of 
the side chain of the alkyne moiety with 104a>104b>104c and 105a>105b>105c under the 
given conditions.   
The readily crystallizing hydrazone 107a allowed the recording of an X-ray crystal 
structure giving information about the conformation of 107a in the solid state (Figure 31).  
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Figure 31. X-ray crystal structures of the alanine analogous propargylhydrazide 104b ( left) 
and of propynal hydrazone 107a  (right).  
 
The short interatomic distance of only 2.246 Å as visualized in the X-ray crystal structure 
indicates a strong intramolecular H-bond between the hydrazone proton and the carbonyl 
moiety of the ester. In a CDCl3-solution, the chemical shift in the 
1H NMR spectrum of the 
amide proton confirms the stability of this H-bond (for a complete and detailed 
visualization of the NMR studies, please see Diagrams EP18-20 in the Experimental Part). 
Whereas the downfield shift in hydrazides 106 in comparison to 104 is already significant 
(a 0.93 ppm, b 0.39 ppm, c 0.86 ppm), the downfield shift in hydrazones 107 versus 
105 is immense (a 4.03 ppm, b 3.19 ppm, c n.a.). Apparently, H-bonds between the 
amide proton and the carbonyl moiety are much stronger in hydrazones 107 than in 
hydrazines 106. Yet, both compounds arrange in a forward -turn analogous motif and are 
likely to form hairpin mimetics.  
 
IV-8. Conclusion  
Based on the pool of peptidomimetics presented in Chapter III, several nonpolar small 
molecules were designed as sterically induced turn mimetics. Thus, naphthoate-based turn 
mimetic 92 was designed as DNA-intercalating warhead of a hairpin mimetic. While 
biphenyl-based peptidomimetic 94 did not form a turn motif, the analogous hairpin mimetic 
97 induced a -sheet by an extended loop. Furthermore, the access to smart azobenzene-
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based peptidomimetics 100 and 101 was reported. Their irradiation-induced complete 
isomerization to the turn forming Z-azobenzene derivatives renders these scaffolds smart 
turn mimetics. Although hydrazines 106 and hydrazones 107 contain the highest number 
of rotationally unconstrained single bonds, they form the most stable turn mimetics. The 
conformational preferences of the novel scaffolds have been investigated by 1H NMR 
spectroscopy, determination of temperature coefficients and X-ray crystal structure 
analysis. Analysis of intramolecular H-bonds showed that all turn mimetics arranged in an 
analogue manner to the non-natural forward - or -turn. In future works, these turn 
mimetics can be incorporated into di- or tripeptides by adding only one or two amino acids 
to the N- and C-termini. The investigation of such short hairpin mimetics will contribute to 
the comprehension and directed application of the discussed scaffolds. As the structures of 
this work differ from peptide-based turns by lower polarity, an application of these turn 
motifs as hydrophobic interaction partners will be another reasonable approach for future 
works.  
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V Structure-Activity Relationship of Propargylamine-Based 
HDAC Inhibitors 
This chapter is a summary of the results, published in 2017 in the article “Structure-Activity 
Relationship of Propargylamine-Based HDAC Inhibitors” (see appendix) [2].  
 
V-1. Peptidomimetics as HDAC Inhibitors 
Histone Deacetylases (HDACs) control cellular functions like transcription and thus are 
valuable therapeutic targets in epigenetic regulation including autoimmunity [170], 
neurological processes [171] and tumor growth suppression [172–174]. The eleven HDAC 
members are divided into four classes according to their function, localization and sequence 
homology [175]. Knockout experiments suggest, that suppression of class I-IIA HDACs 
may lead to serious side effects like cardiac defects, which were not observed in class IIB-
IV HDACs [176–178]. A particularly interesting drug target is HDAC6 belonging to class 
IIB, which also deacetylates -tubulin [179]. Defects in its regulation are related to 
Alzheimer’s disease [171], Huntington’s disease [180–182] and cancer cell metastasis 
[172]. Therefore, we became interested in the development of novel selective HDAC 
inhibitors (in particular HDAC6 inhibitors). In this part, some peptidomimetics inhibiting 
selectively HDAC6 are reported.  
The active site of an HDAC consists of a hydrophobic channel that is terminated by a bound 
Zn2+ ion catalyzing the deacetylation of lysine residues [183–185]. Therefore, potent 
inhibitors consist of a Zn2+ binding group that is linked by a rather rigid, rod-like linker 
with a selectivity inducing cap group [186,187] (Figure 32).  
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Figure 32. HDAC inhibitors composed of a cap group, linked to a Zn 2 + binding group. 
Structural elements for each segment of the scaffold are summarized in the boxes below the 
general structures [175,180,188]. The moieties, selected for the composition of the model 
compound of this SAR are marked. Combination of the segments gives the lead structure 
(molecule below) [189] whose derivatives are discussed in this work.  
 
The bulky, mainly aromatic cap groups interact with the surface of HDACs, allowing 
discrimination between different enzymes. Nonpolar aliphatics, olefins, alkynes or 
aromatics facilitate the entrance of the linker into the hydrophobic channel. The Zn2+ 
complexing group, e.g. a benzamide, boronic- or carboxylic acid, ketone, thiol or 
hydroxamic acid terminates the linker. Sendzik et al. have combined three moieties as 
depicted in Figure 32 extensively varying the cap group [189]. In this work, the linker was 
functionalized with residues of different size (Figure 32, marked magenta) and chirality. 
Furthermore, the aromatic ring was varied, as well (Figure 32, marked light blue).  
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V-2. Synthesis of Inhibitors from Peptidomimetics 
The peptidomimetics inaugurated in chapter III contain the scaffold of the discussed 
inhibitors. They were converted into hydroxamic acids 109a-i in two reaction steps 
(Table 9).  
 
Table 9. Synthesis of hydroxamic acids 109  as HDAC inhibitors. (a) 1) HCl (4 M in dioxane, 
4 eq). 2) 2-Benzofuranoyl chloride (1.5  eq),  NEt3 (6 eq), CH2Cl2,  0 °C, 6-14 h. (b) 
H2NOH/H2O/MeOH/THF (1:1:4:4), NaOH (pH 10-11), rt, 16 h. The given yields refer to 
peptidomimetic 46 ,  50 . Order of the entries: a-c) (S)-Configured peptidomimetics with 
decreasing size. d) Reference compound 109d has been described by Sendzik et al.  [189] .  
e-g) (R)-Configured peptidomimetics with increasing si ze. h-i) Heteroarenes.  
 
After acidic methanolysis of sulfinamides 46 and 50 with diluted HCl, the free amines were 
reacted with 2-benzofuranoyl chloride to give carboxamides 108a-i. Under basic 
conditions, the methyl esters 108a-i were converted with an excess of hydroxylamine into 
hydroxamic acids 109a-i. Hydrolysis of the esters was observed as byproduct of the 
reaction via LCMS. Low solubility in water, acetonitrile or any other solvent except for 
DMSO led to significant losses during the purification process giving total yields of 6-
43 %.  
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V-3. SAR of HDAC Inhibitors 
The inhibitory activity of the synthesized compounds was determined in an enzyme 
inhibiting assay developed by Schwienhorst et al. [190,191]. Application of a fluorescent 
substrate developed by Jung et al. allowed monitoring of the HDAC inhibition by 
fluorescence quantification [192]. The results of the SAR study are summarized in 
Figure 33c and visualized in Figure 33a,b.  
 
 
Figure 33. Results of the SAR study of compounds 109a-i. a) Comparison of inhibition of 
HDAC1 and HDAC6. IC5 0(±SEM) values are given in nM. b) Comparison of inhib ition of 
HDAC8 and cytotoxicity values on KB -3-1 cell line. IC 50(±SEM) values are given in M. c) 
Table with all test results and their corresponding selectivity .  
a The inhibition at each inhibitor concentration was determined as triplicates for HDAC1 
and HDAC6 and as technical and biological duplicates for HDAC8.  
b Cytotoxicity values refer to cell line KB -3-1 and were determined as sixfold replicates.  
 
V-4. References (170-194) 
84 
While (S)-configured hydroxamic acids 109a-c are not very active against HDAC1,6 and 
8, their potency toward HDAC6 even decreases with increasing bulkiness of the substituent 
in the C position. The (R)-configured compounds 109e-i are potent inhibitors of HDAC6 
without significant influence of the R1 substituent size. However, selectivity on HDAC6 is 
largely enhanced for R-configured compounds 109e-i relative to the achiral parent 
compound 109d. Inhibition of HDAC8 by hydroxamic acids 109a-i is significantly weaker 
(Figure 33b). A correlation between cytotoxicity and HDAC1 inhibition could be observed. 
Unexpectedly, the picolinate-based peptidomimetic 109h was inactive. Probably, due to an 
intramolecular H-bond between the hydroxamic acid and the pyridine N-atom, the Zn2+ 
binding is weakened. Thiophene-based peptidomimetic 109i on the other hand shows an 
extraordinarily high HDAC6-inhibitory activity affinity and selectivity. Both features are 
probably related to the slight curvature in the backbone of 109i.  
The observed structure-activity relationships, in particular with respect to the influence of 
the configuration, are clearly supported by molecular docking studies with the recently 
elucidated X-ray crystal structure of the complex of HDAC6 and trichostatin A [193,194].  
The peptidomimetics described in Chapter III were applied as a linker segment for potent 
HDAC inhibitors. (R)-Configured propargylamides mimic (S)-configured lysine-based 
substrates and display high activity and selectivity toward HDAC6. In particular, thiophene 
derivative 109i emerged as a selective low-nanomolar HDAC6 inhibitor with good HDAC6 
selectivity while retaining low cytotoxicity.  
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VI Peptidomimetics as RGD-Mimetics 
In this chapter, the application of the discussed peptidomimetic scaffolds as integrin v3 
antagonists is described. Therefore, the recognition amino acid sequence arginine-glycine-
aspartate will be imitated linking an arginine analogous propargylamide to different 
aspartic acid surrogates. The glycine-spacer will be replaced by a rigid ethynyl-based 
spacer. The geometry of the novel class B peptidomimetics will be compared to established 
mechanistic class D peptidomimetics and class A modified peptides reported in literature. 
 
VI-1. Design of mechanistic Peptidomimetics 
The tripeptide sequence RGD (-Arg-Gly-Asp-) is the recognition epitope of extracellular 
matrix proteins to interact with diverse transmembrane cell adhesion receptors [195], which 
are associated with adhesion [196,197] and signal transduction [198]. Mimicry of this 
recognition sequence is a promising approach to disrupt protein-protein-interaction 
[199,200]. Thus, effective antithrombotic agents based on RGD containing peptides have 
been developed to inhibit aggregation of fibronectin to GPII/III [200,201]. Radiolabeled 
RGD mimetics have been used for integrin imaging [202] and aggressive cytotoxic agents 
have been successfully linked to RGD mimetics to induce selective drug targeting [203].  
In particular, the conformation of RGD mimetics determines the spatial arrangement of the 
functional groups and consequently its affinity for a particular receptor. -Turns [58] and 
type II’ -turn motifs [204] have been discussed as appropriate conformational constraints 
to induce a kink around the glycine moiety and the appropriate distance between the basic 
and acidic functional groups, which support the interaction with integrins [58,204].  
The development of highly potent inhibitors like Cilengitide® proved, that cyclization is a 
convenient constraint to fix such types of conformation and to achieve proteolytic stability 
[50,205]. X-ray crystal structures of the v3 integrin together with the peptide-based 
inhibitor, reveal a stretched and almost linear spatial arrangement of the arginine- and the 
aspartate side chain in the bound conformation [206]. The most important functional groups 
and their three-dimensional arrangement for possible interactions between integrin v3 
and its inhibitors can be deduced from the X-ray crystal structure.  
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Figure 34. Interaction potential of cyclo(RGDfX) (X = V, L, A, …), derived from the X -ray 
crystal structure of integrin v3 co-crystallized with Cilengitide® [206]. a) Interactions of 
Cilengitide® in the binding pocket of integrin v3 found in the X-ray crystal structure. b) 
Cilengitide®:  Important functional groups for the interaction are em phasized and labeled. 
c) Most significant distances and angles of Cilengitide® as representative of RGD-based 
agents.   
 
A different approach to improve bioavailability, selectivity and the recognition of the active 
site of the receptor is the development of small mechanistic class D peptidomimetics, with 
the required functional groups arranged in an appropriate manner within a non-peptidic 
scaffold.  
These mechanistic peptidomimetics represent promising PPI disruptors, since they follow 
Lipinski’s criteria for drug admission and show high stability against proteases [29]. 
Moreover, investigations of the binding pocket of integrins showed, that only the 
guanidine- and the carboxylate moieties of RGD peptides are enlaced in the crevice 
between - and -subunit [206]. The rest of the molecule is exposed to the water surface 
associated with hydrolysis, rendering topographical mimetics more stable than peptide 
structures. Extensive analysis of the topology of bioactive conformations of the RGD motif 
is required to develop potent RGD mimetics. Typically, such mechanistic peptidomimetics 
consist of a basic (guanidine, amidine) and an acidic (carboxylate) functional group, which 
are arranged on a rigid scaffold. Some examples of class D peptidomimetics are displayed 
in Figure 35.  
a) 
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Figure 35. Topographical peptidomimetics of the RGD  sequence. Compound 110 ,  111 ,  112 
[207], compound 113  [208], compound 114  [209], compound 115  [210], compound 116 ,  117  
[211], compound 118  [200], compound 119  [202].  
a IC50 values refer to integrin v3 determined in a cell adhesion assay [202,207,208].  
b IC50 values refer to glycoprotein IIb3 determined in a platelet -rich plasma assay 
[200,207,209–211].  
 
Whereas an ester [212] or hydroxamic acid [212] instead of the carboxylic acid of aspartate 
are rare (e.g. compound 114) [209], diverse surrogates of the guanidine of arginine are 
reported in literature, like 2-aminopyridine moieties (compounds 110, 112, 113 and 119) 
[202,207,208], amidines (compounds 114, 115, 117) [209–211] or piperidines (compound 
118) [200]. As in arginine, the basic group usually terminates an aliphatic side chain, but 
connects onto an alkyne (e.g. compound 117) [211] or a benzene ring (e.g. compounds 114 
and 115) [209,210] are also conversant. The glycine spacer in the model peptide RGD has 
been replaced by various rigid structural elements, such as 1,3- (e.g. 114) [209] or 1,4-
disubstituted aromatics (e.g. compounds 110-112) [207], quinazolinone systems (e.g. 
compounds 115-118) [200,210,211], combined with alkynes (e.g. compounds 116, 118) 
[200,211] and triazoles (e.g. 119) [202], which typically represent the core unit of the 
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mimetics. As the elevated scaffolds of the glycine surrogates allow the introduction of 
versatile components including cytotoxins [203], radiolabels [202] or surface recognition 
elements to adhere to cells [199], the development of functionalized RGD mimetics has 
become subject to various current works. Successful approaches comprise 
polyethylenglycol linker units at the N-terminal part of the topographical mimetic [207] or 
-alanine substituents at the C-terminal part of the backbone structure [202,208,209].  
In this work class B peptidomimetics, referred to the definition of Pelay-Gimeno [31], with 
rigid scaffolds and orthogonal substitutable N- and C-terminus are applied to mimic the 
RGD sequence.  
 
VI-2. Preparation of RGD analogous Class B modified Peptides 
The synthesis of the RGD mimetics started with the arginine analogue propargylamide 6x, 
which has been prepared in Chapter II using Ellman’s chiral sulfonamide [1]. In analogy to 
the RGD sequence, the inhibitors of this work contain an arginine related side chain, which 
is connected via a rigid alkyne-based linker with an aspartate related side chain. The rigid 
linker moieties consist of alkyne-aryl units or 1,2,3-triazoles, which can be formed by 
reliable Click reactions.  
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Table 10. Synthesis of RGD mimetics 133-137  by conversion of the arginine analogous 
propargylamide 6x  with aspartate analogous aromatic halides 38a  and 120-124  via 
Sonogashira  cross-coupling or with azides 125 ,  126  via copper catalyzed 
[3+2]cycloaddition.  
 
a In compounds 122-132 , X = tert-Butyl and Y = Me. In compounds 133-137 ,  X = Y = H.  
b Reaction conditions: (a) PdCl 2(PPh3)2,  CuI, piperidine/THF, 1:3. (b) CuSO 4, sodium 
ascorbate, DMF/H2O, 10:1. (c) TFA/Triisopropylsilane/H 2O 190:5:5, rt, 36 h. (d) 1. LiOH, 
MeOH/H2O, 2:1, 0 °C, 12 h; 2. TFA/Triisopropylsilane/H 2O 190:5:5, rt , 36 h.  
 
The aromatic halides 120 and 38a were obtained by a Sandmeyer type reaction. 
Dimethyl 5-aminoisophthalate and 3-amino-4-(methoxycarbonyl)benzoate were reacted 
with NaNO2 in half-concentrated HCl and subsequent addition of KI and I2 gave the desired 
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aromatic iodides 120 and 38a in yields of 30 % and 87 %, respectively. As the benzoates 
are supposed to resemble the C-terminus of a peptide, carboxylic acid 38a was converted 
into an acid chloride, which was reacted with methylamine to afford methylamide 121 in a 
yield of 43 %. However, neither benzoate 38a nor amide 121 could be successfully coupled 
with propargylamide 6x under Sonogashira conditions. Most probably, the palladium 
catalyst was coordinated by the carboxylic acid of 38a or the amide of 121, respectively.  
To improve the reactivity of halide 38a for the following Sonogashira cross-coupling, the 
carboxy group was protected as tert-butyl ester to provide diester 122 in a yield of 50 %. 
Aryl iodide 122 was coupled in a Sonogashira reaction with the arginine analogous 
propargylamide 6x to provide peptidomimetic 128 in 52 % yield. Under acidic conditions, 
the tert-butylsulfinyl protective group, both Boc protective groups and the tert-butyl ester 
were cleaved simultaneously to form inhibitor 133.  
Geometric considerations of ligand 133 suggest that the size of the phenylethynyl-linker 
unit between the side chains is only 4.9 Å, resulting in a distance of 13.0 Å between the 
guanidino and carboxylate moieties, which was estimated to be rather short. Therefore, the 
size was extended by linking an aspartic acid derivative via an amide bond to 3-iodobenzoic 
acid and 5-bromothiophene-2-carboxylic acid, providing the aromatic halides 123 and 124 
in 48 % and 30 % yield, respectively. Both aromatic halides could be readily coupled with 
alkyne 6x in a Sonogashira cross-coupling reaction leading to 129 and 130 in 74 % and 
64 % yield, respectively. The cleavage of all protective groups was performed 
simultaneously under acidic conditions. Diester 129 was dissolved in HCl (2 M, 
CH2Cl2/dioxane, 1:1), which led to an incomplete cleavage of the protective groups, 
resulting in low yield 3 %. Complete cleavage was accomplished with TFA, 
triisopropylilane and H2O (95:2.5:2.5). 
For the synthesis of RGD-mimetics with a triazole ring, (S)-2-azidosuccinic acid 125 was 
required as C-terminal moiety. Starting from (S)-aspartic acid, methylation and subsequent 
azide transfer yielded the desired precursor 125 in only 11 % yield, whilst the reverse order 
of reaction worked even worse (4 % overall yield). However, conversion of dimethyl 
(R)-malate with NaN3 under Mitsunobu conditions led to azide 125 in 18 % yield (see also 
Scheme EP3, Experimental part). [3+2]-Cycloaddition of azide 125 with propargylamine 
6x and subsequent cleavage of the ester groups with LiOH and of all other protective groups 
under acidic conditions yielded peptidomimetic 136 in 15 % overall yield.  
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As the linker unit of RGD mimetic 136 appeared to be comparatively short, as in 133, a 
triazole-based mimetic with an extended linker unit was prepared.  
Therefore, tert-butyl protected aspartic acid was acylated with azidoacetic acid, which was 
obtained by nucleophilic substitution of bromoacetic acid with NaN3. [3+2]-Cycloaddition 
of azide 126 with propargylamine 6x, followed by simultaneous cleavage of all protective 
groups under acidic conditions yielded triazole 137 in an overall yield of 47 %.  
 
VI-3. Biological Evaluation of novel RGD Mimetics 
The affinity of the RGD analogous peptidomimetics 133-137 to integrin v3 was 
determined in a standardized, competitive ELISA, developed by Frank et al.[213] and 
evaluated by Kapp et al. [143]. In the assay, the inhibition of v3 binding to immobilized 
vitronectin by the competing test compound is measured. As the peroxidase on IgG-POD, 
which is linked via anti-v3 to integrin v3, only converts a colorless substrate into a 
colored one when it’s immobilized on vitronectin, the intensity of the color correlates with 
the amount of integrin, that does not bind the test compound.  
 
Table 11. IC50-values of the peptidomimetics  133-137  on integrin v3, using the 
competitive ELISA, developed b y Frank et al .[213] and evaluated by Kapp et al .[143] All 
IC5 0-values were referenced to Cilengitide® (0.54 nM) [143]. For Sigmoidal Curves of 
ELISA- and cell adhesion assays, see Figures EP5 and EP6, Experimental Part.  
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The aromatic carboxylate 133 has a very low affinity, which could be increased 400-fold 
by an extension of the backbone, like in compound 134. Substitution of the aromatic by a 
thiophene ring in compound 135 surprisingly led to another 4-fold increase of the affinity. 
The triazole based compound 136 has hardly any affinity. However, when the scaffold was 
elongated in compound 137, the most active compound under investigation was obtained 
(IC50 = 3.85 M).  
Docking studies of all compounds to available crystal structures of v3 were performed 
to understand the observed in vitro inhibition data and correlate them with Craig et al.’s 
discussion of the binding site of v3 (also see Figure EP7-11 and Table EP33, EP34, 
Experimental Part) [214]. As expected, the benzoic acid of compound 133 is able to contact 
the MIDAS site of the -subunit, but is too bulky and hydrophobic to enter the 
corresponding crevice (Figure 36, see also Figure EP9, Experimental Part). Yet, the 
guanidino group can reach one side of the highly polar pocket of the v-subunit, forming 
hydrogen bonds to Asp218 and Gln180.  
 
 
 
 
Figure 36. Binding modes of the short RGD mimetics 133  (brown) and 136  (cyan), docked 
into the binding pocket of integrin v3. Left side: Demonstration of the crevices between 
the v- and the 3-segment. Polar regions are colored in red, hydrophobic regions are 
colored in blue and Mn2 +  ions are colored in green. Right side: Most important amino acid 
residues of the binding pocket of integrin v3. The Mn2 + ions are shown as pink dots.  
 
The interaction potential of the smaller triazole-based compound 136 appears to be even 
smaller (see also Figure EP9 and Table EP34, Experimental Part). Although its carboxylic 
acid has an appropriate geometry to enter the crevice of the MIDAS site, the whole 
molecule is too short for the guanidino group to reach the polar binding pocket of the v-
segment, allowing only a weak interaction with Asp218. Both RGD mimetics 133 and 136 
appear to be too short for appropriate interaction of the terminal basic and acid functional 
groups with integrin v3. In order to increase the interaction with integrin v3 the size 
VI-3. Biological Evaluation of novel RGD Mimetics 
95 
of the ligands and thus the distance between the acidic and basic functional groups was 
increased. The ligands with extended linkers including 134, 135 and 137 showed increased 
affinity towards integrin v3 (Figure 37, see also Figure EP10, 11 and Table EP34, 
Experimental Part).  
 
Figure 37. Binding modes of the RGD mimetics 134  (green, left side), 135  (rose, left side) 
with an arylethynyl spacer as well as the triazole -based mimetic 137  (magenta, right side) 
docked into the binding pocket of integrin v3. The Mn2 + ions are shown as pink dots.  
 
Introduction of a spacer between the benzene ring and the carboxy moiety of 133 led to a 
ca. 400-fold increased affinity of 134 towards integrin v3. The higher affinity of 134 is 
explained by stronger interaction in the binding pocket. In particular, H-bonds between the 
guanidine group of 134 and carbonyl moieties of Asp150, Gln180 and Asp218 are found 
and the carboxy group of 134 coordinates the Mn2+ ion within the MIDAS site. Both ends 
are able to enter the polar crevices between the v- and 3-subunits. The additional amide 
group of 134 can contact the backbone-carbonyl moiety of Arg216. Replacement of the 
benzene ring by a thiophene ring (135) does not alter the docking result, but increases the 
affinity 4-fold.  
Introduction of a similar spacer into triazole 136 led to 10000-fold increased affinity. Both 
crevices between v- and 3-subunits can be addressed by the guanidino group and the 
carboxy moiety. The guanidine group can form H-bonds to Gln180 and Asp218 and the 
carboxy group of the aspartic acid can coordinate the MIDAS site. Furthermore, a H-bond 
between the amide NH of the RGD mimetic and the backbone carbonyl moiety of Arg216, 
as well as between the triazole and the backbone carbonyl moiety of Asp218 can be 
detected.  
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Notably, all investigated compounds are far less active than the reference compound, 
Cilengitide®, or any of the topographical class C peptidomimetics compiled in Figure 35. 
Although all compounds are hydrophilic and small (less than 400 g mol-1), they contain a 
lot of H-bond acceptor (10-16) and H-bond donator groups (6-9). So, they inconveniently 
do not comply with Lipinski’s rule of five [29]. Nevertheless, as class B peptidomimetics, 
they retain a N- and C-terminus, maintaining the option of cyclization. The linear tripeptide 
RGD (IC50 = 89±12 nM) [143] shows the highest similarity to the mimetics 133-137 of this 
work. Still, the linear RGD tripeptide has a 43-fold higher affinity to integrin v3 than 
the most active mimetic 137 of this work.  
 
VI-4. Conclusion 
In this chapter, a novel concept to imitate the RGD sequence with versatile class B 
peptidomimetics is presented. In the RGD mimetics, the glycine residue is replaced by an 
arylalkynyl moiety or a triazole ring. Attachment of an aspartic acid moiety to the central 
core unit resulted in a 400- to 10000-fold increased affinity (134, 135, 137). Although the 
presented compounds show moderate v3 affinity, they offer versatile potential for 
further modifications, like the replacement of the amide moiety in compounds 134, 135 and 
137, attachment of cap-groups to the C- and N-terminus of the ligands or cyclization. 
Despite their comparatively low affinity, the newly designed compounds combine the 
proteolytic stability of topographical peptidomimetics with the versatile substitution pattern 
of the linear RGD sequence.  
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VII Summary and Perspectives 
In this thesis, novel devices for the design of peptidomimetics were explored. The amino 
acid isosteric propargylamides were established as elementary building blocks. In a three 
step de novo synthesis 24 propargylamides 6 with diverse functional groups in the side 
chain including aliphatic, aromatic, non-proteinogenic, polar, acidic and basic groups were 
prepared in high diastereomeric purity (Figure 38).  
 
Figure 38. De novo  preparation of diastereomerically pure propargylamides 6  and their 
conversion into peptidomimetics. (a) 1. ( S)-tert-Butylsulfinamide (2), CuSO4,  CH2Cl2, 3 d. 
2. Trimethylsilylethynyl lithium, AlMe 3,  toluene, -78 °C, 2-4 h. 3.  KF, 18-crown-6, 
THF/H2O (98:2), 0 °C, 4-8 h. (b) Haloarenes (26  gave 27 ,  36-39  gave 40-43 ,  45  gave 46 ,  47  
gave 49 ,  48  gave 50), PdCl2(PPh3)2,  CuI, THF/piperidine (3:1),  overnight,  rt.  (c) Methyl  
propynoate 73 , Pd(OAc)2,  TDMPP, toluene, rt, 2  h. (d) Azide 61 , CuSO4,  sodium ascorbate,  
DMF/H2O (10:1), r t, 2d.  
   
Aldehydes 3a-u were condensed with Ellman’s chiral sulfinamide 2. Diastereoselective 
Re-face addition of trimethylsilylethynyl lithium to the (S)-configured sulfinylimines 4 and 
subsequent removal of the TMS group gave propargylamides 6a-x. An electron 
withdrawing group (EWG) in -position resulted in susceptibility of the propargylamides 
towards bases, while an EWG in -position increased the acidity of the adjacent methylene 
moiety leading to a competition between deprotonation and nucleophilic addition during 
the reaction with trimethylsilylethynyl lithium. Surprisingly an azide present in the side 
chain led to an intramolecular non-catalyzed Huisgen [3+2] cycloaddition at ambient 
temperature. This side reaction could be completely suppressed by reduction of the azide 
via Staudinger reaction directly after nucleophilic addition of trimethylsilylethynyl lithium 
at -78 °C. During the reduction of the azide with PPh3 simultaneous cleavage of the TMS 
group was observed (Chapter II).  
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A large set of peptidomimetics 27, 40-43, 46, 49 and 50 with diverse structural elements 
was obtained by connection of the enantiomerically pure propargylamides 6a-x with halo-
benzoates 26, 36-39, 45, 47 and 48 via Sonogashira cross-coupling (Figure 38).  
The backbone curvature of these peptidomimetics was defined by the substitution pattern 
of the arenes. Preferences of particular conformations were analyzed by combination of 
molecular dynamics (MD) simulations with X-ray crystal structure analysis. Remarkably, 
during the preparation of the ortho-substituted benzoic acid derivative 27m an 
intramolecular 5-exo-dig cyclization with the alkyne forming benzofuran 28 was observed 
under Sonogashira conditions. Another investigated side reaction was the Propargylamide-
Enimine rearrangement, which occurred when peptidomimetics with EWGs such as CF3, 
Ph, C6F5 in -position were exposed to alkaline conditions. The discovered tautomerism 
converting propargylamides into -unsaturated N-sulfinylimines 76 was thoroughly 
studied.  
Further peptidomimetic scaffolds were obtained by Pd-catalyzed hydroalkynylation of 
methyl propynoates 73 with propargylamides 6 giving versatile 3-dipeptide isosteres 74. 
Due to the rigid system of 74, the side chain Ri+1 is locked in a particular orientation . 
Copper catalyzed [3+2] cycloaddition of propargylamides 6 with azide 61 gave 
1,4-disubstituted triazoles 62. The backbone of these peptidomimetics accurately 
represents a trans-configured 2-dipeptide.  
Based on the design-concept of the inaugurated peptidomimetics, enhanced aromatic 
systems were introduced to predefine the relative 3D orientation of N- and C-termini with 
the aim to form structural turn motif mimetics and to thereby influence the secondary 
structure of a peptide (Figure 39).  
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Figure 39. Various structural turn mimetics based on the amino -propynyl-benzoate scaffold. 
(a) 1. (S)-6a ,  HCl (4 M in dioxane), MeOH, rt, overnight. 2. Amine transfer reagent 103 ,  
saturated NaHCO 3 solution/THF (1:1, 40 mL), rt,  overnight. (b) (R)-6e, naphthalene 91b,  
PdCl2(PPh3)2, CuI, THF/piperidine (3:1), rt, overnight (=standard conditions). (c) 1.  (S)-6a ,  
HCl (4 M in dioxane), MeOH, rt, overnight. 2.  HO -Gly-Phe-Tyr( tertBu)-NHBoc, HATU, 
HOAt, CH2Cl2, DIPEA, rt, 3 d. 3. Peptide-haloarene 96 , PdCl2(PPh3)2, CuI, 
dioxane/DIPAH/DMSO (15:4:1), microwave, 60  °C, 2 h. (d) (S)-6c,  iodoazobenzoate 99 ,  
standard conditions. (e) 2 -Iodobenzoate 26a , standard conditions.  
 
1H NMR spectroscopy, the temperature coefficient T, CD spectroscopy and X-ray 
crystal structure analysis were used to identify intramolecular H-bonds indicating the 
adoption of non-natural forward - or -turn motifs. The hydrophobic naphthoate-based 
turn mimetic 92 was designed as DNA-intercalating warhead of a hairpin mimetic. 
However, its incorporation into a short peptide and the subsequent biological evaluation 
are not yet completed. Whereas the twisted biphenyl scaffold of peptidomimetic 94 
precluded an alignment as a turn motif, the analogous hairpin mimetic 97 with two short 
peptide chains at the N- and C-termini nucleated a -sheet by an extended loop. When 
exposed to irradiation, smart (E)-configured azobenzene-based peptidomimetics (E)-100 
and (E)-101 completely isomerized into (Z)-configured isomers, which in contrast to the 
(E)-isomers formed a turn mimetic. Using the electrophilic amine transfer reagent 103 
propargylamines 102 were converted into hydrazines 104 and hydrazones 105. 
Sonogashira cross-coupling reactions of 104 and 105 with 2-iodobenzoates 26a provided 
the strong turn motif mimetics 106 and 107. Introduction of one or two amino acids at the 
N- and C-termini of all discussed turn mimetics would be a promising approach to obtain 
valuable information on their properties as hairpin mimetics.  
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At last, some remarkable peptidomimetics of this work are compiled, which were designed 
in analogy to interesting natural templates (Figure 40). The superhydrogelator dipeptide H-
Leu-Phe-OMe was exactly imitated by the alkynylalkene 75b and the triazole 63d. While 
the minimum hydrogel forming concentration of triazole 63b was very high in water (22-
32 mM), stable gels were formed from iPrOH and CH2Cl2 solutions at low concentrations 
(< 2 mM). Structurally related peptidomimetics 63c and 75d were designed to imitate the 
natural dipeptide aspartame, a potent synthetic sweetener. However, the evaluation of their 
sweetness has not been performed. Introduction of additional side chains at the phenyl 
moiety of the meta-substituted aminopropynylbenzoate scaffolds was achieved by using 
appropriately substituted haloarenes prepared by electrophilic aromatic substitution. In 
analogy to the photoswitchable side chain of 4-(phenyldiazenyl)-phenylalanine, compound 
44 was prepared with a phenyldiazenyl substituent in the backbone. The ratio of 
E:Z-isomers was altered upon irradiation of 44 from 87:13 to 45:55. A remarkable 
influence of the isomerization on the backbone conformation was observed. Substituents 
in 4-position were introduced as additional side chains (42) to imitate one -helical turn 
with constrained preorientation  of the side chain Ri+1. Three helix turns of a natural 
peptide could be accurately mimicked by 57 consisting of a dimer of meta-substituted 
aminopropynylbenzoate.  
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Figure 40. Remarkable representatives of peptidomimetics as isoster es of natural templates.  
The headlines represent the natural compartement imitated by the depicted peptidomimetics.  
The IC5 0 value of compound 109i refers to HDAC6 and the IC5 0 value of compounds 135  and 
137  refer to v3. 42 , R i=(CH2)3CN, CHMe2, CH2CHMe2,  R i +1=CO2Me, NH2, N=NPh, 
N=NPh-4-NMe2.  57 , X=CH, N, R i /R i +1=CH2CHMe2 ,  CHMe2.   
 
Linear peptidomimetics 46 and 50 were used as isosteres of -acetylated lysine, the natural 
substrate of histone deacetylases (HDACs). Conversion of peptidomimetics 46 and 50 into 
hydroxamic acids 109 resulted in potent and selective HDAC6 inhibitors. A docking 
supported SAR study confirmed that (R)-configured peptidomimetics with aliphatic side 
chains increased HDAC6 inhibitory activity compared to the HDAC inhibition of the 
achiral, unsubstituted model compound up to 2.4-fold. Moreover, the selectivity over other 
HDACs was increased at least 15.8-fold. Replacement of the benzene ring by a thiophene 
ring led to inhibitor 109i with remarkably enhanced affinity (2.3-fold), selectivity (>1.4-
fold) and reduced cytotoxicity (1.5-fold) in comparison to the analogous para-substituted 
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phenyl derivative 109g. The herein discussed modifications of the linker moiety shall 
contribute to the rational design of novel HDAC inhibitors.  
Imitation of the RGD sequence was approached by connection of arginine analogous 
propargylamide 6x with different carboxylate moieties. The glycine moiety between 
arginine and aspartate of the tripeptide RGD was reproduced by the rigid backbone of the 
benzene-, thiophene- and triazole-based peptidomimetics 133-137. A competitive ELISA 
based assay (supported by docking studies) attested the novel RGD mimetics a low 
micromolar affinity. Although the IC50 values of the novel leads are quite high in 
comparison to the linear RGD sequence, the arginine analogous propargylamide 6x offers 
promising options for the discovery of new RGD mimetics and subsequent SAR studies.  
The diversity of natural products mimicked by the herein reported novel peptidomimetics 
indicates the versatility of the discussed building blocks as devices for the design and 
synthesis of new bioactive lead compounds.  
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IIX Experimental Part 
IIX-1. General Methods and Materials 
If not mentioned differently, all reagents and solvents were purchased from commercial 
sources and applied without further purification. THF and Et2O were kept over KOH before 
being dried with sodium/benzophenone under reflux and were freshly distilled before use. 
Toluene was predried over CaCl2, then dried over sodium under reflux and distilled freshly 
before use. CH2Cl2 used for synthesis was predried over CaCl2, dried over CaH2 under 
reflux and distilled freshly before use. MeOH and EtOH were heated under reflux 
conditions over 2 h with magnesium and iodine, before distillation and storage over 
molsieves (3 Å). NEt3 was refluxed and distilled first over KOH and then over NaH. After 
absolutation, NEt3 was stored over molsieves (4 Å). DMSO was dried under reflux over 
CaH2, distilled and stored over molsieves (4 Å) until use. CH2Cl2, EtOAc, PE and Et2O 
used for aqueous work-ups or column chromatography were purchased in technical grade 
and distilled prior to application.  
Schlenk-conditions: If not mentioned differently, the reactions were carried out under 
exclusion of moisture and oxygen in dried glassware under argon atmosphere. The argon 
gas was supplied from Linde (quality 4.0) and led through a column filled with 
phosphorpentoxide (sicapent®, Merck) before use.  
Solvents were removed on a rotational evaporator at 40 °C and appropriately reduced 
pressure. Solvent residues were removed at rt and 0.001-0.1 mbar.  
For column chromatography, Silica gel 60, 40-63 m (Merck) was used. The eluents and 
their proportions are individually noted. Thin layer chromatography (TLC) was executed 
using silica gel 60 coated aluminium sheets with fluorescence indicator F254 (Merck). 
Spots were identified using different stains, such as KMnO4, iodine, ninhydrin or UV light 
with a wavelength of  = 254 nm or  = 366 nm.  
Preparative HPLC (Thermo Seperation Products): Equipment: UV detector: UV1000; 
pump: Thermo Seperation Products P4000; Method: column: Thermo Scientific Hypersil 
Gold (8 m), 250 x 21.2 mm cartridge; flow rate: 10.00 mL min-1; injection volume: 1.00 
mL; detection at  = 254 nm; solvents: A: water/acetonitrile/trifluoroacetic acid 
(94.9:5:0.1); B: water/acetonitrile/trifluoroacetic acid (5:94.9:0.1). gradient elution: (A %): 
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0-1 min: 100 %, 1-30 min: gradient from 100 % to 0 %, 30-44 min: 0 %, 44-45 min: 
gradient from 100 % to 0 %.  
Melting point: Melting points were determined using a Büchi 540 melting point apparatus 
and are uncorrected.  
Optical rotation was measured on a DIP-360 (Jasco) polarimeter with a sodium vapour light 
source at a specific given temperature. A quartz cell with a path length of 10 cm was used. 
The average of ten single measurements divided by the concentration in units of g/mL and 
the pathlength (1 dm). The sample concentration and solvent is given in c = g/100 mL in 
parentheses. 
Nuclear magnetic resonance (NMR) spectra were recorded on Bruker Avance 300 
(300.13 MHz for 1H, 282.38 MHz for 19F, 75.48 MHz for 13C) or DRX 500 (499.87 MHz 
for 1H, 470.43 MHz for 19F, 125.70 MHz for 13C) or Avance 500 (500.01 MHz for 1H, 
125.74 MHz for 13C) or Avance 500 HD (500.20 MHz for 1H, 125.79 MHz for 13C) or 
Avance 600 (600.13 MHz for 1H, 564.63 MHz for 19F, 150.92 MHz for 13C). chemical 
shifts (δ), given in the experimental section, are reported in ppm relative to TMS (TMS = 
0 ppm) and referenced to the solvent residue signals as internal standard: i [ppm]: CHCl3 
( 7.26 ppm (1H NMR) and  77.2 ppm (13C NMR)) and CHD2OD ( 3.31 ppm (1H NMR) 
and  49.0 ppm (13C NMR)) and D2HCSOCD3 ( 2.50 ppm (1H NMR) and  39.5 ppm 
(13C NMR)). Coupling constants (J) are reported in Hertz (Hz) with 0.05 Hz resolution. 
Multiplicities are described as singlet (s), doublet (d), triplet (t) quartet (q) or multiplet (m). 
The assignments of 13C and 1H NMR signals were supported by 2D NMR techniques 
(COSY, HMQC, HMBC).  
MS: Nano-ESI mass spectra were recorded using an Esquire 3000 ion trap mass 
spectrometer (Bruker Daltonik GmbH, Bremen, Germany) equipped with a standard nano-
ESI source. Samples were introduced by static nano-ESI using in-house pulled glass 
emitters. Nitrogen served both as the nebuliser gas and the dry gas. Nitrogen was generated 
by a Bruker nitrogen generator NGM 11. Helium served as cooling gas for the ion trap and 
collision gas for MSn experiments.  
ESI mass spectra were recorded using an Agilent 6220 time-of-flight mass spectrometer 
(Agilent Technologies, Santa Clara, CA, USA) in extended dynamic range mode equipped 
with a Dual-ESI source, operating with a nitrogen generator NGM 11. Samples were 
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introduced with a 1200 HPLC system consisting of an autosampler, degasser, binary pump, 
column oven and diode array detector (Agilent Technologies, Santa Clara, CA, USA) using 
a C18 Hypersil Gold column (length: 50 mm, diameter: 2.1 mm particle size: 1.9 m) with 
a short gradient (in 4 min from 0 % B to 98 % B, back to 0 % B in 0.2 min, total run time 
7.5 min) at a flow rate of 250 L min-1 and column oven temperature of 40 °C. HPLC 
solvent A consisted of water, acetonitrile and formic acid (94.9:5:0.1), solvent B of water, 
acetonitrile and formic acid (5:94.9:0.1). The mass axis was externally calibrated with ESI-
L Tuning Mix (Agilent Technologies, Santa Clara, CA, USA) as calibration standard.   
Elemental analysis was performed on an Element Analyser EURO EA.  
IR: IR spectra were recorded as neat samples on a FT-IR spectrophotometer Nicolet 380 
(Thermo Scientific) equipped with ATR technique (smart orbit).  
Analytical HPLC (Thermo Scientific Accela): Equipment; UV detector: Thermo 
Seperation Products UV6000LP; pump: Thermo Seperation Products P4000; autosampler: 
Thermo Seperation Products AS100, Method: column: Jupiter 5 C18 Fa. Phenomenex, 250 
x 4.60 mm cartridge; flow rate: 1.00 mL/min; injection volume: 0.2 L; detection at  = 
254 nm; solvents: A: water/acetonitrile/trifluoroacetic acid (95.9:5:0.1); B: 
water/acetonitrile/trifluoroacetic acid (5:95.9:0.1). Gradient elution: (A, method 1): 0-9 
min: gradient from 100 % to 0 %, 9-12 min: 0 %, 12-13 min: gradient from 0 % to 100 %. 
(A, method 1): 0-4.5 min: gradient from 100 % to 0 %, 4.5-7 min: 0 %, 7-8 min: gradient 
from 100 % to 0 %. 
Crystal data were collected on an Agilent SuperNova diffractometer with Cu Kα radiation 
(27n, 29, 31o, 40d, 46j, 49a, 50f, 55c, 76f, 77g, 104b, 120) or Mo K radiation (41a, 52b, 
66g, 71, 75e, 75f, 77c, 107a) was used. The crystals were kept at 100.0(3) K during data 
collection. Using Olex2 [215] the structures were solved and refined with the ShelX 
program package [216] using direct methods and least-squares minimization. The 
experimental part of each chapter contains the supplementary crystallographic data of all 
respective compounds. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
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IIX-2. Propargylamides 
A detailed description of the propargylamide 6a-x synthesis of Chapter II, side reactions 
like the intramolecular Huisgen-reaction forming triazoles 7-8, as well as the corresponding 
NMR spectra and X-ray crystal structures have been recently published in the Beilstein 
JOC “Asymmetric Synthesis of Propargylamines as Amino Acid Surrogates” [1]. This 
experimental part is not attached to the Appendix.  
IIX-3. Peptidomimetics 
IIX-3. a) ortho-Substituted Peptidomimetics (26-27) 
2-Iodobenzoate 26a-c were purchased from Fisher Scientific.  
Methyl 2-Bromonicotinate (26d). 2-Bromonicotinate was esterified in accordance to the 
description of Setliff & Huie [217]. Under argon atmosphere, thionylchloride (0.5 mL, 
6.9 mmol, 1.4 eq) was added over a period of 30 min to a solution of 
2-bromonicotinic acid (1.02 g, 5.06 mmol, 1.0 eq) in CH2Cl2 (30 mL) 
at -30 °C. The reaction mixture was slowly warmed up to rt and stirred for 3 h 
at ambient temperature, before anhydrous methanol (4 mL) was added in one portion. The 
solution was stirred for another 18 h, the solvent removed under reduced pressure and the 
residue was filtered through a short pad of silica gel to yield nicotinate 26d in pure form.  
Slightly yellow fluid. Yield: 426 mg, 1.97 mmol, 39 % (Lit. 89 % [217]). 1H NMR 
(300 MHz, Chloroform-d) δ = 8.53 (dd, 3J = 4.79 Hz, 4J = 2.00 Hz, 1H, ar-6-H), 8.18 (dd, 
3J = 7.72 Hz, 4J = 1.99 Hz, 1H, ar-4-H), 7.34 (dd, 3J = 7.68 Hz, 3J = 4.77 Hz, 1H, ar-5-H), 
3.97 (s, 3H, CO2CH3). C7H6BrNO2 (216.03 g mol
-1). TLC: Rf (EtOAc/PE, 1:1) = 0.71.  
 
Methyl 3-Bromoisonicotinate (26e). The esterification of 3-bromoisonicotinate was 
performed as suggested by Conde et al. [218]. Concentrated sulfuric acid (0.1 mL) was 
carefully dropped into a solution of 3-bromoisonicotinic acid (268 mg, 
1.33 mmol) in MeOH (6.0 mL). The reaction mixture was heated under reflux 
conditions for 4 d. The solvent was removed under reduced pressure and the 
residue was filtered through a short pad of silica gel to yield the isonicotinate 
26e in pure form.  
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Red, viscous oil. Yield: 44.6 mg, 103 mmol, 8 % (Lit. 78 % [218]). 1H NMR (300 MHz, 
Chloroform-d) δ = 8.85 (s, 1H, ar-2-H), 8.61 (d, 3J = 5.0 Hz, 1H, ar-6-H), 7.62 (d, 3J = 
4.9 Hz, 1H, ar-5-H), 3.96 (s, 3H, CO2CH3). C7H6BrNO2 (216.03 g mol
-1). TLC: Rf 
(PE/EtOAc, 1:1) = 0.56.  
 
Methyl 3-Bromopicolinate (26f). 3-Bromopicolinate was esterified under the conditions 
described by Oballa et al. [219]. Under a nitrogen atmosphere, diazomethane (0.1 M, 
19.0 mL, 1.90 mmol, 1.3 eq) was added dropwise to a non-stirred solution of 3-
bromopicolinic acid (289.7 mg, 1.434 mmol, 1.0 eq) in dry THF (10 mL) at 0 °C. The 
reaction mixture was slowly warmed up to rt and stirred for 20 h at ambient temperature. 
The red solution was dilluted with water (40 mL) and acetic acid (1 M, 1 mL, 1 mmol) and 
the aqoueous layer was extracted with Et2O (5 x 30 mL). The combined organic layers were 
washed with brine (10 mL) and dried over Na2SO4. The solvent was evaporated under 
reduced pressure and the residue was filtered through a short pad of silica gel to yield 
picolinate 26f in pure form.  
 Slightly yellow fluid. Yield: 292 mg, 1.35 mmol, 94 %. 1H NMR (300 MHz, 
Chloroform-d) δ = 8.57 (m, 1H, ar-6-H), 7.97 (m, 1H, ar-4-H), 7.23 (m, 1H, ar-
5-H), 3.97 (s, 3H, CO2CH3). C7H6BrNO2 (216.03 g mol
-1). TLC: Rf (EtOAc/PE, 
1:1) = 0.59.  
 
Ethyl 2-((S)-3-(((S)-tert-Butylsulfinyl)amino)-4-methylpent-1-yn-1-yl)benzoate (27a). 
Piperidine (0.3 mL) was added to a solution of L-valine analogous propargylamide 6b 
(46.6 mg, 231 mol, 1 eq) and ethyl 2-iodobenzoate (26b, 102 mg, 370 mol, 1.6 eq) in 
THF (1.0 mL). The reaction mixture was degassed by freeze pump thaw method, until no 
more gas atmosphere could be detected by the manometer (3 x). 
The catalysts, PdCl2(PPh3)2 (1 mg) and CuI (2 mg) were added to 
the frozen reaction mixture and the solution slowly warmed to 
room temperature. After 30-120 min, a colorless precipitate 
formed in the clear solution, indicating the procedure of the reaction. At least 2-8 h later, 
the suspension was diluted with a saturated aqueous NH4Cl solution and KHSO4 (aq, 5 %) 
was added, until the organic layer started to turn faintly red (pH 5-6). The emulsion was 
diluted with Et2O, the organic layer was separated and the organic layer extracted to more 
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times with Et2O. The combined organic layers were dried over Na2SO4 and the solvent was 
evaporated in vacuum. The crude product of peptidomimetic 27a was purified by column 
chromatography (EtOAc/PE, 1:1).  
Colorless oil. Yield: 119 mg, 340 mol, 68 %. 1H NMR (300 MHz, Chloroform-d) δ = 7.90 
(dd, 3J = 7.8 Hz, 4J = 1.3 Hz, 1H, ar-6-H), 7.57 (dd, 3J = 7.7 Hz, 4J = 1.4 Hz, 1H, ar-3-H), 
7.43 (td, 3J = 7.6 Hz, 4J = 1.5 Hz, 1H, ar-4-H), 7.34 (td, 3J = 7.6 Hz, 4J = 1.4 Hz, 1H, ar-5-
H), 4.37 (q, 3J = 7.1 Hz, 2H, CO2CH2CH3), 4.19 (dd, 
3J = 5.4 Hz, 3J = 6.0 Hz, 1H, CαH), 
3.66 (d, 3J = 6.0 Hz, 1H, CαHNH), 2.05 (m, 1H, CH(CH3)2), 1.39 (t, 
3J = 7.1 Hz, 3H, 
CO2CH2CH3), 1.26 (s, 9H, SC(CH3)3), 1.10 (d, 
3J = 6.8 Hz, 3H, CH3CHCH3), 1.07 (d, 
3J 
= 6.7 Hz, 3H, CH3CHCH3). C19H27NO3S (349.49 g mol
-1). TLC: Rf (PE/EtOAc, 1:1) = 
0.51.  
 
Methyl 2-((S)-3-(((S)-tert-Butylsulfinyl)amino)-4-methylpent-1-yne-1-
yl)benzoate (27b). A solution of L-valine analogous propargylamide 6b (500 mg, 
2.48 mmol, 1.0 eq) and methyl 2-iodobenzoate (26a, 0.49 mL, 3.23 mmol, 1.3 eq) in a 
mixture of THF/piperidine (6 mL, 3:1) was thoroughly degassed by the freeze-pump-thaw 
method. While still frozen, the solid catalyst PdCl2(PPh3)2 (1 mol%) 
and CuI (2 mol%) was added in one portion and the mixture was 
allowed to warm up to rt and stirred overnight at ambient 
temperature. A colorless precipitate formed in the course of the 
reaction. The reaction mixture was diluted with a mixture of Et2O and aqueous NH4Cl (5:4, 
90 mL), neutralized with aqueous KHSO4 solution (5 %, 10-15 mL, until pH 7). The phases 
were separated and the aqueous layer was extracted with Et2O (3 x 50 mL). The combined 
organic layers were washed with brine, dried over Na2SO4 and the solvent was evaporated 
under reduced pressure. The crude product of 27b was purified by column chromatography 
(PE/EtOAc, 1:1).  
Highly viscous, pale green oil. Yield: 716 mg, 2.13 mmol, 85 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.64 (d, 3J = 7.8 Hz, 1H, ar-2-H), 7.32 (d, 3J = 7.6 Hz, 1H, ar-5-H), 7.17 
(t, 3J = 7.5 Hz, 1H, ar-4-H), 7.07 (t, 3J = 7.6 Hz, 1H, ar-3-H), 3.91 (dd, 3J = 6.5 Hz, 3J = 
6.0 Hz, 1H, CH), 3.71 (d, 3J = 6.5 Hz, 1H, CHNH), 3.64 (s, 3H, CO2CH3), 1.76 (m, 1H, 
CHCH(CH3)2), 1.00 (s, 9H, SC(CH3)3), 0.84 (d, 
3J = 6.8 Hz, 6H, CHCH(CH3)2). 
13C NMR (126 MHz, Chloroform-d) δ = 165.9 (CO2CH3), 133.7 (ar-C-4), 131.3 (ar-C-5), 
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131.1 (ar-C-6), 129.7 (ar-C-2), 127.4 (ar-C-3), 122.7 (ar-C-1), 92.7 (CHC≡Car), 83.8 
(CHC≡Car), 55.7 (SC(CH3)3), 53.9 (CH), 51.6 (CO2CH3), 33.4 (CHCH(CH3)2), 22.2 
(SC(CH3)3), 18.6 (CHCH(CH3)2), 17.2 (CHCH(CH3)2). C18H25NO3S (335.46 g mol
-1). 
LCMS(ESI): tr = 9.9 min, m/z = 336.16170 (calcd. 336.16279 [M+H]+), 358.1427 (calcd. 
358.1447 [M+Na]+). TLC: Rf (PE/EtOAc, 2:1) = 0.19.  
 
Ethyl 2-((R)-3-(((R)-tert-butylsulfinyl)amino)-5-methylhex-1-yn-1-yl)benzoate (27c). 
Piperidine (0.4 mL) was added to a solution of D-leucine analogous propargylamide 6c 
(163 mg, 757 mol, 1.0 eq) and the ethyl benzoate 26b (162 L, 1.23 mmol, 1.6 eq) in THF 
(1.2 mL). The reaction mixture was degassed by freeze pump thaw method, until no more 
gas atmosphere could be detected by the manometer. The catalysts, PdCl2(PPh3)2 (1.8 mg) 
and CuI (0.9 mg) were added to the frozen reaction mixture and the solution slowly warmed 
to room temperature. After 30-120 min, a colorless precipitate formed in the clear solution, 
indicating the procedure of the reaction. At least 2-8 h later, the suspension was diluted 
with a saturated aqueous NH4Cl solution and KHSO4 (aq, 5%) was added, until the organic 
layer started to turn faintly red (pH 5-6). The emulsion was diluted with Et2O, the organic 
layer separated and the organic layer extracted to more times with Et2O. The combined 
organic layers were dried over Na2SO4 and the solvent was evaporated in vacuum. Crude 
product 27c was purified by column chromatography (EtOAc/PE, 1:1).  
Colorless, highly viscous oil. Yield: 649 mg, 1.79 mmol, 97 %. 
1H NMR (500 MHz, Chloroform-d) δ = 7.89 (dt, 3J = 7.9 Hz, 4J = 
1.1 Hz, 1H, ar-6-H), 7.56 (dd, 3J = 7.7 Hz, 4J = 1.2 Hz, 1H, ar-3-H), 
7.42 (tt, 3J = 7.6 Hz, 4J = 1.3 Hz, 1H, ar-5-H), 7.33 (tt, 3J = 7.7 Hz, 
4J = 1.2 Hz, 1H, ar-4-H), 4.37 (q, 3J = 7.2 Hz, 2H, CO2CH2CH3), 4.32 (m, 1H, C
αH), 3.69 
(d, 3J = 6.4 Hz, 1H, CαHNH), 1.96 (m, 1H, CαHCH2CH(CH3)2), 1.75-1.66 (m, 2H, 
CαHCH2CH(CH3)2), 1.39 (t, 
3J = 7.2 Hz, 3H, CO2CH2CH3), 1.24 (s, 9H, SC(CH3)3), 0.97 
(d, 3J = 6.6 Hz, 6H, CH(CH3)2). 
13C NMR (126 MHz, Chloroform-d) δ = 165.3 
(CO2CH2CH3), 133.5 (ar-C-4), 131.6 (ar-C-5), 130.9 (ar-C-6), 129.5 (ar-C-2), 127.3 (ar-
C-3), 122.5 (ar-C-1), 94.0 (CHC≡C-ar), 82.9 (CHC≡C-ar), 60.4 (CO2CH2CH3), 56.3 
(SC(CH3)3), 46.2 (HNCαHCH2CH(CH3)2), 46.0 (C
αHCH2CH(CH3)2), 25.0 
(CαHCH2CH(CH3)2), 24.3 (C
αHCH2HC(CH3)2), 22.0 (SC(CH3)3), 13.7 (CO2CH2CH3). 
C20H29NO3S (363.52 g mol
-1), MS(ESI): m/z = 386.17499 (calcd. 386.17604 [M+Na]+). 
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TLC: Rf (EtOAc/PE, 1:1) = 0.66. [α]589
21  = -8.4 (c = 0.73, CHCl3). IR(ATR): ῦ [cm-1] = 
3251 (-NH-); 2955, 2925, 2866 (C-CH3, CH2); 1712 (CO2Et); 1597, 1623 (ar, C=C); 1288, 
1271, 1246, 1175, 1126, 1011 (C-H).  
 
Methyl 2-((S)-3-(((S)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-
yl)benzoate (27d). A solution of L-leucine analogue propargylamide 6c (484 mg, 
2.25 mmol, 1.0 eq) and methyl 2-iodobenzoate (26a, 0.44 mL, 2.91 mmol, 1.3 eq) in a 
mixture of THF/piperidine (4.8 mL, 3:1) was thoroughly degassed by the freeze-pump-
thaw method. While still frozen, the solid catalyst PdCl2(PPh3)2 
(1 mol%) and CuI (2 mol%) was added in one portion and the 
mixture was allowed to warm up to rt and stirred overnight at 
ambient temperature. A colorless precipitate formed in the course 
of the reaction. The reaction mixture was diluted with a mixture of Et2O and aqueous NH4Cl 
(5:4, 90 mL), neutralized with aqueous KHSO4 solution (5 %, 10-15 mL, until pH 7). The 
phases were separated and the aqueous layer was extracted with Et2O (3 x 50 mL). The 
combined organic layers were washed with brine, dried over Na2SO4 and the solvent was 
evaporated under reduced pressure. Crude product 27d was purified by column 
chromatography (PE/EtOAc, 1:1).  
Colorless crystalline solid. Yield: 503 mg, 1.44 mmol, 78 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.78 (d, 3J = 7.5 Hz, 1H, ar-6-H), 7.45 (d, 3J = 5.3 Hz, 1H, ar-3-H), 7.31 
(t, 3J = 6.2 Hz, 1H, ar-4-H), 7.21 (t, 3J = 7.2 Hz, 1H, ar-5-H), 4.21 (ddd, 3J = 8.4 Hz, 3J = 
7.8 Hz, 3J = 4.6 Hz, 1H, CHCH2CH(CH3)2), 3.78 (s, 3H, ar-1-CO2CH3), 3.67 (d, 
3J = 
6.7 Hz, 1H, NHCHCH2CH(CH3)2), 1.86 (m, 1H, CHCH2CH(CH3)2), 1.57-1.63 (m, 2H, 
CHCH2CH(CH3)2), 1.13 (s, 9H, SC(CH3)3), 0.86 (d, 
3J = 5.9 Hz, 6H, CHCH2CH(CH3)2). 
13C NMR (126 MHz, Chloroform-d) δ = 166.4 (ar-1-CO2CH3), 134.0 (ar-C-3), 131.7 (ar-
C-2), 131.5 (ar-C-4), 130.1 (ar-C-6), 127.8 (ar-C-5), 123.0 (ar-C-1), 94.4 (CHC≡Car), 
83.3 (CHC≡Car), 56.0 (SC(CH3)3), 51.9 (ar-1-CO2CH3), 46.8 (CH), 45.9 
(CHCH2CH(CH3)2), 24.8 (CHCH2CH(CH3)2), 22.4 (SC(CH3)3), 22.0 
(CHCH2CH(CH3)2). C19H27NO3S (349.49 g mol-1). LCMS(ESI): tr = 10.4 min, m/z = 
350.17730 (calcd. 350.17844 [M+H]+), 372.1666 (calcd. 372.1604 [M+Na]+). TLC: Rf 
(PE/EtOAc, 1:1) = 0.29. [𝛼]589
20  = -0.21 (c 1.794, CHCl3).  
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Methyl 3-((R)-3-(((R)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-
yl)isonicotinate (27f). To a solution of D-leucine analogous propargylamide 6c (27.5 mg, 
128 mol, 1 eq) in a mixture of dry THF and piperidine (3:1, 0.8 mL, 6 eq piperidine), the 
aromatic methyl 3-bromoisonicotinate (26e, 44.2 mg, 204 mol, 
1.6 eq) was added and the mixture was thoroughly degassed by 
freeze pump thaw method (3 x 10-2 mbar). Afterwards the catalysts 
Pd(PPh3)4 (2 mg) and CuI (1 mg) were added and the solution 
warmed to rt. While the slightly yellow solution was stirred for 14 h at ambient temperature, 
a colorless precipitate formed. The suspension was diluted with saturated NH4Cl solution 
(ca. 8 mL) and neutralized with aqueous HCl (2 M, ca. 2 mL). After seperation of the 
phases, the aqueous layer was extracted with Et2O (3 x 20 mL) and the combined organic 
phases dried over Na2SO4. Crude product 27f was purified by column chromatography. In 
this attempt, Glaser homocoupling occurred. Sonogashira/Glaser = 25:75 (determined by 
isolated yield).  
Slightly brown oil. Yield: 8.1 mg, 23 mol, 18 %. 1H NMR (500 MHz, Chloroform-d) δ = 
8.65 (s, 1H, pyridine-2-H), 7.74 (d, 3J = 4.9 Hz, 1H, pyridine-6-H), 7.49 (m, 1H, pyridine-
5-H), 4.34 (q, 3J = 7.5 Hz, 1H, CH), 3.96 (s, 3H, CO2CH3), 3.55 (d, 
3J = 6.9 Hz, 1H, 
CHNH), 1.95 (m, 1H, CHCH2CH(CH3)2), 1.68-1.77 (m, 2H, CHCH2CH(CH3)2), 1.25 
(s, 9H, SC(CH3)3), 0.99 (d, 
3J = 6.6 Hz, 6H, CH(CH3)2). 
13C NMR (126 MHz, 
Chloroform-d) δ = 165.2 (CO2CH3), 154.9 (ar-C-4), 148.9 (ar-C-5), 138.7 (ar-C-3), 133.1 
(ar-C-2), 123.0 (ar-C-6), 97.7 (CHC≡C-ar), 80.6 (CHC≡C-ar), 56.4 (SC(CH3)3), 52.9 
(CO2CH3), 47.2 (CH), 46.2 (CHCH2CH(CH3)2), 25.1 (CHCH2CH(CH3)2), 22.7 
(SC(CH3)3), 22.3 (CHCH2CH(CH3)2). C18H26N2O3S (350.48 g mol
-1). MS (ESI): m/z = 
373.2 (calcd. 373.16 [M+Na]+). TLC: Rf (EtOAc/PE, 1:1) = 0.15.  
 
Methyl 3-((R)-3-(((R)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-
yl)picolinate (27g). To a solution of D-leucine analogous propargylamide 6c (21.5 mg, 
100 mol, 1 eq) in a mixture of dry THF and piperidine (3:1, 1.0 mL, 6 eq piperidine), the 
aromatic methyl 3-bromopicolinate (26f, 34.6 mg, 160 mol, 1.6 eq) was added and the 
mixture was thoroughly degassed by freeze pump thaw method (3 x 10-2 mbar). Afterwards 
the catalysts Pd(PPh3)4 (2 mg) and CuI (1 mg) were added and the solution warmed to rt. 
While the slightly yellow solution was stirred for 14 h at ambient temperature, a colorless 
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precipitate formed. The suspension was diluted with saturated NH4Cl solution (ca. 10 mL) 
and neutralized with aqueous HCl (2 M, ca. 2 mL). After seperation of the phases, the 
aqueous layer was extracted with Et2O (3 x 20 mL) and the combined organic phases dried 
over Na2SO4. Crude product 27g was purified by preparative HPLC.  
Yellow, viscous oil. Yield: 3.5 mg, 10 mol, 10 %. 1H NMR (300 MHz, Chloroform-d): δ 
= 8.62 (dd, 3J = 4.6 Hz, 4J = 1.3 Hz, 1H, ar-6-H), 8.02 (dd, 3J = 
8.2 Hz, 4J = 1.4 Hz, 1H, ar-4-H), 7.57 (dd, 3J = 7.4 Hz, 3J = 4.7 Hz, 
1H, ar-5-H), 4.45 (m, 1H, CHCH2CH(CH3)2), 4.01 (s, 3H, 
CO2CH3), 3.48 (d, 
3J = 7.0 Hz, 1H, CHNH), 1.89 (m, 1H, 
CHCH2CH(CH3)2), 1.63-1.58 (m, 2H, CHCH2CH(CH3)2), 1.22 (s, 9H, SC(CH3)3), 0.96 
(d, 3J = 6.6 Hz, 3H, CHCH2CH(CH3)2), 0.93 (d, 
3J = 6.6 Hz, 3H, CHCH2CH(CH3)2). 
C18H26N2O3S (350.48 g mol
-1). MS(ESI): m/z = 373.3 (calcd. 373.16 [M+Na]+).  
 
Methyl 2-((S)-3-(((S)-tert-Butylsulfinyl)amino)-3-cyclohexylprop-1-yn-1-
yl)benzoate (27h). A solution of L-cyclohexylglycine analogous propargylamide 6e 
(134 mg, 555 mol, 1.0 eq) and methyl 2-iodobenzoate (26a, 129 L, 851 mol, 1.5 eq) in 
a mixture of THF/piperidine (2.33 mL, 6:1) was thoroughly degassed by the freeze-pump-
thaw method. While still frozen, the solid catalyst PdCl2(PPh3)2 (2 mg) and CuI (1 mg) was 
added in one portion and the mixture was allowed to warm up to rt and stirred overnight at 
ambient temperature. A colorless precipitate formed in the course of the reaction. The 
reaction mixture was diluted with a mixture of Et2O and aqueous NH4Cl (1:1, 80 mL), 
neutralized with aqueous KHSO4 solution (5 %, 10-15 mL, until pH 7). The phases were 
separated and the aqueous layer was extracted with Et2O (3 x 50 mL). The combined 
organic layers were washed with brine, dried over Na2SO4 and the solvent was evaporated 
under reduced pressure. Crude product 27h was purified by column chromatography 
(PE/EtOAc, 1:1).  
Colorless, highly viscous oil. Yield: 170.8 mg, 454.8 mol, 82 %. 
1H NMR (500 MHz, Chloroform-d) δ = 7.91 (d, 3J = 7.9 Hz, 1H, 
ar-6-H), 7.58 (d, 3J = 7.7 Hz, 1H, ar-3-H), 7.44 (t, 3J = 7.7 Hz, 1H, 
ar-4-H), 7.35 (t, 3J = 7.7 Hz, 1H, ar-5-H), 4.15 (dd, 3J = 8.0 Hz, 3J 
= 6.5 Hz, 1H, CH), 3.91 (s, 3H, ar-1-CO2CH3), 3.58 (d, 
3J = 6.5 Hz, 1H, NHCH), 1.94 
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(d br., 3J = 8.0 Hz, 1H, cy-1-H), 1.89 (d br., 2J = 12.4 Hz, 1H, cy-4-H), 1.83-1.77 (m br., 
3H, cy-2-H, cy-4-H, cy-6-H), 1.73-1.67 (m br., 3H, cy-2-H, cy-3-H, cy-6-H), 1.27 (s, 9H, 
SC(CH3)3), 1.24-1.16 (m br., 3H, cy-3-H, cy-5-H, cy-5-H). 
13C NMR (126 MHz, 
Chloroform-d) δ = 166.8 (ar-1-CO2CH3), 134.5 (ar-C-3), 132.1 (ar-C-2), 131.8 (ar-C-4), 
130.4 (ar-C-6), 128.0 (ar-C-5), 123.4 (ar-C-1), 93.6 (CHC≡Car), 84.6 (CHC≡Car), 56.5 
(SC(CH3)3), 54.0 (CH), 52.3 (ar-1-CO2CH3), 43.6 (cy-C-1), 29.7 (cy-C-2), 28.4 (cy-C-
6), 26.5 (cy-C-4), 26.2 (cy-C-5), 26.1 (cy-C-3), 22.9 (SC(CH3)3). C21H29NO3S 
(375.53 g mol-1). LCMS(ESI): tr = 11.1 min, m/z = 376.19360 (calcd. 376.19409 [M+H]+), 
398.1780 (calcd. 398.1760 [M+Na]+). TLC: Rf (PE/EtOAc, 2:1) = 0.03, Rf (PE/EtOAc, 
1:1) = 0.06.  
 
Methyl 2-(3-(((S)-tert-Butylsulfinyl)amino)-4,4-dimethylpent-1-yn-1-
yl)benzoate (27i,j). A solution of L- and D-tert-leucine analogous propargylamide 6f 
(80:20, 122 mg, 566 mol, 1.0 eq) and methyl 2-iodobenzoate (26a, 129 L, 851 mol, 
1.5 eq) in a mixture of THF/piperidine (1.33 mL, 3:1) was thoroughly degassed by the 
freeze-pump-thaw method. While still frozen, the solid catalyst PdCl2(PPh3)2 (2 mg) and 
CuI (1 mg) was added in one portion and the mixture was allowed to warm up to rt and 
stirred overnight at ambient temperature. A colorless precipitate formed in the course of 
the reaction. The reaction mixture was diluted with a mixture of Et2O and aqueous NH4Cl 
(1:1, 80 mL), neutralized with aqueous KHSO4 solution (5 %, 10-15 mL, until pH 7). The 
phases were separated and the aqueous layer was extracted with Et2O (3 x 50 mL). The 
combined organic layers were washed with aqueous KHSO4 (5 %, 20 mL) brine (10 mL), 
dried over Na2SO4 and the solvent was evaporated under reduced pressure. The mixture of 
(S,S) and (S,R) configured diastereomers 27i and 27j was separated by automatic column 
chromatography (PE/EtOAc, 1:1).  
Colorless, crystalline solid. Yield: 130 mg, 372.0 mol, 66 %. dr: (S,S):(S,R) = 79:21 
(determined by HPLC), 71:29 (determined by isolated yield of both diastereomers). 
C19H27NO3S (349.49 g mol
-1). HRMS(ESI): m/z = 350.17770 (calcd. 350.17844 [M+H]+).  
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Methyl 2-((S)-3-(((S)-tert-Butylsulfinyl)amino)-4,4-dimethylpent-1-yn-1-
yl)benzoate (27i). Colorless, crystalline solid. Yield: 92.7 mg, 265 mol, 47 %. dr > 99 % 
(determined by 1H NMR spectroscopy). 1H NMR (500 MHz, 
Chloroform-d) δ = 7.86 (d, 3J = 7.9 Hz, 1H, ar-6-H), 7.56 (d, 3J = 
7.7 Hz, 1H, ar-3-H), 7.38 (t, 3J = 7.5 Hz, 1H, ar-4-H), 7.29 (t, 3J = 
7.7 Hz, 1H, ar-5-H), 3.89 (d, 3J = 8.5 Hz, 1H, CH), 3.86 (s, 3H, ar-1-CO2CH3), 3.55 (d, 
3J = 8.5 Hz, 1H, NHCH), 1.23 (s, 9H, SC(CH3)3), 1.04 (s, 9H, CHC(CH3)3). 
13C NMR 
(126 MHz, Chloroform-d) δ = 166.6 (ar-1-CO2CH3), 134.4 (ar-C-3), 131.8 (ar-C-2), 131.6 
(ar-C-4), 130.2 (ar-C-6), 127.9 (ar-C-5), 123.3 (ar-C-1), 93.7 (CHC≡Car), 84.6 
(CHC≡Car), 59.1 (CHC(CH3)3), 56.7 (SC(CH3)3), 52.2 (ar-1-CO2CH3), 36.6 
(CHC(CH3)3), 26.2 (CHC(CH3)3), 22.9 (SC(CH3)3). C19H27NO3S (349.49 g mol
-1). 
HRMS(ESI): m/z = 350.17770 (calcd. 350.17844 [M+H]+). LCMS: tr = 10.2 min. TLC: Rf 
(PE/EtOAc, 2:1) = 0.09, Rf (PE/EtOAc, 1:1) = 0.21. 
 
Methyl 2-((R)-3-(((S)-tert-Butylsulfinyl)amino)-4,4-dimethylpent-1-yn-1-
yl)benzoate (27j). Colorless, crystalline solid. Yield: 37.3 mg, 107 mol, 19 %. dr > 99 % 
(determined by 1H NMR spectroscopy). 1H NMR (500 MHz, Chloroform-d) δ = 7.90 (d, 
3J = 7.8 Hz, 1H, ar-6-H), 7.54 (d, 3J = 7.8 Hz, 1H, ar-3-H), 7.44 (t, 
3J = 7.7 Hz, 1H, ar-4-H), 7.35 (t, 3J = 7.7 Hz, 1H, ar-5-H), 4.07 (d, 
3J = 5.8 Hz, 1H, CH), 3.89 (s, 3H, ar-1-CO2CH3), 3.54 (d, 
3J = 
5.7 Hz, 1H, NHCH), 1.26 (s, 9H, SC(CH3)3), 1.11 (s, 9H, CHC(CH3)3). 
13C NMR 
(126 MHz, Chloroform-d) δ = 166.7 (ar-1-CO2CH3), 134.5 (ar-C-3), 132.1 (ar-C-2), 131.7 
(ar-C-4), 130.4 (ar-C-6), 128.0 (ar-C-5), 123.3 (ar-C-1), 92.5 (CHC≡Car), 85.1 
(CHC≡Car), 58.9 (CHC(CH3)3), 56.3 (SC(CH3)3), 52.4 (ar-1-CO2CH3), 36.4 
(CHC(CH3)3), 26.2 (CHC(CH3)3), 22.7 (SC(CH3)3). C19H27NO3S (349.49 g mol
-1). 
HRMS(ESI): m/z = 350.17770 (calcd. 350.17844 [M+H]+). LCMS: tr = 10.6 min. TLC: Rf 
(PE/EtOAc, 2:1) = 0.21, Rf (PE/EtOAc, 1:1) = 0.43.  
Methyl 2-((S)-6-(tert-Butoxy)-3-(((S)-tert-butylsulfinyl)amino)-6-oxohex-1-yn-1-
yl)benzoate (27k). A solution of L-glutamate analogous propargylamide 6l (80.8 mg, 
281 mol, 1.0 eq) and methyl 2-iodobenzoate (26a, 100 L, 660 mol, 2.3 eq) in a mixture 
of THF/piperidine (1.2 mL, 5:1) was thoroughly degassed by the freeze-pump-thaw 
method. While still frozen, the solid catalyst PdCl2(PPh3)2 (1 mol%) and CuI (2 mol%) was 
IIX-3. a) ortho-Substituted Peptidomimetics (26-27) 
117 
added in one portion and the mixture was allowed to warm up to rt and stirred overnight at 
ambient temperature. A colorless precipitate formed in the course of the reaction. The 
reaction mixture was diluted with a mixture of Et2O and aqueous 
NH4Cl (3:2, 25 mL), neutralized with aqueous KHSO4 solution 
(5 %, 3-5 mL, until pH 7). The phases were separated and the 
aqueous layer was extracted with Et2O (3 x 15 mL). The combined 
organic layers were washed with brine, dried over Na2SO4 and the 
solvent was evaporated under reduced pressure. Crude product 27k was purified by column 
chromatography (PE/EtOAc, 1:1).  
Colorless, crystalline needles. Yield: 92.7 mg, 220 mol, 78 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.89 (d, 3J = 7.8 Hz, 1H, ar-6-H), 7.54 (d, 3J = 7.7 Hz, 1H, ar-3-H), 7.42 
(t, 3J = 7.5 Hz, 1H, ar-4-H), 7.33 (t, 3J = 7.6 Hz, 1H, ar-5-H), 4.38 (ddd, 3J = 6.5 Hz, 3J = 
4.6 Hz, 3J = 6.0 Hz, 1H, CH), 3.89 (s, 3H, CO2CH3), 3.73 (d, 
3J = 6.0 Hz, 1H, NHCH), 
2.54-2.46 (m, 2H, CHCH2CH2CO2), 2.12 (m, 1H, CHCH2CH2CO2), 2.05 (m, 1H, 
CHCH2CH2CO2), 1.42 (s, 9H, CHCH2CH2CO2C(CH3)3), 1.23 (s, 9H, SC(CH3)3). 
13C NMR (126 MHz, Chloroform-d) δ = 172.3 (CHCH2CH2CO2), 166.5 (ar-1-
CO2CH3), 134.3 (ar-C-3), 132.1 (ar-C-2), 131.8 (ar-C-4), 130.4 (ar-C-6), 128.2 (ar-C-5), 
123.0 (ar-C-1), 93.3 (CHC≡Car), 84.3 (CHC≡Car), 80.6 (CHCH2CH2CO2C(CH3)3), 
56.3 (SC(CH3)3), 52.2 (ar-1-CO2CH3), 47.6 (CHCH2CH2CO2), 31.9 
(CHCH2CH2CO2), 31.5 (CHCH2CH2CO2), 28.2 (CHCH2CH2CO2C(CH3)3), 22.7 
(SC(CH3)3). C22H31NO5S (421.55 g mol
-1). MS(ESI): m/z = 422.20090 (calcd. 422.19957 
[M+H]+). TLC: Rf (PE/EtOAc, 2:1) = 0.09, Rf (PE/EtOAc, 1:1) = 0.34.  
 
Methyl 2-((R)-3-(((S)-tert-Butylsulfinyl)amino)-3-(perfluorophenyl)prop-1-yn-1-
yl)benzoate (27l). A solution of L-pentafluoro phenylglycine analogous propargylamide 
6o (106 mg, 326 mol, 1.0 eq) and methyl 2-iodobenzoate (26a, 100 L, 660 mol, 1.3 eq) 
in a mixture of THF/DiPEA (2.34 mL, 6:1) was thoroughly degassed by the freeze-pump-
thaw method. While still frozen, the solid catalyst PdCl2(PPh3)2 (2 mg) and CuI (1 mg) was 
added in one portion and the mixture was allowed to warm up to rt and stirred overnight at 
ambient temperature. A colorless precipitate formed in the course of the reaction. The 
reaction mixture was diluted with a mixture of Et2O and aqueous NH4Cl (1:1, 80 mL), 
neutralized with aqueous KHSO4 solution (5 %, 10-15 mL, until pH 6). The phases were 
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separated and the aqueous layer was extracted with Et2O (3 x 40 mL). The combined 
organic layers were washed with brine, dried over Na2SO4 and the solvent was evaporated 
under reduced pressure. Crude product 27l was purified by column chromatography 
(PE/EtOAc, 1:1).  
Colorless, crystalline solid. Yield: 134 mg, 290 mol, 62 %. 
1H NMR (500 MHz, Chloroform-d) δ = 7.93 (d, 3J = 7.8 Hz, 1H, 
ar-6-H), 7.53 (d, 3J = 7.7 Hz, 1H, ar-3-H), 7.46 (t, 3J = 7.5 Hz, 1H, 
ar-4-H), 7.39 (t, 3J = 7.6 Hz, 1H, ar-5-H), 5.88 (d, 3J = 5.3 Hz, 1H, 
CHN), 4.30 (d, 3J = 5.4 Hz, 1H, CHNH), 3.87 (s, 3H, CO2CH3), 
1.20 (s, 9H, SC(CH3)3). 
19F NMR (471 MHz, Chloroform-d) δ = -141.8 (dd, 3J = 21.1 Hz, 
4J = 6.8 Hz, F5C6-2-F, F5C6-6-F), -153.5 (t, 
3J = 20.8 Hz, F5C6-4-F), -161.1 (td, 
3J = 
21.4 Hz, 4J = 7.3 Hz, F5C6-3-F, F5C6-5-F). 
13C NMR (126 MHz, Chloroform-d) δ = 166.3 
(CO2CH3), 144.95 (d, 
1J = 251.7 Hz, F5C6-C-3, F5C6-C-5), 141.5 (d, 
1J = 255.5 Hz, F5C6-
C-4), 137.8 (dt, 1J = 253.2 Hz, 2J = 12.7 Hz, F5C6-C-2, F5C6-C-6), 134.2 (benzoate-C-3), 
132.4 (benzoate-C-2), 131.9 (benzoate-C-4), 130.6 (benzoate-C-6), 128.8 (benzoate-C-5), 
122.1 (benzoate-C-1), 113.8 (td, 2J = 15.2 Hz, 3J = 4.1 Hz, F5C6-C-1), 89.1 (CH-C≡C-
ar), 84.9 (CH-C≡C-ar), 56.8 (SC(CH3)3), 52.3 (CO2CH3), 41.8 (CHN), 22.4 (SC(CH3)3). 
C21H18F5NO3S (459.43 g mol
-1). LCMS: tr = 10.8 min, m/z = 482.0840 (calcd. 482.0820 
[M+Na]+). HRMS(ESI): m/z = 460.10090 (calcd. 460.10003 [M+H]+). TLC: Rf 
(PE/EtOAc, 2:1) = 0.22, Rf (PE/EtOAc, 1:1) = 0.60, Rf (PE/EtOAc, 2:1) = 0.42. IR(ATR): 
𝜈 ̃ [cm-1] = 3200 (N-H), 2955 (CH3), 2800 (O-CH3), 2363 (C≡C), 1723 (CO2CH3), 1524-
1508 (ar-H), 1121 (S=O). [α]589
22  = 22.8 (c = 1.79, CHCl3).  
 
Methyl 2-((R)-3-(((S)-Butylsulfinyl)amino)-4,4,4-trifluorobut-1-yne-1-
yl)benzoate (27n). A solution of L-trifluoro-alanine analogous propargylamide 6p 
(61.1 mg, 273 mol, 1.0 eq) and methyl 2-iodobenzoate (26a, 100 L, 660 mol, 2.4 eq) 
in a mixture of THF/DIPEA (1.29 mL, 78:22) was thoroughly degassed by the freeze-
pump-thaw method. While still frozen, the solid catalyst PdCl2(PPh3)2 (2 mg) and CuI 
(1 mg) was added in one portion and the mixture was allowed to warm up to rt and stirred 
overnight at ambient temperature. A colorless precipitate formed in the course of the 
reaction. The reaction mixture was diluted with a mixture of Et2O and aqueous NH4Cl (4:5, 
9 mL), neutralized with aqueous KHSO4 solution (5 %, 3-5 mL, until pH 6). The phases 
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were separated and the aqueous layer was extracted with Et2O (3 x 6 mL). The combined 
organic layers were washed with brine, dried over Na2SO4 and the solvent was evaporated 
under reduced pressure. Crude product 27n was purified by column chromatography 
(PE/EtOAc, 1:1).  
Colorless crystalline needles. Yield: 51.6 mg, 142 mol, 52 %. 
1H NMR (500 MHz, Chloroform-d) δ = 7.99 (d, 3JHH = 7.8 Hz, 1H, 
ar-2-H), 7.59 (d, 3JHH = 7.8 Hz, 1H, ar-5-H), 7.49 (t, 
3JHH = 7.5 Hz, 
1H, ar-4-H), 7.44 (t, 3JHH = 7.6 Hz, 1H, ar-3-H), 4.81 (p, 
3JHF = 6.4 Hz, 1H, CHCF3), 4.12 
(d, 3JHH = 6.0 Hz, 1H, CHNH), 3.92 (s, 3H, CO2CH3), 1.29 (s, 9H, SC(CH3)3). 
19F NMR 
(471 MHz, Chloroform-d) δ = -76.2 (d, 3JFH = 6.1 Hz, 3F, CF3). 13C NMR (126 MHz, 
Chloroform-d) δ = 166.3 (CO2CH3), 134.3 (ar-C-5), 132.6 (ar-C-1), 132.0 (ar-C-4), 130.8 
(ar-C-2), 129.3 (ar-C-3), 121.6 (ar-C-6), 119.1 (q, 1JCF = 280.1 Hz, CHCF3), 96.0 
(CHC≡C-ar), 84.6 (CHC≡C-ar), 57.5 (SC(CH3)3), 52.5 (CO2CH3), 51.8 (q, 2JCF = 
34.9 Hz, CHCF3), 22.6 (SC(CH3)3). C16H18F3NO3S (361.38 g mol-1). HRMS(ESI): m/z = 
362.10400 (calcd. 362.10323 [M+H]+), 384.0828 (calcd. 384.0852 [M+Na]+), 745.1850 
(calcd. 745.1811 [2M+Na]+). IR (ATR): 𝜈 ̃ [cm-1] = 3300 (N-H), 2914 (CH3), 2844 (O-
CH3), 2366-2334 (C≡C), 1717 (CO2Me), 1140 (S=O). [α]589
21  = 20.7 (c = 0.21, CHCl3). 
TLC: Rf (PE/EtOAc, 10:1) = 0.02, Rf (PE/EtOAc, 4:1) = 0.05, Rf (PE/EtOAc, 2:1) = 0.21, 
Rf (PE/EtOAc, 1:1) = 0.45. X-ray crystal structure in Chapter IIX-3. n. 
 
Methyl 2-((S)-3-(((S)-Butylsulfinyl)amino)-4,4,4-trifluorobut-1-yne-1-
yl)benzoate (27o). A solution of D-trifluoroalanine analogous propargylamide 6p 
(36.5 mg, 160 mol, 1.0 eq) and methyl 2-iodobenzoate (26a, 80 L, 530 mol, 3.2 eq) in 
a mixture of THF/DIPEA (2.33 mL, 6:1) was thoroughly degassed by the freeze-pump-
thaw method. While still frozen, the solid catalyst PdCl2(PPh3)2 (2.4 mg, 3 mol, 1 mol%) 
and CuI (1.4 mg, 7 mol, 2 mol%) was added in one portion and the mixture was allowed 
to warm up to rt and stirred 15 h at ambient temperature. The orange solution was diluted 
with a mixture of Et2O and aqueous NH4Cl (5:1, 18 mL), neutralized with aqueous KHSO4 
solution (5 %, 3-5 mL, until pH 6). The phases were separated and the aqueous layer was 
extracted with Et2O (3 x 15 mL). The combined organic layers were washed with brine, 
dried over Na2SO4 and the solvent was evaporated under reduced pressure. Crude product 
27o was purified by column chromatography (PE/EtOAc, 1:1).  
IIX-3. a) ortho-Substituted Peptidomimetics (26-27) 
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Colorless, crystalline solid. Yield: 18.2 mg, 50 mol, 32 %. 1H NMR (300 MHz, 
Chloroform-d) δ = 7.98 (dd, 3JHH = 7.7 Hz, 4JHH = 1.6 Hz, 1H, ar-6-
H), 7.64 (dd, 3JHH = 7.6 Hz, 
4JHH = 1.3 Hz, 1H, ar-3-H), 7.50 (td, 
3JHH = 7.5 Hz, 
4JHH = 1.7 Hz, 1H, ar-5-H), 7.43 (td, 
3JHH = 7.6 Hz, 
4JHH = 1.6 Hz, 1H, ar-4-H), 4.90 (qd, 
3JHF = 6.4 Hz,
 3JHH = 5.6 Hz, 1H, CHCF3), 4.34 (m, 
1H, NHCHCF3), 3.91 (s, 3H, CO2CH3), 1.28 (s, 9H, SC(CH3)3). 
19F NMR (282 MHz, 
Chloroform-d) δ = -75.7 (d, 3JFH = 6.3 Hz, CHCF3). 13C NMR (126 MHz, Chloroform-d) 
δ = 166.4 (ar-1-CO2CH3), 134.8 (ar-C-3), 132.5 (ar-C-1), 132.0 (ar-C-5), 130.7 (ar-C-6), 
129.2 (ar-C-4), 123.2 (q, 1J = 281.7 Hz, CHCF3), 121.6 (ar-C-2), 87.7 (CHC≡C-ar), 83.4 
(CHC≡C-ar), 57.2 (SC(CH3)3), 52.4 (CO2CH3), 50.9 (q, 2J = 35.1 Hz, CHCF3), 22.5 
(SC(CH3)3). C16H18F3NO3S (361.38 g mol
-1), MS(ESI): m/z = 362.218 (calcd. 362.1032 
[M+H]+), 384.167 (calcd. 384.0852 [M+Na]+). IR(ATR): 𝜈 ̃ [cm-1] = 3167 (N-H), 2955 
(CH3), 2869 (O-CH3), 2363-2331 (C≡C), 1720 (CO2Me), 1128 (S=O). [α]589
22  = 79.8 (c = 
0.91, CHCl3). TLC: Rf (PE/EtOAc, 2:1) = 0.07.  
 
Methyl 2-((S)-7-((tert-Butoxycarbonyl)amino)-3-(((S)-tert-butylsulfinyl)amino)hept-
1-yn-1-yl)benzoate (27p). A solution of L-lysine analogous propargylamide 6w (94 mg, 
284 mol, 1.0 eq) and methyl 2-iodobenzoate (26a, 100 L, 660 mol, 2.3 eq) in a mixture 
of THF/piperidine (0.67 mL, 3:1) was thoroughly degassed by the freeze-pump-thaw 
method. While still frozen, the solid catalyst PdCl2(PPh3)2 
(1 mol%) and CuI (2 mol%) was added in one portion and the 
mixture was allowed to warm up to rt and stirred overnight at 
ambient temperature. A colorless precipitate formed in the course 
of the reaction. The reaction mixture was diluted with a mixture of 
Et2O and aqueous NH4Cl (3:2, 25 mL), neutralized with aqueous KHSO4 solution (5 %, 3-
5 mL, until pH 7). The phases were separated and the aqueous layer was extracted with 
Et2O (3 x 15 mL). The combined organic layers were washed with brine, dried over Na2SO4 
and the solvent was evaporated under reduced pressure. Crude product 27p was purified by 
column chromatography (PE/EtOAc, 1:1).  
Clear yellow oil. Yield: 26.7 mg, 57.5 mol, 20 %. 1H NMR (500 MHz, Chloroform-d) δ 
= 7.92 (d, 3J = 7.8 Hz, 1H, ar-6-H), 7.56 (d, 3J = 7.7 Hz, 1H, ar-3-H), 7.44 (t, 3J = 7.6 Hz, 
1H, ar-4-H), 7.34 (t, 3J = 7.6 Hz, 1H, ar-5-H), 4.81 (s, 1H, NHBoc), 4.32 (ddd, 3J = 6.5 Hz, 
IIX-3. a) ortho-Substituted Peptidomimetics (26-27) 
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3J = 6.0 Hz, 3J = 5.6 Hz, 1H, NHCHCH2CH2CH2CH2NHBoc), 3.90 (s, 3H, CO2CH3), 
3.66 (d, 3J = 5.7 Hz, 1H, NHCHCH2CH2CH2CH2NHBoc), 3.15 (q, 
3J = 6.6 Hz, 2H, 
NHCHCH2CH2CH2CH2NHBoc), 1.91-1.75 (m, 2H, 
NHCHCH2CH2CH2CH2NHBoc), 1.69-1.53 (m, 4H, 
NHCHCH2CH2CH2CH2NHBoc), 1.41 (s, 9H, NHCO2C(CH3)3), 1.24 (s, 9H, 
SC(CH3)3). 
13C NMR (126 MHz, Chloroform-d) δ = 166.5 (ar-1-CO2CH3), 156.2 
(NHCHCH2CH2CH2CH2NHCO2C(CH3)3), 134.4 (ar-C-3), 131.9 (ar-C-2), 131.9 (ar-
C-4), 130.4 (ar-C-6), 128.1 (ar-C-5), 123.3 (ar-C-1), 94.2 (NHCHC≡Car), 83.9 
(NHCHC≡Car), 79.1 (NHCO2C(CH3)3), 56.3 (CNHSOC(CH3)3), 52.3 (ar-1-CO2CH3), 
48.3 (NHCHCH2CH2CH2CH2NH), 40.4 (NHCHCH2CH2CH2CH2NH), 36.5 
(NHCHCH2CH2CH2CH2NH), 29.6 (NHCHCH2CH2CH2CH2NH), 28.6 
(NHCO2C(CH3)3), 22.8 (NHCHCH2CH2CH2CH2NH), 22.7 (CHNHSOC(CH3)3). 
C24H36N2O5S (464.6210 g mol
-1). LCMS(ESI): tr = 10.04 min, m/z = 465.24240 (calcd. 
465.24177 [M+H]+), 487.2185 (calcd. 487.2237 [M+Na]+). TLC: Rf (PE/EtOAc, 2:1) = 
0.05, Rf (PE/EtOAc, 1:1) = 0.16.  
 
Methyl 2-((S)-6-((E)-2,3-Bis(tert-butoxycarbonyl)guanidino)-3-(((S)-tert-
butylsulfinyl)amino)hex-1-yn-1-yl)benzoate (27q). A solution of L-arginine analogous 
propargylamide 6x (753 mg, 1.64 mmol, 1.0 eq) and methyl 2-iodobenzoate (26a, 320 L, 
2.1 mmol, 1.3 eq) in a mixture of THF/piperidine (4.0 mL, 3:1) was 
thoroughly degassed by the freeze-pump-thaw method. While still 
frozen, the solid catalyst PdCl2(PPh3)2 (1 mol%) and CuI (2 mol%) 
was added in one portion and the mixture was allowed to warm up 
to rt and stirred overnight at ambient temperature. A colorless 
precipitate formed in the course of the reaction. The reaction mixture was diluted with a 
mixture of Et2O and aqueous NH4Cl (1:1, 100 mL), neutralized with aqueous KHSO4 
solution (5 %, 10-15 mL, until pH 7). The phases were separated and the aqueous layer was 
extracted with Et2O (3 x 50 mL). The combined organic layers were washed with brine, 
dried over Na2SO4 and the solvent was evaporated under reduced pressure. The crude 
product was purified by column chromatography (PE/EtOAc, 1:1).  
Catalyzed Hydrocarboxylation of Propargylic Derivatives (28-29) 
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Colorless, highly viscous oil. Yield: 585 mg, 986 mol, 60 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 11.68 (s, 1H, N2CNHBoc), 8.49 (t, 3J = 5.5 Hz, 1H, CNHCN2), 8.00 
(d, 3J = 7.9 Hz, 1H, ar-2-H), 7.66 (d, 3J = 7.8 Hz, 1H, ar-5-H), 7.54 (t, 3J = 7.6 Hz, 1H, ar-
4-H), 7.44 (t, 3J = 7.7 Hz, 1H, ar-3-H), 4.47 (ddd, 3J = 6.2 Hz, 3J = 5.8 Hz, 3J = 4.6 Hz, 1H, 
CH), 4.38 (d, 3J = 6.3 Hz, 1H, CHNH), 3.99 (s, 3H, CO2CH3), 3.63-3.58 (m, 2H, 
CH(CH2)2CH2N), 2.16-1.84 (m, 4H, CH(CH2)2CH2N), 1.58 (s, 9H, NCO2C(CH3)3), 1.57 
(s, 9H, NHCO2C(CH3)3), 1.34 (s, 9H, SC(CH3)3). 
13C NMR (126 MHz, Chloroform-d) δ = 
165.6 (arCO2CH3), 162.9 (CNHCN2), 155.5 (CNHC=NCO2), 152.5 (CNHCHNCO2), 
133.5 (ar-C-4), 131.2 (ar-C-5), 131.1 (ar-C-6), 129.6 (ar-C-2), 127.4 (ar-C-3), 122.5 (ar-
C-1), 93.5 (CC≡Car), 83.1 (CC≡Car), 82.2 (NCO2C(CH3)3), 78.2 (NHCO2C(CH3)3), 
55.4 (SC(CH3)3), 51.4 (arCO2CH3), 47.3 (CHCH2CH2CH2), 39.7 
(CHCH2CH2CH2), 33.4 (CHCH2CH2CH2), 27.6 (NCO2C(CH3)3), 27.3 
(NHCO2C(CH3)3), 24.6 (CHCH2CH2CH2), 22.0 (SC(CH3)3). C29H44N4O7S 
(592.75 g mol-1). LCMS(ESI): tr = 11.1 min, m/z = 593.30190 (calcd. 593.30035 [M+H]+), 
615.2868 (calcd. 615.2823 [M+Na]+). TLC: Rf (PE/EtOAc, 1:1) = 0.23.  
 
Catalyzed Hydrocarboxylation of Propargylic Derivatives (28-29) 
(S)-2-Methyl-N-((R)-2-((Z)-3-Oxoisobenzofuran-1(3H)-ylidene)-1-
(perfluorophenyl)ethyl)propane-2-sulfinamide (28). 2-Iodobenzoate (26c, 61.2 mg, 
250 mol, 2 eq) and DIPEA (120 L, 690 mol, 5.5 eq) was added in one portion to a 
solution of L-pentafluoro-phenylglycine analogue propargylamine 6o 
(39.9 mg, 120 mol, 1.0 eq) in THF (0.34 mL) and the reaction mixture 
was degassed by freeze-pump-thaw method (3 cycles). PdCl2(PPh3)2 
(2 mg, 2.8 mol, 1 mol%) and CuI (0.9 mg, 4 mol, 3 mol%) was 
added and the mixture was stirred at rt for 16 h. Aqueous NH4Cl 
solution (sat., 2 mL) was added to the depply red solution, followed by water (1 mL) and 
hydrochloric acid (1 M, 1 mL) until the pH value was 7. The mixture was extracted with 
Et2O (3 x 5 mL). The combined organic layers were dried over Na2SO4, the solvent was 
evaporated and benzofuranon 28 was isolated by preparative HPLC.  
Pale yellow, crystalline solid. Yield: 14.4 mg, 30 mol, 27 %. 1H NMR (600 MHz, 
Chloroform-d) δ = 7.91 (dt, 3J = 7.7 Hz, 4J = 1.0 Hz, 1H, ar-6-H), 7.72 (dt, 3J = 7.9, 4J = 
IIX-3. b) Oligomerization (30-35) 
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0.9 Hz, 1H, ar-3-H), 7.69 (tt, 3J = 7.9 Hz, 4J = 1.0 Hz, 1H, ar-4-H), 7.59 (ddd, 3J = 7.9 Hz, 
3J = 7.1 Hz, 4J = 1.1 Hz, 1H, ar-5-H), 6.12 (dd, 3J = 9.3 Hz, 3J = 4.5 Hz, 1H, CH), 5.99 
(dt, 3J = 8.9 Hz, 4J = 1.7 Hz, 1H, CHCH=C(O2C)ar), 4.29 (d, 
3J = 7.4 Hz, 1H, CHNH), 
3.78 (s, br., 2H, H2O coordinated), 1.22 (s, 9H, SC(CH3)3). 
19F NMR (565 MHz, 
Chloroform-d) δ = -141.7 (dd, 3JFF = 21.6 Hz, 4JFF = 7.0 Hz, C6F5-2-F, C6F5-6-F), -153.6 
(t, 3JFF = 20.9 Hz, C6F5-4-F), -160.6 (td, 
3JFF = 21.1 Hz, 
4JFF = 6.7 Hz, C6F5-3-F, C6F5-5-F). 
13C NMR (75 MHz, Chloroform-d) δ = 165.7 (ar-1-CO2), 147.2 (CHCH=C(O2C)ar), 
138.5 (ar-C-2), 134.9 (ar-C-3), 131.2 (ar-C-5), 125.9 (ar-C-6), 125.0 (ar-C-1), 120.8 (ar-
C-4), 104.1 (CHCH=C(O2C)ar), 57.1 (SC(CH3)3), 47.7 (CHCH=C(O2C)ar), 22.5 
(SC(CH3)3). C20H16F5NO3S (445.40 g mol-1). MS(EI): m/z = 446.117 (calcd. 446.0844 
[M+H]+), 468.112 (calcd. 468.0663 [M+Na]+), 443.955 (calcd. 443.955 [M-H]-), 479.913 
(calcd. 480.0465 [M+Cl]-), 461.965 (calcd. 462.0804 [M+OH]-). TLC: Rf (PE/EtOAc, 2:1) 
= 0.40.  
Hydrochloric acid (4 M in dioxane, 0.2 mL, 400 mol) was added dropwise to an icecold 
solution of peptidomimetic 28 (14.4 mg, 30 mol) in MeOH (3 mL). The reaction mixture 
was kept at rt overnight. The solvent evaporated at ambient pressure. The crude product 
was digerated with CHCl3 and the solvent was again evaporated at ambient pressure. 
Compound 29 crystallized as tert-butylsulfonate salt in form of colorless needles from a 
concentrated CHCl3 solution. X-ray crystal structure in Chapter IIX-3. n. 
 
IIX-3. b) Oligomerization (30-35) 
2-((R)-3-(((R)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-yl)benzoic Acid (30c). At 
0 °C, an aqueous solution of LiOH x H2O (133.7 mg, 3.19 mmol, 3.3 eq in 4.5 mL H2O) 
was added dropwise to a vigorously stirred solution of ethylester 27c (353.3 mg, 
971.9 mol, 1.0 eq). The reaction mixture was stirred at 0 °C overnight. After full 
conversion of the starting material (checked by TLC), the mixture was diluted with aqueous 
HCl (1 M, 20 mL, pH 1-2) and extracted with Et2O (5 x 15 mL). The combined organic 
layers were dried over Na2SO4 and the solvent was evaporated to yield benzoate 30c in 
pure form.  
IIX-3. b) Oligomerization (30-35) 
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Colorless, amorphous solid. Yield: 289 mg, 861 mol, 89 %. 1H NMR (300 MHz, 
Chloroform-d) δ = 9.62 (s, 1H, CO2H), 7.60 (d, 3J = 7.9 Hz, 1H, ar-
6-H), 7.46 (d, 3J = 7.7 Hz, 1H, ar-3-H), 7.27 (t, 3J = 7.7 Hz, 1H, ar-
4-H), 7.05 (t, 3J = 7.6 Hz, 1H, ar-5-H), 5.33 (d, 3J = 9.2 Hz, 1H, 
CHNH), 4.24 (ddd, 3J = 8.1 Hz, 3J = 7.2 Hz, 3J = 6.9 Hz, 1H, CH), 
2.06 (m, 1H, CHCH2CH(CH3)2), 1.83 (dd, 
2J = 13.2 Hz, 3J = 6.9 Hz, 1H, 
CHCH2CH(CH3)2), 1.74 (dd, 
2J = 13.2 Hz, 3J = 7.2 Hz, 1H, CHCH2CH(CH3)2), 1.30 (s, 
9H, SC(CH3)3), 0.97 (d, 
3J = 6.6 Hz, 6H, CHCH2CH(CH3)2). C18H25NO3S 
(335.46 g mol-1). [𝛼]589
20  = -28.88 (c 0.134, CHCl3).  
 
The preparation and charactierization of amine 31c has been detailedly reported in the 
master thesis [117].  
Methyl (R)-2-(3-Amino-4,4-dimethylpent-1-yn-1-yl)benzoate Hydrochloride (31j). 
Hydrochloride (4 M in dioxane, 0.1 mL, 400 mol) was added dropwise to a vigorously 
stirred solution of peptidomimetic 27j (37.3 mg, 107 mol) in MeOH (15 mL) at 0 °C. The 
reaction mixture was stirred overnight and the solvent was evaporated under reduced 
pressure. The crude product was digerated with CHCl3 and the solvent was evaporated 
under reduced pressure.  
Colorless, amorphous solid. Quantitative yield. 1H NMR 
(500 MHz, Chloroform-d) δ = 7.89 (d, 3J = 7.9 Hz, 1H, ar-6-H), 
7.52 (d, 3J = 7.7 Hz, 1H, ar-3-H), 7.43 (t, 3J = 7.6 Hz, 1H, ar-4-
H), 7.33 (t, 3J = 7.6 Hz, 1H, ar-5-H), 3.91 (s, 3H, ar-1-CO2CH3), 3.53 (s, 1H, CHC(CH3)3), 
1.62 (s, 3H, ClH3NCHC(CH3)3), 1.08 (s, 9H, CHC(CH3)3). 
13C NMR (126 MHz, 
Chloroform-d) δ = 167.0 (ar-1-CO2CH3), 134.3 (ar-C-3), 132.1 (ar-C-1), 131.6 (ar-C-4), 
130.3 (ar-C-6), 127.6 (ar-C-5), 124.0 (ar-C-2), 97.3 (CHC≡Car), 82.2 (CHC≡Car), 54.7 
(CHC(CH3)3), 52.3 (ar-1-CO2CH3), 35.5 (CHC(CH3)3), 26.2 (CHC(CH3)3). 
C15H20ClNO2 (281.78 g mol
-1).  
 
 
IIX-3. b) Oligomerization (30-35) 
125 
2-((S)-3-(2-((S)-3-((tert-Butoxycarbonyl)amino)-4-methylpent-1-yn-1-yl)benzamido)-
4-methylpent-1-yn-1-yl)benzoic Acid (33b). A mixture of acid 30c (71.0 mg, 224 mol, 
1.0 eq), amine 31c (59.4 mg, 222 mol, 1.0 eq), HATU (255.2 mg, 671 mol, 3 eq) and 
HOAt (120.9 mg, 896 mol, 4 eq) was dissolved under argon atmosphere in a mixture of 
DMF and DIPEA (5.25 mL, 95:5). The reaction mixture was stirred for 48 h at ambient 
temperature. After complete consumption of acid 30c (checked by TLC), the clear solution 
was diluted in CH2Cl2 (40 mL) and extractec with aqueous NaHCO3 solution (saturated, 
15 mL), water (20 mL), aqueous KHSO4 solution (5 %, 20 mL) and brine (10 mL). The 
organic layer was dried over Na2SO4 and the solvent was evaporated under reduced 
pressure. Amide 32b was isolated by column chromatography (PE/EtOAc, 1:1).  
An aqueous solution of LiOH (1 M, 1 mL) was added dropwise to a vigorously stirred 
solution of complete peptidomimetic 32b at 0 °C. After complete consumption of the 
peptidomimetic (checked by TLC, ca. 8 h), the reaction mixture was diluted with an 
aqueous KHSO4 solution (5 %, 20 mL) and extracted with CH2Cl2 (4 x 15 mL). The 
combined organic layers were dried over Na2SO4, the solvent was evaporated under 
reduced pressure and the crude product was purified by preparative HPLC.  
Colorless, highly viscous oil. Yield: 40.1 mg, 
77.7 mol, 35 %. 1H NMR (600 MHz, DMSO-d6) δ 
= 8.82 (d, 3J = 8.4 Hz, 1H, CONHCi+1H), 7.82 (d, 
3J = 7.8 Hz, 1H, ari+1-6-H), 7.56-7.51 (m, 2H, ari-3-
H, ari+1-3-H), 7.47-7.44 (m, 3H, ari-6-H, ari-4-H, ari+1-4-H), 7.44-7.39 (m, 2H, ari-5-H, 
ari+1-5-H), 7.29 (d, 3J = 8.9 Hz, 1H, CONHCH), 4.84 (dd, 3J = 8.4 Hz, 3J = 6.3 Hz, 1H, 
Ci+1H), 4.28 (dd, 3J = 8.9 Hz, 3J = 6.5 Hz, 1H, CH), 2.03 (dhept, 3J = 6.3 Hz, 3J = 6.7 Hz, 
1H, Ci+1HCH(CH3)2), 1.81 (dhept, 
3J = 6.5 Hz, 3J = 6.7 Hz, 1H, CHCH(CH3)2), 1.39 
(s, 9H, CO2C(CH3)3), 1.10 (d, 
3J = 6.6 Hz, 3H, Ci+1HCH(CH3)2), 1.05 (d, 
3J = 6.7 Hz, 
3H, Ci+1HCH(CH3)2), 0.94 (d, 
3J = 6.7 Hz, 3H, CHCH(CH3)2), 0.90 (d, 
3J = 6.7 Hz, 
3H, CHCH(CH3)2). 
13C NMR (151 MHz, DMSO-d6) δ = 167.3 (CO2H), 166.9 
(CONHCi+1), 155.1 (O2CNH), 139.1 (ar
i-C-1), 134.1 (ari-C-3), 133.4 (ari+1-C-3), 132.9 
(ari+1-C-4), 131.6 (ari-C-4), 129.9 (ari+1-C-6), 129.6 (ari+1-C-5), 128.3 (ari-C-2), 128.2 
(ari+1-C-2), 127.7 (ari-C-6), 122.4 (ari-C-5), 120.2 (ari+1-C-1), 93.0 (Ci+1HC≡C-ar), 92.6 
(CHC≡C-ar), 81.7 (Ci+1HC≡C-ar), 80.9 (CHC≡C-ar), 78.2 (CO2C(CH3)3), 49.0 
(CHCH(CH3)2), 47.8 (Ci+1HCH(CH3)2), 33.2 (CHCH(CH3)2), 32.9 
IIX-3. c) Peptidomimetics from meta-Substituted Aromatics (36-44) 
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(Ci+1HCH(CH3)2), 28.3 (CO2C(CH3)3), 19.3 (C
i+1HCH(CH3)2), 19.0 
(CHCH(CH3)2), 18.4 (CHCH(CH3)2), 18.3 (C
i+1HCH(CH3)2). C31H36N2O5 
(516.64 g mol-1). MS(ESI): m/z = 517.3 (calcd. 517.2697 [M+H]+), 539.3 (calcd. 539.2516 
[M+Na]+).  
 
The preparation and charactierization of dimer 33c, the N- and C-terminal cleavage of 
protective groups giving amine 34c and acid 33c, as well as their dimerization forming 
tetramer 35c has been detailedly reported in the master thesis [117].  
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Aromatic halides 36a-c were purchased from Fisher Scientific.  
 
N-(3,5-Difluorobenzyl)-3-iodobenzamide (36d). No information on compound 36d has 
been published, yet. However, the FCH Group has assigned CAS nr. 1280343-82-9 to it. A 
solution of EDC (0.6 mL, 2.8 mmol, 1.3 eq) in dry CH2Cl2 (3 mL) was added dropwise to 
an ice-cold solution of of 3-iodobenzoate (36c, 630 mg, 2.54 mmol, 1.2 eq) in CH2Cl2 
(6 mL). After 5 min, 3,5-difluorobenzylamine (0.27 mL, 2.10 mmol, 1.0 eq) and DMAP 
(64 mg, 530 mol, 0.25 eq) was added. The reaction mixture was stirred for 3 d at ambient 
temperature. The reaction mixture was diluted with an aqueous KHSO4 solution (5 %, 
15 mL). The phases were separated and the aqueous layer was extracted with CH2Cl2 (2 x 
10 mL). The combined organic layers were dried over Na2SO4 and the solvent was 
evaporated to yield amide 36d in pure form.  
Colorless crystalline solid. Yield: 930 mg, 2.49 mmol, 99 %. 1H NMR (300 MHz, 
Methanol-d4) δ = 8.18 (t, 4J = 1.8 Hz, 1H, ar-2-H), 7.80 (dd, 3J = 8.1 Hz, 4J = 1.8 Hz, 1H, 
ar-6-H), 7.80 (dd, 3J = 6.6 Hz, 4J = 1.2 Hz, 1H, ar-4-H), 7.15 (t, 3J 
= 7.9 Hz, 1H, ar-5-H), 6.88 (dd, 3JHF = 6.3 Hz, 
4JHH = 2.1 Hz, 2H, 
F2Ph-2-H, F2Ph-6-H), 6.72 (tt, 
3JHF = 9.1 Hz, 
4JHH = 2.4 Hz, 1H, 
F2Ph-4-H), 4.50 (s, 2H, CONHCH2PhF2). 
19F NMR (282 MHz, Methanol-d4) δ = -111.00 
(dd, 3JFH = 9.1 Hz,
 3JFH = 6.3 Hz, F2Ph-3-F, F2Ph-5-F). 
13C NMR (151 MHz, Methanol-d4) 
δ = 168.2 (F2Ph-1-CONH), 164.2 (dd, 1J = 247.6 Hz, 3J = 12.7 Hz, F2Ph-C-3, F2Ph-C-5), 
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144.4 (t, 3J = 8.8 Hz, F2Ph-C-1), 141.6 (ar-C-1), 137.3 (ar-C-4), 136.9 (ar-C-2), 131.2 (ar-
C-5), 127.5 (ar-C-6), 111.1 (d, 2J = 25.0 Hz, F2Ph-C-2, F2Ph-C-6), 103.1 (t, 
2J = 25.8 Hz, 
F2Ph-C-4), 94.9 (ar-C-3), 43.8 (CONHCH2PhF2). C14H10F2INO (373.14 g mol
-1). MS(EI): 
m/z = 374.066 (calcd. 373.9848 [M+H]+), 396.008 (calcd. 395.9667 [M+Na]+). TLC: Rf 
(PE/EtOAc, 2:1) = 0.65. IR (ATR): 𝜈 [cm-1] = 3373 (NH), 3063 (ar-H), 1698 (CONH), 
1619, 1597 (C=C), 1556 (CONH), 1435 (CH2), 1268(C-F), 1112 (C-I), 973, 853 (ar-H).  
 
Methyl 5-Bromonicotinate (37a). The esterification of 5-bromonicotinate was performed 
in accordance to the description of Do-Thanh et al. [220]. 5 Drops of H2SO4 (97 %) were 
carefully added to a solution of 5-bromonicotinic acid (1.12 g, 4.5 mmol) in MeOH 
(15 mL). The reaction mixture was heated for 43 h under reflux conditions 
and afterwards cooled to -18 °C. Colorless crystals of nicotinate 37c 
formed in the reaction mixture, which were isolated by filtration, washed 
with some mL of ice-cold MeOH and dried under fine vacuum (0.499 g, 2.3 mmol, 51 %). 
The mother liquor was concentrated up at 80 °C, until more colorless crystals formed, 
which were isolated like the first fraction and added to the yield.  
Colorless, crystals. Total yield: 721 mg, 3.34 mmol, 74 % (Lit. 88 % [220]). 1H NMR 
(600 MHz, Chloroform-d) δ = 9.13 (d, 4J = 1.5 Hz, 1H, ar-2-H), 8.84 (dd, 4J = 2.3 Hz, 4J = 
1.2 Hz, 1H, ar-6-H), 8.44 (d, 4J = 1.8 Hz, 1H, ar-4-H), 3.97 (s, 3H, CO2CH3). C7H6BrNO2 
(216.03 g mol-1). TLC: Rf (PE/EtOAc 1:1) = 0.58.  
 
Methyl 6-Bromopicolinate (37b). 6-Bromopicolinate was esterified as described by 
Oballa et al. [219]. Under a nitrogen atmosphere, diazomethane (0.1 M, 18.8 mL, 
1.88 mmol, 1.3 eq) was added dropwise to a non-stirred solution of 3-
bromopicolinic acid (312 mg, 1.44 mmol, 1.0 eq) in dry THF (10 mL) at 
0 °C. The reaction mixture was slowly warmed up to rt and stirred for 20 h 
at ambient temperature. The red solution was dilluted with water (40 mL) and acetic acid 
(1 M, 1 mL, 1 mmol) and the aqoueous layer was extracted with Et2O (5 x 30 mL). The 
combined organic layers were washed with brine (10 mL) and dried over Na2SO4. The 
solvent was evaporated under reduced pressure and the residue was filtered through a short 
pad of silica gel to yield methyl ester 37b in pure form.  
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Slightly yellow fluid. Yield: 253 mg, 1.17 mmol, 81 %. 1H NMR (300 MHz, Chloroform-
d) δ = 8.07 (dd, 3J = 7.1 Hz, 4J = 1.5 Hz, 1H, ar-3-H), 7.69 (t, 3J = 7.1 Hz, 1H, ar-4-H), 
7.66 (dd, 3J = 8.0 Hz, 4J = 1.5 Hz, 1H, ar-5-H), 3.97 (s, 3H, CO2CH3). C7H6BrNO2 
(216.03 g mol-1).  
 
3-Iodo-4-(methoxycarbonyl)benzoic Acid (38a). Sandmeyer reactions were performed in 
analogy to the work of Aiken, Gabbutt, Heron, Instone, Horton and Hursthouse [221]. 
Compound 38a has been first described by Kiick, Saxon, Tirrell and Bertozzi [222]. 3-
Amino-4-(methoxycarbonyl)benzoic acid (1.05 g, 5.39 mmol, 1 eq) was dissolved in 
aqueous hydrochloric acid (6 M, 5 mL 1 mL/mmol) and the solution was cooled to -40 °C. 
An aqueous solution of NaNO2 (400 mg, 5.79 mmol, 1.1 eq, in 3 mL) was added dropwise 
under vigorous stirring. The solution was warmed up to rt and solid KI (1.79 g, 10.78 mmol, 
2 eq) and I2 (137 mg, 0.1 mmol, 0.1 eq) was added in one portion, which lead to the 
precipitation of a black solid. The reaction mixture was diluted with a KHSO4 solution 
(5 %, 10 mL) and extracted with CH2Cl2 (5 x 20 mL). The combined organic layers were 
dried over Na2SO4 and the solvent was evaporated under reduced pressure.  
Slightly brown solid. Yield: 1.44 g, 4.71 mmol, 87 %. 1H NMR 
(500 MHz, Chloroform-d) δ = 8.34 (d, 4J = 1.7 Hz, 1H, ar-2-H), 7.83 
(d, 3J = 8.0 Hz, 1H, ar-5-H), 7.77 (dd, 3J = 8.0 Hz, 4J = 1.7 Hz, 1H, ar-6-H), 3.95 (s, 3H, 
CO2CH3). C9H7IO4 (306.06 g mol-1). MS(ESI): m/z = 306.900 (calcd. 306.9462 [M+H]+). 
TLC: Rf (EtOAc/PE, 1:10) = 0.2. Mp = 104 °C (+/- 2 K).  
When the reaction was carried out at 0 °C in a test tube, cooled by an ice bath, hydroxylation 
was observed as side reaction, giving the title compound 38a (30 %) and 3-amino-4-
(methoxycarbonyl)benzoic acid (6 %) in a ratio 75:25 (determined by 1H NMR 
spectroscopy).  
 
Methyl 4-Amino-3-iodobenzoate (38b). The iodination of methyl 4-aminobenzoate was 
performed in accordance with the description of Spivey et al. [149]. A solution of 
iodochloride (1 M in CH2Cl2, 3.35 mL, 3.35 mmol, 1.0 eq) was added dropwise to a 
solution of methyl 4-aminobenzoate (500 mg, 3.31 mmol, 1.0 eq) in glacial acetic acid 
(15 mL) at 0 °C. The deeply purple reaction mixture was stirred for 100 min at ambient 
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temperature. The solvent was evaporated under reduced pressure and the brown residue 
was diluted in a mixture of saturated NaHCO3 and water (1:1, 30 mL), until a clear solution 
was formed. Addition of some solid Na2CO3 made the brown colour of 
the solution vanish. The phases were separated and the organic layer was 
washed with another portion of NaHCO3 solution (5 mL), brine (5 mL) 
and dried over MgSO4. The solvent was evaporated and aromatic halide 38b was purified 
by column chromatography PE/EtOAc (4:1).  
Pale, yellow crystals. Yield: 517 mg, 1.87 mmol, 56 % (Lit: 74 % [149]). 1H NMR 
(300 MHz, Chloroform-d) δ = 8.32 (d, 4J = 1.9 Hz, 1H, ar-2-H), 7.80 (dd, 3J = 8.4 Hz, 4J = 
1.9 Hz, 1H, ar-6-H), 6.69 (d, 3J = 8.4 Hz, 1H, ar-5-H), 4.52 (s, 2H, ar-NH2), 3.84 (s, 3H, 
CO2CH3). C8H8INO2 (277.06 g mol
-1). MS(ESI): m/z = 276.030 (calcd. 275.9527 [M-H+]-). 
TLC: Rf (EtOAc/PE, 1:4) = 0.30.  
 
Methyl (E)-4-((4-(Dimethylamino)phenyl)diazenyl)-3-iodobenzoate (38c). A cooled 
solution of NaNO2 (27.4 mg, 397 mol, 1.1 eq) in water (0.3 mL) was added dropwise to 
a solution of aniline derivative 38b (100 mg, 361 mol, 1.0 eq) 
in hydrochloric acid (half concentrated, 6 M, 0.5 mL) at 0 °C. 
After 5 min, the green mixture was slowly dropped into an 
icecold, vigorously stirred solution of N,N-dimethyl aniline 
(50.4 mg, 541 mol, 1.5 eq) in hydrochloric acid (0.8 mL, 1 M). The reaction mixture 
immediately turned brightly red and was stirred for another 15 min at 0 °C. Afterwards, the 
reaction mixture was diluted with a NaOH solution (1 M, ca. 5 mL) until pH>8 and the 
solution was kept overnight at -20 °C. A red precipitate formed, which was centrifuged, 
filtered off and purified by column chromatography (PE/EtOAc, 2:1).  
Purple solid. Yield: 85.5 mg, 209 mol, 58 %. 1H NMR (300 MHz, Chloroform-d) δ = 8.33 
(d, 4J = 1.9 Hz, 1H, benzoate-2-H), 7.95 (d, 3J = 9.2 Hz, 2H, aniline-2-H, aniline-6-H), 
7.80 (dd, 3J = 8.4 Hz, 4J = 1.9 Hz, 1H, benzoate-6-H), 6.75 (d, 3J = 9.2 Hz, 2H, aniline-3-H, 
aniline-5-H), 6.70 (d, 3J = 8.4 Hz, 1H, benzoate-5-H), 3.85 (s, 3H, CO2CH3), 3.12 (s, 6H, 
N(CH3)2). C16H16IN3O2 (409.23 g mol
-1). MS(ESI): m/z = 409.929 (calcd. 410.0360 
[M+H]+). TLC: Rf (PE/EtOAc, 2:1) = 0.52.  
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Methyl (E)-3-Iodo-4-(phenyldiazenyl)benzoate (38d). No information on synthesis and 
characteristics of azobenzene 38d have been published, yet. However, ChemSpider has 
assigned CAS nr. 1027164-11-9 to the compound. Nitrosylbenzene (2 x 37 mg, 0.72 mmol, 
2.0 eq) was added in two portions to a solution of aniline derivative 38b (100 mg, 
0.361 mmol, 1.0 eq) in AcOH (18 mL). The reaction mixture was heated for 5 d under 
reflux conditions to 120 °C. It turned a dark red colour. After complete conversion of 
aniline 38b, the solution was diluted with H2O (30 mL), lyophilized and purified by column 
chromatography (PE/EtOAc, 4:1) to yield azobenzene 38d in pure form.  
Dark red solid. Yield: 12.0 mg, 25.9 mmol, 7 %. 1H NMR 
(600 MHz, Chloroform-d) δ = 8.68 (d, 4J = 1.4 Hz, 1H, benzoate-
2-H), 8.08 (dd, 3J = 8.3 Hz, 4J = 1.5 Hz, 1H, benzoate-5-H), 8.02 
(dd, 3J = 8.1 Hz, 4J = 1.3 Hz, 1H, benzoate-6-H), 7.90 (dd, 3J = 8.2 Hz, 4J = 1.1 Hz, 2H, 
Ph-2-H, Ph-6-H), 7.57-7.51 (m, 3H, Ph-3-H, Ph-4-H, Ph-5-H), 3.96 (s, 3H, CO2CH3). 
13C NMR (151 MHz, Chloroform-d) δ = 165.4 (CO2CH3), 152.5 (benzoate-C-2), 141.2 
(Ph-C-1), 133.0 (benzoate-C-6), 132.4 (benzoate-C-4), 130.4 (Ph-C-4), 129.4 (Ph-C-3), 
124.8 (Ph-C-5), 124.0 (benzoate-C-3), 122.9 (Ph-C-2), 117.3 (Ph-C-6), 101.1 
(benzoate-C-1), 52.7 (CO2CH3). C14H11IN2O2 (366.16 g mol
-1). LCMS(ESI): m/z = 
367.119 (calcd. 366.9938 [M+H]+).  
 
Methyl 2-Amino-5-iodobenzoate (39a). Methyl 2-aminobenzoate was synthesized by 
methylation of anthranilate as described by Arifuzzaman et al. [223]. Concentrated sulfuric 
acid (98 %, 0.1 mL) was added to a solution of 2-amino benzoic acid (686 mg, 5 mmol) in 
MeOH (35 mL) and the solution was heated for 4 d under reflux conditions to 
90 °C. The solvent was removed under reduced pressure and crude product 
was dried to give a red solid.  
1H NMR (300 MHz, Methanol-d4) δ = 8.15 (dd, 3J = 8.08 Hz, 4J = 1.44 Hz, 1H, ar-6-H), 
7.66 (ddd, 3J = 8.03 Hz, 3J = 7.44 Hz, 4J = 1.61 Hz, 1H, ar-5-H), 7.44-7.32 (m, 2H, ar-3-H, 
ar-4-H), 3.70 (s, 3H, CO2CH3). C8H9NO2 (151.17 g mol
-1). MS(ESI): m/z = 174.06 (calcd. 
174.0525 [M+Na]+).  
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Methyl 2-Amino-5-iodobenzoate (39a) was prepared by iodination of methyl anthranilate 
in accordance to the description of Adepu et al. [224]. A solution of iodchloride (1 M in 
CH2Cl2, 6 mL, 6 mmol, 1.2 eq) was added dropwise to a solution of methyl 2-aminobenzoic 
acid (5 mmol, 1 eq) in acetic acid/CH2Cl2 (5:2, 70 mL). The reaction mixture was stirred 
for 1 h at rt. After complete conversion (monitored by TLC), some drops of a saturated 
Na2S2O3 solution were added at 0 °C and the mixture was neutralized with a saturated 
Na2CO3 solution (90 mL). The forming precipitate was filtered off and the filtrate was 
extracted with CH2Cl2 (2 x 30 mL), EtOAc (1 x 30 mL) and Et2O (2 x 30 mL). The 
combined organic layers were washed with brine (10 mL) and dried over MgSO4. The 
solvent was removed under reduced pressure to yield the crude product of aromatic halide 
39a in pure form.  
Red solid. Yield: 345 mg, 1.25 mmol, 25 % (over two steps, referred to 
anthranilate, Lit: 80 % [224]). 1H NMR (Chloroform-d, 300 MHz): δ = 8.13 
(d, 4J = 2.19 Hz, 1H, ar-6-H), 7.47 (dd, 3J = 8.69 Hz, 4J = 2.18 Hz, 1H, ar-
4-H), 6.46 (d, 3J = 8.70 Hz, 1H, ar-3-H), 3.86 (s, 3H, CO2CH3). C8H8INO2 (277.06 g mol
-
1). MS(ESI): m/z = 277.98 (calcd. 277.9672 [M+H]+).  
 
2-Amino-5-((R)-3-(((R)-tert-butylsulfinyl)amino)-4-methylpent-1-yn-1-
yl)benzoic Acid (39b). Anthranilate was iodinated as described by Wallingford et al. 
[225]. A iodochloride solution (1 M in CH2Cl2, 4.4 mL, 4.4 mmol, 1.0 eq) was added 
dropwise within 3 min to a solution of 2-aminobenzoic acid (600 mg, 
4.38 mmol, 1.0 eq) in glacial acetic acid (20 mL) at 0 °C. The reaction 
mixture immediately turned deeply red and a colorless precipitate formed, 
which was separated by filtration. After extensive drying, the colorless solid 39b was 
recrystallized from EtOH.  
Colorless, crystalline solid. Yield: 599 mg, 2.28 mmol, 52 % (Lit: 90 % [225]). 1H NMR 
(600 MHz, methanol-d4) δ = 8.05 (d, 4J = 2.2 Hz, 1H, ar-6-H), 7.44 (dd, 3J = 8.8 Hz, 4J = 
2.2 Hz, 1H, ar-4-H), 6.56 (d, 3J = 8.7 Hz, 1H, ar-3-H). C7H6INO2 (263.03 g mol
-1). LCMS 
(ESI): tr = 6.8 min, m/z = 264.050 (calcd. 263.9516 [M+H]
+).  
 
IIX-3. c) Peptidomimetics from meta-Substituted Aromatics (36-44) 
132 
(E)-5-Iodo-2-(phenyldiazenyl)benzoic Acid (39c). Methyl 5-iodo-2-aminobenzoate 
(179 mg, 0.65 mmol, 1.0 eq) and nitrosylbenzene (83 mg, 0.78 mmol, 1.1 eq) were 
dissolved in glacial acid (8.5 mL) and the solution was stirred for 5 h at rt, heated for 80 min 
at 65 °C and stirred for another 12 h at rt. As the starting material had not 
been completely converted, yet, another portion of nitrosylbenzene 
(55 mg, 0.51 mmol, 0.8 eq) was added the solution was heated for 3 more 
h to 65 °C. After cooling down to 0 °C, the solution was neutralized with 
a saturated Na2CO3 solution and extracted with Et2O (5 x 30 mL). The combined organic 
layers were washed with brine (10 mL), dried over MgSO4 and the solvent was removed 
under reduced pressure. The crude product was dried under vacuum.  
Brown solid. Yield: 159 mg, 0.45 mmol, 70 %. 1H NMR (300 MHz, Chloroform-d) δ = 
8.80 (d, 4J = 2.03 Hz, 1H, ar-6-H), 8.31 (dd, 3J = 8.44 Hz, 4J = 1.59 Hz, 1H, ar-4-H), 7.65-
7.59 (m, 2H, Ph-2-H, Ph-6-H), 7.56-7.48 (m, 3H, Ph-3-H, Ph-4-H, Ph-5-H), 6.47 (d, 3J = 
8.74 Hz, 1H, ar-3-H). C13H9IN2O2 (352.13 g mol
-1). MS (ESI): m/z = 352.99 (calcd. 
352.9781 [M+H]+).  
 
Ethyl 3-((S)-3-(((S)-tert-Butylsulfinyl)amino)-4-methylpent-1-yn-1-yl)benzoate (40a). 
A solution of L-valine analogous propargylamide 6b (100 mg, 498 mol, 1.0 eq) and 
ethyl 3-iodobenzoate (36b, 120 L, 838 mol, 1.4 eq) in a mixture of THF/piperidine 
(1.3 mL, 3:1) was thoroughly degassed by the freeze-pump-thaw method. While still 
frozen, the solid catalyst PdCl2(PPh3)2 (2 mg) and CuI (1 mg) was added in one portion and 
the mixture was allowed to warm up to rt and stirred over 18 h at ambient temperature. A 
colorless precipitate formed in the course of the reaction. The reaction mixture was diluted 
with a mixture of Et2O and aqueous NH4Cl (1:1, 60 mL), neutralized with aqueous KHSO4 
solution (5 %, 5-10 mL, until pH 6). The phases were separated and the aqueous layer was 
extracted with Et2O (3 x 30 mL). The combined organic layers were washed with brine, 
dried over Na2SO4 and the solvent was evaporated under reduced pressure. Crude product 
40a was purified by column chromatography (PE/EtOAc, 1:1).  
Colorless oil. Yield: 141 mg, 403 mol, 81 %. 1H NMR 
(300 MHz, Chloroform-d): δ = 8.09 (t, 4J = 1.49 Hz, 1H, ar-2-
H), 7.97 (dt, 3J = 7.90 Hz, 4J = 1.46 Hz, 1H, ar-6-H), 7.62 (dt, 
3J = 7.77 Hz, 4J = 1.45 Hz, 1H, ar-4-H), 7.37 (t, 3J = 7.63 Hz, 
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1H, ar-5-H), 4.38 (q, 3J = 7.13 Hz, 2H,  CO2CH2CH3), 4.13 (m, 1H, CHCH(CH3)2), 3.41 
(d, 3J = 6.62 Hz, 1H, CNH), 2.06 (m, 1H, CCH(CH3)2), 1.40 (t, 3J = 7.12 Hz, 3H, 
CO2CH2CH3), 1.25 (s, 9H, SC(CH3)3), 1.07 (d, 
3J = 6.70 Hz, 3H, CHCH(CH3)2), 1.06 (d, 
3J = 6.70 Hz, 3H, CHCH(CH3)2). 
13C NMR (75 MHz, Chloroform-d) δ = 166.1 
(CO2CH2CH3), 136.1 (ar-C-4), 132.9 (ar-C-2), 130.8 (ar-C-1), 129.5 (ar-C-6), 128.5 (ar-
C-5), 123.2 (ar-C-3), 88.6 (CHC≡C-ar), 84.8 (CHC≡C-ar), 61.4 (CO2CH2CH3), 56.5 
(SC(CH3)3), 54.3 (CHCH(CH3)2), 33.9 (CHCH(CH3)2), 22.8 (S(C(CH3)3), 19.2 
(CHCH(CH3)2), 17.7 (CHCH(CH3)2), 14.5 (CO2CH2CH3). C19H27NO3S 
(349.49 g mol-1). TLC: Rf (PE/EtOAc, 1:1) = 0.52. [𝛼]589
20  = +13.75 (c 0.708, CHCl3).  
 
Ethyl 3-((R)-3-(((R)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-yl)benzoate (40b). 
A solution of D-leucine analogous propargylamide 6c (375 mg, 1.74 mmol, 1.0 eq) and 
ethyl 3-iodobenzoate (36b, 500 L, 2.90 mmol, 1.7 eq) in a mixture of THF/piperidine 
(4 mL, 3:1) was thoroughly degassed by the freeze-pump-thaw method. While still frozen, 
the solid catalyst PdCl2(PPh3)2 (2 mg) and CuI (1 mg) was added in one portion and the 
mixture was allowed to warm up to rt and stirred overnight at ambient temperature. A 
colorless precipitate formed in the course of the reaction. The reaction mixture was diluted 
with a mixture of Et2O and aqueous NH4Cl (1:1, 60 mL), neutralized with aqueous KHSO4 
solution (5 %, 10-20 mL, until pH 6). The phases were separated and the aqueous layer was 
extracted with Et2O (3 x 30 mL). The combined organic layers were washed with brine, 
dried over Na2SO4 and the solvent was evaporated under reduced pressure. Crude product 
40b was purified by column chromatography (PE/EtOAc, 1:1).  
 Colorless, highly viscous oil. Yield: 621.7 mg, 1.710 mmol, 
98 %. 1H NMR (500 MHz, Chloroform-d) δ = 8.06 (t, 4J = 
1.7 Hz, 1H, ar-2-H), 7.95 (dt, 3J = 7.8 Hz, 4J = 1.5 Hz, 1H, ar-
6-H), 7.60 (dt, 3J = 7.6 Hz, 4J = 1.5 Hz, 1H, ar-4-H), 7.35 (t, 3J 
= 7.8 Hz, 1H, ar-5-H), 4.35 (q, 3J = 7.1 Hz, 2H, CO2CH2CH3), 4.26 (ddd, 
3J = 4.6 Hz, 3J = 
7.4 Hz, 3J = 7.9 Hz, CHCH2CH(CH3)2), 3.45 (s br., 1H, CNH), 1.90 (m, 1H, 
CCH2CH(CH3)2), 1.82-6.54 (m, 2H, CHCH2CH(CH3)2), 1.37 (t, 3J = 7.1 Hz, 3H, 
CO2CH2CH3), 1.22 (s, 9H, SC(CH3)3), 0.95 (d, 
3J = 6.6 Hz, 6H, CHCH2CH(CH3)2). 
13C NMR (126 MHz, Chloroform-d) δ = 165.9 (CO2CH2CH3), 136.0 (ar-C-4), 132.7 (ar-
C-2), 130.6 (ar-C-6), 129.3 (ar-C-3), 128.3 (ar-C-5), 123.1 (ar-C-1), 90.3 (CHC≡C-ar), 
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83.7 (CHC≡C-ar), 61.2 (CO2CH2CH3), 56.2 (SC(CH3)3), 46.9 (CHCH2CH(CH3)2), 46.2 
(CHCH2CH(CH3)2), 25.0 (CHCH2CH(CH3)2), 22.6 (SC(CH3)3), 22.1 
(CHCH2CH(CH3)2), 21.4 (CHCH2CH(CH3)2), 14.3 (CO2CH2CH3). C20H29NO3S 
(363.52 g mol-1). MS(ESI): m/z = 386.17499 (calcd. 386.17604 [M+Na]+). 
[α]589
22  = -11.0 (c 0.73, CHCl3), [𝛼]589
20  = +13.90 (c 0.854, MeOH). Rf (EtOAc/PE, 1:1) = 
0.48. IR (ATR): ῦ [cm-1] = 3272 (-NH-), 2953, 2866 (C-CH3, -CH2-), 1719 (CO2Et), 1604, 
1581 (ar, C=C), 1281, 1217, 1100, 1053 (C-H). Mp = 160.7 °C (± 1.7 K).  
 
Ethyl 3-((R)-3-(((R)-tert-Butylsulfinyl)amino)-5-(methylthio)pent-1-yn-1-
yl)benzoate (40c). A solution of the D-methionine analogous propargylamide 6d (100 mg, 
430 mol, 1.0 eq) and ethyl 3-iodobenzoate (36b, 1.3 mL, 0.77 mmol, 1.8 eq) in a mixture 
of THF/piperidine (7:3, 1.0 mL) was thoroughly degassed by the freeze-pump-thaw 
method. Afterwards, the catalysts PdCl2(PPh3)2 (30 mg, 43 µmol, 0.1 eq) and CuI (17 mg, 
86 µmol, 0.2 eq) were added in one portion to the cold solution 
and the mixture was stirred at rt. 12 h later, a colorless 
precipitate had formed. The reaction mixture was diluted with 
an aqueous NH4Cl solution (saturated, 10 mL) neutralized with 
hydrochloric acid (1 M, about 3 mL) and extracted with Et2O (3 x 25 mL). The combined 
organic layers were dried over Na2SO4, filtered and the solvent was evaporated under 
reduced pressure. After purification by column chromatography (PE/EtOAc, 1:1), title 
compound 40c was isolated in form of a very pale brown solid.  
Pale brown highly viscous oil. Yield: 138 mg, 362 mol, 85 %. 1H NMR (300 MHz, 
Chloroform-d) δ = 8.08 (t, 4J = 1.8 Hz, 1H, ar-2-H), 7.98 (dt, 3J = 7.9 Hz, 4J = 1.5 Hz, 1H, 
ar-6-H), 7.61 (dt, 3J = 7.7 Hz, 4J = 1.5 Hz, 1H, ar-4-H), 7.37 (td, 3J = 7.8 Hz, 4J = 0.6 Hz, 
1H, ar-5-H), 4.47 (ddd, 3J = 6.6 Hz, 3J = 6.7 Hz, 3J = 5.4 Hz, 1H, CHCH2CH2SCH3), 
4.37 (q, 3J = 7.1 Hz, 2H, CO2CH2CH3), 3.55 (d, 
3J = 6.6 Hz, 1H, CHNH), 2.74 (ddt, 2J = 
11.3 Hz, 3J = 6.7 Hz, 3J = 5.8 Hz, 1H, CHCH2CH2SCH3), 2.67 (ddt, 
2J = 11.9 Hz, 3J = 
5.4 Hz, 3J = 6.3 Hz, 1H, CHCH2CH2SCH3), 2.13 (s, 3H, CHCH2CH2SCH3), 2.12-
2.06 (m, 2H, CHCH2CH2SCH3), 1.39 (t, 
3J = 7.1 Hz, 3H, CO2CH2CH3), 1.24 (s, 9H, 
SC(CH3)3). 
13C NMR (151 MHz, Chloroform-d) δ = 166.0 (CO2CH2CH3), 136.0 (ar-C-4), 
132.9 (ar-C-2), 130.8 (ar-C-1), 129.6 (ar-C-6), 128.5 (ar-C-5), 122.9 (ar-C-3), 89.2 
(CHC≡C-ar), 84.6 (CHC≡C-ar), 61.3 (CO2CH2CH3), 56.4 (SC(CH3)3), 47.4 
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(CHCH2CH2SCH3), 36.2 (CHCH2CH2SCH3), 30.3 (CHCH2CH2SCH3), 22.7 
(SC(CH3)3), 15.7 (CHCH2CH2SCH3), 14.4 (CO2CH2CH3). C19H27NO3S2 
(381.55 g mol-1). MS(EI): m/z = 382.219 (calcd. 382.1505 [M+H]+), 404.198 (calcd. 
404.1325 [M+Na]+). TLC: Rf (EtOAc/PE, 1:2) = 0.14. IR (ATR): ῦ [cm-1] = 3205 (NH), 
2974, 2958, 2914 (CH3, CH2, ar-CH), 2359 (C≡C), 1714 (C=O), 1600, 1578 (ar C=C), 
1473, 1429, 1385, 1365 (δ CH3, δ CH2), 1290, 1223 (CO-O-C), 1059 (S=O), 913, 865 755, 
685 (ar C-H). [𝛼]589
20  = -15.84 (c 5.532, MeOH).  
 
Methyl 3-((R)-3-(((R)-tert-Butylsulfinyl)amino)-3-cyclohexylprop-1-yn-1-
yl)benzoate (40d). Piperidine (0.3 mL) was added to a solution of D-cyclohexylglycine 
analogous propargylamide 6e (46.4 mg, 192.4 mol, 1.3 eq) and methyl 3-iodobenzoate 
(36a, 38.8 mg, 192 mol, 1.3 eq) in THF (0.9 mL). The reaction mixture was degassed by 
freeze pump thaw method, until no more gas atmosphere could be detected by the 
manometer (usually 3 x). The catalysts, PdCl2(PPh3)2 (1 mg) and CuI (2 mg) were added 
to the frozen reaction mixture and the solution slowly warmed to room temperature. After 
2 h, a colorless precipitate formed in the clear solution, indicating the procedure of the 
reaction. 14 h Later, the suspension was diluted with a saturated aqueous NH4Cl (10 mL) 
solution and KHSO4 (aq, 5%, 7 mL) was added, until the organic layer started to turn faintly 
red (pH 5-6). The emulsion was diluted with Et2O (20 mL), the organic layer was separated 
and extracted to more times with Et2O (2 x 20 mL). The combined organic layers were 
dried over Na2SO4 and the solvent was evaporated in vacuum. Crude product 40d was 
purified by column chromatography (PE/EtOAc, 1:1).  
Colorless crystals. Yield: 24.5 mg, 65.2 mol, 44 %. 1H NMR 
(500 MHz, Chloroform-d) δ = 8.08 (d, 4J = 1.8 Hz, 1H, ar-2-
H), 7.95 (dd, 3J = 7.7 Hz, 4J = 1.5 Hz, 1H, ar-6-H), 7.62 (dd, 3J 
= 7.8 Hz, 4J = 1.5 Hz, 1H, ar-4-H), 7.37 (t, 3J = 7.8 Hz, 1H, ar-
5-H), 4.08 (dd, 3J = 7.1 Hz, 3J = 6.4 Hz, 1H, CHcy), 3.91 (s, 3H, CO2CH3), 3.38 (d, 
3J = 
7.1 Hz, 1H, CHNH), 1.90 (d br., 2J = 11.7 Hz, 1H, cy-2-H), 1.88 (d br., 2J = 11.7 Hz, 1H, 
cy-6-H), 1.79 (d br., 2J = 12.6 Hz, 2H, cy-2-H, cy-6-H), 1.72-1.62 (m br., 2H, cy-1-H, cy-
4-H), 1.33-1.26 (m br., 2H, cy-3-H, cy-5-H), 1.25 (s, 9H, SC(CH3)3), 1.22-1.10 (m br., 3H, 
cy-3-H, cy-4-H, cy-5-H). 13C NMR (126 MHz, Chloroform-d) δ = 166.6 (CO2CH3), 136.2 
(ar-C-4), 132.9 (ar-C-4), 130.4 (ar-C-1), 129.4 (ar-C-6), 128.5 (ar-C-5), 123.4 (ar-C-3), 
IIX-3. c) Peptidomimetics from meta-Substituted Aromatics (36-44) 
136 
89.3 (CHC≡Car), 84.8 (CHC≡Car), 56.5 (SC(CH3)3), 53.8 (CH), 52.4 (CO2CH3), 43.6 
(cy-C-1), 29.7 (cy-C-2), 28.5 (cy-C-6), 26.4 (cy-C-4), 26.1 (cy-C-5), 26.0 (cy-C-3), 22.8 
(SC(CH3)3). C21H29NO3S (375.53 g mol-1). MS(ESI): m/z = 376.1998 (calcd. 376.1941 
[M+H]+), 398.1814 (calcd. 398.1760 [M+Na]+). Mp = 101 °C (+/- 3 K).  
 
3-((S)-3-(((S)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-yl)benzoic Acid (40e). A 
solution of L-leucine analogous propargylamide 6c (64 mg, 
320 mol, 1 eq) and 3-iodo benzoate (36c, 122 mg, 480 mol, 
1.5 eq) in a mixture of THF/piperidine (2:1, 1 mL) was 
thoroughly degassed by the freeze pump thaw method. The 
solid catalyst, PdCl2(PPh3)2 (22 mg, 32 mol, 0.1 eq) and CuI (12 mg, 64 mol, 0.2 eq) 
was added in one portion. The reaction mixture was stirred for 16 h at ambient temperature, 
before it was diluted with a mixture of aqueous NH4Cl and Et2O (2:5, 45 mL) and 
neutralized with aqueous HCl (1 M, 3-5 mL, pH 6). The phases were separated and the 
aqueous layer was extracted with Et2O (3 x 25 mL). The combined organic layers were 
washed with brine (8 mL) and dried over Na2SO4. After evaporation of the solvent, crude 
product 40e was purified by column chromatography (CH2Cl2/MeOH, 95:5).  
Pale, orange solid. Yield: 56 mg, 167 mol, 52 %. 1H NMR (300 MHz, Chloroform-d) δ = 
8.16 (t, 4J = 1.7 Hz, 1H, ar-2-H), 7.77 (ddd, 3J = 7.9 Hz, 4J = 1.7 Hz, 4J = 1.4 Hz, 1H, ar-6-
H), 7.41 (ddd, 3J = 7.7 Hz, 4J = 1.7 Hz, 4J = 1.4 Hz, 1H, ar-4-H), 7.16 (t, 3J = 7.8 Hz, 1H, 
ar-5-H), 5.39 (s, 1H, CHNH), 4.19 (ddd, 3J = 7.6 Hz, 3J = 7.4 Hz, 3J = 6.9 Hz, 1H, CH), 
1.90 (m, 1H, CHCH2CH(CH3)2), 1.70 (dt, 
2J = 15.0 Hz, 3J = 7.6 Hz, 1H, 
CHCH2CH(CH3)2), 1.62 (dt, 
2J = 14.6 Hz, 3J = 7.4 Hz, 1H, CHCH2CH(CH3)2), 1.32 (s, 
9H, SC(CH3)3), 0.96 (d, 
3J = 6.6 Hz, 3H, CHCH2CH(CH3)2), 0.94 (d, 
3J = 6.5 Hz, 3H, 
CHCH2CH(CH3)2). C18H25NO3S (335.46 g mol
-1). TLC: Rf (CH2Cl2/MeOH, 95:5) = 0.09.  
 
Ethyl 3-((R)-3-(((S)-tert-Butylsulfinyl)amino)-3-(perfluorophenyl)prop-1-yn-1-
yl)benzoate (40f). A solution of L-pentafluorphenyl-glycine analogous propargylamide 6o 
(50 mg, 154 mol, 1 eq) and ethyl 3-iodobenzoate (36c, 100 mg, 362 mol, 2 eq) in a 
mixture of THF/DIPEA (10:1, 1.1 mL) was thoroughly degassed, before adding the 
catalysts PdCl2(PPh3)2 (1.1 mg, 1.5 µmol, 1 mol%) and CuI (0.7 mg, 3.8 µmol, 2 mol%). 
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The reaction mixture was stirred for 24 h at rt. The now darkly green suspension was diluted 
with an aqueous NH4Cl solution (10 mL) and extracted with CH2Cl2 (3 x 10 mL). The 
combined organic layers were dried over MgSO4, filtered and the solvent was evaporated. 
The brown crude product was purified by column chromatography (EtOAc/PE, 1:2) to yield 
peptidomimetic 40f in pure form.  
Pale yellow, highly viscous oil. Yield: 47 mg, 99 mol, 65 %. 
1H NMR (300 MHz, Chloroform-d) δ = 8.08 (t, 4J = 1.7 Hz, 
1H, ar-2-H), 8.00 (dt, 3J = 7.9 Hz, 4J = 1.5 Hz, 1H, ar-6-H), 
7.60 (dt, 3J = 7.7 Hz, 4J = 1.5 Hz, 1H, ar-4-H), 7.38 (t, 3J = 
7.8 Hz, 1H, ar-5-H), 5.82 (dt, 3JHH = 6.2 Hz, 
4JHF = 1.3 Hz, 1H, 
CHC6F5), 4.37 (q, 
3J = 7.1 Hz, 2H, CO2CH2CH3), 4.13 (d, 
3J = 5.9 Hz, 1H, NHCH), 1.38 
(t, 3J = 7.1 Hz, 3H, CO2CH2CH3), 1.20 (s, 9H, SC(CH3)3). 
19F NMR (282 MHz, 
Chloroform-d) δ = -142.0 (dd, 3JFF = 20.5 Hz, 4JFH = 6.7 Hz, 2F, F5Ph-2-F, F5Ph-6-
F), -153.1 (tt, 3JFF = 20.9 Hz, 
4JFF = 2.2 Hz, 1F, F5Ph-4-F), -160.7 (dd, 
3JFF = 20.8 Hz, 
4JFF 
= 13.9 Hz, 2F, F5Ph-3-F, F5Ph-5-F). 
13C NMR (151 MHz, Chloroform-d) δ = 165.8 (ar-1-
CO2CH2CH3), 144.9 (d, 
1JCF = 259.8 Hz, F5Ph-C-3, F5Ph-C-5), 141.6 (d, 
1JCF = 255.1 Hz, 
F5Ph-C-4), 137.9 (d, 
1JCF = 248.5 Hz, F5Ph-C-2, F5Ph-C-6), 136.1 (ar-C-4), 133.0 (ar-C-
2), 131.0 (ar-C-1), 130.2 (ar-C-6), 128.6 (ar-C-5), 122.1 (ar-C-3), 113.8 (F5Ph-C-1), 85.2 
(CHC≡C-ar), 85.0 (CHC≡C-ar), 61.4 (CO2CH2CH3), 56.9 (SC(CH3)3), 41.9 (CHC6F5), 
22.4 (SC(CH3)3), 14.4 (CO2CH2CH3). C22H20F5NO3S (473.46 g mol-1). MS(EI): m/z = 
496.1 (calcd. 496.0976 [M+Na]+). IR (ATR) 𝜈 [cm-1] = 3227 (w, ν, -NH), 2977 (w, ν, aryl-
H), 2360 (w, ν, -C≡C-), 1717 (s, ν, -C=O), 1518 (s, δ, EtO-C=O), 1502 (vs, δ, -S-NH-), 
1296 (s, ν, -CF), 1078 (vs, ν, S=O).  
 
Methyl 3-((R)-3-(((S)-tert-Butylsulfinyl)amido)-4,4,4-trifluorobut-1-yn-1-
yl)benzoate (40g). A solution of L-trifluoro-alanine analogous propargylamide 6p 
(132 mg, 582 mol, 1.0 eq) and methyl 3-iodobenzoate (36a, 183 mg, 698 mol, 1.2 eq) in 
a mixture of THF/DIPEA (2.33 mL, 6:1) was thoroughly degassed by the freeze-pump-
thaw method. While still frozen, the solid catalyst PdCl2(PPh3)2 (5 mg, 6 mol, 1 mol%) 
and CuI (2.6 mg, 12 mol, 2 mol%) was added in one portion and the mixture was allowed 
to warm up to rt and stirred 15 h at ambient temperature. The orange solution was diluted 
with a mixture of Et2O and aqueous NH4Cl (5:1, 18 mL), neutralized with aqueous KHSO4 
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solution (5 %, 5-10 mL, until pH 6). The phases were separated and the aqueous layer was 
extracted with Et2O (3 x 15 mL). The combined organic layers were washed with brine, 
dried over Na2SO4 and the solvent was evaporated under reduced pressure. The crude 
product 40g was purified by column chromatography (PE/EtOAc, 1:1).  
Faintly yellow oil. Yield: 94.7 mg, 262 mol, 45 %. 1H NMR 
(300 MHz, Chloroform-d) δ = 8.10 (t, 4J = 1.7 Hz, 1H, ar-2-H), 
8.01 (dd, 3J = 7.9 Hz, 4J = 1.5 Hz, 1H, ar-6-H), 7.62 (dd, 3J = 
7.7 Hz, 4J = 1.5 Hz, 1H, ar-4-H), 7.39 (t, 3J = 7.8 Hz, 1H, ar-5-H), 4.77 (dq, 3JHH = 7.6 Hz, 
3JHF = 6.3 Hz, 1H, CHCF3), 4.04 (d, 
3J = 7.6 Hz, 1H, CNH), 3.90 (s, 3H, CO2CH3), 
1.25 (s, 9H, SC(CH3)3). 
19F NMR (282 MHz, Chloroform-d) δ = -76.3 (d, 3JFH = 6.3 Hz, 
CHCF3). 13C NMR (75 MHz, Chloroform-d) δ = 166.2 (CO2(CH3)), 136.2 (ar-C-4), 133.2 
(ar-C-2), 130.6 (ar-C-1), 130.5 (ar-C-6), 128.7 (ar-C-5), 121.5 (ar-C-3), 121.3 (q, 1JCF = 
280.7 Hz, CHCF3), 86.7 (CHC≡Car), 80.6 (q, 3JCF = 2.2 Hz, CHC≡Car), 57.6 
(SC(CH3)3), 52.4 (CO2CH3), 51.5 (q, 
2JCF = 35.1 Hz, CHCF3), 22.5 (SC(CH3)3). 
C16H18F3NO3S (361.38 g mol
-1). MS(ESI): m/z = 362.1022 (calcd. 362.1032 [M+H]+). 
TLC: Rf (EtOAc/PE, 1:1) = 0.63. UV/Vis: max = 252 nm (Diagram EP2b Experimental 
Part).  
 
3-((R)-3-(((S)-tert-Butylsulfinyl)amino)-3-(perfluorophenyl)prop-1-yn-1-yl)-N-(3,5-
difluorobenzyl)benzamide (40h). A solution of L-pentafluorphenyl-glycine analogous 
propargylamide 6o (100 mg, 307 mol, 1 eq) and N-(3,5-Difluorobenzyl)-3-
iodobenzamide (36d, 116 mg, 445 mol, 1.5 eq) in a mixture of THF/DIPEA (6:1, 2.3 mL) 
was thoroughly degassed, before adding the catalysts PdCl2(PPh3)2 (2.2 mg, 3.1 µmol, 
1 mol%) and CuI (1.2 mg, 6.2 µmol, 2 mol%). The reaction mixture was stirred for 24 h at 
rt. The now darkly green suspension was diluted with an aqueous NH4Cl solution (10 mL) 
and extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were dried over 
MgSO4, filtered and the solvent was evaporated. The brown crude product was purified by 
column chromatography (EtOAc/PE, 1:2) to yield peptidomimetic 40h in pure form.  
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Pale brown solid. Yield: 123 mg, 215 mol, 70 %. 1H NMR (500 MHz, Chloroform-d) δ = 
7.82 (d, 4J = 1.4 Hz, 2H, ar-2-H), 7.81 (dt, 3J = 7.1 Hz, 
4J = 1.5 Hz, 1H, ar-4-H), 7.51 (dd, 3J = 7.8 Hz, 4J = 
1.4 Hz, 1H, ar-6-H), 7.48 (t, 3J = 6.8 Hz, 1H, 
CONHCH2), 7.35 (dd, 
3J = 8.6 Hz, 3J = 7.6 Hz, 1H, 
ar-5-H), 6.85 (d, 3JFH = 4.5 Hz, 2H, F2Ph-2-H, F2Ph-
6-H), 6.67 (tt, 3JHF = 8.9 Hz, 
4JHH = 2.3 Hz, 1H, F2Ph-4-H), 5.72 (d, 
3J = 7.0 Hz, 1H, CH), 
4.57 (d, 3J = 5.9 Hz, 2H, CONHCH2PhF2), 4.19 (d, 
3J = 7.2 Hz, 1H, NHCH), 1.17 (s, 9H, 
SC(CH3)3). 
19F NMR (470 MHz, Chloroform-d) δ = -109.5 (t, 3JFH = 7.9 Hz, 2F, F2Ph-3-
F, F2Ph-5-F), -142.1 (dd, 
3JFF = 20.6 Hz, 
4JFF = 6.6 Hz, 2F, F6Ph-2-F, F6Ph-6-F), -153.0 
(t, 3JFF = 20.9 Hz, 1F, F6Ph-4-F), -160.6 (td, 
3JFF = 21.1 Hz, 
4JFF = 7.0 Hz, 2F, F6Ph-3-F, 
F6Ph-5-F). 
13C NMR (126 MHz, Chloroform-d) δ = 166.8 (CONH), 163.2 (dd, 1JCF = 
248.9 Hz, 3JCF = 12.6 Hz, F2Ph-C-3, F2Ph-C-5), 144.7 (d, 
1JCF = 250.1 Hz, F6Ph-C-3, F6Ph-
C-5), 142.6 (t, 3JCF = 8.8 Hz, F2Ph-C-1), 141.4 (d, 
1JCF = 235.3 Hz, F6Ph-C-4), 137.8 (d, 
1JCF = 258.1 Hz, F6Ph-C-2, F6Ph-C-6), 135.0 (ar-C-6), 134.4 (ar-C-1), 130.4 (ar-C-2), 
128.8 (ar-C-5), 128.2 (ar-C-4), 122.0 (ar-C-3), 113.7 (td, 2JCF = 14.7 Hz, 
3JCF = 4.0 Hz, 
F6Ph-C-1), 110.5 (dd, 
2JCF = 19.5 Hz, 
4JCF = 6.0 Hz, F2Ph-C-2, F2Ph-C-6), 102.9 (t, 
2JCF = 
25.3 Hz, F2Ph-C-4), 85.3 (CHC≡C-ar), 85.0 (CHC≡C-ar), 57.0 (SC(CH3)3), 43.3 
(CONHCH2PhF2), 42.1 (CH), 22.4 (SC(CH3)3). C27H21F7N2O2S (570.53 g mol
-1). 
MS(EI): m/z = 593.145 (calcd. 593.1104 [M+Na]+). TLC: Rf (PE/EtOAc, 2:1) = 0.23. IR 
(ATR) 𝜈 (cm-1) = 3307 (w, ν, -NH), 2962 (w, ν, Aryl-H), 2360 (w, ν, -C≡C-), 1648 (m, ν, -
C=O), 1622 (m, ν, -C=C- Aryl), 1521 (s, δ, -C-NH-), 1505 (vs, δ, -S-NH-),  1256 (s, ν, -
CF), 1052 (vs, ν, S=O).  
 
3-((R)-3-(((S)-tert-Butylsulfinyl)amino)-4,4,4-trifluorobut-1-yn-1-yl)-N-(3,5-
difluorobenzyl)benzamide (40i). A mixture of L-trifluoralanin analogous propargylamide 
(6p, 105 mg, 462 mol, 1.0 eq) and N-(3,5-difluorbenzyl)-3-iodobenzamide (36d, 172 mg, 
462 mol, 1.0 eq) in THF/DIPEA (1.3 mL, 3:1) was thoroughly degassed by the freeze-
pump-thaw method. Then, the solid catalyst, PdCl2(PPh3)2 (3.2 mg, 4.6 mol, 1 mol%) and 
CuI (1.8 mg, 9.4 mol, 2 mol%), was added and the reaction mixture was stirred for 24 h 
at ambient temperature. The dark green solution was diluted with an aqueous solution of 
NH4Cl, neutralized with KHSO4 (5 %, 1-3 mL, pH 6) and extracted with Et2O (3 x 10 mL). 
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The combined organic layers were dried over MgSO4, filtered and the solvent was 
evaporated. The crude product was purified by preparative HPLC to yield peptidomimetic 
40i in pure form.  
Pale yellow solid. Yield: 38 mg, 80 mol, 17 %. 
1H NMR (300 MHz, Chloroform-d) δ = 7.90 (t, 4J = 
1.7 Hz, 1H, ar-2-H), 7.85 (dt, 3J = 7.8 Hz, 4J = 1.5 Hz, 
1H, ar-6-H), 7.65 (dt, 3J = 7.8 Hz, 4J = 1.4 Hz, 1H, ar-4-H), 7.44 (t, 3J = 7.7 Hz, 1H, ar-5-
H), 6.87 (dd, 3JHF = 8.0 Hz, 
4JHH = 2.2 Hz, 2H, F2Ph-2-H, F2Ph-6-H), 6.72 (tt, 
3JHF = 
8.9 Hz, 4JHH = 2.3 Hz, 1H, F2Ph-4-H), 4.81 (dq, 
3JHF = 6.4 Hz,
 3JHH = 7.3 Hz, 1H, CHCF3), 
4.61 (d br., 3J = 6.0 Hz, 2H, CONHCH2PhF2), 4.09 (d, 
3J = 7.3 Hz, 1H, NHCH), 1.27 (s, 
9H, SC(CH3)3). 19F NMR (282 MHz, Chloroform-d) δ = -75.7 (d, 3JFH = 6.3 Hz, 3F, 
CHCF3), -109.2 (dd, 3JFH = 8.0 Hz,
 3JFH = 7.7 Hz, 2F, F2Ph-3-F, F2Ph-5-F). 
C22H21F5N2O2S (472.47 g mol
-1). MS(EI): m/z = 473.112 (calcd. 473.1317 [M+H]+), 
495.137 (calcd. 495.1136 [M+Na]+).  
 
Methyl 5-((S)-3-(((S)-tert-Butylsulfinyl)amino)-4-methylpent-1-yn-1-
yl)nicotinate (41a). Piperidine (0.3 mL) was added to a 
solution of the L-valine analogous propargylamide 6b (302 mg, 
1.50 mmol, 1 eq) and methyl 5-bromonicotinate (454 mg, 
2.10 mmol, 1.4 eq) in THF (0.9 mL). The reaction mixture was degassed by freeze pump 
thaw method, until no more gas atmosphere could be detected by the manometer (3 x). The 
catalysts, PdCl2(PPh3)2 (2 mg, 4.8 mol, 0.3 mol%) and CuI (1 mg, 5.3 mol, 0.3 mol%) 
were added to the frozen reaction mixture and the solution slowly warmed to room 
temperature. After 30 min, a colorless precipitate formed in the clear solution, indicating 
the procedure of the reaction. 5 h Later, the suspension was diluted with a saturated aqueous 
NH4Cl solution (13 mL) and KHSO4 (aq, 5%, ca. 5 mL) was added, until the organic layer 
started to turn faintly red (pH 5-6). The emulsion was diluted with Et2O (20 mL), the 
organic layer was separated and the organic layer extracted to more times with Et2O (2 x 
20 mL). The combined organic layers were dried over Na2SO4 and the solvent was 
evaporated in vacuum. The crude product of peptidomimetic 41a was purified by column 
chromatography (EtOAc/PE, 1:1) and recrystallizytion from Et2O.  
IIX-3. c) Peptidomimetics from meta-Substituted Aromatics (36-44) 
141 
Colorless crystals. Yield: 293.5 mg, 872.3 mol, 58 %, dr = 97 % (determined via 
integration of 1H NMR signals of CH, 4.12 ppm), 1H NMR (500 MHz, Chloroform-d) δ 
= 9.10 (s, 1H, ar-6-H), 8.80 (s, 1H, ar-2-H), 8.31 (s, 1H, ar-4-H), 4.12 (ddd, 3J = 9.4 Hz, 3J 
= 7.3 Hz, 3J = 4.6 Hz, 1H, CH), 3.95 (s, 3H, CO2CH3), 3.40 (d, 
3J = 7.3 Hz, 1H, CHNH), 
2.04 (m, 1H, CHCH(CH3)2), 1.25 (s, 9H, SC(CH3)3), 1.08 (d, 
3J = 6.8 Hz, 3H, 
CHCH(CH3)2), 1.07 (d, 
3J = 6.6 Hz, 3H, CHCH(CH3)2). 
13C NMR (126 MHz, 
Chloroform-d) δ = 165.2 (CO2CH3), 155.8 (ar-C-2), 149.7 (ar-C-6), 139.7 (ar-C-4), 125.6 
(ar-C-5), 120.0 (ar-C-3), 92.6 (CHC≡C-ar), 81.5 (CHC≡C-ar), 56.6 (SC(CH3)3), 54.5 
(CH), 52.7 (CO2CH3), 34.0 (CHCH(CH3)2), 22.8 (SC(CH3)3), 19.2 (CHCH(CH3)2), 
17.9 (CHCH(CH3)2). C17H24N2O3S (336.45 g mol-1). EA: C 60.281 (calcd. 60.69), H 
7.149 (calcd. 7.19), N 8.356 (calcd. 8.33), S 9.543 (calcd. 9.53). [α]589
21  = 20.3 (c = 0.71, 
CHCl3). TLC: Rf (PE:EE 1:1) = 0.26. IR (ATR): ν̃ [cm-1] = 3183 (w, NH-VS), 2955, 2920, 
2901, 2866 (m, w, w, w, CH-VS), 2357, 2235 (m, m, C≡C), 1730 (s, COOCH3), 1587 (w, 
NH-DS), 1562 (w), 1448 (m), 1410 (m), 1388 (w), 1362 (w), 1302 (s), 1233 (s), 1163 (w), 
1109 (m), 1055(s, S=O), 1021 (m), 1011 (w), 910 (w), 764 (m), 698 (w), 666 (w). X-ray 
crystal structure in Chapter IIX-3. n.  
 
Methyl 5-((R)-3-(((R)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-
yl)nicotinate (41b). DIPEA (0.25 mL) was added to a solution of the L-leucine analogous 
propargylamide 6c (40.3 mg, 187 mol, 1 eq) and methyl 5-bromonicotinate (37a, 
52.5 mg, 243 mol, 1.3 eq) in THF (0.75 mL). The reaction mixture was degassed by 
freeze pump thaw method (3 x). The catalysts, Pd(PPh3)4 (2 mg, 4.8 mol, 3 mol%) and 
CuI (1 mg, 5.3 mol, 3 mol%) were added to the frozen reaction mixture and the solution 
slowly warmed to room temperature. After 50 min, a colorless precipitate formed in the 
clear solution, indicating the procedure of the reaction. 18 h Later, the suspension was 
diluted with a saturated aqueous NH4Cl solution (13 mL) and KHSO4 (aq, 5%, ca. 5 mL) 
was added, until the organic layer started to turn faintly red (pH 5-6). The emulsion was 
diluted with Et2O (20 mL), the organic layer was separated and the organic layer extracted 
to more times with Et2O (2 x 20 mL). The combined organic layers were dried over Na2SO4 
and the solvent was evaporated in vacuum. Crude product 41b was purified by column 
chromatography (EtOAc/PE, 1:1).  
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Yellow viscous oil. Yield: 52 mg, 148 mol, 79 %. 1H NMR (500 MHz, Chloroform-d) δ 
= 9.10 (s, 1H, ar-2-H), 8.79 (s, 1H, ar-6-H), 8.30 (t, 4J = 2.1 Hz, 
1H, ar-4-H), 4.27 (ddd, 3J = 7.8 Hz, 3J = 7.7 Hz, 3J = 7.4 Hz, 
1H, CH), 3.94 (s, 3H, CO2CH3), 3.52 (d, 
3J = 7.8 Hz, 1H, 
CαHNH), 1.91 (m, 1H, CαHCH2CH(CH3)2), 1.69 (t, 
3J = 
7.4 Hz, 2H, CαHCH2CH(CH3)2), 1.24 (s, 9H, SC(CH3)3), 0.97 (d, 
3J = 6.6 Hz, 6H, 
CH(CH3)2). 
13C NMR (126 MHz, Chloroform-d) δ = 165.2 (CO2CH3), 155.8 (ar-C-6), 
149.6 (ar-C-2), 139.7 (ar-C-4), 132.3 (ar-C-5), 128.7 (ar-C-3), 94.1 (CαHC≡C-ar), 80.6 
(CαHC≡C-ar), 56.6 (SC(CH3)3), 52.7 (CO2CH3), 47.2 (CαH), 46.1 (CαHCH2), 31.1 
(CαHCH2CH(CH3)2), 22.7 (SC(CH3)3), 22.6 (C
αHCH2CH(CH3)2), 22.3 
(CαHCH2CH(CH3)2). C18H26N2O3S (350.48 g mol
-1). MS(ESI): m/z = 373.15581 (calcd. 
373.15563 [M+Na]+). TLC: Rf (EtOAc/PE, 1:1) = 0.1.  
 
Methyl 6-((R)-3-(((R)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-
yl)picolinate (41c). A solution of D-leucine analogous propargylamide 6c (52 mol, 
1.0 eq) and methyl 6-bromopicolinate (37b, 14.6 mg, 67.6 mol, 1.3 eq) in a mixture of 
THF/piperidine (1 mL, 3:1) was thoroughly degassed by the freeze-pump-thaw method. 
While still frozen, the solid catalyst Pd(PPh3)4 (2 mg, 4.8 mol, 
9 mol%) and CuI (1 mg, 5.4 mol, 10 mol%) was added in one 
portion and the mixture was allowed to warm up to rt and 
stirred overnight at ambient temperature. The reaction mixture 
was diluted with a mixture of Et2O and aqueous NH4Cl (1:1, 6 mL), neutralized with 
aqueous KHSO4 solution (5 %, 3 mL, until pH 6). The phases were separated and the 
aqueous layer was extracted with Et2O (3 x 10 mL). The combined organic layers were 
washed with brine (5 mL), dried over Na2SO4 and the solvent was evaporated under 
reduced pressure. Crude product 41c was purified by preparative HPLC.  
Slightly orange oil. Yield: 16.4 mg, 46.8 mol, 90 %. 1H NMR (500 MHz, Chloroform-d) 
δ = 8.06 (d, 3J = 7.8 Hz, 1H, ar-3-H), 7.82 (t, 3J = 7.8 Hz, 1H, ar-4-H), 7.61 (dd, 3J = 7.9 Hz, 
4J = 1.2 Hz, 1H, ar-5-H), 4.24 (d, 3J = 7.8 Hz, 1H, CHNH), 4.11 (ddd, 3J = 7.8 Hz, 3J = 
7.3 Hz, 3J = 7.2 Hz, 1H, CH), 3.98 (s, 3H, CO2CH3), 1.90 (m, 1H, CHCH2CH(CH3)2), 
1.70 (t, 3J = 7.3 Hz, 2H, CHCH2CH(CH3)2), 1.26 (s, 9H, SC(CH3)3), 0.96 (d, 
3J = 7.0 Hz, 
3H, CHCH2CH(CH3)2), 0.94 (d, 
3J = 6.9 Hz, 3H, CHCH2CH(CH3)2). 
13C NMR 
IIX-3. c) Peptidomimetics from meta-Substituted Aromatics (36-44) 
143 
(126 MHz, Chloroform-d) δ = 164.8 (ar-2-CO2CH3), 147.7 (ar-C-2), 142.7 (ar-C-6), 138.0 
(ar-C-4), 130.7 (ar-C-5), 124.5 (ar-C-3), 91.8 (CHC≡C-ar), 82.7 (CHC≡C-ar), 57.3 
(SC(CH3)3), 53.2 (ar-2-CO2CH3), 47.9 (CHCH2CH(CH3)2), 45.3 (CHCH2CH(CH3)2), 
24.8 (CHCH2CH(CH3)2), 22.8 (SC(CH3)3), 22.4 (CHCH2CH(CH3)2), 22.1 
(CHCH2CH(CH3)2). C18H26N2O3S (350.48 g mol
-1). MS(ESI): m/z = 373.15581 (calcd. 
373.15563 [M+Na]+). TLC: Rf (EtOAc/PE, 1:1) = 0.11. IR (ATR): ῦ [cm-1] = 2955, 2927, 
2866 (C-CH3, -CH2-), 2615 (C≡C), 2360, 2339, 2318 (C-CH3, -CH2-), 1726 (CO2Et), 1578, 
1574, 1559 (ar, C=C), 1309,1288, 1243, 1199, 1164, 1138, 1117 (C-H).  
 
3-((S)-3-(((S)-tert-Butylsulfinyl)amino)-6-cyanohex-1-yn-1-yl)-4-
(methoxycarbonyl)benzoic Acid (42a). The catalysts PdCl2(PPh3)2 (2.8 mg, 6.8 mol, 
4 mol%) and CuI (0.9 mg, 4.7 mol, 3 mol%) were added to a 
thoroughly degassed solution of L-Glutamine analogon 
precursor nitrile 6i (40.5 mg, 178.9 mol, 1 eq) and 1-Methyl-
2-iodoterephthalat (38a, 82.1 mg, 268.4 mol, 1.5 eq) in 
HN(iPr)2/THF (1:3, 5 mL). The reaction mixture was stirred 
overnight at ambient temperature. After complete conversion of the starting material 
(checked by TLC), the mixture was diluted with aqueous NH4Cl solution (saturated, 2 mL) 
and hydrochloric acid (1 mL) and extracted with Et2O (3 x 5 mL). The combined organic 
layers were dried over Na2SO4 and the solvent was evaporated under reduced pressure. 
Peptidomimetic 42a was isolated by column chromatography (PE/EtOAc, 4:1).  
Pale yellow crystalline solid. Yield: 20.6 mg, 50.9 mol, 29 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.99 (d, 4J = 1.5 Hz, 1H, ar-2-H), 7.81 (d, 3J = 7.9 Hz, 1H, ar-5-H), 7.40 
(dd, 3J = 7.9 Hz, 4J = 1.6 Hz, 1H, ar-6-H), 3.94 (s, 3H, ar-4-CO2CH3), 3.69 (s br., 1H, 
CHCH2CH2CH2CN), 3.29 (s br., 1H, CHNH), 3.14 (dt, 
2J = 12.5 Hz, 3J = 5.0 Hz, 1H, 
CHCH2CH2CH2CN), 3.00 (dt, 
2J = 12.5 Hz, 3J = 5.2 Hz, 1H, CHCH2CH2CH2CN), 
1.73-1.64 (m, 2H, CHCH2CH2CH2CN), 1.63-1.54 (m, 2H, CHCH2CH2CH2CN), 
1.16 (s, 9H, SC(CH3)3). C20H24N2O5S (404.48 g mol
-1), MS(ESI): m/z = 405.127 (calcd. 
405.1479 [M+H]+), 809.335 (calcd. 809.2885 [2M+H]+). TLC: Rf (PE/EtOAc, 1:1) = 0.29.  
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Methyl 4-Amino-3-((R)-3-(((R)-tert-butylsulfinyl)amino)-4-methylpent-1-yn-1-
yl)benzoate (42b). A solution of D-valine analogous propargylamide 6b (100 mg, 
497 mol, 1.0 eq) and methyl 4-amino-3-iodobenzoate (38b, 158 mg, 570 mol, 1.1 eq) in 
a mixture of THF/piperidine (4:1, 1.25 mL) was thoroughly degassed using the freeze-
pump-thaw method. The catalyst PdCl2(PPh3)2 (3.0 mg, 
4.3 mol, 0.9 mol%) and CuI (1.7 mg, 8.9 mol, 2 mol%) was 
added under argon atmosphere and the reaction mixture was 
stirred 14 h at ambient temperature. A colourless precipitate 
formed, indicating the procedure of the reaction. After dilution with Et2O (4 mL) and 
NH4Cl solution (2 mL), the phases were separated and the aqueous layer was extracted with 
Et2O (2 x 4 mL). The combined organic layers were washed with water (2 x 10 ml) and 
brine (1 x 4 mL) and dried over MgSO4. After evaporation, the crystalline peptidomimetic 
42b was purified by column chromatography (PE/EtOc, 1:1) and recrystallized from Et2O.  
Pale orange, crystalline solid. Yield: 144 mg, 411 mol, 83 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.89 (d, 4J = 2.0 Hz, 1H, ar-2-H), 7.74 (dd, 3J = 8.6 Hz, 4J = 2.1 Hz, 1H, 
ar-6-H), 6.58 (d, 3J = 8.6 Hz, 1H, ar-5-H), 5.26 (s, 2H, ar-4-NH2), 3.99 (dd, 3J = 10.5 Hz, 
3J = 6.2 Hz, 1H, CH), 3.84 (s, 3H, ar-1-CO2CH3), 3.29 (d, 
3J = 10.6 Hz, 1H, CHNH), 
1.98 (dh, 3J = 6.2 Hz, 3J = 6.7 Hz, 1H, CHCH(CH3)2), 1.24 (s, 9H, SC(CH3)3), 1.10 (d, 
3J 
= 6.7 Hz, 3H, CHCH(CH3)2), 1.08 (d, 
3J = 6.8 Hz, 3H, CHCH(CH3)2). 
13C NMR 
(126 MHz, Chloroform-d) δ = 166.9 (ar-1-CO2CH3), 153.7 (ar-C-1), 134.1 (ar-C-2), 131.6 
(ar-C-6), 118.2 (ar-C-4), 113.2 (ar-C-5), 106.0 (ar-C-3), 93.9 (CHC≡C-ar), 82.7 
(CHC≡C-ar), 56.7 (SC(CH3)3), 55.9 (CHCH(CH3)2), 51.7 (CO2CH3), 34.2 
(CHCH(CH3)2), 22.7 (SC(CH3)3), 19.1 (CHCH(CH3)2), 18.7 (CHCH(CH3)2). 
C18H26N2O3S (350.48 g mol
-1). LCMS (ESI): tr = 6.0 min, m/z = 351.309 (calcd. 351.1737 
[M+H]+). TLC: Rf (EtOAc/PE, 1:1) = 0.36. [𝛼]589
21  = 12.0 (c 0.47, MeOH). IR(ATR): ν̃ 
[cm-1] = 3430 (-N-H), 3329 (-N-H), 3212 (-N-H), 2955, 2924, 2870 (-C-H), 1708 (-C=O), 
1622 (-N-H), 1603 (-N-H), 1505 (ar, -C=C-), 1438 (-CH3, -CH2), 1261, 1226, 1147, 1103 
(-C-H). 
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Methyl 3-((R)-3-(((R)-tert-Butylsulfinyl)amino)-4-methylpent-1-yn-1-yl)-4-((E)-(4-
(dimethylamino)phenyl)diazenyl)benzoate (42c). The catalysts PdCl2(PPh3)2 (1.5 mg, 
2.1 mol, 1 mol%) and CuI (1.1 mg, 5.8 mol, 3 mol%) were added to a thoroughly 
degassed solution of D-valine analogous propargylamide 6b 
(35.1 mol, 174 mol, 1 eq) and azobenzene 38c (85.5 mg, 
209 mol, 1.2 eq) in piperidine/THF (1:3, 0.4 mL). The 
reaction mixture was stirred for 16 h at ambient temperature. 
After complete conversion of the starting material (checked by 
LCMS), the mixture was diluted with aqueous NH4Cl solution (saturated, 4 mL) and 
hydrochloric acid (1 mL) and extracted with Et2O (3 x 5 mL). The combined organic layers 
were dried over Na2SO4 and the solvent was evaporated under reduced pressure. Title 
compound 42c was isolated by preparative HPLC.  
Purple oil. Yield: 5.8 g, 12 mol, 7 %. 1H NMR (500 MHz, Chloroform-d) δ = 8.20 (d, 4J 
= 1.9 Hz, 1H, benzoate-2-H), 8.06-7.99 (m, 3H, benzoate-6-H, anilin-2-H, anilin-6-H), 
7.75 (d, 3J = 8.6 Hz, 1H, benzoate-5-H), 6.94 (d, 3J = 9.1 Hz, 2H, anilin-3-H, anilin-5-H), 
4.17 (d br., 3J = 5.8 Hz, 1H, CαH), 3.94 (s, 3H, CO2CH3), 3.27 (s, 6H, N(CH3)2), 2.09 (hd, 
3J = 6.6 Hz, 3J = 5.8 Hz, 1H, CαHCH(CH3)2), 1.29 (s, 9H, SC(CH3)3), 1.12 (d, 
3J = 6.7 Hz, 
3H, CαHCH(CH3)2), 1.11 (d, 
3J = 6.6 Hz, 3H, CαHCH(CH3)2). 
13C NMR (126 MHz, 
Chloroform-d) δ = 166.1 (CO2CH3), 154.8 (benzoate-C-4), 143.0 (anilin-C-1), 135.0 
(benzoate-C-2), 130.6 (benzoate-C-1), 129.8 (benzoate-C-5), 129.0 (anilin-C-2, anilin-C-
6), 119.2 (benzoate-C-6), 116.7 (anilin-C-1), 115.7 (benzoate-C-3), 114.1 (anilin-C-3, 
anilin-C-5), 95.0 (CαHC≡C-ar), 82.2 (CαHC≡C-ar), 57.2 (SC(CH3)3), 55.6 (CαH), 52.5 
(CO2CH3), 41.6 (N(CH3)2), 34.0 (CH(CH3)2), 22.8 (SC(CH3)3), 19.3 (C
αHCH(CH3)2), 18.2 
(CαHCH(CH3)2). C26H34N4O3S (482.64 g mol
-1). MS(ESI): m/z = 379.339 (calcd. 379.2134 
[M-C4H9OS+H]
+). TLC: Rf (PE/EtOAc, 2:1) = 0.37. [α]589
22  = 75.3 (c 0.29, CH3CN). pH 
(c=0.1 M in H2O) = 2.3. UV/Vis: λmax (pH < 7.8) = 448 nm, λmax (pH > 8.2) = 469 nm.  
A sample of azobenzoate 42c was investigated at different pH values (Figure EP1 
Experimental Part). An aqueous solution of NaOH (0.1 M) was added dropwise via 
burette to a vigorously stirred aqueous solution of azobenzoate 42c (0.1 M, pH 2.3) until 
the color of the solution changed from purple to dark yellow (monitored with the naket 
eye). The pH value was monitored by a pH electrode. The color change was determined at 
pH 7.8-8.2 (Diagram EP1 Experimental Part).  
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Figure EP1. pH-Dependent colours of peptidomimetic 42c . a) Protonation of azobenzoate 
derivative 42c in acidic milieu (pH<7.8) and deprotonation in alkaline milieu (pH>8.2). b) 
Solid peptidomimetic 42c . c) 0.1 M Solution of 42c  in water. d) Comparison of the 0.1  M 
aqueous 42c solution at pH 11.0 (left side) and pH 2.7 (right side).  
 
Methyl 3-((R)-3-(((R)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-yl)-4-((E)-
phenyldiazenyl)benzoate (42d). The catalysts PdCl2(PPh3)2 (2 mg, 4.8 mol, 1.5 mol%) 
and CuI (1 mg, 5.2 mol, 1.7 mol%) were added to a thoroughly degassed solution of D-
leucine analogous propargylamide 6c (68.2 mg, 317 mol, 1.0 eq) and azobenzene 38d 
(139 mg, 318 mol, 1.2 eq) in piperidine/THF (1:3, 0.4 mL). The pink reaction mixture 
was stirred for 30 h at ambient temperature. After complete conversion of the starting 
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material (checked by LCMS), the mixture was diluted with aqueous NH4Cl solution 
(saturated, 4 mL), water (10 mL) and hydrochloric acid (1 mL) and extracted with Et2O (3 
x 15 mL) until the aqueous phase had completely lost its pink colour. The combined organic 
layers were dried over MgSO4 and the solvent was evaporated under reduced pressure. 
Peptidomimetic 42d was isolated by preparative HPLC.  
Dark red solid. Yield: 23 mg, 51 mol, 16 %. 1H NMR (600 MHz, Chloroform-d) δ = 8.28 
(d, 4J = 1.5 Hz, 1H, ar-2-H), 8.05 (dt, 3J = 8.5 Hz, 4J = 1.4 Hz, 1H, ar-6-H), 7.99 (dd, 3J = 
6.7 Hz, 4J = 1.4 Hz, 2H, Ph-2-H, Ph-6-H), 7.69 (d, 3J = 8.5 Hz, 
1H, ar-5-H), 7.63-7.41 (m, 3H, Ph-3-H, Ph-4-H, Ph-5-H), 4.39 
(dd, 3J = 8.3 Hz, 3J = 6.9 Hz, 2H, NHCαH), 3.95 (s, 3H, 
CO2CH3), 2.24 (s br., 1H, C
αHNH), 1.99 (m, 1H, 
CαHCH2CH(CH3)2), 1.76 (ddd, 
2J = 14.3 Hz, 3J = 8.7 Hz, 3J 
= 5.8 Hz, 1H, CαHCH2CH(CH3)2), 1.70 (ddd, 
2J = 12.9 Hz, 3J = 8.4 Hz, 3J = 6.7 Hz, 1H, 
CαHCH2CH(CH3)2), 1.26 (s, 9H, SC(CH3)3), 0.96 (d, 
3J = 6.7 Hz, 3H, 
CαHCH2CH(CH3)2), 0.95 (d, 
3J = 6.7 Hz, 3H, CαHCH2CH(CH3)2).
 13C NMR 
(151 MHz, Chloroform-d) δ = 166.1 (CO2CH3), 155.6 (Ph-C-1), 135.2 (ar-C-4), 133.7 (ar-
C-2), 132.0 (Ph-C-4), 131.6 (ar-C-1), 130.1 (ar-C-5), 129.3 (Ph-C-5, Ph-C-3), 123.7 (Ph-
C-2, Ph-C-6), 122.8 (ar-C-6), 116.1 (ar-C-3), 95.8 (CαHC≡C-ar), 81.5 (CαHC≡C-ar), 56.6 
(SC(CH3)3), 52.6 (CO2CH3), 47.5 (CαNH), 31.1 (C
αHCH2CH(CH3)2), 25.2 
(CαHCH2CH(CH3)2), 22.7 (SC(CH3)3), 22.0 (C
αHCH2CH(CH3)2), 21.7 
(CαHCH2CH(CH3)2). C25H31N3O3S (453.60 g mol
-1). MS (ESI): m/z = 454.421 (calcd. 
454.2159 [M+H]+). UV/Vis: max 355 nm (Diagram EP2a).  
 
Methyl 2-Amino-5-((R)-3-(((R)-tert-butylsulfinyl)amino)-3-cyclohexylprop-1-yn-1-
yl)benzoate (43a). A solution of D-cyclohexylglycine analogous propargylamide 6e 
(32.2 mg, 132 mol, 1.0 eq) and Methyl-2-((2-iodo-5-methylphenyl)diazenyl)benzoate 
(39a, 108 mg, 280 mol, 2.2 eq) in a mixture of THF/DIPEA (2 mL, 3:1) was thoroughly 
degassed by the freeze-pump-thaw method. While still frozen, the solid catalyst 
PdCl2(PPh3)2 (1 mol%) and CuI (2 mol%) was added in one portion and the mixture was 
allowed to warm up to rt and stirred overnight at ambient temperature. A colorless 
precipitate formed in the course of the reaction. The reaction mixture was diluted with a 
mixture of Et2O and aqueous NH4Cl (4:5, 12 mL), neutralized with aqueous KHSO4 
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solution (5 %, 3-5 mL, until pH 6). The phases were separated and the aqueous layer was 
extracted with Et2O (3 x 10 mL). The combined organic layers were washed with brine, 
dried over Na2SO4 and the solvent was evaporated under reduced pressure. Crude product 
43a was purified by column chromatography (PE/EtOAc, 1:1).  
Pale yellow oil. Yield: 32.5 mg, 83.2 mol, 63 %. 1H NMR 
(500 MHz, Chloroform-d) δ = 7.90 (d, 3J = 8.2 Hz, 1H, ar-3-
H), 7.83 (s, 1H, ar-6-H), 7.19 (d, 3J = 8.2 Hz, 1H, ar-4-H), 4.04 
(dd, 3J = 7.4 Hz, 3J = 5.9 Hz, 1H, CHcy), 3.92 (s, 3H, 
CO2CH3), 3.37 (d, 
3J = 7.5 Hz, 1H, CHNH), 1.87 (m, 2H, cy-H), 1.83-1.75 (m, 3H, cy-
H), 1.72-1.60 (m, 2H, cy-H), 1.24 (s, 9H, SC(CH3)3), 1.21-1.09 (m, 4H, cy-H). 
13C NMR 
(126 MHz, Chloroform-d) δ = 166.4 (ar-1-CO2CH3), 141.4 (ar-C-3), 135.5 (ar-C-4), 135.2 
(ar-C-1), 134.0 (ar-C-6), 123.2 (ar-C-2), 93.9 (ar-C-5), 90.8 (CHC≡Car), 83.9 
(CHC≡Car), 56.6 (SC(CH3)3), 54.0 (CHcy), 52.8 (ar-2-CO2CH3), 43.6 (cy-C-1), 29.7 
(cy-C-2), 28.6 (cy-C-6), 26.4 (cy-C-4), 26.1 (cy-C-5), 26.0 (cy-C-3), 22.8 (SC(CH3)3). 
C21H30N2O3S (390.54 g mol
-1).  
 
2-Amino-5-((R)-3-(((R)-tert-Butylsulfinyl)amino)-4-methylpent-1-yn-1-
yl)benzoic Acid (43b). A solution of D-valine analogous propargylamide 6b (106 mg, 
527 mol, 1 eq) and 4-iodoanthranilate 39a (207 mg, 
786 mol, 1.5 eq) in a mixture of THF and piperidine (3:1, 
1.3 mL) was thoroughly degassed by the freeze pump thaw 
method. After 3 cycles, the catalysts CuI (2.2 mg, 12 mol, 2 mol%) and PdCl2(PPh3)2 
(3.6 mg, 5.1 mol, 1 mol%) was added in one portion and the reaction mixture was stirred 
for 15 h at rt. A colorless precipitate formed, which had formed dissolved upon dilution 
with a saturated NH4Cl solution (5 mL) and KHSO4 solution (3 mL). The clear solution 
was extracted with Et2O (3 x 15 mL). The combined organic layers were washed with water 
and brine, dried over Na2SO4 and the solvent was removed under reduced pressure. 
Peptidomimetic 43b was isolated by preparative HPLC.  
Yellow, highly viscous oil. Yield: 23.7 mg, 70.4 mol, 13 %. 1H NMR (600 MHz, 
methanol-d4) δ = 7.89 (d, 4J = 2.0 Hz, 1H, ar-6-H), 7.27 (dd, 3J = 8.6 Hz, 4J = 2.1 Hz, 1H, 
ar-4-H), 6.68 (d, 3J = 8.6 Hz, 1H, ar-3-H), 3.96 (d br., 3J = 6.4 Hz, 1H, CHCH(CH3)2), 
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1.97 (dh, 3J = 6.4 Hz, 3J = 6.7 Hz, 1H, CHCH(CH3)2), 1.26 (s, 9H, SC(CH3)3), 1.10 (d, 
3J 
= 6.7 Hz, 3H, CHCH(CH3)2), 1.07 (d, 
3J = 6.7 Hz, 3H, CHCH(CH3)2). 
13C NMR 
(151 MHz, methanol-d4) δ = 198.3 (CO2H), 170.8 (ar-C-1), 157.0 (ar-C-5), 135.3 (ar-C-
3), 134.5 (ar-C-6), 125.7 (ar-C-4), 117.3 (ar-C-2), 110.1 (CHC≡Car), 60.9 (CHC≡Car), 
57.5 (SC(CH3)3), 41.8 (CHCH(CH3)2), 33.7 (CHCH(CH3)2), 23.3 (SC(CH3)3), 19.8 
(CHCH(CH3)2), 18.5 (CHCH(CH3)2). C17H24N2O3S (336.45 g mol
-1). HRMS (ESI): m/z 
= 335.14448 (calcd. 335.14349 [M-H+]-). IR(ATR): ν̃ [cm-1] = 3471 (-O-H), 3360 (-N-H); 
2965 (-C-H); 1619 (-N-H); 1584 (ar, -C=C-); 1299, 1245, 1211, 1169 (C-H). [𝛼]589
22  = -
51.8 (c 1.04, MeOH).  
 
5-((S)-3-(((S)-tert-Butylsulfinyl)amino)-4-methylpent-1-yn-1-yl)-2-((E)-
phenyldiazenyl)benzoic Acid (43c). A solution of L-valine analogous propargylamide 6b 
(75.5 mg, 380 mol, 1.0 eq) and azobenzene 39c (159 mg, 450 mol, 1.2 eq) in THF 
(0.7 mL) and piperidine (0.25 mL) was thoroughly degassed by freeze-pump-thaw. The 
catalyst PdCl2(PPh3)2 (2.6 mg, 6.3 mol, 1.7 mol%) and CuI (1.4 mg, 7.4 mol, 1.9 mol%) 
was added under argon atmosphere and the reaction mixture was stirred 4 h at ambient 
temperature. After complete conversion of the propargylamide (checked by TLC), the 
reaction mixture was diluted with aqueous NH4Cl solution (saturated, 30 mL). The aqueous 
phase was extracted with Et2O (2 x 30 mL) and EtOAc (3 x 30 mL). The combined organic 
layers were washed with brine (10 mL), dried over Na2SO4 and the solvent was evaporated 
under reduced pressure. The crude brown oil was purified by column chromatography 
(CH2Cl2/MeOH, 10:1) and preparative HPLC.  
Red, amorphous solid. Yield: 17.1 mg, 40 mol, 11 %. 
1H NMR (300 MHz, Chloroform-d) δ = 8.44 (d, 4J = 
1.9 Hz, 1H, ar-6-H), 7.95 (d, 3J = 8.5 Hz, 1H, ar-4-H), 
7.93-7.83 (m, 2H, Ph-2-H, Ph-6-H), 7.72 (dd, 3J = 8.5 Hz, 
4J = 1.9 Hz, 1H, ar-3-H), 7.68-7.55 (m, 3H, Ph-3-H, Ph-4-H, Ph-5-H), 4.14 (dd, 3J = 
4.5 Hz, 3J = 4.0 Hz, 1H, CHCH(CH3)2), 3.74 (d, 
3J = 4.0 Hz, 1H, CHNH), 2.05 (m, 1H, 
CHCH(CH3)2), 1.28 (s, 9H, SC(CH3)3), 1.10 (d, 
3J = 6.7 Hz, 3H, CHCH(CH3)2), 1.08 
(d, 3J = 6.7 Hz, 3H, CHCH(CH3)2). 
13C NMR (151 MHz, Chloroform-d) δ = 165.8 (ar-
1-CO2H), 151.8 (ar-C-2), 148.8 (Ph-C-1), 136.8 (ar-C-3), 136.3 (ar-C-6), 133.8 (Ph-C-4), 
130.0 (Ph-C-3, Ph-C-5), 127.7 (ar-C-1), 127.3 (ar-C-5), 123.8 (Ph-C-2, Ph-C-6), 116.2 
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(ar-C-4), 93.0 (CHC≡Car), 84.4 (CHC≡Car), 56.8 (SC(CH3)3), 54.8 (CHCH(CH3)2), 
34.1 (CHCH(CH3)2), 22.8 (SC(CH3)3), 19.2 (CHCH(CH3)2), 18.0 (CHCH(CH3)2). 
C23H27N3O3S (425.55 g mol
-1). MS(ESI): m/z = 426.6 (calcd. 426.1846 [M+H]+), 448.9 
(calcd. 448.1665 [M+Na]+). TLC: Rf (CH2Cl2/MeOH/TFA, 89:10:1) = 0.40. IR (ATR): ν̃ 
[cm-1] = 3205 (w, NH-VS), 2961 (s, CH-VS), 2920 (m, CH-VS), 2866 (m, CH-VS), 2359 
(s, C≡C), 2341 (s, C≡C), 1698 (s, (C=O)OCH3), 1597 (w, NH), 1577 (w, N=N), 1464 (m, 
C=C-VS), 1306 (w), 1220 (m), 1026 (m, S=O), 922 (m), 685 (w). [α]589
22  = -74.3 (c 0.45, 
CHCl3). UV/Vis:  = 33708 cm-1 M-1 (in CH3CN at max = 355 nm, c = 26.4 M, d = 1 cm).  
 
Methyl (5-((S)-3-Amino-4-methylpent-1-yn-1-yl)-2-((E)-phenyldiazenyl)benzoyl)-L-
prolinate Hydrochloride (44). A mixture of peptidomimetic 43c (17.1 mg, 40 mol, 
1.0 eq), L-methyl prolinate (10.3 mg, 80 mol, 2.0 eq), HOAt (16.2 mg, 120 mol, 3.0 eq) 
and HATU (30.4 mg, 80 mol, 2.0 eq) was dissolved in a mixture of DMF (0.8 mL) and 
DIPEA (0.4 mL, 0.25 mmol, 6.3 eq) and stirred for 16 h 
at ambient temperature. After complete conversion of the 
peptidomimetic (checked by LCMS), the solution was 
diluted in CH2Cl2 (7 mL) and washed with aqueous 
NaHCO3 solution (saturated, 10 mL) and hydrochloric acid (1 M, 10 mL). The combined 
aqueous layers were extracted with CH2Cl2 (2 x 30 mL). The combined organic layers were 
washed with brine (10 mL), dried over MgSO4 and purified by column chromatography 
(PE/EtOAc, 1:1). Yield: brown, amorpheous solid, 19 mg, 35 mol, 89 %.  
Hydrochloric acid (4 M in dioxane, 0.2 mL, 0.8 mmol) was added dropwise to a solution 
of the coupling product (19 mg, 35 mol) in MeOH (2 mL) at 0 °C. The reaction mixture 
was stirred 90 min at ambient temperature, until the complete starting material was 
converted. The solvent was evaporated under reduced pressure and azobenzamide 44 was 
isolated by preparative HPLC.  
Amorpheous orange solid. Yield: 13.3 mg, 28.4 mol, 81 % (71 % over two steps, referred 
to peptidomimetic 43c). 1H NMR (600 MHz, Chloroform-d) δ = 8.70 (s, 3H, CHNH3Cl), 
7.97 (s, 1H, ar-3-H), 7.84 (m, 1H, ar-4-H), 7.77 (t, 3J = 8.1 Hz, 1H, Ph-3-H, Ph-5-H), 7.63 
(s, 1H, ar-6-H), 7.56-7.48 (m, 6H, Ph-2-H, Ph-4-H, Ph-6-H), 4.59 (dd, 3J = 8.5 Hz, 3J = 
5.2 Hz, 1H, CHCH2CH2CH2N), 4.27 (d br., 
3J = 5.3 Hz, 1H, CHCH(CH3)2), 3.79 
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(s, 3H, CO2CH3), 3.34 (m, 1H, CHCH2CH2CH2N), 3.19 (m, 1H, 
CHCH2CH2CH2N), 2.29 (dt, 
2J = 15.7 Hz, 3J = 7.9 Hz, 1H, CHCH2CH2CH2N), 
2.22 (m, 1H, CHCH(CH3)2), 2.05 (dq, 
2J = 12.5 Hz, 3J = 6.2 Hz, 1H, 
CHCH2CH2CH2N), 1.95 (dp, 
2J = 13.9 Hz, 3J = 7.1 Hz, 1H, CHCH2CH2CH2N), 
1.82 (dt, 2J = 12.9 Hz, 3J = 6.6 Hz, 1H, CHCH2CH2CH2N), 1.12 (d, 
3J = 6.3 Hz, 3H, 
CHCH(CH3)2), 1.08 (d, 
3J = 6.6 Hz, 3H, CHCH(CH3)2). 
13C NMR (151 MHz, 
Chloroform-d) δ = 172.5 (arCONC), 168.3 (CHCO2CH3), 152.6 (Ph-C-1), 147.6 (ar-
C-2), 133.6 (ar-C-4), 132.1 (ar-C-6), 131.6 (Ph-C-4), 129.4 (Ph-C-2, Ph-C-6), 129.4 (Ph-
C-3, Ph-C-5), 125.1 (ar-C-3), 123.7 (ar-C-5), 123.4 (ar-C-1), 87.0 (CHC≡C-ar), 85.5 
(CHC≡C-ar), 59.2 (CHCH2CH2CH2N), 52.5 (CO2CH3), 50.0 (CHCH(CH3)2), 
49.0 (CHCH2CH2CH2N), 31.5 (CHCH(CH3)2), 29.9 (CHCH2CH2CH2N), 24.9 
(CHCH2CH2CH2N), 19.5 (CHCH(CH3)2), 17.1 (CHCH(CH3)2). C25H28N4O3 
(432.52 g mol-1), MS(ESI): m/z = 433.2 (calcd. 433.2234 [M+H]+). TLC: Rf (EtOAc/PE, 
1:1) = 0.15. IR (ATR): ν̃ [cm-1] = 3452 (w, -CO-NH-), 3056 (s, CH-VS), 2967 (m, CH-
VS), 2879 (m, CH-VS), 2664 (s), 2369 (s, C≡C), 1749 (m, (C=O)OCH ), 1676 (s, 
(C=O)NH), 1622 (m, NH2), 1438 (m, C=C), 1375 (w), 1201 (s), 1179 (s), 1135 (m), 837 
(s, arH). [α]589
21  = -52.4 (c 0.67, CHCl3). UV/Vis: (E-isomer) = 19005 cm-1 M-1 (in CH3CN at 
max=338 nm, c=30.6 M, d=1 cm), (Z-isomer)=657 cm-1 M-1 (in CH3CN at max=442 nm, 
c=30.6 M, d=1 cm), see also UV/Vis spectra EP3,4 and NMR spectra EP5,6 in the 
Experimental Part.  
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Halogenated benzoates methyl 4-iodobenzoate (45a) and ethyl 4-iodobenzoate (45b) were 
purchased at Fisher Scientific.  
 
Methyl 6-Bromonicotinate (45c). The methylation of 6-bromonicotinate has been first 
reported by Wang et al. under acidic conditions [226]. However, the application of 
thionylchloride, as demonstrated here, has not been reported yet.  
Under argon atmosphere, thionylchloride (0.3 mL, 4 mmol, 1.6 eq) was carefully added to 
a solution of 5-bromo nicotinic acid (500 mg, 2.48 mmol, 1.0 eq) in MeOH (40 mL) at 
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0 °C. The clear reaction mixture was stirred overnight at 80 °C under reflux conditions. A 
colorless solid precipitated when the solvent was evaporated to concentrate up the solution. 
The colorless, amorpheous precipitate was dissolved in EtOAc (10 mL), neutralized with a 
saturated, aqueous bicarbonate solution and extracted with EtOAc (3 x 30 mL). The 
combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and 
the solvent was evaporated under reduced pressure. Methyl ester 45c was isolated by 
column chromatography (PE/EtOAc, 4:1).  
Colorless, crystalline solid. Yield: 167.4 mg, 775 mol, 34 %. 1H NMR 
(300 MHz, Chloroform-d) δ = 9.16 (dd, 4J = 2.1 Hz, 5J = 0.9 Hz, 1H, ar-
2-H), 8.33 (dd, 3J = 8.2 Hz, 4J = 2.1 Hz, 1H, ar-4-H), 7.58 (dd, 3J = 8.2 Hz, 5J = 0.9 Hz, 
1H, ar-5-H), 3.96 (s, 3H, CO2CH3). C7H6BrNO2 (216.03 g mol
-1). MS(ESI): m/z = 217.143 
(calcd. 217.9634 [M+H]+).  
 
Methyl 5-Bromopicolinate (45d). The methylation of 5-bromopicolinate was carried out 
analog to the description of Voronkov et al. [227] with minor modifications: 
Thionylchloride (0.3 mL, 4 mmol, 1.6 eq) was added dropwise to a 
solution of 5-bromopicolinic acid (500 mg, 2.48 mmol, 1.0 eq) in dry 
methanol (40 mL) and the reaction mixture was heated to 70 °C under 
reflux for 16 h. Afterwards, the clear solution was cooled to room temperature and the 
solvent was evaporated under reduced pressure. The remainder, a white solid, was 
dissolved in ethyl acetate (10 mL) and neutralized with aqueous bicarbonate. After 
seperation of the phases, the aqueous layer was extracted with ethyl acetate (3 x 30 mL) 
and the combined organic phases were dried over Na2SO4. Filtration through a short 
column of silica gel (EtOAc/PE, 1:2) lead to the isolated title compound.  
Colorless crystalline solid. Yield: 256 mg, 1.185 mmol, 53 % (Lit: 87 % [227]). 1H NMR 
(300 MHz, Chloroform-d) δ = 8.80 (dd, 4J = 2.1 Hz, 5J = 0.9 Hz, 1H, ar-6-H), 8.03 (dd, 3J 
= 8.4 Hz, 5J = 0.9 Hz, 1H, ar-4-H), 7.98 (dd, 3J = 8.3 Hz, 4J = 2.1 Hz, 1H, ar-3-H), 4.01 (s, 
3H, CO2CH3). C7H6BrNO2 (216.03). MS(ESI): m/z = 242.2 (calcd. 242.9 [M+Na
+]). TLC: 
Rf (PE/EtOAc, 2:1) = 0.68.  
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Methyl 4-(3-((tert-Butoxycarbonyl)amino)prop-1-yn-1-yl)benzoate (46a). The 
synthesis of peptidomimetic 46a has been first described by Martin Sendzik [189] and has 
been reproduced with minor modifications: In one portion, a mixture of the catalyst 
PdCl2(PPh3)2 (2 mg, 4.8 mol, 0.1 mol%) and CuI (1 mg, 5.2 mol, 0.1 mol%) was added 
to a thoroughly degassed solution of glycine analogous propargylamide 1 (578.2 mg, 
3.726 mmol, 1.0 eq) and methyl 2-iodobenzoate 45a (1.562 g, 5.960 mmol, 1.6 eq) in a 
mixture of THF/piperidine (3:1, 9.2 mL) under argon atmosphere. After 20 min at rt, 
precipitation of a colorless solid could be observed. The suspension was stirred at ambient 
temperature for 18 h. After complete conversion of propargylamide 1 (checked by TLC), 
the suspension was diluted with Et2O (20 mL) and washed with an aqueous solution of 
KHSO4 (5 %, 2 x 10 mL) and water (1 x 10 mL). The combined aqueous layers were 
extracted with Et2O (2 x 20 mL) and all organic layers were combined, washed with brine 
(10 mL) and dried over Na2SO4. After evaporation oft he solvent under reduced pressure, 
the crude coupling product 46a was purified by column chromatography (PE/EtOAc, 1:1).  
Colorless, crystalline solid. Yield: 335.4 mg, 2.161 mmol, 58 % 
(Lit: Yield not determined [189]). 1H NMR (300 MHz, 
Chloroform-d) δ = 7.87 (d, 3J = 8.3 Hz, 2H, ar-2-H, ar-6-H), 
7.36 (d, 3J = 8.3 Hz, 2H, ar-3-H, ar-5-H), 5.23 (s br., 1H, CH2NH), 4.10 (d, 
3J = 5.6 Hz, 
2H, CH2NHBoc), 3.82 (s, 3H, CO2CH3), 1.38 (s, 9H, C(CH3)3). 
13C NMR (126 MHz, 
Chloroform-d) δ = 166.5 (ar-1-CO2CH3), 156.3 (CHNHCO2C(CH3)3), 131.6 (ar-C-3, ar-
C-5), 129.7 (ar-C-1-CO2CH3), 129.5 (ar-C-2, ar-C-6), 127.4 (ar-C-4), 88.5 (CHC≡C-ar), 
82.4 (CHC≡C-ar), 80.2 (CHNCO2C(CH3)3), 52.2 (ar-1-CO2CH3), 28.4 
(CHNCO2C(CH3)3), 28.4 (CH). C8H13NO2 (155.2 g mol
-1). TLC: Rf (EtOAc/PE, 1:1) = 
0.64.  
 
Methyl 4-((S)-3-(((S)-tert-Butylsulfinyl)amino)-4-methylpent-1-yn-1-
yl)benzoate (46b). A solution of L-valine analogous propargylamide 6b (50.0 mg, 
248 mol, 1.0 eq) and aromatic halide 45a (104 mg, 397 mol, 1.6 eq) in THF (1.0 mL) 
and piperidine (0.3 mL) was thoroughly degassed by freeze-pump-thaw. The catalyst 
PdCl2(PPh3)2 (2 mg, 4.8 mol, 2 mol%) and CuI (1 mg, 5.3 mol, 2 mol%) was added 
under argon atmosphere and the reaction mixture was stirred 10 h at ambient temperature. 
After complete conversion of propargylamide 6b (checked by TLC), the reaction mixture 
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was diluted with aqueous NH4Cl solution (saturated, 5 mL) and KHSO4 (5 %, 10 mL). The 
aqueous phase was extracted with Et2O (3 x 20 mL). The combined organic layers were 
washed with brine (5 mL), dried over Na2SO4 and the solvent was evaporated under 
reduced pressure. The crude coupling product 46b was purified by column chromatography 
(PE/EtOAc, 1:1) and recrystallized from CH2Cl2. 
Colorless crystalline solid. Yield: 69.0 mg, 206 mol, 83 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.93 (d, 3J = 8.3 Hz, 2H,  ar-2-H, ar-6-H), 
7.46 (d, 3J = 8.3 Hz, 2H, ar-3-H, ar-5-H), 4.09 (dd, 3J = 7.0 Hz, 
3J = 5.2 Hz, 1H, HNCHCH(CH3)2), 3.87 (s, 3H, CO2CH3), 
3.41 (d, 3J = 7.0 Hz, 1H, HNCHCH(CH3)2), 2.00 (m, 1H, 
HNCHCH(CH3)2), 1.22 (s, 9H, C(CH3)3), 1.04 (d, 
3J = 6.8 Hz, 3H, HNCHCH(CH3)2), 
1.04 (d, 3J = 6.8 Hz, 3H, HNCHCH(CH3)2). 
13C NMR (126 MHz, Chloroform-d) δ = 
166.6 (ar-1-CO2CH3), 131.8 (ar-C-3), 129.6 (ar-C-1), 129.4 (ar-C-2), 127.5 (ar-C-4), 90.9 
(CHC≡Car), 85.0 (CHC≡Car), 56.4 (SC(CH3)3), 54.4 (CHCH(CH3)2), 52.3 (ar-1-
CO2CH3), 33.9 (CHCH(CH3)2), 22.7 (SC(CH3)3), 19.1 (CHCH(CH3)2), 17.7 
(CHCH(CH3)2). C18H25NO3S (335.46 g mol
-1). MS(ESI): m/z = 358.1452 (calcd. 
358.1447 [M+Na]+). [𝛼]589
20  = 13.7 (c 0.325, CHCl3). IR(ATR): 𝜈[cm-1] = 2958 (CH3/CH3), 
2927-2873 (CH3/CH2), 1720 (CO2Me), 1603 (N-H), 1280 (S=O), 1442/1306/1173 (ar, 
C=C), 770 (S-C).  
 
Methyl 4-((R)-3-(((R)-tert-Butylsulfinyl)amino)-4-methylpent-1-yn-1-
yl)benzoate (46c). The Sonogashira cross coupling reaction of D-valine analogous 
propargylamide 6b (98.9 mg, 492 mol) with methyl 4-iodobenzoate (45a, 193 mg, 
738 mol, 1.5 eq) was performed as reported in the synthesis of 46b.  
Colorless crystalline solid. Yield: 105.7 mg, 315 mol, 64 %. 
1H NMR (600 MHz, Chloroform-d) δ = 7.96 (d, 3J = 8.3 Hz, 
2H, ar-2-H, ar-6-H), 7.50 (d, 3J = 8.3 Hz, 2H, ar-3-H, ar-5-H), 
4.13 (dd, 3J = 6.9 Hz, 3J = 5.7 Hz, 1H, NHCαH), 3.91 (s, 3H, 
CO2CH3), 3.38 (d, 
3J = 6.9 Hz, 1H, CHNH), 2.04 (dqq, 3J = 6.6 Hz, 3J = 6.7 Hz, 3J = 
6.7 Hz, 1H, CHCH(CH3)2), 1.26 (s, 9H, C(CH3)3), 1.07 (d, 
3J = 6.8 Hz, 3H, 
CHCH(CH3)2), 1.07 (d, 
3J = 6.7 Hz, 3H, CHCH(CH3)2). 
13C NMR (126 MHz, 
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Chloroform-d) δ = 166.6 (ar-1-CO2CH3), 131.8 (ar-C-3, ar-C-5), 129.6 (ar-C-1-CO2CH3), 
129.4 (ar-C-2, ar-C-6), 127.5 (ar-C-4), 90.9 (CHC≡Car), 85.0 (CHC≡Car), 56.4 
(SC(CH3)3), 54.4 (HNCαH), 52.3 (ar-1-CO2CH3), 33.9 (CHCH(CH3)2), 22.7 (SC(CH3)3), 
19.1 (CHCH(CH3)2), 17.7 (CHCH(CH3)2). MS(ESI): m/z = 358.2 (calcd. 358.15 
[M+Na]+). IR(ATR): 𝜈[cm-1] = 2958 (CH3/CH3), 2927-2873 (CH3/CH2), 1720 (CO2Me), 
1603 (N-H), 1280 (S=O), 1442/1306/1173 (ar, C=C), 770 (S-C).  
 
Ethyl 4-((S)-3-(((S)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-yl)benzoate (46d). 
The Sonogashira cross coupling reaction of L-leucine analogous propargylamide 6c 
(14.5 mg, 67.3 mol, 1.0 eq) with ethyl 4-iodobenzoate (45b, 22.9 mg, 87.5 mol, 1.3 eq) 
was performed as reported in the synthesis of 46b.  
Colorless, crystalline solid. Yield: 23.0 mg, 63.3 mol, 94 %. 
1H NMR (500 MHz, Chloroform-d) δ = 7.94 (d, 3J = 8.4 Hz, 
2H, ar-2-H, ar-6-H), 7.47 (d, 3J = 8.4 Hz, 2H, ar-3-H, ar-5-H), 
4.35 (q, 3J = 7.1 Hz, 2H, CO2CH2CH3), 4.27 (ddd, 
3J = 7.5 Hz, 
3J = 7.5 Hz, 3J = 7.3 Hz, 1H, CHCH2CH(CH3)2), 3.36 (d br., 
3J = 7.3 Hz, 1H, CHNH), 
1.92 (m, 1H, CHCH2CH(CH3)2), 1.67 (m, 2H, CHCH2CH(CH3)2), 1.37 (t, 
3J = 7.13 Hz, 
3H, CO2CH2CH3), 1.22 (s, 9H, SC(CH3)3), 0.95 (d, 
3J = 6.7 Hz, 3H, CHCH2CH(CH3)2), 
0.95 (d, 3J = 6.7 Hz, 3H, CHCH2CH(CH3)2). 
13C NMR (126 MHz, Chloroform-d) δ = 
166.2 (ar-1-CO2CH2CH3), 131.7 (ar-C-3, ar-C-5), 130.0 (ar-C-1), 129.4 (ar-C-2, ar-C-6), 
127.4 (ar-C-4), 92.4 (CαHC≡C-ar), 84.2 (CαHC≡C-ar), 61.2 (CO2CH2CH3), 56.4 
(SC(CH3)3), 47.1 (CHCH2CH(CH3)2), 46.2 (CHCH2CH(CH3)2), 25.1 
(CHCH2CH(CH3)2), 22.6 (SC(CH3)3), 22.3 (CHCH2CH(CH3)2), 22.2 
(CHCH2CH(CH3)2), 14.4 (CO2CH2CH3). C20H29NO3S (363.52 g mol
-1). MS(ESI): m/z = 
386.17499 (calcd. 386.17604 [C20H29NO3S+Na]
+).  
 
Ethyl 4-((R)-3-(((R)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-yl)benzoate (46e). 
The Sonogashira cross coupling reaction of D-leucine analogous propargylamide 6c 
(418.0 mg, 1944 mol, 1.0 eq) with ethyl 4-iodobenzoate (45b, 814.9 mg, 3.110 mmol, 
1.6 eq) was performed as reported in the synthesis of 46b. 
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Slightly green, viscous oil. Yield: 671.3 mg, 1.847 mmol, 95 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.97 (d, 3J = 8.3 Hz, 2H, ar-2-H, ar-6-H), 
7.49 (d, 3J = 8.4 Hz, 2H, ar-3-H, ar-5-H), 4.37 (q, 3J = 7.1 Hz, 
2H, CO2CH2CH3), 4.29 (ddd, 
3J = 7.5 Hz, 3J = 7.4 Hz, 3J = 
7.4 Hz, 1H, HNCαH), 3.39 (d, 3J = 7.3 Hz, 1H, CHNH), 1.92 
(m, 1H, CHCH2CH(CH3)2), 1.70 (dd, 
3J = 7.4 Hz, 3J = 7.5 Hz, 
2H, CHCH2CH(CH3)2), 1.39 (t, 
3J = 7.1 Hz, 3H, CO2CH2CH3), 1.25 (s, 9H, C(CH3)3), 
0.98 (d, 3J = 6.7 Hz, 3H, CHCH2CH(CH3)2), 0.98 (d, 
3J = 6.7 Hz, 3H, 
CHCH2CH(CH3)2).
 13C NMR (126 MHz, Chloroform-d) δ = 166.2 (ar-1-CO2CH2CH3), 
131.7 (ar-C-3, ar-C-5), 130.0 (ar-C-1-CO2), 129.4 (ar-C-2, ar-C-6), 127.4 (ar-C-4), 92.4 
(CαHC≡C-ar), 84.2 (CαHC≡C-ar), 61.2 (CO2CH2CH3), 56.4 (SC(CH3)3), 47.1 
(CHCH2CH(CH3)2), 46.2 (CHCH2CH(CH3)2), 25.1 (CHCH2CH(CH3)2), 22.6 
(SC(CH3)3), 22.3 (CHCH2CH(CH3)2), 22.2 (CHCH2CH(CH3)2), 14.4 (CO2CH2CH3). 
C20H29NO3S (363.52 g mol
-1). MS(ESI): m/z = 386.17645 (calcd. 386.17604 [M+Na]+). 
CHN: 62.905 % C, 7.822 % H, 3.67 % N, 7.786 % S. TLC: Rf (EtOAc/PE, 1:1) = 0.26.  
 
Methyl 4-((S)-3-(((S)-tert-Butylsulfinyl)amino)-3-cyclohexylprop-1-yn-1-
yl)benzoate (46f). The Sonogashira cross coupling reaction of L-cyclohexylglycine 
analogous propargylamide 6e (99.5 mg, 412.4 mol, 1.0 eq) with methyl 4-iodobenzoate 
(45a, 129.7 mg, 494.9 mol, 1.2 eq) was performed as reported in the synthesis of 46b.  
Colorless, crystalline solid. Yield: 102.2 mg, 272.2 mol, 
66 %. 1H NMR (500 MHz, Chloroform-d) δ = 7.93 (d, 3J = 
8.2 Hz, 2H,  ar-2-H, ar-6-H), 7.47 (d, 3J = 8.1 Hz, 2H, ar-3-H, 
ar-5-H), 4.06 (dd, 3J = 7.5 Hz, 3J = 5.8 Hz, 1H, CHNH), 3.88 
(s, 3H, CO2CH3), 3.36 (d, 
3J = 7.4 Hz, 1H, CHNH), 1.93-1.82 (m, 2H, cy-H), 1.83-1.72 
(m, 2H, cy-H), 1.70-1.61 (m, 2H, cy-H), 1.22 (s, 9H, C(CH3)3), 1.19-1.06 (m, 5H, cy-H). 
13C NMR (126 MHz, Chloroform-d) δ = 166.6 (ar-1-CO2), 131.8 (ar-C-3, ar-C-5), 129.6 
(ar-C-2, ar-C-6), 129.4 (ar-1-C), 127.6 (ar-C-4), 91.4 (CHC≡C-ar), 85.0 (CHC≡C-ar), 
56.5 (SC(CH3)3), 53.8 (ar-1-CO2CH3), 52.3 (CHcy), 43.5 (cy-C-1), 29.7 (cy-C-2), 28.6 
(cy-C-6), 26.4 (cy-C-4), 26.0 (cy-C-5), 25.9 (cy-C-3), 22.7 (SC(CH3)3). C21H29NO3S 
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(375.53 g mol-1). MS(ESI): m/z = 398.2 (calcd. 398.18 [M+Na]+). TLC: Rf (PE/EtOAc, 
1:1) = 0.69.  
 
Methyl 4-((R)-3-(((R)-tert-Butylsulfinyl)amino)-3-cyclohexylprop-1-yn-1-
yl)benzoate (46g). The Sonogashira cross coupling reaction of D-cyclohexylglycine 
analogous propargylamide 6e (99.8 mg, 413.5 mol, 1.0 eq) with methyl 4-iodobenzoate 
(45a, 129.8 mg, 537.6 mol, 1.3 eq) was performed as reported in the synthesis of 46b.  
Colorless, crystalline solid. Yield: 114.8 mg, 306 mol, 74 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.93 (d, 3J = 8.2 Hz,  2H, ar-2-H, ar-6-H), 
7.47 (d, 3J = 8.1 Hz, 2H, ar-3-H, ar-5-H), 4.06 (dd, 3J = 7.5 Hz, 
3J = 5.8 Hz, 1H, HNCH), 3.88 (s, 3H, CO2CH3), 3.36 (d, 
3J = 
7.4 Hz, 1H, NHCH), 1.93-1.82 (m, 2H, cy-H), 1.83-1.72 (m, 
2H, cy-H), 1.70-1.61 (m, 2H, cy-H), 1.22 (s, 9H, C(CH3)3), 1.19-1.06 (m, 5H, cy-H). 
13C NMR (126 MHz, Chloroform-d) δ = 166.6 (ar-1-CO2), 131.8 (ar-C-3, ar-C-5), 129.6 
(ar-C-1-CO2), 129.4 (ar-C-2, ar-C-6), 127.6 (ar-C-4), 91.4 (CHC≡C-ar), 85.0 (CHC≡C-
ar), 56.5 (SC(CH3)3), 53.8 (ar-1-CO2CH3), 52.3 (HNCH), 43.5 (cy-C-1), 29.7 (cy-C-2), 
28.6 (cy-C-6), 26.4 (cy-C-4), 26.0 (cy-C-5), 25.9 (cy-C-3), 22.7 (SC(CH3)3). C21H29NO3S 
(375.53 g mol-1). MS(ESI): m/z = 398.2 (calcd. 398.18 [M+Na]+). TLC: Rf (EtOAc/PE, 
1:1) = 0.69.  
 
Methyl 4-((S)-4-(Benzylthio)-3-(((R)-tert-butylsulfinyl)amino)but-1-yn-1-
yl)benzoate (46h). A mixture of D-cycstein analogous propargylamide 6j (28.6 mg, 
122 mol, 1 eq) and aromatic halide 45a (47.4 mg, 191 mol, 1.6 eq) was dissolved in 
THF/piperidine (0.8 mL, 3:1) and the solution was thoroughly degassed viy freeze pump 
thaw (3 x 10-2 mbar). Under argon atmosphere, the catalyst PdCl2(PPh3)2 (0.86 mg, 
1.2 mol, 1 mol%) and CuI (0.46 mg, 0.24 mol, 2 mol%) was added in one portion and 
the reaction mixture was warmed up to rt. At ambient temperature, the solution was stirred 
for 2 h, before diluting it with saturated aqueous NH4Cl solution (10 mL). After addition 
of aqueous HCl (1 M, 5 mL), the aqueous phase was extracted with Et2O (3 x 10 mL). The 
combined organic layers were washed with brine (5 mL) and dried over Na2SO4. The 
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solvent was evaporated under reduced pressure and the crude cross coupling product 46h 
was purified by preparative HPLC.  
Yellow, foul smelling, highly viscous oil. Yield: 6.0 mg, 14 mmol, 11 %. 1H NMR 
(500 MHz, Chloroform-d) δ = 7.97 (d, 3J = 8.4 Hz, 2H, ar-2-H, ar-6-H), 7.50 (d, 3J = 
8.4 Hz, 2H, ar-2-H, ar-6-H), 7.54-7.12 (m, 5H, Ph-H), 4.36 
(ddd, 3J = 6.4 Hz, 3J = 6.1 Hz, 3J = 3.1 Hz, 1H, CH), 3.91 (s, 
3H, CO2CH3), 3.86 (d, 
3J = 3.1 Hz, 1H, CH), 2.89 (dd, 2J 
= 13.7 Hz, 3J = 6.4 Hz, 1H, CHCH2S), 2.83 (dd, 
2J = 13.7 Hz, 3J = 6.1 Hz, 1H, 
CHCH2S), 2.16 (s, 2H, SCH2Ph), 1.24 (s, 9H, SC(CH3)3). 
13C NMR (126 MHz, 
Chloroform-d) δ = 166.6 (CO2CH3), 138.0 (ar-C-4), 131.9 (ar-C-3, ar-C-5), 130.0 (Ph-C-
1), 129.6 (ar-C-2, ar-C-6), 129.1 (Ph-C-3, Ph-C-5), 128.8 (Ph-C-2, Ph-C-6), 127.5 (Ph-C-
4), 127.0 (ar-C-1), 90.9 (CHC≡C-ar), 85.2 (CHC≡C-ar), 56.9 (SC(CH3)3), 52.4 
(CO2CH3), 48.4 (CH), 38.3 (CCH2), 37.0 (SCH2Ph), 22.7 (SC(CH3)3). C23H27NO3S2 
(429.59 g mol-1). MS(ESI): m/z = 452.1 (calcd.  452.1325 [M+Na]+). [𝛼]589
22  = -23.6 (c 0.30, 
CHCl3). IR(ATR): 𝜈[cm-1] = 2920.3 (CH), 2359.9 (C-C alkyne), 1603.2 (C=C, ar).  
 
Ethyl 4-((R)-3-(((R)-tert-Butylsulfinyl)amino)-4-phenylbut-1-yn-1-yl)benzoate (46i). 
Iodobenzoate 45b (33.8 L, 200 mol, 1.0 eq) and piperidine (1.0 mL) was added to a 
stirred solution of D-phenylalanine analogous propargylamide 6m (50 mg, 200 mol, 
1.0 eq) in THF (3.0 mL) and the mixture was degassed by the freeze pump thaw method 
(3x). PdCl2(PPh3)2 (1 mg, 2.4 mol, 1.2 mol%) and CuI (1 mg, 5.3 mol, 2.7 mol%) was 
added and the reaction mixture was stirred for 14 h at rt. After 2 h, a colorless precipitate 
was observed. The solution was diluted with an aqueous NH4Cl solution (saturated, 20 mL) 
and extracted with Et2O (3 x 20 mL). The combined organic layers were washed with brine, 
dried over MgSO4. Evaporation of the solvent and purification by column chromatography 
(PE/EtOAc, 2:1) yielded the title compound in pure form.  
Yellow, highly viscous oil. Yield: 47 mg, 118 mol, 59 %. 
1H NMR (500 MHz, Chloroform-d) δ = 7.96 (d, 3J = 8.4 Hz, 
2H, ar-2-H, ar-6-H), 7.45 (d, 3J = 8.4 Hz, 2H, ar-3-H, ar-5-H), 
7.36-7.29 (m, 5H, Ph-H), 4.50 (ddd, 3J = 7.0 Hz, 3J = 6.8 Hz, 
3J = 6.7 Hz, 1H, CH), 4.37 (q, 3J = 7.1 Hz, 2H, CO2CH2CH3), 
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3.46 (d, 3J = 7.0 Hz, 1H, CHNH), 3.15 (dd, 2J = 13.5 Hz, 3J = 6.7 Hz, 1H, CHCH2Ph), 
3.10 (dd, 2J = 13.5 Hz, 3J = 6.7 Hz, 1H, CHCH2Ph), 1.39 (t, 
3J = 7.1 Hz, 3H, 
CO2CH2CH3), 1.18 (s, 9H, SC(CH3)3). C23H27NO3S (397.53 g mol
-1). MS(ESI) m/z = 
420.002 (calcd. 420.1604 [M+Na]+). TLC: Rf (PE/EtOAc, 2:1) = 0.20.  
 
Methyl 4-((S)-3-(((S)-tert-Butylsulfinylamido)-3-phenylprop-1-yn-1-
yl)benzoate (46j). 4-Iodobenzoate 45a (192 mg, 733 mol, 1.8 eq) and DIPEA (0.8 mL) 
was added to a stirred solution of D-phenylalanine analogous propargylamide 6n (95.8 mg, 
407 mol, 1.0 eq) in THF (2.4 mL) and the mixture was degassed by the freeze pump thaw 
method (3x). PdCl2(PPh3)2 (1 mg, 2.4 mol, 0.6 mol%) and 
CuI (1 mg, 5.3 mol, 1.3 mol%) was added and the reaction 
mixture was stirred overnight at rt. The solution was diluted 
with an aqueous NH4Cl solution (saturated, 20 mL) and 
extracted with Et2O (3 x 20 mL). The combined organic layers 
were washed with brine, dried over MgSO4. After evaporation of the solvent and 
purification by column chromatography (PE/EtOAc, 2:1) and recrystallization from Et2O, 
peptidomimetic 46j was achieved in pure form.  
Colourless crystalline solid. Yield: 83 mg, 225 mol, 54 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.98 (d, 3J = 8.4 Hz, 2H, ar-2-H, ar-6-H), 7.56 (d, 3J = 6.9 Hz, 1H, Ph-
2-H, Ph-6-H), 7.53 (d, 3J = 8.4 Hz, 2H, ar-3-H, ar-5-H), 7.41 (t, 3J = 7.3 Hz, 2H, Ph-3-H, 
Ph-5-H), 7.37 (m, 1H, Ph-4-H), 5.47 (m, 1H, CαHPh), 3.92 (s, 3H, CO2CH3), 1.27 (s, 9H, 
SC(CH3)3). 
13C NMR (126 MHz, Chloroform-d) δ = 166.6 (CO2CH3), 138.3 (Ph-C-1), 
131.9 (ar-C-3, ar-C-5), 130.1 (ar-C-1), 129.6 (ar-C-2, ar-C-6), 129.0 (Ph-C-3, Ph-C-5), 
128.8 (Ph-C-1), 127.8 (Ph-C-2, Ph-C-6), 127.0 (Ph-C-4), 90.2 (CαHC≡Car), 86.3 
(CαHC≡Car), 57.3 (SC(CH3)3), 52.4 (CO2CH3), 52.3 (Cα), 22.7 (SC(CH3)3). C21H23NO3S 
(369.48 g mol-1). MS(ESI): m/z = 392.975 (calcd. 392.129 [M+Na]+). IR(ATR): ν̃ [cm-1] = 
2977 (CH), 2948 (CH), 2920 (CH), 2328 (C≡C), 2353 (C-C), 1720 (C=O), 1543 (ar, C=C), 
1280 (C-N). TLC: Rf (EtOAc/PE, 1:2) = 0.44. [𝛼]589
19  = 10.4 (c 0.72, CHCl3). X-ray crystal 
structure in Chapter IIX-3. n. 
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Methyl 6-((R)-3-(((R)-tert-Butylsulfinyl)amino)-3-cyclohexylprop-1-yn-1-
yl)nicotinate (46k). The catalysts PdCl2(PPh3)2 (2.9 mg, 4.1 mol, 1 mol%) and CuI 
(1.6 mg, 8.3 mol, 2 mol%) were added under argon atmosphere to a thoroughly degassed 
solution of D-cyclohexylglycine analogous propargylamide 6e (100.0 mg, 414 mol, 
1.0 eq) and aromatic bromide 45c (107.4 mg, 497.2 mol, 1.2 eq) in THF/piperidine 
(1.0 mL, 3:1). The reaction mixture was warmed up to rt and stirred overnight at ambient 
temperature. A colorless precipitate formed during the procedure of the reaction. After 
complete conversion of propargylamde 6e (checked by TLC), the mixture was diluted with 
an aqueous NH4Cl solution (saturated, 10 mL) and neutralized with aqueous HCl (1 M, 
6 mL). The mixture was extracted with EtOAc (3 x 30 mL). The combined organic layers 
were washed with brine (10 mL) and dried over Na2SO4. After filtration and evaporation 
of the solvent under reduced pressure, the crude cross coupling product 46k was purified 
by column chromatography (PE/EtOAc, 2:1).  
Colorless, amorphous solid. Yield: 3.4 mg, 9.0 mol, 2 %. 1H NMR (300 MHz, 
Chloroform-d) δ = 9.16 (dd, 4J = 2.2 Hz, 5J = 0.8 Hz, 1H, ar-
2-H), 8.33  (dd, 3J = 8.2 Hz, 4J = 2.1 Hz, 1H, ar-4-H), 7.58 (dd, 
3J = 8.2 Hz, 5J = 0.9 Hz, 1H, ar-5-H), 4.07 (d, 3J = 5.9 Hz, 1H, 
CH), 3.96 (s, 3H, CO2CH3), 3.53 (s br., 1H, CHNH), 1.92 
(d br., 2J = 11.4 Hz, 2H, cy-2-H, cy-6-H), 1.79 (d br., 2J = 10.8 Hz, 2H, cy-2-H, cy-6-H), 
1.77-1.63 (m, 3H, cy-1-H, cy-4-H, cy-4-H), 1.28 (s, 9H, SC(CH3)3), 1.26-1.04 (m, 4H, cy-
3-H, cy-3-H, cy-5-H, cy-5-H). 13C NMR (126 MHz, Chloroform-d) δ = 164.8 (ar-3-
CO2CH3), 149.9 (ar-C-2), 145.3 (ar-C-6), 138.6 (ar-C-4), 127.5 (ar-C-5), 125.6 (ar-C-3), 
93.8 (CHC≡Car), 83.5 (CHC≡Car), 57.3 (SC(CH3)3), 54.6 (CHcy), 52.9 (CO2CH3), 
43.5 (cy-C-1), 29.6 (cy-C-2), 29.0 (cy-C-6), 27.1 (cy-C-4), 26.3 (cy-C-5), 25.9 (cy-C-3), 
22.8 (SC(CH3)3). C20H28N2O3S (376.51 g mol
-1). MS(EI): m/z = 377.180 (calcd. 377.5225 
[M+H]+), 399.155 (calcd. 399.5042 [M+Na]+). [𝛼]589
21  = -13.3 (c 0.17, CHCl3). TLC: Rf 
(PE/EtOAc, 2:1) = 0.67.  
 
Methyl 5-((R)-3-(((R)-tert-Butylsulfinyl)amino)-3-cyclohexylprop-1-yn-1-
yl)picolinate (46l). The catalysts PdCl2(PPh3)2 (2.9 mg, 4.1 mol, 1 mol%) and CuI 
(1.6 mg, 8.3 mol, 2 mol%) were added under argon atmosphere to a thoroughly degassed 
solution of D-cyclohexylglycine analogous propargylamide 6e (98.7 mg, 419.5 mol, 
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1.0 eq) and aromatic bromide 45d (108 mg, 503 mol, 1.2 eq) in THF/piperidine (1.0 mL, 
3:1). The reaction mixture was warmed up to rt and stirred over 16 h at 60 °C under reflux 
conditions. A colorless precipitate formed during the procedure of the reaction. After 
complete conversion of propargylamde 6e (checked by TLC), the mixture was diluted with 
an aqueous NH4Cl solution (saturated, 10 mL) and neutralized with aqueous HCl (1 M, 
6 mL). The mixture was extracted with EtOAc (3 x 30 mL). The combined organic layers 
were washed with brine (10 mL) and dried over Na2SO4. After filtration and evaporation 
of the solvent under reduced pressure, the crude cross coupling product 46l was purified by 
column chromatography (PE/EtOAc, 2:1).  
 Pale green, highly viscous oil. Yield: 64.6 mg, 172 mol, 
41 %. 1H NMR (300 MHz, Chloroform-d) δ = 8.71 (dd, 4J = 
2.1 Hz, 5J = 0.9 Hz, 1H, py-6-H), 8.04 (dd, 3J = 8.1 Hz, 5J = 
0.9 Hz, 1H, py-3-H), 7.86 (dd, 3J = 8.1 Hz, 4J = 2.1 Hz, 1H, 
py-4-H), 4.07 (dd, 3J = 7.9 Hz, 3J = 5.9 Hz, 1H, HNCH), 3.98 (s, 3H, CO2CH3), 3.37 (d, 
3J = 7.9 Hz, 1H, NHCH), 1.94-1.83 (m, 3H, cy-H), 1.81-1.72 (m, 3H, cy-H), 1.71-1.62 
(m, 2H, cy-H), 1.22 (s, 9H, SC(CH3)3), 1.18-1.07 (m, 3H, cy-H). 
13C NMR (151 MHz, 
Chloroform-d) δ = 165.3 (py-2-CO2CH3), 152.1 (py-C-6), 146.3 (py-C-2), 139.9 (py-C-4), 
124.5 (py-C-3), 123.5 (py-C-5), 95.1 (CHC≡Car), 82.0 (CHC≡Car), 56.7 (SC(CH3)3), 
54.0 (py-2-CO2CH3), 53.1 (C), 43.5 (cy-C-1), 29.6 (cy-C-2), 28.8 (cy-C-6), 26.3 (cy-C-
4), 26.0 (cy-C-5), 25.9 (cy-C-3), 22.7 (SC(CH3)3). C20H28N2O3S (376.51 g mol
-1). 
MS(ESI): m/z = 399.1 (calcd. 399.17 [C20H28N2O3S+Na]
+). IR(ATR): 𝜈[cm-1] = 2927 
(CH2), 2854 (CH2, NH), 1724 (CO2Me), 1448 (ar, C=C), 1302 (ar, C=C). TLC: Rf 
(EtOAc/PE, 1:2) = 0.05.  
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Methyl 5-Bromofuran-2-carboxylate (47a). A similar bromination procedure of methyl 
furan-2-carboxylate has been described by Yu-Sheng and coworkers using AlCl3 instead 
of KClO4 as catalyst, giving 86 % yield of 47a [228]. Bromine (5.76 mL, 18.0 g, 
12.3 mmol, 1.2 eq) was added in one portion to a solution of methyl furan-2-carboxylate 
(10.00 mL, 93.57 mmol, 1.0 eq) in chloroform (100 mL). To the brown solution, solid 
KClO4 (2.59 g, 18.7 mmol, 0.2 eq) was added in one portion and the mixture was heated 
under reflux for 36 h. Afterwards, the mixture was cooled to rt, diluted with a KHSO4 
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solution (5 %, 20 mL) and solid Na2SO3 was added under vigorous stirring until the brown 
solution turned colorless. The organic layer was separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were dried over Na2SO4, 
filtered and the solvent evaporated under reduced pressure. The crude product, a brown oil, 
contained a mixture of brominated 47a and unbrominated species (76 % conversion, 
determined by 1H NMR spectroscopy), was filtered through silica gel (EtOAc/PE, 1:4) and 
sublimated under reduced pressure.  
Colorless crystals. Yield: 8.875 g, 43.29 mmol, 46 %. 1H NMR (600 MHz, Chloroform-d) 
δ = 7.15 (d, 3J = 3.5 Hz, 1H, furan-4-H), 6.52 (d, 3J = 3.5 Hz, 1H, furan-
3-H), 3.90 (s, 3H, CO2CH3). 
13C NMR (126 MHz, Chloroform-d) δ = 
157.4 (furan-2-CO2CH3), 145.8 (furan-C-2), 126.9 (furan-C-4), 119.7 (furan-C-3), 113.6 
(furan-C-5), 51.6 (furan-2-CO2CH3). C6H5BrO3 (205.01 g mol
-1). TLC: Rf (PE/EtOAc, 
1:1) = 0.75.  
 
tert-Butyl 5-Bromofuran-2-carboxylate (47b). Transesterification of 5-bromo fuoroate 
47b has been reported before using Boc2O instead of the herein 
described Steglich esterification [229]. Solid DCC (9.94 g, 48.4 mmol, 
1.3 eq) was added at 0 °C to a solution of 5-bromofuran-2-carboxylic acid (6.944 g, 
36.36 mmol, 1.0 eq) in dry CH2Cl2 (60 mL). After 5 min, a solution of tert-butanol 
(4.043 g, 54.54 mmol, 1.5 eq) in dry CH2Cl2 (20 mL) was added together with DMAP 
(1.11 g, 9.09 mmol, 0.25 eq). The reaction mixture was stirred overnight at ambient 
temperature. The solution had now turned orange and was diluted with H2O (36 ml), 
filtered and the phases were separated. The organic layer was dried over Na2SO4, filtered 
again and the solvent was evaporated. The crude brown oil was digerated with PE. The 
developing white precipitate was centrifuged (5000 rpm, 6 min), filtered off and tert-Butyl 
ester 47b was isolated by column chromatography (gradient PE, PE/EtOAc 4:1, PE/EtOAc 
2:1) of the filtrate.  
Colorless fluid. Yield: 4.460 g, 18.05 mmol, 50 %. 1H NMR (500 MHz, Chloroform-d) δ 
= 7.01 (d, 3J = 3.4 Hz, 1H, furan-3-H), 6.41 (d, 3J = 3.4 Hz, 1H, furan-4-H), 1.56 (s, 9H, 
CO2C(CH3)3). C9H11BrO3 (247.09 g mol-1). MS(ESI): m/z = 247.048 (calcd. 246.9964 
[M+H]+). 248.996 (calcd. 248.9944 [M+Na]+). TLC: Rf (PE/EtOAc, 4:1) = 0.95.  
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Methyl 5-((S)-3-(((S)-tert-Butylsulfinyl)amino)-4-methylpent-1-yn-1-yl)furan-2-
carboxylate (49a). A solution of L-valine analogous propargylamide 6b 
(520.1 mg, 2.587 mmol, 1.0 eq) and methyl 5-bromofuran-2-carboxylate (47a, 
849 mg, 4.14 mmol, 1.6 eq) in a mixture of THF/piperidine (2.7 mL, 3:1) was thoroughly 
degassed by the freeze-pump-thaw method. While still frozen, the solid catalyst 
PdCl2(PPh3)2 (1 mol%) and CuI (2 mol%) was added in one portion and the mixture was 
allowed to warm up to rt and stirred overnight at ambient temperature. A colorless 
precipitate formed in the course of the reaction. The reaction mixture was diluted with a 
mixture of Et2O and aqueous NH4Cl (3:2, 25 mL), neutralized with aqueous KHSO4 
solution (5 %, 3-5 mL, until pH 7). The phases were separated and the aqueous layer was 
extracted with Et2O (3 x 15 mL). The combined organic layers were washed with brine, 
dried over Na2SO4 and the solvent was evaporated under reduced pressure. The crude 
product of 49a was isolated by column chromatography (PE/EtOAc, 1:1) and purified by 
recrystallisation from Et2O.  
Colorless crystals. Yield: 530.5 mg, 1.63 mmol, 63 %. dr ≥ 
99 % (determined via integration of 1H NMR signals of CH, 
4.09 ppm), 1H NMR (600 MHz, Chloroform-d) δ = 7.10 (d, 3J 
= 3.6 Hz, 1H, ar-3-H), 6.61 (d, 3J = 3.6 Hz, 1H, ar-4-H), 4.09 (ddd, 3J = 6.8 Hz, 3J = 5.4 Hz, 
4J = 1.0 Hz, 1H, CCH(CH3)2), 3.86 (s, 3H, CO2CH3), 3.44 (d, 3J = 7.0 Hz, 1H, CHNH), 
2.00 (m, 1H, CCH(CH3)2), 1.21 (s, 9H, SC(CH3)3), 1.02 (d, 3J = 6.8 Hz, 3H, 
CCH(CH3)2), 1.01 (d, 3J = 6.7 Hz, 3H, CCH(CH3)2). 13C NMR (151 MHz, 
Chloroform-d) δ = 158.5 (CO2(CH3)), 144.3 (ar-C-2), 139.8 (ar-C-5), 118.8 (ar-C-3), 117.0 
(ar-C-4), 94.1 (CHC≡Car), 75.2 (CHC≡Car), 56.6 (SC(CH3)3), 54.3 (CCH(CH3)2), 
52.2 (CO2CH3), 33.8 (CCH(CH3)2), 22.7 (SC(CH3)3), 19.0 (CCH(CH3)2), 17.8 
(CCH(CH3)2). C16H23NO4S (325.42 g mol-1). LCMS(ESI): tr = 9.5 min, m/z = 
326.14290 (calcd. 326.14206 [M+H]+), 651.2888 (calcd. 651.2768 [2M+H]+). IR(ATR): ν̃ 
[cm-1] = 3230 (w, NH), 2958, 2930, 2870 (m, w, w, CH), 1723 (s, CO2CH3), 1581 (w, NH), 
1505 (s), 1464 (m), 1432 (w), 1385 (w), 1363 (m), 1299 (s), 1239 (w), 1211 (s), 1192 (w), 
1141(s), 1062 (s, S=O), 1017 (w), 989 (w), 926 (w), 808 (m), 761(s). TLC: Rf (PE/EtOAc, 
1:1) = 0.29. [α]589
23  = 1.0 (c 0.63, CHCl3). X-ray crystal structure in Chapter IIX-3. n.  
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Methyl 5-Bromothiophene-2-carboxylate (48a). Methyl Thiophene-2-carboxylate. 
The methylation of thiophene carboxylate was performed as described by Cardoso et al. 
[230]. Thionylchloride (0.6 mL, 8.3 mmol, 1.1 eq) was added dropwise to a 
cooled solution of thiophene 2-carboxylic acid (1.00 g, 7.034 mmol, 1 eq) in 
dry methanol (15 mL). The clear solution was heated under reflux for 36 h. After cooling 
down to rt, the solvent was evaporated. The crude product was diluted with water and an 
aqueous solution of NaOH (2 M) was added until pH 9-10 before extraction with Et2O (3 
x 30 mL). The combined organic layers were dried over Na2SO4, filtered and the solvent 
evaporated to yield methyl thiophene-2-carboxylate in pure form.  
Colorless, thin liquid. Yield: 1.027 g, 7.22 mmol, 93 % (Lit: 98 % [230]). 1H NMR 
(500 MHz, Chloroform-d) δ = 7.80 (dt, 3J = 3.8 Hz, 4J = 0.9 Hz, 1H, thiophene-3-H), 7.55 
(dt, 3J = 5.0 Hz, 4J = 1.0 Hz, 1H, thiophene-5-H), 7.10 (dd, 3J = 4.8 Hz, 3J = 3.7 Hz, 1H, 
thiophene-4-H), 3.89 (s, 3H, thiophene-2-CO2CH3). 
13C NMR (126 MHz, Chloroform-d) 
δ = 162.9 (thiophene-2-CO2CH3), 133.7 (thiophene-C-2), 133.6 (thiophene-C-3), 132.5 
(thiophene-C-4), 127.9 (thiophene-C-5), 52.3 (CO2CH3). C6H6O2S (142.17 g mol
-1). TLC: 
Rf (EtOAc/PE, 1:1) = 0.89.  
Methyl 5-Bromothiophene-2-carboxylate (48a). Alternative 1: Esterification using the 
Mukaiyama reagent was performed as described by Irina Novosjolova 
[231]. Bromothiophene-2-carboxylic acid (48b, 1.61 g, 7.8 mmol, 1 eq) 
was dissolved in a mixture of CH2Cl2/THF (30 mL, 1:2). 2-Chloro-1-methylpyridin-1-
iumiodide (3.98 g, 15.6 mmol, 2 eq) was added in one portion and the reaction mixture was 
stirred at rt. After 2 h, MeOH (20 mL) was added and the mixture was stirred for another 
2 h at rt. The mixture was diluted with a saturated NH4Cl solution (30 mL), the phases were 
separated and the aqueous layer was extracted with Et2O (6 x 30 mL). The combined 
organic layers were dried over MgSO4 and the solvent was evaporated under reduced 
pressure. The crude product was purified by column chromatography (EtOAc/PE, 1:1). 
Yield: 649 mg, 2.93 mmol, 38 %. 
Alternative 2: The methylation of 48b using thionylchloride was performed similarly to the 
description of [232]. Thionylchloride (0.565 mL, 7.804 mmol, 1 eq) was added dropwise 
to a solution of 5-bromothiophene-2-carboxylate (1.616 g, 7.804 mmol, 
1 eq) in dry methanol (20 mL) and the reaction mixture was heated to 
70 °C. The procedure of the reaction was surveyed by TLC. After 14 h the yellow solution 
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was cooled to room temperature. Aqueous NH4Cl solution (sat, 10 mL) was added and the 
methanol was evaporated under reduced pressure. The aqueous solution was extracted with 
ethyl acetate (3 x 30 mL) and the combined organic layers were dried over Na2SO4. The 
crude product was dissolved in warm EtOAc and precipitated with PE at 4 °C. After 
centrifugation, the remaining clear solvent was decanted and the purified ester 48a was 
isolated in pure form. Yield: 607 mg, 2.7 mmol, 35 % (2 steps, referred to thiophene-2-
carboxylic acid). 
Alternative: Bromine (0.74 mL, 14.4 mmol, 2.0 eq) was added dropwise to a solution of 
methyl thiophene-2-carboxylate (1.027 g, 14.44 mmol, 1.0 eq) in chloroform (10 mL). To 
the brown solution, solid KClO4 (300 mg, 2.17 mmol, 0.3 eq) was added in one portion and 
the mixture was heated under reflux for another 36 h. Afterwards, the mixture was cooled 
to rt, diluted with a KHSO4 solution (5 %, 20 mL) and solid Na2SO3 was added under 
vigorous stirring until the brown solution turned colorless. The organic layer was separated 
and the aqueous layer was extracted with CH2Cl2 (3 x 20 mL). The combined organic layers 
were dried over Na2SO4, filtered and the solvent evaporated under reduced pressure. The 
crude product, a brown oil, contained a mixture of brominated and unbrominated species 
(76 % conversion, determined by 1H NMR spectroscopy). was filtered through silica gel 
(EtOAc/PE, 1:4) and precipitated by addition of a big portion of PE at 0 °C. The colorless 
solid was filtered of, washed with a few milliliters of ice cold PE and dried under vacuum. 
Yield: 1.017 g, 4.601 mmol, 64 %.  
Colorless, crystalline solid. Yield 649 mg, 2.93 mmol, 38 %. 1H NMR (300 MHz, 
Methanol-d4) δ = 7.59 (d, 3J = 4.0 Hz, 1H, thiophene-4-H), 7.20 (d, 3J = 
4.0 Hz, 1H, thiophene-3-H), 3.86 (s, 3H, thiophene-5-CO2CH3). 
1H NMR 
(300 MHz, DMSO-d6) δ = 7.65 (d, 3J = 4.0 Hz, 1H, thiophene-4-H), 7.37 (d, 3J = 4.1 Hz, 
1H, thiophene-3-H), 3.81 (s, 3H, CO2CH3). 
13C NMR (126 MHz, Chloroform-d) δ = 161.7 
(thiophene-5-CO2CH3), 134.8 (thiophene-C-5), 133.8 (thiophene-C-4), 131.0 (thiophene-
C-3), 120.4 (thiophene-C-2), 52.5 (CO2CH3). C6H5BrO2S (221.07 g mol
-1). MS(ESI): m/z 
= 242.2 (calcd. 242.9 [M+Na]+). TLC: Rf (EtOAc/PE, 1:1) = 0.83, Rf (EtOAc/PE, 1:2) = 
0.69, Rf (EtOAc/PE, 1:4) = 0.50.  
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5-Bromothiophene-2-carboxylic Acid (48b). A similar bromination procedure of 
thiophene 2-carboxylic acid has been described by Sun and coworkers using bromine in 
glacial acetic acid [233]. A mixture of thiophene 2-carboxylic acid (1.00 g, 7.034 mmol, 
1 eq) and N-bromosuccinimide (2.003 g, 11.25 mmol, 1.6 eq) was dissolved in DMF 
(50 mL) and heated to 75 °C. After 12 h, the solvent was evaporated under 
reduced pressure. The crude product was diluted with Et2O (30 mL) and 
washed with an aqueous solution of NaOH (1 M, 15 mL) and Na2SO3 (sat, 10 mL). The 
combined aqueous phases were acidified with HCl (10 M, pH = 1) and extracted with Et2O 
(3 x 30 mL). Drying of the organic layers over Na2SO4 and evaporation of the solvent 
yielded 5-bromothiophene-2-carboxylate in pure form.  
Colorless crystalline solid. Yield: 508 mg, 2.45 mmol, 35 %. 1H NMR (300 MHz, 
Methanol-d4) δ = 7.15 (d, 3J = 4.0 Hz, 1H, thiophene-4-H), 7.52 (d, 3J = 4.1 Hz, 1H, 
thiophene-3-H). C5H3BrO2S (207.04 g mol
-1).  
 
5-Iodothiophene-2-carboxylic Acid (48c). Iodochloride (1 M in CH2Cl2, 3.9 mL, 1.0 eq) 
was added dropwise to a solution of thiophene-2-carboxylate (500 mg, 3.90 mmol, 1.0 eq) 
in glacial acetic acid (15 mL) at rt over a period of 10 min. The reaction mixture was heated 
for 3 h to 80 °C under reflux conditions. After cooling down to rt, the volatile parts of the 
mixture were evaporated under reduced pressure. The crude pale brown solid was washed 
with CH3CN (3 x 3 mL) and purified by column chromatography (CH2Cl2/MeOH, 98:2).  
Colorless solid. Yield: 67.8 mg, 266 mol, 7 %. 1H NMR (600 MHz, 
Chloroform-d) δ = 9.94 (s, 1H, CO2H), 7.52 (d, 3J = 3.9 Hz, 1H, 
thiophene-3-H), 7.30 (d, 3J = 3.9 Hz, 1H, thiophene-4-H). C5H3IO2S (254.04 g mol
-1). 
LCMS(ESI): tr = 7.8 min, m/z = 255.129 (calcd. 254.8971 [M+H]
+).  
 
Methyl (S)-5-(4-Methyl-3-((4-nitrophenyl)sulfonamido)pent-1-yn-1-yl)furan-2-
carboxylate (49b). To a suspension of hydrochloride salt 56a (37.4 mg, 145 mol) in THF 
(3 mL), 4-nitrobenzyle sulfuric chloride (47.4 mg, 217 mol, 1.5 eq) and Triethylamine 
(0.2 mL, 1.56 mmol, 10 eq) was added. The suspension 
immediately became a clear solution, which was stirred 
for 21 h at ambient temperature. After complete 
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conversion (checked by LCMS), an aqueous solution of NH4Cl (saturated, 3.5 mL) and 
HCl (aqueous, 1 M, 2 mL) was added to adjust the pH value to 6-7. The resulting solution 
was extracted with Et2O (4 x 15 mL). The combined organic layers were dried over Na2SO4 
and the solvent was evaporated. The crude product was purified by column chromatography 
to yield the desired peptidomimetic 49b in form of a yellow oil (53.4 mg, 131 mol, 91 %). 
TLC: Rf (PE/EtOAc, 1:1) = 0.55. Compound 49b was directly converted to 53b without 
further characterization.  
 
Methyl 5-(3-((tert-Butoxycarbonyl)amino)prop-1-yn-1-yl)thiophene-2-
carboxylate (50a). The catalyst PdCl2(PPh3)2 (3.2 mg, 4.6 mol, 1 mol%) and CuI 
(1.8 mg, 9.1 mol, 2 mol%) was added under argon atmosphere to a thoroughly degassed 
solution of glycine analogous propargylamide 1 (70.7 mg, 455 mol, 1.0 eq) and methyl 5-
bromo-thiophencarboxylate (48a, 100.7 mg, 455 mol, 1.0 eq) in a mixture of 
THF/piperidine (1.6 mL, 3:1) and the reaction mixture was stirred overnight at ambient 
temperature. Formation of a colorless precipitate indicated the reaction procedure. The 
reaction mixture was diluted with an aqueous solution of NH4Cl (saturated, 15 mL) and 
extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine 
(8 mL), dried over Na2SO4 and the solvent was evaporated under reduced pressure. Crude 
product 50a was purified by column chromatography (PE/EtOAc, 2:1).  
Colorless, amorphous solid. Yield: 86.5 mg, 293 mol, 64 %. 
1H NMR (600 MHz, Chloroform-d) δ = 7.63 (d, 3J = 3.9 Hz, 1H, 
thiophene-3-H), 7.12 (d, 3J = 3.9 Hz, 1H, thiophene-4-H), 4.78 (s br., 1H, NHCH2), 4.18 
(d, 3J = 5.7 Hz, 2H, CH2C≡C-thiophene), 3.88 (s, 3H, thiophene-2-CO2CH3), 1.47 (s, 9H, 
CO2C(CH3)3). 13C NMR (151 MHz, Chloroform-d) δ = 162.1 (thiophene-2-CO2CH3), 
134.0 (thiophene-C-2), 133.2 (thiophene-C-3), 132.6 (thiophene-C-4), 129.5 (thiophene-
C-5), 92.3 (CH2C≡C-thiophene), 80.4 (CH2C≡C-thiophene), 76.0 (CO2C(CH3)3), 52.5 
(thiophene-2-CO2CH3), 41.8 (CH2C≡C-thiophene), 28.5 (CO2C(CH3)3). C14H17NO4S 
(295.35 g mol-1). MS(ESI): m/z = 296.353 (calcd. 296.0951 [M+H]+), 318.366 (calcd. 
318.3422 [M+Na]+). TLC: Rf (EtOAc/PE, 1:2) = 0.11.  
 
IIX-3. e) Heteroaromatic Peptidomimetics (47-50) 
168 
Methyl 5-((S)-3-(((S)-tert-Butylsulfinyl)amino)-4-methylpent-1-yn-1-yl)thiophene-2-
carboxylate (50b). The catalyst PdCl2(PPh3)2 (1 mg, 4.6 mol, 1 mol%) and CuI (1.8 mg, 
9.1 mol, 2 mol%) was added under argon atmosphere to a thoroughly degassed solution 
of L-valine analogous propargylamide 6b (73.8 mg, 366.7 mol, 1.0 eq) and 
methyl 5-bromo thiophencarboxylate (48a, 113.5 mg, 
513.4 mol, 1.4 eq) in a mixture of THF/piperidine (1.0 mL, 
3:1) and the reaction mixture was stirred overnight at ambient 
temperature. Formation of a colorless precipitate indicated the reaction procedure. The 
reaction mixture was diluted with an aqueous solution of NH4Cl (saturated, 15 mL) and 
KHSO4 (5 %, 10 mL) and extracted with Et2O (3 x 30 mL). The combined organic layers 
were washed with brine (10 mL), dried over Na2SO4 and the solvent was evaporated under 
reduced pressure. Crude product 50b was purified by column chromatography (PE/EtOAc, 
2:1).  
Colorless, crystalline solid. Yield: 26.2 mg, 77 mol, 21 %. 1H NMR (600 MHz, 
Chloroform-d) δ = 7.62 (d, 3J = 4.0 Hz, 1H, thiophene-3-H), 7.13 (d, 3J = 4.0 Hz, 1H, 
thiophene-4-H), 4.12 (dd, 3J = 6.8 Hz, 3J = 5.3 Hz, 1H, CαH), 3.86 (s, 3H, CO2CH3), 3.42 
(d, 3J = 6.9 Hz, 1H, CαNH), 2.02 (m, 1H, CHCH(CH3)2), 1.24 (s, 9H, SC(CH3)3), 1.05 (d, 
3J = 6.2 Hz, 3H, CHCH(CH3)2), 1.03 (d, 
3J = 6.2 Hz, 3H, CHCH(CH3)2). 
13C NMR 
(151 MHz, Chloroform-d) δ = 162.0 (CO2CH3), 133.9 (thiophene-C-5), 133.2 (thiophene-
C-4), 132.6 (thiophene-C-2), 129.4 (thiophene-C-3), 94.5 (CαHC≡C-ar), 78.4 (CαHC≡C-
ar), 56.6 (SC(CH3)3), 54.5 (CO2CH3), 52.4 (CH), 34.0 (C
αHCH(CH3)2), 22.8 
(SC(CH3)3), 19.1 (CHCH(CH3)2), 17.8 (CHCH(CH3)2). C16H23NO3S2 
(341.48 g mol-1). [𝛼]589
20  = +27.07 (c 4.46, CHCl3). X-ray crystal structure in 
Chapter IIX-3. n. 
 
Methyl 5-((R)-3-(((R)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-yl)thiophene-2-
carboxylate (50c). A solution of D-leucine analogous propargylamide 6c (38 mg, 
180 mol, 1.0 eq) and thiophene derivative 48a (58 mg, 
210 mol, 1.2 eq) in a mixture of THF (12 mL) and piperidine 
(4 mL) was thoroughpy degassed. The catalyst PdCl2(PPh3)2 
(6 mg, 13 mol) and CuI (4 mg, 26 mol) was added under 
argon atmosphere and the reaction mixture was stirred for 5 h at ambient temperature. After 
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complete conversion of the propargylamide (checked by TLC), the reaction mixture was 
diluted with an aqueous NH4Cl solution (halfsaturated, 8 mL). The mixture was extracted 
with Et2O (4 x 10 mL) and the combined organic layers were dried over MgSO4. After 
evaporation of the solvent, crude product 50c was purified by column chromatography 
(PE/EtOAc, 1:1).  
Pale yellow, highly viscous oil. Yield: 28 mg, 79 mol, 44 %. 1H NMR (300 MHz, 
Chloroform-d) δ = 7 .62 (d, 3J = 3.9 Hz, 1H, thiophene-3-H), 7.13 (d, 3J = 3.9 Hz, 1H, 
thiophene-4-H), 4.29 (ddd, 3J = 7.5 Hz, 3J = 7.3 Hz, 3J = 7.3 Hz, 1H, CH), 3.87 (s, 3H, 
CO2CH3), 3.40 (d, 
3J = 7.3 Hz, 1H, CHNH), 1.88 (m, 1H, CHCH2CH(CH3)2), 1.69 (t, 
3J = 7.3 Hz, 2H, CHCH2CH(CH3)2), 1.24 (s, 9H, SC(CH3)3), 0.96 (d, 
3J = 6.6 Hz, 6H, 
CHCH2CH(CH3)2). 
13C NMR (151 MHz, Chloroform-d) δ = 162.1 (thiophene-2-
CO2CH3), 133.9 (thiophene-C-5), 133.2 (thiophene-C-4), 132.7 (thiophene-C-2), 129.4 
(thiophene-C-3), 96.0 (CHC≡C-thiophene), 77.6 (CHC≡C-thiophene), 56.5 (SC(CH3)3), 
52.4 (CO2CH3), 47.2 (CHCH2CH(CH3)2), 46.1 (CHCH2CH(CH3)2), 25.1 
(CHCH2CH(CH3)2), 22.7 (SC(CH3)3), 22.6 (CHCH2CH(CH3)2), 22.3 
(CHCH2CH(CH3)2). C17H25NO3S2 (355.51 g mol
-1). MS(ESI): m/z = 378.1157 (calcd. 
378.1168 [M+Na]+), 733.2452 (calcd. 733.2444 [2M+Na]+). IR (ATR): ν̃ [cm-1] = 3281 (-
N-H), 2951 (=C-H), 2920 (-C-H), 2847 (-O-C-H), 2331 (-C≡C-), 2359 (-C-C-), 1714 (-
C=O), 1545 (-C=C-, arom.), 1284 (C-N). [𝛼]589
20  = -6.9 (c 0.12, CHCl3). TLC: Rf 
(PE/EtOAc, 1:1) = 0.60.  
 
Methyl 5-((R)-3-(((R)-tert-Butylsulfinyl)amino)-3-cyclohexylprop-1-yn-1-
yl)thiophene-2-carboxylate (50d). A solution of D-cyclohexylglycine analogous 
propargylamide 6e (100.7 mg, 417.0 mol, 1.0 eq) and thiophene derivative 48a 
(138.3 mg, 625.4 mol, 1.5 eq) in a mixture of THF (2 mL) and piperidine (0.6 mL) was 
thoroughly degassed. The catalyst PdCl2(PPh3)2 (2 mg, 4.8 mol, 1 mol%) and CuI (3 mg, 
16 mol, 3 mol%) was added under argon atmosphere and the reaction mixture was stirred 
for 5 h at ambient temperature. After complete conversion of the propargylamide (checked 
by TLC), the reaction mixture was diluted with an aqueous NH4Cl solution (halfsaturated, 
8 mL) and neutralized with aqueous HCl (1 M, 3-5 mL). The mixture was extracted with 
Et2O (4 x 10 mL) and the combined organic layers were dried over MgSO4. After 
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evaporation of the solvent, crude product 50c was purified by column chromatography 
(PE/EtOAc, 1:1).  
Colorless, crystalline solid. Yield: 36.6 mg, 95.9 mol, 23 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.62 (d, 3J = 3.9 Hz, 1H, thiophene-2-H), 
7.12 (d, 3J = 3.9 Hz, 1H, thiophene-3-H), 4.06 (d br., 3J = 
6.2 Hz, 1H, CH), 3.87 (s, 3H, CO2CH3), 1.91-1.84 (m, 2H, cy-
H), 1.83-1.74 (m, 2H, cy-H), 1.73-1.62 (m, 2H, cy-H), 1.29 (s, 
9H, C(CH3)3), 1.26-1.02 (m, 5H, cy-H). 
13C NMR (126 MHz, Chloroform-d) δ = 162.1 
(thiophene-CO2CH3), 133.9 (thiophene-C-5), 133.3 (thiophene-C-4), 132.7 (thiophene-C-
2), 129.1 (thiophene-C-3), 94.1 (CHC≡C-thiophene), 78.8 (CHC≡C-thiophene), 57.6 
(SC(CH3)3), 55.1 (thiophene-CO2CH3), 52.5 (CHcy), 43.6 (cy-C-1), 29.6 (cy-C-2), 28.9 
(cy-C-6), 26.3 (cy-C-4), 25.9 (cy-C-5), 25.8 (cy-C-3), 22.8 (SC(CH3)3). C19H27NO3S2 
(381.55 g mol-1). MS(ESI): m/z = 404.1 (calcd. 404.13 [C19H27NO3S2 + Na]
+). [𝛼]589
21  
= -11.3 (c 0.40, MeOH). IR(ATR): 𝜈[cm-1] = 2927 (cy, CH2), 2844 (CH3), 1711 (CO2Me), 
1448 (HNS=O), 1258 (ar, C=C), 1173 (ar, C=C), 1097 (ar, C=C).  
 
5-((R)-3-(((R)-tert-Butylsulfinyl)amino)-4-methylpent-1-yn-1-yl)thiophene-2-
carboxylic Acid (50e). A mixture of D-valine analogous propargylamide 6b (57.3 mg, 
285 mol, 1.0 eq) and iodo thiophene derivative 48c (81.0 mg, 318 mol, 1.1 eq) was 
dissolved in a mixture of THF/piperidine (0.63 mL, 4:1) under argon atmosphere. After 
thoroughly degassing the reaction solution, the solid catalysts PdCl2(PPh3)2 (1.7 mg, 
2.4 mol, 0.8 mol%) and CuI (0.9 mg, 5 mol, 2 mol%) were added in one portion under 
argon atmosphere. The brown solution was stirred 15 h at ambient temperature. 
Precipitation of a colorless solid could be observed. The volatile parts of the mixture were 
evaporated under reduced pressure and peptidomimetic 50e was isolated by preparative 
HPLC.  
Colorless solid. Yield: 46.5 mg, 142 mol, 50 %. 1H NMR (300 MHz, Chloroform-d) δ = 
9.39 (s, 1H, CO2H), 7.42 (d, 
3J = 3.9 Hz, 1H, thiophene-3-H), 
7.00 (d, 3J = 3.9 Hz, 1H, thiophene-4-H), 5.06 (d, 3J = 8.6 Hz, 
1H, CHNH), 4.03 (dd, 3J = 8.5 Hz, 3J = 5.5 Hz, 1H, CH), 1.93 
(m, 1H, CHCH(CH3)2), 1.31 (s, 9H, SC(CH3)3), 1.04 (d, 
3J = 6.7 Hz, 3H, CHCH(CH3)2), 
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1.01 (d, 3J = 6.8 Hz, 3H, CHCH(CH3)2). 
13C NMR (151 MHz, Chloroform-d) δ = 164.2 
(CO2H), 135.8 (thiophene-C-5), 133.2 (thiophene-C-4), 132.9 (thiophene-C-2), 129.4 
(thiophene-C-3), 93.7 (CHC≡C-thiophene), 79.0 (CHC≡C-thiophene), 57.7 (SC(CH3)3), 
56.4 (CH), 35.0 (CHCH(CH3)2), 23.3 (SC(CH3)3), 19.1 (CHCH(CH3)2), 18.4 
(CHCH(CH3)2). C15H21NO3S2 (327.46 g mol
-1). HRMS(ESI): m/z = 350.08647 (calcd. 
350.08551 [M+Na]+). [𝛼]589
22  = 50.3 (c 0.72, MeOH).  
 
IIX-3. f) Oligomerization to access Helix Mimetics (51-60) 
The preparation and charactierization of benzoate 51a has been detailedly reported in the 
master thesis [117].  
5-((S)-3-(((S)-tert-Butylsulfinyl)amino)-4-methylpent-1-yn-1-yl)nicotinate (51b). An aqueous 
solution of LiOH x H2O (61.5 mg, 1.47 mmol in 3.8 mL water, 1 M) was added dropwise 
to a solution of peptidomimetic 41a (159.7 mg, 480 mol, 1.0 eq) in MeOH (7.8 mL) at 
0 °C. The reaction mixture was stirred for 16 h at 0 °C. After 
complete consumption of 41a (checked by TLC), the pH was 
adjusted to 1-2 by adding aqueous HCl (1 M). The solution 
was extracted with CH2Cl2 (4 x 15 mL). The combined organic layers were washed with 
brine (5 mL), dried over Na2SO4, filtered and the solvent was evaporated under reduced 
pressure to give benzoate 51b (258.7 mg, 0.80 mmol) in pure form. Carboxylate 51b was 
directly used for the following dimerization reaction forming dimer 57b without further 
characterization.  
 
4-((R)-3-(((R)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-yl)benzoic Acid (52b). 
An aqueous solution of NaOH (185 mg, 4.63 mmol, 5.4 eq) was added dropwise to a 
solution of peptidomimetic (46e, 311 mg, 856 mol, 1.0 eq) in THF/EtOH (3:1, 8 mL). The 
reaction mixture was stirred overnight at rt, until the starting 
material was completely consumed (checked by TLC). The 
solvent was evaporated and the residue was diluted in water 
(50 mL). At 0 °C, the pH value was adjusted to 2-3 by adding 
an aqueous HCl solution (1 M), which lead to the formation of a colorless precipitate. The 
solution was extracted with CH2Cl2 (3 x 50 mL), and the combined organic layers were 
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washed with brine (20 mL) and dried over MgSO4. Evaporation of the solvent gave acid 
52b in pure form.  
Colorless, amorphous solid. Yield: 269 mg, 803 mol, 94 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.52 (d, 3J = 8.1 Hz, 2H, ar-2-H, ar-6-H), 7.16 (d, 3J = 8.1 Hz, 2H, ar-
3-H, ar-5-H), 4.88 (d, 3J = 9.0 Hz, 1H, CHNH), 4.21 (ddd, 3J = 9.0 Hz, 3J = 7.7 Hz, 3J = 
6.5 Hz, 1H, CH), 1.89 (m, 1H, CHCH2CH(CH3)2), 1.69 (dd, 
2J = 14.1 Hz, 3J = 7.7 Hz, 
3J = 4.6 Hz, 1H, CHCH2), 1.64 (dd, 
2J = 14.9 Hz, 3J = 6.5 Hz, 3J = 6.2 Hz, 1H, CHCH2), 
1.32 (s, 9H, SC(CH3)3), 0.96 (d, 
3J = 6.6 Hz, 3H, CHCH2CH(CH3)2), 0.95 (d, 
3J = 6.6 
Hz, 3H, CHCH2CH(CH3)2). 
13C NMR (126 MHz, Chloroform-d) δ = 168.4 (CO2H), 
131.6 (ar-C-3, ar-C-5), 130.1 (ar-C-1), 129.4 (ar-C-2, ar-C-6), 126.6 (ar-C-4), 91.4 
(CHC≡Car), 84.5 (CHC≡Car), 57.3 (SC(CH3)3), 48.9 (CH), 47.2 (CHCH2), 24.9 
(CHCH2CH(CH3)2), 23.1 (SC(CH3)3), 22.4 (CHCH2CH(CH3)2), 22.3 
(CHCH2CH(CH3)2). C18H25NO3S (335.46 g mol
-1). LCMS(ESI): tr = 10.0 min, m/z = 
336.240 (calcd. 336.1628 [M+H+]), 358.357 (calcd. 358.1447 [M+Na+]), 671.134 (calcd. 
671.3183 [2M+H+]). [𝛼]589
22  = -13.6 (c 0.124, TFE). X-ray crystal structure in 
Chapter IIX-3. n.  
 
5-((S)-3-(((S)-tert-Butylsulfinyl)amino)-4-methylpent-1-yn-1-yl)furan-2-
carboxylate (53a). An aqueous solution of LiOH x H2O (95.8 mg, 2.28 mmol, 3 eq in 
5.5 mL H2O, 1 M) was added dropwise to a solution of peptidomimetic 49a (248.2 mg, 
760 mol, 1.0 eq) in MeOH (11 mL) at 0 °C and the reaction 
mixture was stirred for 17 h at 0 °C. An HCl solution (1 M, ca. 
3.5 mL) was added to adjust the pH value to 5-6. The solution 
was extracted with Et2O (3 x 20 mL). The combined organic layers were washed with brine 
(10 mL) dried over MgSO4, the solvent evaporated under reduced pressure to give acid 53b 
in form of a slightly yellow, highly viscous oil, which was directly converted in the 
following dimerization reaction to form 59a (172.5 mg, 0.55 mg, 68 %).  
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(S)-5-(4-Methyl-3-((4-nitrophenyl)sulfonamido)pent-1-yn-1-yl)furan-2-
carboxylate (53b). An aqueous solution of LiOH (1 M, 1.0 mL, 1.0 mmol, 8 eq) was added 
dropwise to a solution of peptidomimetic 49b (53 mg, 131 mol, 1.0 eq) in MeOH (2 mL) 
at 0 °C and the reaction mixture was stirred for 11 h at 
0 °C. An HCl solution (1M, ca. 1 mL) was added to 
adjust the pH value to 1-2. The solution was extracted 
with Et2O (4 x 8 mL). The combined organic layers were 
dried over Na2SO4, the solvent evaporated under reduced pressure and the crude product 
was purified by preparative HPLC to isolate acid 53b in pure form.  
Slightly yellow, highly viscous oil. Yield: 35 mg, 89 mol, 68 %. 1H NMR (600 MHz, 
Methanol-d4) δ = 8.33 (d, 3J = 8.8 Hz, 2H, ar-2-H, ar-6-H), 8.14 (d, 3J = 8.8 Hz, 2H, ar-3-
H, ar-5-H), 7.05 (d, 3J = 3.5 Hz, 1H, furan-3-H), 6.42 (d, 3J = 3.5 Hz, 1H, furan-4-H), 4.14 
(d br., 3J = 6.5 Hz, 1H, CH), 1.96 (m, 1H, CHCH(CH3)2), 1.07 (d, 
3J = 6.8 Hz, 3H, 
CHCH(CH3)2), 1.06 (d, 
3J = 6.7 Hz, 3H, CHCH(CH3)2). 
13C NMR (151 MHz, 
Methanol-d4) δ = 160.6 (CO2H), 151.4 (ar-C-4), 148.0 (ar-C-1), 146.6 (furan-C-2), 140.0 
(furan-C-5), 129.9 (ar-C-3, ar-C-5), 125.2 (ar-C-2, ar-C-6), 119.3 (furan-C-3), 117.5 
(furan-C-4), 93.6 (CHC≡C-furan), 75.9 (CHC≡C-furan), 53.4 (CH), 34.8 
(CCH(CH3)2), 19.1 (CH(CH3)2), 18.8 (CH(CH3)2). C17H16N2O7S (392.38 g mol
-1).  
 
The preparation and characterization of amine 54a has been detailedly reported in the 
master thesis [117].  
Methyl (S)-5-(3-Amino-4-methylpent-1-yn-1-yl)nicotinate Hydrochloride (54b). 
Hydrogen chloride (4 M in 1,4-dioxane, 0.2 mL, 0.8 mmol, 3 eq) was added dropwise to a 
vigorously stirred solution of N-protected peptidomimetic 41a 
(87.8 mg, 260 mol, 1 eq) in MeOH (12 mL) at ambient 
temperature. After 6 h, the solvent was evaporated under 
reduced pressure. The residue was digerated with CH2Cl2 and the solvent was evaporated 
under reduced pressure again. The title compound was achieved as hydrochloride salt 54b 
(49.6 mg, 0.18 mmol, 70 %) in pure form. Amine 54b was directly used for the 
dimerization reaction to give 57b without further characterization.  
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Ethyl (S)-3-(3-Amino-4-methylpent-1-yn-1-yl)benzoate Hydrochloride (54c). 
Hydrochloric acid (4 M in 1,4-dioxane, 0.5 mL) was added dropwise to a stirred solution 
of N-protected peptidomimetic 40a (123 mg, 352 mol) in MeOH (25 mL) at 0 °C. After 
6 h, the solvent was evaporated at 40 °C. The residue was digerated with CH2Cl2 and the 
solvent was evaporated under reduced pressure again. The title compound was achieved as 
hydrochloride salt in pure form.  
Colorless, amorphous solid. Yield: quantitative. 1H NMR (300 MHz, Chloroform-d) δ = 
9.01  (s, 3H, CHNH3Cl), 8.04 (m, 1H, ar-2-H), 7.94 (dt, 3J = 
7.9 Hz, 4J = 1.5 Hz, 1H, ar-6-H), 7.64 (dt, 3J = 7.7 Hz, 4J = 
1.4 Hz, 1H, ar-4-H), 7.29 (t, 3J = 7.8 Hz, 1H, ar-5-H), 4.34 (q, 
3J = 7.1 Hz, 2H, CO2CH2CH3), 4.14 (d, 
3J = 5.2 Hz, 1H, CHCH(CH3)2), 2.35 (m, 1H, 
CHCH(CH3)2), 1.37 (t, 
3J = 7.1 Hz, 3H, CO2CH2CH3), 1.16 (d, 
3J = 6.6 Hz, 3H, 
CHCH(CH3)2), 1.10 (d, 
3J = 6.7 Hz, 3H, CHCH(CH3)2). C15H20ClNO2 
(281.78 g mol-1).  
 
(R)-3-(3-Amino-3-(perfluorophenyl)prop-1-yn-1-yl)-N-(3,5-difluorobenzyl)benzamid 
Hydrochloride (54d). Hydrochloric acid (4 M in dioxane, 0.2 mL) was added dropwise to 
an ice-cold solution of the N-protected peptidomimetic 40h (571 mg, 215 mol) in MeOH 
(15 mL). After 5 h, the organic solvent was evaporated at 40 °C. The residue was 
resuspended with CH2Cl2 and then dried under fine vacuum.  
Pale yellow solid. Yield: 108 mg, 215 mol, quantitative. 1H NMR (300 MHz, Methanol-
d4) δ = 8.01 (t, 4J = 1.8 Hz, 1H, ar-2-H), 7.93 (dt, 3J 
= 7.9 Hz, 4J = 1.5 Hz, 1H, ar-6-H), 7.69 (dt, 3J = 
7.8 Hz, 4J = 1.4 Hz, 1H, ar-4-H), 7.54 (t, 3J = 7.8 Hz, 
1H, ar-5-H), 6.97 (dd, 3JHF = 6.3 Hz, 
4JHH = 2.2 Hz, 
1H, F2Ph-2-H), 6.92 (dd, 
3JHF = 6.3 Hz, 
4JHH = 
2.2 Hz, 1H, F2Ph-6-H), 6.84 (tt, 
3JHF = 9.1 Hz, 
4JHH = 2.4 Hz, 1H, F2Ph-4-H), 6.01 (m, 1H, 
CH), 4.56 (s, 2H, CONHCH2PhF2). 
19F NMR (282 MHz, Methanol-d4) δ = -111.9 (dd, 
3JFH = 9.0 Hz, 
3JFH = 8.5 Hz, F5Ph-3-F, F5Ph-5-F), -142.3 (dt, 
3JFF = 16.9 Hz, 
4JFF = 2.8 Hz, 
F5Ph-2-F, F5Ph-6-F), -153.4 (t, 
3JFF = 20.2 Hz, 1F, F5Ph-4-F), -163.1 (dd, 
3JFF = 20.0 Hz, 
3JFF = 13.3 Hz, F5Ph-3-F, F5Ph-5-F). 
13C NMR (75 MHz, Methanol-d4) δ = 168.8 (CONH), 
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164.6 (dd, 1JCF = 247.3 Hz, 
3JCF = 12.8 Hz, F2Ph-C-3, F2Ph-C-5), 144.8 (t, 
3JCF = 8.8 Hz, 
F2Ph-C-1), 136.0 (ar-C-1), 135.9 (ar-C-6), 132.1 (ar-C-2), 130.3 (ar-C-5), 129.6 (ar-C-4), 
122.5 (ar-C-3), 111.2 (d, 2JCF = 25.3 Hz, F2Ph-C-2, F2Ph-C-6), 103.23 (t, 
2JCF = 25.8 Hz, 
F2Ph-C-4), 88.2 (CHC≡C-ar), 81.6 (CHC≡C-ar), 43.8 (CHC6F5), 37.6 
(CONHCH2PhF2). C23H14ClF7N2O (502.82 g mol
-1).  
 
Ethyl (R)-4-(3-Amino-5-methylhex-1-yn-1-yl)benzoate Hydrochloride (55b).  
Hydrochloride (4 M in dioxane, 0.4 mL) was added dropwise to an ice-cold solution of the 
N-protected peptidomimetic 46e (399 mg, 1.05 mmol, 1.0 eq) in MeOH (15 mL). After 5 h, 
the organic solvent was evaporated at 40 °C. The residue was digerated with CH2Cl2 and 
then dried under fine vacuum.  
Colorless solid. Yield: 289 mg, 977 mol, 93 %. 1H NMR (500 MHz, DMSO-d6) δ = 8.81 
(s, 3H, CNH3Cl), 7.98 (d, 3J = 8.4 Hz, 2H, ar-2-H, ar-6-H), 
7.60 (d, 3J = 8.4 Hz, 2H, ar-3-H, ar-5-H), 4.35 (ddd, 3J = 
6.5 Hz, 3J = 5.7 Hz, 3J = 3.9 Hz, 1H, CH), 4.32 (q, 3J = 
7.1 Hz, 2H, CO2CH2CH3), 1.87 (m, 1H, 
CHCH2CH(CH3)2), 1.68-1.79 (m, 2H, 
CHCH2CH(CH3)2), 1.32 (t, 
3J = 7.1 Hz, 3H, CO2CH2CH3), 0.97 (d, 
3J = 6.6 Hz, 3H, 
CHCH2CH(CH3)2), 0.93 (d, 
3J = 6.5 Hz, 3H, CHCH2CH(CH3)2). 
13C NMR 
(126 MHz, DMSO-d6) δ = 165.0 (CO2CH2CH3), 131.8 (ar-C-3, ar-C-5), 130.1 (ar-C-1), 
129.5 (ar-C-2, ar-C-6), 125.8 (ar-C-4), 88.5 (CHC≡Car), 85.0 (CHC≡Car), 61.1 
(CO2CH2CH3), 41.5 (CHCH2), 41.2 (CH), 24.7 (CHCH2CH(CH3)2), 22.9 
(CHCH2CH(CH3)2), 21.3 (CHCH2CH(CH3)2), 14.1 (CO2CH2CH3). C16H22ClNO2 
(295.81 g mol-1).  
 
Methyl (S)-5-(3-Amino-4-methylpent-1-yn-1-yl)furan-2-carboxylate 
Hydrochloride (56a). Hydrochloric acid (4 M in dioxane, 0.1 mL, 40 mol, 3 eq) was 
added dropwise to a solution of peptidomimetic 49a (47.2 mg, 
145 mol) in MeOH (6 mL). After stirring for 20 h at rt, the 
solvent was evaporated to yield the hydrochloride salt of 
peptidomimetic 56a quantitatively in form of a faintly yellow solid (37.4 mg, 145 mol, 
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quantitative), which was directly converted to compound 49b without further 
characterization.  
 
Methyl (R)-5-(3-Amino-5-methylhex-1-yn-1-yl)thiophene-2-carboxylate 
trifluoroacetate (56b). HCl (4 M in dioxane, 0.2 mL) was added dropwise to a solution of 
peptidomimetic 50c (24 mg, 70 mol, 1.0 eq) in MeOH (5 mL) at 0 °C. The reaction 
mixture was stirred for 24 h at ambient temperature. After 
complete consumption of 50c (checked by TLC), the solvent 
was evaporated under reduced pressure. The crude product 
was suspended in CH2Cl2 and volatile sideproducts were 
coevaporated under reduced pressure (3 x 10 mL). The crude amine 56b was purified by 
preparative HPLC.  
Colorless crystalline solid. Yield: quantitative. 1H NMR (300 MHz, Chloroform-d) δ = 
8.37 (s, 3H, CHNH3), 7.59 (d, 3J = 3.9 Hz, 1H, thiophene-3-H), 7.16 (d, 3J = 3.9 Hz, 1H, 
thiophene-4-H), 4.17 (dd br., 3J = 9.7 Hz, 3J = 5.2 Hz, 1H, CH), 3.87 (s, 3H, CO2CH3), 
1.92-1.73 (m, 2H, CHCH2CH(CH3)2), 1.65 (m, 1H, CHCH2CH(CH3)2), 0.95 (d, 
3J = 
6.3 Hz, 3H, CHCH2CH(CH3)2), 0.91 (d, 
3J = 6.3 Hz, 3H, CHCH2CH(CH3)2). 
C15H18F3NO4S (365.37 g mol
-1). X-ray crystal structure in Chapter IIX-3. n.  
 
The preparation and charactierization of amine 57a has been detailedly reported in the 
master thesis [117].  
Methyl 5-((S)-3-(5-((S)-3-(((S)-tert-Butylsulfinyl)amino)-4-methylpent-1-yn-1-
yl)nicotinamido)-4-methylpent-1-yn-1-yl)nicotinate (57b). A mixture of amine 54b 
(49.6 mg, 180 mol, 1.0 eq), acid 51b (86.2 mg, 266 mol, 1.5 eq), HOAt (75.8 mg, 
560 mol, 3 eq) and HATU (237.7 mg, 630 mol, 4 eq) was combined under argon 
atmosphere and dissolved in DMF (3.5 mL). DIPEA (0.2 mL, 1.2 mmol) was added and 
the clear orange solution was stirred for 5 h at ambient temperature. After 5 h, CH2Cl2 
(3.5 mL), NH4Cl solution (5 ml, saturated aqueous) and bicarbonate (5 mL, saturated 
aqueous) was added. The aqueous phase was extracted with CH2Cl2 (3 x 15 mL). The 
combined organic layers were washed with aqueous HCl (1 M, 5 mL) and brine (5 mL). 
The organic solution was dried over Na2SO4 and the solvent was evaporated under reduced 
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pressure. The crude productwas purified by column chromatography (PE/EtOAc, 1:1) to 
give dimer 57b in pure form.  
Pale yellow, highly viscous oil. Yield: 56.1 mg, 105 mol, 58 %. 1H NMR (600 MHz, 
Chloroform-d): δ = 9.26 (s, 1H, nici-2-H), 9.13 
(s, 1H, nici+1-2-H), 8.89  (s, 1H, nici+1-6-H), 
8.68 (s, 1H, nici-6-H), 8.52 (s, 1H, nici+1-4-H), 
8.42 (s, 1H, nici-4-H), 8.04 (d, 3J = 7.2 Hz, 1H, 
Ci+1HNHCO), 5.09 (dd, 3J = 7.9 Hz, 3J = 6.8 Hz, 1H, Ci+1H), 4.12 (dd, 3J = 7.6 Hz, 3J = 
5.4 Hz, 1H, CiH), 3.99 (s, 1H, CiHNH), 3.98 (s, 3H, ari+1-3-CO2CH3), 2.18 (m, 1H, 
Ci+1HCH(CH3)2), 2.00 (m, 1H, C
iHCH(CH3)2), 1.29 (s, 9H, SC(CH3)3), 1.14 (d, 
3J = 
6.6 Hz, 3H, Ci+1HCH(CH3)2), 1.11 (d, 
3J = 6.7 Hz, 3H, Ci+1HCH(CH3)2), 1.05 (d, 
3J = 
6.6 Hz, 6H, CiHCH(CH3)2). 13C NMR (151 MHz, Chloroform-d): δ = 163.9 (nici+1-3-
CO2CH3), 162.3 (nic
i-3-CONH), 152.8 (nici+1-C-6), 149.7 (nici-C-6), 146.8 (nici+1-C-2), 
143.8 (nici-C-2), 142.3 (nici-C-3), 42.1 (nici-C-4), 131.4 (nici+1-C-3), 127.3 (nici+1-C-4), 
121.8 (nici-C-5), 121.7 (nici+1-C-5), 95.6 (CiHC≡Car), 93.6 (Ci+1HC≡Car), 79.8 
(Ci+1HC≡Car), 79.0 (Ci+1HC≡Car), 57.7 (SOC(CH3)3), 55.9 (CiH), 53.2 (nici+1-3-
CO2CH3), 49.0 (Ci+1H), 34.4 (C
iHCH(CH3)2), 33.1 (C
i+1HCH(CH3)2), 22.8 
(SOC(CH3)3), 19.3 (C
i+1HCH(CH3)2), 18.9 (C
iHCH(CH3)2), 18.5 (C
iHCH(CH3)2), 18.4 
(Ci+1HCH(CH3)2). C29H36N4O4S (536.69 g mol
-1). MS(ESI): m/z = 537.7 (calcd. 537.2530 
[M+H]+), 559.9 (calcd. 559.2349 [M+Na]+). [α]589
24   = + 6.06 (c 0.34, CHCl3).  
 
4-((S)-3-(4-((S)-3-((tert-Butoxycarbonyl)amino)-4-methylpent-1-yn-1-yl)benzamido)-
4-methylpent-1-yn-1-yl)benzoate (58a). Boc2O (56.1 mg, 257 mol, 2.0 eq) was added 
to a vigorously stirred solution of amine 54c (34.4 mg, 128 mol 1.0 eq) in aqueous 
bicarbonate/THF (1:1, 5 mL). The solution was stirred overnight at ambient temperature. 
After complete conversion of amine 54c (checked by TLC), imidazole (350 mg, 514 mol, 
4 eq) was added to the reaction mixture and the now clear solution was stirred for another 
2 h at rt. The mixture was diluted with Et2O (10 mL) and aqueous KHSO4 (5 %, 10 mL). 
The phases were separated and the aqueous layer was extracted with Et2O (2 x 10 mL). The 
combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and 
the solvent was evaporated to achieve Methyl (S)-4-(3-((tert-Butoxycarbonyl)amino)-4-
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methylpent-1-yn-1-yl)benzoate (39.5 mg, 119 mol, 93 %) in pure form. It was directly 
converted without further characterization.  
An aqueous solution of LiOH (1 M, 1.0 mL, 1.0 mmol) was added dropwise to a solution 
of Methyl (S)-4-(3-((tert-Butoxycarbonyl)amino)-4-methylpent-1-yn-1-yl)benzoate 
(39.5 mg, 119 mol, 1.0 eq) in MeOH (2 mL) at 0 °C and the reaction mixture was stirred 
for 6 h at 0 °C. An HCl solution (1M, ca. 5 mL) was added to adjust the pH value to 1-2. 
The solution was extracted with Et2O (4 x 10 mL). The combined organic layers were dried 
over Na2SO4, the solvent evaporated under reduced pressure and (S)-4-(3-((tert-
Butoxycarbonyl)amino)-4-methylpent-1-yn-1-yl)benzoate (33.6 mg, 106 mol 89 %) was 
achieved in pure form. It was directly reacted with amine 54c without further 
characterization.  
A mixture of amine 54c (51.1 mg, 191 mol, 1.8 eq), (S)-4-(3-((tert-
Butoxycarbonyl)amino)-4-methylpent-1-yn-1-yl)benzoate (33.6 mg, 106 mol 1.0 eq), 
HOAt (86.5 mg, 637 mol, 4 eq) and HATU (182.6 mg, 479 mol, 3 eq) was combined 
under argon atmosphere and dissolved in DMF (5 mL). DIPEA (0.25 mL, 1.47 mmol, 
9.2 eq) was added and the clear orange solution was stirred for 24 h at ambient temperature. 
After 24 h, CH2Cl2 (15 mL), NH4Cl solution (10 ml, saturated aqueous) and bicarbonate 
(10 mL, saturated aqueous) was added. The aqueous phase was extracted with CH2Cl2 (3 x 
15 mL). The combined organic layers were washed with aqueous HCl (1 M, 5 mL) and 
brine (5 mL). The organic solution was dried over Na2SO4 and the solvent was evaporated 
under reduced pressure. The crude productwas purified by column chromatography 
(PE/EtOAc, 1:1) to give Methyl 4-((S)-3-(4-((S)-3-((tert-Butoxycarbonyl)amino)-4-
methylpent-1-yn-1-yl)benzamido)-4-methylpent-1-yn-1-yl)benzoate (24.8 mg, 46.6 mol, 
44 %) in pure form.  
An aqueous solution of LiOH (1 M, 1.0 mL, 1.0 mmol) was added dropwise to a solution 
of Methyl 4-((S)-3-(4-((S)-3-((tert-Butoxycarbonyl)amino)-4-methylpent-1-yn-1-
yl)benzamido)-4-methylpent-1-yn-1-yl)benzoate (24.8 mg, 46.6 mol, 1.0 eq) in MeOH 
(2 mL) at 0 °C and the reaction mixture was stirred for 6 h at 0 °C. An HCl solution (1M, 
ca. 5 mL) was added to adjust the pH value to 1-2. The solution was extracted with Et2O 
(4 x 10 mL). The combined organic layers were dried over Na2SO4 and the solvent 
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evaporated under reduced pressure. Dimer 58a (15.4 mg, 29.8 mol 64 %) was isolated by 
preparative HPLC.  
Colorless, amorpheous solid. Yield: 15.4 mg, 29.8 mol, 19 %. 1H NMR (600 MHz, 
DMSO-d6) δ = 9.03 (d, 3J = 8.4 Hz, 1H, 
CONHCi+1H), 7.92 (d, 3J = 8.3 Hz, 2H, ari+1-2-
H, ari+1-6-H), 7.89 (d, 3J = 8.4 Hz, 2H, ari-2-H, 
ari-6-H), 7.55 (d, 3J = 8.4 Hz, 2H, ari+1-3-H, 
ari+1-5-H), 7.50 (d, 3J = 8.4 Hz, 2H, ari-3-H, ari-5-H), 7.43 (d, 3J = 9.0 Hz, 1H, 
O2CNHCH), 4.87 (dd, 
3J = 8.4 Hz, 3J = 7.8 Hz, 1H, Ci+1HCH(CH3)2), 4.30 (dd, 
3J = 
9.0 Hz, 3J = 7.7 Hz, 1H, CHCH(CH3)2), 2.06 (hd, 
3J = 6.8 Hz, 3J = 7.8 Hz, 1H, 
Ci+1HCH(CH3)2), 1.86 (hd, 
3J = 6.7 Hz, 3J = 7.7 Hz, 1H, CHCH(CH3)2), 1.40 (s, 9H, 
CO2C(CH3)3), 1.09 (d, 
3J = 6.7 Hz, 3H, Ci+1HCH(CH3)2), 1.00 (d, 
3J = 6.7 Hz, 6H, 
CHCH(CH3)2, C
i+1HCH(CH3)2), 0.95 (d, 
3J = 6.7 Hz, 3H, CHCH(CH3)2). 13C NMR 
(151 MHz, DMSO-d6) δ = 166.8 (CO2H), 165.2 (CONHCi+1), 155.2 (O2CNHC), 133.5 
(ari+1-C-4), 131.7 (ari+1-C-3, ari+1-C-5), 131.3 (ari-C-3, ari-C-5), 130.5 (ari+1-C-1), 129.6 
(ari+1-C-2, ari+1-C-6), 128.0 (ari-C-2, ari-C-6), 126.8 (ari+1-C-4), 125.5 (ari-C-1), 91.7 
(Ci+1HC≡C-ar), 91.5 (CHC≡C-ar), 82.3 (Ci+1HC≡C-ar), 82.1 (CHC≡C-ar), 78.4 
(CO2C(CH3)3), 48.9 (CHCH(CH3)2), 47.8 (Ci+1HCH(CH3)2), 33.0 
(Ci+1HCH(CH3)2), 32.8 (CHCH(CH3)2), 28.3 (CO2C(CH3)3), 19.3 
(Ci+1HCH(CH3)2), 19.1 (CHCH(CH3)2), 18.8 (C
i+1HCH(CH3)2), 18.6 
(CHCH(CH3)2). C31H36N2O5 (516.64 g mol
-1). MS(ESI): m/z = 517.8 (calcd. 517.2697 
[M+H]+), 539.7 (calcd. 539.6272 [M+Na]+). TLC: Rf (EtOAc/PE, 1:1) = 0.16.  
 
Ethyl 4-((R)-3-(4-((R)-3-(((R)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-
yl)benzamido)-5-methylhex-1-yn-1-yl)benzoate (58b). Under argon atmosphere, solid 
HOBt (8 mg, 60 mol, 0.3 eq) and TBTU (98 mg, 0.30 mmol, 1.5 eq) were added in one 
portion to a vigorously stirred solution of amine 55b (69 mg, 0.20 mmol, 1.0 eq) and acid 
52b (67 mg, 0.20 mmol, 1.0 eq) in a mixture of DMF/CH2Cl2 (1:1, 18 mL) and DIPEA 
(0.10 mL, 0.6 mmol, 3 eq). The reaction mixture was stirred over 18 h at ambient 
temperature. The solution was diluted with water (150 mL) and extracted with CH2Cl2 (5 
x 100 mL). The combined organic layers were washed with an aqueous solution of K2CO3 
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(saturated, 30 mL), HCl (1 M, 30 mL) and brine (15 mL). The solvent was evaporated and 
the crude product was purified by column chromatography (PE/EtOAc, 1:1) to yield dimer 
58b in pure form.  
Yellow, highly viscous oil. Yield: 98 mg, 
170 mol, 87 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.96 (d, 3J = 8.4 Hz, 2H, 
ar-2-H, ar-6-H), 7.72 (d, 3J = 8.5 Hz, 2H, ar-
2-H, ar-6-H), 7.46 (d, 3J = 8.1 Hz, 4H, ar-3-
H, ar-5-H, ar-3-H, ar-5-H), 6.44  (d, 3J = 8.5 Hz, 1H, CNHCO), 5.25 (ddd, 3J = 7.9 Hz, 3J 
= 7.1 Hz, 3J = 8.5 Hz, 1H, CH), 4.36 (q, 3J = 7.1 Hz, 2H, CHCOCH2CH3), 4.27 (ddd, 
3J = 7.5 Hz, 3J = 7.2 Hz, 3J = 5.4 Hz, 1H, CH), 3.41 (d, 3J = 7.4 Hz, 1H, 
CHNHSC(CH3)3), 1.95-1.85 (m, 2H, CHCH2CH(CH3)2), 1.75 (t, 
3J = 7.4 Hz, 2H, 
CHCH2), 1.68 (t, 3J = 7.4 Hz, 2H, CHCH2), 1.38 (t, 3J = 7.1 Hz, 3H, CHCOCH2CH3), 
1.24 (s, 9H, SC(CH3)3), 1.01 (d, 
3J = 6.6 Hz, 3H, CH(CH3)2), 0.99 (d, 
3J = 6.6 Hz, 3H, 
CH(CH3)2), 0.96 (d, 
3J = 6.7 Hz, 6H, CH(CH3)2). C34H44N2O4S (576.80 g mol
-1). TLC: Rf 
(PE/EtOAc, 1:1) = 0.33. [𝛼]589
21  = -2.61 (c 2.26, CHCl3).  
 
4-((R)-3-(4-((R)-3-(((R)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-yl)benzamido)-
5-methylhex-1-yn-1-yl)benzoate (58c). An aqueous solution of LiOH (1 M, 1.0 mL, 
1.0 mmol, 8 eq) was added dropwise to a solution of peptidomimetic 58b (33.8 mg, 
58.6 mol, 1.0 eq) in MeOH (2 mL) at 0 °C and the reaction mixture was stirred for 8 h at 
0 °C. An HCl solution (1 M, ca. 1 mL) was added to adjust the pH value to 1-2. The solution 
was extracted with Et2O (3 x 10 mL). The combined organic layers were dried over 
Na2SO4, the solvent evaporated under reduced pressure and the crude product was purified 
by preparative HPLC to isolate acid 58c in pure form.  
Highly viscous, colorless oil. Yield: 11.9 mg, 
21.7 mol, 36 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.91 (d, 3J = 8.4 Hz, 2H, 
ari+1-2-H, ari+1-6-H), 7.63 (d, 3J = 8.3 Hz, 2H, 
ar-2-H, ar-6-H), 7.43 (d, 3J = 8.5 Hz, 2H, 
ari+1-3-H, ari+1-5-H), 7.39 (d, 3J = 8.3 Hz, 2H, ar-3-H, ar-5-H), 6.36 (d br., 3J = 8.5 Hz, 
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1H, Ci+1HNHCO), 5.65 (s br., 1H, CO2H), 5.24 (ddd, 
3J = 8.5 Hz, 3J = 7.8 Hz, 3J = 7.4 Hz, 
1H, Ci+1HNCO), 4.58 (s br., 1H, CHNHBuS), 4.24 (ddd, 3J = 7.4 Hz, 3J = 7.6 Hz, 3J = 
5.4 Hz, 1H, CHNHBuS), 1.96-1.83 (m, 2H, CHCH2CH(CH3)2, CHCH2CH(CH3)2), 
1.74 (dd, 3J = 7.4 Hz, 3J = 7.6 Hz, 2H, Ci+1HCH2CH(CH3)2), 1.69 (dd, 
3J = 7.4 Hz, 3J = 
7.8 Hz, 2H, CHCH2CH(CH3)2), 1.29 (s, 9H, SC(CH3)3), 1.01 (d, 
3J = 6.5 Hz, 3H, 
CHCH2CH(CH3)2), 1.00 (d, 
3J = 6.6 Hz, 3H, CHCH2CH(CH3)2), 0.97 (d, 
3J = 6.5 Hz, 
3H, Ci+1HCH2CH(CH3)2), 0.96 (d, 
3J = 6.6 Hz, 3H, Ci+1HCH2CH(CH3)2). 
13C NMR 
(126 MHz, Chloroform-d) δ = 169.5 (ari+1-C-1-CO2H), 165.9 (ar-C-1-CONH), 133.3 (ar-
C-1), 132.0 (ar-C-3, ar-C-5), 131.7 (ari+1-C-3, ari+1-C-5), 130.0 (ari+1-C-2, ari+1-C-6), 
129.7 (ari+1-C-1), 127.7 (ari+1-C-4), 126.9 (ar-C-2, ar-C-6), 126.4 (ar-C-4), 92.0 
(Ci+1HC≡Car), 91.8 (CHC≡Car), 84.1 (CHC≡Car), 82.6 (Ci+1HC≡Car), 57.1 
(SC(CH3)3), 48.0 (CHCH2CH(CH3)3), 46.1 (C
i+1HCH2CH(CH3)3), 45.2 
(Ci+1HCH2CH(CH3)3), 41.2 (Ci+1HCH2CH(CH3)3), 25.5 (C
i+1HCH2CH(CH3)3), 25.0 
(CHCH2CH(CH3)3), 22.8 (SC(CH3)3), 22.4 (C
i+1HCH2CH(CH3)3), 22.4 
(Ci+1HCH2CH(CH3)3), 22.2 (CHCH2CH(CH3)3), 22.2 (CHCH2CH(CH3)3). 
C32H40N2O4S (548.74 g mol
-1). MS(ESI): m/z = 549.195 (calcd. 549.2782 [M+H]+). [𝛼]589
21  
= -19.13 (c 0.60, CHCl3).  
Ethyl 4-((R)-3-(4-((R)-3-Amino-5-methylhex-1-yn-1-yl)benzamido)-5-methylhex-1-
yn-1-yl)benzoate Hydrochloride (58d). Dimer 58b (197.0 mg, 341.6 mol) was 
dissolved in EtOH (11.5 mL). After addition of HCl (4 M in dioxane, 0.35 mL, 1.4 mmol, 
4 eq), the reaction mixture was stirred overnight at ambient temperature. The solvent was 
evaporated, digerated with CH2Cl2 and volatile parts were coevaporated. Colorless solid. 
Dissolved in an aqueous solution of K2CO3 (1M, 10 mL) and extracted with Et2O (3 x 
20 mL). Evaporation of the solvent achieved the free amine 58d.  
Colorless fluid. Yield: 141.9 mg, 300.2 mol, 88 %. 1H NMR (500 MHz, Chloroform-d) δ 
= 8.58 (s, 2H, CNH2), 7.91 (d, 3J = 8.3 Hz, 
2H, ari+1-2-H, ari+1-6-H), 7.60 (d, 3J = 8.1 Hz, 
2H, ari-2-H, ari-6-H), 7.41 (d, 3J = 8.3 Hz, 
2H, ari+1-3-H, ari+1-5-H), 7.31 (d, 3J = 8.1 Hz, 
2H, ari-3-H, ari-5-H), 7.02 (d, 3J = 8.5 Hz, 
1H, Ci+1NHCO), 5.25 (ddd, 3J = 7.9 Hz, 3J = 7.8 Hz, 3J = 5.4 Hz, 1H, CH), 4.35 (q, 3J = 
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7.1 Hz, 2H, CO2CH2CH3), 4.18 (ddd, 
3J = 10.0 Hz, 3J = 7.8 Hz, 3J = 5.3 Hz, 1H, Ci+1H), 
1.93-1.84 (m, 2H, CHCH2CH(CH3)2, C
i+1HCH2CH(CH3)2), 1.83 (m, 1H, 
CHCH2CH(CH3)2), 1.77 (t, 
3J = 7.4 Hz, 2H, Ci+1HCH2CH(CH3)2), 1.67 (m, 1H, 
CHCH2CH(CH3)2), 1.37 (t, 
3J = 7.1 Hz, 3H, CO2CH2CH3), 1.00 (d, 
3J = 6.6 Hz, 6H, 
Ci+1HCH2CH(CH3)2), 0.92 (d, 
3J = 6.4 Hz, 3H, CHCH2CH(CH3)2), 0.89 (d, 
3J = 6.4 Hz, 
3H, CHCH2CH(CH3)2). 13C NMR (126 MHz, Chloroform-d) δ = 166.3 (CNHCO), 
166.2 (ari+1CO2CH2CH3), 134.3 (ar
i-C-1), 132.1 (ari-C-3, ari-C-5), 131.7 (ari+1-C-3, ari+1-
C-5), 130.0 (ari+1-C-1), 129.5 (ari+1-C-2, ari+1-C-6), 127.4 (ari+1-C-4), 127.2 (ari-C-2, ari-
C-6), 124.8 (ari-C-4), 91.8 (CH-C≡C-ar), 86.6 (CH-C≡C-ar), 85.1 (Ci+1H-C≡C-ar), 
82.5 (Ci+1H-C≡C-ar), 61.3 (CO2CH2CH3), 45.0 (Ci+1HCH2CH(CH3)2), 42.8 (CH), 42.3 
(CHCH2CH(CH3)2), 41.2 (Ci+1H), 25.5 (CHCH2CH(CH3)2), 25.2 
(Ci+1HCH2CH(CH3)2), 22.9 (C
i+1HCH2CH(CH3)2), 22.9 (C
i+1HCH2CH(CH3)2), 22.3 
(CHCH2CH(CH3)2), 21.2 (CHCH2CH(CH3)2), 14.4 (CO2CH2CH3). C30H36N2O3 
(472.63 g mol-1). MS(ESI): m/z = 473.222 (calcd. 473.278 [M+H]+). [𝛼]589
21  = -2.81 (c 1.71, 
CHCl3). Replacement of EtOH by MeOH leads to a partial formation of methylester.  
 
Methyl 5-((S)-3-(5-((S)-3-(((S)-tert-Butylsulfinyl)amino)-4-methylpent-1-yn-1-
yl)furan-2-carboxamido)-4-methylpent-1-yn-1-yl)furan-2-carboxylate (59a). Under 
argon atmosphere, solid HOAt (150 mg, 1.1 mmol, 1 eq) and HATU (418 mg, 1.1 mmol, 
1 eq) were added in one portion to a vigorously stirred solution of amine 56a (247.3 mg, 
0.96 mmol, 2 eq) and acid 53a (172.5 mg, 0.55 mmol, 1.0 eq) in DMF (15 mL) and DIPEA 
(0.55 mL, 3.2 mmol, 3 eq). The reaction mixture was stirred over 16 h at ambient 
temperature. After 16 h, CH2Cl2 (50 mL) and an aqueous solution of bicarbonate (saturated, 
30 mL) was added. After separation of the phases, the organic phase was washed with a 
KHSO4 solution (5 % in water, 20 mL) and brine (8 mL). The solvent of the organic phase 
was evaporated under reduced pressure and the crude dipeptidomimetic 59a was purified 
by column chromatography (PE/EtOAc, 1:1).  
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Pale yellow, viscous oil, 100.3 mg, 195 mol, 35 %. de ≥ 99% (determined by 1H NMR 
integration: 4.93 (dd, 3J = 8.9 Hz, 3J = 6.3 Hz, 1H) and 4.00 ppm (dd, 3J = 7.2 Hz, 3J = 
5.4 Hz, 1H). 1H NMR (600 MHz, Chloroform-d): δ = 7.04 (d, 3J = 3.6 Hz, 1H, furani+1-3-
H), 7.02 (d, 3J = 3.6 Hz, 1H, furani-3-H), 6.90 (d, 3J 
= 9.0 Hz, 1H, Ci+1HNH), 6.52 (d, 3J = 3.7 Hz, 1H, 
furani+1-4-H), 6.52 (d, 3J = 3.7 Hz, 1H, furani-4-H), 
4.93 (dd, 3J = 8.9 Hz, 3J = 6.3 Hz, 1H, 
Ci+1HCi+1H(CH3)2), 4.00 (dd, 
3J = 7.2 Hz, 3J = 
5.4 Hz, 1H, CiHCiH(CH3)2), 3.78 (s, 3H, furan
i+1-
2-CO2CH3), 3.59 (d, 
3J = 7.6 Hz, 1H, CiHNH), 2.01 (m, 1H, Ci+1HCi+1H(CH3)2), 1.92 
(m, 1H, CiHCiH(CH3)2), 1.14 (s, 9H, SC(CH3)3), 1.00 (d, 
3J = 6.7 Hz, 3H, 
Ci+1HCi+1H(CH3)2), 0.97 (d, 
3J = 6.8 Hz, 3H, Ci+1HCi+1H(CH3)2), 0.95 (d, 
3J = 6.7 Hz, 
6H, CiHCiH(CH3)2). 
13C NMR (151 MHz, Chloroform-d): δ = 158.2 (furani+1-2-
CO2CH3), 156.6 (furan
i-2-CONH) 147.1 (furani-C-2), 144.2 (furani+1-C-2), 139.6 
(furani+1-C-5), 137.7 (furani-C-5), 118.6 (furani+1-C-3), 117.3 (furani-C-3), 116.6 (furani+1-
C-4), 115.7 (furani-C-4), 93.8 (CiHC≡C-furani), 93.4 (Ci+1HC≡C-furani+1), 74.9 
(CiHC≡C-furani), 73.4 (Ci+1HC≡C-furani+1), 56.4 (SC(CH3)3), 54.4 (CiHCiH(CH3)2), 
52.0 (furani+1-2-CO2CH3), 47.4 (Ci+1HC
i+1H(CH3)2), 33.9 (C
iHCiH(CH3)2), 33.1 
(Ci+1HCi+1H(CH3)2), 22.5 (SC(CH3)3), 18.9 (C
iHCiH(CH3)2, C
i+1HCi+1H(CH3)2), 
18.2 (Ci+1HCi+1H(CH3)2), 17.8 (C
i+1HCi+1H(CH3)2). C27H34N2O6S (514.64 g mol
-1). 
MS(ESI): m/z = 515.6 (calcd. 515.22 [M+H]+), 537.7 (calcd. 537.20 [M+Na]+). TLC: Rf 
(PE/EtOAc, 1:1) = 0.38.  
 
5-((S)-3-(5-((S)-3-((tert-Butoxycarbonyl)amino)-4-methylpent-1-yn-1-yl)furan-2-
carboxamido)-4-methylpent-1-yn-1-yl)furan-2-carboxylate (59b). An aqueous solution 
of LiOH (1 M, 5.0 mL, 5.0 mmol) was added dropwise to a solution of dimer 59a (24.8 mg, 
46.6 mol, 1.0 eq) in MeOH (10 mL) at 0 °C and the reaction mixture was stirred for 6 h 
at 0 °C. An aqueous KHSO4 solution (5 %, ca. 10 mL) was added to adjust the pH value to 
1-2. The solution was extracted with Et2O (4 x 10 mL). The combined organic layers were 
dried over Na2SO4 and the solvent evaporated under reduced pressure. Dimer 59b 
(15.4 mg, 29.8 mol 64 %) was isolated by preparative HPLC.  
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Colorless, highly viscous oil. Yield: 17.1 mg, 
34.5 mmol, 34 %. 1H NMR (600 MHz, DMSO-d6) δ 
= 9.07 (d, 3J = 8.5 Hz, 1H, CONHCi+1H), 7.49 (d, 3J 
= 8.9 Hz, 1H, CONHCH), 7.24 (d, 3J = 3.6 Hz, 1H, 
furani-3-H), 7.23 (d, 3J = 3.6 Hz, 1H, furani+1-3-H), 
6.92 (d, 3J = 3.6 Hz, 1H, furani+1-4-H), 6.88 (d, 3J = 
3.6 Hz, 1H, furani-4-H), 4.77 (dd, 3J = 8.2 Hz, 3J = 6.8 Hz, 1H, Ci+1H), 4.32 (dd, 3J = 
8.0 Hz, 3J = 6.5 Hz, 1H, CH), 2.05 (m, 1H, Ci+1HCH(CH3)2), 1.86 (dh, 
3J = 7.6 Hz, 3J 
= 6.8 Hz, 1H, CHCH(CH3)2), 1.39 (s, 9H, CO2C(CH3)3), 1.05 (d, 
3J = 6.7 Hz, 3H, 
Ci+1HCH(CH3)2), 0.98 (d, 
3J = 6.7 Hz, 3H, CHCH(CH3)2), 0.95 (d, 
3J = 6.7 Hz, 3H, 
Ci+1HCH(CH3)2), 0.93 (d, 
3J = 6.9 Hz, 3H, CHCH(CH3)2). 13C NMR (151 MHz, 
DMSO-d6) δ = 158.7 (CO2H), 156.5 (CONH), 155.2 (NHCO2C(CH3)3), 147.3 (furani-C-
2), 145.2 (furani+1-C-2), 138.5 (furani+1-C-5), 137.4 (furani-C-5), 118.7 (furani+1-C-3), 
117.3 (furani+1-C-4), 117.1 (furani-C-4), 115.4 (furani-C-3), 95.3 (CHC≡C-furan), 94.8 
(Ci+1HC≡C-furan), 78.6 (CO2C(CH3)3), 72.6 (CHC≡C-furan), 72.6 (Ci+1HC≡C-furan), 
49.0 (CHCH(CH3)2), 47.2 (Ci+1HCH(CH3)2), 32.7 (CHCH(CH3)2), 32.4 
(Ci+1HCH(CH3)2), 28.3 (CO2C(CH3)3), 19.1 (C
i+1HCH(CH3)2), 19.0 (CHCH(CH3)2, 
Ci+1HCH(CH3)2), 18.7 (CHCH(CH3)2). C27H32N2O7 (496.56 g mol
-1). MS(MALDI): 
m/z = 497.7 (calcd. 497.2282 [M+H]+), 519.8 (calcd. 519.2102 [M+Na]+). TLC: Rf 
(PE/EtOAc, 1:1) = 0.2.  
 
The dimerization of dimer 57a giving tetramer 60 has been reported in detail in the master 
thesis [117].  
 
IIX-3. g) Triazole-Based Peptidomimetics (61-63) 
Methyl (S)-2-Azido-3-phenylpropanoate (61). The synthesis of the phenylalanine-based 
azide 61 was performed as reported by Ri-Bai et al. [234]: Trifluormethanesulfonic 
anhydride (0.36 mL, 604 mg, 2.14 mmol, 1.5 eq) was added to a vigorously stirred solution 
of NaN3 (140.4 mg, 2.160 mmol, 1.5 eq) in CH3CN (5.5 mL). The reaction mixture was 
stirred for 2 h at room temperature, before methyl (S)-phenylalaninate hydrochloride 
(300 mg, 1.391 mmol, 1.0 eq) was added in one portion. After another 2 h, the starting 
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material was consumed completely (checked by TLC) and an aqueous solution of KHSO4 
(5 %, 30 mL) was added. The mixture was extracted with CH2Cl2 (3 x 30 mL), the organic 
layers were combined, dried over Na2SO4 and filtered. After evaporation of the solvent, 
azide 61 was adsorbed on silica and purified by filtration through a short column of silica 
gel (PE/EtOAc, 10:1).  
Pale green oil. Yield: 129.1 mg, 629 mol, 45 % (Lit: 95 % [234]). 1H NMR (500 MHz, 
Chloroform-d) δ = 7.32 (t, 3J = 7.7 Hz, 2H, ar-3-H, ar-5-H), 7.26 (t, 3J = 
7.0 Hz, 1H, ar-4-H), 7.22 (d, 3J = 7.6 Hz, 2H, ar-2-H, ar-6-H), 4.07 (dd, 3J = 
8.8 Hz, 3J = 5.5 Hz, 1H, N3CHCH2Ph), 3.77 (s, 3H, CO2CH3), 3.18 (dd, 
2J 
= 13.9 Hz, 3J = 5.5 Hz, 1H, N3CHCH2Ph), 3.00 (dd, 
2J = 13.9 Hz, 3J = 8.7 Hz, 1H, 
N3CHCH2Ph). 
13C NMR (126 MHz, Chloroform-d) δ = 170.6 (N3CHCO2CH3), 136.0 
(Ph-C-1), 129.3 (Ph-C-2, Ph-C-6), 128.8 (Ph-C-3, Ph-C-5), 127.4 (Ph-C-4), 63.4 
(N3CHCH2Ph), 52.8 (N3CHCO2CH3), 37.8 (N3CHCH2Ph). C10H11N3O2 
(205.22 g mol-1). TLC: Rf (PE/EtOAc, 4:1) = 0.77.  
 
Methyl (S)-2-(4-((S)-1-(((S)-tert-Butylsulfinyl)amino)-3-methylbutyl)-1H-1,2,3-
triazol-1-yl)-3-phenylpropanoate (62a). CuSO4 x 5 H2O (77 mg, 308 mol, 0.5 eq) and 
sodium ascorbate (123 mg, 621 mol, 1.0 eq) were added in one portion to a vigorously 
stirred solution of leucine analogous propargylamide 6c (132 mg, 613 mol, 1.0 eq) and 
phenylalanine analogous azide 61 (198 mg, 965 mol, 1.5 eq) in DMF/H2O (10:1, 6 mL). 
The reaction mixture was stirred for 18 h at ambient temperature, diluted with brine 
(50 mL) and extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were washed 
with H2O (50 mL), dried over MgSO4 and the solvent was removed under reduced pressure. 
Triazole 62b was isolated by column chromatography (PE/EtOAc, 1:1).  
Conversion: 62 % of propargylamine 6c. Colorless, highly 
viscous oil. Yield: 97.2 mg, 231 mol, 38 %. 1H NMR 
(500 MHz, Chloroform-d) δ = 7.70 (s, 1H, triazol-5-H), 7.25-
7.17 (m, 3H, Ph-3-H, Ph-4-H, Ph-5-H), 7.04 (d, 3J = 7.2 Hz, 
2H, Ph-2-H, Ph-6-H), 5.51 (ddd, 3J = 8.9 Hz, 3J = 6.4 Hz, 3J = 8.1 Hz, 1H, Phe-CH), 4.51 
(dd, 3J = 7.5 Hz, 3J = 7.4 Hz, 1H, Leu-CH), 3.74 (s, 3H, CO2CH3), 3.60 (d, 
3J = 8.1 Hz, 
1H, Phe-CHNH), 3.50 (dd, 2J = 14.0 Hz, 3J = 6.4 Hz, 1H, Phe-CHCH2Ph), 3.44 (dd, 
2J 
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= 13.8 Hz, 3J = 8.9 Hz, 1H, Phe-CHCH2), 1.83 (dd, 
3J = 7.5 Hz, 3J = 7.2 Hz, 2H, Leu-
CHCH2), 1.69-1.57 (m, 1H, Leu-CHCHCH(CH3)2), 1.21 (s, 9H, SC(CH3)3), 0.92 (d, 
3J = 6.7 Hz, 3H, CH(CH3)2), 0.90 (d, 
3J = 6.4 Hz, 3H, CH(CH3)2). 
13C NMR (126 MHz, 
Chloroform-d) δ = 168.8 (Phe-CHCO2CH3), 150.0 (triazol-C-4), 134.9 (Ph-C-1), 129.2 
(Ph-C-3, Ph-C-5), 128.9 (Ph-C-2, Ph-C-6), 127.6 (Ph-C-4), 122.2 (triazol-C-5), 64.2 (Phe-
CH), 56.4 (SC(CH3)3), 53.2 (CO2CH3), 51.4 (Leu-CH), 45.3 (Leu-CHCH2), 39.0 (Phe-
CHCH2), 24.3 (Leu-CHCHCH(CH3)2), 22.8 (SC(CH3)3), 22.6 (CH(CH3)2), 22.0 
(CH(CH3)2). C21H32N4O3S (420.57 g mol-1). LCMS(ESI): tr = 9.7 min, m/z = 421.22590 
(calcd. 421.22679 [M+H]+). TLC: Rf (PE/EtOAc, 1:1) = 0.19.  
 
tert-Butyl (S)-4-(((S)-tert-Butylsulfinyl)amino)-4-(1-((S)-1-methoxy-1-oxo-3-
phenylpropan-2-yl)-1H-1,2,3-triazol-4-yl)butanoate (62b). CuSO4 x 5 H2O (40 mg, 
160 mol, 0.5 eq) and sodium ascorbate (66 mg, 333 mol, 1.1 eq) were added in one 
portion to a vigorously stirred solution of glutamic acid analogous propargylamide 6l 
(86.6 mg, 301 mol, 1.0 eq) and phenylalanine analogous azide 61 (100 mg, 487 mol, 
1.6 eq) in DMF/H2O (10:1, 3 mL). The reaction mixture was stirred for 18 h at ambient 
temperature, diluted with brine (40 mL) and extracted with CH2Cl2 (3 x 40 mL). The 
combined organic layers were washed with water (40 mL), dried over MgSO4 and the 
solvent was evaporated under reduced pressure. The crude triazole 62b was purified by 
column chromatography (PE/EtOAc, 1:1, then CH2Cl2/MeOH, 10:1).  
Recovered propargylamide 6l (33.7 mg, 39 %), conversion: 
61 %. Colorless solid. Yield: 32.6 mg, 66.2 mol, 22 %. 
1H NMR (500 MHz, Chloroform-d) δ = 7.70 (s, 1H, triazol-5-
H), 7.35-7.09 (m, 3H, Ph-3-H, Ph-4-H, Ph-5-H), 7.02 (d, 3J = 
7.2 Hz, 2H, Ph-2-H, Ph-6-H), 5.51 (dd, 3J = 8.4 Hz, 3J = 6.3 Hz, 1H, Phe-CH), 4.53 (ddd, 
3J = 7.0 Hz, 3J = 5.6 Hz, 3J = 7.7 Hz, 1H, Glu-CH), 3.92 (d, 3J = 7.7 Hz, 1H, Glu-CHNH), 
3.73 (s, 3H, Phe-CHCO2CH3), 3.50 (dd, 
2J = 14.2 Hz, 3J = 6.4 Hz, 1H, Phe-CHCH2Ph), 
3.43 (dd, 2J = 14.2 Hz, 3J = 8.7 Hz, 1H, Phe-CHCH2Ph), 2.32-2.22 (m, 2H, Glu-
CHCH2), 2.20-2.11 (m, 2H, Glu-CHCH2CH2), 1.43 (s, 9H, Glu-
CHCH2CH2CO2C(CH3)3), 1.22 (s, 9H, SC(CH3)3). 
13C NMR (126 MHz, Chloroform-d) 
δ = 172.5 (Glu-CHCH2CH2CO2C(CH3)3), 168.7 (Phe-CHCO2CH3), 149.0 (triazol-C-
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4), 134.9 (Ph-C-1), 129.1 (Ph-C-3, Ph-C-5), 128.9 (Ph-C-2, Ph-C-6), 127.6 (Ph-C-4), 
122.3 (triazol-C-5), 80.7 (CO2C(CH3)3), 64.2 (Phe-CH), 56.4 (SC(CH3)3), 53.2 
(CO2CH3), 52.3 (Glu-CH), 38.9 (Phe-CHCH2Ph), 31.7 (Glu-CHCH2CH2), 31.3 
(Glu-CHCH2CH2), 28.2 (CO2C(CH3)3), 22.8 (SC(CH3)3). C24H36N4O5S 
(492.64 g mol-1). LCMS(ESI): tr = 9.8 min, m/z = 493.24740 (calcd. 493.24792 [M+H]+). 
TLC: Rf (PE/EtOAc, 1:1) = 0.33, Rf (CH2Cl2/MeOH, 10:1) = 0.70.  
 
Methyl (S)-2-(4-((S)-1-Amino-3-methylbutyl)-1H-1,2,3-triazol-1-yl)-3-
phenylpropanoate Trifluoroacetate (63a). A hydrochloride solution (4 M in dioxane, 
0.1 mL) was added dropwise to a solution of triazole 62a in MeOH (2.5 mL). After stirring 
the reaction mixture at room temperature overnight, the 
solvent was evaporated under reduced pressure at 40 °C. 
The colorless solid residue was dissolved in MeOH (1 mL) 
and purified by preparative HPLC. Colorless, amorpheous 
solid. Yield: 24.16 mg, 56.1 mol, 24 %. 1H NMR (500 MHz, DMSO-d6) δ = 8.39 (s, 3H, 
[CHNH3]+), 8.24 (s, 1H, triazol-5-H), 7.20-7.13 (m, 3H, Ph-3-H, Ph-4-H, Ph-5-H), 7.09 
(d, 3J = 6.5 Hz, 2H, Ph-2-H, Ph-6-H), 5.93 (dd, 2J = 11.0 Hz, 3J = 4.4 Hz, 1H, Phe-
CHCH2), 4.37 (dd br., 
3J = 9.9 Hz, 3J = 5.0 Hz, 1H, Leu-CHCH2), 3.72 (s, 3H, CO2CH3), 
3.58 (dd, 2J = 14.1 Hz, 3J = 4.5 Hz, 1H, Phe-CHCH2Ph), 3.46 (dd, 
2J = 14.1 Hz, 3J = 
11.5 Hz, 1H, Phe-CHCH2Ph), 1.78 (m, 1H, Leu-CHCH2), 1.62 (m, 1H, Leu-CHCH2), 
1.12 (m, 1H, Leu-CHCH2CH(CH3)2), 0.81 (d, 
3J = 6.8 Hz, 3H, CH(CH3)2), 0.76 (d, 
3J = 
6.3 Hz, 3H, CH(CH3)2). 
13C NMR (126 MHz, DMSO-d6) δ = 168.6 (Phe-CHCO2CH3), 
158.1 (q, 2JCF = 30.97 Hz, [CF3CO2]
-), 143.5 (triazol-C-4), 135.6 (Ph-C-1), 128.9 (Ph-C-
3, Ph-C-5), 128.3 (Ph-C-2, Ph-C-6), 126.9 (Ph-C-4), 124.3 (triazol-C-5), 117.3 (q, 1JCF = 
300.31 Hz, [CF3CO2]
-), 63.1 (Phe-CH), 53.0 (Phe-CHCO2CH3), 45.0 (Leu-CH), 41.8 
(Leu-CHCH2), 36.8 (Phe-CHCH2), 23.9 (Leu-CH(CH3)2), 22.9 (Leu-CH(CH3)2), 
21.2 (Leu-CH(CH3)2). C19H25F3N4O4 (430.63 g mol
-1). LCMS(ESI): tr = 6.0 min, m/z = 
317.2004 (calcd. 317.1972 [M+H]+), 339.1856 (calcd. 339.1791 [M+Na]+).  
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Gelation experiments with H-Leu-Phe-OMe analogue 63a.  
Buffer solution. 14.8 mL of KH2PO4 (907.8 mg in 100 mL H2O) + 85.2 mL of Na2HPO4 x 
2 H2O (1.4890 g in 100 mL H2O) -> 100 mL buffer at pH 7.4.  
Samples: 100 mg mL-1 (10 % w/v): 4.83 mg in 48.3 L buffer solution. 75 mg mL-1 (7.5 % 
w/v): 4.55 mg in 113.8 L buffer solution. 50 mg mL-1 (5 % w/v): 3.97 mg in 198.5 L 
buffer solution. 25 mg mL-1 (2.5 % w/v): 2.97 mg in 222.8 L buffer solution. 10 mg mL-
1 (1 % w/v): 7.15 mg in 715 L buffer solution.  
Procedure: 1) Vortex. 2) Sonication at 40 °C, 5 min. 3) store in fridge -20 °C, 30 min, then 
4 °C overnight. 4) 40 °C for 20 min. 5) -20 °C for 1 h and ice stored overnight at 4 °C. 
30 min rt. The procedure was repeated once with all samples, in which no hydrogelation 
had occurred. Results are visualized in picture EP2b. Hydrogelation only occurred at high 
concentrations. Minium gel concentration (MGC) was between 75 and 50 mg.  
Other solvents: All samples were prepared with a concentration of 10 mg mL-1 in varied 
solvents. Rhodamin B (10 L, 280 nM, 2.8 nmol) was added to each sample for 
visualization. Results are summed up in picture EP2c. Gel formation was observed in 
solutions of CH2Cl2 (MGC < 0.5 % w/v) and 
iPrOH (MGC < 0.5 % w/v).  
 
Picture EP2. Gelation experiments with superhydrogelinducing H -Leu-Phe-OMe mimetic 
63a . a) Visualization of amphiphilicity in the appropriate conformation for an alignment of 
polar- and nonpolar regions on one side, each. b) Photography of inverted -tube method. 
Samples in aqueous buffer solution at pH 7.4 are ordered in increasing dilution from left to 
right: 100 mg mL -1  hydrogel, 75 mg mL - 1 hydrogel, 50 mg mL - 1 precipitate, 25 mg mL - 1  
precipitate, 10 mg mL - 1  precipitate. c) Photography of inverted tube method with a 
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concentration of 10 mg mL- 1 in different solvents, ordered with increasing polarity from left 
to right: CH3CN precipitate, Et2O precipitate, CH2Cl2  hydrogel, CHCl3  solution, EtOAc 
suspension, MeOH solution, iPrOH hydrogel.  Samples have been visualized by addition of 
Rhodamin B (10 L, 280 nM, 2.8 nmol in each vial).  
 
tert-Butyl (S)-4-Amino-4-(1-((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)-1H-1,2,3-
triazol-4-yl)butanoate Trifluoroacetate (63b). A solution of hydrochloric acid (4 M in 
dioxane, 0.1 mL, 0.4 mmol) was added dropwise to a vigorously stirred, icecold solution 
of triazole 62b (97.2 mg, 231 mol) in MeOH (2.5 mL). The reaction mixture was stirred 
overnight at ambient temperature, before evaporating the solvent under reduced pressure. 
The crude amine 63b was diluted with MeOH and the residual solvent was coevaporated.  
Colorless solid. Yield: quantitative. 1H NMR (500 MHz, 
Methanol-d4) δ = 8.08 (s, 1H, triazol-5-H), 7.35-7.03 (m, 3H, 
Ph-3-H, Ph-4-H, Ph-5-H), 7.09 (d, 3J = 7.3 Hz, 2H, Ph-2-H, 
Ph-6-H), 5.81 (dd, 3J = 11.1 Hz, 3J = 4.9 Hz, 1H, Phe-CH), 
4.53 (dd br., 3J = 9.7 Hz, 3J = 5.3 Hz, 1H, Glu-CH), 3.79 (s, 
3H, CO2CH3), 3.67 (dd, 
2J = 14.3 Hz, 3J = 5.0 Hz, 1H, Phe-CHCCH2Ph), 3.52 (dd, 
2J = 
13.1 Hz, 3J = 11.5 Hz, 1H, Phe-CHCCH2Ph), 2.28-2.17 (m, 2H, Glu-
CHCH2CH2CO2C(CH3)3), 2.12-2.06 (m, 2H, Glu-CHCH2CH2CO2C(CH3)3), 1.45 (s, 
9H, Glu-CHCH2CH2CO2C(CH3)3). 
13C NMR (126 MHz, Methanol-d4) δ = 172.9 (Glu-
CHCH2CH2CO2C(CH3)3), 169.9 (Phe-CHCO2CH3), 143.7 (triazol-C-4), 136.8 (Ph-C-
1), 130.0 (Ph-C-3, Ph-C-5), 129.7 (Ph-C-2, Ph-C-6), 128.3 (Ph-C-4), 125.8 (triazol-C-5), 
82.2 (Glu-CHCH2CH2CO2C(CH3)3), 65.4 (Phe-CH), 53.6 (CO2CH3), 47.8 (Glu-CH), 
38.8 (Phe-CHCH2Ph), 31.8 (Glu-CHCH2CH2CO2), 29.5 (Glu-CHCH2CH2CO2), 
28.3 (Glu-CHCH2CH2CO2C(CH3)3). C20H29ClN4O4 (424.93 g mol-1). LCMS(ESI): 
tr(polar method) = 11.2 min, m/z = 389.2284 (calcd. 389.2183 [M-Cl+H]
+).  
 
(S)-4-Amino-4-(1-((S)-1-methoxycarbonyl-3-phenylpropan-2-yl)-1H-1,2,3-triazol-4-
yl)butanoic Acid (63c). Triazole 63b (231 mol) was dissolved in a mixture of 
TFA/TIPS/H2O (95:2.5:2.5, 2 mL) and stirred overnight at ambient temperature. After 
complete conversion (checked by LCMS), the crude amine 63c was precipitated with 
icecold Et2O (10 mL), centrifuged and isolated in form of a colorless solid, which was 
purified by preparative HPLC.  
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Colorless crystalline solid. Yield: 12.45 mg, 37.46 mol, 57 %. 
1H NMR (500 MHz, DMSO-d6) δ = 12.33 (s, 1H, 
Glu-CHCH2CH2CO2H), 8.44 (s, 3H, Glu-CHNH3
+), 8.26 (s, 
1H, triazol-5-H), 7.33-7.03 (m, 3H, Ph-3-H, Ph-4-H, Ph-5-H), 
7.09 (d, 3J = 7.2 Hz, 2H, Ph-2-H, Ph-6-H), 5.94 (dd, 3J = 11.2 Hz, 
3J = 4.9 Hz, 1H, Phe-CH), 4.44 (m, 1H, Glu-CH), 3.72 (s, 3H, Phe-CHCO2CH3), 3.59 
(dd, 2J = 14.3 Hz, 3J = 4.9 Hz, 1H, Phe-CHCH2Ph), 3.47 (dd, 
2J = 14.4 Hz, 3J = 10.9 Hz, 
1H, Phe-CHCH2Ph), 2.15-1.98 (m, 4H, Glu-CHCH2CH2CO2). 
13C NMR (126 MHz, 
DMSO-d6) δ = 173.3 (Glu-CHCH2CH2CO2H), 168.5 (Phe-CHCO2H), 142.9 (triazol-
C-4), 135.6 (Ph-C-1), 128.9 (Ph-C-3, Ph-C-5), 128.3 (Ph-C-2, Ph-C-6), 126.9 (Ph-C-4), 
124.3 (triazol-C-5), 63.2 (Phe-CH), 53.0 (Phe-CHCO2CH3), 45.8 (Glu-CH), 36.8 (Phe-
CHCH2), 29.3 (Glu-CHCH2CH2CO2), 28.2 (Glu-CHCH2CH2CO2). C16H20N4O4 
(332.36 g mol-1). LCMS(ESI): tr(polar method) = 333.1701 (calcd. 333.1557 [M+H]
+), 
355.1491 (calcd. 355.1377 [M+Na]+).  
 
 
 
Scheme EP1. Analytical chromatogram and mass spectra of aspartame analogue 63c to prove 
its purity.  
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4-Methoxybenzaldehyde (64) was purchased from Fisher Scientific.  
Methyl-2-(diethoxyphosphoryl)propanoate (65). The Michaelis-Arburzov reaction was 
performed following the description in the Organikum [235]: P(OEt)3 
(21.66 mL, 179 mmol) was added to a solution of methyl 2-
bromopropanoate (20.0 mL, 179 mmol) in dry toluene (300 mL) at 0 °C. The reaction 
mixture was heated for 3 d to 120 °C under reflux conditions. Afterwards, the solvent was 
evaporated and the crude product was isolated by distillation (p = 5.3 mbar, Tk = 125 °C).  
Colorless fluid. Yield: 12.93 g, 57.68 mmol, 32 %, dr = 1:1. 1H NMR (500 MHz, 
Chloroform-d) δ = 4.19-4.06 (m, 4H, POCH2CH3), 3.74 (s, 3H, CO2CH3), 3.03 (dq, 2JHP = 
23.5 Hz, 3JHH = 7.3 Hz, 1H, POCHCH3), 1.43 (dd, 
3JHP = 18.0 Hz, 
3JHH = 7.3 Hz, 3H, 
POCHCH3), 1.32 (td, 3JHH = 7.1 Hz, 
4JHP = 2.6 Hz, 6H, POCH2CH3).
 31P NMR (202 MHz, 
Chloroform-d) δ = 23.6. 13C NMR (126 MHz, Chloroform-d) δ = 170.4 (d, 2JCP = 4.8 Hz, 
CHCO2CH3), 62.8 (d, 
2JCP = 6.7 Hz, POCH2CH3), 52.6 (s, CO2CH3), 39.4 (d, 
1JCP = 
133.6 Hz, POCHCH3), 16.5 (d, 
3JCP = 4.9 Hz, POCH2CH3), 11.9 (d, 
2JCP = 6.3 Hz, 
POCH2CH3). C8H17O5P (224.19 g mol
-1). Tk = 125 °C (p = 5.3 mbar).  
 
Methyl (E)-3-(4-Methoxyphenyl)-2-methylacrylate (66). The preparation of 66 has been 
described before by Li Ze-Yu et al. under different conditions [236]. An nBuLi solution 
(1.6 M in hexanes, 4.1 mL, 6.6 mmol, 1.2 eq) was added dropwise to a solution of methyl-
2-(diethoxyphosphoryl)propanoate (1.5 g, 6.6 mmol, 1.2 eq) in THF (10 mL) at -78 °C. 
After 15 min stirring at -78 °C, 4-methoxy-benzaldehyde (0.70 mL, 5.5 mmol, 1.0 eq) was 
carefully added and the reaction mixture was stirred for another 15 min at -78 °C bevore 
warming up to rt. The slightly yellow suspension was stirred for 12 h at ambient 
temperature, then diluted with an aqueous NH4Cl solution (saturated, 10 mL) and extracted 
with Et2O (3 x 20 mL). The combined organic layers were washed with brine, dried over 
Na2SO4 and the solvent was evaporated under reduced pressure to give olefin 66 in pure 
form.  
Colorless fluid. Yield: 1.4 g, quantitative. 1H NMR (500 MHz, Chloroform-d) δ = 7.62 (s, 
1H, ar-CH=C(CH3)CO2CH3), 7.35 (d, 
3J = 8.1 Hz, 2H, ar-3-H, ar-
5-H), 6.89 (d, 3J = 8.8 Hz, 2H, ar-2-H, ar-6-H), 3.79 (s, 3H, ar-
IIX-3. h) Synthesis of Olefin Halides (64-72) 
192 
OCH3), 3.77 (s, 3H, ar-CH=C(CH3)CO2CH3), 2.10 (s, 3H, ar-CH=C(CH3)CO2CH3). 
13C NMR (126 MHz, Chloroform-d) δ = 169.4 (ar-CH=C(CH3)CO2CH3), 159.7 (ar-C-1), 
138.7 (ar-CH=C(CH3)CO2CH3), 131.5 (ar-C-3, ar-C-5), 128.4 (ar-CH=C(CH3)CO2CH3), 
126.0 (ar-C-4), 113.9 (ar-C-2, ar-C-6), 55.3 (ar-1-OCH3), 52.0 (ar-CH=C(CH3)CO2CH3), 
14.1 (ar-CH=C(CH3)CO2CH3). C12H14O3 (206.24 g mol-1).  
 
Methyl 2,3-Dibromo-3-(3-bromo-4-methoxyphenyl)-2-methylpropanoate (67). A 
solution of bromine (0.8 mL, 15.3 mmol, 2.0 eq) in CH2Cl2 (5 mL) 
was added dropwise to a solution of olefin 66 (1.58 g, 7.66 mmol, 
1.0 eq) in CH2Cl2 (20 mL) at -78 °C, until the brown color of the 
reaction mixture stopped vanishing. The purple solution was stirred for 2 h at -78 °C and 
then 30 min at ambient temperature. Water (20 mL) and an aqueous Na2SO3 solution was 
added until the the red color had completely disappeared. The phases were separated and 
the aqueous layer was extracted with EtOAc (3 x 15 mL). The combined organic layers 
were washed with brine (10 mL) dried over Na2SO4 and the solvent was evaporated under 
reduced pressure. The crude dibromide 67 was purified by column chromatography 
(PE/EtOAc, 25:1).  
Colorless, crystalline solid. Yield: 3.05 g, 6.86 mmol, 90 %. dr = 37:63. 1H NMR 
(500 MHz, Chloroform-d) δ = 7.66 (d, 4J = 2.4 Hz, 1H, ar-6-H), 7.40 (dd, 3J = 8.7 Hz, 4J = 
2.4 Hz, 1H, ar-4-H), 6.81 (d, 3J = 8.6 Hz, 1H, ar-3-H), 5.55 (s, 1H, ar-CHBr-C(Br)CH3), 
3.89 (s, 3H, ar-CHBr-C(Br)CH3), 3.76 (s, 3H, ar-2-OCH3), 2.02 (s, 3H, ar-CHBr-
C(Br)CH3). 13C NMR (126 MHz, Chloroform-d) δ = 169.1 (ar-CHBr-C(Br)CO2CH3), 
156.4 (ar-C-2), 134.7 (ar-C-6), 130.2 (ar-C-4), 129.7 (ar-C-5), 113.3 (ar-C-1), 111.2 (ar-
C-3), 64.8 (ar-CHBr-C(Br)CO2CH3), 59.3 (ar-CHBr-C(Br)CO2CH3), 56.4 (ar-2-OCH3), 
53.6 (ar-CHBr-C(Br)CO2CH3), 25.7 (ar-CHBr-C(Br)CH3). C12H13Br3O3 (444.95 g mol
-1). 
TLC: Rf (PE/EtOAc, 25:1) = 0.22. X-ray crystal structure in Chapter IIX-3. n.  
 
Methyl 3-Bromo-3-(3-bromo-4-methoxyphenyl)-2-methylacrylate (68). A solution of 
KOtBu (430 mg, 3.84 mmol, 1.5 eq) in dry THF (15 mL) was slowly added over a period 
of 30 min to a solution of dibromide 67 (927 mg, 2.54 mmol, 1.0 eq) in dry THF (25 mL) 
at -78 °C. The reaction mixture was stirred for 30 min at the same temperature before 
warming up to rt. After stirring the yellow suspension for 12 more hours at rt, water (10 mL) 
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and Na2SO3 (aq., sat., 5 mL) were added. The mixture was extracted with Et2O (3 x 10 mL), 
washed with brine (5 mL) and dried over Na2SO4. After evaporation of the solvent under 
reduced pressure, the crude E/Z mixture of 68 was separated by column chromatography 
(PE/EtOAc, 25:1). Yield: 163.4 mg, 450 mol, 41%, E/Z = 37:63.  
E-68: Colorless, highly viscous oil. Yield: 98.1 mg, 270 mol, 15 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.51 (d, 4J = 2.3 Hz, 1H, ar-6-H), 7.23 (dd, 3J = 8.5 Hz, 4J = 2.3 Hz, 1H, 
ar-4-H), 6.83 (d, 3J = 8.5 Hz, 1H, ar-3-H), 3.91 (s, 3H, ar-2-OCH3), 
3.52 (s, 3H, CO2CH3), 2.21 (d, 
4J = 1.7 Hz, 3H, BrC=CCH3). 
13C NMR (126 MHz, Chloroform-d) δ = 167.8 (CO2CH3), 156.1 (ar-
C-2), 134.3 (ar-C-), 133.2 (ar-C-), 131.4 (ar-C-), 131.0 (BrC=CCH3), 128.6 (ar-C-), 113.9 
(BrC=CCH3), 111.0 (ar-C-), 56.3 (ar-2-OCH3), 52.1 (CO2CH3), 21.6 (BrC=CCH3). 
C12H12Br2O3 (364.03 g mol
-1). 
Z-68: Colorless, highly viscous oil. Yield: 65.3 g, 180 mol, 26 %. 1H NMR (600 MHz, 
Chloroform-d) δ = 7.55 (d, 4J = 2.2 Hz, 1H, ar-2-H), 7.28 (d, 4J = 2.2 Hz, 1H, ar-6-H), 6.89 
(d, 3J = 8.6 Hz, 1H, ar-5-H), 3.92 (s, 3H, COCH3), 3.86 (s, 3H, 
CO2CH3), 1.90 (s, 3H, =CCH3). 
13C NMR (151 MHz, 
Chloroform-d) δ = 169.2 (CO2CH3), 156.3 (ar-C-4), 133.8 
(ar-C-2), 132.5 (ar-C-1), 132.1 (BrC=C(CH3)CO2), 129.4 (ar-C-6), 120.2 (BrC=CCH3), 
111.6 (ar-C-5), 56.5 (ar-2-COCH3), 52.5 (CO2CH3), 18.9 (BrC=CCH3). C12H12Br2O3 
(364.03 g mol-1). IR(ATR): 𝜈 ̃ [cm-1] = 2946 sh/m, 2838 w, 2366 w, 2337 w, 1714 s, 1590 
m, 1492 s, 1483 s, 1454 m, 1438 m, 1283 s, 1249 s, 1213 m, 1128 m, 1055 m, 1024 m, 964 
w, 916 w, 805 m, 761 m, 682 m. 
 
Methyl (S,E)-3-(3-Bromo-4-methoxyphenyl)-6-(((S)-tert-butylsulfinyl)amino)-2-
methylhept-2-en-4-ynoate (69). A solution of alanine analogous propargylamide 6a 
(50 mg, 270 mol, 1.0 eq) and vinylbromide E-68 (98.1 mg, 270 mol, 1.0 eq) in 
THF/piperidine (3:1, 0.66 mL) was thoroughly degassed by 
freeze pump thaw method. After adding the catalysts 
PdCl2(PPh3)2 (2 mg) and CuI (1 mg) to the solution, the reaction 
mixture was stirred 2 hours at rt and 2 more hours at 40 °C. 
Afterwards, the pale yellow solution was diluted with Et2O 
(10 mL), washed with NH4Cl solution (half concentrated, 6 mL) and aqueous HCl (1 M, 
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10 mL). The combined aqueous layers were extracted with Et2O (3 x 10 mL) and the 
combined organic layers were washed with brine (5 mL), dried over Na2SO4. After 
evaporation of the solvent under reduced pressure, the crude product was purified by 
column chromatography (EtOAc/PE, 1:1).  
Pale yellow, highly viscous oil. Yield: 6.2 mg, 14 mol, 5 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.48 (d, 4J = 2.2 Hz, 1H, ar-6-H), 7.23 (dd, 3J = 8.5 Hz, 4J = 2.2 Hz, 1H, 
ar-4-H), 6.83 (d, 3J = 8.5 Hz, 1H, ar-3-H), 4.40 (dq, 3J = 5.9 Hz, 3J = 6.8 Hz, 1H, CH), 
3.89 (s, 3H, ar-OCH3), 3.56 (s, 3H, CO2CH3), 3.37 (d, 
3J = 5.9 Hz, 1H, CNH), 2.25 (s, 
3H, C=CCH3), 1.52 (d, 3J = 6.8 Hz, 3H, CHCH3), 1.22 (s, 9H, SC(CH3)3). 
13C NMR 
(126 MHz, Chloroform-d) δ = 169.8 (CO2CH3), 155.8 (ar-C-2), 136.2 (ar-C=C-CO2CH3), 
132.9 (ar-C-6), 132.0 (ar-C=C-CO2CH3), 128.4 (ar-C-4), 126.2 (ar-C-5), 111.4 (ar-C-3), 
111.3 (ar-C-1), 100.0 (CHC≡C), 82.7 (CHC≡C), 56.4 (SC(CH3)3), 56.2 (ar-OCH3), 52.0 
(CO2CH3), 43.7 (CH), 23.5 (CCH3), 22.6 (SC(CH3)3), 19.7 (C=CCH3). C20H26BrNO4S 
(456.40 g mol-1). MS(ESI): m/z = 456.173/458.979 (calcd. 456.0839/458.979 [M+H]+), 
478.163/480.125 (calcd. 478.0658/480.0638 [M+Na]+). TLC: Rf (EtOAc/PE 1:1) = 0.29.  
 
IIX-3. i) Hydroalkynylation of Propynoates (73-75) 
Propynoates 73a-c,e were purchased from Fisher Scientific.  
Methyl 4-((Methoxycarbonyl)oxy)but-2-ynoate (73d). The di-formiation of propargylic 
alcohol to form alkyne 73d as precursor for hydroalkinylation reactions has been previously 
reported by Trost et al. [130]. nButhyllithium (1.6 M in hexanes, 5.7 mL 9.1 mmol, 2.1 eq) 
was added dropwise to a solution of propargylalcohol (250 L, 243 mg, 4.33 mmol, 1.0 eq) 
in dry THF (10 mL) at -78 °C. After 30 min, methyl chloroformate (0.70 mL, 859 mg, 
9.1 mmol, 2.1 eq) was carefully added to the vigorously solution at -78 °C. After complete 
conversion, the reaction mixture was allowed to warm up to rt and stirred for 2 h at ambient 
temperature. The solution was washed with water (3 x 10 mL) and brine (10 mL). After 
drying over Na2SO4, filtration end evaporation of the solvent, the crude alkyne 73d was 
purified by column chromatography (PE/EtOAc, 4:1).  
Colorless fluid. 306.7 mg, 1.782 mmol, 41 % (Lit: 49 % [130]). 
1H NMR (500 MHz, Chloroform-d) δ = 4.84 (s, 2H, CH2), 3.83 (s, 
3H, CH2OCO2CH3), 3.78 (s, 3H, CH2C≡CCO2CH3). 13C NMR 
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(126 MHz, Chloroform-d) δ = 155.1 (OCO2CH3), 153.3 (CH2-C≡CCO2CH3), 80.6 (CH2-
C≡CCO2CH3), 78.4 (CH2C≡CCO2CH3), 55.6 (OCO2CH3), 54.7 (CH2), 53.1 
(CH2C≡CCO2CH3). C7H8O5 (172.14 g mol-1). MS(ESI): m/z = 195.0276 (calcd. 195.0264 
[M+Na]+). TLC: Rf (PE/EtOAc, 4:1) = 0.59.  
 
Methyl (Z)-2-Benzylidene-5-((tert-butoxycarbonyl)amino)pent-3-ynoate (74a). 
Hydroalkynylation reactions were carried out as  described by Trost et al. [130]. To build 
the catalyst, a mixture of Pd(OAc)2 (21.2 mg, 94 µmol, 3 mol%) and the ligand 
Tris(2,6-dimethoxyphenyl)phosphan (TDMPP, 42.0 mg, 
95 µmol, 3 mol%) were dissolved in dry toluene (3.1 mL) and 
stirred for 15 min at rt under argon atmosphere, giving a deeply 
purple solution. Glycin analogous propargylamide 1 (727 mg, 
4.68 mmol, 1.5 eq) and phenylglycin analogous propynoate 
73b (460 µL, 3.1 mmol, 1 eq) were added in one portion. Immediately, the reaction mixture 
turned a black colour. After stirring the black solution for 51 h at rt, it was filtered through 
a pad of charcoal (0.5 cm) and silica (1 cm) with vacuum. The pad was washed with 
Et2O/CH2Cl2 (1:1, 5 mL) and then Et2O (5 mL) and the solvent was evaporated. The crude 
product was purified by column chromatography (PE/EtOAc, 2:1).  
Pale green fluid. Yield: 854.8 mg, 2.711 mmol, 87 %. 1H NMR (500 MHz, Chloroform-d) 
δ = 7.42-7.38 (m, 2H, ar-2-H, ar-6-H), 7.37-7.33 (m, 3H, ar-3-H, ar-4-H, ar-5-H), 6.28 (s, 
1H, Ph-CH=C-CO2CH3), 4.71 (s br., 1H, CH2NHBoc), 4.11 (d, 
3J = 5.8 Hz, 2H, 
CH2NHBoc), 3.61 (s, 3H, CO2CH3), 1.45 (s, 9H, CH2NHCO2C(CH3)3). 
13C NMR 
(126 MHz, Chloroform-d) δ = 165.7 (Ph-CH=C-CO2CH3), 138.1 (Ph-CH=C-CO2CH3), 
136.3 (ar-C-1), 129.1 (ar-C-2, ar-C-6), 128.5 (ar-C-3, ar-C-5), 128.0 (ar-C-4), 124.7 (Ph-
CH=C-CO2CH3), 91.9 (CH2C≡C(CO2CH3)=), 83.9 (CH2C≡C(CO2CH3)=), 80.3 
(NHCO2C(CH3)3), 60.5 (CH2NHBoc), 51.6 (CO2CH3), 28.5 (CH2NHCO2C(CH3)3). 
C18H21NO4 (315.37 g mol
-1), LCMS(ESI): tr = 10.0 min, m/z = 316.1535 (calcd. 316.1543 
[M+H]+), 338.1371 (calcd. 338.1363 [M+Na]+). TLC: Rf (PE/EtOAc, 1:1) = 0.67.  
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Methyl (S,E)-6-(((S)-tert-Butylsulfinyl)amino)-8-methyl-3-phenylnon-2-en-4-
ynoate (74b). Hydroalkynylation reactions were carried out as  described by Trost et al. 
[130]. A mixture of Pd(OAc)2 (3 mol%) and the ligand 
Tris(2,6-dimethoxyphenyl)phosphan (TDMPP, 3 mol%) was 
dissolved in dry toluene (3 mL) and stirred for 15 min at rt under 
argon atmosphere. After formation of the catalytist complex, 
leucine analogous propargylamide 6c (100.6 mg, 467.1 mol, 0.94 eq) and phenylglycine 
analogous propynoate 73b (61 L, 500 mol, 1.0 eq) were added in one portion to the 
deeply purple solution, which turned immediately black. After stirring the reaction mixture 
overnight, it was filtered through a pad of charcoal (1 cm) on silica (1 cm). The pad was 
washed with CH2Cl2/Et2O (1:1, 6 mL) and Et2O (6 mL), the solvent was evaporated and 
the crude product was purified by column chromatography (PE/EtOAc, 2:1).  
Pale yellow highly viscous oil. Yield: 82.2 mg, 218.9 mol, 45 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.43-7.37 (m, 2H, Ph-2-H, Ph-6-H), 7.33-7.29 (m, 3H, Ph-3-H, Ph-4-
H, Ph-5-H), 6.27 (s, 1H, CHC≡C-C=CHCO2), 3.84 (ddd, 3J = 7.4 Hz, 3J = 7.5 Hz, 3J = 
6.4 Hz, 1H, CHC≡C-C=CHCO2), 3.57 (s, 3H, CO2CH3), 3.32 (t br., 3J = 7.4 Hz, 1H, 
CHNH), 1.81 (m, 1H, CHCH2CH(CH3)2), 1.56 (dd, 
3J = 7.5 Hz, 3J = 7.2 Hz, 2H, 
CHCH2CH(CH3)2), 1.19 (s, 9H, SC(CH3)3), 0.89 (d, 
3J = 6.7 Hz, 6H, 
CHCH2CH(CH3)2). 
13C NMR (126 MHz, Chloroform-d) δ = 165.7 (CHC≡C-
C=CHCO2), 137.8 (CHC≡C-C=CHCO2), 136.0 (Ph-C-1), 129.0 (Ph-C-3, Ph-C-5), 
128.6 (Ph-C-4), 127.9 (Ph-C-2, Ph-C-6), 124.6 (CHC≡C-C=CHCO2), 95.4 (CHC≡C-
C=CHCO2), 84.1 (CHC≡C-C=CHCO2), 56.2 (SC(CH3)3), 53.6 (CO2CH3), 51.4 
(CHC≡C-C=CHCO2), 46.1 (CHCH2CH(CH3)2), 33.5 (CHCH2CH(CH3)2), 24.8 
(CHCH2CH(CH3)2), 22.6 (SC(CH3)3), 22.1 (CHCH2CH(CH3)2). C21H29NO3S 
(375.53 g mol-1), MS (ESI): m/z = 376.19490 (calcd. 376.1941 [M+H]+), 751.3791 (calcd. 
751.3809 [2M+H]+). TLC: Rf (PE/EtOAc, 2:1) = 0.22, Rf (PE/EtOAc, 1:1) = 0.50.  
 
Methyl (S,E)-6-(((S)-tert-Butylsulfinyl)amino)-6-cyclohexyl-3-phenylhex-2-en-4-
ynoate (74c). Hydroalkynylation reactions were carried out as  
described by Trost et al. [130]. After forming the catalyst 
complex of Pd(OAc)2 (3 mol%) and the ligand 
Tris(2,6-dimethoxyphenyl)phosphan (TDMPP, 3 mol%), 
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stirring the mixture for 15 min in dry toluene (3 mL) under argon atmosphere, 
cyclohexylglycine analogous propargylamide 6e (120.7 mg, 500.0 mol, 1.0 eq) and 
phenylglycine analogous propynoate 73b (74 L, 500 mol, 1.0 eq) were added in one 
portion to the purple solution. The black reaction mixture was stirred overnight at ambient 
temperature and then filtered through a pad of charcoal (1 cm) and silica (1 cm). After 
washing the pad with CH2Cl2/Et2O (1:1, 6 mL) and Et2O (6 mL) and evaporation of the 
solvent, the crude product was purified by column chromatography (PE/EtOAc, 2:1).  
Pale yellow oil. Yield: 127.8 mg, 318.3 mol, 64 %. 1H NMR (500 MHz, Chloroform-d) δ 
= 7.47-7.42 (m, 2H, Ph-2-H, Ph-6-H), 7.36-7.34 (m, 3H, Ph-3-H, Ph-4-H, Ph-5-H), 6.32 
(s, 1H, CHC≡C-C=CHCO2), 4.04 (dd, 3J = 6.4 Hz, 3J = 7.1 Hz, 1H, CHC≡C-
C=CHCO2), 3.62 (s, 3H, CO2CH3), 3.29 (d, 
3J = 7.1 Hz, 1H, CHNH), 1.82 (d br., 2J = 
12.4 Hz, 2H, cy-1-H, cy-4-H), 1.76 (d br., 2J = 13.1 Hz, 2H, cy-2-H, cy-6-H), 1.72-1.62 
(m, 2H, cy-2-H, cy-6-H), 1.25 (m, 1H, cy-4-H), 1.22 (s, 9H, SC(CH3)3), 1.18-1.03 (m, 4H, 
cy-3-H, cy-5-H). 13C NMR (126 MHz, Chloroform-d) δ = 165.8 (CHC≡C-C=CHCO2), 
138.0 (CHC≡C-C=CHCO2), 136.2 (Ph-C-1), 129.1 (Ph-C-3, Ph-C-5), 128.7 (Ph-C-2, 
Ph-C-6), 128.0 (Ph-C-4), 124.7 (CHC≡C-C=CHCO2), 94.4 (CHC≡C-C=CHCO2), 
86.5 (CHC≡C-C=CHCO2), 56.6 (SC(CH3)3), 53.8 (CHC≡C-C=CHCO2), 51.6 
(CO2CH3), 43.6 (cy-C-1), 29.7 (cy-C-2), 28.5 (cy-C-6), 26.4 (cy-C-4), 26.0 (cy-C-5), 26.0 
(cy-C-3), 22.8 (SC(CH3)3). C23H31NO3S (401.57 g mol
-1), MS(ESI): m/z = 402.21020 
(calcd. 402.20974 [M+H]+). TLC: Rf (PE/EtOAc, 1:1) = 0.61, Rf (PE/EtOAc, 2:1) = 0.28.  
 
8-(tert-Butyl) 1-Methyl (S)-2-((Z)-Benzylidene)-5-(((S)-tert-butylsulfinyl)amino)oct-3-
ynedioate (74d). Hydroalkynylation reactions were carried out as  described by Trost et al. 
[130]. A mixture of Pd(OAc)2 (6 mg, 27 mol, 18 mol%) and the ligand 
Tris(2,6-dimethoxyphenyl)phosphan (TDMPP, 12 mg, 27 mol, 18 mol%) was dissolved 
in dry toluene (3 mL) and stirred for 15 min at rt under argon atmosphere. To the red 
catalyst solution, glutamic acid analogous propargylamide 6l (43.5 mg, 151 mol, 1.0 eq) 
and phenylglycine analogous propynoate 73b (36 mg, 225 mol, 1.5 eq) were added in one 
portion and the mixture was stirred overnight at ambient temperature. The black solution 
was filtered through a pad of charcoal (1 cm) and silica (1 cm), the pad was washed with 
CH2Cl2/Et2O (1:1, 6 mL) and Et2O (6 mL) and the solvent was evaporated. The title 
compound was isolated by column chromatography (PE/EtOAc, 2:1).  
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Brightly yellow oil. Yield: 26.9 mg, 60.1 mol, 40 %. 1H NMR 
(500 MHz, Chloroform-d) δ = 7.45-7.39 (m, 2H, Phe-2-H, Phe-
6-H), 7.38-7.34 (m, 3H, Phe-3-H, Phe-4-H, Phe-5-H), 6.32 (s, 
1H, Ph-C=CHCO2CH3), 4.30 (ddd, 
3J = 6.2 Hz, 3J = 6.7 Hz, 3J = 
5.4 Hz, 1H, CH), 3.61 (s, 3H, CO2CH3), 3.47 (d, 
3J = 6.7 Hz, 
1H, CHNH), 2.49-2.26 (m, 2H, CCH2CH2CO2), 2.13-1.89 (m, 2H, CHCH2CH2CO2), 
1.44 (s, 9H, CO2C(CH3)3), 1.21 (s, 9H, SC(CH3)3). 
13C NMR (126 MHz, Chloroform-d) δ 
= 172.1 (CCO2C(CH3)3), 165.7 (CO2CH3), 137.6 (C(Ph)=CHCO2), 136.0 (Ph-C-1), 129.2 
(Ph-C-3, Ph-C-5), 128.6 (Ph-C-4), 128.0 (Ph-C-2, Ph-C-6), 125.1 (C(Ph)=CHCO2), 94.1 
(CHC≡C-C(Ph)=), 86.0 (CHC≡C-C(Ph)=), 81.0 (CO2C(CH3)3), 56.5 (SC(CH3)3), 51.6 
(CO2CH3), 47.6 (C), 32.0 (CHCH2CH2CO2), 31.6 (CHCH2CH2CO2), 28.2 
(CO2C(CH3)3), 22.7 (SC(CH3)3). C24H33NO5S (447.59 g mol
-1), MS(ESI): tr = 10.6 min, 
m/z = 448.2283 (calcd. 448.2152 [M+H]+), 470.2093 (calcd. 470.1972 [M+Na]+). TLC: Rf 
(PE/EtOAc, 4:1) = 0.17.  
 
Ethyl (S,E)-6-(((S)-tert-Butylsulfinyl)amino)-3,8-dimethylnon-2-en-4-ynoate (74e). 
Hydroalkynylation reactions were carried out as  described by Trost et al. [130]. A mixture 
of Pd(OAc)2 (3 mol%) and the ligand TDMPP (3 mol%) was dissolved in dry toluene 
(3 mL) and stirred for 15 min at rt under argon atmosphere. L-Leucine analogous 
propargylamide 6c (101.2 mg, 469.9 μmol, 0.94 eq) and alanine analogous propynoate 73a 
(58 μL, 500 μmol, 1.00 eq) were added in one portion and the reaction mixture was stirred 
overnight at ambient temperature. The blak solution was filtered through a pad of charcoal 
(1 cm) and silica (1 cm). After washing the pad with CH2Cl2/Et2O (1:1, 6 mL) and Et2O 
(6 mL), the solvent was evaporated and the crude product was purified by column 
chromatography (PE/EtOAc, 2:1).  
Colorless crystalline needles. Yield: 116.4 mg, 355.4 mol, 76 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 6.02 (s, 1H, CHC≡C-C(CH3)=CHCO2), 4.17 (ddd, 3J = 8.1 Hz, 3J = 
7.4 Hz, 3J = 7.2 Hz, 1H, CHC≡C-C(CH3)=CHCO2), 4.13 
(q, 3J = 7.6 Hz, 2H, CO2CH2CH3), 3.27 (d br., 
3J = 7.2 Hz, 1H, 
CHNH), 2.24 (s, 3H, CHC≡C-C(CH3)=CHCO2), 1.82 
(hd, 3J = 6.8 Hz, 3J = 7.4 Hz, 1H, CHCH2CH(CH3)2), 1.59 (dd, 
3J = 7.5 Hz, 3J = 7.4 Hz, 
2H, CHCH2CH(CH3)2), 1.24 (t, 
3J = 7.2 Hz, 3H, CO2CH2CH3), 1.19 (s, 9H, SC(CH3)3), 
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0.92 (d, 3J = 6.8 Hz, 3H, CHCH2CH(CH3)2), 0.90 (d, 
3J = 6.8 Hz, 3H, 
CHCH2CH(CH3)2). 
13C NMR (126 MHz, Chloroform-d) δ = 166.0 (CHC≡C-
C(CH3)=CHCO2), 137.3 (CHC≡C-C(CH3)=CHCO2), 124.7 (CHC≡C-
C(CH3)=CHCO2), 93.7 (CHC≡C-C(CH3)=CHCO2), 86.7 (CHC≡C-
C(CH3)=CHCO2), 60.1 (CO2CH2CH3), 56.3 (SC(CH3)3), 46.9 (CHC≡C-
C(CH3)=CHCO2), 46.0 (CHCH2CH(CH3)2), 25.1 (CHCH2CH(CH3)2), 22.6 
(SC(CH3)3), 22.5 (CHCH2CH(CH3)2), 22.2 (CHCH2CH(CH3)2), 19.8 (CHC≡C-
C(CH3)=CHCO2), 14.3 (CO2CH2CH3). C17H29NO3S (327.48 g mol
-1). MS(ESI): m/z = 
328.19450 (calcd. 328.19409 [M+H]+), 350.1811 (calcd. 350.1760 [M+Na]+), 655.3905 
(calcd. 655.3809 [2M+H]+). TLC: Rf (PE/EtOAc, 2:1) = 0.25, Rf (PE/EtOAc, 1:1) = 0.48. 
[𝛼]589
20  = +32.80 (c 0.399, CHCl3).  
 
Ethyl (S,E)-6-(((S)-tert-Butylsulfinyl)amino)-6-cyclohexyl-3-methylhex-2-en-4-
ynoate (74f). Hydroalkynylation reactions were carried out as  described by Trost et al. 
[130]. A mixture of Pd(OAc)2 (3 mol%) and the ligand TDMPP (3 mol%) was dissolved 
in dry toluene (3 mL) and stirred for 15 min at rt under argon atmosphere. In one portion, 
cycloheylglycine analogous propargylamide 6e (121.7 mg, 504.2 mol, 1.01 eq) and 
alanine analogous propynoate 73a (61 L, 500 mol, 1.00 eq) were added to the red 
solution, which immediately turned black. After stirring the solution for 24 h at ambient 
temperature, the solution was filtered through a pad of charcoal (1 cm) and silica (1 cm) 
and the pad was purged with CH2Cl2/Et2O (6 mL) and Et2O (6 mL). The filtrate was 
concentrated up to dryness and purified by column chromatography (PE/EtOAc, 2:1).  
Colorless, highly viscous oil. Yield: 122.3 mg, 345.9 mol, 
69 %. 1H NMR (500 MHz, Chloroform-d) δ = 6.06 (s, 1H, 
CHC≡C-C(CH3)=CHCO2), 4.16 (q, 3J = 7.1 Hz, 2H, 
CO2CH2CH3), 4.00 (dd, 
3J = 6.5 Hz, 3J = 7.2 Hz, 1H, CHC≡C-C(CH3)=CHCO2), 3.26 
(d, 3J = 7.2 Hz, 1H, CHNH), 2.28 (s, 3H, CHC≡C-C(CH3)=CHCO2), 1.82 (d br., 3J = 
13.8 Hz, 2H, cy-2-H, cy-6-H,), 1.77 (d br., 2J = 13.2 Hz, 2H, cy-2-H, cy-6-H), 1.69 (d br., 
2J = 12.6 Hz, 1H, cy-4-H), 1.65-1.55 (m, 1H, cy-1-H, cy-4-H), 1.27 (t, 3J = 7.1 Hz, 3H, 
CO2CH2CH3), 1.23 (s, 9H, SC(CH3)3), 1.18-1.03 (m, 4H, cy-3-H, cy-5-H). 
13C NMR 
(126 MHz, Chloroform-d) δ = 166.1 (CHC≡C-C(CH3)=CHCO2), 137.5 (CHC≡C-
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C(CH3)=CHCO2), 124.7 (CHC≡C-C(CH3)=CHCO2), 92.7 (CHC≡C-
C(CH3)=CHCO2), 87.6 (CHC≡C-C(CH3)=CHCO2), 60.1 (CO2CH2CH3), 56.6 
(SC(CH3)3), 53.7 (CHC≡C-C(CH3)=CHCO2), 43.5 (cy-C-1), 29.7 (cy-C-2), 28.5 (cy-
C-6), 26.4 (cy-C-4), 26.1 (cy-C-5), 26.0 (cy-C-3), 22.8 (SC(CH3)3), 19.9 (CHC≡C-
C(CH3)=CHCO2), 14.4 (CO2CH2CH3).  C19H31NO3S (353.52 g mol
-1). MS(ESI): m/z = 
354.20950 (calcd. 354.20974 [M+H]+), 707.4102 (calcd. 707.4122 [2M+H]+). TLC: Rf 
(PE/EtOAc, 1:1) = 0.63, Rf (PE/EtOAc, 2:1) = 0.33.  
 
Methyl (S,E)-6-(((S)-tert-Butylsulfinyl)amino)-3-hexyl-8-methylnon-2-en-4-
ynoate (74h). Hydroalkynylation reactions were carried out as  described by Trost et al. 
[130]. Pd(OAc)2 (3 mol%) and TDMPP (3 mol%) were mixed in dry toluene (3 mL) and 
stirred for 15 min at rt under argon atmosphere. L-Leucine analogous propargylamide 6c 
(101.4 mg, 470.8 mol, 0.94 eq) and n-hexylglycine analogous propynoate 73c (92 L, 
500 mol, 1.00 eq) were added in one portion and the reaction mixture was stirred 
overnight at ambient temperature. The black solution was filtered through a pad of charcoal 
(1cm) and silica (1 cm). After purging the pad with CH2Cl2/Et2O (1:1, 6 mL), Et2O (6 mL), 
the solvent was evaporated and the title compound was isolated by column chromatography 
(PE/EtOAc, 2:1).  
Colorless, highly viscous oil. Yield: 31.1 mg, 84.2 mol, 18 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 6.04 (s, 1H, CHC≡C-C=CHCO2), 4.20 
(ddd, 3J = 7.4 Hz, 3J = 6.7 Hz, 3J = 7.8 Hz, 1H, CHC≡C-
C=CHCO2), 3.68 (s, 3H, CO2CH3), 3.31 (d br., 
3J = 6.7 Hz, 
1H, CHNH), 2.71 (t, 3J = 7.8 Hz, 2H, CCH2), 1.84 (m, 1H, 
CHCH2CH(CH3)2), 1.63 (dd, 
3J = 7.4 Hz, 3J = 7.8 Hz, 2H, CHCH2CH(CH3)2), 1.55 
(tt, 3J = 7.5 Hz, 3J = 7.4 Hz, 2H, CCH2CH2CH2CH2CH2CH3), 1.36-1.23 (m, 6H, 
CCH2CH2CH2CH2CH2CH3), 1.21 (s, 9H, SC(CH3)3), 0.93 (t, 
3J = 5.8 Hz, 6H, 
CHCH2CH(CH3)2), 0.86 (t, 
3J = 7.2 Hz, 3H, CCH2CH2CH2CH2CH2CH3). 
13C NMR (126 MHz, Chloroform-d) δ = 166.3 (CHC≡C-C=CHCO2), 143.0 
(CHC≡C-C=CHCO2), 124.0 (CHC≡C-C=CHCO2), 94.4 (CHC≡C-C=CHCO2), 
85.7 (CHC≡C-C=CHCO2), 56.4 (SC(CH3)3), 51.3 (CO2CH3), 46.9 (CHC≡C-
C=CHCO2), 46.1 (CHCH2CH(CH3)2), 32.3 (CCH2CH2CH2CH2CH2CH3), 
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31.8 (CCH2CH2CH2CH2CH2CH3), 29.0 (CCH2CH2CH2CH2CH2CH3), 28.4 
(CCH2CH2CH2CH2CH2CH3), 25.2 (CHCH2CH(CH3)2), 22.7 
(CCH2CH2CH2CH2CH2CH3), 22.7 (CHCH2CH(CH3)2), 22.6 (SC(CH3)3), 22.1 
(CHCH2CH(CH3)2), 14.2 (CCH2CH2CH2CH2CH2CH3). C21H37NO3S 
(383.59 g mol-1), MS (ESI): m/z = 384.25790 (calcd. 384.25669 [M+H]+). TLC: Rf 
(PE/EtOAc, 1:1) = 0.66, Rf (PE/EtOAc, 2:1) = 0.32.  
 
Methyl (S,Z)-6-(((S)-tert-Butylsulfinyl)amino)-6-cyclohexyl-3-
(((methoxycarbonyl)oxy)methyl)hex-2-en-4-ynoate (74i). Hydroalkynylation reactions 
were carried out as  described by Trost et al. [130]. Pd(OAc)2 (6 mg, 27 mol, 5 mol%) 
and TDMPP (12 mg, 27 mol, 5 mol%) were mixed in dry toluene (1.5 mL) and stirred for 
15 min at rt under argon atmosphere. Cyclohexylglycine analogous propargylamide 6e 
(100 mg, 415 mol, 1.0 eq) and serine analogous propynoate 73d (102 mg, 580 mol, 
1.4 eq) were added in one portion. The reaction mixture was stirred overnight at rt, before 
filtering the black solution through a pad of charcoal (1 cm) on silica (1 cm). The pad was 
purged with CH2Cl2/Et2O (1:1, 6 mL) and Et2O (6 mL). The solvent was evaporated and 
the crude product was purified by column chromatography (PE/EtOAc, 2:1).  
Faintly yellow, highly viscous oil. Yield: 81.0 mg, 196 mol, 47 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 6.17 (t, 4J = 1.9 Hz, 1H, 
NHCHC≡CC=CH-CO2CH3), 5.21 (d, 4J = 1.9 Hz, 3H, 
CCH2OCO2CH3), 4.00 (dd, 
3J = 6.2 Hz, 3J = 6.9 Hz, 1H, 
CH), 3.78 (s, 3H, NHCHC≡CC=CH-CO2CH3), 3.70 (s, 3H, 
CCH2OCO2CH3), 3.37 (d, 
3J = 6.9 Hz, 1H, NHCH), 1.80 (d br., 2J = 9.6 Hz, 2H, cy-2-
H, cy-6-H), 1.74 (d br., 2J = 14.5 Hz, 3H, cy-2-H, cy-4-H, cy-6-H), 1.65 (d br., 2J = 
12.2 Hz, 1H, cy-4-H), 1.57 (m, 1H, cy-1-H), 1.20 (s, 9H, SC(CH3)3), 1.16-0.99 (m, 4H, cy-
3-H, cy-5-H). 13C NMR (126 MHz, Chloroform-d) δ = 165.6 (CCH2OCO2CH3), 155.6 
(NHCHC≡CC=CH-CO2CH3), 136.9 (NHCHC≡CC=CH-CO2CH3), 125.4 
(NHCHC≡CC=CH-CO2CH3), 96.7 (NHCHC≡CC=CH-CO2CH3), 82.5 
(NHCHC≡CC=CH-CO2CH3), 64.9 (CCH2OCO2CH3), 56.5 (SC(CH3)3), 55.1 
(CCH2OCO2CH3), 53.6 (NHCHC≡CC=CH-CO2CH3), 51.8 (CCH2OCO2CH3), 
43.3 (cy-C-1), 29.5 (cy-C-2), 28.2 (cy-C-6), 26.2 (cy-C-4), 26.0 (cy-C-5), 25.9 (cy-C-3), 
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22.7 (SC(CH3)3). C20H31NO6S (413.53 g mol
-1). MS(ESI): m/z = 414.2011 (calcd. 
414.1945 [M+H]+), 436.1677 (calcd. 436.1764 [M+Na]+). TLC: Rf (PE/EtOAc, 2:1) = 
0.14. [𝛼]589
20  = +17.30 (c 0.334, CHCl3).  
 
Dimethyl 2-((S)-3-(((S)-tert-Butylsulfinyl)amino)-4-methylpent-1-yn-1-
yl)maleate (74j). Hydroalkynylation reactions were carried out as  described by Trost et 
al. [130]. A mixture of Pd(OAc)2 (6 mg, 27 mol, 5 mol%), TDMPP (12 mg, 27 mol, 
5 mol%) in dry toluene (3 mL) was stirred 15 min at ambient temperature under argon 
atmosphere to give a brightly red catalyst solution. Valine analogous propargylamide 6b 
(99.0 mg, 492 mol, 1.0 eq) and aspartic acid analogous propynoate 73e (90 L, 732 mol, 
1.5 eq) were added in one portion and the dark reaction mixture was stirred overnight at rt. 
After complete reaction (checked by TLC), the mixture was filtered through a pad of 
charcoal (1 cm) on silica (1 cm), the pad was purged with CH2Cl2/Et2O (1:1, 6 mL) and 
Et2O (6 mL) and the solvent was evaporated. The title compound was isolated by column 
chromatography (PE/EtOAc, 2:1). During the purification, starting material 6b was 
retrieved (45.8 mg, 228 mol, 46 %), indicating a conversion of only 54 %.  
Colorless oil. Yield: 13.9 mg, 40.5 mol, 8 %. 1H NMR (500 MHz, Chloroform-d) δ = 6.33 
(s, 1H, NHCHC≡CC=CH-CO2CH3), 4.06 (dd, 3J = 6.8 Hz, 3J = 5.4 Hz, 1H, CH), 3.85 
(s, 3H, NHCHC≡CC=CH-CO2CH3), 3.75 (s, 3H, CCO2CH3), 3.39 (d, 3J = 6.2 Hz, 
1H, CHNH), 2.03-1.96 (m, 1H, CHCH), 1.23 (s, 9H, 
SC(CH3)3), 1.01 (d, 
3J = 6.6 Hz, 3H, CHC(CH3)HCH3), 0.99 
(d, 3J = 6.5 Hz, 1H, CHC(CH3)HCH3). 
13C NMR (126 MHz, 
Chloroform-d) δ = 165.0 (CCO2CH3), 164.7 
(NHCHC≡CC=CH-CO2CH3), 129.5 (NHCHC≡CC=CH-CO2CH3), 129.0 
(NHCHC≡CC=CH-CO2CH3), 97.0 (NHCHC≡CC=CH-CO2CH3), 80.4 
(NHCHC≡CC=CH-CO2CH3), 56.7 (SC(CH3)3), 54.3 (NHCHC≡CC=CH-
CO2CH3), 53.3 (NHCHC≡CC=CH-CO2CH3), 52.4 (CCO2CH3), 33.9 
(CHCH(CH3)2), 22.7 (SC(CH3)3), 19.1 (CHC(CH3)HCH3), 17.7 
(CHC(CH3)HCH3). C16H25NO5S (343.44 g mol
-1), MS(ESI): m/z = 344.1607 (calcd. 
344.1526 [M+H]+), 366.1376 (calcd. 366.1346 [M+Na]+). TLC: Rf (PE/EtOAc, 2:1) = 
0.19, Rf (PE/EtOAc, 4:1) = 0.09. [𝛼]589
20  = -39.13 (c 0.104, CHCl3).  
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Dimethyl 2-((S)-3-(((S)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-
yl)maleate (74k). Hydroalkynylation reactions were carried out as  described by Trost et 
al. [130]. A mixture of Pd(OAc)2 (3 mol%), TDMPP (3 mol%) in dry toluene (3 mL) was 
stirred 15 min at ambient temperature under argon atmosphere to give a brightly red 
catalyst solution. Leucine analogous propargylamide 6c (100.6 mg, 467.1 mol, 0.94 eq) 
and aspartic acid analogous propynoate 73e (61 μL, 500 μmol, 1.00 eq) were added in one 
portion and the reaction mixture was stirred overnight at rt. The mixture was filtered 
through a pad of charcoal (1 cm) on silica (1 cm) and the pad was purged with CH2Cl2/Et2O 
(1:1, 6 mL) and Et2O (6 mL). The title compound was isolated by column chromatography 
(PE/EtOAc, 2:1).  
Yellow, highly viscous oil. Yield: 18.0 mg, 50.4 mol, 11 %. 
1H NMR (500 MHz, Chloroform-d) δ = 6.30 (s, 1H, CHC≡C-
C(CO2CH3)=CHCO2), 3.85 (s, 3H, CHC≡C-
C(CO2CH3)=CHCO2), 3.74 (s, 3H, CHC≡C-
C(CO2CH3)=CHCO2CH3), 3.47 (ddd, 
3J = 7.0 Hz, 3J = 7.4 Hz, 3J = 7.2 Hz, 1H, 
CHC≡C-C(CO2CH3)=CHCO2), 3.33 (d, 3J = 7.2 Hz, 1H, CHNH), 1.83 (m, 1H, 
CHCH2CH(CH3)2), 1.64 (t, 
3J = 7.4 Hz, 2H, CHCH2CH(CH3)2), 1.21 (s, 9H, 
SC(CH3)3), 0.93 (d, 
3J = 6.7 Hz, 6H, CHCH2CH(CH3)2). 
13C NMR (126 MHz, 
Chloroform-d) δ = 164.9 (CHC≡C-C(CO2CH3)=CHCO2), 164.7 (CHC≡C-
C(CO2CH3)=CHCO2), 129.3 (CHC≡C-C(CO2CH3)=CHCO2), 103.7 (CHC≡C-
C(CO2CH3)=CHCO2), 98.5 (CHC≡C-C(CO2CH3)=CHCO2), 79.5 (CHC≡C-
C(CO2CH3)=CHCO2), 56.5 (SC(CH3)3), 53.2 (CHC≡C-C(CO2CH3)=CHCO2CH3), 
52.4 (CHC≡C-C(CO2CH3)=CHCO2CH3), 45.8 (CHCH2CH(CH3)2), 25.0 
(CHCH2CH(CH3)2), 22.6 (SC(CH3)3), 22.5 (CHCH2CH(CH3)2), 22.3 
(CHCH2CH(CH3)2). C17H27NO5S (357.47 g mol
-1). MS(ESI): m/z = 358.16750 (calcd. 
358.16827 [M+H]+). TLC: Rf (PE/EtOAc, 1:1) = 0.37, Rf (PE/EtOAc, 2:1) = 0.15.  
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Methyl (S,E)-6-Amino-8-methyl-3-phenylnon-2-en-4-ynoate Hydrochloride (75b). 
Hydrochloric acid (4 M in dioxane, 0.2 mL) was added dropwise to a solution of 
peptidomimetic 74b (82.2 mg, 218.9 mol) in MeOH (4 mL). After stirring the solution 
overnight, the solvent was evaporated under reduced pressure. 
The desired amine was achieved quantitatively with minor 
impurities as hydrochloric salt. Brightly yellow amorphous solid.  
Yield: 67.4 mg, 219 mol, quantitative. 1H NMR (500 MHz, Methanol-d4) δ = 7.29-6.97 
(m, 5H, Ph-H), 6.12 (s, 1H, CHC≡C-C=CHCO2), 4.06 (m, 1H, CHC≡C-
C=CHCO2), 3.83 (s, 3H, CO2CH3), 1.82 (s, 3H, CHNH3Cl), 1.47 (m, 1H, 
CHCH2CH(CH3)2), 1.10 (d, 
2J = 21.3 Hz, 1H, CHCH2CH(CH3)2), 1.04 (d, 
2J = 
21.1 Hz, 1H, CHCH2CH(CH3)2), 0.80 (d, 
3J = 6.6 Hz, 3H, CHCH2CH(CH3)2), 0.75-
0.62 (m, 3H, CHCH2CH(CH3)2). 
13C NMR (126 MHz, Methanol-d4) δ = 166.9 
(CHC≡C-C=CHCO2), 137.1 (CHC≡C-C=CHCO2), 136.8 (Ph-C-3, Ph-C-5), 130.3 
(Ph-C-1), 129.4 (Ph-C-2, Ph-C-6), 129.1 (Ph-C-1), 127.1 (CHC≡C-C=CHCO2), 79.3 
(CHC≡C-C=CHCO2), 78.0 (CHC≡C-C=CHCO2), 52.2 (CO2CH3), 42.7 
(CHC≡C-C=CHCO2), 32.3 (CHCH2CH(CH3)2), 26.2 (CHCH2CH(CH3)2), 23.3 
(CHCH2CH(CH3)2), 21.5 (CHCH2CH(CH3)2). C17H22ClNO2 (307.82 g mol
-1). 
LCMS(ESI): tr = 6.7 min, m/z = 272.1725 (calcd. 272.1645 [M+H]+), 294.1352 (calcd. 
294.1465 [M+Na]+). [𝛼]589
20  = +129.0 (c 3.00, MeOH).  
 
Methyl (S,E)-6-Amino-6-cyclohexyl-3-phenylhex-2-en-4-ynoate Hydrochloride (75c). 
Hydrochloric acid (4 M in dioxane, 0.2 mL) was added dropwise to a solution of 
peptidomimetic 74c (127.8 mg, 318.3 mol) in MeOH (4 mL). After stirring the solution 
overnight, the solvent was evaporated under reduced pressure. The desired amine was 
achieved quantitatively with minor impurities as hydrochloric salt. Brightly yellow 
amorphous solid.  
Yield: 106.2 mg, 318.3 mol, quantitative. 1H NMR (500 MHz, 
Methanol-d4) δ = 7.47-7.41 (m, 2H, Ph-2-H, Ph-6-H), 7.40-7.35 
(m, 3H, Ph-3-H, Ph-4-H, Ph-5-H), 6.42 (s, 1H, CHC≡C-
C=CHCO2), 4.22 (d br., 
3J = 5.2 Hz, 1H, CHC≡C-
C=CHCO2), 3.61 (s, 3H, CO2CH3), 1.90 (d br., 
2J = 13.6 Hz, 1H, cy-4-H), 1.86-1.78 (m, 
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3H, cy-1-H, cy-2-H, cy-6-H), 1.71 (d br., 2J = 13.2 Hz, 1H, cy-4-H), 1.40-1.27 (m, 3H, 
cyH), 1.21 (dt, 2J = 18.8 Hz, 3J = 6.5 Hz, 2H, cyH), 1.15 (s, 3H, CHNH3Cl). 13C NMR 
(126 MHz, Methanol-d4) δ = 166.9 (CO2CH3), 137.1 (Ph-C-1), 136.8 (CHC≡C-
C=CHCO2), 130.3 (Ph-C-4), 129.5 (Ph-C-3, Ph-C-5), 129.1 (Ph-C-2, Ph-C-6), 127.0 
(CHC≡C-C=CHCO2), 89.1 (CHC≡C-C=CHCO2), 89.0 (CHC≡C-C=CHCO2), 
52.2 (CO2CH3), 49.5 (CHC≡C-C=CHCO2), 41.9 (cy-C-1), 30.5 (cy-C-2), 28.6 (cy-C-
6), 26.9 (cy-C-4), 26.6 (cy-C-5), 26.4 (cy-C-3). C19H24ClNO2 (333.86 g mol
-1). MS(ESI): 
tr = 6.9 min, m/z = 298.1894 (calcd. 298.1802 [M+H]+). [𝛼]589
20  = +3.78 (c 6.14, CHCl3).  
 
9-(tert-Butyl) 1-Methyl (S,E)-6-Amino-3-phenylnon-2-en-4-ynedioate 
Hydrochloride (75d). Hydrochloric acid (4 M in dioxane, 0.2 mL, 0.8 mmol) was added 
dropwise to a vigorously stirred solution of propargyl-3-acrylate 74d (26.9 mg, 60.1 mol) 
in MeOH (4 mL). The reaction mixture was stirred overnight at rt before evaporating the 
solvent under reduced pressure.  
Pale yellow oil. Yield: 22.8 mg, 60.1 mol, quantitative. 1H NMR (500 MHz, Methanol-
d4) δ = 7.49-7.43 (m, 2H, ar-2-H, ar-6-H), 7.41 (m, 1H, ar-4-H), 7.45-7.29 (m, 2H, ar-3-H, 
ar-5-H), 6.45 (s, 1H, CHC≡C-C=CHCO2), 4.46 (ddt, 3J = 
8.4 Hz, 3J = 5.5 Hz, 3J = 2.8 Hz, 1H, CHC≡C-C=CHCO2), 
3.62 (s, 3H, CO2CH3), 2.67-2.51 (m, 2H, CHCH2CH2CO2), 
2.24 (m, 1H, CHCH2CH2CO2), 2.07 (m, 1H, 
CHCH2CH2CO2), 1.15 (s, 9H, CO2C(CH3)3). 
13C NMR 
(126 MHz, Methanol-d4) δ = 174.0 (CHCH2CH2CO2), 166.8 (CHC≡C-C=CHCO2), 
135.8 (CHC≡C-C=CHCO2), 130.4 (Ph-C-1), 129.5 (Ph-C-3, Ph-C-5), 129.2 (Ph-C-2, 
Ph-C-6), 128.7 (Ph-C-4), 127.5 (CHC≡C-C=CHCO2), 89.1 (CHC≡C-C=CHCO2), 
88.1 (CHC≡C-C=CHCO2), 72.4 (CO2C(CH3)3), 62.2 (CO2CH3), 44.0 
(CHCH2CH2CO2), 30.6 (CHCH2CH2CO2), 29.5 (CHCH2CH2CO2), 21.5 
(CO2C(CH3)3). C20H26ClNO4 (379.88 g mol
-1). LCMS(ESI): tr = 6.7 min, m/z = 344.0866 
(calcd. 344.1856 [M+H]+). [𝛼]589
20  = +27.88 (c 0.294, CHCl3). 
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Ethyl (S,E)-6-Amino-3,8-dimethylnon-2-en-4-ynoate Hydrochloride (75e). 
Hydrochloric acid (4 M in dioxane, 0.2 mL, 0.8 mmol) was added dropwise to a vigorously 
stirred solution of propargyl-3-acrylate 74e (116.4 mg, 355.4 mol) in MeOH (4 mL). The 
reaction mixture was stirred overnight at rt before evaporating the solvent under reduced 
pressure. 
Colorless crystals. Yield: 88.7 mg, 355.4 mol, quantitative. 1H NMR (500 MHz, 
Methanol-d4) δ = 6.12 (s, 1H, CHC≡C-C(CH3)=CHCO2), 
4.34 (dd, 3J = 9.5 Hz, 3J = 3.7 Hz, 1H, CHC≡C-
C(CH3)=CHCO2), 4.17 (q, 
3J = 6.9 Hz, 2H, CO2CH2CH3), 
2.28 (s, 3H, CHC≡C-C(CH3)=CHCO2), 1.89 (m, 1H, 
CHCH2CH(CH3)2), 1.80 (m, 1H, CHCH2CH(CH3)2), 1.71 (m, 1H, 
CHCH2CH(CH3)2), 1.27 (t, 
3J = 6.9 Hz, 3H, CO2CH2CH3), 1.15 (s, 3H, CHNH3Cl), 
1.03 (d, 3J = 6.4 Hz, 3H, CHCH2CH(CH3)2), 0.99 (d, 
3J = 6.3 Hz, 3H, 
CHCH2CH(CH3)2). 
13C NMR (126 MHz, Methanol-d4) δ = 166.7 (CO2CH2CH3), 136.9 
(CHC≡C-C(CH3)=CHCO2), 126.8 (CHC≡C-C(CH3)=CHCO2), 89.4 (CHC≡C-
C(CH3)=CHCO2), 88.7 (CHC≡C-C(CH3)=CHCO2), 61.4 (CO2CH2CH3), 43.3 
(CHCH2CH(CH3)2), 43.0 (CHCH2CH(CH3)2), 26.4 (CHCH2CH(CH3)2), 23.3 
(CHCH2CH(CH3)2), 21.6 (CHCH2CH(CH3)2), 19.6 (CHC≡C-C(CH3)=CHCO2), 
14.6 (CO2CH2CH3). C13H22ClNO2 (259.77 g mol
-1). MS(ESI): tr = 6.4 min, m/z = 
224.1805 (calcd. 224.1645 [M-Cl-]+), 246.1580 (calcd. 246.1465 [M-HCl+Na]+). [𝛼]589
20  = 
+5.91 (c 2.70, CHCl3). X-ray crystal structure in Chapter IIX-3. n. 
 
Ethyl (S,E)-6-Amino-6-cyclohexyl-3-methylhex-2-en-4-ynoate Hydrochloride (75f). 
Hydrochloric acid (4 M in dioxane, 0.2 mL, 0.8 mmol) was 
added dropwise to a vigorously stirred solution of propargyl-
3-acrylate 74f (122.3 mg, 345.9 mol) in MeOH (4 mL). The 
reaction mixture was stirred overnight at rt before evaporating 
the solvent under reduced pressure. Colorless, crystalline needles.  
Yield: 98.9 mg, 346 mol, quantitative. 1H NMR (500 MHz, Methanol-d4) δ = 6.06 (s, 1H, 
C=CHCO2), 4.12 (d br., 
3J = 5.3 Hz, 1H, CH), 4.09 (q, 3J = 6.8 Hz, 2H, CO2CH2CH3), 
2.23 (s, 3H, CCH3), 1.86 (d br., 2J = 12.7 Hz, 1H, cy-1-H), 1.82-1.74 (m, 4H, CNH3Cl, 
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cy-H), 1.67 (d br., 2J = 12.9 Hz, 1H, cy-4-H), 1.29-1.26 (m, 2H, cy-H), 1.21 (t, 3J = 7.1 Hz, 
3H, CO2CH2CH3), 1.19-1.11 (m, 3H, cy-H), 1.09 (m, 3H, cy-H). 13C NMR (126 MHz, 
Methanol-d4) δ = 166.7 (CO2CH2CH3), 137.0 (CHC≡C-C(CH3)=CHCO2), 126.8 
(CHC≡C-C(CH3)=CHCO2), 90.3 (CHC≡C-C(CH3)=CHCO2), 87.8 (CHC≡C-
C(CH3)=CHCO2), 61.4 (CO2CH2CH3), 41.8 (CIH), 30.5 (cy-C-1), 28.6 (cy-C-2), 26.9 
(cy-C-6), 26.7 (cy-C-4), 26.5 (cy-C-5), 21.5 (cy-C-3), 19.6 (CCH3), 14.6 
(CO2CH2CH3). C15H24ClNO2 (285.81 g mol
-1). MS(ESI): tr = 6.5 min, m/z = 250.1917 
(calcd. 250.1802 [M-Cl-]+), 272.1711 (calcd. 272.1621 [M-HCl+Na]+). [𝛼]589
20  = +0.09 
(c 3.20, CHCl3). X-ray crystal structure in Chapter IIX-3. n. 
 
Methyl (S,E)-6-Amino-3-hexyl-8-methylnon-2-en-4-ynoate Hydrochloride (75h). 
Hydrochloric acid (4 M in dioxane, 0.2 mL, 0.8 mmol) was added dropwise to a vigorously 
stirred solution of propargyl-3-acrylate 74h (31.1 mg, 84.2 mol) in MeOH (4 mL). The 
reaction mixture was stirred overnight at rt before evaporating the solvent under reduced 
pressure. 
Yellow oil. Yield: 21.0 mg, 84.2 mol, quantitative. 1H NMR (500 MHz, Methanol-d4) δ 
= 6.13 (s, 1H, CHC≡C-C=CHCO2), 4.34 (dd br., 3J = 
11.0 Hz, 3J = 4.9 Hz, 1H, CHC≡C-C=CHCO2), 3.71 (s, 3H, 
CO2CH3), 2.77 (t, 
3J = 7.7 Hz, 2H, CCH2), 1.89 (m, 1H, 
CHCH2CH(CH3)2), 1.80 (m, 1H, CHCH2CH(CH3)2), 
1.68 (m, 1H, CHCH2CH(CH3)2), 1.59 (tt, 
3J = 7.6 Hz, 3J = 7.4 Hz, 2H, CCH2CH2), 
1.40-1.28 (m, 6H, CCH2CH2CH2CH2CH2CH3), 1.15 (s, 3H, CHNH3Cl), 1.04 (d, 
3J = 6.8 Hz, 3H, CHCH2CH(CH3)2), 1.00 (d, 
3J = 6.4 Hz, 3H, CHCH2CH(CH3)2), 
0.92 (t, 3J = 6.28 Hz, 3H, CCH2CH2CH2CH2CH2CH3). 
13C NMR (126 MHz, 
Methanol-d4) δ = 167.0 (CHC≡C-C=CHCO2), 142.3 (CHC≡C-C=CHCO2), 126.4 
(CHC≡C-C=CHCO2), 89.3 (CHC≡C-C=CHCO2), 88.6 (CHC≡C-C=CHCO2), 
51.9 (CO2CH3), 43.3 (CHCH2CH(CH3)2), 43.2 (CHCH2CH(CH3)2), 32.8 
(CCH2CH2CH2CH2CH2CH3), 32.7 (CCH2CH2CH2CH2CH2CH3), 29.9 
(CCH2CH2CH2CH2CH2CH3), 29.4 (CCH2CH2CH2CH2CH2CH3), 26.6 
(CHCH2CH(CH3)2), 23.6 (CCH2CH2CH2CH2CH2CH3), 23.3 
(CHCH2CH(CH3)2), 21.5 (CHCH2CH(CH3)2), 14.4 
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(CCH2CH2CH2CH2CH2CH3). C17H30ClNO2 (315.88 g mol
-1). MS(ESI): tr = 
8.2 min, m/z = 280.2325 (calcd. 280.2271 [M-Cl-]+), 302.2138 (calcd. 302.2091 
[M-HCl+Na]+).  
 
Methyl (S,Z)-6-Amino-6-cyclohexyl-3-(((methoxycarbonyl)oxy)methyl)hex-2-en-4-
ynoate Hydrochloride (75i). Hydrochloric acid (4 M in dioxane, 0.2 mL, 0.8 mmol) was 
added dropwise to a vigorously stirred solution of propargyl-3-acrylate 74i (81.0 mg, 
196 mol) in MeOH (4 mL). The reaction mixture was stirred overnight at rt before 
evaporating the solvent under reduced pressure.  
Colorless crystalline solid. Yield: 67.6 mg, 196 mol, 
quantitative. 1H NMR (500 MHz, Methanol-d4) δ = 6.30 (t, 4J 
= 2.0 Hz, 1H, H2NCHC≡C-
C(CH2OCO2CH3)=CHCO2CH3), 5.25 (dd, 
2J = 15.2 Hz, 4J = 
1.9 Hz, 1H, H2NCHC≡C-C(CH2OCO2CH3)=CHCO2CH3), 5.22 (dd, 2J = 15.2 Hz, 4J = 
1.9 Hz, 1H, H2NCHC≡C-C(CH2OCO2CH3)=CHCO2CH3), 4.19 (d, 3J = 5.6 Hz, 1H, 
H2NCHC≡C-C(CH2OCO2CH3)=CHCO2CH3), 3.80 (s, 3H, 
H2NCHC≡C-C(CH2OCO2CH3)=CHCO2CH3), 3.75 (s, 3H, H2NCHC≡C-
C(CH2OCO2CH3)=CHCO2CH3), 1.92 (d br., 
2J = 13.5 Hz, 1H, cy-2-H), 1.89-1.81 (m, 
6H, cy-1-H, cy-2-H, cy-4-H, cy-5-H, cy-6-H, cy-6-H), 1.78 (d br., 2J = 12.4 Hz, 1H, cy-4-
H), 1.73 (d br., 2J = 13.4 Hz, 1H, cy-3-H), 1.30-1.17 (m, 2H, cy-3-H, cy-5-H). 13C NMR 
(126 MHz, Methanol-d4) δ = 166.4 (H2NCHC≡C-C(CH2OCO2CH3)=CHCO2CH3), 
157.0 (H2NCHC≡C-C(CH2OCO2CH3)=CHCO2CH3), 147.6 (H2NCHC≡C-
C(CH2OCO2CH3)=CHCO2CH3), 128.0 (H2NCHC≡C-
C(CH2OCO2CH3)=CHCO2CH3), 90.9 (H2NCHC≡C-
C(CH2OCO2CH3)=CHCO2CH3), 85.6 (H2NCHC≡C-
C(CH2OCO2CH3)=CHCO2CH3), 65.5 (H2NCHC≡C-
C(CH2OCO2CH3)=CHCO2CH3), 55.7 (H2NCHC≡C-
C(CH2OCO2CH3)=CHCO2CH3), 52.4 (H2NCHC≡C-
C(CH2OCO2CH3)=CHCO2CH3), 42.0 (cy-C-1), 30.3 (cy-C-2), 28.8 (cy-C-6), 28.4 
(cy-C-4), 26.7 (cy-C-5), 26.5 (cy-C-3). C16H24ClNO5 (345.82 g mol
-1).  
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Dimethyl (S)-2-(3-Amino-4-methylpent-1-yn-1-yl)maleate Hydrochloride (75j). 
Hydrochloric acid (4 M in dioxane, 0.2 mL, 0.8 mmol) was added dropwise to a vigorously 
stirred solution of propargyl-3-acrylate 74j (13.9 mg, 40.5 mol) in MeOH (4 mL). The 
reaction mixture was stirred overnight at rt before evaporating the solvent under reduced 
pressure.  
Deeply yellow highly viscous oil. Yield: 11.1 mg, 40.5 mol, quantitative. 1H NMR 
(500 MHz, Methanol-d4) δ = 6.59 (s, 1H, 
NHCHC≡CC=CH-CO2CH3), 4.25 (d, 3J = 5.7 Hz, 1H, 
NHCHC≡CC=CH-CO2CH3), 3.82 (s, 3H, CCO2CH3), 
3.77 (s, 3H, NHCHC≡CC=CH-CO2CH3), 2.15 (m, 1H, 
CHCH(CH3)2), 1.12 (d, 
3J = 6.7 Hz, 3H, CHCH(CH3)2), 1.10 (d, 
3J = 6.8 Hz, 3H, 
CHCH(CH3)2). 
13C NMR (126 MHz, Methanol-d4) δ = 165.9 (CO2CH3), 165.3 
(CO2CH3), 133.1 (NHCHC≡CC=CH-CO2CH3), 127.9 (NHCHC≡CC=CH-
CO2CH3), 91.1 (NHCHC≡CC=CH-CO2CH3), 83.4 (NHCHC≡CC=CH-CO2CH3), 
53.7 (CO2CH3), 52.9 (CO2CH3), 50.2 (CHCH(CH3)2), 32.8 (CHCH(CH3)2), 19.4 
(CHCH(CH3)2), 17.3 (CHCH(CH3)2). C12H18ClNO4 (275.73 g mol
-1). LCMS(ESI): tr = 
5.1 min, m/z = 240.1275 (calcd. 240.1230 [M+H]+), 262.0925 (calcd. 262.1050 [M+Na]+), 
479.2488 (calcd. 479.2388 [2M+H]+).  
 
Dimethyl (S)-2-(3-Amino-5-methylhex-1-yn-1-yl)maleate Hydrochloride (75j). 
Hydrochloric acid (4 M in dioxane, 0.2 mL, 0.8 mmol) was added dropwise to a solution 
of the peptidomimetic in MeOH (4 mL). After stirring the 
solution overnight, the solvent was evaporated under reduced 
pressure. The desired amine was achieved quantitatively with 
minor impurities as hydrochloric salt. Brightly yellow oil. Yield: 
17.4 mg, 50.4 mol, quantitative. 1H NMR (500 MHz, Methanol-d4) δ = 6.57 (s, 1H, 
CHC≡C-C(CO2CH3)=CHCO2), 4.37 (m, 1H, CHC≡C-C(CO2CH3)=CHCO2CH3), 
3.81 (s, 3H, CHC≡C-C(CO2CH3)=CHCO2CH3), 3.76 (s, 3H, CHC≡C-
C(CO2CH3)=CHCO2CH3), 2.02 (s, 3H, CHNH3Cl), 1.86 (m, 1H, 
CHCH2CH(CH3)2), 1.52-1.43 (m, 2H, CHCH2CH(CH3)2), 1.05-0.94 (m, 6H, 
CHCH2CH(CH3)2). 
13C NMR (126 MHz, Methanol-d4) δ = 165.9 (CHC≡C-
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C(CO2CH3)=CHCO2CH3), 165.2 (CHC≡C-C(CO2CH3)=CHCO2CH3), 137.4 
(CHC≡C-C(CO2CH3)=CHCO2CH3), 133.0 (CHC≡C-C(CO2CH3)=CHCO2CH3), 
92.6 (CHC≡C-C(CO2CH3)=CHCO2CH3), 82.5 (CHC≡C-
C(CO2CH3)=CHCO2CH3), 53.7 (CHC≡C-C(CO2CH3)=CHCO2CH3), 52.9 
(CHC≡C-C(CO2CH3)=CHCO2CH3), 43.3 (CHCH2CH(CH3)2), 42.9 
(CHCH2CH(CH3)2), 26.4 (CHCH2CH(CH3)2), 23.2 (CHCH2CH(CH3)2), 21.6 
(CHCH2CH(CH3)2). C13H20ClNO4 (289.76 g mol
-1), MS(ESI): tr = 5.9 min, m/z = 
254.1436 (calcd. 254.1387 [M-Cl-]+), 276.1234 (calcd. 276.1206 [M-HCl+Na]+).  
 
(E)-6-((tert-Butoxycarbonyl)amino)-3-phenylhex-2-en-4-ynoic Acid (75a). An aqueous 
solution of LiOH (1 M, 5.0 mL) was carefully dropped into a vigorously stirred solution of 
propargyl-3-acrylate 74a (507 mg, 1.61 mmol) in MeOH (10 mL) at 0 °C. The reaction 
mixture was continued stirring at 0 °C until the starting material was completely consumed 
(checked by TLC, about 3 h). The mixture was poured into an aqueous KHSO4 solution 
(5 %, 20 mL) and immediately extracted with CH2Cl2 (3 x 15 mL). The combined organic 
layers were washed with brine (5 mL) and dried over Na2SO4. After evaporation of the 
solvent under reduced pressure, the crude acid 75a was purified by preparative HPLC.  
Slightly brown highly viscous oil. Yield: 392 mg, 1.30 mmol, 
81 %. 1H NMR (500 MHz, Chloroform-d) δ = 8.06 (t, 3J = 
7.8 Hz, 1H, CH2NHBoc), 7.45-7.38 (m, 2H, ar-2-H, ar-6-H), 
7.35-7.31 (m, 3H, ar-3-H, ar-4-H, ar-5-H), 6.27 (s, 1H, 
CH2C≡C-C=CHCO2H), 4.11 (s, 2H, CH2C≡C-C=CHCO2H), 1.44 (s, 9H, 
NHCO2C(CH3)3). 
13C NMR (126 MHz, Chloroform-d) δ = 169.0 (CH2C≡C-
C=CHCO2H), 157.6 (NHCO2C(CH3)3), 136.0 (CH2C≡C-C=CHCO2H), 130.2 (Ph-
C-1), 129.2 (Ph-C-4), 128.7 (Ph-C-3, Ph-C-5), 128.1 (Ph-C-2, Ph-C-6), 124.4 (CH2C≡C-
C=CHCO2H), 92.7 (CH2C≡C-C=CHCO2H), 84.0 (NHCO2C(CH3)3), 80.4 
(CH2C≡C-C=CHCO2H), 31.4 (CH2C≡C-C=CHCO2H), 28.4 (NHCO2C(CH3)3). 
C17H19NO4 (301.34 g mol
-1). MS(ESI): m/z = 246.0724 (calcd. 246.0761 [M-
C(CH3)3+H]
+).  
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(S,E)-4-Amino-9-methoxy-9-oxo-7-phenylnon-7-en-5-ynoate (75l). Crude ester 75d 
(22.8 mg, 60.1 mol) was carefully dissolved in a mixture of TFA/H2O/TIPS (95:2.5:2.5, 
1 mL) and stirred overnight at ambient temperature. The clear yellow solution was poured 
into icecold Et2O (20 mL). This lead to precipitation of a fine, colorless solid which was 
separated by centrifugation. After removing the solvent with a cannula, the crude product 
was purified by preparative HPLC.  
Colorless, amorphous solid. Yield: 4.15 mg, 14.4 mol, 24 %. 
1H NMR (500 MHz, Methanol-d4) δ = 7.42-7.39 (m, 2H, Ph-2-H, Ph-
6-H), 7.39-7.36 (m, 3H, Ph-3-H, Ph-4-H, Ph-5-H), 6.44 (s, 1H, 
H2NCHC≡C-CPh=CHCO2CH3), 4.45 (dd, 3J = 9.4 Hz, 3J = 
5.3 Hz, 1H, CHCH2CH2CO2H), 3.62 (s, 3H, H2NCHC≡C-
CPh=CHCO2CH3), 2.60 (dd, 
2J = 17.3 Hz, 3J = 6.4 Hz, 1H, CHCH2CH2CO2H), 2.54 
(dd, 2J = 17.3 Hz, 3J = 7.4 Hz, 1H, CHCH2CH2CO2H), 2.21 (dtd, 
2J = 13.0 Hz, 3J = 
7.6 Hz, 3J = 5.3 Hz, 1H, CHCH2CH2CO2H), 2.06 (ddt, 
2J = 13.5 Hz, 3J = 9.4 Hz, 3J = 
6.7 Hz, 1H, CHCH2CH2CO2H). 
13C NMR (126 MHz, Methanol-d4) δ = 175.4 
(CHCH2CH2CO2H), 167.0 (CHC≡C-C(Ph)=CHCO2CH3), 166.8 (CHC≡C-
C(Ph)=CHCO2CH3), 136.8 (Ph-C-1), 130.4 (Ph-C-4), 129.4 (Ph-C-3, Ph-C-5), 129.2 
(Ph-C-2, Ph-C-6), 127.6 (CHC≡C-C(Ph)=CHCO2CH3), 89.0 (CHC≡C-
C(Ph)=CHCO2CH3), 88.9 (CHC≡C-C(Ph)=CHCO2CH3), 52.2 (CHC≡C-
C(Ph)=CHCO2CH3), 44.0 (CHCH2CH2CO2H), 30.6 (CHCH2CH2CO2H), 29.6 
(CHCH2CH2CO2H). C16H17NO4 (287.32 g mol
-1). LCMS(ESI): tr = 8.4 min, m/z = 
288.1256 (calcd. 288.1230 [M+H]+).  
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IIX-3. j) Propargylamide-Enimine Rearrangement (76-78) 
Description and characterization of -unsaturated imines 76c,f and 77c has been 
previously published [1].  
Methyl 2-((1E,3Z)-3-(((S)-tert-Butylsulfinyl)imino)-3-(perfluorophenyl)prop-1-en-1-
yl)benzoate (76a). Piperidine (0.2 mL, 2.0 mmol) was added to a solution of 
peptidomimetic 27l (4.2 mg, 9.1 mol) in THF (0.5 mL). The reaction mixture was stirred 
30 min at ambient temperature. After dilution of the crude solution with an aqueous KHSO4 
solution (5 %, 0.5 mL) and extraction with Et2O (3 x 5 mL), the solvent of the combined 
organic layers was evaporated under reduced pressure. The crude product was purified by 
preparative HPLC.  
Brightly yellow oil. Yield: 1.8 mg, 3.9 mol, 43 %. 1H NMR 
(500 MHz, Chloroform-d) δ = 8.15 (d, 3J = 16.0 Hz, 1H, N=C(C6F5)-
CH=CH-ar), 7.96 (d, 3J = 8.0 Hz, 1H, ar-6-H), 7.66 (d, 3J = 7.1 Hz, 
1H, ar-3-H), 7.54 (t, 3J = 7.6 Hz, 1H, ar-5-H), 7.43 (t, 3J = 7.6 Hz, 
1H, ar-3-H), 6.97 (d, 3J = 16.0 Hz, 1H, N=C(C6F5)-CH=CH-ar), 3.82 (s, 3H, CO2CH3), 
1.31 (s, 9H, SC(CH3)3). 
19F NMR (470 MHz, Chloroform-d) δ = -170.9 (t, 3J = 20.2 Hz, 
C6F5-3-F, C6F5-5-F), -171.1 (dd, 
3J = 22.3 Hz, 3J = 6.3 Hz, C6F5-4-F), -171.5 (dd, 
3J = 
22.1 Hz, 3J = 7.3 Hz, C6F5-2-F, C6F5-6-F). C21H18F5NO3S (459.43 g mol
-1). MS(ESI): m/z 
= 460.10090 (calcd. 460.10003 [M+H]+).  
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Methyl 2-((1E,3Z)-3-(((R)-tert-Butylsulfinyl)imino)-4,4,4-trifluorobut-1-en-1-
yl)benzoate (76b). Piperidine (0.2 mL, 2.0 mmol) was added to a solution of 
peptidomimetic 27o (4.4 mg, 10 mol) in THF (0.5 mL). The 
reaction mixture was stirred 30 min at ambient temperature. After 
dilution of the crude solution with an aqueous KHSO4 solution (5 %, 
0.5 mL) and extraction with Et2O (3 x 5 mL), the solvent of the combined organic layers 
was evaporated under reduced pressure. The crude product was purified by preparative 
HPLC.  
Brightly yellow oil. Yield: 1.0 mg, 2.7 mol, 24 %. 1H NMR (300 MHz, Chloroform-d) δ 
= 8.79 (d, 3J = 16.0 Hz, 1H, N=C(CF3)-CH=CH-ar), 8.04 (dd, 
3J = 7.6 Hz, 4J = 1.6 Hz, 1H, 
ar-6-H), 7.68 (dd, 3J = 7.6 Hz, 4J = 1.6 Hz, 1H, ar-3-H), 7.60 (td, 3J = 7.6 Hz, 4J = 1.7 Hz, 
1H, ar-5-H), 7.54 (td, 3J = 7.5 Hz, 4J = 1.6 Hz, 1H, ar-4-H), 6.84 (d, 3J = 16.0 Hz, 1H, 
N=C(CF3)-CH=CH-ar), 3.95 (s, 2H, CO2CH3), 1.23 (s, 9H, SC(CH3)3). 19F NMR 
(282 MHz, Chloroform-d) δ = -82.8 (s, 3F, CF3). C16H18F3NO3S (361.38 g mol-1). 
MS(ESI): m/z = 362.218 (calcd. 362.1032 [M+H]+), 384.167 (calcd. 384.0852 [M+Na]+).  
 
Methyl 5-((1E,3Z)-3-(((S)-tert-Butylsulfinyl)imino)-4,4,4-trifluorobut-1-en-1-
yl)nicotinate (76d). Under argon atmosphere, PdCl2(PPh3)2 (1.2 mg) and CuI (1.8 mg) was 
added in one portion to a thoroughly degassed solution of propargylamide 6p (51.0 mg, 
224 mol, 1.0 eq) and arBr 37a (91.5 mg, 424 mol, 1.9 eq) in a mixture of THF/DIPAH, 
(3:1, 1 mL). The reaction mixture was stirred over 3 d at rt. The clear brightly yellow 
solution was diluted with an aqueous NH4Cl- (saturated, 5 mL) and KHSO4 solution (5 %, 
5 mL) and the mixture was extracted with Et2O (3 x 10 mL). The combined organic layers 
were washed with brine, dried over Na2SO4 and the solvent was evaporated under reduced 
pressure. The crude brightly yellow oil was purified by column chromatography 
(PE/EtOAc, 4:1).  
Yellow oil. Yield: 2.3 mg, 6.3 mol, 3 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 9.28 (s, 1H, ar-2-H), 8.98 (s, 1H, ar-6-H), 
8.56 (s, 1H, ar-4-H), 7.99 (d, 3J = 16.1 Hz, 1H, 
C(CF3)CH=CHar), 7.16 (d, 
2J = 16.1 Hz, 1H, C(CF3)CH=CHar), 4.01 (s, 3H, CO2CH3), 
1.25 (s, 9H, SC(CH3)3). C15H17F3N2O3S (362.37 g mol
-1). LCMS(ESI): tr = 8.7 min, m/z = 
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363.0987 (calcd. 363.0985 [M+H]+). TLC: Rf (PE/EtOAc, 1:1) = 0.6, Rf (PE/EtOAc, 2:1) 
= 0.37. [𝛼]589
20  = +26.35 (c 0.39, MeOH).  
 
Ethyl (2E,4E,6Z)-6-(((R)-tert-Butylsulfinyl)imino)-3-methyl-6-phenylhexa-2,4-
dienoate (76f). A mixture of Pd(OAc)2 (6 mg, 27 mol, 11 mol%), TDMPP (12 mg, 
27 mol, 11 mol%) in dry toluene (3 mL) was stirred 15 min at ambient temperature under 
argon atmosphere to give a brightly red catalyst solution. D-Glycine analogous 
propargylamide 6n (55.9 mg, 238 mol, 1.0 eq) and alanin analogous propynoate 73a 
(41 L, 350 mol, 1.5 eq) were added in one portion, turning the solution a black colour. 
After stirring the reaction mixture overnight, it was filtered through a pad of charcoal 
(1 cm) on silica (1 cm). The pad was purged with CH2Cl2/Et2O (1:1, 6 mL) and Et2O 
(6 mL) and the solvent was removed under reduced pressure. The crude product was 
purified by column chromatography (PE/EtOAc, 4:1).  
Brightly yellow oil. Yield: 11.1 mg, 32.0 mol, 13 %. 1H NMR 
(500 MHz, Chloroform-d) δ = 7.84 (d, 3J = 7.7 Hz, 2H, Ph-2-
H, Ph-6-H), 7.48 (t, 3J = 7.6 Hz, 1H, Ph-4-H), 7.40 (t, 3J = 
6.8 Hz, 2H, Ph-3-H, Ph-5-H), 6.69 (dd, 3J = 12.7 Hz, 4J = 2.4 Hz, 1H, 
N=C(Ph)CHCHC(CH3)CHCO2), 6.46 (d, 
2J = 12.9 Hz, 1H, 
N=C(Ph)CHCHC(CH3)CHCO2), 5.80 (s, 1H, N=C(Ph)CHCHC(CH3)CHCO2), 
4.08 (q, 6.88 Hz, 2H, CO2CH2CH3), 2.03 (s, 3H, N=C(Ph)CHCHC(CH3)CHCO2), 1.35 
(s, 9H, SC(CH3)3), 1.22 (t, 
3J = 6.9 Hz, 3H, CO2CH2CH3).
 13C NMR (126 MHz, 
Chloroform-d) δ = 175.6 (N=C(Ph)CHCHC(CH3)CHCO2), 166.3 
(N=C(Ph)CHCHC(CH3)CHCO2), 151.0 (N=C(Ph)CHCHC(CH3)CHCO2), 137.3 
(Ph-C-1), 137.0 (N=C(Ph)CHCHC(CH3)CHCO2), 132.4 (Ph-C-4), 128.8 
(N=C(Ph)CHCHC(CH3)CHCO2), 128.7 (Ph-C-3, Ph-C-5), 128.5 (Ph-C-2, Ph-C-6), 
122.5 (N=C(Ph)CHCHC(CH3)CHCO2), 60.0 (CO2CH2CH3), 57.8 (SC(CH3)3), 22.7 
(SC(CH3)3), 16.8 (N=C(Ph)CHCHC(CH3)CHCO2), 14.4 (CO2CH2CH3).  C19H25NO3S 
(347.16 g mol-1). LCMS(ESI): tr = 10.3 min, m/z = 348.1759 (calcd. 348.1628 [M+H]+), 
370.1556 (calcd. 370.1447 [M+Na]+). TLC: Rf (PE/EtOAc, 4:1) = 0.39. UV/Vis:  = 
126136 cm-1 M-1 (in MeOH at max = 287 nm, c = 17.6 M, d = 1 cm). [𝛼]589
20  = -38.37 (c 
0.020, CHCl3).  
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Ethyl (2E,4E)-3-Methyl-6-oxo-6-phenylhexa-2,4-dienoate (78f). A solution of 
hydrochloric acid (4 M in dioxane, 0.2 mL, 0.8 mmol) was added dropwise to a vigorously 
stirred, icecold solution of rearrangement product 76g (11.1 mg, 32.0 mol) in MeOH 
(4 mL). The reaction mixture was stirred overnight at ambient temperature, before 
evaporating the solvent under reduced pressure. The crude product was diluted with MeOH 
and the residual solvent was coevaporated.  
Orange crystals. Yield: 11.1 mg, 32.0 mol, 13 %. 1H NMR (500 MHz, Methanol-d4) δ = 
8.68 (d, 3J = 15.8 Hz, 1H, PhCOCH=CH-C(CH3)=CH-CO2), 
8.04 (d, 3J = 7.2 Hz, 2H, ar-2-H, ar-6-H), 7.56-7-52 (m, 3H, ar-
3-H, ar-5-H, ar-4-H), 7.40 (dd, 3J = 15.6 Hz, 4J = 0.8 Hz, 1H, 
PhCOCH=CH-C(CH3)=CH-CO2), 6.20 (s, 1H, PhCOCH=CH-C(CH3)=CH-CO2), 4.20 (q, 
3J = 7.1 Hz, 2H, CO2CH2CH3), 2.42 (t, 
4J = 1.5 Hz, 3H, PhCOCH=CH-C(CH3)=CH-CO2), 
1.30 (t, 3J = 7.1 Hz, 3H, CO2CH2CH3). 
13C NMR (126 MHz, Methanol-d4) δ = 190.5 
(PhCOCH=CH-C(CH3)=CH-CO2), 166.2 (PhCOCH=CH-C(CH3)=CH-CO2), 149.7 
(PhCOCH=CH-C(CH3)=CH-CO2), 146.4 (PhCOCH=CH-C(CH3)=CH-CO2), 133.1 (ar-C-
1), 128.5 (ar-C-3, ar-C-5), 128.3 (ar-C-2, ar-C-6), 127.9 (ar-C-4), 125.9 (PhCOCH=CH-
C(CH3)=CH-CO2), 60.8 (CO2CH2CH3), 13.2 (CO2CH2CH3), 12.6 (PhCOCH=CH-
C(CH3)=CH-CO2). C15H16O3 (244.29 g mol
-1). LCMS(ESI): m/z = 245.1178 (calcd. 
245.1172 [M+H]+), 267.0454 (calcd. 267.0992 [M+Na]+). [𝛼]589
20  = -13.35 (c 0.120, 
CHCl3). X-ray crystal structure in Chapter IIX-3. n.  
IIX-3. k) UV/Vis Spectra, pH-Dependence and Photoisomerization Experiments 
216 
IIX-3. k) UV/Vis Spectra, pH-Dependence and Photoisomerization 
Experiments 
 
Diagram EP1. a) UV/Vis  Spectra of peptidomimetic 42c  (0.1 M) in aqueous solution at 
pH 11.0 (red curve) and at pH 2.7 (orange curve).  b) Chemical structures of neutral - and 
protonated peptidomimetic 42c.   
 
 
Diagram EP2: UV/Vis Spectra of azobenzene based peptidomimetic 42d in comparison to 
other peptidomimetics.  a) 42d  (c = 26.4 M) in CH3CN and a pathlength of 1  cm. b) 
Peptidomimetics with EWG CF 3-glycine analogous propargylamide moiety 40g  and 
phenylglycine analogous propargylamide moiety 46j  in CH3CN.  
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Diagram EP3: Photoisomerisation of compound 44 . a) UV/Vis Spectra of one sample of 
peptidomimetic 44 ,  measured at a concentration of 30.6  M in CH3CN and a pathlength of 
1 cm. Black line: UV/Vis spectra of compound 44 .  Blue line: UV/Vis Spectra of compound 
44  after 15 min irradiation at 350 nm. Red line: UV/Vis Spectra of compound 44  after 15 min 
irradiation at 420 nm. All measurements were performed at a concentration of 30.6  M in 
CH3CN and a pathlength of 1  cm. b) Chemical structures of 44  with E  and Z configurated 
azobenzene isomer.  
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Diagram EP4: Reversibility of the photoisomerization of peptidomimetic 44 . Black line: 
UV/Vis Spectra of compound 44 . Blue line: UV/Vis  Spectra of compound 44  after 15 min 
irradiation at 350 nm. Red line: UV/Vis Spectra of isomerized compound 44  after 15 min 
irradiation at 420 nm. Violet line: UV/Vis Spectra of isomerized compound 44  after another 
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15 min irradiation at 350 nm. Orange line: UV/Vis Spectra of isomerized compound 44  after 
15 min irradiation at 420  nm. All measurements were performed with the same sample on 
the same day in a sequence at a concentration of 30.6  M in CH3CN and a pathlength of 
1 cm. 
 
 
Diagram EP5: Influence of light irradiation on the 1H NMR spectra of compound 44 . Above: 
after 15 min irradiation at 420 nm shows E :Z = 8.93:1.00 (11.2 % isomerization). Below: 
after 15 min irradiation at 350 nm shows E :Z = 2.16:1.00 (46.3 % isomerization).  
 
 
Diagramm EP6: Influence of irradiation on compound 44 , observed by 1H NMR 
spectroscopy. Comparison of the region of the C -proton in the 1H NMR spectra (4.8-
3.0 ppm). Above: after 15 min irradiation at 420 nm shows E:Z = 8.93:1.00 (11.2 % 
isomerization).  Below: after 15 min irradiation at 350 nm shows E:Z = 2.16:1.00 (46.3 % 
isomerization).  
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Diagram EP7: UV/Vis  Spectra of diverse rearranged propargylamides. a) The EWG of the 
C was CF3 in 76c and Ph in 76e. b) Analogue of H-Phe-Ala-OMe (76f).   = 126136 cm- 1 M - 1 
(in MeOH at ma x = 287 nm, c = 17.6 M, d = 1 cm, rt).  
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IIX-3. l) CD Spectroscopy 
CD measurements were performed on a J-810 Jasco (Gross-Umstadt) in a range of at least 
190-300 nm and at most 180-450 nm. A quartz tube with a pathlength of 1 mm was applied. 
CH3CN and TFE solutions of the samples were diluted until the H(T) parameter was below 
750 V. Each measurement was repeated with a dilution of 1:10 and compared qualitatively 
to the first measurement to detect intermolecular interaction. All spectra were baseline 
corrected and smoothed by Gauss approximation (f=25, 1x).  
 
 
Diagram EP8. Comparison of CD spectra of 2 -benzoate based peptidomimetic monomer 27c  
and dimer 32c, measured in a) CH3CN and b) in TFE.  
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Diagram EP9: Photoisomerization of the conformation of peptidomimetic 44 .  Black line: CD 
spectrum of compound 44 . Blue line: CD spectra of compound 44  after 15 min irradiation at 
350 nm. Red line: CD spectra of isomerized compound 44  after 15 min irradiation at 420 nm. 
Violet line: CD spectra of isomerized compound 44  after another 15 min irradiation at 
350 nm. All measurements were performed with the same sample on the same day in a 
sequence at a concentration of 765  M in CH3CN and a pathlength of 1  mm.  
 
 
Diagram EP10. Comparison of CD spectra of 3 -benzoate based peptidomimetic monomer 
40d, dimer 57a  and 60 , measured in a) CH3CN and b) in TFE.  
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Diagram EP11. Comparison of CD spectra of a) nicotinate based peptidomimetic monomer 
37a  and dimer 57b measured in CH3CN and in TFE and of b) 4 -benzoate based 
peptidomimetic monomer 52b and dimer 58b.   
 
 
Diagram EP12. Comparison of CD spectra of furan based peptidomimetics 49a  and 59a ,  
measured in a) CH3CN and b) in TFE.  
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Diagram EP13. CD spectra of furan based peptidomimetic 53b,  measured in CH3CN and 
TFE. 
 
IIX-3. m) Molecular Dynamics (MD) Simulations 
Accurate potentials of the backbone torsion angles     and 2 are critical for a 
proper description of the conformational properties of the peptidomimetic scaffolds and 
were determined as described in the work of Krieger et al. [68]. Conformations of the 
peptidomimetics were optimized using the Merck Molecular Force Field (MMFF94) within 
Avogadro (number of steps: 5000, algorithm: steepest descent, convergence: 10e-7) with 
the torsion angles     and 2 constrained at intervals of 20° over a range of 360°. 
The conformational energy (table 1) and the distance of (C(n)-C(n+1)) (table 2) was 
calculated after optimization. The energy profiles, derived from the calculations were 
validated by assignement of the dihedral angles, measured in the X-ray crystal structure. 
The dihedral angles of all D-configured peptidomimetics were mirrored prior to the 
assignment.  
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Diagram EP14. Exemplary energy profile of dihedral angle   in the model compound of 
the ortho-substituted peptidomimetics. The points represent the relative (molecular 
mechanics) energy of the molecule, calculated using  the Merck  Molecular Force Field 
(MMFF94). The rotation of 6the discussed angle was constrained at angles in the range [ -
180°, 180°] at intervals of 20° prior to the structure optimization and energy calculation. 
The model has been designed in order to derive an energy profile which depends only on the 
examined angle.  
 
Table EP1. Energy values of the ortho-substituted peptidomimetic model compound for 
energy profile determination.  
 
rotation      
° G [kJ/mol] G [kJ/mol] G [kJ/mol] G [kJ/mol] G [kJ/mol] 
-180 -113,1 -120,7 -108,5 -97,3 -112,8 
-160 -116,2 -122,6 -109,5 -111,6 -122 
-140 -110,8 -120 -110,5 -117,1 -115,6 
-120 -97 -115 -111,6 -117,6 -103,4 
-100 -77,4 -112,2 -113 -116,3 -85,5 
-80 -54,9 -109,3 -114,7 -111,9 -62,8 
-60 -30,9 -102,9 -115,3 -114,5 -39,5 
-40 -60,4 -91,5 -119,1 -114,5 -103 
-20 -90,1 -73,4 -122,2 -111,4 -104,7 
0 -93 -49,8 -121,2 -103,3 -104,2 
20 -93,3 -64,1 -116,5 -106,6 -100,6 
40 -89,8 -78,6 -108,7 -110,6 -93,6 
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60 -82,6 -91 -105,1 -110,6 -83,4 
80 -71,3 -91,4 -104,5 -113,4 -70,5 
100 -56,2 -87,7 -105 -115,6 -55,6 
120 -38,5 -94,6 -105,6 -122,1 -96,8 
140 -113,4 -102,1 -106,3 -123 -108,8 
160 -120,8 -112,4 -107 -119,9 -115,8 
180 -122,5 -120 -108 -112,6 -117 
 
Table EP2. Energy values of the meta-substituted peptidomimetic model compound for 
energy profile determination.  
 
rotation      
° G [kJ/mol] G [kJ/mol] G [kJ/mol] G [kJ/mol] G [kJ/mol] 
-180 -147,5 -143,9 -146,3 -144,1 -148,2 
-160 -145,8 -146,8 -146,3 -147,6 -147,1 
-140 -138,4 -145 -146,7 -147,3 -140,3 
-120 -125 -141,3 -147,2 -143,3 -127,7 
-100 -105,9 -140,2 -147,5 -137 -108,7 
-80 -103,6 -139,3 -147,9 -136,4 -115,7 
-60 -114,4 -134,6 -148,1 -143,7 -122,3 
-40 -122 -125,6 -148,4 -147,8 -126,3 
-20 -128,9 -108,4 -148,5 -147,9 -128,1 
0 -132 -96,6 -148,7 -144,6 -127,1 
20 -132,1 -109,4 -148,6 -147,1 -123,4 
40 -128,8 -122,2 -148,4 -146,7 -117,1 
60 -121,7 -128,2 -147,9 -142,5 -114,5 
80 -110,3 -130,1 -147,3 -135,5 -114,4 
100 -101,8 -126,1 -146,7 -134,9 -106,1 
120 -121,5 -120,9 -146,2 -141,7 -123,6 
140 -134,8 -125 -145,8 -146,1 -135,5 
160 -142,9 -136,2 -145,6 -146,8 -143,1 
180 -146,3 -143,8 -145,7 -144 -147,4 
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Figure EP2. Comparison of the torsion angles  of peptidomimetics 46j ,  52b and 55c.  a) Model 
compound, used for the calculation of the energy profiles corresponding to the torsion 
angles.  The angles observed in the X-ray crystal structures are flagged with a pentagon (L -
46j), a star (D-52b)  and a triangle (D-55c)  in the colors, corresponding to the respective 
angles. b) X-ray crystal structures of compounds L-46j  (1 = -146°,   = -136°,  = -53°,   =  
180°,  =  and 2 = 179°), c) D-52b (mirrored angles: 1 = -150°,  = -104°,  = 
38°,   = °,  =  and 2 = -174°) and d) D-55c  (mirrored angles: 1 n.a.,   = -56°, 
 = -130°,   = °,  = − and 2 = -176°) (for more details, see Table EP3).  
 
Table EP3. Energy values of the para-substituted peptidomimetic model compound for 
energy profile determination.  
 
rotation      
° G [kJ/mol] G [kJ/mol] G [kJ/mol] G [kJ/mol] G [kJ/mol] 
-180 -122,9 -121,3 -122,6 -119,6 -102 
-160 -121,1 -124 -123,1 -122,8 -99,4 
-140 -113,6 -122,1 -123,6 -122,5 -91,7 
-120 -100,1 -118,4 -123,9 -118,4 -78,8 
-100 -80,9 -117,8 -124 -111,9 -83,2 
-80 -77,6 -116,9 -123,7 -111,2 -99,8 
-60 -88,6 -112,3 -123,3 -118 -112,3 
-40 -96,2 -102,3 -122,9 -122,9 -120,4 
-20 -102,7 -84,5 -122,5 -123,2 -123,5 
0 -105,8 -70,3 -122,3 -120 -122,2 
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20 -106 -83,5 -122,4 -122,7 -118,4 
40 -102,8 -96 -122,5 -122,3 -118,8 
60 -95,6 -102,2 -122,5 -118 -112 
80 -84,6 -103,3 -122,4 -111,1 -99,4 
100 -78,8 -100 -122,2 -110 -82,8 
120 -89,8 -95,5 -122,1 -116,9 -71 
140 -112,4 -99,9 -122 -122,1 -86 
160 -120,6 -110,8 -122,1 -122,8 -100,1 
180 -123,9 -119,6 -122,4 -120 -102,9 
 
 
 
Figure EP3. Comparison of the torsion angles of the peptidomimetics with the results from 
MD calculations.  Left side: Model compound, used for the calculation of the energy profiles 
corresponding to the torsion angles. The angles observed in the X -ray crystal structures are 
flagged with a star  (L-49a) in the colors, corresponding to the respective angles. Right side: 
X-ray crystal structure of compound L-49a  (1 = -162°,  = -92°,  = -112°,   =  129°,  
 = − and 2 = 178°). (For more details, see Table EP4).  
 
Table EP4: Energy values of the furan-based peptidomimetic model compound for energy 
profile determination.  
rotation      
° G [kJ/mol] G [kJ/mol] G [kJ/mol] G [kJ/mol] G [kJ/mol] 
-180 -183,1 -176,7 -180,1 -180 -209,7 
-160 -181,5 -179,3 -180,8 -180,1 -208,7 
-140 -174,2 -177,2 -181,5 -176,6 -202,8 
-120 -160,9 -174,3 -182,2 -169,9 -191,6 
-100 -141,8 -176,3 -182,8 -162,7 -174,6 
-80 -119,6 -176 -183,4 -172,7 -153,4 
-60 -147,6 -172,1 -183,9 -188,8 -171,3 
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-40 -155,3 -162,2 -184,1 -200,4 -178,3 
-20 -162,5 -144,4 -184 -207,1 -182,1 
0 -166 -132,8 -183,5 -209,1 -183,1 
20 -166,2 -144,7 -182,8 -206,4 -181,8 
40 -162,9 -152,6 -181,8 -199,1 -177,7 
60 -155,7 -165,7 -182,9 -187,2 -170,5 
80 -144,5 -165,9 -180,1 -171,3 -160 
100 -129,4 -161,5 -179,5 -160,5 -174,5 
120 -110,6 -155,9 -179,1 -167,6 -191,2 
140 -168,7 -160,8 -179 -175 -202,6 
160 -176,3 -171,7 -179,2 -179,2 -208,4 
180 -179,2 -178,9 -179,7 -182,9 -209,6 
 
 
 
Figure EP4. Comparison of the torsion angles  of the two conformers of peptidomimetic x  
with the results from MD calculations.  Left side: Model compound, used for the calculation 
of the energy profiles corresponding to the torsion angles. The angles observed in the X -ray 
crystal structures are flagged with a triangle ( 56b A) and a star (56b B) in the colors, 
corresponding to the respective angles. Right side: X -ray crystal structures of both 
conformers of compound D-56b A (mirrored angles: 1 n.a.,   = 65°,   = -112°,   =  151°,  
 = − and 2 = -178°) and D-Leux 56b  (mirrored angles: 1 n.a.,   = 55°,   = -109°,   =  
142°,  = − and 2 = -179°). (for more details, see Table EP5).  
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Table EP5. Energy values of the thiophene -based peptidomimetic model compound for 
energy profile determination.  
rotation      
° G [kJ/mol] G [kJ/mol] G [kJ/mol] G [kJ/mol] G [kJ/mol] 
-180 -219,2 -217,3 -217,8 -219,5 -231,8 
-160 -217,7 -220,2 -218,3 -220,2 -230,6 
-140 -210,4 -218,6 -218,9 -217,7 -224,4 
-120 -197,1 -215,2 -219,4 -211,9 -212,7 
-100 -178 -214,7 -219,9 -204,6 -195,4 
-80 -174,6 -213,9 -220,2 -206,9 -182,8 
-60 -185,5 -209,3 -220,5 -217,3 -188,8 
-40 -193,1 -199,5 -220,7 -225,4 -192,1 
-20 -200,2 -182,2 -220,7 -230,4 -194,2 
0 -203,3 -170,8 -220,5 -231,9 -194,1 
20 -203,5 -183 -220,1 -230 -190,3 
40 -200,3 -194,9 -219,6 -224,6 -184,4 
60 -193 -202,9 -219,1 -216,2 -189,5 
80 -181,8 -203,1 -218,5 -205,5 -186,3 
100 -172,6 -198,7 -218 -201,2 -180,7 
120 -192,5 -193,1 -217,6 -209,5 -199,4 
140 -206,1 -197,5 -217,4 -215,8 -212,3 
160 -214,4 -208,4 -217,4 -219,4 -219,3 
180 -219,1 -216,3 -217,7 -219,4 -220,5 
 
 
Table EP6. Energy values of the olefin -based peptidomimetic model compound for energy 
profile determination.  
 
rotation      
° G [kJ/mol] G [kJ/mol] G [kJ/mol] G [kJ/mol] G [kJ/mol] 
-180 -295,3 -292,8 -295,6 -295,4 -295,9 
-160 -292,1 -295,6 -295,5 -295,4 -293,2 
-140 -283,6 -293,9 -295,4 -294,2 -284,7 
-120 -268,4 -290,2 -295,3 -291,5 -270,2 
-100 -247,5 -287,5 -294,5 -288,7 -250 
-80 -237,6 -284,5 -294,2 -289,3 -249 
-60 -253,9 -278,4 -294,1 -290,6 -264,5 
-40 -265,9 -267,9 -293,5 -289,2 -275,9 
-20 -274,6 -259,6 -292,9 -284 -282,6 
0 -277,9 -251,8 -292,8 -275,3 -284,3 
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20 -276,3 -265,3 -293,2 -282,8 -281,1 
40 -269,9 -275,8 -293,9 -288,1 -274,3 
60 -258,6 -280,4 -294,6 -289,4 -265,6 
80 -242,4 -279,7 -295,1 -287,8 -250,2 
100 -246,7 -275,1 -295,4 -287 -248,9 
120 -268,7 -269,1 -295,5 -290 -269,1 
140 -283,9 -273,7 -295,5 -293,4 -284,1 
160 -292,8 -285 -295,4 -294,9 -292,7 
180 -295,6 -292,8 -295,4 -295,5 -295,6 
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Details of crystal and refinement data can be found in Table EP7-EP29, which contain the 
supplementary crystallographic data for this paper.  
 
Table EP7. Crystal data and structure refinement for the ortho-substituted peptidomimetics 
27n,  29  and 31o .   
compound 27n 29 31o 
Diffractometer SuperNova, Dual, Cu at 
zero, Atlas 
Rigaku Supernova 
diffractometer 
SuperNova, Dual, Cu at 
zero, Atlas 
Radiation Source CuKα (λ = 1.54184) CuKα (λ = 1.54184 Å) CuKα (λ = 1.54184) 
Identification code  wuensch25 Wuensch28 wuensch12 
Empirical formula  C16H18F3NO3S C20H18F5NO5S C12H11ClF3NO2 
Formula weight  361.37 479.41 293.67 
Temperature/K  100.01(10) 100.0(1) 100.01(10) 
Crystal system  triclinic orthorhombic monoclinic 
Space group  P1 P212121 P21 
a/Å  6.6342(2) 6.2681(3) 6.95431(14) 
b/Å  9.9578(6) 12.7729(9) 9.75251(17) 
c/Å  13.8970(8) 25.830(2) 19.1760(3) 
α/°  72.512(5) 90 90 
β/°  83.885(4) 90 95.3554(16) 
γ/°  79.078(4) 90 90 
Volume/Å3  858.57(8) 2068.0(3) 1294.88(4) 
Z  2 4 4 
ρcalcmg/mm3  1.398 1.540 1.506 
μ/mm-1  2.096 2.120 2.966 
F(000)  376.0 984.0 600.0 
Crystal size/mm3  0.163 × 0.098 × 0.024 0.192 × 0.047 × 0.01 0.187 × 0.05 × 0.027 
2Θ range for data 
collection  
6.678 to 144.108 6.844 to 135.054 9.264 to 143.942° 
Index ranges  -8 ≤ h ≤ 8, -12 ≤ k ≤ 12, -
17 ≤ l ≤ 17 
-7 ≤ h ≤ 6, -15 ≤ k ≤ 11, -
29 ≤ l ≤ 30 
-7 ≤ h ≤ 8, -12 ≤ k ≤ 12, -
23 ≤ l ≤ 23 
Reflections collected  14748 8878 21714 
Independent reflections  5946 [Rint = 0.0244, Rsigma 
= 0.0285] 
3580 [Rint = 0.0588, Rsigma 
= 0.0734] 
5106[R(int) = 0.0414] 
Data/restraints/parameters  5812 3580/0/304 5106/1/347 
Goodness-of-fit on F2  1.044 1.095 1.098 
Final R indexes [I>=2σ (I)]  R1 = 0.0265, wR2 = 0.0673 R1 = 0.0684, wR2 = 
0.1707 
R1 = 0.0486, wR2 = 0.1305 
Final R indexes [all data]  R1 = 0.0274, wR2 = 0.0683 R1 = 0.0810, wR2 = 
0.1787 
R1 = 0.0510, wR2 = 0.1325 
Largest d. peak/hole / e Å-3  0.17/-0.20 0.90/-0.41 0.33/-0.21 
Flack parameter -0.013(7) -0.03(3) 0.03(2) 
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Table EP8. Crystal data and structure refinement for the furan-based structures and the meta-
substituted peptidomimetics 40d,  41a  and 46j .   
compound 40d 41a 46j 
Diffractometer SuperNova, Dual, Cu at 
zero, Atlas 
SuperNova, Dual, Cu at 
zero, Atlas 
SuperNova, Dual, Cu at 
zero, Atlas 
Radiation Source CuKα (λ = 1.54184) (Mo Ka) X-ray Source CuKα (λ = 1.54184) 
Identification code  wuensch26 wuensch03 wuensch09 
Empirical formula  C21H29NO3S C17H24N2O3S C21H23NO3S 
Formula weight  375.51 336.44 369.46 
Temperature/K  100.01(10) 100.00(10) 100.00(10) 
Crystal system  monoclinic orthorhombic monoclinic 
Space group  P21 P212121 P21 
a/Å  10.4953(5) 8.82565(14) 10.3754(9) 
b/Å  5.9572(3) 10.48674(13) 5.8828(3) 
c/Å  16.4920(7) 19.8727(3) 15.9341(16) 
α/°  90 90 90 
β/°  99.901(5) 90 101.162(8) 
γ/°  90 90 90 
Volume/Å3  1015.76(8) 1839.26(4) 954.17(14) 
Z  2 4 2 
ρcalcmg/mm3  1.228 1.215 1.288 
μ/mm-1  1.568 0.191 1.668 
F(000)  404.0 720.0 392.0 
Crystal size/mm3  0.181 × 0.043 × 0.02 0.3 × 0.3 × 0.2754 0.358 × 0.071 × 0.02 
2Θ range for data 
collection  
5.44 to 144.256 5.648 to 64.608° 5.654 to 143.896° 
Index ranges  -12 ≤ h ≤ 12, -7 ≤ k ≤ 7, -
20 ≤ l ≤ 20 
-12 ≤ h ≤ 13, -15 ≤ k ≤ 15, 
-29 ≤ l ≤ 29 
-12 ≤ h ≤ 11, -7 ≤ k ≤ 7, -
19 ≤ l ≤ 19 
Reflections collected  16407 111421 5148 
Independent reflections  3961 [Rint = 0.0466, Rsigma 
= 0.0358] 
6285[R(int) = 0.0655] 5148[R(int) = ?] 
Data/restraints/parameters  3961/1/243 6285/7/244 5148/1/244 
Goodness-of-fit on F2  1.107 1.084 1.128 
Final R indexes [I>=2σ (I)]  R1 = 0.0415, wR2 = 0.1139 R1 = 0.0321, wR2 = 0.0885 R1 = 0.0574, wR2 = 0.1628 
Final R indexes [all data]  R1 = 0.0445, wR2 = 0.1182 R1 = 0.0335, wR2 = 0.0900 R1 = 0.0613, wR2 = 0.1651 
Largest d. peak/hole / e Å-3  0.51/-0.48 0.37/-0.33 0.72/-0.45 
Flack parameter -0.003(13) 0.004(12) -0.03(3) 
 
Table EP9. Crystal data and structure refinement for the thiophene-based structures and the 
para-substituted peptidomimetics 49a ,  50f  and 52b.   
compound 49a 50f 52b 
Diffractometer SuperNova, Dual, Cu at 
zero, Atlas 
SuperNova, Dual, Cu at 
zero, Atlas 
SuperNova, Dual, Cu at 
zero, Atlas 
Radiation Source SuperNova (Cu Ka) X-ray 
Source 
SuperNova (Cu Ka) X-ray 
Source 
SuperNova (Mo Ka) X-ray 
Source 
Identification code  wuensch04 wuensch06 wuensch02  
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Empirical formula  C16H23NO4S C15H18F3NO4S C18H25NO3S  
Formula weight  325.41 365.36 335.45  
Temperature/K  100.0(1) 100.0(1) 291(4)  
Crystal system  monoclinic orthorhombic orthorhombic  
Space group  P21 P212121 P212121  
a/Å  9.85826(13) 6.38314(9) 8.56680(14)  
b/Å  5.86078(10) 13.1674(2) 11.7350(3)  
c/Å  14.6079(2) 21.3573(3) 19.5702(4)  
α/°  90 90 90 
β/°  97.4233(13) 90 90 
γ/°  90 90 90 
Volume/Å3  836.93(2) 1795.08(5) 1967.43(7)  
Z  2 4 4 
ρcalcmg/mm3  1.291 1.352 1.132 
μ/mm-1  1.867 2.053 0.177  
F(000)  348.0 760.0 720.0  
Crystal size/mm3  0.2753 × 0.1293 × 0.0858 0.2985 × 0.0613 × 0.0436 0.3919 × 0.354 × 0.2328  
2Θ range for data 
collection  
9.046 to 144.258° 7.888 to 152.728° 5.19 to 59.998°  
Index ranges  -12 ≤ h ≤ 12, -7 ≤ k ≤ 6, -
18 ≤ l ≤ 18 
-7 ≤ h ≤ 7, -16 ≤ k ≤ 16, -
26 ≤ l ≤ 26 
-12 ≤ h ≤ 12, -16 ≤ k ≤ 16, 
-27 ≤ l ≤ 27  
Reflections collected  13609 31815 115409 
Independent reflections  3048[R(int) = 0.0342] 3739[R(int) = 0.0362] 5734[R(int) = 0.0402]  
Data/restraints/parameters  3048/1/291 3739/19/364 5734/0/221  
Goodness-of-fit on F2  1.051 1.028 1.069 
Final R indexes [I>=2σ (I)]  R1 = 0.0232, wR2 = 0.0590 R1 = 0.0279, wR2 = 0.0718 R1 = 0.0305, wR2 = 0.0831  
Final R indexes [all data]  R1 = 0.0235, wR2 = 0.0592 R1 = 0.0294, wR2 = 0.0730 R1 = 0.0333, wR2 = 0.0849  
Largest d. peak/hole / e Å-3  0.18/-0.23 0.19/-0.24 0.15/-0.19  
Flack parameter 0.002(7) -0.005(7) 0.000(10) 
 
Table EP10. Crystal data and structure refinement for the para-substituted peptidomimetic 
55c and the olefin-based peptidomimetics 75e,f  generated by the hydroalkinylation reaction.  
compound 55c 75e 75f 
Diffractometer Rigaku Supernova 
diffractometer 
Rigaku Supernova 
diffractometer 
Rigaku Supernova 
diffractometer 
Radiation Source CuKα (λ = 1.54184 Å) MoKα (λ = 0.71073 Å) MoKα (λ = 0.71073 Å) 
Identification code  Wuensch31 Wuensch29 Wuensch30 
Empirical formula  C19H22F3NO4 C13H22ClNO2 C30H48Cl2N2O4 
Formula weight  385.37 259.76 571.60 
Temperature/K  100.00(10) 100.0(2) 100.0(2) 
Crystal system  orthorhombic monoclinic orthorhombic 
Space group  P212121 C2 C2221 
a/Å  6.4600(2) 28.7444(4) 20.4594(14) 
b/Å  14.0712(6) 6.81340(10) 22.3693(13) 
c/Å  21.0520(7) 15.9919(2) 14.3402(8) 
α/°  90 90 90 
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β/°  90 99.0930(10) 90 
γ/°  90 90 90 
Volume/Å3  1913.62(12) 3092.61(7) 6563.0(7) 
Z  4 8 8 
ρcalcmg/mm3  1.338 1.116 1.157 
μ/mm-1  0.963 0.239 0.232 
F(000)  808.0 1120.0 2464.0 
Crystal size/mm3  0.163 × 0.067 × 0.03 0.223 × 0.181 × 0.126 0.58 × 0.037 × 0.02 
2Θ range for data 
collection  
7.556 to 151.392 3.542 to 60.064 3.642 to 50.7 
Index ranges  -7 ≤ h ≤ 7, -17 ≤ k ≤ 9, -
18 ≤ l ≤ 26 
-40 ≤ h ≤ 40, -9 ≤ k ≤ 9, -22 
≤ l ≤ 22 
-22 ≤ h ≤ 24, -26 ≤ k ≤ 23, 
-17 ≤ l ≤ 17 
Reflections collected  6929 91051 25863 
Independent reflections  3824 [Rint = 0.0374, 
Rsigma = 0.0650] 
9077 [Rint = 0.0298, Rsigma = 
0.0156] 
6010 [Rint = 0.0530, Rsigma 
= 0.0543] 
Data/restraints/parameters  3824/15/342 9077/1/380 6010/4/338 
Goodness-of-fit on F2  1.021 1.086 1.040 
Final R indexes [I>=2σ (I)]  R1 = 0.0422, wR2 = 
0.0888 
R1 = 0.0296, wR2 = 0.0791 R1 = 0.0825, wR2 = 0.2082 
Final R indexes [all data]  R1 = 0.0591, wR2 = 
0.0966 
R1 = 0.0316, wR2 = 0.0803 R1 = 0.1231, wR2 = 0.2395 
Largest d. peak/hole / e Å-3  0.18/-0.20 0.30/-0.17 0.53/-0.31 
Flack parameter -0.16(14) -0.003(11) 0.04(4) 
 
Table EP12. Crystal data and structure refinement for peptidomimetics, after undergoing the 
Propargylamide-Enimine rearrangement, 76f  and 77c,g .   
compound 76f 77c 77g 
Diffractometer SuperNova, Dual, Cu at 
zero, Atlas 
SuperNova, Single source at 
offset, Eos 
Rigaku Supernova 
diffractometer 
Radiation Source CuKα (λ = 1.54184) Mo Kα (0.71073 Å) CuKα (λ = 1.54184) 
Identification code  wuensch07 Wuensch17 wuensch32b 
Empirical formula  C21H24NO3S C11H7F3O3 C15H16O3 
Formula weight  370.47 244.17 244.28 
Temperature/K  100.01(10) 100.0(1) 100.01(10) 
Crystal system  orthorhombic monoclinic triclinic 
Space group  P212121 C2/c P-1 
a/Å  6.03357(10) 15.9688(11) 6.3379(3) 
b/Å  10.31093(18) 10.3072(7) 7.9472(3) 
c/Å  31.0591(6) 13.6073(13) 13.9013(4) 
α/°  90 90 104.048(3) 
β/°  90 104.846(8) 92.626(3) 
γ/°  90 90 112.032(4) 
Volume/Å3  1932.24(6) 2164.9(3) 622.30(4) 
Z  4 8 2 
ρcalcmg/mm3  1.274 1.498 1.304 
μ/mm-1  1.648 0.141 0.730 
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F(000)  788.0 992.0 260.0 
Crystal size/mm3  0.2716 × 0.123 × 0.028 0.393 × 0.307 × 0.193 0.285 × 0.24 × 0.047 
2Θ range for data 
collection  
9.036 to 143.992° 4.8 to 52.0° 
12.416 to 144.25 
Index ranges  -7 ≤ h ≤ 7, -12 ≤ k ≤ 12, -
38 ≤ l ≤ 38 
-17 ≤ h ≤ 19, -12 ≤ k ≤ 7, -16 
≤ l ≤ 13 
-7 ≤ h ≤ 7, -9 ≤ k ≤ 9, -17 
≤ l ≤ 17 
Reflections collected  47179 4376 9772 
Independent reflections  3806[R(int) = 0.0443] 2089[R(int) = 0.0339] 2432 [Rint = 0.0201, 
Rsigma = 0.0158] 
Data/restraints/parameters  3806/0/239 2089/0/182 2432/0/198 
Goodness-of-fit on F2  1.039 1.060 1.098 
Final R indexes [I>=2σ (I)]  R1 = 0.0382, wR2 = 
0.0996 
R1 = 0.0509, wR2 = 0.1105 R1 = 0.0603, wR2 = 
0.1621 
Final R indexes [all data]  R1 = 0.0391, wR2 = 
0.1005 
R1 = 0.0798, wR2 = 0.1307 R1 = 0.0629, wR2 = 
0.1642 
Largest d. peak/hole / e Å-3  0.82/-0.41 0.28/-0.30 0.32/-0.50 
 
 
Methyl 2-((R)-3-(((S)-Butylsulfinyl)amino)-4,4,4-trifluorobut-1-yne-1-
yl)benzoate (27n) 
Single crystals of C16H18F3NO3S were achieved by evaporation of the solvent of a 
concentrated MeOH solution at rt.  
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Table EP13. Fractional Atomic Coordinates (×10 4)  and Equivalent Isotropic Displacement 
Parameters (Å2×103)  for peptidomimetic 27n . U eq  is defined as 1/3 of of the trace of t he 
orthogonalised U I J tensor.   
Atom x y z U(eq) 
S1 7136.5(8) 2316.1(6) 2907.8(5) 24.12(14) 
F1 6362(2) 5077.9(19) 4485.9(12) 31.0(3) 
F2 8524(2) 6263.8(18) 3486.2(12) 29.7(3) 
F3 5277(3) 7072.7(19) 3382.9(13) 35.0(4) 
O1 7957(3) 2018(2) 1940.6(15) 33.3(5) 
O2 8020(2) 6149.4(19) -2023.1(13) 21.9(4) 
O3 7595(3) 5234.2(19) -345.2(13) 22.9(4) 
N1 7987(3) 3740(2) 3021.3(16) 21.8(4) 
C1 8596(4) 929(3) 3904(2) 25.6(5) 
C2 10887(4) 972(3) 3726(2) 31.2(6) 
C3 8101(5) -485(3) 3838(2) 35.7(7) 
C4 7725(4) 1183(3) 4910(2) 30.1(6) 
C5 6540(4) 5085(3) 2768.7(19) 20.6(5) 
C6 6683(4) 5879(3) 3537(2) 24.1(5) 
C7 6813(3) 6028(3) 1747.0(19) 19.8(5) 
C8 6970(3) 6836(3) 916.2(19) 18.8(5) 
C9 7049(3) 7941(3) -19.5(19) 18.7(5) 
C10 6698(3) 9349(3) 45(2) 22.9(5) 
C11 6646(4) 10502(3) -812(2) 25.9(6) 
C12 6979(4) 10284(3) -1766(2) 26.0(5) 
C13 7356(3) 8907(3) -1843.8(19) 21.5(5) 
C14 7378(3) 7731(3) -989.8(19) 18.5(5) 
C15 7711(3) 6305(3) -1179.3(19) 18.8(5) 
C16 7743(4) 3842(3) -493(2) 27.6(6) 
S2 3006.1(7) 3682.8(6) 7199.8(4) 20.24(13) 
F4 3958(3) 7320.3(19) 5413.3(12) 36.3(4) 
F5 1492(2) 8397.2(18) 6182.2(12) 32.3(4) 
F6 4635(3) 8494.0(18) 6375.7(13) 33.0(4) 
O4 2445(3) 2860(2) 8242.7(14) 27.4(4) 
O5 2016(3) 4680(2) 12028.2(14) 24.6(4) 
O6 2519(3) 4666(2) 10408.2(14) 25.8(4) 
N2 2088(3) 5422(2) 6996.4(16) 19.0(4) 
C17 1328(4) 3312(3) 6361.6(19) 20.0(5) 
C18 1922(4) 4082(3) 5281(2) 28.8(6) 
C19 1855(4) 1694(3) 6554(2) 31.0(6) 
C20 -924(4) 3764(3) 6642(2) 27.2(6) 
C21 3487(3) 6290(3) 7172.9(18) 18.6(5) 
C22 3393(4) 7631(3) 6279.9(19) 24.0(5) 
C23 3020(3) 6683(3) 8118.3(19) 19.3(5) 
C24 2645(3) 7027(3) 8880.7(19) 19.0(5) 
C25 2196(3) 7653(3) 9704.8(18) 18.4(5) 
C26 1977(3) 9145(3) 9425(2) 22.5(5) 
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C27 1522(4) 9886(3) 10145(2) 24.4(5) 
C28 1309(4) 9137(3) 11160(2) 26.7(6) 
C29 1541(3) 7661(3) 11449(2) 22.8(5) 
C30 1976(3) 6900(3) 10729.7(19) 19.2(5) 
C31 2168(3) 5316(3) 11133.9(19) 21.1(5) 
C32 2714(5) 3126(3) 10738(2) 30.4(6) 
 
(R,Z)-3-(2-Amino-2-(perfluorophenyl)ethylidene)isobenzofuran-1(3H)-one (29) 
Single crystals of C20H18F5NO5S were achieved by evaporation of the solvent of a 
concentrated MeOH solution at rt.  
 
Table EP15. Fractional Atomic Coordinates (×10 4)  and Equivalent Isotropic Displacement 
Parameters (Å2×103)  for  benzofuran 29 .  U eq is defined as 1/3 of of the tra ce of the 
orthogonalised U I J tensor.   
Atom x y z U(eq) 
S1 9982(3) 5536.1(14) 5440.0(8) 28.9(4) 
O3 7839(9) 5671(4) 5221(3) 35.6(14) 
O4 10093(9) 5730(4) 5985(2) 35.0(13) 
O5 11545(8) 6146(4) 5135(2) 32.0(13) 
C17 10685(12) 4171(6) 5351(4) 33(2) 
C18 13074(12) 4060(7) 5479(4) 41(2) 
C19 10265(14) 3881(7) 4796(4) 40(2) 
C20 9300(14) 3537(7) 5723(4) 44(2) 
F1 1153(7) 8180(4) 5728(2) 36.8(11) 
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F2 -444(8) 10108(4) 5893(2) 44.1(13) 
F3 1749(9) 11507(4) 6479(2) 50.2(15) 
F4 5647(9) 10998(4) 6863(2) 49.1(14) 
F5 7330(8) 9097(4) 6672(2) 39.7(12) 
O1 7889(9) 6600(4) 6870(2) 33.8(13) 
O2 10802(10) 6081(5) 7311(3) 48.2(17) 
N1 5160(12) 7267(5) 5507(3) 29.5(14) 
C1 9047(14) 5885(7) 7156(4) 37(2) 
C2 7743(14) 4948(7) 7210(3) 33.4(19) 
C3 8190(16) 3995(8) 7438(4) 43(2) 
C4 6618(18) 3225(7) 7421(4) 47(2) 
C5 4656(17) 3427(7) 7198(4) 44(2) 
C6 4197(15) 4377(7) 6961(4) 37(2) 
C7 5777(14) 5135(6) 6972(3) 31.6(19) 
C8 5922(13) 6175(6) 6728(3) 32.3(18) 
C9 4653(12) 6632(6) 6386(3) 31.9(18) 
C10 5404(11) 7541(6) 6067(3) 30.6(18) 
C11 4316(13) 8583(6) 6185(3) 29.4(18) 
C12 2307(12) 8862(6) 6006(4) 30.9(18) 
C13 1451(14) 9837(7) 6098(4) 34.9(19) 
C14 2559(15) 10555(7) 6388(4) 40(2) 
C15 4549(14) 10307(6) 6583(4) 36(2) 
C16 5394(12) 9321(7) 6476(3) 33.1(18) 
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Methyl (S)-2-(3-Amino-4,4,4-trifluorobut-1-yn-1-yl)benzoate (31o) 
Single crystals of C12H11ClF3NO2 were achieved by evaporation of the solvent of a 
concentrated CHCl3 solution at rt.  
 
Table EP14. Fractional Atomic Coordinates (×10 4)  and Equivalent Isotropic Displacement 
Parameters (Å2×103)  for amine 31o .  Ue q is defined as 1/3 of of the trace of the orthogonalised 
U IJ tensor.  
Atom x y z U(eq) 
Cl1 5078.1(14) 6507.5(9) 5619.1(5) 27.0(2) 
F1 -316(6) 9044(3) 7125.5(16) 51.5(9) 
F2 -48(6) 9466(3) 6038.5(17) 45.4(8) 
F3 2351(5) 8617(3) 6679.3(18) 46.0(7) 
O1 398(5) 6030(4) 9663.4(17) 37.4(8) 
O2 595(5) 6982(4) 8611.3(16) 34.0(7) 
N1 573(6) 6666(4) 5731.9(18) 25.9(7) 
C1 433(7) 8591(6) 6555(2) 33(1) 
C2 -293(7) 7155(5) 6373(2) 27.2(8) 
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C3 153(6) 6211(5) 6956(2) 27.3(9) 
C4 431(6) 5453(5) 7444(2) 25.9(9) 
C5 714(6) 4382(5) 7958(2) 26.3(9) 
C6 931(7) 3059(5) 7695(2) 29.7(10) 
C7 1182(7) 1946(5) 8139(2) 33.2(9) 
C8 1201(7) 2124(5) 8861(3) 35(1) 
C9 985(7) 3427(6) 9126(2) 31.5(9) 
C10 756(6) 4572(5) 8690(2) 26.7(9) 
C11 564(7) 5922(5) 9046(2) 29.3(9) 
C12 493(8) 8317(5) 8932(3) 36.7(10) 
Cl2 237.7(14) 3436.8(9) 5628.3(5) 27.0(2) 
F4 6453(6) 944(4) 7140.3(16) 50.4(8) 
F5 5618(6) 504(3) 6053.5(17) 44.1(8) 
F6 3531(5) 1332(3) 6699.6(18) 44.6(7) 
O3 5830(6) 3913(4) 9671.7(18) 41.4(9) 
O4 6122(5) 3016(4) 8611.4(16) 32.6(7) 
N2 4796(5) 3288(4) 5736.1(18) 26.2(7) 
C13 5386(8) 1384(6) 6572(3) 33.7(10) 
C14 5976(7) 2827(4) 6384(2) 26.0(8) 
C15 5775(6) 3770(5) 6961(2) 26.6(9) 
C16 5682(6) 4527(5) 7446(2) 25.0(9) 
C17 5592(6) 5606(5) 7957(2) 25.5(9) 
C18 5390(6) 6931(5) 7685(2) 28.4(9) 
C19 5266(7) 8053(5) 8123(3) 32.6(9) 
C20 5354(8) 7862(6) 8847(3) 35.2(10) 
C21 5548(7) 6548(6) 9119(2) 32.6(10) 
C22 5669(7) 5407(5) 8685(2) 28.5(9) 
C23 5873(7) 4054(6) 9047(2) 31.6(10) 
C24 6339(8) 1678(5) 8932(3) 36.2(10) 
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Methyl 3-((R)-3-(((R)-tert-Butylsulfinyl)amino)-3-cyclohexylprop-1-yn-1-
yl)benzoate (40d) 
Single crystals of C21H29NO3S were achieved by evaporation of the solvent of a 
concentrated CHCl3 solution at rt.  
 
Table EP17. Fractional Atomic Coordinates (×10 4)  and Equivalent Isotropic Displacement 
Parameters (Å2×103) for  C2 1H2 9NO3S 40d. Ueq  is defined as 1/3 of of the trace of the 
orthogonalised U I J tensor.  
Atom x y z U(eq) 
S1 3503.7(6) 1314.6(11) 4801.1(4) 17.41(19) 
O1 4634(2) 1693(3) 4375.2(12) 21.1(5) 
O2 8021(3) 9971(5) 10142.7(15) 35.1(6) 
O3 6071(2) 9933(4) 9330.8(13) 23.8(5) 
N1 3734(2) 2611(4) 5704.3(15) 18.7(5) 
C1 2179(3) 3078(5) 4246.5(18) 19.0(6) 
C2 2486(3) 5568(5) 4355(2) 24.4(7) 
C3 970(3) 2430(6) 4596(2) 27.0(7) 
C4 2054(3) 2370(6) 3347.5(19) 27.7(7) 
C5 4101(3) 1111(5) 6430.2(16) 17.8(6) 
C6 2899(3) 508(5) 6803.4(18) 18.3(6) 
C7 3208(3) -1230(5) 7491.7(19) 21.3(6) 
C8 1995(3) -1878(6) 7840(2) 25.6(7) 
C9 1338(3) 184(6) 8130(2) 26.5(7) 
C10 1032(3) 1913(5) 7444(2) 24.0(7) 
C11 2252(3) 2564(5) 7109.5(19) 20.4(6) 
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C12 5099(3) 2221(6) 7034.2(18) 19.5(6) 
C13 5897(3) 3118(6) 7533.9(17) 20.7(6) 
C14 6879(3) 4189(5) 8124.8(17) 18.5(6) 
C15 8120(3) 3267(6) 8298.5(17) 21.8(6) 
C16 9079(3) 4302(6) 8864.7(19) 24.6(7) 
C17 8798(3) 6238(7) 9269.0(17) 23.3(6) 
C18 7556(3) 7153(6) 9104.6(17) 19.3(6) 
C19 6600(3) 6155(6) 8525.1(16) 18.3(5) 
C20 7277(3) 9171(6) 9582.4(19) 22.9(6) 
C21 5715(4) 11838(5) 9784(2) 30.9(8) 
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Methyl 5-((S)-3-(((S)-tert-butylsulfinyl)amino)-4-methylpent-1-yn-1-
yl)nicotinate (41a) 
Single crystals of C17H24N2O3S were achieved by evaporating an Et2O solution. The fine 
needles were placed in a saturated solution of C17H24N2O3S in Et2O at -18 °C to let them 
grow.  
 
Table EP18. Fractional Atomic Coordinates (×10 4)  and Equivalent Isotropic Displacement 
Parameters (Å2×103) for nicotinate derivative 41a . Ueq is defined as 1/3 of of the trace of 
the orthogonalized U IJ tensor.  
Atom x y z U(eq) 
S1 5173.0(4) 2082.6(3) 4376.0(2) 20.13(8) 
O1 5672.5(14) 1912.0(12) 5090.8(6) 29.0(2) 
O2 5184.0(14) 8144.1(11) 7973.3(5) 26.5(2) 
O3 6406.9(19) 6469.6(14) 7533.2(7) 41.3(3) 
N1 3822.8(14) 3150.0(11) 4293.6(6) 20.7(2) 
N2 2527.8(18) 8617.2(13) 6299.6(7) 29.8(3) 
C1 4069.9(17) 639.4(13) 4178.4(8) 22.2(3) 
C2 2800(2) 459.4(16) 4684.0(9) 31.1(3) 
IIX-3. n) X-ray Crystal Structure Analysis 
244 
C3 5220(2) -441.9(15) 4229.6(10) 34.2(4) 
C4 3480(2) 763.9(18) 3461.6(9) 30.9(3) 
C5 4290(2) 4466.8(13) 4140.5(7) 23.5(3) 
C6A 3584(6) 4963(6) 3492(3) 26.4(10) 
C6B 3150(16) 5025(13) 3562(6) 33(3) 
C7A 4155(5) 4231(4) 2889.4(15) 39.0(7) 
C7B 3285(18) 4337(10) 2906(5) 60(3) 
C8A 1849(3) 4922(3) 3562.4(13) 31.0(6) 
C8B 3586(9) 6404(6) 3392(4) 47(2) 
C9 4087.2(18) 5312.6(13) 4724.1(7) 22.1(3) 
C10 3935.6(18) 6008.0(14) 5200.2(7) 22.7(3) 
C11 3783.3(17) 6819.7(13) 5776.6(7) 21.3(3) 
C12 2715.5(19) 7813.3(14) 5784.5(8) 26.7(3) 
C13 3407.1(18) 8452.8(14) 6841.5(8) 24.2(3) 
C14 4476.2(15) 7475.8(13) 6891.1(7) 19.6(2) 
C15 4665.5(17) 6645.5(13) 6349.6(7) 20.8(2) 
C16 5457.7(17) 7290.7(13) 7491.6(7) 22.4(3) 
C17 6137(2) 8037.3(19) 8563.8(8) 34.6(4) 
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Methyl 4-((S)-3-(((S)-tert-Butylsulfinylamido)-3-phenylprop-1-yn-1-yl)benzoate (46j) 
Single crystals of C21H23NO3S were achieved by evaporation of the solvent of a 
concentrated Et2O solution at -20 °C.  
 
Table EP21. Fractional Atomic Coordinates (×10 4)  and Equivalent Isotropic Displacement 
Parameters (Å2×103)  for C21H23NO3S 46j .  Ue q is defined as 1/3 of of the trace of the 
orthogonalised U I J tensor.   
Atom x y z U(eq) 
S1 3625.0(14) 1722(3) 5182.7(8) 17.6(3) 
O1 5017(4) 2166(8) 5617(3) 21.3(10) 
O2 8272(6) 5050(11) -390(4) 39.8(14) 
O3 7635(5) 8606(9) -177(3) 25.5(11) 
N1 3295(6) 3101(10) 4254(3) 20.3(11) 
C1 2594(6) 3384(12) 5789(4) 21.5(13) 
C2 1180(6) 2645(13) 5458(4) 24.9(14) 
C3 3065(7) 2617(14) 6717(4) 28.3(16) 
C4 2786(7) 5923(12) 5694(4) 25.4(14) 
C5 3283(6) 1620(13) 3498(3) 18.0(11) 
C6 1901(6) 1006(11) 3050(3) 18.7(13) 
C7 1676(7) -1122(13) 2655(4) 23.8(14) 
C8 445(7) -1634(13) 2184(4) 24.6(14) 
C9 -573(7) -43(13) 2103(4) 25.1(14) 
C10 -351(6) 2018(14) 2513(4) 24.7(15) 
C11 885(7) 2566(12) 2984(4) 22.4(13) 
C12 3964(6) 2721(13) 2873(4) 20.1(13) 
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C13 4477(6) 3494(13) 2324(4) 20.2(13) 
C14 5203(6) 4279(12) 1692(4) 20.5(14) 
C15 5001(6) 6405(13) 1306(4) 22.0(14) 
C16 5779(6) 7106(12) 736(4) 21.1(14) 
C17 6741(6) 5669(12) 536(3) 19.0(13) 
C18 6922(7) 3527(13) 897(4) 21.6(13) 
C19 6160(6) 2839(12) 1477(4) 21.4(14) 
C20 7613(6) 6354(13) -59(4) 22.9(15) 
C21 8496(7) 9386(15) -739(4) 29.8(16) 
 
 
Methyl 5-((S)-3-(((S)-tert-butylsulfinyl)amino)-4-methylpent-1-yn-1-yl)furan-2-
carboxylate (49a)  
Single crystals of C16H23NO4S were achieved by evaporation of the solvent of a 
concentrated Et2O solution at rt.  
 
 
 
IIX-3. n) X-ray Crystal Structure Analysis 
247 
Table EP16. Fractional Atomic Coordinates (×10 4)  and Equivalent Isotropic Displacement 
Parameters (Å2×103) for furan derivative 49a . Ue q  is defined as 1/3 of of the trace of the 
orthogonalized U I J tensor. 
Atom x y z U(eq) 
S1 3951.2(4) 4957.6(8) 6571.9(2) 14.59(11) 
O1 -1272.7(12) 5231(2) 9043.6(8) 16.6(3) 
O2 -3094.0(15) 7092(3) 10854.6(9) 24.1(3) 
O3 -2999.5(14) 3700(3) 10136.3(9) 21.4(3) 
O15 4060.6(14) 7002(3) 7174.8(9) 22.6(3) 
N1 3030.6(15) 2884(3) 6972.3(10) 15.7(3) 
C1 5638.1(17) 3526(4) 6770.7(12) 17.2(4) 
C2 5920(2) 2585(4) 7751.2(15) 27.0(5) 
C3 6657.2(19) 5396(4) 6610.1(14) 22.8(4) 
C4 5616(2) 1649(4) 6045.2(15) 23.6(4) 
C5 1540.3(17) 2960(3) 6694.7(11) 15.2(4) 
C6 1001.6(17) 498(3) 6548.4(12) 16.2(4) 
C7 1562(2) -541(4) 5715.3(14) 21.7(4) 
C8 -562.6(18) 394(4) 6408.6(13) 20.0(4) 
C9 827.3(18) 4245(3) 7359.8(12) 16.5(4) 
C10 244.9(17) 5260(4) 7903.6(12) 17.7(4) 
C11 -448.1(17) 6492(4) 8544.3(12) 16.4(4) 
C12 -474.4(19) 8729(4) 8783.7(13) 19.2(4) 
C13 -1356.5(19) 8904(4) 9476.7(12) 19.0(4) 
C14 -1806.0(18) 6760(4) 9612.5(12) 16.7(4) 
C15 -2697.2(19) 5896(3) 10267.2(13) 17.2(4) 
C16 -3832(3) 2728(4) 10792.2(16) 28.9(5) 
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Methyl (R)-5-(3-Amino-5-methylhex-1-yn-1-yl)thiophene-2-carboxylate x TFA (50f) 
Single crystals of C15H18F3NO4S were achieved out of a saturated solution in MeOH/CHCl3 
(1:4) at rt. The concentration was gradually increased by evaporation of the solvent.  
 
Table EP19. Fractional Atomic Coordinates (×10 4)  and Equivalent Isotropic Displacement 
Parameters (Å2×103) for thiophene derivative 50f . Ueq is defined as 1/3 of of the trace of the 
orthogonalized U I J tensor. 
Atom x y z U(eq) 
S1A 3561(2) 3606.8(19) 6998.6(9) 44.4(5) 
S1B 3304(3) 4056(3) 6875.2(8) 37.3(5) 
F1A 1420(3) 5704.9(11) 3882.5(11) 58.3(5) 
F1B 1660(20) 5118(15) 3378(6) 54.5(5) 
F2A 1682(2) 4578.4(17) 3169.4(7) 54.5(5) 
F2B -860(30) 4773(16) 4000(9) 45.7(5) 
F3A -900(3) 4518.3(16) 3810.9(9) 45.7(5) 
F3B 1120(20) 5793(9) 4272(9) 58.3(5) 
O1A 7200(5) 2130(3) 8163.3(15) 64.7(10) 
O1B 7330(6) 4423(4) 7529.8(18) 46.8(12) 
O2A 7253(7) 3723(4) 7789(2) 47.1(12) 
O2B 7283(7) 2966(4) 8079(2) 45.7(12) 
O3 1536(2) 3570.1(9) 4621.7(6) 31.4(3) 
O4 4389.1(19) 4142.7(10) 4119.8(6) 34.4(3) 
N1A -2790(20) 3381(14) 4939(7) 29.5(14) 
N1B -2460(30) 3340(20) 4865(12) 29.5(14) 
C1A -3813(14) 5732(5) 5232(4) 42(2) 
C1B -3772(6) 5771(2) 5788.9(18) 56(1) 
C2A -6180(30) 5671(12) 5478(5) 35(2) 
C2B -2905(10) 6845(3) 5733(3) 83.5(17) 
C3A -3110(20) 6858(7) 5264(8) 62(3) 
C3B -6132(13) 5766(6) 5713(5) 98(3) 
C4A -2346(15) 5108(6) 5633(6) 39(2) 
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C4B -2736(5) 5088(2) 5299.7(19) 38.9(8) 
C5A -2960(60) 3970(30) 5525(10) 41.4(14) 
C5B -2930(80) 3930(40) 5444(15) 41.4(14) 
C6A -1452(16) 3610(20) 5993(4) 40.2(6) 
C6B -1480(20) 3560(30) 5916(5) 40.2(6) 
C7A -129(12) 3233(7) 6333(9) 40.2(6) 
C7B -198(18) 3417(10) 6311(13) 40.2(6) 
C8A 1420(20) 2873(8) 6782(5) 37(2) 
C8B 1480(30) 3167(11) 6702(9) 34(3) 
C9A 1502(15) 1951(7) 7069(5) 48.8(18) 
C9B 1828(19) 2284(9) 7010(6) 41(2) 
C10A 3252(9) 1847(5) 7474(2) 52.6(13) 
C10B 3691(13) 2305(7) 7382(3) 37.7(16) 
C11A 4504(9) 2673(6) 7475(2) 44.0(12) 
C11B 4636(9) 3228(6) 7355(2) 34.3(13) 
C12A 6466(8) 2795(3) 7845(2) 45.1(10) 
C12B 6549(14) 3606(9) 7655(4) 41.2(19) 
C13A 9118(7) 3907(4) 8166(3) 57.1(13) 
C13B 9158(10) 3316(7) 8405(3) 56.2(17) 
C14 2497(3) 4076.6(13) 4217.7(8) 27.5(3) 
C15A 1150(4) 4719(2) 3765.5(12) 35.7(5) 
C15B 1140(30) 4948(16) 3965(9) 35.7(5) 
 
Single crystals of C15H18F3NO4S 50f were analyzed several times. All crystals show 
entirely disordered molecules. Except C14, O3 and O4 all atoms are disordered showing 
different conformers. Same distance restraints were used for: C-F bonds, C-N bonds, C5-
C6, C6-C7, C7-C8. ADP's were constrained to be equivalent for the four atoms of the 
acetylene bridge and pairwise for C5, C6, all F and N atoms. A suitable crystal was selected 
and mounted on a SuperNova, Dual, Cu at zero, Atlas diffractometer. The crystal was kept 
at 100.0(1) K during data collection.  
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4-((R)-3-(((R)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-yl)benzoic Acid (52b) 
Single crystals of C18H25NO3S were achieved out of a saturated solution in MeOH/EtOAc 
(2:1) at -18 °C.  
 
Table EP20. Fractional Atomic Coordinates (×10 4)  and Equivalent Isotropic Displacement 
Parameters (Å2×103) for C1 8H2 5NO3S 52b. Ueq  is defined as 1/3 of of the trace of the 
orthogonalized U I J tensor. 
Atom x y z U(eq) 
S1 3097.1(4) 2722.9(3) 4253.5(2) 38.08(9) 
O1 2585.8(13) 2011.4(11) 4852.8(6) 49.7(3) 
O2 4952(2) 5074.2(14) 9220.3(8) 72.7(4) 
O3 6117(2) 6711.9(15) 8940.6(8) 68.0(4) 
N1 4537.8(15) 3566.6(12) 4456.2(7) 45.2(3) 
C1 4135(2) 1724.9(15) 3687.2(8) 48.5(4) 
C2 4764(3) 2414(3) 3087.2(10) 79.6(7) 
C3 2871(3) 894(2) 3455.0(15) 85.4(8) 
C4 5410(2) 1103.1(18) 4070.8(11) 62.3(5) 
C5 4190.9(19) 4768.8(13) 4614.5(8) 43.6(3) 
C6 5406(2) 5516.8(17) 4262.3(11) 60.3(4) 
C7 5215(3) 6800.6(19) 4374.9(12) 75.3(6) 
C8 3681(4) 7245(2) 4103.3(19) 102.9(9) 
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C9 6595(5) 7416(3) 4038(2) 120.5(13) 
C10 4151(2) 4976.4(14) 5357.0(9) 46.0(3) 
C11 4185(2) 5170.9(14) 5950.5(8) 47.4(3) 
C12 4338.0(19) 5377.4(14) 6671.2(8) 44.4(3) 
C13 3797(3) 4600.7(16) 7144.4(10) 57.6(4) 
C14 4095(3) 4748.2(17) 7835.6(10) 58.5(4) 
C15 4932(2) 5676.2(15) 8062.0(8) 46.5(3) 
C16 5433(3) 6465.9(18) 7590.7(10) 68.9(6) 
C17 5120(3) 6331.8(19) 6901.3(10) 68.8(6) 
C18 5326(2) 5771.8(17) 8802.0(9) 51.1(4) 
 
 
Methyl (R)-4-(3-Amino-3-cyclohexylprop-1-yn-1-yl)benzoate (55c) 
Single crystals of C19H22F3NO4 were achieved by evaporation of the solvent of a 
concentrated CHCl3 solution at rt. 
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Table EP22. Fractional Atomic Coordinates (×10 4)  and Equivalent Isotropic Displacement 
Parameters (Å2×103)  for C19H22F3NO4  55c.  Ue q is defined as 1/3 of of the trace of the 
orthogonalised U I J tensor.   
Atom x y z U(eq) 
F1A 5747(5) 2083(3) 7249.6(13) 42.2(10) 
F1B 5400(40) 2550(20) 7354(8) 42.2(10) 
F2A 5487(6) 3581(3) 7067(2) 47.9(12) 
F2B 6210(40) 3760(12) 6822(13) 47.9(12) 
F3A 8104(5) 2778(6) 6704(3) 33.6(11) 
F3B 8120(30) 2630(50) 6820(20) 33.6(11) 
O3 5838(4) 2407.7(17) 5705.2(10) 23.2(5) 
O4 2927(4) 2536(2) 6278.6(12) 31.7(6) 
C18 4803(5) 2542(2) 6202.7(14) 19.9(6) 
C19 6072(5) 2764(3) 6806.7(14) 26.7(7) 
O1 16586(4) 6209.3(17) 6657.1(11) 25.0(5) 
O2 16437(4) 7302.0(19) 5880.8(11) 31.4(6) 
N1 4908(5) 3198(2) 4538.7(12) 20.1(6) 
C1 4873(5) 4238(2) 4706.6(14) 21.0(6) 
C2 6787(5) 4496(3) 5037.6(14) 22.8(7) 
C3 8324(5) 4808(3) 5278.8(15) 23.8(7) 
C4 10157(5) 5251(2) 5522.5(14) 20.7(6) 
C5 11257(5) 4870(2) 6037.7(14) 22.1(7) 
C6 13054(5) 5304(2) 6245.8(14) 21.7(6) 
C7 13787(5) 6124(2) 5945.7(14) 21.2(6) 
C8 12687(5) 6508(3) 5432.6(16) 23.2(7) 
C9 10889(5) 6076(3) 5226.0(15) 23.3(7) 
C10 15724(5) 6613(2) 6145.7(14) 22.3(7) 
C11 18399(6) 6690(3) 6902.3(18) 29.7(8) 
C12 4503(5) 4892(3) 4132.7(14) 21.5(7) 
C13 6218(6) 4854(3) 3638.7(17) 31.4(8) 
C14 5837(6) 5594(3) 3117.6(18) 37.6(10) 
C15 3721(6) 5478(3) 2811.9(16) 29.7(8) 
C16 1996(6) 5468(3) 3304.9(16) 26.2(7) 
C17 2399(5) 4721(3) 3815.0(15) 22.6(7) 
 
Methyl 2,3-Dibromo-3-(3-bromo-4-methoxyphenyl)-2-methylpropanoate (67) 
Single crystals of C12H13Br3O3 were achieved by evaporation of the solvent of a 
concentrated EtOAc solution at rt. SuperNova, Single source at offset, Eos. Micro-focus 
sealed X-ray tube, Mo Kα/0.71073 Å. Wuensch18, C12H13Br3O3, M=444.95 g mol-1. 
T=100.00(10) K. Monoclinic, P21, a=8.4652(3) Å, b=7.16932(18) Å, c=12.2165(4) Å, 
α=90°, β=102.518(3)°, γ=90°, Volume=723.79(4) Å3, Z=2, crystal size=0.293 × 0.235 × 
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0.18. 2Θ range for data collection=3.4 to 60.1°. Index ranges: -11 ≤ h ≤ 11, -9 ≤ k ≤ 9, -17 
≤ l ≤ 17. 11113 Reflections. Goodness-of-fit on F2=1.043.  
 
Table EP24. Fractional Atomic Coordinates (×10 4)  and Equivalent Isotropic Displacement 
Parameters (Å2×103) for  C12H1 3Br3O3 67 . Ue q is defined as 1/3 of of the trace of the 
orthogonalised U I J tensor.  
Atom x y z U(eq) 
Br1 6722.2(7) 4695.7(9) -319.2(4) 24.68(13) 
Br2 4363.8(7) 7708.8(7) 3403.3(5) 23.19(13) 
Br3 2162.9(7) 1781.2(8) 3117.9(5) 29.42(15) 
O1 8210(5) 1283(6) 896(3) 24.6(9) 
O2 -51(5) 5903(6) 3221(4) 25.6(9) 
O3 1884(5) 5299(7) 4743(3) 27.0(9) 
C1 5305(6) 4104(7) 2714(4) 18.3(10) 
C2 5500(6) 4752(9) 1673(4) 20.3(10) 
C3 6494(7) 3800(8) 1100(4) 19.5(10) 
C4 7303(6) 2172(7) 1537(5) 19.2(10) 
C5 7166(6) 1583(8) 2596(5) 20.5(10) 
C6 6174(6) 2542(8) 3169(4) 21.4(10) 
C7 4161(6) 4958(8) 3357(4) 17.9(10) 
C8 2369(6) 4538(8) 2923(4) 18.0(9) 
C9 1401(7) 5303(8) 3742(4) 19.7(10) 
C10 1645(8) 4929(12) 1687(5) 31.6(14) 
C11 -1059(8) 6566(12) 3968(6) 36.6(16) 
C12 8745(8) -558(8) 1225(5) 26.1(12) 
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Ethyl (S,E)-6-Ammonium-3,8-dimethylnon-2-en-4-ynoate Hydrochloride (75e) 
Single crystals of C13H22ClNO2 were achieved by evaporation of the solvent of a 
concentrated MeOH solution at rt.  
 
Table EP25. Fractional Atomic Coordinates (×10 4)  and Equivalent Isotropic Displacement 
Parameters (Å2×103) for C1 3H2 2ClNO2 75e . U eq is defined as 1/3 of of the trace of the 
orthogonalised U I J tensor.   
Atom x y z U(eq) 
Cl1 5770.9(2) 6949.0(7) 9844.4(2) 23.31(8) 
Cl2 4747.5(2) 1965.9(7) 8633.9(2) 22.51(8) 
O1 5808.7(4) 1989(3) 5276.5(6) 29.5(2) 
O2 6600.2(5) 1971(4) 5476.1(8) 45.6(3) 
N1 5753.3(5) 1544(2) 9760.1(9) 23.1(3) 
C1 5306.2(9) 2081(6) 3939.2(11) 50.6(6) 
C2 5809.6(7) 2013(5) 4366.2(9) 36.6(4) 
C3 6235.5(6) 1977(4) 5761.8(9) 27.7(3) 
C4 6181.4(6) 1993(3) 6667.2(9) 25.0(3) 
C5 6538.1(5) 1981(4) 7316.9(9) 26.5(3) 
C6 6427.1(5) 2037(4) 8166.5(9) 25.3(3) 
C7 6347.3(5) 2130(3) 8875.6(9) 23.7(3) 
C8 6228.5(6) 2398(2) 9729.2(10) 21.6(3) 
C9 6584.6(6) 1494(3) 10434.1(10) 26.5(4) 
C10 7075.5(7) 2399(4) 10503.4(11) 42.5(6) 
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C11 7067.9(11) 4616(5) 10686.0(17) 59.3(8) 
C12 7054.4(6) 1951(7) 7256.0(11) 47.3(5) 
C13 7413.1(9) 1320(6) 11183.2(16) 72.2(13) 
O3 3212.4(5) 7104(3) 4041.1(7) 34.9(3) 
O4 3726.4(5) 6951(4) 5244.4(8) 44.5(3) 
N2 5198.3(5) 7294(2) 1375.0(8) 22.9(3) 
C14 2380.2(8) 7276(5) 3957.7(14) 50.1(7) 
C15 2833.3(7) 7153(5) 4549.8(11) 38.4(5) 
C16 3646.5(6) 7016(4) 4482.9(11) 33.3(3) 
C21 5313.3(6) 6564(2) 2268.1(10) 21.9(3) 
C22 5746.4(6) 7637(3) 2726.9(10) 24.7(3) 
C23 6206.4(6) 7121(4) 2403.2(10) 32.1(4) 
C24 6588.4(9) 8570(4) 2779.0(16) 50.0(6) 
C26 6357.1(8) 5014(4) 2637.1(16) 43.3(5) 
C17A 4062.5(10) 6970(7) 4036.6(19) 23.9(5) 
C18A 4060.5(7) 6993(4) 3193.9(12) 19.5(4) 
C19A 4509.9(9) 6918(5) 2902.5(17) 22.2(4) 
C20A 4871.4(17) 6798(12) 2628(3) 21.7(7) 
C25A 3642.4(7) 7033(5) 2497.8(12) 23.4(5) 
C17B 3926(2) 7006(13) 3729(4) 20.6(11) 
C18B 4392.1(17) 7047(11) 3938(3) 21.3(10) 
C19B 4678.6(19) 6958(12) 3271(4) 21.1(9) 
C20B 4957(5) 6860(30) 2800(7) 21.7(7) 
C25B 4669.1(18) 7127(14) 4814(3) 31.3(13) 
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Ethyl (S,E)-6-Ammonium-6-cyclohexyl-3-methylhex-2-en-4-
ynoate Hydrochloride (75f) 
Single crystals of C30H48Cl2N2O4 were achieved by evaporation of the solvent of a 
concentrated MeOH solution at rt. 
 
Table EP26. Fractional Atomic Coordinates (×10 4)  and Equivalent Isotropic Displacement 
Parameters (Å2×103) for olefin 75f . Ueq is defined as 1/3 of of the trace of the orthogonalised 
U IJ tensor.  
Atom x y z U(eq) 
Cl1 5848.6(9) 5734.6(7) 3832.6(14) 45.1(5) 
Cl2 4208.7(9) 4407.6(8) 3824.1(15) 46.5(5) 
O1 3318(3) 2052(3) 3921(5) 72.3(19) 
O2 4060(4) 1328(3) 3758(7) 94(2) 
N1 5734(3) 4330(2) 3967(4) 38.9(14) 
C1 2186(6) 1905(6) 3981(11) 108(5) 
C2 2804(6) 1588(4) 3905(9) 85(3) 
C3 3935(5) 1852(4) 3818(7) 61(2) 
C4 4392(5) 2353(3) 3770(6) 52(2) 
C5 5041(5) 2305(3) 3720(5) 50(2) 
C6 5416(4) 2844(3) 3642(5) 46(2) 
C7 5738(4) 3291(4) 3558(5) 46(2) 
C8 6066(4) 3854(3) 3399(6) 44.4(19) 
C9 6794(4) 3843(4) 3566(8) 66(3) 
C10 7098(5) 4464(5) 3288(10) 85(3) 
C11 7805(6) 4453(6) 3303(11) 108(5) 
C12 8067(7) 3982(6) 2662(9) 99(4) 
C13 7816(7) 3377(6) 2952(12) 119(6) 
C14 7112(6) 3358(5) 2955(11) 102(5) 
C15 5421(5) 1738(3) 3714(8) 68(3) 
N33 4295(3) 4190(3) 6009(5) 51.8(17) 
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C20 4960(5) 2177(4) 6203(6) 60(2) 
C21 4580(4) 2703(4) 6294(6) 53(2) 
C22 4268(5) 3153(4) 6376(5) 49(2) 
C23 3917(5) 3717(4) 6514(6) 51(2) 
C24 3196(5) 3707(4) 6222(9) 71(3) 
C25 3051(5) 3468(5) 5291(7) 74(3) 
C26 2312(5) 3464(5) 5124(8) 87(4) 
C27 1999(6) 4068(6) 5286(8) 89(4) 
C28 2131(5) 4276(5) 6241(9) 89(4) 
C29 2869(5) 4301(4) 6447(8) 76(3) 
C30 5679(5) 2276(7) 6155(8) 100(4) 
O3B 4805(13) 751(12) 6897(17) 156(8) 
O4B 5673(8) 1045(7) 6126(12) 83(4) 
C16B 5294(18) -138(15) 7450(30) 161(15) 
C17B 5130(40) 110(20) 6570(40) 320(40) 
C18B 5143(16) 1118(12) 6370(20) 101(8) 
C19B 4588(12) 1652(8) 6027(16) 68(4) 
O3A 4399(8) 622(7) 5854(12) 95(5) 
O4A 5397(11) 855(9) 5735(14) 108(6) 
C16A 3960(20) -180(40) 5020(70) 260(30) 
C17A 4560(20) -60(20) 5510(30) 190(20) 
C18A 4866(13) 997(11) 5858(18) 85(7) 
C19A 4736(12) 1633(8) 6307(16) 68(4) 
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Methyl 4-((1E,3Z)-3-(((R)-tert-Butylsulfinyl)imino)-3-phenylprop-1-en-1-
yl)benzoate (76e).  
Single crystals of C21H24NO3S were achieved by evaporation of the solvent of a 
concentrated CHCl3 solution at -20 °C.  
 
Table EP28. Fractional Atomic Coordinates (×10 4)  and Equivalent Iso tropic Displacement 
Parameters (Å2×103) for enimin 76e. Ue q is defined as 1/3 of of the trace of the 
orthogonalised U I J tensor.  
Atom x y z U(eq) 
S1 5313.5(11) 5191.5(6) 3501.6(2) 26.65(17) 
O1 3568(4) 6178(2) 3586.6(8) 40.6(6) 
O2 -7437(3) 5126(2) 5629.0(7) 33.0(5) 
O3 -5236(3) 6883.7(17) 5585.6(6) 28.8(4) 
N1 4352(4) 3670(2) 3444.7(7) 24.7(5) 
C1 6103(4) 5394(3) 2929.1(8) 23.5(5) 
C2 7134(6) 6752(3) 2910.6(10) 37.5(7) 
C3 4073(5) 5320(3) 2643.6(10) 35.3(7) 
C4 7818(5) 4369(3) 2822.5(10) 32.6(6) 
C5 2672(4) 3189(3) 3652.1(8) 21.8(5) 
C6 2266(4) 1784(2) 3565.6(8) 20.8(5) 
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C7 296(5) 1351(2) 3386.1(8) 24.2(5) 
C8 -3(5) 38(3) 3299.2(9) 26.5(5) 
C9 1650(5) -848(3) 3403.3(9) 28.0(6) 
C10 3592(5) -420(3) 3591.3(10) 30.6(6) 
C11 3923(5) 892(3) 3668.3(9) 27.3(6) 
C12 1280(4) 3866(2) 3967.0(8) 22.5(5) 
C13 -305(4) 3275(2) 4199.4(8) 22.0(5) 
C14 -1651(4) 3914(2) 4530.8(8) 21.1(5) 
C15 -3746(4) 3405(2) 4629.2(8) 22.4(5) 
C16 -5087(4) 3993(2) 4932.5(8) 22.9(5) 
C17 -4345(4) 5092(2) 5150.5(8) 21.0(5) 
C18 -2247(5) 5597(3) 5062.6(9) 25.5(6) 
C19 -924(4) 5005(3) 4755.1(9) 24.3(5) 
C20 -5837(5) 5680(3) 5480.5(8) 23.9(6) 
C21 -6645(6) 7512(3) 5898.5(10) 35.2(7) 
 
Methyl (E)-3-(4,4,4-Trifluoro-3-oxobut-1-en-1-yl)benzoate (78c) 
Single crystals of C11H7F3O3 were achieved by evaporation of the solvent of a concentrated 
MeOH solution at rt. 
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Table EP27. Fractional Atomic Coordinates (×10 4)  and Equivalent Isotropic Displacement 
Parameters (Å2×103) for keton 77c . Ue q is defined as 1/3 of of the trace of the or thogonalised 
U IJ tensor.  
Atom x y z U(eq) 
F1 1467.9(9) 6458.8(17) 1152.3(11) 49.7(5) 
F2 1058(1) 6633.7(18) 2521.6(13) 56.5(5) 
F3 583.9(10) 5069.4(19) 1493.9(16) 82.2(8) 
O1 1913(1) 3810.2(18) 2611.1(13) 37.3(5) 
O2 6460.9(10) 2704.4(18) 4669.3(12) 33.6(5) 
O3 7476.2(10) 4218(2) 4694.8(13) 34.1(5) 
C1 4484.7(13) 5390(2) 3557.0(15) 21.7(5) 
C2 5145.0(14) 4473(3) 3864.5(17) 24.0(6) 
C3 6004.6(13) 4855(3) 4202.6(16) 22.9(5) 
C4 6213.4(14) 6167(3) 4242.9(17) 26.6(6) 
C5 5567.0(15) 7082(3) 3956.6(17) 26.9(6) 
C6 4707.5(14) 6706(3) 3608.7(17) 24.8(6) 
C7 3593.3(14) 4922(3) 3204.7(17) 24.5(6) 
C8 2877.7(13) 5612(3) 2801.6(17) 24.7(6) 
C9 2046.3(14) 4945(3) 2468.1(18) 27.8(6) 
C10 1276.7(15) 5782(3) 1898(2) 39.0(7) 
C15 6668.0(14) 3833(3) 4538.2(16) 25.9(6) 
 
 
Ethyl (2E,4E)-3-Methyl-6-oxo-6-phenylhexa-2,4-dienoate (78f) 
Single crystals of C15H16O3 were achieved by evaporation of the solvent of a concentrated 
MeOH solution at rt.  
 
IIX-3. n) X-ray Crystal Structure Analysis 
261 
 
Table EP29. Fractional Atomic Coordinates (×10 4)  and Equivalent Isotropic Displacement 
Parameters (Å2×103) for keton 77f .  Ue q is defined as 1/3 of of the trace of the orthogonalised 
U IJ tensor. Disorder B was 15 %.  
Atom x y z U(eq) 
O1 7540(4) 6064(4) 6105.8(17) 43.7(6) 
O1B 7160(20) 5355(18) 6097(10) 35(3) 
O2 3873(4) -2668(3) 2154.0(19) 39.3(5) 
O2B 4260(20) -2375(18) 1903(9) 26(3) 
O3 1317(2) -1451.9(19) 1862.4(10) 33.2(4) 
C1 12300(3) 5201(3) 7117.2(15) 32.0(4) 
C2 14109(3) 6044(3) 7913.0(15) 32.8(4) 
C3 14226(4) 7605(3) 8657.3(15) 34.7(5) 
C4 12552(4) 8319(3) 8607.6(15) 34.9(5) 
C5 10746(3) 7482(3) 7820.7(15) 31.0(4) 
C6 10607(3) 5911(3) 7067.2(13) 28.6(4) 
C7 8705(5) 5172(5) 6205(2) 30.4(6) 
C7B 8380(30) 4600(20) 6281(12) 20(4) 
C8 8233(4) 3312(4) 5489.6(17) 30.7(6) 
C8B 7908(19) 2475(17) 5759(9) 22(3) 
C9 6499(4) 2569(4) 4725.5(17) 34.2(6) 
C9B 5690(16) 1492(14) 4968(7) 13(2) 
C10 5938(4) 804(4) 3936.0(16) 30.3(6) 
C10B 5393(18) -69(16) 4264(8) 21(2) 
C11 7504(3) -258(3) 3892.5(15) 35.4(5) 
C12 4059(4) 258(3) 3254.2(15) 25.2(5) 
C12B 2972(18) -1033(15) 3624(8) 21(2) 
C13 3215(5) -1383(4) 2367(2) 29.3(6) 
C13B 2770(20) -1842(19) 2497(10) 11(3) 
C14 350(4) -3024(3) 946.9(15) 40.2(5) 
C15 -1597(5) -2865(4) 442(2) 56.9(7) 
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IIX-4. a) Halogenated Naphthoate Derivatives (91-92) 
8-Iodo-1-naphthoic Acid (91a).  
 
Scheme EP2. Synthesis of iodo nachthoat derivative 91a  via mercury-organyle.  
The synthesis was carried out in analogy to the description of Wiley et al. [167].  
1,8-Naphthoic acid anhydride (3.95 g, 19.9 mmol, 1.0 eq) was dissolved in aqueous NaOH 
(2.85 g in 120 mL) at 100 °C under reflux conditions. The clear solution was 
cooled down to rt and neutralized by adding glacial acetic acid (2 mL). A 
solution of Hg(OAc)2 (6.35 g, 19.9 mmol, 1.0 eq) in water/glacial acetic acid 
(2:1, 30 mL) was very carefully added and the reaction mixture was heated under reflux 
conditions for 30 min to 120 °C. More glacial acetic acid (3.6 mL) was added and the 
suspension was heated for 48 h under reflux conditions to 120 °C. A colorless solid 
precipitated in the course of the reaction, which was filtered off, washed with water and 
dried over 5 days in an exsikkator over P4O10.  
Iodine (4.9 g, 19.7 mmol, 1.0 eq) was added to a vigorously stirred aqueous solution of 
anhydro-8-(hydroxymercury)-1-naphthalic acid anhydrid (7.29 g, 19.7 mmol, 1.0 eq) and 
KI (14.00 g, 84.58 mmol, 4.3 eq) and the solution was heated to 110 °C for 
24 h under reflux conditions. Afterwards, remaining solid was filtered off and 
the filtrate was washed with an aqueous Na2S2O3 solution. By careful addition 
of concentrated HCl, the iodo naphthoate 91a was precipitated, isolated by filtration and 
purified by recrystallization from CHCl3.  
Colorless, crystalline solid. Yield: 2.48 g, 8.35 mmol, 42 % (Lit: 52 % [167]). 1H NMR 
(300 MHz, Chloroform-d) δ = 8.28 (dd, 3J = 7.4 Hz, 4J = 1.2 Hz, 1H, naphthoate-2-H), 
7.96-7.89 (m, 3H, naphthoate-4-H, naphthoate-6-H, naphthoate-8-H), 7.52 (dd, 3J = 
8.2 Hz, 3J = 7.1 Hz, 1H, naphthoate-3-H), 7.23 (t, 3J = 7.9 Hz, 1H, naphthoate-3-H). 
13C NMR (75 MHz, Chloroform-d) δ = 174.1 (naphthoate-1-CO2H), 155.1 (naphthoate-C-
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5), 153.8 (naphthoate-C-10), 142.1 (naphthoate-C-8), 135.5 (naphthoate-C-1), 133.3 
(naphthoate-C-9), 132.8 (naphthoate-C-4), 129.7 (naphthoate-C-6), 129.6 (naphthoate-C-
2), 127.6 (naphthoate-C-7), 125.2 (naphthoate-C-3). C11H7IO2 (298.08 g mol-1). LCMS 
(ESI): tr = 6.9 min, m/z = 298.937 (calcd. 298.9563 [M+H]+).  
 
Methyl 8-Iodo-1-naphthoate (91b). Similar methylation reactions, as well as the 
characterization of naphthoate 91b have been reported by Bailey et al. [237]. 
A solution of trimethylsilyl diazomethane (2 M in THF, 0.25 mL, 0.50 mmol, 
1.0 eq) and DIPEA (0.16 mL, 124 mg, 0.96 mmol, 2.0 eq) was added 
dropwise to a vigorously stirred solution of iodo naphthoic acid (143 mg, 0.48 mmol, 
1.0 eq) in THF (10 mL). The reaction mixture was stirred for 1 h at ambient temperature. 
After complete consumption of the acid (checked by TLC), the reaction mixture was diluted 
with acetic acid (1 M, 20 mL) and extracted with Et2O (4 x 20 mL). The combined organic 
layers were washed with brine (10 mL), dried over Na2SO4 and filtered. After evaporation 
of the solvent under reduced pressure, methyl naphthoate 91b was afforded in pure form.  
Colorless crystalline solid. Yield: 150 mg, 0.48 mmol, 96 %. 1H NMR (300 MHz, 
Chloroform-d) δ = 8.21 (dd, 3J = 7.4 Hz, 4J = 1.2 Hz, 1H, naphthoate-2-H), 7.88 (dd, 3J = 
8.1 Hz, 4J = 1.3 Hz, 1H, naphthoate-6-H), 7.85 (dd, 3J = 8.0 Hz, 4J = 1.3 Hz, 1H, 
naphthoate-8-H), 7.69 (dd, 3J = 7.1 Hz, 4J = 1.4 Hz, 1H, naphthoate-4-H), 7.46 (dd, 3J = 
8.2 Hz, 3J = 7.1 Hz, 1H, naphthoate-3-H), 7.16 (t, 3J = 7.8 Hz, 1H, naphthoate-7-H), 4.00 
(s, 3H, CO2CH3). C12H9IO2 (312.12 g mol-1). LCMS (ESI): m/z = 313.531 (calcd. 312.9720 
[M+H]+).  
 
Methyl 8-((R)-3-(((R)-tert-Butylsulfinyl)amino)-3-cyclohexylprop-1-yne-1-yl)-1-
naphthoate (92). Under argon atmosphere, the solid catalysts PdCl2(PPh3)2 (2.4 mg, 
3.6 mol, 1.0 mol%) and CuI (1.4 mg, 7.2 mol, 2.0 mol%) were added in one portion to 
a thoroughly degassed solution of propargylamide 6e (86 mg, 360 mol, 1.0 eq) and iodo 
naphthoate 91b (169 mg, 540 mol, 1.5 eq) in a mixture of THF/piperidine (2:1, 0.7 mL). 
The reaction mixture was stirred overnight at ambient temperature. After complete 
consumption of propargylamide 6e (checked by TLC), the mixture was diluted with water 
(5 mL), aqueous NH4Cl (saturated, 10 mL) and aqueous hydrochloric acid (1 M, 3-4 mL 
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until pH was 7). The aqueous phase was extracted with Et2O (3 x 15 mL). The combined 
organic layers were washed with brine (5 mL), dried over Na2SO4 and the solvent was 
evaporated under reduced pressure. The crude naphthoate 92 was purified by preparative 
HPLC.  
Colorless, highly viscous oil. Yield: 36.7 mg, 90 mmol, 17 %. 1H NMR (300 MHz, 
Chloroform-d) δ = 7.92 (dd, 3J = 8.4 Hz, 4J = 1.4 Hz, 1H, 
naphthoate-2-H), 7.86 (dd, 3J = 8.3 Hz, 4J = 1.3 Hz, 1H, 
naphthoate-6-H), 7.75 (dd, 3J = 7.2 Hz, 4J = 1.3 Hz, 1H, 
naphthoate-7-H), 7.61 (dd, 3J = 7.1 Hz, 3J = 1.4 Hz, 1H, naphthoate-4-H), 7.49 (dd, 3J = 
8.1 Hz, 3J = 7.1 Hz, 1H, naphthoate-3-H), 7.46 (dd, 3J = 8.2 Hz, 3J = 7.3 Hz, 1H, 
naphthoate-8-H), 4.32 (d br., 3J = 4.9 Hz, 1H, CH), 4.00 (s, 3H, CO2CH3), 2.03-1.64 (m, 
6H, cy-H), 1.35 (s, 9H, SC(CH3)3), 1.30-1.11 (m, 5H, cy-H). 
13C NMR (126 MHz, 
Chloroform-d) δ = 171.8 (CO2CH3), 134.2 (naphthoate-C-10), 133.8 (naphthoate-C-8), 
131.7 (naphthoate-C-2), 131.4 (naphthoate-C-5), 129.7 (naphthoate-C-6), 128.9 
(naphthoate-C-1), 127.7 (naphthoate-C-4), 126.0 (naphthoate-C-7), 125.3 (naphthoate-C-
3), 118.8 (naphthoate-C-9), 93.3 (CHC≡Car), 85.2 (CHC≡Car), 57.1 (SC(CH3)3), 53.6 
(CH), 52.9 (CO2CH3), 43.0 (cy-C-1), 29.8 (cy-C-2), 28.0 (cy-C-6), 26.5 (cy-C-4), 26.2 
(cy-C-5), 26.0 (cy-C-3), 23.0 (SC(CH3)3). C25H31NO3S (425.59 g mol
-1). MS(ESI): m/z = 
426.326 (calcd. 426.2097 [M+H]+), 448.299 (calcd. 448.1917 [M+Na]+). IR(ATR): ῦ 
[cm-1] = 3262 (NH), 2923, 2850 (CH3, CH2), 1720 (CO2Me), 1042 (S=O).  
 
IIX-4. b) Biphenyl-Based Turn Motifs (93-94) 
Methyl 2'-Amino-[1,1'-biphenyl]-3-carboxylate (93a). A similar Suzuki reaction using 
3-chlorobenzoat instead of 26a, as well as the characterization of 93a has been reported by 
Anderson et al. [238]. (2-Aminophenyl)boronic acid hydrochloride 
(100 mg, 577 mol, 1 eq), methyl 3-iodobenzoate (26a, 0.15 g 58 mol, 
1 eq) and K3PO4 (0.37 g, 1.7 mmol, 3 eq) was placed  under an argon 
atmosphere and suspended in a mixture of dioxane/H2O (2 mL, 4:1). 
PdCl2(PPh3)2 (1 mol%) was added in one portion and the suspension was sonicated for a 
short time at 40 °C, until a fine, colorless suspension formed. The reaction mixture was 
stirred under nitrogen overnight at rt, which lead to a slightly yellow solution with a 
colloidal colorless precipitate. The solution was diluted with a solution of NaHCO3 
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(saturated, 20 mL) and extracted with Et2O (5 x 20 mL). The combined organic layers were 
washed with brine and dried over Na2SO4. Purification of the crude product by column 
chromatography (EtOAc/PE, 2:1) lead to the title compound in pure form.  
Colorless fluid. Yield: 76.2 mg, 335 mol, 58 % (Lit: 94 % [238]). 1H NMR (500 MHz, 
Chloroform-d) δ = 8.16 (d, 4J = 1.8 Hz, 1H, ar-2-H), 8.03 (dt, 3J = 7.8 Hz, 4J = 1.4 Hz, 1H, 
ar-6-H), 7.67 (dt, 3J = 7.7 Hz, 4J = 1.5 Hz, 1H, ar-4-H), 7.52 (t, 3J = 7.7 Hz, 1H, ar-5-H), 
7.18 (td, 3J = 7.6 Hz, 4J = 1.3 Hz, 1H, ar’-5-H), 7.13 (d, 3J = 7.5 Hz, 1H, ar’-3-H), 6.84 (td, 
3J = 7.4, 4J = 1.1 Hz, 1H, ar’-4-H), 6.78 (d, 3J = 8.0 Hz, 1H, ar’-6-H), 3.93 (s, 3H, ar-3-
CO2CH3), 3.67 (s, 2H, ar’-2-NH2). 13C NMR (126 MHz, Chloroform-d) δ = 167.0 (ar-3-
CO2CH3), 143.6 (ar’-C-1), 139.9 (ar-C-3), 133.7 (ar-4-H), 130.8 (ar’-C-3), 130.5 (ar-C-2), 
130.3 (ar-5-H), 129.0 (ar’-C-5), 128.9 (ar-C-1), 128.4 (ar-6-H), 126.5 (ar’-C-2), 118.8 (ar’-
C-4), 115.8 (ar’-C-6), 52.3 (ar-3-CO2CH3). C14H13NO2 (227.26 g mol-1). LCMS(ESI): tr = 
8.8 min, m/z = 228.1064 (calcd. 228.1019 [M+H]+). TLC: Rf (EtOAc/PE, 1:4) = 0.59, Rf 
(EtOAc/PE, 1:10) = 0.44.  
 
Methyl 2'-Iodo-[1,1'-biphenyl]-3-carboxylate (93b). Rickhaus et al. have reported before 
the characterization of 93b, which they accessed by a completely different synthesis 
strategy [239]. NaNO2 (110 mg, 1.59 mmol, 1.2 eq) was added to a vigorously stirred 
solution of methyl 2'-amino-[1,1'-biphenyl]-3-carboxylate (301 mg, 1.32 mmol, 1.0 eq) 
and NaI (594 mg, 3.96 mmol, 3.0 eq) in half concentrated, aqueous HCl 
(6 M, 20 mL) at 0 °C in one portion. After stirring the reaction mixture for 
5 min, solid iodine (33.5 mg, 264 mol, 0.2 eq) was added in one portion. 
The reaction mixture was allowed to warm up to room temperature 
overnight. After 14 h, an aqueous solution of Na2SO3 (saturated, 10 mL) was added until 
the red color of the solution had completely vanished. The aqueous phase was extracted 
with Et2O (3 x 20 mL) and the combined organic layers were washed with aqueous 
NaHCO3 (saturated, 10 mL) and brine (10 mL), dried over Na2SO4 and the solvent was 
evaporated under reduced pressure. The crude product was purified by column 
chromatography (PE/EtOAc, 4:1) to yield the title compound in pure form.  
Colorless, highly viscous oil. Yield: 63.9 mg, 189 mol, 14 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 8.08 (d, 3J = 7.6 Hz, 1H, ar-6-H), 8.03 (s, 1H, ar-2-H), 7.97 (d, 3J = 
7.9 Hz, 1H, ar’-6-H), 7.56 (d, 3J = 7.5 Hz, 1H, ar’-4-H), 7.50 (t, 3J = 7.5 Hz, 1H, ar-5-H), 
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7.41 (t, 3J = 7.5 Hz, 1H, ar’-4-H), 7.31 (d, 3J = 7.6 Hz, 1H, ar’-3-H), 7.06 (t, 3J = 7.6 Hz, 
1H, ar’-5-H), 3.93 (s, 3H, ar-1-CO2CH3). 13C NMR (126 MHz, Chloroform-d) δ = 167.0 
(ar-1-CO2CH3), 145.7 (ar’-C-2), 144.4 (ar-C-3), 139.7 (ar’-C-6), 134.0 (ar-C-4), 130.5 (ar-
C-2), 130.1 (ar’-C-3), 130.1 (ar’-C-5), 129.3 (ar-C-1), 129.0 (ar-C-6), 128.4 (ar’-C-4), 
128.2 (ar-C-5), 98.5 (ar’-C-1), 52.3 (ar-1-CO2CH3). C14H11IO2 (338.14 g mol-1). LCMS 
(ESI): tr = 11.3 min, m/z = 338.9969 (calcd. 338.9876 [M+H]+). TLC: Rf (PE/EtOAc, 2:1) 
= 0.69.  
 
Methyl 2'-((S)-3-(((S)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-yl)-[1,1'-
biphenyl]-3-carboxylate (94a). Under argon atmosphere, the solid catalysts PdCl2(PPh3)2 
(4 mg, 6 mol, 2 mol%) and CuI (3 mg, 16 mol, 4 mol%) were added in one portion to a 
thoroughly degassed solution of propargylamide 6c (76 mg, 370 mol, 1.0 eq) and iodo 
biphenyl 93b (127 mg, 376 mol, 1.0 eq) in a mixture of THF/piperidine (3:1, 1.2 mL). 
The reaction mixture was stirred over 16 h at ambient temperature. After complete 
consumption of propargylamide 6c (checked by TLC), the mixture was diluted with Et2O 
(20 mL) and washed with aqueous KHSO4 (5 %, 2 x 15 mL). The aqueous layers were 
extracted with Et2O (2 x 20 mL). The combined organic layers were washed with brine 
(8 mL), dried over Na2SO4, filtered and the solvent was evaporated under reduced pressure. 
The crude biphenyl derivative 94a was purified by column chromatography (PE/EtOAc, 
2:1).  
Colorless, highly viscous oil. Yield: 43.6 mg, 102 mol, 27 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 8.24 (s, 1H, ar-2-H), 8.02 (d, 3J = 7.8 Hz, 1H, ar-6-H), 7.78 (d, 3J = 
7.7 Hz, 1H, ar-4-H), 7.58 (d, 3J = 7.6 Hz, 1H, ar’-6-H), 7.49 (t, 
3J = 7.8 Hz, 1H, ar-5-H), 7.39-7.33 (m, 2H, ar’-4-H, ar’-3-H), 
7.30 (t, 3J = 7.3 Hz, 1H, ar’-5-H), 4.12 (ddd, 3J = 7.6 Hz, 3J = 
7.2 Hz, 3J = 4.6 Hz, 1H, CH), 3.92 (s, 3H, ar-3-CO2CH3), 3.29 
(d, 3J = 6.7 Hz, 1H, CHNH), 1.58 (m, 1H, CHCH2CH(CH3)2), 1.54-1.40 (m, 2H, 
CHCH2CH(CH3)2), 1.18 (s, 9H, SC(CH3)3), 0.80 (d, 
3J = 6.5 Hz, 6H, 
CHCH2CH(CH3)2). C25H31NO3S (425.59 g mol-1). TLC: Rf (EtOAc/PE, 1:1) = 0.51.  
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Methyl 2'-((R)-3-(((R)-tert-Butylsulfinyl)amino)-3-cyclohexylprop-1-yn-1-yl)-[1,1'-
biphenyl]-3-carboxylate (94b). Under argon atmosphere, the solid catalysts PdCl2(PPh3)2 
(4 mg, 6 mol, 2 mol%) and CuI (3 mg, 16 mol, 4 mol%) were added in one portion to a 
thoroughly degassed solution of propargylamide 6e (23.7 mg, 99 mol, 1.0 eq) and iodo 
biphenyl 93b (65.7 mg, 198 mol, 2.0 eq) in a mixture of THF/DIPAH (3:1, 1.5 mL). The 
reaction mixture was stirred overnight at ambient temperature. After complete consumption 
of propargylamide 6e (checked by TLC), the mixture was diluted with Et2O (30 mL) and 
washed with aqueous KHSO4 (5 %, 2 x 20 mL). The aqueous layers were extracted with 
Et2O (2 x 20 mL). The combined organic layers were washed with brine (10 mL), dried 
over Na2SO4, filtered and the solvent was evaporated under reduced pressure. The crude 
biphenyl derivative 94b was purified by column chromatography (PE/EtOAc, 2:1).  
Pale yellow, crystalline very thin needles. Yield: 14.7 mg, 
32.6 mol, 33 %. 1H NMR (500 MHz, Chloroform-d) δ = 8.07 
(dd, 3J = 7.1 Hz, 4J = 1.7 Hz, 1H, ar-6-H), 7.98 (s, 1H, ar-2-H), 
7.88 (d, 3J = 8.2 Hz, 1H, ar-6-H), 7.54-7.46 (m, 3H, ar-5-H, 
ar’-3-H, ar’-5-H), 7.37 (m, 1H, ar’-4-H), 7.12 (dd, 3J = 8.2 Hz, 
4J = 1.9 Hz, 1H, ar’-6-H), 4.05 (dd, 3J = 7.3 Hz, 3J = 6.5 Hz, 1H, CHcy), 3.93 (s, 3H, ar-
1-CO2CH3), 3.36 (d br., 
3J = 7.3 Hz, 1H, NHCHcy), 1.91-1.84 (m, 2H, cy-H), 1.80-1.72 
(m, 3H, cy-H), 1.72-1.62 (m, 6H, cy-H), 1.24 (s, 9H, SC(CH3)3). 
13C NMR (126 MHz, 
Chloroform-d) δ = 166.9 (ar-1-CO2CH3), 145.8 (ar’-C-1), 143.7 (ar-C-3), 139.6 (ar-C-4), 
133.9 (ar’-C-3), 133.0 (ar’-C-4), 132.3 (ar’-C-6), 130.4 (ar-C-2), 130.2 (ar’-C-5), 129.2 
(ar-C-6), 128.3 (ar-C-5), 123.3 (ar-C-1), 98.4 (ar’-C-2), 90.1 (CHC≡Car), 84.6 
(CHC≡Car), 56.1 (SC(CH3)3), 52.4 (ar-1-CO2CH3), 42.8 (cy-C-1), 29.1 (cy-C-2), 28.7 
(cy-C-6), 28.4 (cy-C-4), 26.7 (cy-C-5), 26.5 (cy-C-3), 22.9 (SC(CH3)3). C27H33NO3S 
(451.63 g mol-1). MS(ESI): m/z = 452.2254 (calcd. 452.2242 [M+H]+).  
 
Methyl 2'-((R)-3-(((S)-tert-Butylsulfinyl)amino)-4,4,4-trifluorobut-1-yn-1-yl)-[1,1'-
biphenyl]-3-carboxylate (94c). Under argon atmosphere, the solid catalysts PdCl2(PPh3)2 
(2 mg, 3 mol, 2 mol%) and CuI (1 mg, 5 mol, 4 mol%) 
were added in one portion to a thoroughly degassed solution 
of propargylamide 6p (32 mg, 141 mol, 1.0 eq) and iodo 
biphenyl 93b (63.9 mg, 189 mol, 1.3 eq) in a mixture of 
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THF/DIPEA (3:1, 2.8 mL). The reaction mixture was stirred overnight at ambient 
temperature. After complete consumption of propargylamide 6p (checked by TLC), the 
mixture was diluted with aqueous NH4Cl (saturated, 20 mL), CH2Cl2 (20 mL) and aqueous 
KHSO4 (5 %, 20 mL). The phases were separated and the aqueous layers were extracted 
with CH2Cl2 (3 x 20 mL). The combined organic layers were dried over MgSO4, filtered 
and the solvent was evaporated under reduced pressure. The crude biphenyl derivative 94c 
was purified by column chromatography (PE/EtOAc, 2:1).  
Pale yellow oil. Yield: 11.9 mg, 27.8 mol, 20 %. 1H NMR (500 MHz, Chloroform-d) δ = 
8.26 (s, 1H, ar-2-H), 8.03 (d, 3J = 7.5 Hz, 1H, ar-6-H), 7.76 (d, 3J = 7.6 Hz, 1H, ar-4-H), 
7.62 (d, 3J = 7.7 Hz, 1H, ar‘-6-H), 7.52 (t, 3J = 7.7 Hz, 1H, ar-5-H), 7.45 (t, 3J = 7.9 Hz, 
1H, ar‘-5-H), 7.42 (d, 3J = 7.5 Hz, 1H, ar‘-3-H), 7.34 (t, 3J = 7.4 Hz, 1H, ar‘-4-H), 4.63 
(dq, 3J = 7.8 Hz, 3J = 6.4 Hz, 1H, CHCF3), 3.93 (s, 3H, ar-1-CO2CH3), 3.72 (d br., 
3J = 
7.8 Hz, 1H, NHCH), 1.22 (s, 9H, SC(CH3)3). 
13C NMR (126 MHz, Chloroform-d) δ = 
167.3 (ar-1-CO2CH3), 143.5 (ar’-C-1), 140.1 (ar-C-3), 133.8 (ar’-C-6), 133.7 (ar-C-4), 
130.5 (ar-C-2), 130.2 (ar-C-1), 129.9 (ar‘-C-3), 129.5 (ar‘-C-5), 128.8 (ar-C-6), 128.5 (ar-
C-5), 127.7 (ar‘-C-4), 123.0 (q, 1JCF = 282.0 Hz, CHCF3), 119.6 (ar‘-C-2), 87.2 
(CHC≡Car), 82.9 (CHC≡Car), 57.5 (SC(CH3)3), 51.7 (q, 2JCF = 34.9 Hz, CHCF3), 22.5 
(SC(CH3)3). C22H22F3NO3S (437.48 g mol
-1). MS(ESI): m/z = 438.13490 (calcd. 438.1345 
[M+H]+). TLC: Rf (PE/EtOAc, 2:1) = 0.39.  
 
IIX-4. c) Introduction of Peptidomimetics into Peptides (95-97) 
Methyl (tert-Butoxycarbonyl)-L-valyl-L-valinate. The dimerization of valine under  
analogous conditions has been reported by Jana et al. [240]. A mixture of tert-
butoxycarbonyl-L-valine (1.08 g, 4.97 mmol, 1.0 eq) and methyl L-valinate hydrochloride 
(1.09 g, 6.50 mmol, 1.3 eq), TBTU (4.79 g, 14.9 mmol, 3.0 eq) and HOBt (201 mg, 
1.49 mmol, 0.3 eq) was dissolved under argon atmosphere in a mixture of DMF/DIPEA 
(12.5 mL, 4:1) and stirred for three days at ambient temperature. The reaction mixture was 
diluted with aqueous NH4Cl (saturated, 25 mL) and extracted with CH2Cl2 (3 x 25 mL). 
The combined organic layers were dried over Na2SO4, filtered and purified by column 
chromatography (PE/EtOAc, 2:1).  
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Colorless crystalline solid. Yield: 1.52 g, 4.60 mmol, 92 % (Lit: 84 % [240]). 1H NMR 
(500 MHz, Chloroform-d) δ = 6.94 (d, 3J = 8.4 Hz, 1H, CONH-Val), 5.43 (d, 3J = 9.0 Hz, 
1H, Val-NHBoc), 4.38 (dd, 3J = 8.5 Hz, 3J = 5.2 Hz, 1H, Val-CαH), 
3.93 (dd, 3J = 8.1 Hz, 3J = 8.1 Hz, 1H, Val-CαH), 3.57 (s, 3H, 
CO2CH3), 2.02 (dh, 
3J = 7.3 Hz, 3J = 6.7 Hz, 1H, Val-CαHCH(CH3)2), 1.92 (dh, 
3J = 6.8 Hz, 
3J = 5.2 Hz, 1H, Val-CαCH(CH3)2), 1.28 (s, 9H, CO2C(CH3)3), 0.82 (d, 
3J = 6.9 Hz, 3H, 
Val-(CH3)CHCH3), 0.79 (d, 
3J = 6.9 Hz, 6H, Val-CH(CH3)2), 0.76 (d, 
3J = 7.0 Hz, 3H, 
Val-(CH3)CHCH3). 
13C NMR (126 MHz, Chloroform-d) δ = 172.1 (Val-CO2CH3, Val-
CONH), 155.8 (NHCO2C(CH3)3), 79.2 (CO2C(CH3)3), 59.7 (Val-C
αH), 57.1 (Val-CαH), 
51.8 (CO2CH3), 30.8 (Val-C
αHCH2CH(CH3)2), 30.7 (Val-C
αHCH(CH3)2), 28.2 
(CO2C(CH3)3), 19.0 (Val-(CH3)CHCH3), 18.8 (Val-(CH3)CHCH3), 18.0 (Val-
(CH3)CHCH3), 17.8 (Val-(CH3)CHCH3). C16H30N2O5 (330.43 g mol
-1). MS(ESI): m/z = 
353.2011 (calcd. 353.2047 [M+Na]+). TLC: Rf (EtOAc/PE, 1:2) = 0.55.  
 
Methyl ((S)-2-((tert-Butoxycarbonyl)amino)-3-(4-methoxyphenyl)propanoyl)-L-
phenylalaninate. This dipeptide has been first characterized by Chapman et al., who 
accessed it in a completely different way [241]. A mixture of tert-butoxycarbonyl L-4-
methoxyphenylalanine (1.08 g, 3.66 mmol, 1.0 eq) and methyl L-phenylalaninate 
hydrochloride (1.09 g, 5.05 mmol, 1.4 eq), TBTU (3.53 g, 11.0 mmol, 3.0 eq) and HOBt 
(150 mg, 1.48 mmol, 0.3 eq) was dissolved under argon atmosphere in DMF (10 mL). 
DIPEA (2.6 mL, 1.94 g, 15 mmol, 3.0 eq) was added and the reaction mixture was stirred 
for three days at ambient temperature. The reaction mixture was diluted with aqueous 
NH4Cl (saturated, 25 mL) and extracted with CH2Cl2 (3 x 25 mL). The combined organic 
layers were dried over Na2SO4, filtered and purified by column chromatography 
(PE/EtOAc, 2:1). The title compound was obtained as EtOAc adduct in form of a gel.  
Colorless gel. Yield: 1.697 g, 3.116 mmol, 85 %, 1H NMR (500 
MHz, Chloroform-d) δ = 7.13 (t, 3J = 7.3 Hz, 2H, Phe-ar-3-H, 
Phe-ar-5-H), 7.09 (t, 3J = 7.0 Hz, 1H, Phe-ar-4-H), 7.00 (d, 3J = 
8.2 Hz, 2H, Tyr-ar-3-H, Tyr-ar-5-H), 6.96 (d, 3J = 7.3 Hz, 2H, 
Phe-ar-2-H, Phe-ar-6-H), 6.84 (d, 3J = 7.7 Hz, 1H, CONH-Phe), 
6.68 (d, 3J = 8.1 Hz, 2H, Tyr-ar-2-H, Tyr-ar-6-H), 5.38 (d, 3J = 8.2 Hz, 1H, Tyr-NHBoc), 
4.71 (ddd, 3J = 6.8 Hz, 3J = 8.2 Hz, 3J = 5.7 Hz, 1H, Phe-CαH), 4.33 (ddd, 3J = 8.3 Hz, 3J = 
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4.6 Hz, 3J = 6.5 Hz, 1H, Tyr-CαH), 4.00 (q, 3J = 7.1 Hz, 2H, CH3CO2CH2CH3), 3.62 (s, 
3H, Tyr-ar-OCH3), 3.53 (s, 3H, Phe-CO2CH3), 2.98 (dd, 
2J = 13.8 Hz, 3J = 6.1 Hz, 1H, 
Phe-CαHCH2), 2.93 (m, 1H, Tyr-C
αCH2), 2.90 (d, 
2J = 13.5 Hz, 3J = 5.7 Hz, 1H, Phe-
CαHCH2), 2.82 (m, 1H, Tyr-C
αHCH2), 1.91 (s, 3H, CH3CO2CH2CH3), 1.30 (s, 9H, Phe-
CO2C(CH3)3), 1.14 (t, 
3J = 7.1 Hz, 3H, CH3CO2CH2CH3). 
13C NMR (126 MHz, 
Chloroform-d) δ = 171.3 (Tyr-CONH), 171.1 (Phe-CO2Me), 170.7 (CH3CO2CH2CH3), 
158.2 (Tyr-ar-C-1), 155.1 (Tyr-NHCO2
tBu), 135.7 (Phe-ar-C-1), 130.1 (Tyr-ar-C-3, Tyr-
ar-C-5), 129.0 (Phe-ar-C-2, Phe-ar-C-6), 128.5 (Phe-ar-C-3, Phe-ar-C-5), 128.2 (Tyr-ar-
C-4), 126.7 (Phe-ar-C-4), 113.6 (Tyr-ar-C-2, Tyr-ar-C-6), 79.4 (Phe-CO2C(CH3)3), 60.0 
(CH3CO2CH2CH3), 55.5 (Tyr-C
αH), 54.8 (Tyr-ar-OCH3), 53.2 (Phe-C
αH), 51.8 
(Phe-CO2CH3), 37.7 (Tyr-C
αHCH2), 37.2 (Phe-C
αHCH2), 28.0 (Tyr-CO2C(CH3)3), 20.6 
(CH3CO2CH2CH3), 13.9 (CH3COOCH2CH3). C29H40N2O8 (544.65 g mol
-1). MS(ESI): m/z 
= 457.2235 (calcd. 457.2333 [C25H32N2O6+H]
+). TLC: Rf (PE/EtOAc, 2:1) = 0.38.  
 
Methyl (tert-Butoxycarbonyl)-L-valyl-L-leucinate. The preparation of this dipeptide 
was performe das described by Styers et al. [242]. A mixture of tert-butoxycarbonyl L-
valine (460 mg, 2.53 mmol, 1.2 eq) and methyl L-Leucinate hydrochloride (460 mg, 
2.12 mmol, 1.0 eq), TBTU (2.04 g, 6.36 mmol, 3.0 eq) and HOBt (86 mg, 0.64 mmol, 
0.3 eq) was dissolved under argon atmosphere in a mixture of CH2Cl2/DIPEA (12.5 mL, 
4:1) and the reaction mixture was stirred for three days at ambient temperature. The solution 
was diluted with aqueous NH4Cl (saturated, 25 mL) and extracted with CH2Cl2 (3 x 
25 mL). The combined organic layers were dried over Na2SO4, filtered and purified by 
column chromatography (PE/EtOAc, 2:1).  
Colorless crystalline solid. Yield: 718.3 mg, 2.085 mmol, 76 % (Lit: 94 % [242]). 1H NMR 
(500 MHz, DMSO-d6) δ = 8.14 (d br., 3J = 7.6 Hz, 1H, Leu-CαHNH), 6.60 (d br., 3J = 
9.1 Hz, 1H, Val-CαHNH), 4.31 (ddd, 3J = 10.0 Hz, 3J = 7.6 Hz, 
3J = 4.9 Hz, 1H, Leu-CαH), 3.79 (dd, 3J = 8.2 Hz, 3J = 9.1 Hz, 
1H, Val-CαH), 3.60 (s, 3H, Leu-CO2CH3), 1.91 (dh, 
3J = 8.2 Hz, 
3J = 6.9 Hz, 1H, Val-CH(CH3)2), 1.66 (m, 1H, Leu-CH(CH3)2), 1.57 (ddd, 
2J = 15.0 Hz, 3J 
= 10.3 Hz, 3J = 5.0 Hz, 1H, Leu-CαH-CH2), 1.47 (ddd, 
2J = 13.8 Hz, 3J = 9.1 Hz, 3J = 
4.8 Hz, 1H, Leu-CαH-CH2), 1.37 (s, 9H, Val-OC(CH3)3), 0.88 (d, 
3J = 6.6 Hz, 3H, Leu-
CHCH2CH(CH3)2, 0.85 (d, 
3J = 6.8 Hz, 3H, Val-CHCH(CH3)2, 0.82 (d, 
3J = 6.6 Hz, 6H, 
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Val-CHCH2CH(CH3)2, Leu-CHCH2CH(CH3)2. 
13C NMR (126 MHz, DMSO-d6) δ = 
172.8 (Leu-CO2CH3), 171.6 (Val-CHCONH), 155.3 (Val-CHNHCO2C(CH3)3), 77.9 
(Val-NHCO2C(CH3)3), 59.5 (Val-C
αH), 51.7 (Leu-CO2CH3), 50.0 (Leu-C
αH), 39.7 (Leu-
CαHCH2), 30.3 (Val-CHCH(CH3)2), 28.1 (Val-CHNHCO2C(CH3)3), 24.0 (Leu-
CHCH2CH(CH3)2), 22.8 (Leu-CHCH2CH(CH3)2), 21.1 (Val-CHCH(CH3)2), 19.1 (Leu-
CHCH2CH(CH3)2), 18.2 (Val-CHCH2CH(CH3)2). C17H32N2O5 (344.45 g mol
-1). 
MS(ESI): m/z = 367.2143 (calcd. 367.2203 [M+Na]+). TLC: Rf (EtOAc/PE, 1:1) = 0.82.  
 
Methyl (tert-Butoxycarbonyl)-L-alanyl-L-valyl-L-leucinate. This tripeptide has been 
first described and characterized by Abiko and Sekino. Their synthesis was completely 
different [243]. A mixture of H2N-Val-Leu-OMe (540 mg, 1.93 mmol, 1.0 eq) and 
BocH-Ala-OH x HCl (480 mg, 2.51 mmol, 1.3 eq), TBTU (1.86 g, 5.79 mmol, 3.0 eq) and 
HOBt (78 mg, 0.58 mmol, 0.3 eq) was dissolved under argon atmosphere in a mixture of 
CH2Cl2/DIPEA (12.5 mL, 4:1) and the reaction mixture was stirred for three days at 
ambient temperature. The solution was diluted with aqueous NH4Cl (saturated, 25 mL) and 
extracted with CH2Cl2 (3 x 25 mL). The combined organic layers were dried over Na2SO4, 
filtered and purified by column chromatography (PE/EtOAc, 2:1).  
Pale yellow, highly viscous oil. Yield: 819 mg, 1.93 mmol, quantitative. 1H NMR 
(500 MHz, Chloroform-d) δ = 7.45-6.96 (m, 2H, Val-
CHNHCOCH-Ala, Leu-CHNHCOCH-Val), 5.52 (m, 
1H, Ala-CHNHCO2C(CH3)3), 4.48 (dd, 
3J = 8.7 Hz, 3J = 
4.7 Hz, 1H, Leu-CHCH2CH(CH3)2), 4.22 (dh, 
3J = 
6.5 Hz, 3J = 7.5 Hz, 1H, Val-CHCH(CH3)2), 4.03 (qd, 
3J = 7.6 Hz, 3J = 5.6 Hz, 3J = 4.1 Hz, 
1H, Ala-CHCH3), 3.62 (s, 3H, Leu-CO2CH3), 2.02 (m, 1H, Val-CHCH(CH3)2), 1.95 (m, 
1H, Leu-CHCH2CH(CH3)2), 1.59-1.45 (m, 2H, Leu-CHCH2CH(CH3)2), 1.34 (s, 9H, 
Ala-CHNHCO2C(CH3)3), 1.28-1.21 (m, 3H, Ala-CHCH3), 0.90-0.75 (m, 12H, Val-
CHCH(CH3)2, Leu-CHCH2CH(CH3)2). 
13C NMR (126 MHz, Chloroform-d) δ = 175.5 
(Ala-CHCONHCH-Val), 173.1 (Val-CHCO2CH3), 171.4 (Val-CHCONHCH-Leu), 
155.5 (Ala-CHNHCO2C(CH3)3), 79.7 (Ala-CHNHCO2C(CH3)3), 60.3 (Ala-CHCH3), 
52.1 (Leu-CHCH2CH(CH3)2), 50.8 (Leu-CHCO2CH3), 50.1 (Val-CHCH(CH3)2), 40.8 
(Leu-CHCH2CH(CH3)2), 31.0 (Val-CHCH(CH3)2), 28.3 (Ala-CHNHCO2C(CH3)3), 
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24.7 (Leu-CHCH2CH(CH3)2), 22.7 (Leu-CHCH2CH(CH3)2), 21.7 (Val-CHCH(CH3)2), 
19.0 (Val-CHCH(CH3)2), 14.1 (Ala-CHCH3). C20H37N3O6 (415.53 g mol
-1). 
LCMS(ESI): tr = 9.0 min, m/z = 416.2725 (calcd. 416.2755 [M+H]+), 438.2550 (calcd. 
438.2575 [M+Na]+).  
 
Methyl ((S)-2-((tert-Butoxycarbonyl)amino)-3-(4-methoxyphenyl)propanoyl)-L-
phenylalanylglycinate. A mixture of ((S)-2-(tertButoxycarbonylamino)-3-(4-
methoxyphenyl)propanoyl)-L-phenylalanine (700 mg, 1.58 mmol, 1.0 eq) and methyl 
L-Glycinate hydrochloride (300 mg, 2.37 mmol, 1.5 eq), TBTU (1.52 g, 4.74 mmol, 
3.0 eq) and HOBt (64 mg, 0.47 mmol, 0.3 eq) was dissolved under argon atmosphere in a 
mixture of CH2Cl2/DIPEA (8 mL, 4:1) and the reaction mixture was stirred for three days 
at ambient temperature. The solution was diluted with aqueous NH4Cl (saturated, 25 mL) 
and extracted with CH2Cl2 (3 x 25 mL). The combined organic layers were dried over 
Na2SO4, filtered and purified by column chromatography (PE/EtOAc, 2:1).  
 Colorless crystalline solid. Yield: 807 mg, 1.57 mmol, 99 %. 1H NMR (500 MHz, 
DMSO-d6) δ = 8.48 (t, 3J = 6.0 Hz, 1H, Gly-CαHNH), 8.01 (d, 3J = 8.6 Hz, 1H, Phe-
CαHNH), 7.28 (d, 3J = 7.9 Hz, 2H, Phe-ar-2-H, Phe-ar-6-H), 7.25 (d, 3J = 7.6 Hz, 2H, Tyr-
ar-3-H, Tyr-ar-5-H), 7.19 (t, 3J = 6.8 Hz, 2H, Phe-ar-3-H, Phe-ar-5-H), 7.09 (d, 3J = 8.1 Hz, 
2H, Phe-ar-2-H, Phe-ar-6-H), 6.82 (d, 3J = 8.9 Hz, 1H, 
Tyr-CαHNH), 6.79 (d, 3J = 8.3 Hz, 2H, Tyr-ar-2-H, Tyr-
ar-6-H), 4.64 (ddd, 3J = 8.7 Hz, 3J = 4.8 Hz, 3J = 6.5 Hz, 
1H, Phe-CαH), 4.10 (ddd, 3J = 9.3 Hz, 3J = 7.2 Hz, 3J = 
4.3 Hz, 1H, Tyr-CαH), 3.91 (dd, 2J = 17.8 Hz, 3J = 5.6 Hz, 
1H, Gly-CαH2), 3.86 (dd, 
2J = 17.8 Hz, 3J = 6.0 Hz, 1H, Gly-CαH2), 3.69 (s, 3H, Tyr-ar-
OCH3), 3.63 (s, 3H, Gly-CO2CH3), 3.07 (dd, 
2J = 14.0 Hz, 3J = 4.7 Hz, 1H, Phe-CαHCH2), 
2.86 (dd, 2J = 13.9 Hz, 3J = 9.0 Hz, 1H, Phe-CαHCH2), 2.81 (dd, 
2J = 13.9 Hz, 3J = 4.3 Hz, 
1H, Tyr-CαHCH2), 2.61 (dd, 
2J = 13.9 Hz, 3J = 10.1 Hz, 1H, Tyr-CαHCH2), 1.29 (s, 9H, 
Tyr-C(CH3)3). 
13C NMR (126 MHz, DMSO-d6) δ = 171.5 (Phe-CαHCON), 171.4 (Tyr-
CαHCON), 170.1 (Gly-CαHCO2), 157.8 (Tyr-ar-C-1), 155.1 (Tyr-NHCO2C(CH3)3), 137.6 
(Tyr-ar-C-4), 130.2 (Phe-ar-C-1), 129.4 (Phe-ar-C-3, Phe-ar-C-5), 128.1 (Tyr-ar-C-3, Tyr-
ar-C-5), 126.3 (Phe-ar-C-4), 113.5 (Tyr-ar-C-2, Tyr-ar-C-6), 78.2 (Tyr-CO2C(CH3)3), 56.2 
(Tyr-CαH), 54.9 (Tyr-ar-OCH3), 53.5 (Phe-C
αH), 51.7 (Gly-CO2CH3), 40.6 (Gly-C
αH2), 
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37.9 (Phe-CαHCH2), 36.8 (Tyr-C
αHCH2), 28.1 (Tyr-C(CH3)3). C27H35N3O7 
(513.59 g mol-1). MS(ESI): m/z = 514.2642 (calcd. 514.2548 [M+H]+). TLC: Rf 
(EtOAc/PE, 1:1) = 0.14.  
 
tert-Butyl ((S)-1-(((S)-1-(((S)-But-3-yn-2-yl)amino)-1-oxo-3-phenylpropan-2-
yl)amino)-3-(4-methoxyphenyl)-1-oxopropan-2-yl)carbamate. A mixture of ((S)-2-
((tert-Butoxycarbonyl)amino)-3-(4-methoxyphenyl)propanoyl)-L-phenylalanylglycine 
(200 mg, 0.46 mmol, 1 eq) and (S)-but-3-yne-2-amine hydrochloride (50 mg, 0.46 mmol, 
1 eq), TBTU (443 mg, 1.38 mmol, 3.0 eq) and HOBt (19 mg, 0.14 mmol, 0.3 eq) was 
dissolved under argon atmosphere in a mixture of DMF/DIPEA (6 mL, 4:1) and the 
reaction mixture was stirred for three days at ambient temperature. The solution was diluted 
with aqueous NH4Cl (saturated, 25 mL) and extracted with CH2Cl2 (3 x 25 mL). The 
combined organic layers were dried over Na2SO4, filtered and purified by preparative 
HPLC.  
Colorless amorphous solid. Yield: 8.1 mg, 16.4 mol, 4 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.23 (d, 3J = 7.6 Hz, 2H, Phe-Ph-2-H, Phe-Ph-6-H), 7.20 (t, 3J = 7.0 Hz, 
1H, Phe-Ph-4-H), 7.07 (d, 3J = 8.2 Hz, 2H, Tyr-ar-3-H, Tyr-ar-5-H), 7.04 (t, 3J = 5.3 Hz, 
2H, Phe-Ph-3-H, Phe-Ph-5-H), 6.83 (d, 3J = 8.2 Hz, 2H, Tyr-ar-2-H, Tyr-ar-6-H), 6.45 (s 
br., 2H, Phe-CHNHCOCH-Tyr, CHNHCOCH-Phe), 4.86 (d br., 3J = 6.4 Hz, 1H, Tyr-
CHNHCO2C(CH3)3), 4.68 (ddd, 
3J = 7.2 Hz, 3J = 6.5 Hz, 
4J = 2.3 Hz, 1H, CHCH3), 4.62 (ddd, 
3J = 7.4 Hz, 3J = 
6.5 Hz, 3J = 5.4 Hz, 1H, Phe-CHCH2Ph), 4.24 (ddd, 
3J = 
6.4 Hz, 3J = 7.2 Hz, 3J = 4.7 Hz, 1H, Tyr-CHCH2ar), 3.77 
(s, 3H, Tyr-ar-OCH3), 3.18 (d, 2J = 13.7 Hz, 1H, Phe-
CHCH2Ph), 2.97 (dd, 
2J = 14.0 Hz, 3J = 6.1 Hz, 1H, Tyr-CHCH2ar), 2.94-2.86 (m, 2H, 
Tyr-CHCH2ar, Phe-CHCH2Ph), 2.21 (d, 
4J = 2.2 Hz, 1H, CHC≡CH), 1.33 (s, 9H, Tyr-
CHNHCO2C(CH3)3), 1.29 (d, 
3J = 6.9 Hz, 3H, CHCH3). 13C NMR (126 MHz, 
Chloroform-d) δ = 171.1 (Tyr-CHCONH), 169.4 (Phe-CHCONH), 158.9 (Tyr-
CHNHCO2C(CH3)3), 155.7 (Tyr-ar-C-1-OCH3), 136.2 (Phe-C-1), 130.4 (Tyr-C-3, Tyr-
C-5), 129.5 (Phe-C-3, Phe-C-5), 128.8 (Phe-C-4), 128.1 (Tyr-C-4), 127.2 (Phe-C-2, Phe-
C-6), 114.4 (Tyr-C-2, Tyr-C-6), 83.6 (Ala-CHC≡CH), 80.7 (Tyr-CHNHCO2C(CH3)3), 
70.6 (Ala-CHC≡CH), 56.3 (Tyr-CHCH2ar), 55.4 (Tyr-ar-1-OCH3), 53.8 (Phe-
IIX-4. c) Introduction of Peptidomimetics into Peptides (95-97) 
276 
CHCH2Ph), 37.8 (Phe-CHCH2Ph), 37.2 (Ala-CHCH3), 37.0 (Tyr-CHCH2Ph), 28.3 
(Tyr-CHNHCO2C(CH3)3), 22.0 (Ala-CHCH3). C28H35N3O5 (493.60 g mol
-1). MS(ESI): 
m/z = 494.2650 (calcd. 494.2649 [M+H]+).  
 
tert-Butyl ((S)-1-(((S)-1-((2-(((S)-But-3-yn-2-yl)amino)-2-oxoethyl)amino)-1-oxo-3-
phenylpropan-2-yl)amino)-3-(4-methoxyphenyl)-1-oxopropan-2-yl)carbamate (95). 
A mixture of ((S)-2-((tert-Butoxycarbonyl)amino)-3-(4-methoxyphenyl)propanoyl)-L-
phenylalanylglycine (710 mg, 1.42 mmol, 1 eq) and (S)-but-3-yne-2-amine hydrochloride 
(180 mg, 1.70 mmol, 1.2 eq), TBTU (1.37 mg, 4.26 mmol, 3.0 eq) and HOBt (58 mg, 
0.43 mmol, 0.3 eq) was dissolved under argon atmosphere in a mixture of DMF/DIPEA 
(6 mL, 4:1) and the reaction mixture was stirred for three days at ambient temperature. The 
solution was diluted with aqueous NH4Cl (saturated, 25 mL) and extracted with CH2Cl2 (3 
x 25 mL). The combined organic layers were dried over Na2SO4, filtered and the crude 
product 95 was purified by preparative HPLC.  
Pale yellow, crystalline solid. Yield: 454 mg, 830 mol, 59 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.31-7.21 (m, 5H, Phe-Ph-H), 7.09 (d, 3J = 8.2 Hz, 2H, Tyr-ar-3-H, Tyr-
ar-5-H), 7.05 (d br., 3J = 7.0 Hz, 1H, Tyr-
CHNHBoc), 6.95 (t br., 3J = 9.5 Hz, 1H, 
CHNHCOCH-Gly), 6.86 (d, 3J = 8.3 Hz, 2H, Tyr-
ar-2-H, Tyr-ar-6-H), 6.61 (m, 1H, Phe-
CHNHCOCH-Tyr), 6.37 (s br., 1H, Gly-
CHNHCOCH-Phe), 5.00 (ddd, 3J = 6.2 Hz, 5.0 Hz, 3J = 7.0 Hz, 1H, Tyr-CHCH2ar), 
4.79 (qd, 3J = 7.0 Hz, 3J = 3.7 Hz, 1H, Ala-CHCH3), 4.56 (ddd, 
3J = 6.6 Hz, 3J = 4.8 Hz, 
3J = 7.2 Hz, 1H, Phe-CHCH2Ph), 4.22 (m, 1H, Gly-CH2), 4.14 (m, 1H, Gly-CH2), 3.98-
3.90 (m, 2H, Tyr-CHCH2ar), 3.80 (s, 3H, Tyr-ar-1-OCH3), 3.16 (m, 2H, Phe-CHCH2Ph), 
3.02 (m, 1H, Phe-CHCH2Ph), 2.27 (d, 
4J = 2.3 Hz, 1H, CHC≡CH), 1.44 (d, 3J = 7.0 Hz, 
3H, CHCH3), 1.33 (s, 9H, Tyr-CHNHCO2C(CH3)3). 
13C NMR (126 MHz, 
Chloroform-d) δ = 172.0 (Tyr-CHCONHCH-Phe), 171.1 (Phe-CHCONHCH-Ala), 
167.9 (Gly-CHCONHCH-Ala), 159.0 (Tyr-ar-C-1-OCH3), 156.2 (Tyr-
CHNHCO2C(CH3)3), 136.2 (Phe-C-1), 130.4 (Tyr-C-3, Tyr-C-5), 130.3 (Tyr-C-4), 129.2 
(Phe-C-3, Phe-C-5), 129.0 (Phe-C-2, Phe-C-6), 127.4 (Phe-C-4), 114.4 (Tyr-C-2, Tyr-C-
IIX-4. c) Introduction of Peptidomimetics into Peptides (95-97) 
277 
6), 84.2 (CHC≡CH), 81.1 (Tyr- CHNHCO2C(CH3)3), 70.4 (CHC≡CH), 56.6 (Tyr-
CHCH2ar), 55.4 (Tyr-ar-1-OCH3), 54.7 (Phe-CHCH2Ph), 45.5 (CHCH3), 43.4 (Gly-
CH2), 36.9 (Tyr-CHCH2ar), 36.5 (Phe-CHCH2Ph), 28.3 (Tyr-CHNHCO2C(CH3)3), 
22.1 (CHCH3). C30H38N4O6 (550.66 g mol
-1). MS(ESI): tr = 9.3 min, m/z = 551.290 
(calcd. 551.28600 [M+H]+), 573.269 (calcd. 573.26841 [M+Na]+).  
 
Methyl (2'-Iodo-[1,1'-biphenyl]-3-carbonyl)-L-alanyl-L-valyl-L-leucinate (96). A 
mixture of methyl L-alanyl-L-valyl-L-leucinate (0.16 mg, 0.39 mmol, 1.0 eq) and 2'-iodo-
[1,1'-biphenyl]-3-carboxylate (93c, 0.17 g, 0.53 mmol, 1.4 eq), HATU (445 mg, 
1.17 mmol, 3.0 eq) and HOAt (16 mg, 0.12 mmol, 0.3 eq) was dissolved under argon 
atmosphere in a mixture of CH2Cl2/DIPEA (18 mL, 10:1) and the reaction mixture was 
stirred for three days at ambient temperature. The solution was diluted with aqueous NH4Cl 
(saturated, 25 mL) and extracted with CH2Cl2 (3 x 25 mL). The combined organic layers 
were dried over Na2SO4, filtered and isolated by column chromatography (PE/EtOAc, 4:1). 
Afterwards, the crude product 96 was purified by preparative HPLC.  
Pale yellow, highly viscous oil. Yield: 105 mg, 170 mol, 44 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.87 (d, 3J = 7.9 Hz, 1H, ar’-6-H), 7.82 (d, 3J = 7.4 Hz, 1H, ar-6-H), 
7.75 (s, 1H, ar-2-H), 7.56 (d br., 3J = 8.7 Hz, 1H, Ala-CHNHCO), 7.45 (d br., 3J = 9.2 Hz, 
1H, Val-CHNHCO), 7.40 (t, 3J = 6.5 Hz, 1H, ar-5-H), 
7.37 (d, 3J = 7.3 Hz, 1H, ar-4-H), 7.32 (d, 3J = 7.3 Hz, 1H, 
ar’-4-H), 7.29 (d br., 3J = 8.8 Hz, 1H, Leu-C-NHCO), 
7.21 (d, 3J = 7.4 Hz, 1H, ar’-3-H), 6.97 (t, 3J = 7.5 Hz, 1H, ar’-5-H), 4.87 (dq, 3J = 6.2 Hz, 
3J = 7.1 Hz, 1H, Ala-CH), 4.50 (m, 1H, Leu-CH), 4.37 (dd, 3J = 8.0 Hz, 3J = 7.1 Hz, 1H, 
Val-CH), 3.61 (s, 3H, Leu-CO2CH3), 2.08 (dh,
 3J = 7.5 Hz, 3J = 6.9 Hz, 1H, Val-
CHCH(CH3)2), 1.60-1.54 (m, 2H, Leu-CHCH2CH(CH3)2), 1.50 (m, 1H, Leu-
CHCH2CH(CH3)2), 1.41 (d, 
3J = 7.0 Hz, 3H, Ala-CCH3), 0.87 (d, 3J = 7.4 Hz, 3H, Val-
CCH3), 0.86 (d, 3J = 7.5 Hz, 3H, Leu-CHCH3), 0.81-0.74 (m, 6H, Val-CCH3, Leu-
CHCH3). 13C NMR (126 MHz, Chloroform-d) δ = 173.2 (Leu-CHCO2CH3), 172.8 (Ala-
CHCONH), 171.2 (Val-CHCONH), 166.9 (Leu-NHCOar), 145.6 (ar’-C-2), 144.3 (ar-
C-3), 139.5 (ar’-C-6), 133.8 (ar-C-5), 132.6 (ar’-C-3), 130.1 (ar’-C-5), 129.1 (ar-C-2), 
128.2 (ar’-C-4), 128.0 (ar-C-4), 126.6 (ar-C-6), 120.8 (ar-C-1), 98.3 (ar’-C-1), 58.6 (Val-
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C), 52.1 (Leu-CO2CH3), 50.8 (Leu-C), 49.3 (Ala-C), 40.9 (Leu-CHCH2), 31.0 (Val-
C), 24.8 (Leu-C), 22.8 (Val-CCH3), 21.8 (Val-CCH3), 19.2 (Leu-CHCH3), 18.5 (Leu-
CHCH3), 18.2 (Ala-CCH3). C28H36IN3O5 (621.52 g mol-1). LCMS(ESI): tr = 10.5 min, 
m/z = 622.1773 (calcd. 622.1772 [M+H]+), 644.1553 (calcd. 644.1592 [M+Na]+). TLC: Rf 
(PE/EtOAc, 4:1) = 0.11.  
 
Methyl (2'-((S)-3-(2-((S)-2-((S)-2-((tert-Butoxycarbonyl)amino)-3-(4-
methoxyphenyl)propanamido)-3-phenylpropanamido)acetamido)but-1-yn-1-yl)-
[1,1'-biphenyl]-3-carbonyl)-L-alanyl-L-valyl-L-leucinate (97). Under argon 
atmosphere, the solid catalysts PdCl2(PPh3)2 (2 mg, 3 mol, 2 mol%) and CuI (1 mg, 
5 mol, 4 mol%) were added in one portion to a thoroughly degassed solution of BocHN-
4-methoxyPhe-Phe-Gly-propargylamide 95 (68.2 mg, 120 mol, 1.0 eq) and iodo 
biphenyl-Ala-Val-Leu-OMe 96 (76.7 mg, 120 mol, eq) in a mixture of 
1,4-dioxane/DIPEA (3:1, 1.9 mL). The reaction mixture was stirred for 3 h at 60 °C. After 
complete consumption of propargylamide 6p (checked by LCMS), the mixture was diluted 
with aqueous NH4Cl (saturated, 20 mL), CH2Cl2 (20 mL) and aqueous KHSO4 (5 %, 
20 mL). The phases were separated and the aqueous layers were extracted with CH2Cl2 (3 
x 20 mL). The combined organic layers were dried over Na2SO4, filtered and the solvent 
was evaporated under reduced pressure. The crude hairpin mimetic 97 was purified by 
preparative HPLC.  
Colorless, amorphous solid. Yield: 19.8 mg, 19.0 mol, 15 %. 1H NMR (600 MHz, 
Methanol-d3) δ = 8.15 (s br., 1H, Val-NH), 7.98 (d br., 3J = 8.7 Hz, 1H, propargylamine-
NH), 7.91 (d br., 3J = 7.9 Hz, 
1H, Ala-NH), 7.87 (d br., 3J 
= 7.4 Hz, 1H, Leu-NH), 7.83 
(d br., 3J = 7.7 Hz, 1H, Phe-
NH), 7.76 (d br., 3J = 7.7 Hz, 
1H, Gly-NH), 7.74 (d, 3J = 
7.9 Hz, 1H, ar-6-H), 7.64 (d, 
3J = 7.9 Hz, 1H, ar’-6-H), 7.48 (d, 3J = 7.8 Hz, 1H, ar-4-H), 7.45 (t, 3J = 7.7 Hz, 1H, ar-5-
H), 7.37 (d, 4J = 1.9 Hz, 1H, ar-2-H), 7.35 (td, 3J = 7.3 Hz, 4J = 1.1 Hz, 1H, ar’-4-H), 7.26 
(td, 3J = 7.4 Hz, 4J = 1.7 Hz, 1H, ar’-5-H), 7.18 (t, 3J = 7.5 Hz, 2H, Phe-Ph-3-H, Phe-Ph-
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5-H), 7.12 (t, 3J = 7.4 Hz, 1H, Phe-Ph-4-H), 7.09 (d, 3J = 7.8 Hz, 2H, Phe-Ph-2-H, Phe-Ph-
6-H), 7.02 (td, 3J = 7.8 Hz, 4J = 1.8 Hz, 1H, ar’-3-H), 6.99 (d, 3J = 8.1 Hz, 2H, Tyr-ar-3-
H, Tyr-ar-5-H), 6.73 (d, 3J = 8.6 Hz, 2H, Tyr-ar-2-H, Tyr-ar-6-H), 5.64 (d br., 3J = 7.7 Hz, 
1H, Tyr-NHBoc), 4.80-4.72 (m, 2H, Ala-CH, propargylamine-CH), 4.55 (dd, 3J = 
7.3 Hz, 3J = 4.6 Hz, 1H, Val-CH), 4.49 (m, 1H, Leu-CH), 4.08 (m, 1H, Tyr-CαH), 3.87 
(dd, 2J = 17.0 Hz, 3J = 5.7 Hz, 1H, Gly-CαH), 3.77 (dd, 2J = 16.9 Hz, 3J = 5.3 Hz, 1H, Gly-
CαH), 3.72 (m, 1H, Phe-CαH), 3.70 (s, 3H, Tyr-O-CH3), 3.66 (s, 3H, Leu-CO2CH3), 3.08 
(dd, 2J = 13.9 Hz, 3J = 6.3 Hz, 1H, Phe-CH2), 2.92 (dd, 
2J = 13.9 Hz, 3J = 8.0 Hz, 1H, Phe-
CH2), 2.87 (dd, 
2J = 14.1 Hz, 3J = 5.8 Hz, 1H, Tyr-CH2), 2.68 (dd, 
2J = 14.0 Hz, 3J = 
8.2 Hz, 1H, Tyr-CH2), 2.04 (m, 1H, Val-CH), 1.59 (dt, 
2J = 13.3 Hz, 3J = 7.1 Hz, 2H, 
Leu-CαCβH2), 1.54 (m, 1H, Leu-CH(CH3)2), 1.39 (d, 
3J = 7.1 Hz, 3H, Ala-CH3), 1.29 (s, 
9H, Tyr-NHCO2C(CH3)3), 1.23 (d, 
3J = 6.8 Hz, 3H, propargylamine-CH3), 0.92 (d, 3J = 
6.6 Hz, 3H, Val-CCH3), 0.90 (d, 3J = 6.8 Hz, 3H, Val-CCH3), 0.87 (d, 3J = 6.1 Hz, 3H, 
Leu-CCH3), 0.84 (d, 3J = 5.9 Hz, 3H, Leu-CCH3). 13C NMR (151 MHz, Methanol-d3) δ 
= 173.7 (Phe-CONH), 173.5 (Leu-CO2CH3), 172.6 (Tyr-CONH), 171.9 (Ala-CONH), 
171.8 (Val-CONH), 168.5 (Gly-CONH), 168.3 (ar-CONH), 158.6 (Tyr-ar-C-1), 156.1 
(Tyr-NHCO2
tBu), 142.7 (Phe-Ph-C-1), 140.7 (ar-C-3), 136.7 (ar’-C-6), 133.2 (ar-C-4), 
132.6 (ar-C-1), 130.4 (Tyr-ar-C-3, Tyr-ar-C-5), 130.3 (Tyr-ar-C-4), 129.3 (Phe-Ph-C-3, 
Phe-Ph-C-5), 129.3 (ar’-C-3), 129.2 (ar-C-2), 128.9 (ar’-C-4), 128.7 (Phe-Ph-C-2, Phe-
Ph-C-6), 128.6 (ar-C-5), 128.5 (Phe-Ph-C-4), 127.6 (ar’-C-5), 127.0 (ar’-C-1), 125.9 (ar-
C-6), 121.0 (ar’-C-2), 114.0 (Tyr-ar-C-2, Tyr-ar-C-6), 92.6 (CHC≡C-ar), 81.9 (CHC≡C-
ar), 80.2 (Tyr-NHCO2C(CH3)3), 59.0 (Val-CH), 56.1 (Tyr-CH), 55.2 (Tyr-O-CH3), 54.9 
(Phe-CH), 52.2 (Leu-CO2CH3), 51.1 (Leu-C), 49.8 (Ala-CH), 42.7 (Gly-CαH2), 42.1 
(Val-C), 40.7 (Leu-CβH2), 37.8 (CHC≡C-ar), 37.6 (Phe-C), 37.5 (Tyr-C), 31.1 (Val-
C), 28.2 (Tyr-NHCO2C(CH3)3), 24.9 (Leu-C(CH3)2), 22.7 (Val-CCH3), 21.9 (Leu-
CCH3), 21.6 (C(-CH3)HC≡C-ar), 19.1 (Leu-CCH3), 18.2 (Val-CCH3), 18.2 (Ala-
CH3). C58H73N7O11 (1044.26 g mol
-1). MS(ESI): m/z = 1044.5356 (calcd. 1044.5441 
[M+H]+).  
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Methyl (E)-2-((2-Amino-5-methylphenyl)diazenyl)benzoate. An aqueous solution of 
NaNO2 (489 mg, 7.08 mmol, 1.1 eq in 9 mL HCl, 4 M) was carefully dropped into a 
vigorously stirred colorless suspension of methyl anthranilate (1.00 g, 6.62 mmol, 1.0 eq) 
in aqueous hydrochloric acid (6 M, 4.5 mL) at 0 °C. The suspension was stirred at 0 °C, 
until it became a clear solution (5 min). After 5 min, the reaction mixture was poured in a 
solution of para-toluidine (722 mg, 6.74 mmol, 1.0 eq) in aqueous hydrochloric acid (6 M, 
7 mL) at 0 °C. This reaction mixture was allowed to warm up to rt and stirred for 6 h at 
ambient temperature. After 6 h, the mixture was neutralized with an aqueous solution of 
NaOH. When the pH was in the range of 7, the aqueous solution turned a deep purple color 
and was extracted with CH2Cl2 until it had completely lost its color (6 x 60 mL). The 
combined organic layers were dried over Na2SO4 and the solvent was removed under 
reduced pressure. The crude product was purified by column chromatography (PE/EtOAc, 
10:1).  
Deeply purple liquid. Yield: 1.675 g, 6.22 mmol, 94 %. 1H NMR 
(500 MHz, Chloroform-d) δ = 12.33 (s, 2H, benzoate-CO-H-N2), 8.01 
(d, 3J = 8.2 Hz, 1H, benzoate-6-H), 7.93 (d, 3J = 8.4 Hz, 1H, benzoate-
3-H), 7.63-7.43 (m, 3H, benzoate-5-H, N2Ph-4-H, N2Ph-6-H), 7.23 (d, 
3J = 8.0 Hz, 1H, 
N2Ph-3-H), 7.00 (t, 
3J = 7.7 Hz, 1H, benzoate-4-H), 3.94 (s, 3H, benzoate-1-CO2CH3), 3.55 
(s, 2H, N2Ph-2-NH2), 2.40 (s, 3H, N2Ph-5-CH3). C15H15N3O2 (269.30 g mol
-1). 
LCMS(ESI): m/z = 270.1315 (calcd. 270.1237 [M+H]+). TLC: Rf (PE/EtOAc, 4:1) = 0.66, 
Rf (PE/EtOAc, 10:1) = 0.36.  
 
Methyl (E)-2-((2-Iodo-5-methylphenyl)diazenyl)benzoate. An aqueous hydroiodine 
solution (50 %, 1.7 mL) was slowly added to a solution of Methyl (E)-2-((2-Amino-5-
methylphenyl)diazenyl)benzoate (795 mg, 2.95 mmol, 1.0 eq) and KI (975 mg, 5.87 mmol, 
2 eq) in H2O (20 mL). At 0 °C, an aqueous solution of NaNO2 (243 mg, 3.52 mmol, 1.2 eq 
in 1.6 mL) was added dropwise. The reaction mixture was stirred at 80 °C for 2 h. Then, 
another portion of NaNO2 (451 mg, 6. 54 mmol, 2.2 eq) was added and the solution was 
heated once more to 80 °C for 1 h. The red mixture was cooled to rt, extracted with CH2Cl2 
(3 x 50 mL) and the combined organic layers were washed with an aqueous Na2SO3 
solution (2 x 15 mL), brine (1 x 10 mL) and dried over Na2SO4. After evaporation of the 
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solvent, the brown crude product was purified by column chromatography (PE/EtOAc, 
10:1).  
Deep purple, amorphous solid. Yield: 193 mg, 510 mol, 17 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 8.10 (d, 4J = 1.7 Hz, 1H, N2Ph-6-H), 7.99 (d, 3J = 
8.1 Hz, 1H, benzoate-6-H), 7.80 (d, 3J = 7.8 Hz, 1H, benzoate-3-H), 7.67 
(d, 3J = 8.2 Hz, 1H, N2Ph-3-H), 7.42 (dd, 
3J = 8.3 Hz, 4J = 1.7 Hz, 1H, 
N2Ph-4-H), 7.39 (t, 
3J = 7.6 Hz, 1H, benzoat-4-H), 7.14 (t, 3J = 7.7 Hz, 1H, 
benzoat-5-H), 3.93 (s, 3H, benzoat-1-CO2CH3), 2.28 (s, 3H, N2Ph-5-CH3). 
13C NMR (126 MHz, Chloroform-d) δ = 167.0 (benzoat-1-CO2CH3), 142.8 (N2Ph-C-1), 
141.6 (benzoat-C-2), 141.4 (benzoat-C-6), 139.7 (N2Ph-C-6), 137.5 (N2Ph-C-4), 136.7 
(N2Ph-C-5), 135.1 (N2Ph-C-3), 132.7 (benzoat-C-5), 131.0 (benzoat-C-3), 127.9 (benzoat-
C-4), 122.8 (benzoat-C-1-CO2CH3), 90.3 (N2Ph-C-2-I), 52.6 (benzoat-1-CO2CH3), 21.1 
(N2Ph-5-CH3). C15H13IN2O2 (380.19 g mol
-1). LCMS(ESI): tr = 10.8, m/z = 381.0027 
(calcd. 381.0094 [M+H]+). TLC: Rf (PE/EtOAc, 4:1) = 0.76.  
 
Methyl (E)-2-((2-Iodophenyl)diazenyl)benzoate (98a).  
Methyl 2-Nitrosobenzoate. The synthesis of the azobenzene derivatives was 
performed following the detailed descriptions of Osorio-Planes, Rodríguez-
Escrich and Pericàs [161]. An aqueous solution of oxone (7.36 g, 12.0 mmol, 
3.6 eq in 72 mL, 0.17 M) was slowly added to a solution of methyl 2-amino benzoate 
(1.00 g, 6.62 mmol, 2.0 eq) in CH2Cl2 (18 mL, 0.5 M). The resulting two-phase system was 
vigorously stirred for 20 h, turning brightly green. The phases were separated and the 
aqueous layer was extracted with CH2Cl2 (2 x 30 mL). The combined organic layers were 
washed with aqueous HCl (1 M, 20 mL), aqueous NaHCO3 (saturated, 20 mL), water 
(15 mL) and brine (15 mL). The organic phase was dried over Na2SO4, filtered and the 
solvent was removed under vacuum. The crude product has been described to be a mixture 
of nitrosyl- and nitro benzoate (1:1) by the group of Pericàs. Furthermore, they reported the 
aromatic nitrosyl derivatives to be prone to disproportionation [161]. Thus, further 
purifications of the nitrosyl compound were not attempted. The crude product was directly 
applied for the subsequent reaction, as proposed by Osorio-Planes et al. C8H7NO3 
(165.15 g mol-1).  
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Methyl (E)-2-((2-Iodophenyl)diazenyl)benzoate (98a). A solution of the complete crude 
methyl 3-nitrosobenzoate in AcOH (7.5 mL, 0.5 M) was added dropwise in two portions 
over a period of 1 h to a stirred solution of 2-iodoanilin (510 mg, 2.44 mmol, 1.0 eq) in 
AcOH (5 mL, 0.6 M) at 0 °C. The reaction mixture was allowed to warm up to room 
temperature overnight. After 14 h, the green color of the solution had vanished and a deeply 
purple solution had developed. An aqueous solution of NaHCO3 (saturated, ca. 50 mL) was 
added dropwise, until no more gas developed. Then, the aqueous phase was carefully 
extracted with EtOAc (3 x 50 mL). After the combined organic layers had been washed 
with aqueous NaHCO3 (saturated, 30 mL), water (40 mL) and brine (20 mL), they were 
dried over Na2SO4 and the solvent was evaporated under reduced pressure. A deeply purple 
oil remained as crude product of 98a, which was purified by a short column 
chromatography (PE, the first fraction to elute is the title compound).  
Deeply purple oil. Yield: 227 mg, 620 mol, 25 %. 1H NMR (500 MHz, Chloroform-d) δ 
= 7.99 (d, 3J = 7.9 Hz, 1H, N2Ph-6-H), 7.85 (d, 
3J = 7.7 Hz, 1H, benzoate-6-H), 7.72 (d, 3J 
= 8.0 Hz, 1H, benzoate-3-H), 7.65 (d, 3J = 8.0 Hz, 1H, N2Ph-3-H), 7.58 
(d, 3J = 7.9 Hz, 1H, N2Ph-5-H), 7.47 (t, 
3J = 7.5 Hz, 1H, benzoate-5-H), 
7.39 (t, 3J = 7.6 Hz, 1H, benzoate-4-H), 7.12 (t, 3J = 7.5 Hz, 1H, N2Ph-4-
H), 4.11 (br. s, 1H, benzoate-CO-H-N2), 3.93 (s, 3H, benzoate-1-
CO2CH3). 
13C NMR (126 MHz, Chloroform-d) δ = 167.2 (benzoate-1-CO2CH3), 151.3 
(N2Ph-C-1), 151.1 (benzoate-C-2), 139.6 (N2Ph-C-6), 132.5 (N2Ph-C-4), 132.0 (N2Ph-C-
5), 130.3 (benzoate-C-5), 129.7 (benzoate-C-6), 128.9 (benzoate-C-4), 119.6 (benzoate-C-
1), 118.5 (benzoate-C-3), 117.9 (N2Ph-C-3), 102.4 (N2Ph-C-2), 52.4 (benzoate-1-
CO2CH3). C14H11IN2O2 (366.16 g mol
-1). MS(ESI): m/z = 366.9941 (calcd. 366.9938 
[M+H]+), 388.9735 (calcd. 388.9757 [M+Na]+).  
(E)-2-((2-Iodophenyl)diazenyl)benzoic Acid (98c). An aqueous LiOH solution (1 M, 
2.5 mL) was added dropwise to a solution of benzoate 98a (432 mg, 1.18 mmol) in MeOH 
(5.0 mL) at 0 °C. The reaction mixture was allowed to warm up to rt overnight. After 
complete consumption of ester 98a, the solution was diluted with aqueous KHSO4 (5 %, 
20 mL). After extraction of the aqueous phase with CH2Cl2 (3 x 30 mL) the organic layers 
were combined, dried over Na2SO4, filtered and the solvent was removed under reduced 
pressure. The crude product was purified by column chromatography (PE/EtOAc, 1:1). A 
photoisomerization of 19 % was observed by 1H NMR spectroscopy.  
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Deeply purple amorphous solid. Yield: 148 mg, 420 mol, 36 %. 
1H NMR (500 MHz, Chloroform-d) δ = 8.48 (d, 3J = 7.4 Hz, 1H, 
benzoate-3-H), 8.13 (d, 3J = 7.8 Hz, 2H, N2Ph-6-H, benzoate-6-H), 7.78-
7.72 (m, 2H, benzoate-5-H, benzoate-4-H), 7.52 (t, 3J = 7.6 Hz, 1H, N2Ph-
4-H), 7.47 (d, 3J = 7.9 Hz, 1H, N2Ph-3-H), 7.30 (t, 
3J = 7.5 Hz, 1H, N2Ph-5-H). 
13C NMR 
(126 MHz, Chloroform-d) δ = 159.4 (benzoate-C-1-CO2H), 150.9 (N2Ph-C-1), 149.4 
(benzoate-C-2-N2), 146.9 (N2Ph-C-3), 140.9 (benzoate-C-4), 139.1 (N2Ph-C-4), 133.4 
(benzoate-C-5), 129.7 (N2Ph-C-5), 129.5 (benzoate-C-6), 120.1 (N2Ph-C-6), 117.3 
(benzoate-C-3), 116.8 (benzoate-C-1), 114.9 (N2Ph-C-2). C13H9IN2O2 (352.13 g mol
-1).  
 
Methyl (E)-3-((3- and 2-Iodophenyl)diazenyl)benzoate (98b, 99). 
Methyl 3-Nitrosobenzoate. The synthesis of the azobenzene derivatives was performed 
following the detailed descriptions of Osorio-Planes, Rodríguez-Escrich and Pericàs [161]. 
An aqueous solution of oxone (4.25 g, 13.8 mmol, 4.0 eq in 72 mL, 0.2 M) was slowly 
added to a solution of methyl 3-amino benzoate (1.00 g, 6.62 mmol, 
2.0 eq) in CH2Cl2 (18 mL, 0.5 M). The resulting two-phase system was 
vigorously stirred for 20 h, turning brightly green. The phases were 
separated and the aqueous layer was extracted with CH2Cl2 (2 x 30 mL). The combined 
organic layers were washed with aqueous HCl (1 M, 20 mL), aqueous NaHCO3 (saturated, 
20 mL), water (15 mL) and brine (15 mL). The organic phase was dried over Na2SO4, 
filtered and the solvent was removed under vacuum. The crude product has been described 
to be a mixture of nitrosyl- and nitro benzoate (1:1) by the group of Pericàs. Furthermore, 
they reported the aromatic nitrosyl derivatives to be prone to disproportionation [161]. 
Thus, further purifications of the nitrosyl compound were not attempted. The crude product 
was directly applied for the subsequent reaction, as proposed by Osorio-Planes et al. [161].  
Methyl (E)-3-((2-Iodophenyl)diazenyl)benzoate (98b). A solution of the complete crude 
methyl 3-nitrosobenzoate in AcOH (7.5 mL, 0.5 M) was added dropwise in two portions 
over a period of 1 h to a stirred solution of 2-iodoanilin (722.8 mg, 
3.30 mmol, 1.0 eq) in AcOH (5 mL, 0.7 M) at 0 °C. The reaction mixture 
was allowed to warm up to room temperature overnight. After 14 h, the 
green color of the solution had vanished and a deeply purple solution had 
developed. An aqueous solution of NaHCO3 (saturated, ca. 50 mL) was 
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added dropwise, until no more gas developed. Then, the aqueous phase was carefully 
extracted with EtOAc (3 x 50 mL). After the combined organic layers had been washed 
with aqueous NaHCO3 (saturated, 30 mL), water (40 mL) and brine (20 mL), they were 
dried over Na2SO4 and the solvent was evaporated under reduced pressure. A deeply purple 
oil remained as crude product, which was purified by a short column chromatography (PE, 
the first fraction to elute is the title compound).  
Deeply purple, crystalline needles. Yield: 457.6 mg, 1.250 mmol, 38 %. 1H NMR 
(500 MHz, Chloroform-d) δ = 8.65 (s, 1H, benzoate-2-H), 8.18 (d, 3J = 7.2 Hz, 1H, 
benzoate-6-H), 8.16 (d, 3J = 7.2 Hz, 1H, benzoate-4-H), 8.05 (d, 3J = 7.9 Hz, 1H, N2Ph-6-
H), 7.66 (d, 3J = 8.2 Hz, 1H, N2Ph-3-H), 7.61 (d, 
3J = 7.9 Hz, 1H, benzoate-5-H), 7.44 (t, 
3J = 7.7 Hz, 1H, N2Ph-4-H), 7.20 (t, 
3J = 7.7 Hz, 1H, N2Ph-5-H), 3.98 (s, 3H, benzoate-1-
CO2CH3). 
13C NMR (126 MHz, Chloroform-d) δ = 166.6 (benzoate-1-CO2CH3), 152.4 
(N2Ph-C-1), 151.3 (benzoate-C-3), 140.1 (N2Ph-C-3), 132.8 (N2Ph-C-4), 132.4 (benzoate-
C-6), 129.5 (N2Ph-C-5), 129.1 (benzoate-C-5), 126.4 (benzoate-C-4), 126.1 (N2Ph-C-6), 
120.1 (benzoate-C-1), 117.5 (benzoate-C-2), 103.0 (N2Ph-C-2), 52.6 (benzoate-1-
CO2CH3). C14H11IN2O2 (366.16 g mol
-1). TLC: Rf (PE) = 0.50.  
 
Methyl (E)-3-((3-Iodophenyl)diazenyl)benzoate (99). A solution of the complete crude 
methyl 3-nitrosobenzoate in AcOH (7.5 mL, 0.5 M) was added dropwise in two portions 
over a period of 1 h to a stirred solution of 3-iodoanilin 
(0.40 mL, 728 mg, 3.33 mmol, 1.0 eq) in AcOH (5 mL, 0.7 M) 
at 0 °C. The reaction mixture was allowed to warm up to room 
temperature overnight. After 14 h, the green color of the solution had vanished and a deeply 
purple solution had developed. An aqueous solution of NaHCO3 (saturated, ca. 50 mL) was 
added dropwise, until no more gas developed. Then, the aqueous phase was carefully 
extracted with EtOAc (3 x 50 mL). After the combined organic layers had been washed 
with aqueous NaHCO3 (saturated, 30 mL), water (40 mL) and brine (20 mL), they were 
dried over Na2SO4 and the solvent was evaporated under reduced pressure. A deeply purple 
oil remained as crude product, which was purified by a short column chromatography (PE, 
the first fraction to elute is the title compound).  
Deeply purple, crystalline needles. Yield: 921.1 mg, 2.516 mmol, 76 %. 1H NMR 
(500 MHz, Chloroform-d) δ = 8.57 (s, 1H, benzoate-2-H), 8.28 (s, 1H, N2Ph-2-H), 8.18 (d, 
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3J = 7.8 Hz, 1H, benzoate-6-H), 8.11 (d, 3J = 8.0 Hz, 1H, benzoate-4-H), 7.95 (d, 3J = 
8.0 Hz, 1H, N2Ph-6-H), 7.83 (d, 
3J = 7.9 Hz, 1H, N2Ph-4-H), 7.61 (t, 
3J = 8.4 Hz, 1H, 
benzoate-5-H), 7.29 (t, 3J = 8.1 Hz, 1H, N2Ph-5-H), 3.98 (s, 3H, benzoate-1-CO2CH3). 
13C NMR (126 MHz, Chloroform-d) δ = 166.6 (benzoate-1-CO2CH3), 152.4 (N2Ph-C-1), 
140.1 (benzoate-C-3), 132.3 (N2Ph-C-4), 131.6 (N2Ph-C-2), 130.9 (benzoate-C-6), 130.9 
(N2Ph-C-5), 129.4 (benzoate-C-5), 127.3 (benzoate-C-2), 124.3 (benzoate-C-4), 123.9 
(N2Ph-C-6), 111.0 (benzoate-C-1), 94.7 (N2Ph-C-3), 52.6 (benzoate-1-CO2CH3). 
C14H11IN2O2 (366.16 g mol
-1). TLC: Rf (PE) = 0.52, Rf (PE/EtOAc, 2:1) = 0.74.  
 
Methyl (E)-2-((2-(3-((tert-Butoxycarbonyl)amino)prop-1-yn-1-
yl)phenyl)diazenyl)benzoate (100a). Under argon atmosphere, the solid catalysts 
PdCl2(PPh3)2 (2 mg, 3 mol, 2 mol%) and CuI (1 mg, 5 mol, 3 mol%) were added in one 
portion to a thoroughly degassed solution of glycine analogous propargylamide 1 (51 mg, 
329 mol, 1.8 eq) and iodo azobenzene 98a (65.4 mg, 179 μmol, 1.0 eq) in a mixture of 
THF/piperidine (5:2, 0.7 mL). The reaction mixture was stirred overnight at ambient 
temperature. After complete consumption of propargylamide 1 (checked by TLC), the 
mixture was diluted with aqueous NH4Cl (saturated, 10 mL), Et2O (20 mL) and aqueous 
KHSO4 (5 %, 10 mL). The phases were separated and the aqueous layers were extracted 
with Et2O (3 x 20 mL). The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and the solvent was evaporated under reduced pressure. The crude 
peptidomimetic 100a was purified by column chromatography (PE/EtOAc, 2:1).  
Purple oil. Yield: 30.0 mg, 73 mol, 41 %. 1H NMR (500 MHz, Chloroform-d) δ = 8.03 
(d, 3J = 7.9 Hz, 1H, benzoate-6-H), 7.86 (d, 3J = 7.4 Hz, 1H, benzoate-3-H), 7.72 (d, 3J = 
8.0 Hz, 1H, N2Ph-6-H), 7.64 (d, 
3J = 7.8 Hz, 1H, N2Ph-3-H), 
7.62 (t, 3J = 7.5 Hz, 1H, N2Ph-4-H), 7.52 (t, 
3J = 7.5 Hz, 1H, 
benzoate-4-H), 7.44 (t, 3J = 7.6 Hz, 1H, N2Ph-5-H), 7.19 (t, 
3J 
= 7.4 Hz, 1H, benzoate-5-H), 5.71 (s br., 1H, CH2NHBoc), 
3.95 (s, 3H, benzoate-1-CO2CH3), 3.87 (s br., 2H, 
CH2NHBoc), 1.26 (s, 9H, CH2NCO2C(CH3)3). 
13C NMR (126 MHz, Chloroform-d) δ = 
167.7 (benzoate-1-CO2CH3), 155.1 (CH2NHCO2C(CH3)3), 151.7 (benzoate-C-2), 151.5 
(N2Ph-C-1), 140.0 (benzoate-C-6), 132.7 (benzoate-C-5), 132.3 (N2Ph-C-3), 130.5 
(benzoate-C-4), 130.0 (benzoate-C-3), 129.2 (N2Ph-C-5), 120.1 (benzoate-C-1), 118.9 
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(N2Ph-C-6), 118.2 (N2Ph-C-4), 114.8 (N2Ph-C-2), 102.4 (CH2C≡Car), 92.2 
(CH2NHCO2C(CH3)3), 84.3 (CH2C≡Car), 52.7 (benzoate-1-CO2CH3), 32.1 
(CH2C≡Car), 29.9 (CH2NHCO2C(CH3)3). C22H23N3O4 (393.44 g mol-1). LCMS(ESI): tr 
= 9.9 min, m/z = 394.1757 (calcd. 394.17613 [M+H]+). TLC: Rf (PE/EtOAc, 1:1) = 0.22.  
 
Methyl 2-((E)-(2-((R)-3-(((R)-tert-Butylsulfinyl)amino)-3-cyclohexylprop-1-yne-1-
yl)phenyl)diazenyl)benzoate (100b). Under argon atmosphere, the solid catalysts 
PdCl2(PPh3)2 (2 mg) and CuI (1 mg) were added in one portion to a thoroughly degassed 
solution of D-cyclohexylglycine analogous propargylamide 6e (36.0 mg, 149 mol, 1.0 eq) 
and iodo azobenzene 98a (65.7 mg, 179 mol, 1.2 eq) in a mixture of THF/DIPAH (3:1, 
1.0 mL). The reaction mixture was stirred overnight at ambient temperature. After complete 
consumption of propargylamide 6e (checked by TLC), the mixture was diluted with 
aqueous NH4Cl (saturated, 10 mL), Et2O (20 mL) and sulfuric acid (0.5 M, ca. 10 mL until 
pH 2). The phases were separated and the aqueous layers were extracted with Et2O (3 x 
20 mL). The combined organic layers were washed with brine (10 mL) dried over Na2SO4, 
filtered and the solvent was evaporated under reduced pressure. The crude peptidomimetic 
100b was purified by column chromatography (PE/EtOAc, 2:1).  
Deeply purple oil. Yield: 5.46 mg, 11.3 mol, 8 %. 1H NMR (500 MHz, Chloroform-d) δ 
= 7.80 (d, 3J = 7.5 Hz, 1H, benzoate-6-H), 7.73 (d, 3J = 8.0 Hz, 
1H, benzoate-3-H), 7.69 (d, 3J = 8.0 Hz, 1H, N2Ph-6-H), 7.64 
(d, 3J = 7.4 Hz, 1H, N2Ph-3-H), 7.58 (t, 
3J = 7.6 Hz, 1H, 
benzoate-5-H), 7.49 (t, 3J = 7.6 Hz, 1H, benzoate-4-H), 7.430-
7.35 (m, 2H, N2Ph-4-H, N2Ph-5-H), 4.17 (dd br., 
3J = 6.2 Hz, 3J = 5.4 Hz, 1H, CαH), 3.89 
(s, 3H, CO2CH3), 3.80 (d br., 
3J = 6.6 Hz, 1H, CαNH), 1.92 (d br., 3J = 10.5 Hz, 1H, cy-1-
H), 1.87 (d br., 3J = 10.9 Hz, 1H, cy-2-H), 1.75-1.66 (m, 4H, cy-6-H2, cy-2-H), 1.63 (d br., 
2J = 13.5 Hz, 1H, cy-4-H), 1.25 (s, 9H, SC(CH3)3), 1.23-1.19 (m, 3H, cy-5-H2, cy-4-H), 
1.19-1.14 (m, 3H, cy-3-H2). 13C NMR (126 MHz, Chloroform-d) δ = 168.2 (CO2CH3), 
153.2 (N2Ph-C-1), 152.1 (benzoate-C-2), 133.9 (N2Ph-C-3), 131.9 (benzoate-C-5), 131.2 
(N2Ph-C-5), 130.1 (benzoate-C-4), 129.8 (benzoate-C-6), 129.0 (N2Ph-C-4), 128.9 
(benzoate-C-1), 124.2 (N2Ph-C-2), 119.9 (benzoate-C-3), 116.2 (N2Ph-C-6), 94.9 
(CαHC≡C-ar), 82.7 (CαHC≡C-ar), 56.5 (SC(CH3)3), 54.1 (CαH), 52.7 (benzoate-1-
CO2CH3), 43.7 (cy-C-1), 29.8 (cy-C-6), 28.4 (cy-C-2), 26.4 (cy-C-4), 26.1 (cy-C-5), 26.0 
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(cy-C-3), 22.9 (SOC(CH3)3). C27H33N3O3S (479.64 g mol
-1). MS(ESI): m/z = 480.2319 
(calcd. 480.2315 [M+H]+). TLC: Rf (PE/EtOAc, 2:1) = 0.21.  
 
Methyl 3-((E)-(3-((S)-3-(((S)-tert-Butylsulfinyl)amino)-5-methylhex-1-yn-1-
yl)phenyl)diazenyl)benzoate (101). Under argon atmosphere, the solid catalysts 
PdCl2(PPh3)2 (2 mg, 3 mol, 2 mol%) and CuI (1 mg, 5 mol, 3 mol%) were added in one 
portion to a thoroughly degassed solution of L-leucin analogous propargylamide 6c (40 mg, 
186 μmol, 1.0 eq) and iodo azobenzene 99 (101 mg, 276 μmol, 1.5 eq) in a mixture of 
THF/piperidine (3:1, 4.0 mL). The reaction mixture 
was stirred for 20 h at ambient temperature. After 
complete consumption of propargylamide 6c (checked 
by TLC), the mixture was diluted with aqueous NH4Cl 
(saturated, 20 mL), Et2O (20 mL) and aqueous KHSO4 (0.5 M, ca. 20 mL until pH 7). The 
phases were separated and the aqueous layers were extracted with Et2O (3 x 40 mL). The 
combined organic layers were washed with water (30 mL) and brine (10 mL), dried over 
Na2SO4, filtered and the solvent was evaporated under reduced pressure. The crude 
peptidomimetic 101 was purified by column chromatography (PE/EtOAc, 2:1).  
Deeply purple oil. Yield: 60.1 mg, 132 mol, 48 %. 1H NMR (500 MHz, Chloroform-d) δ 
= 8.54 (s, 1H, benzoate-2-H), 8.14 (d, 3J = 7.7 Hz, 1H, benzoate-6-H), 8.08 (d, 3J = 8.0 Hz, 
1H, benzoate-4-H), 7.99 (s, 1H, N2Ph-2-H), 7.87 (d, 
3J = 8.0 Hz, 1H, N2Ph-6-H), 7.59 (d, 
3J = 8.0 Hz, 1H, benzoate-5-H), 7.55 (d, 3J = 8.7 Hz, 1H, N2Ph-4-H), 7.44 (t, 
3J = 8.0 Hz, 
1H, N2Ph-5-H), 4.29 (ddd, 
3J = 7.5 Hz, 3J = 6.6 Hz, 3J = 5.4 Hz, 1H, CHCH2CH(CH3)2), 
3.95 (s, 3H, benzoate-1-CO2CH3), 3.44 (d br., 
3J = 6.6 Hz, 1H, NHCH), 1.94 (ddh, 3J = 
7.1 Hz, 3J = 7.5 Hz, 3J = 6.8 Hz, 1H, CHCH2CH(CH3)2), 1.70 (t, 
3J = 7.5 Hz, 1H, 
CHCH2CH(CH3)2), 1.27-1.19 (m, 9H, SC(CH3)3), 1.08 (d, 
3J = 6.7 Hz, 3H, 
CHCH2CH(CH3)2), 0.97 (d, 
3J = 6.6 Hz, 3H, CHCH2CH(CH3)2). 
13C NMR 
(126 MHz, Chloroform-d) δ = 166.6 (benzoate-1-CO2CH3), 152.5 (N2Ph-C-1), 152.2 
(benzoate-C-3), 134.5 (N2Ph-C-4), 132.0 (benzoate-C-1), 131.4 (benzoate-C-6), 129.3 
(benzoate-C-5), 129.2 (N2Ph-C-5), 127.1 (benzoate-C-4), 126.1 (N2Ph-C-2), 124.2 
(benzoate-C-2), 123.9 (N2Ph-C-3), 123.2 (N2Ph-C-4), 90.3 (CHC≡Car), 84.0 
(CHC≡Car), 56.3 (SC(CH3)3), 52.4 (benzoate-3-CO2CH3), 47.0 (CHCH2CH(CH3)2), 
46.3 (CHCH2CH(CH3)2), 25.1 (CHCH2CH(CH3)2), 22.7 (SC(CH3)3), 19.2 
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(CHCH2CH(CH3)2), 17.7 (CHCH2CH(CH3)2). C25H31N3O3S (453.60 g mol
-1). 
LCMS(ESI): tr = 11.0 min, m/z = 454.2088 (calcd. 454.2159 [M+H]+),  TLC: Rf 
(PE/EtOAc, 1:1) = 0.24, Rf (PE/EtOAc, 2:1) = 0.15. [𝛼]589
20  = +9.73 (c 3.86, CHCl3).  
 
IIX-4. e) Propargyl Hydrazides (102-106) 
Prop-2-yn-1-amine (102a) was purchased commercially from Fisher Scientific.  
(S)-But-3-yn-2-amine Hydrochloride (102b). Compound 102b has been synthesized 
following the instructions of Beierle et al., who also published a full characterization [244]. 
Hydrochloric acid (4 M, 1.2 mL, 4.7 mmol, 3 eq) was added dropwise to a solution of 
N-protected propargylamide 6a (273 mg, 1.58 mmol, 1.0 eq) in MeOH (5 mL) at 0 °C. The 
reaction mixture was allowed to warm up to rt and stirred for 5-6 h at ambient temperature. 
After complete consumption of propargylamide 6a (checked by TLC), the solvent was 
evaporated under reduced pressure. The crude material 102b was suspended in toluene and 
the solvent was removed under reduced pressure. This procedure was repeated, until color 
and odor of the material had vanished and the title compound was afforded in pure form. 
Yield: 167 mg, 1.58 mmol, quantitative.  
(S)-5-Methylhex-1-yn-3-amine Hydrochloride (102c). Compound 102c has been 
synthesized following the instructions of Chen et al., who also published a full 
characterization [245]. Hydrochloric acid (4 M, 170 L, 680 mol, 3 eq) was added 
dropwise to a solution of N-protected propargylamide 6c (49.2 mg, 229 mol, 1.0 eq) in 
MeOH (2 mL) at 0 °C. The reaction mixture was allowed to warm up to rt and stirred for 
5-6 h at ambient temperature. After complete consumption of propargylamide 6c (checked 
by TLC), the solvent was evaporated under reduced pressure. The crude material 102c was 
suspended in toluene and the solvent was removed under reduced pressure. This procedure 
was repeated, until color and odor of the material had vanished and the title compound was 
afforded in pure form. Yield: 33.9 mg, 229 mol, quantitative.  
 
2-(tert-Butyl) 3,3-Diethyl 1,2-Oxaziridine-2,3,3-tricarboxylate (103). The Boc-amine 
transfer reagent 103 was prepared following the instructions of Kang et al. [59].  
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tert-Butyl 2-(Prop-2-yn-1-yl)hydrazine-1-carboxylate (104a). The synthesis of 
hydrazides was performed in analogy to the reports of Kang et al. [59]. Compound 104a 
has been first characterized by Bonnet et al., who prepared it by conversion of 
propargylbromide with Boc protected hydrazine [246]. A solution of propargylamine 102a 
(0.3 mL, 0.34 g 6.2 mmol, 1.3 eq) in THF (0.3 mL) was added dropwise to a vigorously 
stirred solution of transfer reagent 103 (1.39 g, 4.80 mmol, 1.0 eq) in a mixture of 
THF/saturated aqueous NaHCO3 solution (1:1, 10 mL) at 0 °C. A pale yellow suspension 
formed which was stirred overnight at ambient temperature. After about 12 h, the solvents 
in the flask separated, forming a two-phase system of clear solutions. The phases were 
separated and the aqueous phase was extracted with Et2O (4 x 15 mL). The combined 
organic layers were washed with an aqueous KHSO4 solution (5 %, 20 mL), water (20 mL) 
and brine (10 mL). Afterwards, they were dried over Na2SO4, filtered and the solvent was 
evaporated under reduced pressure. The crude hydrazide 104a was purified by column 
chromatography (PE/EtOAc, 1:1).  
Pale yellow, crystalline solid. Yield: 413 mg, 2.43 mmol, 51 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 6.19 (s br., 1H, BocNHNHCH2C≡CH), 3.96 (s br., 1H, 
BocNHNHCH2C≡CH), 3.63 (d, 4J = 2.4 Hz, 2H, 
BocNHNHCH2C≡CH), 2.25 (t, 4J = 2.4 Hz, 1H, 
BocNHNHCH2C≡CH), 1.47 (s, 9H, NHCO2C(CH3)3). 13C NMR (126 MHz, 
Chloroform-d) δ = 156.4 (NHCO2C(CH3)3), 81.0 (BocNHNHCH2C≡CH), 80.0 
(NHCO2C(CH3)3), 72.5 (BocNHNHCH2C≡CH), 41.4 (BocNHNHCH2C≡CH), 28.5 
(NHCO2C(CH3)3). C8H14N2O2 (170.21 g mol
-1).  
 
tert-Butyl (S)-2-(But-3-yn-2-yl)hydrazine-1-carboxylate (104b). The synthesis of 
hydrazides was performed in analogy to the reports of Kang et al. [59]. Compound 104b 
has been first characterized by Bare et al., who prepared it by Mitsunobu reaction of but-3-
yn-2-ol with Boc protected hydrazine [247]. A solution of propargylamine 102b (167 mg, 
1.58 mmol, 1.0 eq) in THF (0.2 mL) was added dropwise to a vigorously stirred solution 
of transfer reagent 103 (684 mg, 2.40 mmol, 1.5 eq) in a mixture of THF/saturated aqueous 
NaHCO3 solution (1:1, 5 mL) at 0 °C. A pale yellow suspension formed which was stirred 
overnight at ambient temperature. After about 12 h, the solvents in the flask separated, 
forming a two-phase system of clear solutions. The phases were separated and the aqueous 
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phase was extracted with Et2O (4 x 15 mL). The combined organic layers were washed 
with an aqueous KHSO4 solution (5 %, 20 mL), water (20 mL) and brine (10 mL). 
Afterwards, they were dried over Na2SO4, filtered and the solvent was evaporated under 
reduced pressure. The crude hydrazide 104b was purified by column chromatography 
(PE/EtOAc, 1:1). 
Colorless, crystalline needles. Yield: 339 mg, 1.84 mmol, 86 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 6.72 (s br., 1H, CHNHNHBoc), 4.15 (m, 1H, CHNHNHBoc), 3.67 
(dq, 4J = 2.0 Hz, 3J = 7.0 Hz, 1H, CHCH3), 2.13 (d, 
4J = 2.0 Hz, 1H, 
CHC≡CH), 1.26 (s, 9H, CO2C(CH3)3), 1.11 (d, 3J = 6.6 Hz, 3H, 
CHCH3). 13C NMR (126 MHz, Chloroform-d) δ = 156.3 (NHCO2C(CH3)3), 84.1 
(CHC≡CH), 80.0 (CO2C(CH3)3), 71.2 (CHC≡CH), 47.1 (CHCH3), 27.9 (CO2C(CH3)3), 
18.9 (CHCH3). C9H16N2O2 (184.24 g mol
-1). TLC: Rf (PE/EtOAc, 1:1) = 0.62. X-ray 
crystal structure in Chapter IIX-4. i. 
 
tert-Butyl (S)-2-(5-Methylhex-1-yn-3-yl)hydrazine-1-carboxylate (104c). The synthesis 
of hydrazides was performed in analogy to the reports of Kang et al. [59]. A solution of 
propargylamine 102c (33.9 mg, 229 mol, 1.0 eq) in THF (0.2 mL) was added dropwise to 
a vigorously stirred solution of transfer reagent 103 (197 mg, 680 mol, 3.0 eq) in a 
mixture of THF/saturated aqueous NaHCO3 solution (1:1, 5 mL) at 0 °C. A pale yellow 
suspension formed which was stirred overnight at ambient temperature. After about 12 h, 
the solvents in the flask separated, forming a two-phase system of clear solutions. The 
phases were separated and the aqueous phase was extracted with Et2O (4 x 15 mL). The 
combined organic layers were washed with an aqueous KHSO4 solution (5 %, 20 mL), 
water (20 mL) and brine (10 mL). Afterwards, they were dried over Na2SO4, filtered and 
the solvent was evaporated under reduced pressure. The crude hydrazide 104c was purified 
by column chromatography (PE/EtOAc, 1:1).  
Colorless, crystalline, superfine needles. Yield: 83.9 mg, 371 mol, 
62 %. 1H NMR (500 MHz, Chloroform-d) δ = 6.28 (s br., 1H, 
CHNHNHCO2C(CH3)3), 3.92 (s br., 1H, CHNHNHCO2C(CH3)3), 
3.73 (dd, 3J = 6.2 Hz, 3J = 5.6 Hz, 1H, CHNHNHCO2C(CH3)3), 2.25 (d, 
4J = 1.9 Hz, 1H, 
CHC≡CH), 1.82 (m, 1H, CHCH2CH(CH3)2), 1.42 (s, 9H, CHNHNHCO2C(CH3)3), 
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1.28-1.21 (m, 1H, CHCH2CH(CH3)2), 1.22-1.18 (m, 1H, CHCH2CH(CH3)2), 0.92 (d, 
3J = 6.7 Hz, 3H, CHCH2CH(CH3)2), 0.87 (d, 
3J = 6.7 Hz, 3H, CHCH2CH(CH3)2). 
C12H22N2O2 (226.32 g mol
-1). MS(ESI): m/z = 227.1186 (calcd. 227.1754 [M+H]+). TLC: 
Rf (PE/EtOAc, 1:1) = 0.71.  
 
tert-Butyl 2-(3-(2-(Methoxycarbonyl)phenyl)prop-2-yne-1-yl)hydrazine-1-
carboxylate (106a). Under argon atmosphere, the solid catalysts PdCl2(PPh3)2 (2 mg, 
3 mol, 0.3 mol%) and CuI (1 mg, 5 mol, 0.4 mol%) were added in one portion to a 
thoroughly degassed solution of glycine analogous propargylhydrazide 104a (220 mg, 
1.18 mmol, 1.0 eq, containing 44 % hydrazone 105a) and iodo benzoate 26a (200 L, 
356 mg, 1.36 mmol, 1.2 eq) in a mixture of THF/piperidine (3:1, 3.2 mL). The reaction 
mixture was stirred for 18 h at ambient temperature. After complete consumption of 
propargylhydrazide 104a (checked by TLC), the mixture was diluted with aqueous NH4Cl 
(saturated, 20 mL), Et2O (20 mL) and aqueous KHSO4 (0.5 M, ca. 20 mL until pH 7). The 
phases were separated and the aqueous layers were extracted with Et2O (3 x 40 mL). The 
combined organic layers were washed with water (30 mL) and brine (10 mL), dried over 
Na2SO4, filtered and the solvent was evaporated under reduced pressure. 
Propargylhydrazide 106a and hydrazone 107a were separated by column chromatography 
(PE/EtOAc, 2:1).  
Pale yellow, highly viscous oil. Yield: 173.0 mg, 568.4 mol, 48 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.91 (d, 3J = 7.9 Hz, 1H, ar-2-H), 7.49 (d, 3J 
= 8.0 Hz, 1H, ar-5-H), 7.42 (t, 3J = 7.9 Hz, 1H, ar-3-H), 7.32 (t, 
3J = 7.7 Hz, 1H, ar-4-H), 7.00 (s br., 1H, CH2NH-NHBoc), 3.89 
(s, 3H, CO2CH3), 3.83 (s, 2H, CH2NH-NHBoc), 3.67 (s br., 1H, CH2NH-NHBoc), 1.44 
(s, 9H, NHCO2C(CH3)3). 
13C NMR (126 MHz, Chloroform-d) δ = 166.5 (CO2CH3), 156.4 
(NHCO2C(CH3)3), 133.8 (ar-C-5), 131.9 (ar-C-4), 131.7 (ar-C-6), 130.4 (ar-C-2), 127.9 
(ar-C-3), 123.6 (ar-C-1), 91.4 (CH2C≡C-ar), 83.5 (CH2C≡C-ar), 80.3 (NHCO2C(CH3)3), 
52.3 (CO2CH3), 42.3 (CH2NH), 28.4 (NHCO2C(CH3)3). C16H20N2O4 (304.35 g mol
-1). 
LCMS(ESI): tr = 8.98 min, m/z = 305.1489 (calcd. 305.14958 [M+H]+), 327.1313 (calcd. 
327.1315 [M+Na]+). IR(ATR): ῦ [cm-1] = . TLC: Rf (PE/EtOAc, 2:1) = 0.31.  
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tert-Butyl (E)-2-(3-(2-(Methoxycarbonyl)phenyl)prop-2-yne-1-ylidene)hydrazine-1-
carboxylate (107a). Colorless crystals. Yield: 144.0 mg, 476.3 mmol, 40 %. 1H NMR 
(500 MHz, Chloroform-d) δ = 10.20 (s, 1H, CHN), 8.11 (d, 3J = 7.9 Hz, 1H, ar-2-H), 7.61 
(d, 3J = 7.7 Hz, 1H, ar-5-H), 7.56 (t, 3J = 7.5 Hz, 1H, ar-3-H), 7.48 (t, 3J = 7.6 Hz, 1H, ar-
4-H), 6.76 (s br., 1H, C=N-NHBoc), 3.98 (s, 3H, CO2CH3), 1.58 
(s, 9H, NHCO2C(CH3)3). 
13C NMR (126 MHz, Chloroform-d) δ 
= 165.8 (CO2CH3), 152.7 (NHCO2C(CH3)3), 134.2 (ar-C-5), 
132.6 (ar-C-4), 131.3 (ar-C-6), 131.0 (ar-C-2), 129.6 (ar-C-3), 122.4 (C=NNHNoc), 121.0 
(ar-C-1), 100.4 (CNC≡C-ar), 84.7 (CNC≡C-ar), 52.7 (ar-1-CO2CH3), 28.5 
(NHCO2C(CH3)3). C16H18N2O4 (302.33 g mol
-1). LCMS(ESI): tr = 9.19 min, m/z = 
303.1336 (calcd. 303.13393 [M+H]+), 325.1182 (calcd. 325.1159 [M+Na]+). TLC: Rf 
(PE/EtOAc, 2:1) = 0.48. X-ray crystal structure in Chapter IIX-4. i.  
 
tert-Butyl (S)-2-(4-(2-(Methoxycarbonyl)phenyl)but-3-yne-2-yl)hydrazine-1-
carboxylate (106b). Under argon atmosphere, the solid catalysts PdCl2(PPh3)2 (2 mg, 
3 mol, 0.2 mol%) and CuI (1 mg, 5 mol, 0.4 mol%) were added in one portion to a 
thoroughly degassed solution of glycine analogous propargylhydrazide 104b (380 mg, 
1.26 mmol, 1.0 eq, containing 44 % hydrazone 105b) and iodo benzoate 26a (400 L, 
702 mg, 2.6 mmol, 2.1 eq) in a mixture of THF/piperidine (3:1, 6.0 mL). The reaction 
mixture was stirred for 18 h at ambient temperature. After complete consumption of 
propargylhydrazide 104b (checked by TLC), the mixture was diluted with aqueous NH4Cl 
(saturated, 20 mL), Et2O (20 mL) and aqueous KHSO4 (0.5 M, ca. 20 mL until pH 7). The 
phases were separated and the aqueous layers were extracted with Et2O (3 x 40 mL). The 
combined organic layers were washed with water (30 mL) and brine (10 mL), dried over 
Na2SO4, filtered and the solvent was evaporated under reduced pressure. 
Propargylhydrazide 106b and hydrazone 107b were separated by column chromatography 
(PE/EtOAc, 2:1).  
Pale yellow oil. Yield: 123 mg, 386 mol, 31 %. 1H NMR (500 MHz, Chloroform-d) δ = 
7.93 (d, 3J = 7.9 Hz, 1H, ar-2-H), 7.50 (d, 3J = 7.8 Hz, 1H, ar-5-H), 7.44 (t, 3J = 7.7 Hz, 
1H, ar-3-H), 7.33 (t, 3J = 7.7 Hz, 1H, ar-4-H), 7.10 (m, 1H, 
CHNHNHBoc), 4.29 (m, 1H, CHNHNHBoc), 4.05 (dq, 3J = 
5.4 Hz, 3J = 6.6 Hz, 1H, CH), 3.91 (s, 3H, CO2CH3), 1.45 (s, 
IIX-4. e) Propargyl Hydrazides (102-106) 
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9H, NHCO2C(CH3)3), 1.40 (d, 
3J = 6.8 Hz, 3H, CHCH3). 13C NMR (126 MHz, 
Chloroform-d) δ = 166.6 (ar-CO2CH3), 156.5 (NHCO2C(CH3)3), 133.9 (ar-C-5), 131.9 (ar-
C-4), 131.8 (ar-C-6), 130.5 (ar-C-2), 127.9 (ar-C-3), 123.7 (ar-C-1), 95.6 (CHC≡C-ar), 
82.5 (CHC≡C-ar), 80.2 (NHCO2C(CH3)3), 52.3 (ar-CO2CH3), 48.9 (C), 28.5 
(NHCO2C(CH3)3), 19.1 (CHCH3). C17H22N2O4 (318.37 g mol-1). MS(ESI): m/z = 
319.1887 (calcd. 319.1652 [M+H]+). IR(ATR): ῦ [cm-1] = 3316, 3060, 2974, 2933, 2867, 
2357, 2341, 1714, 1366, 1274, 1242, 1141, 1078, 752. TLC: Rf (PE/EtOAc, 2:1) = 0.45. 
[𝛼]589
20  = -56.56 (c 3.45, MeOH).  
tert-Butyl (E)-2-(4-(2-(Methoxycarbonyl)phenyl)but-3-yne-2-ylidene)hydrazine-1-
carboxylate (107b). Pale yellow oil. Yield: 96.6 mg, 305 mol, 24 %. 1H NMR 
(500 MHz, Chloroform-d) δ = 9.89 (s br., 1H, C=NNHBoc), 
8.08 (d, 3J = 7.9 Hz, 1H, ar-2-H), 7.61 (d, 3J = 7.7 Hz, 1H, ar-5-
H), 7.54 (t, 3J = 7.6 Hz, 1H, ar-3-H), 7.46 (t, 3J = 7.8 Hz, 1H, 
ar-4-H), 3.95 (s, 3H, ar-CO2CH3), 2.22 (s, 3H, CNCH3), 1.54 (s, 
9H, NHCO2C(CH3)3). 
13C NMR (126 MHz, Chloroform-d) δ = 165.7 (ar-CO2CH3), 152.9 
(NHCO2C(CH3)3), 134.4 (ar-C-5), 132.5 (ar-C-4), 131.2 (ar-C-6), 130.9 (ar-C-2), 130.2 
(CH3C=N), 129.5 (ar-C-3), 122.3 (ar-C-1), 99.3 (CHC≡C-ar), 85.8 (CHC≡C-ar), 80.8 
(NHCO2C(CH3)3), 52.6 (CO2CH3), 28.4 (NHCO2C(CH3)3), 22.3 (CH3C=N). C17H20N2O4 
(316.36 g mol-1). MS(ESI): m/z = (calcd. 317.1496 [M+H]+). IR(ATR): ῦ [cm-1] = 3259, 
2977, 2924, 2867, 2360, 2338, 1793, 1736, 1711, 1565, 1502, 1432, 1258, 1141, 1081, 755. 
TLC: Rf (PE/EtOAc, 2:1) = 0.55. [𝛼]589
20  = -13.0 (c 2.17, MeOH).  
 
tert-Butyl (S)-2-(1-(2-(Methoxycarbonyl)phenyl)-5-methylhex-1-yn-3-yl)hydrazine-1-
carboxylate (106c). Under argon atmosphere, the solid catalysts PdCl2(PPh3)2 (2 mg, 
3 mol, 0.4 mol%) and CuI (1 mg, 5 mol, 0.7 mol%) were added in one portion to a 
thoroughly degassed solution of glycine analogous propargylhydrazide 104c (197 mg, 
680 mol, 1.0 eq, containing 44 % hydrazone 105c) and iodo benzoate 26a (150 L, 
260 mg, 980 mol, 2.1 eq) in a mixture of THF/piperidine (3:1, 2.5 mL). The reaction 
mixture was stirred for 18 h at ambient temperature. After complete consumption of 
propargylhydrazide 104c (checked by TLC), the mixture was diluted with aqueous NH4Cl 
(saturated, 20 mL), Et2O (20 mL) and aqueous KHSO4 (0.5 M, ca. 20 mL until pH 7). The 
phases were separated and the aqueous layers were extracted with Et2O (3 x 40 mL). The 
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combined organic layers were washed with water (30 mL) and brine (10 mL), dried over 
Na2SO4, filtered and the solvent was evaporated under reduced pressure. 
Propargylhydrazide 106c was purified by column chromatography (PE/EtOAc, 4:1). 
Hydrazone 107c could be observed by LCMS, but not be isolated due to its low amount.  
Pale yellow, viscous oil. Yield: 31.8 mg, 88.2 mol, 13 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 7.94 (d, 3J = 7.9 Hz, 1H, ar-6-H), 7.51 (d, 3J = 7.8 Hz, 1H, ar-3-H), 7.45 
(t, 3J = 7.5 Hz, 1H, ar-4-H), 7.35 (t, 3J = 7.7 Hz, 1H, ar-5-H), 7.14 (s br., 1H, C-NH-
NHBoc), 3.97 (ddd, 3J = 7.0 Hz, 3J = 5.7 Hz, 3J = 3.6 Hz, 1H, 
CHCH2CH(CH3)2), 3.92 (s, 3H, CO2CH3), 1.97 (m, 1H, 
CHCH2CH(CH3)2), 1.80 (s br., 1H, CHNH-NHBoc), 1.58 
(m, 2H, CHCH2CH(CH3)2), 1.47 (s, 9H, CO2C(CH3)3), 
0.99 (d, 3J = 6.7 Hz, 3H, CHCH2CH(CH3)2), 0.95 (d, 
3J = 6.7 Hz, 3H, 
CHCH2CH(CH3)2). 
13C NMR (126 MHz, Chloroform-d) δ = 166.7 (ar-CO2CH3), 156.5 
(NHCO2
tBu), 134.0 (ar-C-2), 132.0 (ar-C-4), 131.8 (ar-C-3), 130.5 (ar-C-6), 127.9 (ar-C-
5), 123.9 (ar-C-1), 95.2 (CHC≡C-ar), 83.4 (CHC≡C-ar), 80.1 (CO2C(CH3)3), 52.6 
(CO2CH3), 52.4 (CHCH2CH(CH3)2), 41.9 (CHCH2CH(CH3)2), 28.4 (CO2C(CH3)3), 
25.3 (CHCH2CH(CH3)2), 23.0 (CHCH2CH(CH3)2), 22.3 (CHCH2CH(CH3)2). 
C20H28N2O4 (360.45 g mol
-1). MS(ESI): m/z = 361.2123 (calcd. 361.2122 [M+H]+). TLC: 
Rf (PE/EtOAc, 2:1) = 0.53. IR(ATR): 𝜈[cm-1] = 3322 (br, NH), 2952 (s, CH), 2936 (s, CH), 
2867 (s, CH), 2360 (s, C≡C), 2338 (s, C≡C), 1726 (s, CO), 1720 (s, CO), 1432(s, arH), 
1367 (s, arH), 1293 (s, arH), 1255 (s, arH), 1157 (s, arH), 1081 (s, arH), 764 (CC).  
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Diagram EP15. Comparison of the 1H NMR shifts of propargylamides 6  to turn mimetics 94  
in chloroform-d .  From top to bottom: 94c,  6p,  94b ,  6e,  94a ,  6c.  Magenta: CH, multipletts 
A, D. Blue: Methyl ester protons, singlet B. Red: Amide protons, doublets C, E.  
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Diagram EP16. Visualization of temperature coefficients of turn mimetic 94  incorporated in 
a short peptide giving hairpin mimetic 97 . Temperature coefficient s were derived from the 
gradient of 1H NMR shifts in dependence of the temperature.  
 
 
Diagram EP17. 1H NMR spectroscopic observation of the photoisomerization  of compound 
101  in chloroform-d . The aromatic region (9.0 -7.0 ppm, left side), as well as the a mide 
region (4.5-3.5 ppm, right side) of the same sample is shown in dependence of irradiation a) 
Aromatic region of the 1H NMR spectra just after the isolation. Compound 101  was kept in 
the dark until the measurement was performed. b)  5  min irradiation at 420 nm. c) Irradiated 
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sample kept in the dark for relaxation for 2  h. d) Irradiated sample kept in the dark for 
relaxation for three weeks.  
 
 
 
Diagram EP18. 1H NMR spectroscopic observation of the amide shift of glycine analogous 
derivatives to deduce intramolecular H -bonds. Singletts A are assigned to the protons 
flagged in the chemical structures on the right. Top, hydrazine 104a ,  (NH)=6.17 ppm. 
Middle, peptidomimetic 106a ,  (NH)=7.00 ppm. Bottom, hydrazone 107a ,  
(NH)=10.20 ppm.  
 
 
Diagram EP19. 1H NMR spectroscopic observation of the amide shift of alanine analogous 
derivatives to deduce intramolecular H -bonds. Singletts A are assigned to the protons 
flagged in the chemical structures on the right.  Top, hydrazine 104b,  (NH)=6.70 ppm. 
Middle, peptidomimetic 106b,  (NH)=7.09 ppm. Bottom, hydrazone 107b,  (NH)=9.89 ppm.  
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Diagram EP20. 1H NMR spectroscopic observation of the amide shift of leucine analogous 
derivatives to deduce intramolecular H-bonds. Singletts A are assigned to the protons 
flagged in the chemical structures on the right. Top, hydrazine 104c,  (NH)=6.29 ppm. 
Bottom, peptidomimetic 106c,  (NH)=7.34 ppm.  
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Diagram EP21. UV/Vis spectroscopic observation of the photoisomerization of 98b  (in 
CH3CN, c = 160 nM, d = 1 cm). Black curve: Pure sample in relaxed state,   = 
10375000 cm-1 M -1  (ma x = 296 nm). Green curve: Same sample after 45  min irradiation at 
360 nm,   = 9687500 cm - 1  M - 1 (max  = 296 nm). Red curve: Same sample after 10  min 
irradiation at 300 nm and 200 W,   = 3875000 cm-1 M -1 (max = 274 nm). Violet curve: Same 
sample after 20 min irradiation at 254 nm,   = 8562500 cm- 1 M - 1 (max = 296 nm). Blue 
curve: Same sample after 30  min irradiation at 254 nm,   = 9675000 cm - 1 M - 1 (ma x = 
296 nm).  
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Diagram EP22. UV/Vis spectroscopic observation of the photoisomeriz ation of 100b  (in 
CH3CN, c=300 nM, d=1 cm). Black curve: Pure sample in relaxed state,   = 
7033333 cm-1  M - 1 (max  = 311 nm). Green curve: Same sample after 20  min irradiation at 
360 nm,   = 6888889 cm - 1 M - 1 (max  = 309 nm). Red curve: Same sample after 10  min 
irradiation at 300 nm and 200 W,   = 4833333 cm- 1 M -1 (max = 314 nm). Blue curve: Same 
sample after 10 min irradiation at 360 nm,   = 6666666 cm- 1 M - 1 (ma x = 314 nm). Violet 
curve: Same sample after 40  min irradiation at 254 nm,   = 7230000 cm - 1 M - 1 (ma x = 
311 nm).  
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Diagram EP23. UV/Vis spectroscopic observation of the photoisomerization of 101  (in 
CH3CN, c = 500 nM, d = 1 cm). Blue curve: Pure sample in relaxed state,   = 
520000 cm- 1 M - 1 (max = 437 nm). Red curve: Same sample after 10  min irradiation at 
420 nm,   = 90200 cm -1 M -1 (max = 434 nm). Green curve: Irradiated sample after 3.5  h in 
the dark at rt,   = 90200 cm -1 M -1 (max = 434 nm).  
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Diagram EP24. Investigation of naphthoate -based turn mimetics via CD spectroscopy. Left 
side: CD spectra of turn mimetic 92  (c=120 M in TFE). Right side: Temperature -resolved 
CD spectra of turn motif mimetic 92  incorporated in a peptide giving H -Pro-Tyr-Thr-92-
Leu-Thr-Val-OH (c=71 M in TFE). Peptide strands connected by Sonogashira  cross 
coupling: iodo naphthoate (20  mg, 26 mol),  propargylamide (23.8  mg, 30 mol), 1,4-
dioxane/DIPAH (10:1), CuI/  PdCl2(PPh3)2, 60 °C, microwave, 2 h. H-Pro-Tyr-Thr-92-Leu-
Thr-Val-OH 7.81 mg, 7.07 mol, 27 %. MS(ESI): m/z  = 1105.541 [M+H]+,  1127.609 
[M+Na]+.   
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Diagram EP25. Comparison of CD spectra of turn mimetic 94b  (c=130 M) to hairpin 
mimetic 97  (c=67 M) in CH3CN.  
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Diagram EP26. Temperature-dependent development of the CD-effect to determine the 
stability of  -strand alignment in hairpin mimetic 97 . a) CD-Spectra of hairpin mimetic 97  
(c = 67 M in CH3CN) at temperatures of 20-80 °C. Every 2 K one spectra was measured 
with only 2 accumulations. b) CD(T) at relative maxima/minima of Diagram EP26a to 
visualize the development.  
 
IIX-4. i) X-ray Structure Analysis 
Table EP30. Crystal data and structure refinement for  hydrazides 104b and hydrazone 107a .    
compound 104b 107a 
Identification code wuensch24 wuensch23 
Empirical formula C9H16N2O2 C16H18N2O4 
Formula weight 184.24 302.32 
Temperature/K 100.0(1) 100.00(10) 
Crystal system orthorhombic monoclinic 
Space group P212121 P21/c 
a/Å 5.15904(6) 8.27678(19) 
b/Å 10.30935(12) 9.6836(2) 
c/Å 19.4194(3) 19.5096(4) 
α/° 90 90 
β/° 90 91.720(2) 
γ/° 90 90 
Volume/Å3 1032.85(2) 1562.97(6) 
Z 4 4 
ρcalcg/cm3 1.185 1.285 
μ/mm-1 0.687 0.093 
F(000) 400.0 640.0 
Crystal size/mm3 0.303 × 0.108 × 0.038 0.465 × 0.247 × 0.157 
Radiation/Å CuKα (λ = 1.54184) MoKα (λ = 0.71073) 
2Θ range for data collection/° 9.108 to 151.966 5.93 to 60.16 
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Index ranges -6 ≤ h ≤ 6, -12 ≤ k ≤ 12, -24 ≤ 
l ≤ 23 
-11 ≤ h ≤ 11, -13 ≤ k ≤ 13, -
27 ≤ l ≤ 27 
Reflections collected 15511 43744 
Independent reflections 2155 [Rint = 0.0160, Rsigma = 
0.0075] 
4582 [Rint = 0.0218, Rsigma = 
0.0097] 
Data/restraints/parameters 2155/0/183 4582/0/271 
Goodness-of-fit on F2 1.041 1.099 
Final R indexes [ I > 2σ(I) ] R1 = 0.0203, wR2 = 0.0509 R1 = 0.0351, wR2 = 0.0971 
Final R indexes [all data] R1 = 0.0203, wR2 = 0.0509 R1 = 0.0369, wR2 = 0.0983 
Largest diff. peak/hole / e Å-3 0.15/-0.12 0.39/-0.24 
Flack parameter 0.03(2)   
 
tert-Butyl (S)-2-(But-3-yn-2-yl)hydrazine-1-carboxylate (104b). 
Single crystals of hydrazine 104b were achieved by evaporation of the solvent of a 
concentrated CHCl3 solution at ambient temperature. Single crystals were collected and put 
in a concentrated solution of 104b at -20 °C to increase their size.  
 
Table EP31. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103) for hydrazide 104b.  Ueq is defined as 1/3 of of the trace of the 
orthogonalised UIJ tensor.  
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Atom x y z U(eq) 
O1 2702.4(16) 6923.0(8) 6278.1(4) 19.51(19) 
O2 5680.4(14) 7141.1(9) 7143.5(4) 18.9(2) 
N1 6747.1(19) 6659.4(9) 5358.4(5) 15.7(2) 
N2 7031.5(19) 6838.4(10) 6076.1(5) 17.0(2) 
C1 9910(3) 3655.3(12) 5348.7(7) 24.1(3) 
C2 8202(2) 4422.7(11) 5295.2(6) 18.9(2) 
C3 5984(2) 5306.7(11) 5198.9(6) 16.4(2) 
C4 5024(3) 5251.8(12) 4457.1(6) 23.0(3) 
C5 4928(2) 6960.9(10) 6487.0(5) 14.9(2) 
C6 3724(2) 7306.2(12) 7693.3(6) 18.6(2) 
C7 2059(3) 6099.2(12) 7751.9(7) 23.8(3) 
C8 2110(3) 8517.9(12) 7567.6(7) 22.8(3) 
C9 5392(3) 7476.0(19) 8331.1(7) 34.1(4) 
 
 
tert-Butyl (E)-2-(3-(2-(Methoxycarbonyl)phenyl)prop-2-yne-1-ylidene)hydrazine-1-
carboxylate (107a). 
Single crystals of hydrazone 107a were achieved by evaporation of the solvent of a 
concentrated EtOAc solution at ambient temperature. Similar crystals were achieved from 
other organic solvents like Et2O, CH2Cl2, chloroform, MeOH and EtOH. 
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Table EP32. Fractional Atomic Coordinates (×10 4)  and Equivalent Isotropic Displacement 
Parameters (Å2×103)  for hydrazone 107a . Ueq  is defined as 1/3 of of the trace of the 
orthogonalised U I J tensor.   
Atom x y z U(eq) 
O1 6305.7(8) 6348.8(7) 7783.4(3) 17.01(13) 
O2 7420.6(8) 5711.7(7) 8821.4(3) 18.61(14) 
O3 7885.6(9) 5999.8(7) 6293.5(3) 21.37(14) 
O4 7141.7(10) 6658.2(8) 5228.2(4) 26.43(17) 
N1 8603.5(9) 5235.5(8) 7797.3(4) 14.73(14) 
N2 9807.2(9) 4472.2(8) 8103.3(4) 15.85(14) 
C1 4827(1) 6952.2(9) 8061.5(4) 16.70(16) 
C2 3847.6(13) 7278.6(11) 7409.6(5) 25.3(2) 
C3 5258.6(13) 8254.3(10) 8460.0(5) 23.52(19) 
C4 3938.1(12) 5900.4(11) 8490.2(6) 23.78(19) 
C5 7427.8(10) 5771.5(8) 8203.2(4) 14.10(15) 
C6 10640.2(11) 3720.0(9) 7693.7(4) 17.45(17) 
C7 10295.8(10) 3628.1(9) 6974.4(4) 17.12(16) 
C8 9755.5(10) 3620.2(9) 6394.4(4) 16.70(16) 
C9 9138(1) 3434.1(9) 5706.8(4) 15.84(16) 
C10 9507.8(12) 2185.2(10) 5382.1(5) 20.89(18) 
C11 8934.5(13) 1915.0(11) 4720.7(5) 24.6(2) 
C12 8004.2(14) 2896.2(11) 4371.6(5) 26.6(2) 
C13 7632.7(13) 4139(1) 4683.5(5) 22.76(19) 
IIX-4. j) References (237-247) 
305 
C14 8181(1) 4422.3(9) 5354.2(4) 16.22(16) 
C15 7742.8(11) 5751.2(9) 5685.8(4) 17.15(16) 
C16 6707.6(17) 7994.0(11) 5499.4(6) 31.3(2) 
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IIX-5. Peptidomimetics as HDAC Inhibitors 
The syntheses of all compounds associated with Chapter V are published in 
ChemMedChem “SAR of Propargylamine-Based HDAC Inhibitors” [2] and are attached to 
the Appendix.  
IIX-6. Peptidomimetics as RGD-Mimetics 
IIX-6. a) Synthesis of Aromatic Halides (120-124) 
Dimethyl 5-Iodoisophthalate (120). The Sandmeyer reactions were performed in analogy 
to the work of Aiken, Gabbutt, Heron, Instone, Horton and Hursthouse [221]. Compound 
120 has been first described by Sundberg and Heintzelman, who prepared it in a different 
way [248]. Dimethyl 5-aminoisophthalate (1.02 g, 4.88 mmol, 1 eq) was dissolved in 
aqueous hydrochloric acid (6 M, 5 mL, 1 mL/mmol) and the solution was cooled to -40 °C. 
An aqueous solution of NaNO2 (408 mg, 5.91 mmol, 1.2 eq in 2.2 mL H2O) was added 
dropwise under vigorous stirring. The solution was warmed to rt and solid KI (1.62 g, 
9.76 mmol, 2 eq) and I2 (122 mg, 480 mol, 0.1 eq) was added in one portion, which lead 
to the precipitation of a black solid. Heating to 60 °C for 1 h completed the reaction 
(checked by TLC). The reaction mixture was diluted with a KHSO4 solution (5 %, 10 mL) 
and extracted with CH2Cl2 (3 x 30 mL). The combined organic layers were dried over 
Na2SO4 and the solvent was evaporated under reduced pressure. The crude product of 
halogenated isophthalate 120 was filtered through a pad of silica gel with a mixture of 
EtOAc/PE (1:10).  
Slightly yellow, crystalline solid. Yield: 767 mg, 2.39 mmol, 49 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 8.63 (t, 4J = 1.5 Hz, 1H, ar-2-H), 8.54 (d, 4J = 1.5 Hz, 
2H, ar-4-H, ar-6-H), 3.95 (s, 6H, ar-1-CO2CH3, ar-3-CO2CH3). 
13C NMR 
(126 MHz, Chloroform-d) δ = 165.0 (ar-1-CO2CH3, ar-3-CO2CH3), 142.6 
(ar-C-4, ar-C-6), 132.3 (ar-C-3, ar-C-1), 130.0 (ar-C-2), 93.6 (ar-C-5), 52.8 (ar-1-CO2CH3, 
ar-3-CO2CH3). C10H9IO4 (320.08 g mol
-1). MS(ESI): m/z = 320.908 (calcd. 320.9618 
[M+H]+). TLC: Rf (EtOAc/PE, 1:10) = 0.2.  
When the addition of NaNO2 was attempted with insufficient cooling, hydroxylation was 
observed as side reaction, giving dimethyl 5-hydroxyisophthalate in a yield of 30 %. X-ray 
crystal structure in Chapter IIX-6. i.  
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N,O-Dimethyl 2-Iodoterephthalamate (121). Under argon atmosphere, a solution of 1-
methyl 2-iodo terephthalat (38a, 694 mg, 2.27 mmol, 1.0 eq) in dry 
THF (10 mL) was cooled to -30 °C. IBCF (0.3 mL, 2.31 mmol, 1.0 eq) 
and NMM (0.15 mL, 1.36 mmol, 0.6 eq) was simultaneously added 
dropwise. The formation of a thin, colorless precipitate was observed. After 30 min, 
methylamine (0.75 mL, 16.7 mmol, 7.3 eq) was slowly added and the reaction mixture was 
stirred for another 4 h at -30 °C. After complete conversion of the terephthalate (checked 
by TLC), the reaction mixture was diluted with aqueous HCl (1 M, 30 mL) and the solution 
was stirred for 3 days at ambient temperature, while it turned a brightly orange emulsion. 
EtOAc (10 mL) was added, the phases were separated and the aqueous phase was extracted 
with EtOAc (3 x 20 mL). The organic layers were combined, dried over Na2SO4 and the 
solvent was evaporated under reduced pressure. The dark brown crude product was purified 
by column chromatography (CH2Cl2/MeOH, 9:1) to yield the title compound 121 in pure 
form.  
Faintly orange solid. Yield: 308 mg, 0.97 mmol, 43 %. 1H NMR (500 MHz, Chloroform-
d) δ = 8.34 (d, 4J = 1.6 Hz, 1H, ar-3-H), 7.84 (dd, 3J = 8.1 Hz, 4J = 1.2 Hz, 1H, ar-5-H), 
7.77 (d, 3J = 8.0 Hz, 1H, ar-6-H), 6.11 (s br., 1H, ar-4-CONHCH3), 3.95 (s, 3H, ar-1-
CO2CH3), 3.03 (d, 
3J = 5.0 Hz, 3H, ar-4-CONHCH3). C10H10INO3 (319.10 g mol
-1).  
 
4-(tert-Butyl) 1-Methyl 2-Iodoterephthalate (122). The preparation of ester 122 was 
performed in analogy to the work of Pintér, Haberhauer, Hyla-
Krypsin and Grimme [249]. Compound 122 has been mentioned 
before by Hangauer and Bertozzi, who prepared it in a different way 
[250]. 1-Methyl 2-iodo terephthalate (38a, 748 mg, 2.45 mmol, 1.0 eq) was dissolved 
under an argon atmosphere in dry THF (18 mL). 4-Dimethylaminopyridine (88 mg, 
0.72 mmol, 0.3 eq) and Boc2O (586 mg, 2.69 mmol, 1.1 eq) was added in one portion under 
vigorous stirring. While the reaction mixture was stirred overnight at room temperature, it 
turned into a brightly orange color. After complete conversion of the starting material 
(checked by TLC), the solvent was evaporated under reduced pressure. The crude product 
was diluted with aqueous hydrochloric acid (1 M) and extracted with CH2Cl2 (3 x 15 mL). 
The combined organic layers were dried over Na2SO4, the solvent was evaporated and the 
residue was purified by column chromatography (CH2Cl2/MeOH, 9:1) to yield title 
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compound 122 in form of a light orange solid. Yield: 442 mg, 1.22 mmol, 50 %. 1H NMR 
(500 MHz, Chloroform-d) δ = 8.54 (s, 1H, ar-3-H), 7.98 (d, 3J = 8.1 Hz, 1H, ar-6-H), 7.78 
(d, 3J = 8.1 Hz, 1H, ar-5-H), 3.95 (s, 3H, ar-1-CO2CH3), 1.60 (s, 9H, ar-4-CO2C(CH3)3). 
13C NMR (126 MHz, Chloroform-d) δ = 166.8 (ar-1-CO2CH3), 163.5 (ar-4-CO2C(CH3)3), 
142.1 (ar-C-3), 138.8 (ar-C-1), 135.6 (ar-C-4), 130.5 (ar-C-6), 128.9 (ar-C-5), 93.5 (ar-C-
2), 82.5 (ar-4-CO2C(CH3)3), 52.9 (ar-1-CO2CH3), 28.3 (ar-4-CO2C(CH3)3). C13H15IO4 
(362.16 g mol-1).  
 
Di-tert-butyl (3-Iodobenzoyl)-L-aspartate (123). Oxalylchloride (0.11 mL, 1.28 mmol, 
2.0 eq) was slowly added to a suspension of 3-iodobenzoate (317 mg, 1.28 mmol, 2.0 eq) 
in a mixture of CH2Cl2/DMF (15 mL, 2:1) at 0 °C over a period of 10 min. The reaction 
mixture was stirred for 2 h at rt, until the conversion of the starting material was complete 
(checked by TLC). A solution of di-tert-butyl aspartate (182 mg, 0.64 mmol, 1.0 eq) in 
THF (5 mL), DIPEA (1.3 mL, 0.96 g, 7.44 mmol, 9.2 eq) was added dropwise, followed 
by DMAP (10 mg, 82 mol, 0.1 eq) and the reaction mixture was stirred on at rt. After 
another 24 h, the solution was diluted with water (30 mL) and a saturated NH4Cl-solution 
(20 mL) and the aqueous phase was extracted with CH2Cl2 (5 x 50 mL). The combined 
organic layers were washed with water (50 mL), brine (20 mL) and dried over Na2SO4. 
Evaporation of the solvent lead to the slightly brown crude product of 123, which was 
purified by column chromatography (PE/EtOAc, 4:1).  
Colorless, crystalline solid. Yield: 146.5 mg, 308 mol, 48 %. 
1H NMR (500 MHz, Chloroform-d) δ = 8.15 (s, 1H, ar-2-H), 7.84 
(d, 3J = 7.9 Hz, 1H, ar-6-H), 7.75 (d, 3J = 7.8 Hz, 1H, ar-4-H), 7.17 
(t, 3J = 7.9 Hz, 1H, ar-5-H), 7.15 (d br., 3J = 7.2 Hz, 1H, ar-1-
CONHCH), 4.84 (ddd, 3J = 8.1 Hz, 3J = 4.2 Hz, 3J = 4.3 Hz, 1H, NHCHCH2CO2), 2.98 
(dd, 2J = 17.1 Hz, 3J = 4.2 Hz, 1H, NHCHCH2CO2), 2.84 (dd, 
2J = 17.1 Hz, 3J = 4.3 Hz, 
1H, NHCHCH2CO2), 1.49 (s, 9H, CO2C(CH3)3), 1.45 (s, 9H, CO2C(CH3)3). 
13C NMR 
(126 MHz, Chloroform-d) δ = 170.6 (NHCHCH2CO2), 169.9 (NHCHCO2), 165.5 (ar-
1-CONHCH), 140.7 (ar-C-6), 136.4 (ar-C-2), 136.2 (ar-C-1), 130.4 (ar-C-5), 126.3 (ar-
C-4), 94.4 (ar-C-3), 82.8 (CO2C(CH3)3), 81.9 (CO2C(CH3)3), 49.7 (NHCHCH2), 37.6 
(NHCHCH2), 28.2 (CO2C(CH3)3), 28.1 (CO2C(CH3)3). C19H26INO5 (475.32 g mol-1). 
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MS(ESI): m/z = 476.0906 (calcd. 476.0928 [M+H]+), 498.0730 (calcd. 498.0748 
[M+Na]+). TLC: Rf (PE/EtOAc, 4:1) = 0.55.  
 
Di-tert-butyl (5-Bromothiophene-2-carbonyl)-L-aspartate (124). Oxalylchloride 
(0.11 mL, 1.28 mmol, 2.0 eq) was slowly added to a suspension of 5-bromothiophene-2-
carboxylic acid (265 mg, 1.28 mmol, 2.0 eq) in a mixture of CH2Cl2/DMF (5 mL, 99:1) at 
0 °C over a period of 10 min. The reaction mixture was stirred for 2 h at rt, until the 
conversion of the starting material was complete (checked by TLC). A solution of di-tert-
butyl aspartate (182 mg, 0.64 mmol, 1.0 eq) in THF (5 mL), DIPEA (1.3 mL, 0.96 g, 
7.44 mmol, 9.2 eq) was added dropwise, followed by DMAP (10 mg, 82 mol, 13 mol%) 
and the reaction mixture was stirred on at rt. After another 24 h, the solution was diluted 
with water (20 mL) and a saturated NH4Cl solution (10 mL) and the aqueous phase was 
extracted with CH2Cl2 (5 x 30 mL). The combined organic layers were washed with water 
(30 mL), brine (10 mL) and dried over Na2SO4. Evaporation of the solvent lead to the 
slightly brown crude product of 124, which was purified by column chromatography 
(PE/EtOAc, 4:1).  
Colorless, crystalline solid. Yield: 85.0 mg, 195 mol, 30 %. 
1H NMR (500 MHz, Chloroform-d) δ = 7.28 (d, 3J = 3.8 Hz, 1H, 
thiophene-3-H), 7.04 (d, 3J = 3.9 Hz, 1H, thiophene-4-H), 6.99 (d, 
3J = 7.9 Hz, 1H, CHNHCO), 4.78 (ddd, 3J = 7.8 Hz, 3J = 4.3 Hz, 
3J = 4.1 Hz, 1H, CH), 2.95 (dd, 2J = 17.2 Hz, 3J = 4.4 Hz, 1H, CHCH2), 2.82 (dd, 
2J = 
17.1 Hz, 3J = 4.3 Hz, 1H, CaHCbH2), 1.47 (s, 9H, CO2C(CH3)3), 1.45 (s, 9H, CO2C(CH3)3). 
13C NMR (126 MHz, Chloroform-d) δ = 170.5 (CHCH2CO2C(CH3)3), 160.5 
(CHCO2C(CH3)3), 159.0 (CNHCO), 140.1 (thiophene-C-2), 130.8 (thiophene-C-3), 
128.5 (thiophene-C-4), 118.5 (thiophene-C-5), 82.9 (CHCH2CO2C(CH3)3), 81.9 
(CHCO2C(CH3)3), 49.6 (CHCH2), 37.6 (CHCH2CO2C(CH3)3), 28.2 
(CHCH2CO2C(CH3)3), 28.1 (CHCO2C(CH3)3). C17H24BrNO5S (434.35 g mol
-1). 
MS(ESI): m/z = 456.04570 (calcd. 456.0451 [M+Na]+). TLC: Rf (PE/EtOAc, 4:1) = 0.59.  
 
 
IIX-6. b) Azides in Aspartic Acid Derivatives (125-126) 
310 
IIX-6. b) Azides in Aspartic Acid Derivatives (125-126) 
Dimethyl (S)-2-Azidosuccinate (125).  
 
Scheme EP3. Different synthesis pathways for the preparation of azide 125 .   
 
1H-Imidazol-1-sulfurylazide Hydrochloride. The synthesis and application of the azide 
transfer reagent was carried out according to Wang et al. [251]. Sulfurylchloride (5.0 mL, 
61.8 mmol, 1.0 eq) was added at 0 °C to a solution of NaN3 (4.10 g, 62.9 mmol, 1.0 eq) in 
dry CH3CN (30 mL). After stirring the reaction mixture 16 h at ambient temperature, 
imidazole 88.43 g, 124 mmol, 2.0 eq) was added at 0 °C and the solution was allowed to 
warm up to room temperature. The mixture was diluted in EtOAc and washed with water 
(2 x 30 mL) and saturated aqueous NaHCO3 (30 mL) and dried over Na2SO4. A Solution 
of HCl (6.5 mL of acetylchloride in 25 mL of absolute EtOH) was added to the solution of 
crude material in EtOAc at 0 °C. Immediately, a colorless precipitate formed, which was 
filtered off, washed with a few milliliters of ice cold EtOAc and dried under vacuum. 1H-
Imidazol-1-sulfurylazide was isolated in form of a colorless solid.  
Yield: 8.81 g, 50.9 mmol, 82 %. 1H NMR (500 MHz, DMSO-d6) δ = 8.53 (m, 
1H, imidazole-2-H), 7.95 (d, 4J = 1.5 Hz, 1H, imidazole-4-H), 7.30 (d, 4J = 
2.3 Hz, 1H, imidazole-5-H). C3H3N5O2S (173.15 g mol
-1).  
 
(S)-2-Azidosuccinic Acid. This synthesis was performed analogously to the procedure of 
Bachl et al., who prepared a glutamic acid based azide [252]. (S)-2-
Azidosuccinic acid has been first described by Li et al. [141]. Imidazol-1-
sulfonylazide hydrochloride (1.88 g, 9 mmol, 1.2 eq), K2CO3 (2.8 g, 20 mmol, 
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2.7 eq) and CuSO4 x 5 H2O (19 mg, 75 mol, 1 mol%) was added in small portions to a 
solution of (S)-aspartic acid (1.0 g, 7.5 mmol, 1.0 eq) in MeOH (10 mL). After stirring for 
15 h at room temperature, the solvent was evaporated under reduced pressure. The residue 
was diluted with water (15 mL) the pH value was adjusted to 2 by the addition of aqueous 
HCl (1 M) and extracted with EtOAc (3 x 20 mL). The combined organic layers were dried 
over Na2SO4 and the solvent was evaporated to yield (S)-2-azidosuccinic acid in pure form.  
Yellow solid. Yield: 336 mg, 2.1 mmol, 28 %. 1H NMR (500 MHz, Chloroform-d) δ = 
10.97 (s, 2H, CO2H), 4.42 (dd, 
3J = 7.5 Hz, 3J = 5.0 Hz, 1H, CH), 2.91 (dd, 2J = 17.2 Hz, 
3J = 5.2 Hz, 1H, CCH2), 2.78 (dd, 
2J = 17.3 Hz, 3J = 7.5 Hz, 1H, CCH2). C4H5N3O4 
(159.10 g mol-1). [𝛼]589
20  = -137 (c 0.57, CHCl3). IR(ATR): 𝜈 [cm-1] = 3249 (OH), 2961 
(CH), 2106 (N3), 1720 (CO), 1359 (CH2), 1182 (OH).  
 
Dimethyl L-Aspartate. The synthesis was carried out according to Jung and Fletcher 
[253]. Under argon atmosphere, thionyl chloride (5.62 g, 47.3 mmol, 2.1 eq) was added 
dropwise to a solution of (S)-aspartic acid (3.00 g, 22.5 mmol, 1.0 eq) in MeOH (30 mL). 
The reaction mixture was stirred for 15 h at 60 °C. After cooling down to room temperature, 
the pH value of the solution was adjusted to 8 by adding a saturated solution of NaHCO3. 
Extracted with Et2O (3 x 20 mL), combination of the organic layers, drying over Na2SO4 
and evaporation of the solvent lead to the isolation of dimethyl (S)-aspartic acid. Slightly 
yellow oil. Yield: 1.432 g, 8.88 mmol, 39 % (Lit: 100 % [253]). 1H NMR 
(500 MHz, Chloroform-d) δ = 3.83 (dd, 3J = 7.4 Hz, 3J = 4.7 Hz, 1H, CH), 
3.75 (s, 3H, CO2CH3), 3.71 (s, 3H, CO2CH3), 2.81 (dd, 
2J = 16.5 Hz, 3J = 
4.6 Hz, 1H, CCH2), 2.71 (dd, 
2J = 16.5 Hz, 3J = 7.4 Hz, 1H, CCH2). 
13C NMR (126 MHz, Chloroform-d) δ = 174.8 (CO2CH3), 171.8 (CO2CH3), 52.5 
(CO2CH3), 52.1 (CO2CH3), 51.3 (C), 38.9 (CCH2). C6H11NO4 (161.16 g mol
-1). TLC: 
Rf (EtOAc/PE, 1:4) = 0.36.  
 
Dimethyl Malate. The methylation of Äpfelsäure was performed according to Hao Bao-Yu 
et al. [254]. Thionylchloride (7.5 mL, 104 mmol, 3.1 eq) was added dropwise to a solution 
of D-Äpfelsäure (4.46 g, 33.3 mmol, 1.0 eq) in dry methanol. The reaction mixture was 
stirred for 5 h at rt. Afterwards, the solvent was evaporated. The residue was dissolved in 
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an aqueous solution of NH4Cl (saturated, 30 mL) and extracted with CH2Cl2 (3 x 30 mL). 
The combined organic layers were dried over Na2SO4 and the solvent was evaporated to 
yield the dimethyl malate in pure form.  
Pale, yellow liquid. Yield: 3.547 g, 21.9 mmol, 66 %. 1H NMR (500 MHz, Chloroform-d) 
δ = 4.50 (ddd, 3J = 5.8 Hz, 3J = 5.5 Hz, 3J = 4.4 Hz, 1H, CHOH), 3.81 
(s, 3H, CHCO2CH3), 3.71 (s, 1H, CHCH2CO2CH3), 3.23 (d, 
3J 
= 5.6 Hz, 1H, CHOH), 2.93-2.72 (m, 2H, CHCH2CO2CH3). 
13C NMR (126 MHz, 
Chloroform-d) δ = 173.8 (CHCO2CH3), 171.1 (CHCH2CO2CH3), 67.4 (CHOH), 53.0 
(CHCO2CH3), 52.2 (CHCH2CO2CH3), 38.6 (CHCH2CO2CH3). C6H10O5 
(162.14 g mol-1).  
 
Dimethyl (S)-2-Azidosuccinate (125). The azide transfer was carried out as proposed by 
Wang et al. [251], as well as by Bachl et al., who prepared a glutamic acid based azide in 
an analogous manner [252]. To a solution of dimethyl-(S)-aspartic acid (1.43 g, 8.88 mmol, 
1.0 eq) in methanol (15 mL), imidazol-1-sulfonylazide hydrochloride (2.23 g, 10.7 mmol, 
1.2 eq), K2CO3 (3.31 g, 24.0 mmol, 2.7 eq) and CuSO4 x 5 H2O (22 mg, 88 µmol, 1 mol%) 
were added one after another. After stirring the reaction mixture 15 h at rt, the solvent was 
evaporated. The residue was dissolved in aqueous HCl (20 mL, pH = 2) and extracted with 
EtOAc (3 x 20 mL). The combined organic layers were washed with brine (10 mL), dried 
over Na2SO4 and the solvent was evaporated under reduced pressure. Dimethyl (S)-2-
azidosuccinate (125, 336 mg, 2.1 mmol, 28 %, total: 11 %, over two steps) was obtained in 
form of a slightly orange, crystalline solid.  
Thionylchloride (403 mg, 3.38 mmol, 2.1 eq) was added dropwise to a solution of (S)-2-
azidosuccinic acid (257 mg, 1.61 mmol, 1.0 eq) in dry methanol (5 mL) at 0 °C. After 15 h 
of stirring the reaction mixture at rt, the solvent was evaporated. The residue was dissolved 
in an aqueous solution of NH4Cl (saturated, 10 mL) and an aqueous solution of NaOH 
(1 M) was added dropwise to adjust the pH value to 8. The solution was extracted with 
Et2O (3 x 20 mL), the combined organic layers were dried over Na2SO4 and the solvent 
was evaporated under reduced pressure to yield dimethyl (S)-2-azidosuccinate (125, 
56.6 mg, 1.07 mmol, 16 %, total: 4 %, over two steps) in form of a slightly orange, 
crystalline solid.  
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The Mitsunobu reaction was carried out according to Castro et al. [142]. The (R)-configured 
analogue of azide 125 has been described by Hoffman and Kim [255]. Simultaneously, a 
solution of DPPA (9.5 mL, 44.1 mmol, 2.0 eq) in THF (10 mL) and a solution of dimethyl 
malate (3.55 g, 21.9 mmol, 1 eq) in THF (10 mL) were added dropwise into a suspension 
of DIAD (4.2 mL, 22.2 mmol, 1 eq) and triphenylphosphane (5.75 g, 21.9 mmol, 1 eq) in 
THF (40 mL) at 0 °C. After stirring the reaction mixture for 17 h at rt, the reaction mixture 
was poured into an aqueous NH4Cl solution (50 mL). The phases were separated and the 
aqueous phase was extracted with Et2O (3 x 30 mL). The combined organic layers were 
washed with brine (10 mL) and dried over Na2SO4. After evaporating the solvent under 
reduced pressure, the crude material was dissolved in PE and filtered. Silica gel was added 
to the filtrate to adsorb crude product 125 and dimethyl-(S)-2-azidsuccinat and separate 
them by column chromatography.  
Pale yellow, highly viscous oil. Yield: 754.4 mg, 4.03 mmol, 18 %. 1H NMR 
(500 MHz, Chloroform-d) δ = 4.32 (dd, 3J = 7.8 Hz, 3J = 5.3 Hz, 1H, N3CH), 
3.73 (s, 3H, CHCO2CH3), 3.63 (s, 3H, CHCH2CO2CH3), 2.78 (dd, 
2J = 
16.7 Hz, 3J = 5.3 Hz, 1H, CHCH2), 2.64 (dd, 
2J = 16.8 Hz, 3J = 7.8 Hz, 1H, CHCH2).
 
13C NMR (126 MHz, Chloroform-d) δ = 170.0 (CCO2CH3), 169.5 (CHCH2CO2CH3), 
58.2 (N3CH), 52.8 (CO2CH3), 52.0 (CO2CH3), 35.8 (CHCH2). C6H9N3O4 
(187.16 g mol-1). IR(ATR): 𝜈 [cm-1] = 2977 (CH), 2107 (N3), 1733 (CO2Me), 1711 
(CO2CH3), 1613, 1454, 1366, 1299, 1245, 1144, 919, 846, 733, 669. [𝛼]589
20  = -38.58 (c 
1.244, CHCl3).  
 
(S)-3-Aminosuccinic anhydride. This synthesis was performed in accordance with the 
description of Yan et al. [256]. Under argon atmosphere, PCl3 (2.75 g, 
15.87 mmol, 0.4 eq) was added dropwise to a solution of (S)-aspartic acid 
(5.00 g, 37.57 mmol, 1 eq) in THF (15 mL). A colorless precipitate 
formed, which was filtered off after 15 h and washed with cold THF. The colorless, 
crystalline solid was dried under reduced pressure and stored under argon atmosphere.  
Colorless crystalline solid. Yield: 6.01 g, 36.32 mmol, 97 % (Lit: 100 % [256]). 
C4H6ClNO3 (151.55 g mol
-1). IR(ATR): 𝜈 [cm-1] = 2967 (CH), 2863 (CH2), 1802 (C=O), 
1774 (C=O).  
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Di-tert-butyl (2-Azidoacetyl)-L-aspartate (126)  
2-Azidoacetic Acid. The synthesis of 2-azidoacetic acid has been performed as described 
by Liu et al. [257]. In one portion, NaN3 (1.38 g, 18.0 mmol, 5 eq) was added at 0 °C to an 
aqueous solution of 2-bromoacetic acid (500 mg, 3.60 mmol, 0.72 M, 1 eq). 
The faintly yellow reaction mixture was stirred for 48 h at room temperature. 
After complete conversion of the starting material (checked by TLC), the solution was 
acidified with aqueous HCl (2 mL) to pH 2 and extracted with Et2O (3 x 10 mL). The 
combined organic layers were dried over Na2SO4 and the solvent was evaporated under 
reduced pressure.  
Highly viscous, colorless oil. Yield: 350 mg, 3.46 mmol, 96 % (Lit: 95 % [257]). 1H NMR 
(500 MHz, Chloroform-d) δ = 10.86 (s, 1H, CO2H), 3.97 (s, 2H, N3CH2). C2H3N3O2 
(101.07 g mol-1). IR(ATR): 𝜈 [cm-1] = 2965 (OH), 2936 (CH), 2876 (CH), 2103 (N3), 1708 
(CO2H), 1451, 1229, 945.  
 
Di-tert-butyl (2-Azidoacetyl)-L-aspartate (126). A mixture of 2-azidoacetic acid 
(184 mg, 1.82 mmol, 1.0 eq), di-tert-butyl aspartate (515 mg, 1.83 mmol, 1.0 eq), HOAt 
(75.2 mg, 0.55 mmol, 0.3 eq) and HATU (1.390 mg, 3.66 mmol, 2.0 eq) was placed under 
argon atmosphere in a Schlenk-flask. A mixture of CH2Cl2/DMF/DIPEA (17 mL, 59:30:11) 
was added until the mixture was completely dissolved. After stirring the reaction mixture 
for 2 days at rt, brine (50 mL) was added and the aqueous phase was extracted with CH2Cl2 
(3 x 50 mL). The combined organic layers were washed with water (50 mL), brine (10 mL) 
and dried over Na2SO4. After evaporation of the solvent, the crude product of 126 was 
purified by column chromatography (PE/EtOAc, 4:1).  
Colorless, crystalline solid. Yield: 458.4 mg, 1.396 mmol, 77 %. 
1H NMR (500 MHz, Chloroform-d) δ = 7.24 (d br., 3J = 8.3 Hz, 1H, 
CONH), 4.66 (ddd, 3J = 8.6 Hz, 3J = 4.3 Hz, 3J = 4.4 Hz, 1H, CH), 
3.99-3.95 (m, 2H, N3CH2CONH), 2.88 (dd, 
2J = 16.9 Hz, 3J = 4.3 Hz, 
1H, CHCH2CO2), 2.69 (dd, 
2J = 17.2 Hz, 3J = 4.2 Hz, 1H, CHCH2CO2), 1.44 (s, 9H, 
CHCO2C(CH3)3), 1.43 (s, 9H, CHCH2CO2C(CH3)3). 
13C NMR (126 MHz, Chloroform-
d) δ = 170.0 (CHCO2C(CH3)3), 169.3 (CHCH2CO2C(CH3)3), 166.5 (N3CH2CONH), 
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82.7 (CHCO2C(CH3)3), 81.9 (CHCH2CO2C(CH3)3), 52.6 (N3CH2CO), 49.1 (CH), 37.4 
(CHCH2), 28.1 (CHCO2C(CH3)3), 28.0 (CHCH2CO2C(CH3)3). C14H24N4O5 
(328.37 g mol-1). MS(ESI): m/z = 351.1675 (calcd. 351.1639 [M+Na]+). Mp = 56.1 °C 
(+/- 0.6 K). [𝛼]589
20  = +10.67 (c 1.28, CHCl3).  
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 Dimethyl 5-((S)-6-((Z)-2,3-Bis(tert-butoxycarbonyl)guanidino)-3-(((S)-tert-
butylsulfinyl)amino)hex-1-yn-1-yl)isophthalate (127). Sonogashira cross-coupling: 
Under Schlenk-conditions, piperidine (0.3 mL) was added to a solution of propargylamide 
6x (109 mg, 239 mol, 1.0 eq) and dimethyl 5-iodo isophthalat (120, 157 mg, 491 mol, 
2.1 eq) in THF (1.0 mL). The reaction mixture was thoroughly degassed by freeze pump 
thaw method. The catalysts, PdCl2(PPh3)2 (21 mg, 30 mol, 0.1 eq) and CuI (14 mg, 
74 mol, 0.3 eq) were added to the frozen reaction mixture and the solution slowly warmed 
up to room temperature. After 45 min, a colorless precipitate formed in the clear solution, 
indicating the progress of the reaction. 21 h later, the suspension was diluted with a 
saturated aqueous NH4Cl solution (10 mL) and KHSO4 (aq, 5 %, 4 mL) was added, until 
the organic layer started to turn faintly red (pH 5-6). The emulsion was diluted with Et2O 
(20 mL), the organic layer separated and the aqueous layer extracted to more times with 
Et2O (2 x 20 mL). The combined organic layers were dried over Na2SO4 and the solvent 
was evaporated under reduced pressure. The crude product of 127 was purified by column 
chromatography (PE/EtOAc, 1:1).  
Colorless, highly viscous oil. Yield: 66.5 mg, 102 mol, 43 %. 1H NMR (500 MHz, 
Chloroform-d) δ = 11.48 (s br., 1H, NHBoc), 8.58 (d, 4J = 1.8 
Hz, 1H, ar-2-H),  8.35 (t br., 3J = 5.3 Hz, 1H, CNHCH2), 8.23 
(t, 4J = 1.8 Hz, 2H, ar-4-H, ar-6-H), 4.32 (ddd, 3J = 6.6 Hz, 3J 
= 6.2 Hz, 3J = 5.3 Hz, 1H, CH), 3.92 (s, 6H, (CO2CH3)2), 
3.50 (m, 1H, tBuSNH), 3.49-3.44 (m, 2H, NHCH2), 1.89-1.82 
(m, 2H, CHCH2), 1.82-1.76 (m, 2H, CHCH2CH2), 1.47 (s, 
9H, C=NCO2C(CH3)3), 1.46 (s, 9H, CHNCO2C(CH3)3), 1.23 (s, 9H, SC(CH3)3). 
13C NMR 
(126 MHz, Chloroform-d) δ = 165.6 (ar(CO2CH3)2), 163.7 (N=CN2), 156.3 
(C=NCO2C(CH3)3), 153.4 (CHNCO2C(CH3)3), 136.8 (ar-C-4, ar-C-6), 131.0 (ar-C-1, ar-
C-3), 130.4 (ar-C-2), 123.6 (ar-C-5), 90.6 (C=NCO2C(CH3)3), 83.3 (CHC≡C-ar), 83.2 
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(CHNCO2C(CH3)3), 79.4 (CHC≡C-ar), 56.4 (SC(CH3)3), 52.6 (CO2CH3), 47.9 (C), 40.3 
(CHNCH2), 34.1 (CCH2), 28.4 (C=NCO2C(CH3)3), 28.2 (CHNCO2C(CH3)3), 25.4 
(CCH2CH2), 22.7 (SC(CH3)3). C31H46N4O9S (650.79 g mol
-1). MS(ESI): m/z = 651.3047 
(calcd. 651.30583 [M+H]+).  
 
The synthesis of peptidomimetics 128a,b was attempted in an analog way to 128c, using 
halogenides 38a and 121 as starting material. However, none of the products 128a,b could 
be isolated.  
 
4-(tert-Butyl) 1-Methyl 2-((S)-6-((E)-2,3-Bis(tert-butoxycarbonyl)guanidino)-3-(((S)-
tert-butylsulfinyl)amino)hex-1-yn-1-yl)terephthalate (128c). Sonogashira 
cross-coupling: Under Schlenk-conditions, piperidine (0.6 mL) was added to a solution of 
arginine analogous propargylamide 6x (262 mg, 572 mol, 1.0 eq) and 4-(tert-butyl)-1-
methyl 2-iodoterephthalate (122, 350 mg, 966 mol, 1.7 eq) in THF (2.0 mL). The reaction 
mixture was thoroughly degassed by freeze pump thaw method. The catalysts, 
PdCl2(PPh3)2 (15 mg, 21 mol, 4 mol%) and CuI (17 mg, 91 mol, 0.2 eq) were added to 
the frozen reaction mixture and the solution slowly warmed to room temperature. After 
60 min, a colorless precipitate formed in the clear solution, indicating the progress of the 
reaction. 30 h Later, the suspension was diluted with a saturated aqueous NH4Cl solution 
(10 mL) and KHSO4 (aq, 5 %, 6 mL) was added, until the organic layer started to turn 
faintly red (pH 5-6). The emulsion was diluted with Et2O (20 mL), the organic layer 
separated and the aqueous layer extracted to more times with Et2O (2 x 20 mL). The 
combined organic layers were dried over Na2SO4 and the solvent was evaporated in 
vacuum. The crude product of 128c was purified by column chromatography (PE/EtOAc, 
1:1).  
Colorless oil, Yield: 200 mg, 289 mol, 52 %. 1H NMR 
(500 MHz, Chloroform-d) δ = 11.44 (s br., 1H, NHBoc), 
8.32 (t br., 3J = 5.3 Hz, 1H, NHCN2), 8.04 (d, 
4J = 1.6 Hz, 
1H, ar-3-H), 7.89 (d, 3J = 8.2 Hz, 1H, ar-6-H), 7.86 (dd, 3J = 
8.2 Hz, 4J = 1.6 Hz, 1H, ar-5-H), 4.36 (ddd, 3J = 5.6 Hz, 3J = 
4.8 Hz, 3J = 5.2 Hz, 1H, CH), 3.86 (s, 3H, ar-1-CO2CH3), 
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3.71 (d, 3J = 5.4 Hz, 1H, CHNHS), 3.48-3.41 (m, 2H, CCH2CH2CH2), 1.86-1.79 (m, 4H, 
CCH2CH2, CCH2CH2), 1.53 (s, 9H, ar-4-CO2C(CH3)3), 1.43 (s, 9H, C=NCO2C(CH3)3), 
1.41 (s, 9H, CHNCO2C(CH3)3), 1.20 (s, 9H, SC(CH3)3).
13C NMR (126 MHz, Chloroform-
d) δ = 165.8 (ar-1-CO2CH3), 164.1 (ar-4-CO2C(CH3)3), 163.6 (N=CN2), 156.2 
(C=NCO2C(CH3)3), 153.2 (CHNCO2C(CH3)3), 135.1 (ar-C-4), 134.8 (ar-C-2), 134.8 (ar-
C-3), 130.2 (ar-C-6), 128.7 (ar-C-5), 123.1 (ar-C-1), 94.3 (CHC≡C-ar), 83.3 (CHC≡C-
ar), 83.0 (CHNCO2C(CH3)3), 82.1 (ar-4-CO2C(CH3)3), 79.2 (C=NCO2C(CH3)3), 56.2 
(SC(CH3)3), 52.4 (ar-1-CO2CH3), 47.7 (C), 40.4 (CCH2CH2CH2), 33.8 (CCH2), 28.3 
(CHNCO2C(CH3)3), 28.1 (C=NCO2C(CH3)3), 28.0 (ar-4-CO2C(CH3)3), 25.0 
(CCH2CH2), 22.6 (SC(CH3)3). C34H52N4O9S (692.87 g mol
-1). MS(ESI): m/z = 693.1764 
(calcd. 693.3528 [M+H]+), 715.0878 (calcd. 715.3347 [M+Na]+).  
 
Di-tert-butyl (3-((S)-6-((E)-2,3-bis(tert-butoxycarbonyl)guanidino)-3-(((S)-tert-
butylsulfinyl)amino)hex-1-yn-1-yl)benzoyl)-L-aspartate (129). Sonogashira 
cross-coupling: Under Schlenk-conditions, piperidine (183 µL, 1.85 mmol, 6.0 eq) was 
added to a solution of arginine analogous propargylamide 6x (143 mg, 312 µmol, 1.0 eq) 
and di-tert-butyl (3-iodobenzoyl)-L-aspartate (123, 146.5 mg, 308 µmol, 1.0 eq) in dry 
THF (3.0 mL). The reaction mixture was thoroughly degassed by freeze pump thaw 
method. The catalysts, PdCl2(PPh3)2 (7 mg, 10 mol, 3 mol%) and CuI (5 mg, 30 mol, 
10 mol%) were added to the frozen reaction mixture and the solution slowly warmed to 
room temperature. After about 60 min, a colorless precipitate formed in the clear solution, 
indicating the progress of the reaction. Three days later, the suspension was diluted with a 
saturated aqueous NH4Cl solution (10 mL) and Et2O (10 mL), before the pH-value was 
brought to about 7 by the addition of an aqueous KHSO4 solution (5 %, 2-3 mL). After 
separation of the phases, the aqueous layer was extracted with Et2O (3 x 20 mL). The 
combined organic layers were washed with brine (10 mL), dried over Na2SO4 and the 
solvent was evaporated under reduced pressure. The crude product of 129 was purified by 
column chromatography (PE/EtOAc, 1:1).  
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Colorless oil. Yield: 183.4 mg, 227.5 mol, 74 %. 1H NMR (500 MHz, Chloroform-d) δ = 
11.49 (s br., 2H, C(NBoc)NHBoc), 8.37 (t br., 3J = 
3.9 Hz, 1H, CH2NH), 7.86 (s, 1H, ar-2-H), 7.75 (d, 
3J 
= 7.9 Hz, 1H, ar-6-H), 7.58 (d, 3J = 7.7 Hz, 1H, ar-4-
H), 7.38 (t, 3J = 7.7 Hz, 1H, ar-5-H), 7.19 (d br., 3J = 
7.9 Hz, 1H, COHNCH), 4.86 (ddd, 3J = 7.8 Hz, 3J = 
7.2 Hz, 3J = 4.3 Hz, 1H, CH), 4.35 (dd, 3J = 6.1 Hz, 3J = 7.1 Hz, 3J = 4.5 Hz, 1H, CH), 
3.23 (td, 3J = 6.8 Hz, 3J = 3.9 Hz, 2H, CHCH2CH2CH2NH), 3.07 (d br., 
3J = 6.8 Hz, 
1H, NHCH), 2.97 (dd, 2J = 17.4 Hz, 3J = 4.3 Hz, 1H, CHCH2CO2), 2.85 (dd, 
2J = 
16.9 Hz, 3J = 4.3 Hz, 1H, CHCH2CO2), 1.85-1.78 (m, 2H, CHCH2CH2CH2NH), 
1.75-1.67 (m, 2H, CHCH2CH2CH2NH), 1.50 (s, 9H, CHCH2CO2C(CH3)3), 1.49 (s, 
9H, CHCO2C(CH3)3), 1.44 (s, 18H, N=CO2C(CH3)3, NHCO2C(CH3)3), 1.21 (s, 9H, 
SC(CH3)3). 
13C NMR (126 MHz, Chloroform-d) δ = 170.6 (CHCH2CO2), 170.0 
(CHCO2), 166.2 (COHNCH), 163.8 (NHC(=NBoc)NHBoc), 156.3 (NCO2C(CH3)3), 
153.4 (NHCO2C(CH3)3), 135.1 (ar-C-6), 134.4 (ar-C-1), 130.5 (ar-C-2), 128.8 (ar-C-5), 
128.2 (ar-C-3), 127.2 (ar-C-4), 89.6 (CHC≡Car), 84.4 (NCO2C(CH3)3), 83.2 
(NHCO2C(CH3)3), 82.7 (CO2C(CH3)3), 81.8 (CO2C(CH3)3), 79.4 (CHC≡Car), 56.6 
(SC(CH3)3), 56.0 (CH), 49.7 (CH), 47.8 (CHCH2CH2CH2NH), 40.9 
(CHCH2CO2), 35.7 (CHCH2CH2CH2NH), 33.4 (CHCH2CH2CH2NH), 28.5 
(NCO2C(CH3)3), 28.2 (CHCH2CO2C(CH3)3, CHCO2C(CH3)3), 28.1 
(NHCO2C(CH3)3), 22.9 (SC(CH3)3). C40H63N5O10S (806.03 g mol
-1). MS(ESI): m/z = 
806.43940 (calcd. 806.4368 [M+H]+).  
 
Di-tert-butyl (5-((S)-6-((E)-2,3-Bis(tert-butoxycarbonyl)guanidino)-3-(((S)-tert-
butylsulfinyl)amino)hex-1-yn-1-yl)thiophene-2-carbonyl)-L-aspartate (130). 
Sonogashira cross-coupling: Under Schlenk-conditions, piperidine (116 µL, 1.17 mmol, 
6.0 eq) was added to a solution of arginine analogous propargylamide 6x (90 mg, 
196 µmol, 1.0 eq) and di-tert-butyl (5-bromothiophene-2-carbonyl)-L-aspartate (124, 
350 mg, 966 mol, 1.7 eq) in THF (3.0 mL). The reaction mixture was thoroughly 
degassed by freeze pump thaw method. The catalysts, PdCl2(PPh3)2 (7 mg, 10 mol, 
5 mol%) and CuI (5 mg, 30 mol, 15 mol%) were added to the frozen reaction mixture and 
the solution slowly warmed to room temperature. After 60 min, a colorless precipitate 
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formed in the clear solution, indicating the progress of the reaction. After 30 h, the 
suspension was diluted with a saturated aqueous NH4Cl solution (10 mL) and KHSO4 (aq, 
5 %, 6 mL) was added, until the organic layer started to turn faintly red (pH 5-6). The 
emulsion was diluted with Et2O (20 mL), the organic layer separated and the aqueous layer 
extracted to more times with Et2O (2 x 20 mL). The combined organic layers were dried 
over Na2SO4 and the solvent was evaporated in vacuum. The crude product of 130 was 
purified by column chromatography (PE/EtOAc, 1:1).  
Pale yellow oil. Yield: 101.8 mg, 125.4 mol, 64 %. 1H NMR (500 MHz, Chloroform-d) δ 
= 11.47 (s br., 1H, N=CNHBoc), 8.30 (s br., 1H, CHCH2CH2CH2NH), 7.35 (d, 
3J = 
3.8 Hz, 1H, thiophene-3-H), 7.12 (d, 3J = 3.7 Hz, 1H, 
thiophene-4-H), 7.01 (d br., 3J = 7.9 Hz, 1H, 
CNHCO), 4.77 (ddd, 3J = 8.2 Hz, 3J = 7.5 Hz, 3J = 
4.4 Hz, 1H, CH-CO2), 4.32 (ddd, 
3J = 6.4 Hz, 3J = 
4.4 Hz, 3J = 4.3 Hz, 1H, CH-C≡C), 3.55 (d br., 3J = 
6.3 Hz, 1H, CHNH), 3.45 (dt, 3J = 7.8 Hz, 3J = 
8.0 Hz, 2H, CHCH2CH2CH2NH), 2.92 (dd, 
2J = 
17.2 Hz, 3J = 4.3 Hz, 1H, CHCH2CO2), 2.79 (dd, 
2J = 17.1 Hz, 3J = 4.4 Hz, 1H, 
CHCH2CO2), 1.86-1.81 (m, 2H, CHCH2CH2CH2NH), 1.80-1.74 (m, 2H, 
CHCH2CH2CH2NH), 1.47 (s, 18H, CH2CO2C(CH3)3, CHCO2C(CH3)3), 1.44 (s, 9H, 
N=CO2C(CH3)3), 1.41 (s, 9H, NHCO2C(CH3)3), 1.21 (s, 9H, SC(CH3)3). 
13C NMR 
(126 MHz, Chloroform-d) δ = 171.3 (CH2CO2C(CH3)3), 169.7 (CHCO2C(CH3)3), 163.7 
(CHNHCO-thiophene), 160.7 (CH2NHC(NBoc)NHBoc), 156.3 (C=NCO2C(CH3)3), 
153.4 (CHNCO2C(CH3)3), 139.2 (thiophene-C-2), 132.9 (thiophene-C-3), 128.1 
(thiophene-C-4), 127.2 (thiophene-C-5), 94.7 (CH-C≡C-thiophene), 83.3 
(NCO2C(CH3)3), 83.2 (NHCO2C(CH3)3), 82.8 (CH-C≡C-thiophene), 81.9 
(CH2CO2C(CH3)3), 79.4 (CHCO2C(CH3)3), 56.0 (SC(CH3)3), 49.6 (CHCH2CO2), 
48.0 (CHCH2CH2CH2NH), 40.9 (CHCH2CO2), 35.6 (CHCH2CH2CH2NH), 
33.4 (CHCH2CH2CH2NH), 28.4 (CH2CO2C(CH3)3, CHCO2C(CH3)3), 28.2 
(C=NCO2C(CH3)3), 28.0 (CHNCO2C(CH3)3), 27.8 (CHCH2CH2CH2NH), 22.8 
(SC(CH3)3). C38H61N5O10S2 (812.05 g mol
-1). MS(ESI): m/z = 812.39340 (calcd. 812.3933 
[M+H]+).  
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Dimethyl (S)-2-(4-((S)-4-((E)-2,3-Bis(tert-butoxycarbonyl)guanidino)-1-(((S)-tert-
butylsulfinyl)amino)butyl)-1H-1,2,3-triazol-1-yl)succinate (131). Copper catalyzed 
[3+2] cycloaddition (Click reaction): CuSO4 x 5 H2O (165 mg, 0.7 mmol, 0.6 eq) and 
Sodium ascorbate (243.8 mg, 1.2 mmol, 1.0 eq) were simultaneously added in one portion 
to a heavily stirred solution of arginine analogous propargylamide 6x (545 mg, 1.2 mmol, 
1.0 eq) and dimethyl (S)-2-azidosuccinate (125, 288 mg, 1.5 mmol, 1.3 eq) in DMF/H2O 
(10:1, 11 mL). The reaction mixture was stirred for 23 h at rt and the procedure checked by 
TLC. After complete conversion, the solution was concentrated up under reduced pressure, 
diluted with a saturated NH4Cl solution (100 mL) and extracted with CH2Cl2 (3 x 50 mL). 
The combined organic layers were washed with brine (30 mL), dried over Na2SO4 and the 
solvent was removed under reduced pressure. The crude product of 131 was purified by 
column chromatography CH2Cl2/MeOH (10:1).  
Yield: 303 mg, 470 mol, 39 %. 1H NMR (500 MHz, Chloroform-d) δ = 11.47 (s br., 1H, 
NHBoc), 8.32 (t br., 3J = 5.3 Hz, 1H, CCH2CH2CH2NH), 7.84 
(s, 1H, C=CH), 5.64 (dd, 3J = 6.6 Hz, 3J = 7.4 Hz, 1H, 
CH3O2CC'H), 4.54 (ddd, 
3J = 7.4 Hz, 3J = 4.6 Hz, 3J = 6.4 Hz, 
1H, NHCH), 3.84 (d br., 3J = 7.4 Hz, 1H, CHNH), 3.77 (s, 3H, 
C‘HCO2CH3), 3.70 (s, 3H, C‘HCH2CO2CH3), 3.43 (td, 3J = 
6.8 Hz, 3J = 6.3 Hz, 2H, CHCH2CH2CH2), 3.36 (dd, 
2J = 17.4 Hz, 3J = 6.2 Hz, 1H, 
CH3O2CCH2C'H), 3.30 (dd, 
2J = 17.3 Hz, 3J = 7.1 Hz, 1H, CH3O2CCH2C'H), 2.12 (m, 
1H, CCH2), 1.94 (m, 1H, CCH2), 1.69 (m, 1H, CCH2CH2), 1.61 (m, 1H, 
CCH2CH2), 1.49 (s, 9H, C=NCO2C(CH3)3), 1.48 (s, 9H, CHNCO2C(CH3)3), 1.23 (s, 
9H, SC(CH3)3). 
13C NMR (126 MHz, Chloroform-d) δ = 169.9 (C'HCH2CO2CH3), 167.9 
(C'HCO2CH3), 163.7 (N=CN2), 156.3 (C=NCO2C(CH3)), 153.4 (CHNCO2C(CH3)), 
149.5 (CHC=CH), 123.1 (CHC=CH), 83.2 (CHNCO2C(CH3)3), 79.4 
(C=NCO2C(CH3)3), 58.8 (CH3O2CC'HN), 56.5 (SC(CH3)3), 53.6 (C‘HCO2CH3), 52.9 
(NHC-C=CH), 52.6 (C‘HCH2CO2CH3), 40.6 (CCH2CH2CH2), 36.4 (CH3O2C-
CH2HC'N), 33.5 (NHCHCH2), 28.4 (C=NCO2C(CH3)3), 28.2 (CHNCO2C(CH3)3), 25.4 
(CCH2CH2), 22.8 (SC(CH3)3). C27H47N7O9S (645.77 g mol-1). MS(ESI): m/z = 
646.3243 (calcd. 646.3229 [M+H]+). IR(ATR): ῡ [cm-1] = 3329, 3291, 3142, 2977, 2955, 
2936, 2870, 1739, 1720, 1635, 1610, 1575, 1413, 1366, 1328, 1226, 1154, 1128, 1046, 
1024, 913, 808, 729. TLC: Rf (CH2Cl2/MeOH, 10:1) = 0.59.  
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Di-tert-butyl (2-(4-((S)-4-((E)-2,3-Bis(tert-butoxycarbonyl)guanidino)-1-(((S)-tert-
butylsulfinyl)amino)butyl)-1H-1,2,3-triazol-1-yl)acetyl)-L-aspartate (132). Copper 
catalyzed [3+2] cycloaddition (Click reaction): Di-tert-butyl (2-Azidoacetyl)-L-aspartate 
(126, 85 mg, 260 µmol, 1.2 eq) and arginine analogous propargylamide 6x (102 mg, 
222 µmol, 1.0 eq) were dissolved in a mixture of DMF/H2O (10:1, 3 mL). Under vigorous 
stirring, solid CuSO4 x 5 H2O (28 mg, 112 µmol, 0.5 eq) and sodium ascorbate (48 mg, 
242 µmol, 1.1 eq) was added in one portion. The reaction mixture was stirred over 56 h at 
rt. After complete conversion of alkyne 6x (checked by TLC), the solution was 
concentrated under reduced pressure, diluted with brine (75 mL) and extracted with CH2Cl2 
(3 x 75 mL). The combined organic layers were washed with water (2 x 75 mL), brine 
(40 mL) and dried over Na2SO4. The solvent was evaporated under reduced pressure to 
yield the crude product of the desired triazole. Purification by column chromatography 
(CH2Cl2/MeOH, 10:1) allowed the isolation of triazole 132.  
Colorless fluid. Yield: 103.4 mg, 131.4 mol, 59 %. 1H NMR (500 MHz, Chloroform-d) δ 
= 11.47 (s br., 1H, Arg-N2CNHBoc), 8.31 (t br., 
3J = 
4.9 Hz, 1H, Arg-CHCH2CH2CH2NH), 7.83 (s, 1H, 
triazol-5-H), 6.94 (t br., 3J = 6.6 Hz, 1H, Gly-
CCONHC-Asp), 5.08 (d, 2J = 16.8 Hz, 1H, Gly-
CH2), 5.04 (d, 
2J = 16.8 Hz, 1H, Gly-CH2), 4.66 
(ddd, 3J = 8.9 Hz, 3J = 6.2 Hz, 3J = 4.9 Hz, 1H, Asp-CH), 4.53 (ddd, 3J = 7.4 Hz, 3J = 
6.3 Hz, 3J = 4.5 Hz, 1H, Arg-CH), 3.84 (d br., 3J = 8.1 Hz, 1H, Arg-CHNH), 3.46-3.40 
(m, 2H, Arg-CHCH2CH2CH2NH), 2.82 (dd, 
2J = 17.1 Hz, 3J = 4.7 Hz, 1H, Asp-
CHCH2CO2), 2.68 (dd, 
2J = 17.1 Hz, 3J = 4.5 Hz, 1H, Asp-CHCH2CO2), 2.14 (m, 
1H, Arg-CHCH2CH2CH2NH), 1.96 (m, 1H, Arg-CHCH2CH2CH2NH), 1.73 (m, 
1H, Arg-CHCH2CH2CH2NH), 1.64 (m, 1H, Arg-CHCH2CH2CH2NH), 1.48 (s, 9H, 
CH2CO2C(CH3)3), 1.47 (s, 9H, CHCO2C(CH3)3), 1.42 (s, 9H, NCO2C(CH3)3), 1.41 (s, 
9H, NHCO2C(CH3)3), 1.21 (s, 9H, SC(CH3)3). 
13C NMR (126 MHz, Chloroform-d) δ = 
170.0 (CH2CO2C(CH3)3), 169.2 (CHCO2C(CH3)3), 165.0 (Gly-CH2CONHC-Asp), 
163.7 (NHC(N)NH), 156.3 (NCO2C(CH3)3), 153.4 (NHCO2C(CH3)3), 150.2 (triazol-C-4), 
123.9 (triazol-C-5), 83.2 (NHCO2C(CH3)3), 82.8 (CH2CO2C(CH3)3), 81.9 
(CHCO2C(CH3)3), 79.4 (N=CO2C(CH3)3), 56.5 (SC(CH3)3), 53.2 (Asp-CHCH2CO2), 
52.7 (Gly-CH2), 49.5 (Arg-CHCH2CH2CH2NH), 40.6 (Arg-
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CHCH2CH2CH2NH), 37.2 (Asp-CHCH2CO2), 33.1 (Arg-
CHCH2CH2CH2NH), 28.4 (Asp-CHCH2CO2C(CH3)3), 28.2 (Asp-
CHCO2C(CH3)3), 28.1 (NCO2C(CH3)3), 28.0 (NHCO2C(CH3)3), 25.5 (Arg-
CHCH2CH2CH2NH), 22.8 (SC(CH3)3). C35H62N8O10S (786.99 g mol
-1). MS(ESI): m/z 
= 787.4354 (calcd. 787.43824 [M+H]+). TLC: Rf (CH2Cl2/MeOH, 10:1) = 0.48.  
 
IIX-6. d) Cleavage of Protective Groups to obtain RGD Mimetics 133-137 
(S)-3-(3-Amino-6-guanidinohex-1-yn-1-yl)-4-(methoxycarbonyl)benzoic Acid (133). 
Hydrochloric acid (4 M in dioxane, 3 mL) was added dropwise to an ice-cold solution of 
peptidomimetic 128 (200 mg, 298 mol, 1.0 eq) in CH2Cl2 (3 mL). The reaction mixture 
was warmed up to rt and stirred 12 h at ambient temperature until the starting material was 
completely consumed (checked by LCMS) before evaporating the solvent at 40 °C. 
Inhibitor 133 was isolated by preparative HPLC as TFA adduct.  
Colorless solid. Yield: 37.0 mg, 111 mol, 37 %. 1H NMR (500 MHz, DMSO-d6) δ = 8.66 
(s br., 3H, CNH3+), 8.12 (d, 4J = 1.6 Hz, 1H, ar-2-H),  8.05 
(dd, 3J = 8.2 Hz, 4J = 1.7 Hz, 1H, ar-6-H), 8.01 (d, 3J = 8.2 Hz, 
1H, ar-5-H), 7.35 (s br., 4H, NH2C=NH2+), 4.44 (dd, 3J = 
8.9 Hz, 3J = 5.2 Hz, 1H, CH), 3.89 (s, 3H, ar-4-CO2CH3), 
3.21 (td, 3J = 6.5 Hz, 3J = 4.8 Hz, 2H, N2CNCH2), 1.86 (dt, 
2J = 12.2 Hz, 3J = 5.8 Hz, 1H, CCH2), 1.82-1.75 (m, 2H, CCH2, CCH2CH2), 1.68 
(m, 1H, CCH2CH2). 13C NMR (126 MHz, DMSO-d6) δ = 165.8 (ar-4-CO2CH3), 165.3 
(ar-1-CO2H), 156.9 (HN=CN2), 134.9 (ar-C-1), 134.7 (ar-C-4), 134.5 (ar-C-2), 130.6 (ar-
C-5), 129.8 (ar-C-6), 121.3 (ar-C-3), 90.4 (CHC≡C-ar), 84.0 (CHC≡C-ar), 52.6 (ar-4-
CO2CH3), 42.4 (C), 40.1 (N2CNHCH2), 30.2 (CCH2), 24.8 (CCH2CH2). 
C18H21F3N4O6 (446.38 g mol
-1). MS(ESI): m/z = 333.1544 (calcd. 333.1557 
[C16H20N4O4+H]
+).  
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(3-((S)-3-Amino-6-guanidinohex-1-yn-1-yl)benzoyl)-L-aspartic Acid 
Trifluoroacetate (134). Peptidomimetic 129 (183.4 mg, 227.5 mol) was dissolved in a 
mixture of TFA/TIPS/H2O (190:5:5, 2 mL) and stirred vigorously overnight. After 
complete conversion (checked by LCMS), the crude product was precipitated with ice-cold 
Et2O and sucked off through a frit. The colorless precipitate of 134 was dissolved in MeOH 
and purified by preparative HPLC.  
Pale yellow oil. Yield: 2.39 mg, 6.14 mol, 3 % (the main part of the product was lost 
during a previous deprotection attempt under the conditions described in the cleavage of 
the protective groups of 128 to form 133. The method described above did not complete 
the cleavage, leading to the loss of a great part of the material). 1H NMR (500 MHz, 
DMSO-d6) δ = 8.90 (d br., 3J = 7.9 Hz, 1H, CHNHCO), 8.53-8.44 (s br., 4H, 
CH2NHC(NH)-NH2), 7.94 (t, 
3J = 2.2 Hz, 1H, ar-2-
H), 7.92 (d, 3J = 7.7 Hz, 1H, ar-6-H), 7.64 (dt, 3J = 
7.7 Hz, 4J = 1.4 Hz, 1H, ar-4-H), 7.56 (t, 3J = 7.7 Hz, 
1H, ar-5-H), 4.75 (td, 3J = 8.0 Hz, 3J = 5.4 Hz, 1H, 
CHCH2CO2H), 4.42 (dt, 
3J = 9.8 Hz, 3J = 5.1 Hz, 
1H, CHCH2CH2CH2NH), 3.19 (dt, 
3J = 7.0 Hz, 3J = 6.7 Hz, 2H, 
CHCH2CH2CH2NH), 2.85 (dd, 
2J = 16.5 Hz, 3J = 5.5 Hz, 1H, CHCH2CO2H), 2.72 
(dd, 2J = 16.5 Hz, 3J = 8.3 Hz, 1H, CHCH2CO2H), 1.87-1.71 (m, 2H, 
CHCH2CH2CH2NH), 1.75-1.59 (m, 2H, CHCH2CH2CH2NH). C18H23N5O5 
(389.41 g mol-1). LCMS(ESI): m/z = 390.1828 (calcd. 390.1772 [M+H]+).  
 
(5-((S)-3-Amino-6-guanidinohex-1-yn-1-yl)thiophene-2-carbonyl)-L-aspartic Acid 
Trifluoroacetate (135). Peptidomimetic 130 (101.8 mg, 125.4 mol) was dissolved in a 
mixture of TFA/TIPS/H2O (190:5:5, 2 mL) and stirred vigorously overnight. After 
complete conversion (checked by LCMS), the crude product was precipitated with ice-cold 
Et2O and sucked off through a frit. The colorless precipitate of 135 was dissolved in MeOH 
and purified by preparative HPLC.  
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Pale yellow highly viscous oil. Yield: 10.87 mg, 
27.49 mol, 22 %. 1H NMR (500 MHz, DMSO-d6) δ = 
8.99 (d br., 3J = 8.0 Hz, 1H, CONHCHCH2CO2), 
8.51 (s br., 4H, NHC(NH2)2), 7.79 (d, 
3J = 3.9 Hz, 1H, 
thiophene-3-H), 7.64 (t br., 3J = 6.4 Hz, 1H, 
CHCH2CH2CH2NH), 7.40 (d, 
3J = 3.8 Hz, 1H, 
thiophene-4-H), 4.69 (dd, 3J = 7.1 Hz, 3J = 6.0 Hz, 1H, CHCH2CO2), 4.46 (m, 1H, 
CHCH2CH2CH2NH), 3.18 (td, 
3J = 6.6 Hz, 3J = 5.8 Hz, 1H, CHCH2CH2CH2NH), 
2.85 (dd, 2J = 16.8 Hz, 3J = 5.5 Hz, 1H, CHCH2CO2H), 2.68 (dd, 
2J = 16.4 Hz, 3J = 
8.4 Hz, 1H, CHCH2CO2H), 1.89-1.73 (m, 2H, CHCH2CH2CH2NH), 1.72-1.59 (m, 
2H, CHCH2CH2CH2NH). 
13C NMR (126 MHz, DMSO-d6) δ = 172.2 
(CHCH2CO2H), 171.6 (CHCO2H), 160.0 (NHC(NH2)2), 156.9 (thiophene-
COHNCH), 141.3 (thiophene-C-2), 134.3 (thiophene-C-3), 128.7 (thiophene-C-4), 
124.5 (thiophene-C-5), 93.0 (CHC≡C-thiophene), 82.1 (CHC≡C-thiophene), 50.3 
(CHCH2CO2), 49.4 (CHCH2CH2CH2NH), 40.4 (CHCH2CH2CH2NH), 35.7 
(CHCH2CO2), 31.7 (CHCH2CH2CH2NH), 22.0 (CHCH2CH2CH2NH). 
C16H21N5O5S (395.43 g mol
-1), LCMS (ESI): m/z = 396.0498 (calcd. 396.1336 [M+H]+), 
418.0259 (calcd. 418.1156 [M+Na]+).  
 
(S)-2-(4-((S)-1-Amino-4-guanidinobutyl)-1H-1,2,3-triazol-1-yl)succinic Acid 
Trifluoroacetate (136). An aqueous solution of LiOH (1 M, 3.8 mL) was added dropwise 
to an icecold solution of peptidomimetic 131 (303 mg, 0.47 mmol, 1 eq) in MeOH (8 mL). 
After complete addition, the reaction mixture was warmed up to rt and stirred for 2.3 h, 
until the starting material was completely consumed (checked by LCMS). The solution was 
concentrated up under reduced pressure, diluted with an aqueous KHSO4 solution (5 %, 
10 mL) to adjust the pH value to 1-2 and extracted with EtOAc (5 x 10 mL). The combined 
organic layers were dried over Na2SO4 and the solvent was removed under reduced 
pressure.  
The crude product was dissolved in a mixture of TFA/TIPS/H2O (9 mL, 95:2.5:2.5) and 
stirred overnight at ambient temperature. After complete consumption of the starting 
material (checked by LCMS), the crude product was precipitated with ice-cold Et2O and 
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sucked off through a frit. The colorless precipitate of 136 was dissolved in MeOH and 
purified by preparative HPLC. 
 Colorless solid, yield: 75.7 mg, 177 mol, 38 %. 1H NMR (500 MHz, DMSO-d6) δ = 
13.03 (s br., 1H, CO2H), 8.52 (s br., 3H, CHNH3
+), 8.31 (s, 
1H,  CHC=CH), 7.96 (t, 3J = 5.8 Hz, 1H, 
CHCH2CH2CH2NH), 7.37 (s br., 5H, H2N-C=NH2
+), 5.73 (dd, 
3J = 7.8 Hz, 3J = 5.9 Hz, 1H, CO2CHN-CH2CO2), 4.50 (dd, 
3J 
= 7.3 Hz, 3J = 4.8 Hz, 1H, +H3N-CH), 3.25 (dd, 
2J = 17.0 Hz, 
3J = 6.5 Hz, 2H, CO2CHCH2CO2), 3.19 (dd, 
2J = 17.0 Hz, 3J = 8.0 Hz, 1H, CO2CHN-
CH2CO2), 3.11 (dt, 
3J = 6.7 Hz, 3J = 7.3 Hz, 2H, CCH2CH2CH2NH), 1.92 (dd, 
3J = 7.7 Hz, 
3J = 6.5 Hz, 2H, CCH2CH2CH2NH), 1.49 (m, 1H, CCH2CH2CH2NH), 1.38 (m, 1H, 
CCH2CH2CH2NH).
 19F NMR (471 MHz, DMSO-d6) δ = -73.85 (CF3CO2H). 13C NMR 
(126 MHz, DMSO-d6) δ = 170.9 (CH2-CO2), 169.2 (CHN-CO2), 159.0 (q, 2JCF = 31.9 Hz, 
F3C-CO2), 157.1 (N=CN2), 143.4 (CHC=CH), 124.5 (C=CH), 117.1 (q, 
1J = 295.7 Hz, 
CF3CO2H), 59.1 (CO2-CHN-CH2CO2), 46.4 (CNH3
+), 40.1 (CCH2CH2CH2NH), 36.0 
(CO2CHN-CH2CO2), 30.2 (CCH2CH2CH2NH), 24.8 (CCH2CH2CH2NH). 
C13H20F3N7O6 (427.34 g mol
-1). MS(ESI): m/z = 314.1564 (calcd. 314.1571 [M+H]+).  
 
(2-(4-((S)-1-Amino-4-guanidinobutyl)-1H-1,2,3-triazol-1-yl)acetyl)-L-aspartic Acid 
Trifluoroacetate (137). Peptidomimetic 132 (103.4 mg, 131.4 mol) was dissolved in a 
mixture of TFA/TIPS/H2O (190:5:5, 2 mL) and stirred vigorously overnight. After 
complete conversion (checked by LCMS), the crude product was precipitated with ice-cold 
Et2O and sucked off through a frit. The colorless precipitate of 137 was dissolved in MeOH 
and purified by preparative HPLC.  
Colorless amorphous solid. Yield: 38.90 mg, 105.0 mol, 80 %. 1H NMR (500 MHz, 
DMSO-d6) δ = 8.81 (d br., 3J = 7.9 Hz, 1H, Gly-
CHCOHNCHCH2CO2), 8.38 (s br., 4H, 
NHC(NH2)2), 8.22 (s br., 1H, Arg-
CHCH2CH2CH2NH), 8.14 (s, 1H, triazol-5-H), 7.53 
(ddd, 3J = 5.8 Hz, 3J = 7.0 Hz, 3J = 6.8 Hz, 1H, Asp-
CH), 5.22 (d, 2J = 17.4 Hz, 1H, Gly-CH2CONH), 5.18 (d, 
2J = 16.9 Hz, 1H, Gly-
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CH2CONH), 4.53 (ddd, 
3J = 6.8 Hz, 3J = 5.4 Hz, 3J = 6.9 Hz, 1H, Arg-CH), 3.08 (d, 3J 
= 6.9 Hz, 3H, Arg-CHNH3), 2.70 (dd, 2J = 17.0 Hz, 3J = 5.8 Hz, 1H, Asp-
CHCH2CO2H), 2.64 (dd, 
2J = 16.9 Hz, 3J = 7.0 Hz, 1H, Asp-CHCH2CO2H), 1.91 
(ddd, 3J = 7.9 Hz, 3J = 7.7 Hz, 3J = 5.9 Hz, 2H, CHCH2CH2CH2NH), 1.46 (m, 1H, 
CHCH2CH2CH2NH), 1.35 (m, 1H, CHCH2CH2CH2NH). 
13C NMR (126 MHz, 
DMSO-d6) δ = 172.2 (Asp-CHCH2CO2H), 171.3 (Asp-CHCO2H), 170.2 (Gly-
CH2CONH), 165.5 (NHC(=NH)NH2), 156.9 (triazol-C-4), 143.5 (triazol-C-5), 51.7 
(Asp-CHCH2CO2H), 50.9 (Arg-CHCH2CH2CH2NH), 49.1 (Gly-CH2), 46.6 
(Asp-CHCH2CO2H), 36.2 (Arg-CHCH2CH2CH2NH), 30.3 (Arg-
CHCH2CH2CH2NH), 24.9 (Arg-CHCH2CH2CH2NH). C13H22N8O5 
(370.37 g mol-1), LCMS (ESI): m/z = 371.1800 (calcd. 371.1786 [M+H]+).  
 
IIX-6. e) Chromatograms of Samples 133-137 for the Affinity Assays 
 
 
Diagram EP27. Analytical chromatogram of (S)-3-(3-Amino-6-guanidinohex-1-yn-1-yl)-4-
(methoxycarbonyl)benzoic  Acid (133). Purity >99 %.  
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Diagram EP28. Analytical chromatogram of (3-((S)-3-Amino-6-guanidinohex-1-yn-1-
yl)benzoyl)-L-aspartic Acid (134). Purity >99 %.  
 
 
 
Diagram EP29. Analytical chromatogram of (5-((S)-3-Amino-6-guanidinohex-1-yn-1-
yl)thiophene-2-carbonyl)-L-aspartic Acid (135). Purity >95 %. 
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Diagram EP30. Analytical chromatogram of (S)-2-(4-((S)-1-Amino-4-guanidinobutyl) -1H-
1,2,3-triazol-1-yl)succinic Acid (136). Purity >99 %.  
 
 
 
Diagram EP31. Analytical chromatogram of (2-(4-((S)-1-Amino-4-guanidinobutyl) -1H-
1,2,3-triazol-1-yl)acetyl)-L-aspartic Acid (137). Purity >99 %.  
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IIX-6. f) Integrin Binding Assay 
The activity and selectivity of integrin ligands were determined by a solid-phase binding 
assay according to the previously reported protocol [213] as adapted by Kapp et al. [143], 
using coated extracellular matrix proteins and soluble integrins. Cilengitide® 
(c(RGDf(NMe)V) was used as internal standard for v3 (0.54 nM). Flat-bottom 96-well 
Immuno Plates (BRAND, Wertheim, Germany) were coated overnight at 4 °C with human 
vitronectin (1.0 g mL-1, 100 L per well, R&D) in carbonate buffer (15 mM Na2CO3, 
35 mM NaHCO3, pH 9.6). Each well was then washed with PBS-T-buffer (phosphate-
buffered saline/Tween20, 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, 
0.01 % Tween20, pH 7.4; 3 x 200 L) and blocked for 1 h at room temperature with TS-
B-buffer (Tris-saline/BSA buffer, 150 L/well, 20 mM Tris-HCl, 150 mM NaCl, 1 mM 
CaCl2, 1 mM MgCl2, 1 mM MnCl2, pH 7.5, 1 % BSA). In the meantime, a dilution series 
of the compound and internal standard was prepared in an extra plate, starting from 
2000 M to 7.1 nM (reference compound 20 M to 0.43 nM) in 1:5 dilution steps. After 
washing the assay plate three times with PBS-T (200 L), 50 l of the dilution series was 
transferred to each well from B–G. Well A was filled with 100 l TSB-solution (blank) and 
well H was filled with 50 l TS-B-buffer. 50 l of a solution of human v3-integrin 
(2.0 g ml-1, R&D) in TS-B-buffer was transferred to wells H–B and incubated for 1 h at 
rt. The plate was washed three times with PBS-T buffer, and then the primary antibody 
(2.0 g mL, mouse anti-human CD51/61, BD Biosciences, 100 L per well) was added to 
the plate. After incubation for 1 h at rt, the plate was washed three times with PBS-T. Then, 
the secondary peroxidase-labeled antibody (1.0 g mL-1, anti-mouse IgG-POD, Sigma-
Aldrich, 100 L well-1) was added to the plate and incubated for 1 h at rt. After washing 
the plate three times with PBS-T, the plate was developed by quick addition of 
SeramunBlau (50 L well-1, Seramun Diagnostic GmbH, Heidesee, Germany) and 
incubation until a colour gradient was visible. The reaction was stopped with 3 M H2SO4 
(50 L well-1), and the absorbance was measured at 450 nm with a plate reader (Tecan 
Reader). The IC50 of each compound was tested in duplicate, and the resulting inhibition 
curves were analyzed using OriginPro 2017G (32-bit) SR1 software. The inflection point 
describes the IC50 value. All determined IC50 were referenced to the activity of the internal 
standard Cilengitide® (0.54 nM) [143].  
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Figure EP5. Determination of the IC 50 values using the ELISA based assay. Sigmoidal dose -
response curves of the compounds 133  (JP19), 134  (TS127), 135  (TS128), 136  (JP63), 137 
(TS140) and Cilengitide® .   
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IIX-6. g) Cell Adhesion Assay  
The cell adhesion tests were performed as previously described by Conradi et al. [258]. 
Competition assays were performed with WM-115 human epithelial cancer cells. 
Therefore, WM-115 cells were cultivated to a confluence of 70 %, detached with Trypsin-
EDTA (0.05 % / 0.02 % in D-PBS) (PAA, Pasching, Austria), washed with MEM medium, 
resuspended in MEM medium with 1 mg mL-1 fluorescein diacetate (Sigma-Aldrich, St. 
Louis, USA) to a cell density of 1 x 105 cells mL-1, and incubated at 37 °C under steady 
shaking for 30 min. Subsequently, cells were washed two times with MEM medium, 
resuspended with MEM medium containing divalent cations Ca2+ and Mg2+ (2 mM) to 
obtain a cell density of 1 x 105 cells mL-1 and incubated in the dark on ice for 30 min. For 
the cell adhesion assay CagLWT was immobilized on a Nunc MaxisorpTM surface and WM-
115 cells pre-incubated with varying concentrations of vitronectin were dispensed to the 
immobilized CagLWT. Likewise, WM-115 cells were pre-incubated with different CagLWT 
concentrations before adding to immobilized vitronectin (1 g mL-1). The cell suspension 
was added to the peptide solutions to give concentrations ranging from milimolar to 
nanomolar and incubated 30 min at 37 °C. It was then dispensed on the coated microtiter 
plate (5 x 104 cells well–1) and incubated for 1 h at 37 °C. Unbound cells were aspirated 
and bound cells were washed twice with MEM medium. Fluorescence was measured (ex 
= 485 nm; em = 514 nm) in an InfiniteTM 200 Microplate Reader (Tecan, Männedorf, 
Switzerland). IC50 values (50 % cell binding inhibition) of the tested peptides were 
evaluated with the GraphPad Prism 4.03 software (GraphPad, San Diego, USA). In cell 
adhesion assays the murine monoclonal antibodies LM609 (EMD Millipore, Billerica, 
USA) against human integrin V3, 3S3 (AbD Serotec, MorphoSys AG, Germany) against 
b1 integrin, and P1F6 (EMD Millipore, Billerica, USA) against V5 were used in final 
concentrations of 25 g mL-1. The assay was performed as described above. Instead of 
staining the cells with fluorescein diacetate, they were washed with Puck’s salt solution 
(5.4 mM KCl, 0.4 mM KH2PO4, 5.6 mM D-glucose, 136 mM NaCl, 2 mM MgCl2, 2 mM 
MnCl2), fixed for 30 min at rt using 5 % (w/v) glutaraldehyde, and stained with crystal 
violet 1 % (w/v) in 100 mM MES (pH 6.0) over 60 min at rt. After a second washing step 
with Puck’s salt solution, 100 mM citric acid in ethanol was added and the cells were 
incubated 30 min at rt for visualization. Absorption at 485 nm and emission at 514 nm was 
measured using the Tecan M200 Microplate Reader and the data was processed with Origin 
(Dose-Response). 
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Figure EP6. Sigmoidal dose-response plots of the competitive cell adhesion assays for 
peptidomimetics 133  and 137 , inhibiting the binding of WM -115 cells to the CagLWT  
proteins. a) Reference inhibitor was Cilengitide®, IC50  1.9 M. b) Therephthalate 133 ,  
referenced to Cilengitide® IC50 > 250 M. c) triazole 136 ,  referenced to Cilengitide®. IC5 0 
> 1000 M.  
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IIX-6. h) Docking Studies 
Docking studies were performed with the AutoDock Vina software tool using default 
parameters (exhaustiveness = 8) [259]. The crystal structure of the complex of v3 and 
Cilengitide®, which has been presented by Xiong et al. [206] and published in the Research 
Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank under the ID 15LG, 
was chosen. The cocrystallized RGD peptide and water molecules in the binding pocket 
were detached using the AutoDock Tools software [260]. Polar hydrogen atoms were added 
at heteroatoms only. The 3D structures of test compounds 133-137 were constructed using 
Avogadro software [261] and optimized with the MMFF94s force-field method option 
[262]. Degrees of freedom and rotatable bonds were defined by the AutoDock Tools 
software [260]. The binding pocket was defined as the location of the co-crystallized 
Cilengitide® as the grid (x = 19.0, y = 44.6, z = 43.0) with a size of 16 × 22 × 16 Å3 and a 
distance of points of 1 Å. The evaluation of the docking results and the visualization were 
performed using PyMOL viewer software [263].  
Cilengitide® was re-modelled into the binding pocket of integrin v3 using the AotoDock 
Vina software tool [259]. The results were compared to the crystal structure in order to 
evaluate the results (Figure EP7).  
 
Figure EP7. Evaluation of the docking method by comparison of the X -ray structure analysis 
of Cilengitide®, co-crystallized with integrin v3 [206]. Left side: Co-crystallized binding 
pocket of v3 and Cilengitide®. Right side: Superimposition of co -crystalline Cilengitide® 
(colored green) and Cilengitide® computed as described above (colored rose). Regions of 
the binding pocket of integrin v3 were colored according to their polarity (blue = 
hydrophobic, red = hydrophilic, green = metal ions).  
 
Coumpounds 110-119 were computed into the binding pocket of integrin v3 as described 
above in order to define the bioactive conformation of the ligands. The bond lengths and 
angles, which have been used to characterize the class D peptidomimetics and their affinity 
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potential to the binding pocket have been measured in the results of the docking 
experiments and summarized in Table EP33.  
 
Figure EP8. Mechanistic class D peptidomimetics,  used for docking experiments in order to 
deduce information about convenient bond lengths and dihedral angles. Crucial atoms for 
the conformation are labeled.  
a IC50 values refer to GP II /III determined in a platelet -rich plasma assay.  
 
Table EP33. Important conformational parameters of topographical peptidomimetic 
scaffolds 110-119  model peptide Cilengitide® for comparison with the scaffolds 
investigated in this work. Atom numbers refer to Figure  EP8. Torsion angles and distances 
of the peptidomimetics have been measured in convenient conformations, which were 
derived from docking experiments.  Torsion angle and distances of the bioactive 
conformation of Cilengitide® has been measured in its X-ray crystal structure of the complex 
with v3 [206].   
Compound 
d(atom1-2) 
[Å] 
d(atom2-3) 
[Å] 
d(atom3-4) 
[Å] 
-torsion 
[°] 
d(atom1-4) 
[Å] 
IC50 
[nM] 
Cilengitide® 5.54 6.43 2.55 118 13.72 0.54 
110 6.73 5.68 2.49 109 11.83 0.6 
111 6.23 6.46 1.51 140 12.74 0.8 
112 5.86 5.68 2.49 102 13.03 0.3 
113 4.89 5.68 2.50 159 12.14 190 
114 5.67 9.13 1.53 -100 14.78 32 a 
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115 5.79 7.60 2.48 -104 14.19 90 a 
116 4.64 8.70 3.40 40 14.50 10800 a 
117 4.07 4.88 3.01 78 11.34 34 a 
118 5.03 9.83 2.48 155 16.19 37 a 
119 4.58 6.24 2.51 -105 12.32 100 
 
a IC50 values refer to glycoprotein GP II /III.  Values for integrin v3 were not available.  
The shown pictures of the compounds, modeled into the respective binding pocket of 
integrin V3 have been made using PMV and ADT software [260]. Visualisation was 
realised using a Visual Programming Environment for Python [263], programmed by 
Sanner et al..  
 
Figure EP9. Integrin v3 docking results. Docking poses of the first, shorter integrin v3 
inhibitors 133  (colored brown) and 136  (colored cyan). The molecular surface of integrin 
v3 is displayed and colored according to the hydrophobicity (blue = hydrophobic, red = 
hydrophilic, green = metal ions).  
 
 
Figure EP10. Integrin v3 docking results. Left side: docking poses of the aromatic 
integrin v3 inhibitors 134  (colored green) and 135  (colored rose).  Right side: docking 
pose of the triazole based inhibitor 137  (colored magenta), which is the most potent inhibitor 
under study. The molecular surface of integrin v3 is displayed and colored according to 
the hydrophobicity (blue = hydrophobic, red = hydrophilic, green = metal ions).  
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Figure EP11: Class B peptidomimetics 133-137  as analogues of the RGD sequence (also 
depicted). All compounds were used for docking experiments in order to deduce information 
about bond lengths and dihedral angles in convenient conformations for interaction with 
integrin v3. The linear RGD sequence  was used as reference compound [143]. Crucial 
atoms for the conformation are labeled.  
 
Table EP34: Bond lengths and dihedral angles in compounds 133-137 . Distances and angles 
were derived from conformations, convenient for the interaction with integrin v3. 
Appropriate conformations were determined by docking experiments. Atom numbers refer 
to Figure EP11.  
Compound 
d(atom1-2) 
[Å] 
d(atom2-3) 
[Å] 
d(atom3-4) 
[Å] 
-torsion 
[°] 
d(atom1-4) 
[Å] 
IC50 [M] 
133 6.61 4.89 2.95 180 12.98 73390 
134 5.90 9.35 2.57 -84 13.48 173.8 
135 5.13 9.88 2.49 -124 15.21 41.91 
136 6.61 4.05 3.81 141 13.33 388461 
137 5.78 7.98 2.45 121 12.81 3.85 
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IIX-6. i) X-ray Structure Analysis 
Dimethyl 5-Hydroxyisophthalate, the side product in the synthesis of aromatic halide 120. 
Colorless crystals, appropriate for X-ray structure analysis were obtained by concentrating 
slowly up a solution of dimethyl 5-hydroxyisophthalat in a mixture of PE/EtOAc (2:1) at 
ambient temperature and pressure. 
Crystal Data for C10H10O5 (M = 210.18 g mol
-1): orthorhombic, space group Fdd2 (no. 43), 
a = 41.5876(15) Å, b = 23.9061(9) Å, c = 3.78390(10) Å, V = 3761.9(2) Å3, Z = 16, T = 
100.01(10) K, μ(CuKα) = 1.032 mm-1, Dcalc = 1.484 g/cm3, 9822 reflections measured 
(8.504° ≤ 2Θ ≤ 152.12°), 1731 unique (Rint = 0.0244, R = 0.0158) which were used in all 
calculations. The final R1 was 0.0256 for 1648 reflections with I > 2σ(I) and wR2 was 
0.0732 for all data. 
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Table EP35. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103) for Dimethyl 5-Hydroxyisophthalat . Ueq is defined as 1/3 of of the 
trace of the orthogonalised UIJ tensor.  
Atom x y z U(eq) 
O8 5370.7(4) 5266.9(6) -676(5) 19.2(4) 
O14 5203.2(3) 3349.7(6) 3845(5) 20.7(4) 
O12 5630.2(4) 2908.4(6) 6175(5) 18.8(4) 
O15 6554.8(4) 4226.8(7) 5102(5) 22.0(4) 
O10 5821.3(4) 5730.9(6) 739(5) 23.6(4) 
C2 5587.1(5) 4303.8(9) 2523(7) 16.1(5) 
C3 5711.0(5) 3814.6(9) 3958(7) 15.6(5) 
C11 5485.0(5) 3340.9(9) 4618(7) 15.6(5) 
C1 5789.7(5) 4760.5(9) 2040(6) 15.4(5) 
C5 6236.6(5) 4236.3(9) 4290(7) 16.9(5) 
C6 6113.3(5) 4730.3(9) 2929(7) 16.9(5) 
C7 5666.9(5) 5300.0(9) 649(7) 16.8(5) 
C4 6036.7(5) 3777.8(9) 4827(7) 16.1(5) 
C13 5423.5(6) 2436.8(10) 7001(8) 19.0(5) 
C9 5236.4(6) 5782.6(10) -2062(7) 20.3(5) 
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